<SEC-DOCUMENT>0001447028-22-000025.txt : 20220506
<SEC-HEADER>0001447028-22-000025.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160602
ACCESSION NUMBER:		0001447028-22-000025
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arbutus Biopharma Corp
		CENTRAL INDEX KEY:			0001447028
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980597776
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34949
		FILM NUMBER:		22896159

	BUSINESS ADDRESS:	
		STREET 1:		701 VETERANS CIRCLE
		CITY:			WARMINSTER
		STATE:			PA
		ZIP:			18974
		BUSINESS PHONE:		604-419-3200

	MAIL ADDRESS:	
		STREET 1:		701 VETERANS CIRCLE
		CITY:			WARMINSTER
		STATE:			PA
		ZIP:			18974

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS Corp
		DATE OF NAME CHANGE:	20110607

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKMIRA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20081003
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>abus-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0,d:4d1c0ae544ca49e89401026bf23c9474--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:abus="http://arbutusbio.com/20220331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abus-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8xLTEtMS0xLTI5MzIx_37ccede8-9dd6-467e-b0b4-b6536525ddb1">false</ix:nonNumeric><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8yLTEtMS0xLTI5MzIx_d01814df-4730-4123-9f2d-b88a2791c5fa">0001447028</ix:nonNumeric><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8zLTEtMS0xLTI5MzIx_6eefa3d5-8af9-4945-b31f-a25dddabdb17">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF80LTEtMS0xLTI5MzIx_d14d8799-d160-4fff-9978-7a8704f21088">2022</ix:nonNumeric><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF81LTEtMS0xLTI5MzIx_16566202-c1a0-4899-853c-454b30ee5559">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abus-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ff9c3983f4b4ac4a65444acd7a38ba7_I20220503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb159623bc541d1b5ec342caea83932_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:CollaborationAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d20c312d38544f9bd612a684dcc1831_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:CollaborationAndContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01b82303f97d4df4a95fd381074c09f0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17287f28a3a3401ab7bf4647bec4c75b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ic52d6065eb09463296c5f6564f7e3bc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86367f2c4ca14273aa29c338129293e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8346a78b814432d98fb8f1fc40a22c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106be97586e5476f95a81fc1db43de35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052e4eb49038437097e6489137f6506c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bcfb45fbd545a3a593fb87947be374_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief63021f67754f038c0196c4f7a220c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5236eb0aea334ba6a6ac833d4c6c22df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0df84842ad046e9b85fd86ec798224a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a62aee5f464630a521ca887a7075e7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970a3c27243f432f8c84f282ad9db987_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d7fd13bcc74c299377045d32e83e2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2601c2c8d0a44ae9b8cb8405c6b4ef8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc1996fb96b4d5daac0e417a6c7f2d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf2d5f4bb024a6398e8ca10beda360a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0453799dbcc4307847b039a4848dedd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20fbb288c20f47a99438e41bbee9a692_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99bbb8943c6e4d28a7642f2253e96007_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338c23e7885d44f2925e13fde9eebadf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b29770c1294814900bbc415d9f0848_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2f2d16cd4d4be188f3dda7b49732a6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82d76d58cf924d8383205f275ac7662f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e91e406b5a42c18158f3225f58684b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>abus:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="idd98aaf228d443bfa99d0a12b844de6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ca92d833848428fbad2a29503fd9fbd_I20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70dcc32cab84091a414d114000ea384_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7820392be70c42cea55c46eb141bfcbd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a049cff7d741e796edd187de00eb6f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711a0a90695f46ef8552c9299d3498e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2c2988cb54498a88205e9749e91abe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7440144805e64bbd9476e8bc698f3da0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fbfd866f2424809b3d908c81b3d684b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7455aad25d9f402397dfad6f05220540_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba87cbb7f15b4facadb3e5b5747a6fdf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd22b5593e2744f68646be67d090d0c4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624eddd7b8ae4655ac59e95730e93120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbad88517d4f4037b2bad380a2b21006_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100b46b4a64d427faa1e681084d9bd07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia387d060fc5249a1876b226e2cfa8c1a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6afb52fbbc104a09b75948cb08a8bf93_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentMoneyMarkeTFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f71f74bd334db090c35763085f2594_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbcc1b73bcd42d98797c743e412a754_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie39a0f5344c6417eb981eb066ec304be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a026a23b8a4596bd788df2c75ed5df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f5f771802c4176a602d03f3977a1e1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb2c36817bb45738c25a5631ff9a54f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentMoneyMarkeTFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cdab202f75a4297866c250a068cd12d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide871516fa03491795c8b51d22d71071_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa844129bf484cc98902853bb3e8413b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i161fa77486694f6aa841fc6ee122232b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacc617e1d9442d58a84e6cfc75788aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c58bd3a223344a9a04669315e016fe3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i849f8840cc1f40369b37a736474e7316_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4dc98c87a0247e6a3f4347246739782_D20190702-20190702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2019-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0286773ab94cf7a483c6b8bc8e1785_D20190702-20190702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2019-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2019-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428973c6db9541269463d60bbdc135c7_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-02</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167905b8454f403bbc363d3a741afda6_D20201218-20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-18</xbrli:startDate><xbrli:endDate>2020-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22f8361c99954dfa827a9008f0da81b3_I20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce501d18c8a4c21ab64d7e145ce4bb0_I20141031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3a998dc61042eda3caff10aef9779e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abus:OneTimeUpfrontCashPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-05</xbrli:startDate><xbrli:endDate>2022-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia483bef565574680a3a9c1bd2564b825_I20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7161a12d542a4969901ecf181c8d5cf4_I20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9336fe97b44836842a01da01d42937_D20220106-20220106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-06</xbrli:startDate><xbrli:endDate>2022-01-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9829026bc73479093b8029eac0806e0_I20211213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1163dbec3a7848eca95205175b1da9b0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0f3d36adae54e1d9276dd03b947cf45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702949ca2cfd4a0a9bb7f02fd91035b8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AssemblyBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01ce59d6936428c930e28b71f7c5359_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AssemblyBiosciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f12239ea971423693eb1924756cc84c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:XChemIncAndProterosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9be38c6e9064432bd40073b87596f3c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:XChemIncAndProterosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>abus:product</xbrli:measure></xbrli:unit><xbrli:context id="iecc67e9256ab4b9dbea33b02a1658a89_D20130101-20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cae881ec75e4bc18cff9b5347823e59_D20130101-20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie759772fc0d34889b5b1773813066150_D20130101-20130630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46281ecd5fb744a99a4fb28bba9e853c_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i518670b3fac0479e89bccbd3cf48a756_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AcuitasTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3e5de0afd64224841a930f2a7a0b40_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AcuitasTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad95e89d07d4219962809e6980f2c99_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc54f0d5f1e425684acf6e743b66eaf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a7bfc3b496414582720db787c9cf6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OtherMilestoneandRoyaltyPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232b5a40e86b4942a256e843e353e388_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OtherMilestoneandRoyaltyPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6007cbaa2fc842dbb22efaa19e85a21c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c626debfbf4e20bbb17e393ea68c3d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95f34ecb804c43bd860c37e292eda8dc_I20200110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fd91415d144f359a29ef040e182e92_I20200110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Jan2020ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721c0159d357459e82fda7a1d2aaa5a2_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Aug2020ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4e708fcedd480aa26d4c73a4f87927_I20201022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb32b3f5a01140a19a6306f86a2a8fd5_I20210304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Mar2021ProspectusSupplementAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab6748705d0d4226ba4a82a1e22ee083_I20211008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:October2021ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia52a417f6ada4560b9f6eb2b6fd7a96a_I20220303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:March2022ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020Oct2020AndNov2021RegistrationStmtsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf4d6c3fa5a4105a94421a222392925_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670e4df1980948ec8c216e9200afc61f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2e4c170332429cb6b01ee5963528a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i045ad8ba8ec9498a8558014661ce50fe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd670c983a7433cb7bd93372158078d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:October2021ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida00744ff3624de0be467e4cae72015e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:March2022ProspectusSupplementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a5dd2c6ac51433dbaefbe4e3fc47c85_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d02dff95ec415dab33999ff0c85e85_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98fa33af9af34a29a59381fcf1cbe51d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a64dd48949e4cba85f1ccfe32f2819e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3988f17b1bc94d529eadea44681fdf65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e6d8e3249e848a0b9453c69b8b92b5d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-02</xbrli:startDate><xbrli:endDate>2017-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib605935fd5db48b7a59105e11ada7c5f_I20171002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac91ec4cb9804633b6568f3d3cafd8e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0515a8eeb4984632a6fdb800c50fd8bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001447028</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4d1c0ae544ca49e89401026bf23c9474_1"></div><div style="min-height:31.5pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> UNITED STATES</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMx_11a65fae-c19c-4d2b-a0a8-5d8f521ff69b">10-Q</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQw_7b7bdcc5-fad6-454c-89ee-973acff9edda">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMTU_86dfdbfb-5205-40c3-9796-d21e2e610f76">March&#160;31, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQx_db26ed36-a715-4ec1-bcfd-034bd1e2d1b5">&#9744;</ix:nonNumeric>&#160;&#160;  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM3_d82e931c-aff4-4971-99cd-281e449c40cd">001-34949</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMz_c8b21286-e29f-4779-987e-a62765e1833c">ARBUTUS BIOPHARMA CORP</ix:nonNumeric>ORATION</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6YTA2NDM0YmMxMTc2NDk3OWIzZDc4NDgzZjQzYTZlMmQvdGFibGVyYW5nZTphMDY0MzRiYzExNzY0OTc5YjNkNzg0ODNmNDNhNmUyZF8wLTAtMS0xLTI5MzIx_754e631a-b840-46f6-bc3f-c0e3305cada4">British Columbia, Canada</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6YTA2NDM0YmMxMTc2NDk3OWIzZDc4NDgzZjQzYTZlMmQvdGFibGVyYW5nZTphMDY0MzRiYzExNzY0OTc5YjNkNzg0ODNmNDNhNmUyZF8wLTItMS0xLTI5MzIx_9a3d3199-b492-40fe-bb2c-b551c2562f99">98-0597776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMw_c928ac3f-c26a-4933-bb20-455e502a61e7">701 Veterans Circle</ix:nonNumeric>, <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQy_1cac55e8-cbac-46f7-bb33-5a0408cf08bd">Warminster</ix:nonNumeric>, <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM4_1f6ef05c-eb3e-47cd-a57e-856b8d4a9ab9">PA</ix:nonNumeric> <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF81MjY_5eecea02-0454-4f93-901f-ca34dcaee7ed">18974</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF81ODM_40bffda3-a00b-487c-9f4b-00a3cfdaef69">267</ix:nonNumeric>-<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQz_7d31f249-93c0-493e-827a-528f16d43bb1">469-0914</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.555%"><tr><td style="width:1.0%"></td><td style="width:33.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTAtMS0xLTI5MzIx_6f4bd984-44f9-4701-baf7-03a8558c3fa8">Common Shares, without par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTEtMS0xLTI5MzIx_d3107d1e-480d-4209-be6d-ec4a05f837a1">ABUS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTItMS0xLTI5MzIx_88258794-886c-48b8-8b8a-881bae9a442b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM5_8c9f817b-c065-4d49-97dd-27705e890766">Yes</ix:nonNumeric>  &#9746;&#160;&#160;&#160;&#160;&#160; &#160;No  &#9744;&#160; &#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM0_122a3ea0-c6b6-43ad-8e1f-3ddbd9b44f55">Yes</ix:nonNumeric>  &#9746;&#160;&#160;&#160;&#160;&#160; &#160;No  &#160;&#9744; &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8wLTItMS0xLTI5MzIx_ce3dc62d-00e3-4bf3-baf0-9f033ed8a8d7">Non-accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8xLTMtMS0xLTI5MzIx_50ed6159-afd4-4fac-aca6-a818f7b9ff34">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8xLTQtMS0xLTI5MzIx_540e5753-1d28-4888-8584-adb96c64e545">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes &#160;<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM1_7b85875a-454d-48e9-9a7d-4cdc0e79aa90">&#9744;</ix:nonNumeric>&#160; &#160;&#160;&#160;No  &#9746; </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;3, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i0ff9c3983f4b4ac4a65444acd7a38ba7_I20220503" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMTgw_53803f9b-a5e3-4215-a30a-e98bd5260ad6">148,728,237</ix:nonFraction>&#160;common shares, without par value, outstanding. </span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_10">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_13">&#160; &#160; &#160; &#160; &#160; &#160;ITEM 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_13">FINANCIAL STATEMENTS (UNAUDITED)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_67">&#160; &#160;ITEM 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_67">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_67">19</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_91">ITEM 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_91">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_91">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_94">ITEM 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_94">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_94">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_97">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_100">ITEM 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_100">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_100">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_103"> &#160;ITEM 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_103">RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_103">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_106">&#160;ITEM 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_106">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_106">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_109">ITEM 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_109">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_109">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; &#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_112">ITEM 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_112">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_112">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_115">&#160;ITEM 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_115">38</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; &#160; &#160; &#160; &#160; </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4d1c0ae544ca49e89401026bf23c9474_118">&#160;ITEM 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_118">EXHIBITS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4d1c0ae544ca49e89401026bf23c9474_118">39</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_13"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_16"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMy0xLTEtMS0yOTMyMQ_3d8cb485-c766-4c81-b8a6-70cdcf1f2f56">81,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMy0zLTEtMS0yOTMyMQ_0aa4933e-9ee8-42f5-b210-30ac9378d019">109,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNC0xLTEtMS0yOTMyMQ_1d29e26b-a665-4c5f-9db3-10714b52b8ab">84,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNC0zLTEtMS0yOTMyMQ_e0925597-fb67-42dc-8536-c5669d4cca22">46,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNS0xLTEtMS0yOTMyMQ_c7e41ed7-a802-4932-9b00-f0a84ee5af90">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNS0zLTEtMS0yOTMyMQ_073b009b-6269-4534-80f2-9899d866d047">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNi0xLTEtMS0yOTMyMQ_7e52e537-0a44-45ee-afdc-309caf0b475f">5,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNi0zLTEtMS0yOTMyMQ_6d816009-964d-40c9-b1a0-5b23be21cdc1">4,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNy0xLTEtMS0yOTMyMQ_138bb0ae-0166-46af-afc1-b02258d8482d">172,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNy0zLTEtMS0yOTMyMQ_b8a3a485-16b9-4644-90f5-8fcfbab13d62">160,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0wLTEtMS0yOTMyMS90ZXh0cmVnaW9uOmNjNGRkOTFlNTJjNTRmN2M5Zjc1ODhhYTIyNmZhYzc5XzYz_4f5e0368-016a-43e0-84c8-e15b9ef2f089">9,768</ix:nonFraction> </span></div><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(December 31, 2021: $<ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0wLTEtMS0yOTMyMS90ZXh0cmVnaW9uOmNjNGRkOTFlNTJjNTRmN2M5Zjc1ODhhYTIyNmZhYzc5Xzg3_f719effd-2cfd-480c-9f6a-1f527f446d5a">9,374</ix:nonFraction>) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0xLTEtMS0yOTMyMQ_fc1f59d7-867f-4a6a-931c-28f7b7b77f2a">5,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0zLTEtMS0yOTMyMQ_314d6f24-fff9-4d1a-a10f-0553e9be4f74">5,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOS0xLTEtMS0yOTMyMQ_9af4ade0-8f80-4aa2-8dc6-24f480f44f9f">56,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOS0zLTEtMS0yOTMyMQ_3262a6c4-7753-4a00-a546-dc686905892c">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTAtMS0xLTEtMjkzMjE_49483a58-3f88-461e-bcde-bb152c8d3e4b">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTAtMy0xLTEtMjkzMjE_d04e7695-25c6-496e-8e87-feaec5bd1397">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTEtMS0xLTEtMjkzMjE_48b6ba7c-3aef-4303-8d3b-84e1ddc32b96">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTEtMy0xLTEtMjkzMjE_d7a782a9-2366-43de-a4df-60ed44099c74">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTItMS0xLTEtMjkzMjE_f6dd86a8-2a4c-404e-88eb-139f3ba506ba">236,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTItMy0xLTEtMjkzMjE_1808fbd4-6b40-4841-a86f-cee27e2b51dc">204,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTUtMS0xLTEtMjkzMjE_5aac3118-e758-4143-9d8f-0e4f2771da07">8,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTUtMy0xLTEtMjkzMjE_d852a758-9833-461d-83ad-173b8d00f5bf">10,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred license revenue, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMS0xLTEtMzIxMDc_8c447e10-3673-49ec-8a5e-b76276cd2318">23,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMy0xLTEtMzIxMzc_2dfa2a4c-ed35-49f2-922d-613f36295866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMS0xLTEtMjkzMjE_0cc78a12-e796-4bec-9cd4-6b851f9d938f">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMy0xLTEtMjkzMjE_23c33888-3995-4053-b988-6b7d1f8d2ad1">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTctMS0xLTEtMjkzMjE_af99431e-20a1-41ca-ae46-0e90b07cbae7">32,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTctMy0xLTEtMjkzMjE_ef9b17c6-7441-472c-ae2f-9d36deda5509">11,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability related to sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTgtMS0xLTEtMjkzMjE_74d8e745-7b03-4b04-916f-6feadde77e54">15,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTgtMy0xLTEtMjkzMjE_88b59b2b-0570-4eee-91ec-e6419c805dcc">16,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred license revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMS0xLTEtMzIxMTU_99d5e0f3-0bb2-43b1-b745-5742b1b45a88">15,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMy0xLTEtMzIxNDg_40e0eed9-4074-4589-a166-c03dc80e6516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTktMS0xLTEtMjkzMjE_e9f55e9a-e853-44ed-a5ad-a455387a8bb7">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTktMy0xLTEtMjkzMjE_865801dd-bc66-4e8e-be85-6e47fb330375">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMS0xLTEtMjkzMjE_6a65b3fe-526d-4d73-b205-99531292da6f">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMy0xLTEtMjkzMjE_685fa6bb-c5dd-4459-828d-c696f0400b41">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMS0xLTEtMjkzMjE_bf8f2c78-aab5-4bc9-8c51-f797ef7ff616">71,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_037ca5b4-d3c2-4273-902a-8ebee405cda1"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_45269d27-7f8c-4762-b566-014f208331de"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_fa036173-de1d-44d9-9570-f53618e5dfba">35,046</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized: unlimited number without par value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF8yOA_29ff57d9-8a04-4197-8cd5-1b92f6fba749"><ix:nonFraction unitRef="shares" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF8yOA_e09e3cb9-d6c1-498b-89f0-cccf1f88949f">148,728,237</ix:nonFraction></ix:nonFraction> (December 31, 2021: <ix:nonFraction unitRef="shares" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF81MQ_9ccdcd0a-27ec-4382-a60b-91119fdd909b"><ix:nonFraction unitRef="shares" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF81MQ_c947ff9c-4b20-486b-93d9-96b331e130d8">144,987,736</ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMS0xLTEtMjkzMjE_9d9d572e-b65a-4e42-93b7-c770f0c0cafb">1,298,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMy0xLTEtMjkzMjE_0aba2c60-72e2-4ad1-8311-49f141bd8416">1,286,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjktMS0xLTEtMjkzMjE_d0e8f76e-6f20-4577-a34c-00d5b6bbf6a9">67,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjktMy0xLTEtMjkzMjE_b7b7b937-8f85-4245-b352-1f804bc01def">65,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzAtMS0xLTEtMjkzMjE_199b3cc8-234d-48ad-a4cb-ead6723cc251">1,150,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzAtMy0xLTEtMjkzMjE_b5ccef7a-d692-4077-82fb-1e010ea43b99">1,134,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzEtMS0xLTEtMjkzMjE_5051ce51-fc61-41d6-a294-e91a585bd849">49,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzEtMy0xLTEtMjkzMjE_93f901d1-3047-44f0-8185-2dbf4c8e318a">48,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzItMS0xLTEtMjkzMjE_c7e7ea43-8c39-4f25-b337-f42a7d241981">165,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzItMy0xLTEtMjkzMjE_3b7737a1-a8ab-4df2-86a2-c863fe5df688">169,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzMtMS0xLTEtMjkzMjE_e09d934a-ff52-4cf6-993d-18f3f7be6d9c">236,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzMtMy0xLTEtMjkzMjE_8c294360-fc4e-4828-a584-6e4aa84e7852">204,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaborations and licenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb159623bc541d1b5ec342caea83932_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMy0xLTEtMS0yOTMyMQ_e1c3fc1c-dc54-4236-b02d-d453a4b4da2e">11,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d20c312d38544f9bd612a684dcc1831_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMy0zLTEtMS0yOTMyMQ_00810e8e-35da-4ae4-8c96-50e73bacea3a">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01b82303f97d4df4a95fd381074c09f0_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNC0xLTEtMS0yOTMyMQ_9553edd3-f0fe-4a7c-a7ec-e352a8f2ae4c">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17287f28a3a3401ab7bf4647bec4c75b_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNC0zLTEtMS0yOTMyMQ_d4fbdcb5-09d3-40a8-9032-b264185ff7fb">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNS0xLTEtMS0yOTMyMQ_a8e4f448-3a5f-4358-b865-2bccd836ee66">12,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNS0zLTEtMS0yOTMyMQ_c787634b-abed-452c-8cf5-0d05cb103317">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNy0xLTEtMS0yOTMyMQ_15d32447-b161-49df-b172-58557ef30288">18,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNy0zLTEtMS0yOTMyMQ_934534d2-eb0d-4adf-8ac9-8f9faa888117">13,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfOC0xLTEtMS0yOTMyMQ_947871aa-7774-4667-9c71-37715e07d9db">4,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfOC0zLTEtMS0yOTMyMQ_8f34b054-18a4-42ca-83dd-824c3c11dab9">3,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTAtMS0xLTEtMjkzMjE_c2cdd649-e9c4-471d-a044-c30c41cb713e">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTAtMy0xLTEtMjkzMjE_a585131f-d469-4c1f-880e-c9fa66625316">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTUtMS0xLTEtMjkzMjE_c5b2cd25-d7b4-4688-8d22-ad467ad07f31">23,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTUtMy0xLTEtMjkzMjE_0957aeee-66bf-4764-8f12-37561315744d">17,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTYtMS0xLTEtMjkzMjE_1b0b645b-193f-4600-9114-1a91b1eabbd4">10,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTYtMy0xLTEtMjkzMjE_fd536681-29ef-461a-bba8-487e517f5621">15,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTgtMS0xLTEtMjkzMjE_181fbc1d-3e68-4b77-8c96-676e327619a0">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTgtMy0xLTEtMjkzMjE_e9d4065b-0c44-496e-ace9-8ca9f01008f1">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTktMS0xLTEtMjkzMjE_ba5655fe-0fdf-4cf1-80e7-cc37f6753450">506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTktMy0xLTEtMjkzMjE_64a109af-0f14-4fcb-b5e9-6a54df8954d3">772</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (loss) gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjAtMS0xLTEtMjkzMjE_9c88cff4-546e-40c6-84d9-acaca93396e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjAtMy0xLTEtMjkzMjE_dee2c9ba-709b-4a0f-b02f-e6506d33fdbf">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjItMS0xLTEtMjkzMjE_70a5ad23-3955-49f0-a940-56a72964c3b1">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjItMy0xLTEtMjkzMjE_2a3f7527-7daf-4402-ac7f-0d9822193777">705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjMtMS0xLTEtMjkzMjE_e1e7a8e4-7f2b-451d-95b3-e0b79c90787c">11,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjMtMy0xLTEtMjkzMjE_242f45a2-7dd3-411a-95b0-6a539c65d9d7">16,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjQtMS0xLTEtMjkzMjE_a6a6475f-5d58-4b7e-b9a1-3005ebe21a12">4,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjQtMy0xLTEtMjkzMjE_33d33172-692a-4cfe-bdee-4926b5dfce2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjUtMS0xLTEtMjkzMjE_953f8108-aa9f-4e22-a23e-db4e863b16b3">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjUtMy0xLTEtMjkzMjE_ecc0d223-aa76-4c90-ab97-09e512e7bf00">16,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items applicable to preferred shares:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend accretion of convertible preferred shares.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjctMS0xLTEtMjkzMjE_9ed535e7-e8fd-4cce-a7d1-6e63716481e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:PreferredStockDividendsAndOtherAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjctMy0xLTEtMjkzMjE_d36d2c81-41b4-4807-be6b-f9b92039a608">3,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shares</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjgtMS0xLTEtMjkzMjE_18456d84-4485-4dfe-a325-0640a23eea2f">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjgtMy0xLTEtMjkzMjE_9b60932c-c738-4a3c-9942-c93322bdc9a9">19,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMS0xLTEtMjkzMjE_567d724a-c232-466e-8f4a-6773b2282691"><ix:nonFraction unitRef="usdPerShare" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMS0xLTEtMjkzMjE_e0189138-9da8-4d53-b684-2b030e43caab">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMy0xLTEtMjkzMjE_60709576-ba26-42d0-8d83-6752e9aad10b"><ix:nonFraction unitRef="usdPerShare" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMy0xLTEtMjkzMjE_63b67af4-7c7b-4f8c-b062-e45b95398e08">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMS0xLTEtMjkzMjE_8d7d7ee2-5b91-4a5a-8420-83ba42da7895"><ix:nonFraction unitRef="shares" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMS0xLTEtMjkzMjE_d0e847ce-f714-48c0-9e09-1100ee975c28">148,428,326</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMy0xLTEtMjkzMjE_5f3db547-770d-4e2d-8fdb-bbe468febc25"><ix:nonFraction unitRef="shares" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMy0xLTEtMjkzMjE_81379fe3-444c-4d25-aa99-fbdacee9f982">93,434,378</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzYtMS0xLTEtMjkzMjE_9fefe923-c993-45ca-8484-84f2535c3620">1,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzYtMy0xLTEtMjkzMjE_48b66421-58fa-4472-8ce8-74cbbe59cc37">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzgtMS0xLTEtMjkzMjE_4736409d-f7b4-41f7-ad47-a9366f232465">16,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzgtMy0xLTEtMjkzMjE_b2014198-607b-4a2a-9c5c-2bb576c74796">16,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic52d6065eb09463296c5f6564f7e3bc3_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi01LTEtMS0yOTMyMQ_ad5b32ff-a58f-46ea-b25b-a33ea14b19d8">144,987,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52d6065eb09463296c5f6564f7e3bc3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi03LTEtMS0yOTMyMQ_36678c1b-fbf5-491a-8d90-11629cd1f5b7">1,286,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86367f2c4ca14273aa29c338129293e4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi05LTEtMS0yOTMyMQ_451f46b7-e8cb-44d2-a9d8-dfafda592652">65,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8346a78b814432d98fb8f1fc40a22c3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xMS0xLTEtMjkzMjE_ab5c784a-b982-42ee-9be2-c82f3b51e68f">1,134,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i106be97586e5476f95a81fc1db43de35_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xMy0xLTEtMjkzMjE_9f501d79-f2c7-42df-bede-f73e2ca41fb4">48,335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xNS0xLTEtMjkzMjE_16d9e4e7-73b3-40e0-bf48-72ff04c446b6">169,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNC05LTEtMS0yOTMyMQ_6818c709-ad23-4462-9914-92537ab6f35a">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNC0xNS0xLTEtMjkzMjE_9f6ec52b-c796-48e1-980b-cfccd41ccebb">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain fair value adjustments to liability stock option awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331" decimals="-3" name="abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNS05LTEtMS0yOTMyMQ_d5f060d3-e18f-4e5f-b9e3-b5e0f69475a4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNS0xNS0xLTEtMjkzMjE_fabce909-a931-40a7-b00a-edfc7e5a0e38">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to the Open Market Sale Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi01LTEtMS0yOTMyMQ_e1bfed05-efa2-457c-83fb-461bb042bc9f">69,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi03LTEtMS0yOTMyMQ_d6356d77-8cf1-4c9b-99da-9c17afad830a">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052e4eb49038437097e6489137f6506c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi0xNS0xLTEtMjkzMjE_b841d452-7bfc-47ad-914e-22f15f3f4429">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy01LTEtMS0yOTMyMQ_c4e939b5-1881-497a-aaa3-42e926365402">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy03LTEtMS0yOTMyMQ_9b6041cb-3c29-45e9-b46f-03e7c12e8ea0">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy05LTEtMS0yOTMyMQ_76002b00-b1d2-4054-bf7b-0975cf682170">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy0xNS0xLTEtMjkzMjE_31e6f43f-3f25-4675-8523-e3237132e65c">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC01LTEtMS0yOTMyMQ_d09306c9-ab53-4b49-a313-90e563c080d7">86,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC03LTEtMS0yOTMyMQ_178c1d98-7d99-449c-9d6d-a386dcc9b19b">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC05LTEtMS0yOTMyMQ_de73ecad-3217-4657-980b-600d6595a392">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xNS0xLTEtMjkzMjE_4a09e1c0-afb7-42c4-89c2-599ddca48903">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to Share Purchase Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xLTEtMS0zMzAyMw_842f9841-7aa7-462b-b2e6-5e3386b19256">3,579,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0zLTEtMS0zMzAyMw_49608fee-113b-4f12-bf12-795bbe8b6139">10,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xMS0xLTEtMzMwMjM_ebdf55ae-ff20-4b84-aff0-d3d43e2eb6cc">10,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0bcfb45fbd545a3a593fb87947be374_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOS0xMy0xLTEtMjkzMjE_0a49c2d4-ec5f-4f36-a87f-a81a3c966c3c">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOS0xNS0xLTEtMjkzMjE_fbca599d-2363-49a0-8af7-3086ef025fa9">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief63021f67754f038c0196c4f7a220c6_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTAtMTEtMS0xLTI5MzIx_81496014-5e5d-45ab-88ec-e8ce9c112c36">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTAtMTUtMS0xLTI5MzIx_1c5b4534-03d4-471e-9965-c16ea128050e">15,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtNS0xLTEtMjkzMjE_7cf6f9d3-b023-4b87-92c7-42a0506f528a">148,728,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtNy0xLTEtMjkzMjE_9434c3f7-07da-44a1-b9ba-d3d22c8a90d6">1,298,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5236eb0aea334ba6a6ac833d4c6c22df_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtOS0xLTEtMjkzMjE_6fd7a269-97f7-40f0-99bd-a764d80fc32d">67,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0df84842ad046e9b85fd86ec798224a_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTEtMS0xLTI5MzIx_f14ee7e4-e73d-4d02-8d87-759f034400b4">1,150,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a62aee5f464630a521ca887a7075e7_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTMtMS0xLTI5MzIx_3d071618-8dea-4244-9b6e-402e1e49fb96">49,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTUtMS0xLTI5MzIx_a6c739a3-79f7-4f01-9d07-4e10d933e6f7">165,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statement of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.717%"><tr><td style="width:1.0%"></td><td style="width:21.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.531%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Convertible Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i970a3c27243f432f8c84f282ad9db987_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xLTEtMS0yOTMyMQ_f71c238c-4986-4428-8537-0cabe2bf6fb0">1,164,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970a3c27243f432f8c84f282ad9db987_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0zLTEtMS0yOTMyMQ_c6b70b76-4461-44bf-a032-0d4ca663a133">149,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi01LTEtMS0yOTMyMQ_c15beb21-482c-4a62-9e16-c1b7763bb198">89,678,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi03LTEtMS0yOTMyMQ_6c97b1ce-56a7-43e3-b1ae-a53db8462676">985,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d7fd13bcc74c299377045d32e83e2c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi05LTEtMS0yOTMyMQ_eb0897f4-2164-44bd-8e69-2c0827f9f709">60,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2601c2c8d0a44ae9b8cb8405c6b4ef8c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xMS0xLTEtMjkzMjE_4bbcc6e0-305a-44a4-81f1-eafece26b4b9">1,045,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cc1996fb96b4d5daac0e417a6c7f2d4_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xMy0xLTEtMjkzMjE_22b82c72-c22c-4320-9cc4-52c754a6b346">48,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xNS0xLTEtMjkzMjE_7d71f944-91ee-4839-b418-3d9c597a6947">101,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accretion of accumulated dividends on Preferred Shares</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf2d5f4bb024a6398e8ca10beda360a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0zLTEtMS0yOTMyMQ_36b33f5d-8a7e-4e0a-a507-09614dc2d595">3,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331" decimals="-3" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0xMS0xLTEtMjkzMjE_a9bc770d-e604-40e6-b365-ace8b10c9718">3,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0xNS0xLTEtMjkzMjE_d4ebc25e-8987-4c12-b386-0da9f5ec8b74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNC05LTEtMS0yOTMyMQ_ba9f9ad9-5824-4132-bc90-78870d01d398">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNC0xNS0xLTEtMjkzMjE_5b727163-19bc-47a4-83e0-256015da8b30">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Certain fair value adjustments to liability stock option awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331" decimals="-3" name="abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNS05LTEtMS0yOTMyMQ_364e3396-29f1-4e94-976a-3ab79eb805b7">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNS0xNS0xLTEtMjkzMjE_5ce28335-6be7-434d-a600-a4f77996f0d9">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common shares pursuant to the Open Market Sale Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi01LTEtMS0yOTMyMQ_fcf45fa8-939b-4361-b29a-d4a7f600dfb0">6,395,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi03LTEtMS0yOTMyMQ_54ddb7d1-3715-492f-8032-cfd16f6f3d48">26,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi0xNS0xLTEtMjkzMjE_ae6ad3e6-91da-4901-a33f-ac2a13576434">26,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common shares pursuant to exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy01LTEtMS0yOTMyMQ_1765be5c-e9bd-4a14-b44d-01b34dadabf4">65,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy03LTEtMS0yOTMyMQ_23287805-0115-4796-ad32-a7ed40e2c0a6">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy05LTEtMS0yOTMyMQ_8e750024-05a2-4ec6-a000-22ba0ef6bb1f">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy0xNS0xLTEtMjkzMjE_7ab29231-a185-46dd-aff4-bf42132af4fe">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance of common shares pursuant to ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC01LTEtMS0yOTMyMQ_16cac958-63b8-47f8-b7e5-abe098012cb7">104,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC03LTEtMS0yOTMyMQ_7f4f4516-2165-4ad7-ab82-667e2a60b886">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC05LTEtMS0yOTMyMQ_36a48187-d974-466b-9319-ef30c7b590a5">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC0xNS0xLTEtMjkzMjE_ff5e378c-4cde-4fbd-a01a-28e239394ed2">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0453799dbcc4307847b039a4848dedd_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOS0xMy0xLTEtMjkzMjE_62861617-5ef5-46a8-9db3-7961c42994ff">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOS0xNS0xLTEtMjkzMjE_d9d20688-22fe-4dd1-9978-6c1ca8761458">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTEtMS0xLTI5NDQ4_9b0a5567-455a-465a-b54e-40754d3642ac">16,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTUtMS0xLTI5NDQ4_6c101612-2986-412b-b4bc-2ef5b0967de9">16,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20fbb288c20f47a99438e41bbee9a692_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMS0xLTEtMjkzMjE_38df985d-6c33-49c7-9a56-ec2570e7049f">1,164,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20fbb288c20f47a99438e41bbee9a692_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMy0xLTEtMjkzMjE_b27ee813-8cf9-4951-8646-752163d57471">152,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99bbb8943c6e4d28a7642f2253e96007_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtNS0xLTEtMjkzMjE_8b1ebd21-f2dc-4bd2-84c2-d902d5516752">96,245,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99bbb8943c6e4d28a7642f2253e96007_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtNy0xLTEtMjkzMjE_3a197102-11fb-4c31-83e0-12823560836b">1,013,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338c23e7885d44f2925e13fde9eebadf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtOS0xLTEtMjkzMjE_c9771aba-c22b-46da-88bb-83a285d603ec">62,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5b29770c1294814900bbc415d9f0848_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTEtMS0xLTI5MzIx_b56d594f-d544-4587-88de-566ab8ce57ce">1,065,554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2f2d16cd4d4be188f3dda7b49732a6_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTMtMS0xLTI5MzIx_7d071e5e-86a0-4a88-8d53-63adf9f4ec67">48,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTUtMS0xLTI5MzIx_24c25600-9577-45ea-836f-a60aae243d86">114,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flow</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands of U.S. Dollars)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMy0xLTEtMS0yOTMyMQ_3b95b8b0-d9ea-4e52-a067-2532c3aef002">15,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMy0zLTEtMS0yOTMyMQ_37c0b305-d449-4810-a83f-bfa047d3a4a3">16,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNS0xLTEtMS0yOTMyMQ_b9425cc9-7af1-44f1-af20-31829b5fd0fe">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNS0zLTEtMS0yOTMyMQ_72cbd9e9-abbd-46fa-af4c-e2237bb3c6e4">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNy0xLTEtMS0yOTMyMQ_7d82c593-d765-42a6-b166-b876188d1931">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNy0zLTEtMS0yOTMyMQ_f60ca06e-4266-4850-a26f-aa3057997a3e">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized foreign exchange losses (gains)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOC0xLTEtMS0yOTMyMQ_7be2efcc-b411-4cae-9d38-0afe8ce7216f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOC0zLTEtMS0yOTMyMQ_cb1682ea-ec3e-4032-b1bc-074832df9fd4">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOS0xLTEtMS0yOTMyMQ_f992fa97-5325-4ac2-82dd-195ff657aece">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOS0zLTEtMS0yOTMyMQ_f8b5c8aa-09fd-4846-a09e-76ecacd1c4b2">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTEtMS0xLTEtMjkzMjE_4a49b08c-be20-42c5-8996-c5e37dcc8432">1,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTEtMy0xLTEtMjkzMjE_a728cb60-35f1-4354-b45e-ad89776fb949">959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTItMS0xLTEtMjkzMjE_8c9978db-e5d8-45fe-af4c-b7208f239d49">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTItMy0xLTEtMjkzMjE_13def931-f218-4bba-928e-7072e83c14b9">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net accretion and amortization of investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTMtMS0xLTEtMjkzMjE_e42e77fe-2d44-4fc7-8452-0f0da8f12fde">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTMtMy0xLTEtMjkzMjE_6f5a28e9-9063-49aa-aefd-a9ae3113c725">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in operating items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTUtMS0xLTEtMjkzMjE_a9cc1574-72ad-468d-81ad-145e9b3806c2">414</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTUtMy0xLTEtMjkzMjE_e0347e38-d0eb-4c07-b03d-15a2bcd9cbe9">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTYtMS0xLTEtMjkzMjE_070d8eed-e743-4da4-8998-1282c597871a">1,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTYtMy0xLTEtMjkzMjE_92f2e416-6fff-43a0-aced-40fb90778cdc">857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTctMS0xLTEtMjkzMjE_7d0b5edb-531f-44de-bde3-e4381c33be44">2,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTctMy0xLTEtMjkzMjE_cb67fcfa-5dd3-4954-b3dd-364174d01bdc">2,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMS0xLTEtMzI0OTE_ad5c02b4-23e9-4937-b336-3513fd004db2">38,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMy0xLTEtMzI0OTE_f8d1a43c-e77f-49a5-8a7c-40f7f6a6d368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTktMS0xLTEtMjkzMjE_ac7ac4a9-c610-4996-b047-c1a7c9bc218b">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTktMy0xLTEtMjkzMjE_7b9dd22f-5a57-4b90-83cb-91f434b2dd06">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMS0xLTEtMjkzMjE_719b266e-eba6-437b-955b-7b65bd8793bd">20,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMy0xLTEtMjkzMjE_f130e46b-08d2-42ff-907a-147d3f2c8ec5">17,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjItMS0xLTEtMjkzMjE_42bd118a-2714-4113-914a-f8721b8d7620">61,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjItMy0xLTEtMjkzMjE_8bd38cdc-0fa4-44ee-8d80-86627a51a7cd">2,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposition of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjMtMS0xLTEtMjkzMjE_365ed3bb-e971-486b-b7e2-e81d87ee6bb1">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjMtMy0xLTEtMjkzMjE_a5f03371-6e27-40cd-936a-651017a3c815">20,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjYtMS0xLTEtMjkzMjE_e68907bb-27a0-4556-b12d-ab3e4de7a13f">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjYtMy0xLTEtMjkzMjE_91b2a4fe-b82e-4c95-b37b-5786bfefdbd2">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjctMS0xLTEtMjkzMjE_0d92af70-957d-4265-bac8-34ed29df462d">60,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjctMy0xLTEtMjkzMjE_a912efde-1964-4ad8-90d1-f413bbc7cde4">18,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to Share Purchase Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMS0xLTEtMzI0OTk_42171980-b171-4c7f-8809-06e7db379bf3">10,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82d76d58cf924d8383205f275ac7662f_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMy0xLTEtMzI0OTk_9c441915-b443-4127-881d-791d0ad11894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to the Open Market Sale agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052e4eb49038437097e6489137f6506c_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzAtMS0xLTEtMjkzMjE_5301ac7b-4dda-48e1-ac88-46141aa13c86">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e91e406b5a42c18158f3225f58684b_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzAtMy0xLTEtMjkzMjE_4a474d79-c99b-4f18-8b9b-2e3a10300669">26,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzEtMS0xLTEtMjkzMjE_401ff1fc-a5a2-414c-ba53-4d79648b6455">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzEtMy0xLTEtMjkzMjE_bdf0960f-da7d-40d9-a734-06c3957bba39">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzItMS0xLTEtMjkzMjE_d6026992-c254-4a98-be25-c86ff7a15e98">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzItMy0xLTEtMjkzMjE_e8a8325e-cdd9-453c-b1b9-5c72253a2dbd">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMS0xLTEtMjkzMjE_338323f3-874c-493b-b43c-6cdb0362fdd9">11,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMy0xLTEtMjkzMjE_c000863b-5507-40a3-bc71-c110a59faccf">26,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzQtMS0xLTEtMjkzMjE_2ba2a089-287d-4e96-b9cb-e624e49328f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzQtMy0xLTEtMjkzMjE_2244aa92-155e-4a00-9d2b-1ee8d4ed44b9">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Decrease) Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzUtMS0xLTEtMjkzMjE_9ae15bc0-9817-4c51-8e58-1b50d921dfba">27,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzUtMy0xLTEtMjkzMjE_af9bb3f1-13cb-4d22-9fc0-0a3a4f6218e9">27,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzYtMS0xLTEtMjkzMjE_9ee69ca7-4b67-4a05-a8b1-84cf9e7ee56b">109,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzYtMy0xLTEtMjkzMjE_7826e519-f8bc-471c-97c8-d4dc66dbf445">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzctMS0xLTEtMjkzMjE_4b48a6a5-c0d8-49b8-bc59-0cd5d686e26a">81,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzctMy0xLTEtMjkzMjE_601d4eb5-50c7-4519-b67f-5a7402dafd18">79,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred shares dividends accrued</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:DividendsPreferredStockCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNDAtMS0xLTEtMjkzMjE_0091d5be-7ec2-4842-aa64-d7921d6480c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:DividendsPreferredStockCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNDAtMy0xLTEtMjkzMjE_c20c8889-9be7-476c-b428-750d806412f4">3,212</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_28"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARBUTUS BIOPHARMA CORPORATION</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Tabular amounts in thousands of U.S. Dollars, except share and per share amounts)&#160;</span></div><div style="text-align:center"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfNDIyOQ_c2b50469-3f6f-49ae-865c-adf684f12b8d" continuedAt="i547d424f55ed43d38e305daeca09bd25" escape="true">Nature of business and future operations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i547d424f55ed43d38e305daeca09bd25" continuedAt="i431393c5a471458b9cc39ec1b9c5355b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (&#8220;Arbutus&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company&#8217;s current focus areas include Hepatitis B virus (&#8220;HBV&#8221;) and coronaviruses, including SARS-CoV-2. In HBV, the Company is developing an RNA interference (&#8220;RNAi&#8221;) therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (&#8220;cHBV&#8221;) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. The Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company had an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfMjA5NA_15e32a8a-74da-4f6e-ae49-a5174cca5823">221.8</ix:nonFraction> million in cash, cash equivalents and investments in marketable securities. The Company had <ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfMTA5OTUxMTYzNDkzMQ_748fee8e-b89a-47a1-a000-6dbf6ae226c9">no</ix:nonFraction> outstanding debt as of March&#160;31, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company&#8217;s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company&#8217;s existing or future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i431393c5a471458b9cc39ec1b9c5355b">The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials.  While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company&#8217;s plans and timelines in the future.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 6</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyOQ_fa790ef3-3380-466e-8747-cb17bcfc982a" continuedAt="iadc44dd40c4d47ebb22570962c31e858" escape="true">Significant accounting policies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iadc44dd40c4d47ebb22570962c31e858" continuedAt="ifc29b08187a8454aa13dc702287bca0b"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjczOA_e40e0eab-793f-4f25-80bf-68827805ed95" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation and principles of consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and its <ix:nonFraction unitRef="subsidiary" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0ODc2MA_ef06cdec-dcdd-4a69-8b1b-c4b78c26487a">one</ix:nonFraction> wholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company&#8217;s financial position as of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s results of operations for the three months ended March 31, 2022 and 2021, and the Company&#8217;s cash flows for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2021, except as described below under Recent Accounting Pronouncements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTYyOTk5ODg_fa5b78fc-328b-4533-95aa-e2146967c733" escape="true">All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyMg_34f2b494-a761-4cf0-ade8-2ad4c036ef4f" continuedAt="i08940c1e4dae444d92dd16cb64922a3b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss attributable to common shareholders per share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three months ended March 31, 2022 and 2021, since the effect of including potential common shares would be anti-dilutive. For the three months ended March 31, 2022, potential common shares of <ix:nonFraction unitRef="shares" contextRef="idd98aaf228d443bfa99d0a12b844de6f_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MzEzMA_ec946bf5-bee2-4505-90f8-5d020f2abe84">15.7</ix:nonFraction> million pertaining to outstanding stock options were excluded from the calculation of net loss attributable to common shareholders per share. A total of approximately <ix:nonFraction unitRef="shares" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MzA5OA_e2e3eb50-6c36-43e1-a8fb-d119e8c6273f">35.0</ix:nonFraction> million outstanding stock options and if-converted Series A participating convertible preferred shares (&#8220;Preferred Shares&#8221;) were excluded from the calculation for the three months ended March 31, 2021. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i08940c1e4dae444d92dd16cb64922a3b">On October 18, 2021, the Company&#8217;s outstanding Preferred Shares were converted into <ix:nonFraction unitRef="shares" contextRef="i9ca92d833848428fbad2a29503fd9fbd_I20211018" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MTU1Ng_0199f6b2-a1c5-4d0c-b617-838cf4549553">22,833,922</ix:nonFraction> common shares. Prior to that date, the Company followed the two-class method when computing net loss attributable to common shareholders per share as the Preferred Shares met the definition of participating securities. The Preferred Shares entitled the holders to participate in dividends but did not require the holders to participate in losses of the Company. Accordingly, net losses attributable to holders of the Company&#8217;s common shares were not allocated to holders of the Preferred Shares.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjc0MA_5db1241a-c95c-4138-ba40-9e13e55b0e8b" continuedAt="i89dd0e93c8634c9ca7b6f39a5aac62e1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from collaborations and licenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments and royalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements fall under the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) when both parties are active participants in the arrangement and are exposed to significant risks and rewards. For certain arrangements under the scope of ASC 808, the Company analogizes to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;) for some aspects, including for the delivery of a good or service (i.e., a unit of account).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ifc29b08187a8454aa13dc702287bca0b"><ix:continuation id="i89dd0e93c8634c9ca7b6f39a5aac62e1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When consideration is received or is unconditionally due from a customer, collaborator or licensee prior to the Company completing its performance obligation to the customer, collaborator or licensee under the terms of a contract, deferred revenue is recorded. Deferred revenue expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a current liability. Deferred revenue not expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a long-term liability. In accordance with ASC Topic 210-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet - Offsetting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s deferred revenue is offset by a contract asset as further discussed in Note 9.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjczNA_eff4c44a-22b4-4336-ad08-002356cbc34d" continuedAt="if943bd3f520646bdbbb0d2c3f54a5c02" escape="true">Segment information</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if943bd3f520646bdbbb0d2c3f54a5c02">The Company operates as a single segment.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyMQ_0dd18b6c-0a9d-47c8-938e-5e5502c0556f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed all recently issued standards and has determined that such standards will not have a material impact on the Company&#8217;s financial statements or do not otherwise apply to the Company&#8217;s operations.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwMQ_d2ae3f95-3b4d-43dd-9f64-9e592a70b02e" continuedAt="i1e4c43b1d4b74679aeb70eed58ccaa7d" escape="true"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwNA_62b155d6-4b67-42f0-80f6-5a6f365a3bef" continuedAt="i4655f4e2dce7403da27da7b1a6cfed7e" escape="true">Fair value measurements</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1e4c43b1d4b74679aeb70eed58ccaa7d" continuedAt="i32d5d4579c16452681a1d9900c84387e"><ix:continuation id="i4655f4e2dce7403da27da7b1a6cfed7e" continuedAt="id7ad72442cb5456e90b064d341aaf340"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial instruments and other items at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs are quoted market prices for identical instruments available in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i32d5d4579c16452681a1d9900c84387e" continuedAt="i2255062a7594412f9483d647a1518249"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7ad72442cb5456e90b064d341aaf340">To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices.</ix:continuation> The Company determined the fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMjQ0Nw_9e33f38e-6d88-46aa-b145-0f8dee96778f">5.5</ix:nonFraction> million as of March&#160;31, 2022 and the increase of $<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMjQ3Mw_5dae5a1f-05c1-41d7-a092-5e4359570e7f">0.2</ix:nonFraction> million from December&#160;31, 2021 has been recorded as a component of total operating expenses in the statement of operations and comprehensive loss for the three months ended March 31, 2022. The assumptions used in the discounted cash flow model are level 3 inputs as defined above. The Company assessed the sensitivity of the fair value measurement to changes in these unobservable inputs, and determined that changes within a reasonable range would not result in a materially different assessment of fair value. &#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzM5OA_fb7ed743-651c-469c-ac0c-ad5e63d6a168" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy0xLTEtMS0yOTMyMQ_800ff2ac-1810-46a4-a2e8-c6d56b6d30a3">81,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy0zLTEtMS0yOTMyMQ_b5253193-8d8e-4b1e-af21-681b6a257441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy01LTEtMS0yOTMyMQ_a8334cee-bfc8-446a-b768-f14564225039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy03LTEtMS0yOTMyMQ_e63cc78a-f887-40c6-9d8b-1b308d09bf9a">81,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC0xLTEtMS0yOTMyMQ_dc8359e1-0754-473d-a03a-bb625694d289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC0zLTEtMS0yOTMyMQ_f2e93775-dd09-4baf-9ad9-56bcc52f233a">84,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC01LTEtMS0yOTMyMQ_29a06557-13a1-4406-b053-4b9e0e0a6d0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC03LTEtMS0yOTMyMQ_0b8b46e4-4666-468e-b99c-07135efc5059">84,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS0xLTEtMS0yOTMyMQ_fbaafd98-01b9-4aa3-9456-79aaa82c3c57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS0zLTEtMS0yOTMyMQ_a62c885c-6604-450b-869e-75ec1ca0c3e2">56,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS01LTEtMS0yOTMyMQ_af459169-e860-404d-8c8e-cb87b2fca779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS03LTEtMS0yOTMyMQ_10e743d1-d9a7-4ad6-933e-e4c6e8528525">56,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi0xLTEtMS0yOTMyMQ_c47576d3-3b21-4fe5-800e-150855ea5128">81,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi0zLTEtMS0yOTMyMQ_9412cbbc-a819-4969-a794-706c2c07c2e9">140,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi01LTEtMS0yOTMyMQ_e78f0a17-83e4-4d10-b9ff-41fe24cdb4f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi03LTEtMS0yOTMyMQ_d966dfb2-78cb-44e2-9133-307f67b56735">221,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC0xLTEtMS0yOTMyMQ_c0042b28-e58b-4bf0-9644-473e46055191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC0zLTEtMS0yOTMyMQ_eecfb603-96ab-4774-9abe-a3a19cd5f203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC01LTEtMS0yOTMyMQ_676122cf-d460-4476-b333-de6992706cd0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC03LTEtMS0yOTMyMQ_696ba728-e130-4940-8e58-dabbb9c093e7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS0xLTEtMS0yOTMyMQ_cd7a1b45-802d-43fa-8c12-5113296f4472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS0zLTEtMS0yOTMyMQ_f9a76bf0-8744-48d8-b350-5f288a8405ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS01LTEtMS0yOTMyMQ_f336a34d-4203-4c94-9314-7e9d33700307">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS03LTEtMS0yOTMyMQ_dbd518c4-717a-473c-928d-0f32c264ac4c">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70dcc32cab84091a414d114000ea384_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtMS0xLTEtMjkzMjE_47025575-fe93-469b-87bc-8ceb63f138db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtMy0xLTEtMjkzMjE_bcc4706a-aef8-4832-a2be-eb6e7d58696a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtNS0xLTEtMjkzMjE_ebde8da5-4ee5-44a6-84d4-6e54b0d915aa">5,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtNy0xLTEtMjkzMjE_8b9ab7d7-a636-4f14-9d21-7f95a7408d83">5,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy0xLTEtMS0yOTMyMQ_83c7956a-d5dd-43d3-9e65-a5f05810ee10">109,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy0zLTEtMS0yOTMyMQ_6d31cf94-ee52-435f-9f0d-584f43c26447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy01LTEtMS0yOTMyMQ_6f56a40d-cba3-48a5-b3b5-2d6ee2f85eaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy03LTEtMS0yOTMyMQ_036d35b2-8018-4927-84ad-f155634bc541">109,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC0xLTEtMS0yOTMyMQ_bb491d8b-ade6-4dcc-adba-f89eedd9ebe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC0zLTEtMS0yOTMyMQ_5dfe526a-6bcd-4df6-8d61-189acbb4cd97">46,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC01LTEtMS0yOTMyMQ_ddceba99-2e55-4b17-a292-1da1d23babe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC03LTEtMS0yOTMyMQ_bd83bfde-3cb1-489f-b333-d144fa86079f">46,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0xLTEtMS0zNzc4Mw_4440cfe9-409d-4d7f-81ff-fe5320c440e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba87cbb7f15b4facadb3e5b5747a6fdf_I20210331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0zLTEtMS0zMzI2Ng_fd7f938e-e59f-46a4-bc68-21fc97d556e0">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS01LTEtMS0zNzgwMQ_fa73e004-754a-4419-b973-8e4f09854285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd22b5593e2744f68646be67d090d0c4_I20210331" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS03LTEtMS0zMzI2Ng_36d890c9-1fca-4a81-b91b-96fda96c6ab8">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0xLTEtMS0yOTMyMQ_271c7cca-179d-4f55-a88f-ddaf2ddaa66e">109,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0zLTEtMS0yOTMyMQ_4fb8e412-102d-410d-8860-350bf5364832">81,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS01LTEtMS0yOTMyMQ_3752a3a6-7bf3-44db-84d8-8cc9a04ef78d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS03LTEtMS0yOTMyMQ_9f634dd3-891b-4ac1-86a5-f39fe2071299">191,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy0xLTEtMS0yOTMyMQ_8cafc977-2d9a-467f-bda1-39855c886c1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy0zLTEtMS0yOTMyMQ_5114c72a-c468-4ab2-a5af-d41bbcadb221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy01LTEtMS0yOTMyMQ_a7fbdd17-7858-4a8f-a970-8e854f754bc1">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy03LTEtMS0yOTMyMQ_70b4db20-7f1a-401d-b797-9b5d60bcae74">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC0xLTEtMS0yOTMyMQ_f807b8f7-599b-4523-a664-8e487d2896ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC0zLTEtMS0yOTMyMQ_ac8e0db6-cc77-4906-b277-bc01ba1e0589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC01LTEtMS0yOTMyMQ_493b185d-f932-4f0d-b6d6-e227bc24e554">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC03LTEtMS0yOTMyMQ_cd6ed3d6-8574-495b-9a67-dd4f2891094d">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS0xLTEtMS0yOTMyMQ_e46e11b4-e783-4f15-ba24-b2ac1914b2ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS0zLTEtMS0yOTMyMQ_c1e64a6c-95f3-4ecb-9bba-03cc68ac8b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS01LTEtMS0yOTMyMQ_fb054023-6c9d-49d9-a319-9382cd98a022">5,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7455aad25d9f402397dfad6f05220540_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS03LTEtMS0yOTMyMQ_98ee766b-0c53-43e2-8920-fdb67e1311d8">5,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i2255062a7594412f9483d647a1518249"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="abus:ChangesInFairValueofLiabilityOptionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzM5NA_37f88e25-9bf2-462c-b74c-4bb739ff51f5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value of liability-classified options exercised in the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624eddd7b8ae4655ac59e95730e93120_I20211231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi0xLTEtMS0yOTMyMQ_bd0552d0-2d2b-4e32-82ff-20aad24e2ce0">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331" decimals="-3" name="abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi0zLTEtMS0yOTMyMQ_8481401c-2e37-4b5e-a81b-6541a641eaee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331" decimals="-3" sign="-" name="abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi01LTEtMS0yOTMyMQ_57a80f8d-1337-4eb1-b112-546af5bfa5f2">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbad88517d4f4037b2bad380a2b21006_I20220331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi03LTEtMS0yOTMyMQ_a2a2e568-f6bc-4906-bc60-e63699f934bf">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100b46b4a64d427faa1e681084d9bd07_I20201231" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy0xLTEtMS0yOTMyMQ_2997ed2e-5ea8-4798-a4e0-dcd87c4bddd8">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331" decimals="-3" name="abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy0zLTEtMS0yOTMyMQ_d93c0ba9-3b43-45b4-8745-13c4b30598c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331" decimals="-3" sign="-" name="abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy01LTEtMS0yOTMyMQ_6332d5ff-6de9-4d96-bd7f-6da0411146a7">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia387d060fc5249a1876b226e2cfa8c1a_I20210331" decimals="-3" name="abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy03LTEtMS0yOTMyMQ_45c26427-de1a-4377-b09f-b959ea310199">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwMA_19046e5f-2a37-465b-8498-117a08bd998e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:37.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi0xLTEtMS0yOTMyMQ_330aa391-b12b-428f-a31d-741fe39def94">5,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi0zLTEtMS0yOTMyMQ_8840635b-80df-431c-bb89-ed66fda55ee4">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi01LTEtMS0yOTMyMQ_c97cf08d-7c42-4369-ace2-bb1990d31d4b">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy0xLTEtMS0yOTMyMQ_7f26b2d2-a479-4459-94bc-cd7dc0db3e35">3,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy0zLTEtMS0yOTMyMQ_1765b1b1-21ad-4a4e-9f81-02897ba51127">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy01LTEtMS0yOTMyMQ_7fbdf84b-7796-4a6e-9cc5-9a073dd1aa01">3,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 10</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNzQw_01c11daa-b206-4d43-a8f6-70802d96dcc8" continuedAt="i21543d3397694062ac677972a8f5eb84" escape="true">Investments in marketable securities</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i21543d3397694062ac677972a8f5eb84" continuedAt="i351f38bb342140c09a02b6c205bd29e0">&#160;</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i351f38bb342140c09a02b6c205bd29e0" continuedAt="ie3ba20a2d8054c588bf241179b44012c"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNzQy_fcb33477-ee7f-47ab-9505-f4072a9d1d13" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afb52fbbc104a09b75948cb08a8bf93_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNC0xLTEtMS0yOTMyMQ_08f5c817-ec51-44a3-8039-01fed0d1474e">37,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afb52fbbc104a09b75948cb08a8bf93_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNC03LTEtMS0yOTMyMQ_99087be0-c0c2-4858-9f5d-507e88e4e9c2">37,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f71f74bd334db090c35763085f2594_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNi0xLTEtMS0yOTMyMQ_38705d44-bd42-4771-85cb-6fd4ddec7cf3">37,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f71f74bd334db090c35763085f2594_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNi03LTEtMS0yOTMyMQ_05950e5a-6dd4-4b51-b5b1-26d7d1c00c0b">37,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC0xLTEtMS0yOTMyMQ_a38ed702-f952-449c-8647-b1f8bccc65db">15,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC0zLTEtMS0yOTMyMQ_1efc4776-59d7-4316-8b11-92aae4fc1e9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC01LTEtMS0yOTMyMQ_1a21e840-ee9b-4224-9737-ac4173eccfdb">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC03LTEtMS0yOTMyMQ_0a7bb387-4320-40be-b2df-0a922d9c5b10">15,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS0xLTEtMS0yOTMyMQ_686c5857-560e-4f25-b5bb-f0101b97a32b">8,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS0zLTEtMS0yOTMyMQ_3f11ad2c-c2ca-4cdf-ac35-6f7720e29076">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS01LTEtMS0yOTMyMQ_4b40c8c1-de34-4442-b8d1-c4bddf333db4">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS03LTEtMS0yOTMyMQ_4fc7073c-59c6-4c03-a2d9-c734b0847370">8,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtMS0xLTEtMjkzMjE_de966c56-5f7b-4bce-b6b3-b749a2dcadf1">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtMy0xLTEtMjkzMjE_b6f447c6-f697-417d-b9c3-b4ef11a199b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtNS0xLTEtMjkzMjE_894393f4-653b-4b85-8768-543c0c7d6799">393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtNy0xLTEtMjkzMjE_51e3af1c-82be-415d-8cc3-a833179a4353">60,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtMS0xLTEtMjkzMjE_cf19e8e3-252b-4bc7-a656-78dfb3f2919b">84,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtMy0xLTEtMjkzMjE_22c01f20-be08-47c2-8f46-e5a7d23cce48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtNS0xLTEtMjkzMjE_5582a4fe-9558-4bd9-8b0b-a5248ff5b108">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtNy0xLTEtMjkzMjE_22052d3e-63d2-46af-a048-19eba8161d33">84,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtMS0xLTEtMjkzMjE_78ac5fd3-709e-44c6-b4e5-edefe8652020">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtMy0xLTEtMjkzMjE_236ee811-0f27-4c5e-ac7b-aaaa3767ec60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtNS0xLTEtMjkzMjE_16568708-2d6b-4035-82d4-4459720d39bc">213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtNy0xLTEtMjkzMjE_18019e05-027e-449a-9a46-d38bbc10a031">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtMS0xLTEtMjkzMjE_1c437e30-add2-4912-af82-41f6e5788e93">44,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtMy0xLTEtMjkzMjE_7adf69e7-6d1b-4a7a-82e3-8d382f585bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtNS0xLTEtMjkzMjE_58014d73-27f7-4fe6-9603-1ad8c5e3db61">457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtNy0xLTEtMjkzMjE_8150e27c-8193-4502-829f-631dcd74621c">44,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtMS0xLTEtMjkzMjE_9e7cec9a-1a1a-47fb-be58-d4f1b9851a2d">56,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtMy0xLTEtMjkzMjE_08161b01-a270-4bcd-8b10-8bfee09b0df0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtNS0xLTEtMjkzMjE_98318ee4-05b0-4c71-a658-bd65b1cd8afd">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtNy0xLTEtMjkzMjE_ed3ec232-c65a-46ae-8601-69751485a7ec">56,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb2c36817bb45738c25a5631ff9a54f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMy0xLTEtMS0yOTMyMQ_ca0714b3-49d0-42fb-817e-a40024c2952e">62,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb2c36817bb45738c25a5631ff9a54f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMy03LTEtMS0yOTMyMQ_bd092645-77cb-4bfb-af14-7ffc866514cf">62,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cdab202f75a4297866c250a068cd12d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfNi0xLTEtMS0yOTMyMQ_448ae6d7-6d6e-43bc-a69f-be2bcbd62b36">62,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cdab202f75a4297866c250a068cd12d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfNi03LTEtMS0yOTMyMQ_38afcbda-b2ca-4cc0-819f-009197f3e42b">62,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide871516fa03491795c8b51d22d71071_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC0xLTEtMS0yOTMyMQ_17b2c148-89d8-41b5-8f23-3a9cac458217">8,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide871516fa03491795c8b51d22d71071_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC0zLTEtMS0yOTMyMQ_17223223-22b7-4392-a5dc-1d3e836d6322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide871516fa03491795c8b51d22d71071_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC01LTEtMS0yOTMyMQ_9e61db42-4cee-4e57-9aac-f251d05c8e8c">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide871516fa03491795c8b51d22d71071_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC03LTEtMS0yOTMyMQ_402c11ad-2bb7-40ed-bac7-fb515df8a6a5">8,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS0xLTEtMS0yOTMyMQ_9da43022-c967-4bb6-ae22-11dfb1dfe480">37,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS0zLTEtMS0yOTMyMQ_9d565797-f175-4388-bd18-711834d36a8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS01LTEtMS0yOTMyMQ_a1e458da-d034-49f3-8aff-d7bced915b4b">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS03LTEtMS0yOTMyMQ_05e239cf-fe59-42d1-98b7-f7cb7e2b9efd">37,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtMS0xLTEtMjkzMjE_f5f9aafe-00b8-4e2e-bf83-6158e270163a">46,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtMy0xLTEtMjkzMjE_d023b511-7b94-40b0-8784-2be0411a9bf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtNS0xLTEtMjkzMjE_98cbe178-ed09-47b7-ad16-a4662cbfb73e">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtNy0xLTEtMjkzMjE_090cbfa5-a86c-4033-abe3-9df7c73f8283">46,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItMS0xLTEtMzc0MTY_cd243bf8-7a7c-4525-897c-cc60b929d3a2">13,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItMy0xLTEtMzc0MTY_ba8cf9f6-57a8-4516-a906-e1dd80e6c8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItNS0xLTEtMzc0MTY_c65dd550-8c0b-4f71-ad5b-2d4939fa658b">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItNy0xLTEtMzc0MTY_bb419982-58cb-43b2-8acd-426f6339a729">13,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtMS0xLTEtMzc0MTY_c35ef218-61af-4649-9d8d-4616431c8364">22,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtMy0xLTEtMzc0MTY_e645fcfb-bf5c-4a0e-be14-5b94326191fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtNS0xLTEtMzc0MTY_b79564eb-ec5d-4e9b-84eb-5fb3b8a57c9c">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtNy0xLTEtMzc0MTY_561a4164-0ece-48d6-a32b-6227ef2cd7dc">22,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtMS0xLTEtMzc0MTY_4473e704-c488-4db2-bfbe-0f8612ce69ad">35,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtMy0xLTEtMzc0MTY_7f0f373e-68a0-41a1-9513-8f58b507836b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtNS0xLTEtMzc0MTY_270b8d3e-531b-486c-905f-88ea1da16759">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtNy0xLTEtMzc0MTY_3849bbc1-50ac-4aeb-a024-04873403e98a">35,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual term to maturity of the $<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfMzQw_b80caff0-c2d9-4f96-a2a5-fa07a4d93e1d">84.1</ix:nonFraction>&#160;million of short-term marketable securities held by the Company as of March&#160;31, 2022 is less than one year.  As of March&#160;31, 2022, the Company held $<ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNDUz_42d38d88-82a7-4ffc-a6f9-facb1e832608">56.3</ix:nonFraction> million of long-term marketable securities with contractual maturities of more than one year, but less than five years.  As of December&#160;31, 2021, the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNTkz_2314e46c-c6e7-4d86-be28-40f0d77a2446">46.0</ix:nonFraction> million of short-term marketable securities had contractual maturities of less than one year, while the Company&#8217;s $<ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-5" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfMTA5OTUxMTYyODcxNw_10473f62-4961-4e4c-a5e5-458661de91e5">35.7</ix:nonFraction> million of long-term marketable securities had maturities of more than one year, but less than five years.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie3ba20a2d8054c588bf241179b44012c">There were <ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_6ecf2e13-3be5-4a18-a6b3-efd324977150"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_9811151a-049c-4ec5-91b3-2626c10c6564"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_c6b52913-f811-46e5-887d-63516c63058d"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_ccdd7243-efe6-43a4-831e-a1bd3eda27b8">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> realized gains or losses for the three months ended March 31, 2022 or 2021.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 11</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzE3MQ_80cb4674-fc74-4a4a-8292-7bc91f20fc77" continuedAt="i396bd68e9b514ce7a14f9fb09dfcaee1" escape="true">Investment in Genevant</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i396bd68e9b514ce7a14f9fb09dfcaee1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), its largest shareholder, to launch Genevant Sciences Ltd. (&#8220;Genevant&#8221;), a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company&#8217;s lipid nanoparticle (&#8220;LNP&#8221;) and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV, except to the extent certain rights had already been licensed to other third parties (the &#8220;Genevant License&#8221;). The Company retained all rights to its LNP and conjugate delivery platforms for HBV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Genevant License, as amended, if a third party sublicensee of intellectual property licensed by Genevant from the Company commercializes a sublicensed product, the Company becomes entitled to receive a specified percentage of certain revenue that may be received by Genevant for such sublicense, including royalties, commercial milestones and other sales-related revenue, or, if less, tiered low single-digit royalties on net sales of the sublicensed product. The specified percentage is <ix:nonFraction unitRef="number" contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331" decimals="INF" name="abus:SubLicensingRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMTYyNg_58975876-6e5e-4e44-9c01-26a654c011f3">20</ix:nonFraction>% in the case of a mere sublicense (i.e., naked sublicense) by Genevant without additional contribution and <ix:nonFraction unitRef="number" contextRef="i849f8840cc1f40369b37a736474e7316_D20220101-20220331" decimals="2" name="abus:BonaFideCollaborationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMTU2Mw_01c0ec98-cdc6-4436-8684-57d98f58894f">14</ix:nonFraction>% in the case of a bona fide collaboration with Genevant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, if Genevant receives proceeds from an action for infringement by any third parties of the Company&#8217;s intellectual property licensed to Genevant, the Company would be entitled to receive, after deduction of litigation costs, <ix:nonFraction unitRef="number" contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331" decimals="INF" name="abus:SubLicensingRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMjY3OQ_a9613d19-fa2c-44ce-b5da-58d6de535fc8">20</ix:nonFraction>% of the proceeds received by Genevant or, if less, tiered low single-digit royalties on net sales of the infringing product (inclusive of the proceeds from litigation or settlement, which would be treated as net sales). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounts for its interest in Genevant as equity securities without readily determinable fair values. Accordingly, an estimate of the fair value of the securities is based on the original cost less previously recognized equity method losses, less impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or a similar Genevant securities. As of March&#160;31, 2022, the carrying value of the Company&#8217;s investment in Genevant was <ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzA4OQ_2d7a7796-2a13-4202-bcdd-11d51949790c">zero</ix:nonFraction> and the Company owned approximately <ix:nonFraction unitRef="number" contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzEyOA_2e04eac6-f592-4ff3-804a-242a84ce213b">16</ix:nonFraction>% of the common equity of Genevant.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RleHRyZWdpb246ODdkYjRiMTUyYmNkNGZkYjlkMmU2ZGZkNTNjMWFiODVfMTM1_aa993319-7889-4bf1-8760-af1b57ef7661" continuedAt="iecf8d1b8acd44c2d932bba1ccdf99fa4" escape="true">Accounts payable and accrued liabilities</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iecf8d1b8acd44c2d932bba1ccdf99fa4"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RleHRyZWdpb246ODdkYjRiMTUyYmNkNGZkYjlkMmU2ZGZkNTNjMWFiODVfMTM3_06112874-6491-4977-bc33-9ed555348d1d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMi0xLTEtMS0yOTMyMQ_23d4a90a-f5f7-4686-b325-40e89ea677cd">1,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccountsPayableTradeCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMi0zLTEtMS0yOTMyMQ_20b99030-26e9-4ba3-ad83-09084e2ba1f9">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="abus:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMy0xLTEtMS0yOTMyMQ_bcbdaca9-0dd2-4122-b2c1-2c55d9b6ea8e">5,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="abus:AccruedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMy0zLTEtMS0yOTMyMQ_e25eafe9-b51f-4d57-9feb-2d9103e991b2">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fee accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNC0xLTEtMS0yOTMyMQ_66d0b9b5-af74-46fd-bb2e-e919689c63e5">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNC0zLTEtMS0yOTMyMQ_c4749ba1-9663-4479-b782-59ed89576c25">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="abus:AccruedPayrollCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNS0xLTEtMS0yOTMyMQ_0628bfc2-67df-4776-bae8-296c09d785f3">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="abus:AccruedPayrollCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNS0zLTEtMS0yOTMyMQ_7785a84a-5604-449d-91ae-42932d1413ea">4,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOC0xLTEtMS0yOTMyMQ_8599e00d-5566-47d6-95ed-251c406075fd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOC0zLTEtMS0yOTMyMQ_eb721ae9-aaff-47ae-a627-07a1660333d9">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOS0xLTEtMS0yOTMyMQ_19f1f8c5-f11e-4f16-b5e8-4902f44a51b8">8,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOS0zLTEtMS0yOTMyMQ_3fe54459-fb47-4828-9d40-c95cca9a9f74">10,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4d1c0ae544ca49e89401026bf23c9474_52"></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMzI0MQ_e96a0c2d-85d4-4277-9bb8-b0b2acb547a7" continuedAt="iaac6011b30df449492737a022c4c679f" escape="true">Sale of future royalties </ix:nonNumeric></span></div><ix:continuation id="iaac6011b30df449492737a022c4c679f" continuedAt="i64a4a906265748ba975510972707b0c0"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the &#8220;Agreement&#8221;) with the Ontario Municipal Employees Retirement System (&#8220;OMERS&#8221;), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Patisiran) (&#8220;ONPATTRO&#8221;), an RNA interference therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONPATTRO utilizes the Company&#8217;s LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &#8220;LNP License Agreement&#8221;).&#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from <ix:nonFraction unitRef="number" contextRef="ie4dc98c87a0247e6a3f4347246739782_D20190702-20190702" decimals="4" name="abus:RoyaltyPercentageofInterestSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfNzg3_9152d1ec-b350-4b74-beae-0f15f0bb30b7">1.00</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9e0286773ab94cf7a483c6b8bc8e1785_D20190702-20190702" decimals="4" name="abus:RoyaltyPercentageofInterestSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfNzkz_b7bba55f-1fb3-47f1-9e40-a8e33bc8a122">2.33</ix:nonFraction>% after offsets, with the highest tier applicable to annual net sales above $<ix:nonFraction unitRef="usd" contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702" decimals="-6" name="abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfODcw_3a9b1670-8398-412e-80c5-fad1aa02a9f4">500</ix:nonFraction> million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $<ix:nonFraction unitRef="usd" contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101" decimals="-6" name="abus:GrossProceedsFromRoyaltyInterestSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfOTUy_524577a2-8427-4e4c-97c4-f5cbe177ed28">20</ix:nonFraction> million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $<ix:nonFraction unitRef="usd" contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702" decimals="-6" name="abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA1Mg_f3a7c5d3-35e6-4b3f-b953-729264887171">30</ix:nonFraction> million in royalties, at which point <ix:nonFraction unitRef="number" contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702" decimals="INF" name="abus:RoyaltyGuaranteesCommitmentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA4NA_ea232e60-925d-453f-bfab-32cad529cac0">100</ix:nonFraction>% of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to $<ix:nonFraction unitRef="usd" contextRef="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702" decimals="-6" name="abus:RoyaltyPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTIyNg_ab72d9ca-e5b4-46ed-ae36-df34ef823a59">30</ix:nonFraction> million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i64a4a906265748ba975510972707b0c0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702" decimals="-6" name="abus:RoyaltyPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTM3Nw_0efef4b9-80ec-484a-98a9-c72626ad0d57">30</ix:nonFraction> million in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as $<ix:nonFraction unitRef="usd" contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702" decimals="-5" name="abus:TransactionCostsRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTU3NA_f0c59fd0-7c2c-45d4-8bf8-6cdc201b5bfc">1.5</ix:nonFraction> million of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. As of March&#160;31, 2022, the Company estimated an effective annual interest rate of approximately <ix:nonFraction unitRef="number" contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331" decimals="2" name="abus:EffectiveAnnualInterestRateOfRoyaltyLiability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTgwNA_abfa3e54-7fff-4bf4-af63-2220a5dc5f5c">16</ix:nonFraction>%.  Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability is effectively repaid over the life of the Agreement. From the inception of the royalty sale through March&#160;31, 2022, the Company has recorded an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331" decimals="-5" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMjU0OQ_7a75d914-6d91-4680-bf1e-13e8e862856c">12.5</ix:nonFraction> million of non-cash royalty revenue for royalties earned by OMERS. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company&#8217;s control. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company recognized non-cash royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331" decimals="-3" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTYwMw_07cf36d0-0a37-4153-91fe-bf9f5e7a537a">1.4</ix:nonFraction> million and non-cash interest expense of $<ix:nonFraction unitRef="usd" contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTg5NQ_6b9bb77a-da29-4fd7-89bb-4e712c154e03">0.5</ix:nonFraction> million. During the three months ended March 31, 2021, the Company recognized non-cash royalty revenue of $<ix:nonFraction unitRef="usd" contextRef="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331" decimals="-3" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTYyMQ_f8c96f99-f763-4d07-8a1a-bea4556c1784">1.0</ix:nonFraction> million and related non-cash interest expense of $<ix:nonFraction unitRef="usd" contextRef="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTg5OQ_c8e5313a-4486-4f9f-99d3-283402074fe8">0.8</ix:nonFraction> million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMzIzNA_9e6e5b07-546f-4043-9196-02b1bbd04fee" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the activity related to the net liability for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfMy0xLTEtMS0yOTMyMQ_f549695e-3b75-40b5-9255-11c06c34177d">16,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfMy0zLTEtMS0yOTMyMQ_b7db8f07-d14d-40fe-8b00-f573f667e21d">19,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNC0xLTEtMS0yOTMyMQ_e45816c1-44fb-40e9-be9e-ddbaa5daf1df">1,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNC0zLTEtMS0yOTMyMQ_bdd85158-4aea-49e0-9751-43c773b3a51a">959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNS0xLTEtMS0yOTMyMQ_29ef9c6f-4315-4207-ae1b-b07a95fdaacf">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNS0zLTEtMS0yOTMyMQ_d9284b35-204d-4ad5-9e22-7dc7056ca267">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNi0xLTEtMS0yOTMyMQ_58df21e2-853f-4cdf-a870-0ec6212fdfe9">15,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331" decimals="-3" name="abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNi0zLTEtMS0yOTMyMQ_432e0a15-0e41-43a3-892b-bcf8bbfca454">19,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalty from the LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#8220;Acuitas&#8221;). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjgzNw_bdaea566-435a-4fd7-9955-3806e490c323" continuedAt="ic660b40676bf4b87a7ea0f784ca79e64" escape="true">Contingencies and commitments</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic660b40676bf4b87a7ea0f784ca79e64" continuedAt="ib775eaa9d16a426db657c2b774ddc53e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arbitration with the University of British Columbia </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (&#8220;UBC&#8221;), as well as by the Company that was subsequently assigned to UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to certain third parties, including Alnylam.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, UBC delivered to the Company a notice of arbitration alleging that under the cross license between UBC and Arbutus, it is due royalties of $<ix:nonFraction unitRef="usd" contextRef="i167905b8454f403bbc363d3a741afda6_D20201218-20201218" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMTE2Nw_6adeff7c-3b85-465c-9ced-d784fa6c5661">2.0</ix:nonFraction> million plus interest arising from the Company&#8217;s sale to OMERS of part of its royalty interest on future global net sales of ONPATTRO, currently being sold by Alnylam. Oral hearings for this matter were held on April 25-26, 2022. The Company does not believe that any royalties are due to UBC and the Company intends to vigorously contest UBC&#8217;s allegation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ib775eaa9d16a426db657c2b774ddc53e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement with Enantigen</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Arbutus Inc., the Company&#8217;s wholly-owned subsidiary, acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;) pursuant to a stock purchase agreement. The amount paid to Enantigen&#8217;s selling shareholders could be up to an additional $<ix:nonFraction unitRef="usd" contextRef="i22f8361c99954dfa827a9008f0da81b3_I20141031" decimals="-5" name="abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMTg1Nw_d41ba7e7-2426-47d1-bc07-389fee3ae90b">102.5</ix:nonFraction> million in sales performance milestones in connection with the sale of the first commercialized product by the Company for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of $<ix:nonFraction unitRef="usd" contextRef="i22f8361c99954dfa827a9008f0da81b3_I20141031" decimals="-5" name="abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjIwNQ_d1041672-7718-4268-8033-0979b75f194b">1.0</ix:nonFraction> million that, if paid, would be offset against the Company&#8217;s milestone payment obligations.  Certain other development milestones related to the acquisition were tied to programs which are no longer under development by the Company, and therefore the contingency related to those development milestones is <ix:nonFraction unitRef="usd" contextRef="i1ce501d18c8a4c21ab64d7e145ce4bb0_I20141031" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjUwNg_2c22073a-f6f2-4296-9253-4989a46fec5f">zero</ix:nonFraction>.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is a financial liability and is measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statements of operations and comprehensive loss (see note 3).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="i9b3a998dc61042eda3caff10aef9779e_I20220331" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjgyMw_9a5ad74e-1e36-4a34-b564-871c51a743c3">5.5</ix:nonFraction> million as of March&#160;31, 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTYzMzUxMjE_1b7aa693-88b8-4af8-a1dc-c8300508be9f" continuedAt="i07d638c748bc47f9bab0c288d1ed8e23" escape="true">Collaborations, contracts and licensing agreements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i07d638c748bc47f9bab0c288d1ed8e23" continuedAt="i981683a2782d478b890c9fc1dd0820fd"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu Pharmaceutical Co., Ltd.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company entered into a technology transfer and licensing agreement (the &#8220;License Agreement&#8221;) with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;), pursuant to which the Company granted Qilu a sublicensable, royalty-bearing license, under certain intellectual property owned by the Company, which is non-exclusive as to development and manufacturing and exclusive with respect to commercialization of AB-729, including pharmaceutical products that include AB-729, for the treatment or prevention of hepatitis B in China, Hong Kong, Macau and Taiwan (the &#8220;Territory&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration for the rights granted by the Company, Qilu paid the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzY3OQ_7a9691df-25e1-4d0b-b588-fb09d922f805">40.0</ix:nonFraction> million on January 5, 2022, and agreed to pay the Company milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213" decimals="-3" name="abus:PotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzY5Ng_7f560ba5-34d6-4241-bec6-b9c0ba2fd9dc">245.0</ix:nonFraction> million, net of withholding taxes, upon the achievement of certain technology transfer, development, regulatory and commercialization milestones. Qilu also paid $<ix:nonFraction unitRef="usd" contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzcyNw_36b8ecd0-e59a-4643-908f-abe42c17acfd">4.4</ix:nonFraction> million of withholding taxes to the Chinese taxing authority on the Company&#8217;s behalf, related to the upfront cash payment.  In addition, Qilu agreed to pay the Company double digit royalties into the low twenties percent based upon annual net sales of AB-729 in the Territory. The royalties are payable on a product-by-product and region-by-region basis, subject to certain limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval for, and commercializing AB-729 for the treatment or prevention of hepatitis B in the Territory. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one AB-729 product candidate in the Territory. A joint development committee has been established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans. Both parties also have entered into a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of AB-729 necessary for Qilu to develop and commercialize in the Territory until the Company has completed manufacturing technology transfer to Qilu and approval of a product manufactured by Qilu, or its designated contract manufacturing organization, by the National Medical Products Administration in China for AB-729.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the execution of the License Agreement, the Company entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Anchor Life Limited, a company established pursuant to the applicable laws and regulations of Hong Kong and an affiliate of Qilu (the &#8220;Investor&#8221;), pursuant to which the Investor purchased <ix:nonFraction unitRef="shares" contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDEzOQ_8241c280-64a3-4678-86a0-f2a82713b0e8">3,579,952</ix:nonFraction> of the Company&#8217;s common shares, without par value (the &#8220;Common Shares&#8221;), at a purchase price of USD $<ix:nonFraction unitRef="usdPerShare" contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDExNw_078cc951-a0b0-4886-aab2-0745f97d36f8">4.19</ix:nonFraction> per share, which was a <ix:nonFraction unitRef="number" contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213" decimals="2" name="abus:PremiumonClosingStockPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDEzMw_0632c641-d9f1-45d0-8b4e-b798fbed6127">15</ix:nonFraction>%  premium on the thirty-day average closing price of the Common Shares as of the close of trading on December 10, 2021 (the &#8220;Share Transaction&#8221;). The Company received $<ix:nonFraction unitRef="usd" contextRef="i6b9336fe97b44836842a01da01d42937_D20220106-20220106" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDE3Mg_38a7c8b0-a0b1-4886-ac14-faff6bb2355a">15.0</ix:nonFraction> million of gross proceeds from the Share Transaction on January 6, 2022. The Common Shares sold to the Investor in the Share Transaction represented approximately <ix:nonFraction unitRef="number" contextRef="if9829026bc73479093b8029eac0806e0_I20211213" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDIwNA_2e54c6e0-4f73-4818-8b1a-29337c2bef20">2.5</ix:nonFraction>% of the Common Shares outstanding immediately prior to the execution of the Share Purchase Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement falls under the scope of ASC 808 as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for some aspects of this arrangement, including for the delivery of a good or service (i.e., a unit of account). In accordance </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i981683a2782d478b890c9fc1dd0820fd" continuedAt="i3a28cb63c36c4ce0b303c8f9f4452be7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the guidance, the Company identified the following commitments under the arrangement: (i) rights to develop, use, sell, have sold, offer for sale and import any product comprised of Licensed Product (the &#8220;Qilu License&#8221;) and (ii) drug supply obligations and manufacturing technology transfer (the &#8220;Manufacturing Obligations&#8221;). The Company determined that these two commitments are not distinct performance obligations for purposes of recognizing revenue as the manufacturing process is highly specialized and Qilu would not be able to benefit from the Qilu License without the Company&#8217;s involvement in the manufacturing activities until the transfer of the manufacturing know-how is complete. As such, the Company will combine these commitments into one performance obligation to which the transaction price will be allocated to and will recognize this transaction price associated with the bundled performance obligation over time using an inputs method based on labor hours expended by the Company on its Manufacturing Obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price of the combined performance obligation to be $<ix:nonFraction unitRef="usd" contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzkwOA_1bed5c96-9c8a-4f1f-9c70-8057bed101b4">49.1</ix:nonFraction> million, which includes the $<ix:nonFraction unitRef="usd" contextRef="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4Mzk0MA_f029e2b2-76b5-4591-bda7-92ff9716f521">40.0</ix:nonFraction> million upfront fee, $<ix:nonFraction unitRef="usd" contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4Mzk3Mw_43db5e92-a141-4c17-a674-2df84c9fa6b2">4.4</ix:nonFraction> million of withholding taxes paid by Qilu on behalf of the Company, the premium paid for the Share Transaction of $<ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDAwMw_82c05527-a9b1-4325-ad31-9928182072f7">4.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTAzMQ_26e996d6-e1f8-433a-aa58-d2c3e85524fe">0.7</ix:nonFraction> million associated with certain manufacturing costs expected to be reimbursed by Qilu. The Company determined the Milestone Payments to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTYzMzUxMTk_fa5f9cd9-fd3d-4581-9916-ff5bca1ee04a" continuedAt="i3bef742ceb544485873c7dc2f6e4b6ba" escape="true">The following table outlines the transaction price and the changes to the related asset and liability balances during the three months ended March&#160;31, 2022:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i3bef742ceb544485873c7dc2f6e4b6ba"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:30.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.067%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.674%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.676%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Collaboration Revenue Recognized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred License Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined performance obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0xLTEtMS0zMDkxMw_c31ea57a-0a76-4402-8f00-e5dcba3c16be">49,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0yLTEtMS0zMDkxMw_1772d9f9-3953-4550-8910-7e7bc04c1cb6">9,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331" decimals="-3" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0zLTEtMS0zMDkxMw_d9ee14f3-a46d-4e13-a3cb-0544b4f0fa83">39,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less contract asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331" decimals="-3" name="us-gaap:RecoveryOfDirectCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMy0zLTEtMS0zMDkxMw_4bb348a3-1b65-4a82-b03b-6cdd8c2423bf">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNC0zLTEtMS0zMDkxMw_b077a667-357b-4a82-a8e4-9cceeedc17fc">38,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of deferred license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331" decimals="-3" name="us-gaap:DeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNi01LTEtMS0zNTg5MA_f95a1854-832c-409d-af0e-d663d9900eb7">23,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f3d36adae54e1d9276dd03b947cf45_I20220331" decimals="-3" name="us-gaap:DeferredRevenueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNS0zLTEtMS0zMDkxMw_250519d8-c8c6-45cf-b429-51c9ef5928a5">15,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the balance of the deferred license revenue was $<ix:nonFraction unitRef="usd" contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTEwMA_8fbdf226-d3e4-4a09-a8d1-f2ba13c7b760">39.5</ix:nonFraction> million, which, in accordance with ASC 210-20, was partially offset by the contract asset associated with the manufacturing cost reimbursement of $<ix:nonFraction unitRef="usd" contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331" decimals="-5" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTA2Ng_a438420c-be86-4803-9035-cdc23e6e2199">0.7</ix:nonFraction>&#160;million, resulting in a net deferred license revenue liability of $<ix:nonFraction unitRef="usd" contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDM2MQ_fe78728e-9604-45a1-9e1f-b1682ca0686e">38.8</ix:nonFraction> million. The $<ix:nonFraction unitRef="usd" contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTQ5NzU1ODE5Mjc4OQ_36b8ecd0-e59a-4643-908f-abe42c17acfd">4.4</ix:nonFraction> million of withholding taxes paid by Qilu on behalf of the Company was recorded as income tax expense during the three months ended March&#160;31, 2022. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213" decimals="-3" name="us-gaap:OtherDeferredCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTY0OTI2NzQ2NTM2MA_151d7176-a84e-4837-98ec-9cd16f2e8e38">0.6</ix:nonFraction> million of incremental costs in obtaining the Qilu License, which the Company capitalized in other current assets and other assets and will amortize as a component of general and administrative expense commensurate with the recognition of the combined performance obligation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reevaluates the transaction price and the total estimated labor hours expected to be incurred to satisfy the performance obligations and adjusts the deferred revenue at the end of each reporting period. Such changes will result in a change to the amount of collaboration revenue recognized and deferred revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccitech plc</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a clinical collaboration agreement with Vaccitech plc (&#8220;Vaccitech&#8221;) to evaluate AB-729 followed by Vaccitech&#8217;s VTP-300, a proprietary T cell stimulating therapeutic vaccine, in nucleos(t)ide reverse transcriptase inhibitor (&#8220;NrtI&#8221;)-suppressed patients with cHBV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for managing this Phase 2a proof-of-concept clinical trial, subject to oversight by a joint development committee comprised of representatives from the Company and Vaccitech. The Company and Vaccitech retain full rights to their respective product candidates and will split all costs associated with the clinical trial.  </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i3a28cb63c36c4ce0b303c8f9f4452be7" continuedAt="i02554262f5a74e17ad8fc6194770a4c8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assembly Biosciences, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a clinical collaboration agreement with Assembly Biosciences, Inc. (&#8220;Assembly&#8221;) to evaluate AB-729 in combination with Assembly&#8217;s lead HBV core inhibitor (capsid inhibitor) candidate vebicorvir (&#8220;VBR&#8221;) and standard-of-care NA therapy for the treatment of patients with HBV infection. The Company and Assembly are sharing in the costs of the collaboration. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i702949ca2cfd4a0a9bb7f02fd91035b8_D20220101-20220331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjQ1OA_eb48db4b-b4ee-46e0-a6d6-7751b6b9f987">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib01ce59d6936428c930e28b71f7c5359_D20210101-20210331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjc0ODc3OTEwMzkzNw_53baa5dc-8c95-4a74-b417-a7acbcffd132">0.8</ix:nonFraction> million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statement of operations and comprehensive loss. Except to the extent necessary to carry out Assembly&#8217;s responsibilities with respect to the collaboration trial, the Company has not provided any license grant to Assembly for use of its AB-729 compound.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">X-Chem, Inc. and Proteros biostructures GmbH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into a discovery research and license agreement with X-Chem, Inc. (&#8220;X-Chem&#8221;) and Proteros biostructures GmbH (&#8220;Proteros&#8221;) to focus on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This collaboration brings together the Company&#8217;s expertise in the discovery and development of antiviral agents with X-Chem&#8217;s industry leading DNA-encoded library (DEL) technology and Proteros&#8217; protein sciences, biophysics and structural biology capabilities and provides important synergies to potentially identify safe and effective therapies against coronaviruses including SARS-CoV-2. The collaboration allows for the rapid screening of one of the largest small molecule libraries against M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an essential protein required for the virus to replicate itself) and the use of state-of-the-art structure guided methods to rapidly optimize M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitors, which the Company could potentially progress to clinical candidates. The agreement provides for payments by the Company to X-Chem and Proteros upon satisfaction of certain development, regulatory and commercial milestones, as well as royalties on sales. Through this collaboration, the Company has identified and obtained a worldwide exclusive license to several molecules that inhibit M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks.  The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i0f12239ea971423693eb1924756cc84c_D20220101-20220331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY0NTUzNw_121d34a0-e3b0-407c-86fd-af509516acd7">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic9be38c6e9064432bd40073b87596f3c_D20210101-20210331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjc0ODc3OTEwNDc4Nw_85ee28c3-a849-4f3b-b38c-1bb311ee5323">0.9</ix:nonFraction> million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Entitlements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="product" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="abus:RoyaltyEntitlements" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDI1Ng_e7cba949-5110-4fc1-b775-0d7001282c8d">two</ix:nonFraction> royalty entitlements to Alnylam Pharmaceuticals, Inc.&#8217;s (&#8220;Alnylam&#8221;) global net sales of ONPATTRO.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company&#8217;s LNP technology. Alnylam launched ONPATTRO, the first approved application of the Company&#8217;s LNP technology, in 2018. Under the terms of this license agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from <ix:nonFraction unitRef="number" contextRef="iecc67e9256ab4b9dbea33b02a1658a89_D20130101-20130630" decimals="4" name="abus:RoyaltyPercentageofInterestSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDk1MA_baec0912-2289-4b21-a2d0-2605e0091f6d">1.00</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i0cae881ec75e4bc18cff9b5347823e59_D20130101-20130630" decimals="4" name="abus:RoyaltyPercentageofInterestSold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDk1NQ_b8e2078a-7a27-4f87-bed3-d3aa7c19f695">2.33</ix:nonFraction>% after offsets, with the highest tier applicable to annual net sales above $<ix:nonFraction unitRef="usd" contextRef="ie759772fc0d34889b5b1773813066150_D20130101-20130630" decimals="-6" name="abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTAzMg_a6d2fde9-e438-4efe-9e21-c16af1ec2e94">500</ix:nonFraction> million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $<ix:nonFraction unitRef="usd" contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101" decimals="-6" name="abus:GrossProceedsFromRoyaltyInterestSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTEwMQ_73cf6f5a-8620-4c51-b7f3-094cf9c94b6a">20</ix:nonFraction> million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $<ix:nonFraction unitRef="usd" contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101" decimals="-6" name="abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTIwMQ_35a76eec-355b-4f13-b9b0-6019b3e03eee">30</ix:nonFraction> million in royalties, at which point <ix:nonFraction unitRef="number" contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101" decimals="INF" name="abus:RoyaltyGuaranteesCommitmentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTIzMw_7ffb855e-c62e-4a98-bbd7-b0d4b86a806d">100</ix:nonFraction>% of this royalty entitlement on future global net sales of ONPATTRO will revert back to the Company. OMERS has assumed the risk of collecting up to $<ix:nonFraction unitRef="usd" contextRef="i46281ecd5fb744a99a4fb28bba9e853c_I20190101" decimals="-6" name="abus:RoyaltyPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTM4Mw_8043c9ac-7e8f-439b-8147-43db2fbbce08">30</ix:nonFraction> million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to the Company, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part. From the inception of the royalty sale through March&#160;31, 2022, an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331" decimals="-5" name="abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY0NjU2OQ_7a75d914-6d91-4680-bf1e-13e8e862856c">12.5</ix:nonFraction> million of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">royalties have been earned by OMERS. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has rights to a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#8220;Acuitas&#8221;).&#160; This royalty entitlement from Acuitas has been retained by the Company and was not part of the royalty entitlement sale to OMERS. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i02554262f5a74e17ad8fc6194770a4c8"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNjA2Nw_cf0dd0a9-cb31-484b-86ee-134f12bcf4f7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborations and licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acuitas Therapeutics, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518670b3fac0479e89bccbd3cf48a756_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNC0xLTEtMS0yOTMyMQ_8a2c624e-8d2a-470f-8e94-6c970a99904e">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3e5de0afd64224841a930f2a7a0b40_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNC0zLTEtMS0yOTMyMQ_7288afe7-30b3-425a-bbee-3d80dee76dd3">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qilu Pharmaceutical Co., Ltd.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad95e89d07d4219962809e6980f2c99_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNS0xLTEtMS0yOTMyMQ_c6dac01e-3d41-457d-977e-4b79621c2aba">9,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc54f0d5f1e425684acf6e743b66eaf_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNS0zLTEtMS0yOTMyMQ_795db415-d5cf-4f50-9195-c326151dcfed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other milestone and royalty payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a7bfc3b496414582720db787c9cf6f_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNi0xLTEtMS0yOTMyMQ_b359a877-80b1-43b2-b010-d8397d12e441">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i232b5a40e86b4942a256e843e353e388_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNi0zLTEtMS0yOTMyMQ_5685c87e-46a0-41d8-9c85-a4c527e186fd">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnylam Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6007cbaa2fc842dbb22efaa19e85a21c_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOC0xLTEtMS0yOTMyMQ_0748b17f-8167-45dd-88ba-7293cd47cec6">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c626debfbf4e20bbb17e393ea68c3d_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOC0zLTEtMS0yOTMyMQ_926327a8-9a48-4f8d-a7de-83553e06e697">959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOS0xLTEtMS0yOTMyMQ_3db955cc-9611-4a01-b7bd-623219bced14">12,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOS0zLTEtMS0yOTMyMQ_f79da025-66ef-4288-b9a2-6e6796d45ebd">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4d1c0ae544ca49e89401026bf23c9474_61"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.         <ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTYyOTQ4Nzg_466d747e-0a45-4f52-a3f5-c2256a6c50b4" continuedAt="i16a3e7a1d434407e8d216ceab99046dc" escape="true">Shareholders&#8217; equity</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i16a3e7a1d434407e8d216ceab99046dc" continuedAt="if92a7d2dac3a4902a7196a8aa066a8b8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s authorized share capital consists of an unlimited number of common shares and preferred shares, without par value, and <ix:nonFraction unitRef="shares" contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDg3NA_eef6e3ad-6da0-4980-9b53-4a0264444282">1,164,000</ix:nonFraction>  Series A participating convertible preferred shares, without par value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Open Market Sale Agreement with Jefferies LLC (&#8220;Jefferies&#8221;) dated December 20, 2018, as amended by Amendment No. 1, dated December 20, 2019, Amendment No. 2, dated August 7, 2020 and Amendment No. 3, dated March 4, 2021 (as amended, the &#8220;Sale Agreement&#8221;), under which it may issue and sell common shares, from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2019, the Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the &#8220;SEC&#8221;) (File No. 333-235674) and accompanying base prospectus, which was declared effective by the SEC on January 10, 2020 (the &#8220;January 2020 Registration Statement&#8221;), for the offer and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i95f34ecb804c43bd860c37e292eda8dc_I20200110" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDc4NQ_106619eb-8440-4106-85a1-64ddff1240cf">150.0</ix:nonFraction>&#160;million of the Company&#8217;s securities. The January 2020 Registration Statement also contained a prospectus supplement in connection with the offering of up to $<ix:nonFraction unitRef="usd" contextRef="i48fd91415d144f359a29ef040e182e92_I20200110" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgwMQ_605a3781-a1a7-41c5-a345-6c84651a9ec5">75.0</ix:nonFraction>&#160;million of the Company&#8217;s common shares pursuant to the Sale Agreement. This prospectus supplement was fully utilized during 2020. On August 7, 2020, the Company filed a prospectus supplement with the SEC (the &#8220;August 2020 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $<ix:nonFraction unitRef="usd" contextRef="i721c0159d357459e82fda7a1d2aaa5a2_I20200807" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgxNg_a340715c-3736-4738-866e-9065a4201da7">75.0</ix:nonFraction>&#160;million of its common shares pursuant to the Sale Agreement under the January 2020 Registration Statement. The August 2020 Prospectus Supplement was fully utilized during 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-248467) and accompanying base prospectus, which was declared effective by the SEC on October 22, 2020 (the &#8220;October 2020 Registration Statement&#8221;), for the offer and sale of up to $<ix:nonFraction unitRef="usd" contextRef="ida4e708fcedd480aa26d4c73a4f87927_I20201022" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgzMQ_1ec8f8fa-a75a-4383-99b9-c1641491dd9b">200.0</ix:nonFraction>&#160;million of the Company&#8217;s securities. On March 4, 2021, the Company filed a prospectus supplement with the SEC (the &#8220;March 2021 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $<ix:nonFraction unitRef="usd" contextRef="ieb32b3f5a01140a19a6306f86a2a8fd5_I20210304" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfNzI1_05dbc33d-3a7f-4684-b204-c2639158cda9">75.0</ix:nonFraction> million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. The March 2021 Prospectus Supplement was fully utilized during 2021. On October 8, 2021, the Company filed a prospectus supplement with the SEC (the &#8220;October 2021 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $<ix:nonFraction unitRef="usd" contextRef="iab6748705d0d4226ba4a82a1e22ee083_I20211008" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3ODEzMw_5ed62e6d-8cf3-40e0-89fc-94ae9bc25c69">75.0</ix:nonFraction>&#160;million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Company filed a prospectus supplement with the SEC (the &#8220;March 2022 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $<ix:nonFraction unitRef="usd" contextRef="ia52a417f6ada4560b9f6eb2b6fd7a96a_I20220303" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDg0Nw_8332e85e-7b55-44ad-b15d-fc877f292da3">100.0</ix:nonFraction>&#160;million of its common shares pursuant to the Sale Agreement under: (i) the January 2020 Registration Statement; (ii) the October 2020 Registration Statement; and (iii) a shelf registration statement on Form S-3 (File No. 333-260782) that was declared effective by the SEC on November 18, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 , the Company issued <ix:nonFraction unitRef="shares" contextRef="i2bf4d6c3fa5a4105a94421a222392925_D20220101-20220331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfODUw_84a4d90c-83f7-4353-ba72-a9e89418fa3c">69,048</ix:nonFraction> common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i670e4df1980948ec8c216e9200afc61f_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfOTY0_10c35e94-9ee6-4558-9f5c-f8b5230a36bf">0.3</ix:nonFraction> million. For the three months ended March 31, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i5f2e4c170332429cb6b01ee5963528a9_D20210101-20210331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTAyMA_979e67fe-3548-4b40-b962-6a4c356d2f01">6,395,780</ix:nonFraction> common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i045ad8ba8ec9498a8558014661ce50fe_D20210101-20210331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTEzNA_bb356f76-ba00-4809-9739-4012ffed9227">26.4</ix:nonFraction> million. As of March&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i6dd670c983a7433cb7bd93372158078d_I20220331" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NzIwMg_2ddc86e4-89fd-45f9-ad0d-89976cbb310e"><ix:nonFraction unitRef="usd" contextRef="ida00744ff3624de0be467e4cae72015e_I20220331" decimals="-5" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NzIwMg_b771850c-e8e5-49c1-9e32-04b868f26aff">152.0</ix:nonFraction></ix:nonFraction> million remaining available in aggregate under the October 2021 Prospectus Supplement and the March 2022 Prospectus Supplement.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if92a7d2dac3a4902a7196a8aa066a8b8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMzM0Mg_0c9ada2f-286d-40cc-995c-33542c0aa438" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes information about the Company&#8217;s stock based compensation for the three months ended March&#160;31, 2022 and 2021 and the expense recognized in the condensed consolidated statements of operations: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a5dd2c6ac51433dbaefbe4e3fc47c85_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfMy0xLTEtMS0yOTMyMQ_e3a14b30-3230-444c-a4c5-7dd3c0d1eca1">4,372,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55d02dff95ec415dab33999ff0c85e85_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfMy0zLTEtMS0yOTMyMQ_ccbdbc00-7f93-448e-b875-ce15c7e4da8b">2,896,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNC0xLTEtMS0yOTMyMQ_046fec56-717a-4e6b-bde3-bfe6eaef076c">2.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNC0zLTEtMS0yOTMyMQ_4f26c23b-6eeb-4bbf-adb5-3583c13f8829">4.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98fa33af9af34a29a59381fcf1cbe51d_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNi0xLTEtMS0yOTMyMQ_101ef21f-29da-4243-a5a0-2a41bf603187">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64dd48949e4cba85f1ccfe32f2819e_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNi0zLTEtMS0yOTMyMQ_e457a622-0428-4fd4-81e0-43568857b443">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3988f17b1bc94d529eadea44681fdf65_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNy0xLTEtMS0yOTMyMQ_db1192bf-e719-4fa8-a1b0-b55e90ba01b6">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e6d8e3249e848a0b9453c69b8b92b5d_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNy0zLTEtMS0yOTMyMQ_38405b47-8197-4fed-8d3a-de93089aa3be">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfOC0xLTEtMS0yOTMyMQ_f4e96de6-148e-4ae3-aab5-e52069896541">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfOC0zLTEtMS0yOTMyMQ_d3d4cbc2-a0b6-48e6-a74f-d757d7cc9d3a">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a subscription agreement with Roivant for the sale of Preferred Shares to Roivant for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTkyMA_dfbac869-f68c-46b4-8680-ee9487398a90">116.4</ix:nonFraction>&#160;million.  The Preferred Shares were non-voting and were convertible into common shares at a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjAyNw_db3953d6-acc1-48d4-91e9-84fddd486bdd">7.13</ix:nonFraction> per share (which represented a <ix:nonFraction unitRef="number" contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002" decimals="2" name="abus:PremiumonClosingStockPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjA2MA_9c5a5129-5509-4a8b-afb6-df4561cb3501">15</ix:nonFraction>% premium to the closing price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjA5NQ_973c5f71-0a9a-47c6-b2c7-97040fe38f8b">6.20</ix:nonFraction> per share). The purchase price for the Preferred Shares plus an amount equal to <ix:nonFraction unitRef="number" contextRef="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjE3OA_7d5f90e2-8bec-4453-9a18-0cef95d742ec">8.75</ix:nonFraction>% per annum, compounded annually, was subject to mandatory conversion into common shares on October 18, 2021, at which time the Preferred Shares were converted into <ix:nonFraction unitRef="shares" contextRef="i9ca92d833848428fbad2a29503fd9fbd_I20211018" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTYzMjU1OQ_854cfc97-f330-43af-8c2d-bcab68467d58">22,833,922</ix:nonFraction> common shares and both the lockup and standstill periods that Roivant had previously agreed to expired. As of March&#160;31, 2022, Roivant owned approximately <ix:nonFraction unitRef="number" contextRef="iac91ec4cb9804633b6568f3d3cafd8e5_I20220331" decimals="2" name="abus:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NTA4Nw_42537612-4091-4629-883c-72a4dbfa9543">26</ix:nonFraction>% of the Company&#8217;s outstanding common shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the Preferred Shares wholly as equity with no bifurcation of the conversion feature from the host contract, given that the Preferred Shares could not be cash settled and the redemption features were within the Company&#8217;s control, which included a fixed conversion ratio with predetermined timing and proceeds. The Company accrued for the <ix:nonFraction unitRef="number" contextRef="i0515a8eeb4984632a6fdb800c50fd8bf_D20220101-20220331" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMzE2Mg_df87a483-8c9a-490d-bc7f-d6c09e291255">8.75</ix:nonFraction>% per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see statement of stockholders&#8217; equity).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_64"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160; &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMzEx_d5d41ac0-fdba-4ad9-a311-9630de9bfb39" continuedAt="iaa08c02b9e694d359c21ac74fe76cde2" escape="true">Related party transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa08c02b9e694d359c21ac74fe76cde2">During the three months ended March&#160;31, 2022 and 2021, Genevant purchased certain administrative services from the Company. Income from these services was less than $<ix:nonFraction unitRef="usd" contextRef="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_16d1ed7b-89d6-4ab3-aee1-da7b1a86e3f4"><ix:nonFraction unitRef="usd" contextRef="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_9ab63c71-7033-4d55-913e-a5fe0de02667"><ix:nonFraction unitRef="usd" contextRef="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_9cbe55c7-b3c6-4f18-93fd-fcd2dd5eef00"><ix:nonFraction unitRef="usd" contextRef="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331" decimals="-5" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_cd1e1228-eb6c-4b67-b30a-46cf441abaf0">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million in both periods and is netted against research and development expenses in the condensed consolidated statements of operations.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis by our management of our financial position and results of operations in conjunction with our audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and our unaudited condensed consolidated financial statements for the three months ended March 31, 2022. Our consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles and are presented in U.S. dollars.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_70"></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REFERENCES TO ARBUTUS BIOPHARMA CORPORATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form 10-Q (&#8220;Form 10-Q&#8221;), the &#8220;Company,&#8221; &#8220;Arbutus,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Arbutus Biopharma Corporation and its consolidated subsidiaries, and &#8220;our board of directors&#8221; refers to the board of directors of Arbutus Biopharma Corporation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q contains &#8220;forward-looking statements&#8221; or &#8220;forward-looking information&#8221; within the meaning of applicable United States and Canadian securities laws (we collectively refer to these items as &#8220;forward-looking statements&#8221;). Forward-looking statements are generally identifiable by use of the words &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;budgets,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and similar expressions that are not based on historical fact or that are predictions of or indicate future events and trends, and the negative of such expressions. Forward-looking statements in this Form 10-Q, including the documents incorporated by reference, include statements about, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy, future operations, pre-clinical research, pre-clinical studies, clinical trials, prospects and the plans of management;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for our product candidates to achieve their desired or anticipated outcomes;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected cost, timing and results of our clinical development plans and clinical trials, including our clinical collaborations with third parties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business and clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery, development and commercialization of a curative combination regimen for chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (&#8220;HBV&#8221;);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential of our product candidates to improve upon the standard of care and contribute to a functional curative combination treatment regimen;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining necessary regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining adequate financing through a combination of financing activities and operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for us to discover and/or develop new molecular entities for treating coronaviruses, including COVID-19;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected returns and benefits from strategic alliances, licensing agreements, and research collaborations with third parties, and the timing thereof;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our technology licensed to third parties, and the timing thereof;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated revenue and expense fluctuation and guidance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of announcing data from our ongoing clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding current patent disputes and litigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation of a net cash burn between $90 million and $95 million in 2022; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we have sufficient cash resources to fund our operations into the second quarter of 2024; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possibility that our and our collaboration partner&#8217;s clinical development plans could be further delayed or suspended as a result of the military action by Russia in Ukraine.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as other statements relating to our future operations, financial performance or financial condition, prospects or other future events. Forward-looking statements appear primarily in the sections of this Form 10-Q entitled &#8220;Part I, Item 1- Financial Statements (Unaudited),&#8221; and &#8220;Part I, Item 2-Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based upon current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Form 10-Q and our Annual Report on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Form 10-K&#8221;), and in particular the risks and uncertainties discussed under &#8220;Item 1A-Risk Factors&#8221; of this Form 10-Q and the Form 10-K. As a result, you should not place undue reliance on forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the forward-looking statements contained in this Form 10-Q represent our views only as of the date of this Form 10-Q (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the periodic and current reports that we file with the Securities and Exchange Commission.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing cautionary statements are intended to qualify all forward-looking statements wherever they may appear in this Form 10-Q. For all forward-looking statements, we claim protection of the safe harbor for the forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221;) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (&#8220;HBV&#8221;) and coronaviruses, including SARS-CoV-2. In HBV, we are developing an RNA interference (&#8220;RNAi&#8221;) therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that we intend to combine to provide a functional cure for patients with chronic HBV infection (&#8220;cHBV&#8221;) by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is currently being evaluated in multiple phase 2 clinical trials. We have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. We are also exploring oncology applications for our internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The core elements of our strategy include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Developing a broad portfolio of compounds that target cHBV.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our HBV product pipeline includes a subcutaneously-delivered RNAi therapeutic, an oral capsid inhibitor, an oral HBV RNA destabilizer compound and an oral PD-L1 inhibitor. We believe that by combining these compounds to suppress HBV DNA replication and hepatitis B surface antigen (&#8220;HBsAg&#8221;) expression as well as reawaken patients&#8217; HBV-specific immune response, we can address the most important elements to achieving a functional cure. We define a functional cure as unquantifiable plasma HBV DNA and HBsAg levels more than six months after treatment with or without quantifiable anti-HBsAg antibodies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-729, our proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses HBsAg expression, which is thought to be a key prerequisite to enable reawakening of a patient&#8217;s immune system to respond to HBV, is currently in one ongoing Phase 1a/1b clinical trial (&#8220;AB-729-001&#8221;) and two Phase 2a proof-of-concept clinical trials in combination with other agents with potentially complementary mechanisms of action. Preliminary data from AB-729-001 has shown that treatment with AB-729 resulted in meaningful declines in HBsAg while being well tolerated with no serious adverse events (SAEs) noted after both single and repeat dosing. Preliminary data also suggests that long-term suppression of HBsAg with AB-729 results in increased HBV-specific immune response. We anticipate presenting long-term on- and off-treatment follow-up data from AB-729-001 at a medical conference in 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-836, our proprietary next-generation oral capsid inhibitor that suppresses HBV DNA replication, is currently in an ongoing Phase 1a/1b clinical trial (&#8220;AB-836-001&#8221;) where preliminary data from healthy subjects and HBV patients have shown that AB-836 is generally safe and well-tolerated with robust antiviral activity. AB-836 is from a novel chemical series differentiated from competitor compounds and has the potential to provide increased efficacy and an enhanced resistance profile. We expect to announce additional data from AB-836-001 in the first half of 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-101, our oral PD-L1 inhibitor that has the potential to reawaken patients&#8217; HBV-specific immune response by inhibiting PD-L1, is advancing through IND-enabling studies that are anticipated to be completed in the second half of 2022. We are also exploring potential oncology applications for our internal PD-L1 portfolio.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-161, our next-generation oral HBV specific RNA destabilizer, is advancing through IND-enabling studies that are anticipated to be completed in the second half of 2022. We have conducted extensive non-clinical safety evaluations with AB-161 that gives us confidence in this molecule&#8217;s ability to circumvent the peripheral neuropathy findings seen in non-clinical safety studies with our first-generation oral RNA destabilizer, AB-452.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combining therapeutic product candidates with complementary mechanisms of action to find a functional cure for people with cHBV. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our proprietary product candidates AB-729, AB-836, AB-101 and AB-161, along with existing approved therapies, may provide our first proprietary combination therapy for people with cHBV. In-line with our strategy to position AB-729 as a potential cornerstone therapeutic in future HBV combination regimens, and to help guide future development of combination therapies of AB-729 with other compounds from our proprietary HBV portfolio, we are evaluating AB-729 in combination with other agents with potentially complementary mechanisms of action, including the following:</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently enrolling patients with cHBV in a Phase 2a proof-of-concept clinical trial to evaluate AB-729 in combination with ongoing standard-of-care nucleos(t)ide analogues (&#8220;NA&#8221;) therapy and short courses of Peg-IFN&#945;-2a, with preliminary data anticipated in the second half of 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Through our collaboration with Assembly BioSciences, Inc. (&#8220;Assembly&#8221;), enrollment is complete in a Phase 2a proof-of-concept clinical trial evaluating a triple combination of AB-729, Assembly&#8217;s lead HBV core inhibitor (capsid inhibitor) product candidate, vebicorvir (&#8220;VBR&#8221;), and NA therapy in patients with cHBV. Assembly is conducting this clinical trial and expects preliminary data in the second half of 2022.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Through our collaboration with Antios Therapeutics, Inc. (&#8220;Antios&#8221;), enrollment was completed in a cohort of patients in Antios&#8217; ongoing Phase 2a proof-of-concept clinical trial evaluating a triple combination of AB-729, Antios&#8217; proprietary Active Site Polymerase Inhibitor Nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate), a nucleos(t)ide reverse transcriptase inhibitor. However, the majority of patients in this cohort were enrolled in Ukraine, which is currently in a state of war, and as a result these patients have been lost to follow-up before completing the clinical trial. Therefore, we and Antios do not expect to report data on this cohort.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Through our collaboration with Vaccitech plc (&#8220;Vaccitech&#8221;), we filed a Clinical Trial Application (CTA) in the fourth quarter of 2021 and anticipate starting to enroll patients in the first half of 2022, in a Phase 2a clinical trial (&#8220;AB-729-202&#8221;) to evaluate a triple combination of AB-729 with Vaccitech&#8217;s VTP-300, a proprietary T cell stimulating therapeutic vaccine, and NA therapy for the treatment of patients with cHBV. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advancing small molecule antiviral product candidates to treat COVID-19 and future coronavirus outbreaks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This program is focused on the discovery and development of new molecular entities for treating coronaviruses (including COVID-19) that address specific viral targets including the nsp12 viral polymerase and the nsp5 viral protease. Through our collaboration with X-Chem, Inc. (&#8220;X-Chem&#8221;) and Proteros biostructures GmbH (&#8220;Proteros&#8221;), we have identified and obtained a worldwide exclusive license to several molecules that inhibit the SARS-CoV-2 nsp5 main protease (&#8220;Mpro&#8221;), a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks. We expect to nominate a candidate that inhibits Mpro in the first half of 2022 and advance into IND-enabling studies in the second half of 2022. We are also continuing lead optimization activities for an nsp12 viral polymerase candidate. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product pipeline includes multiple product candidates that target various steps in the HBV viral lifecycle and pan-coronavirus compounds that target essential enzymes for replication, the viral protease (Mpro) and polymerase (nsp12).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product pipeline consists of the following programs:</span></div><div style="text-align:justify"><img src="abus-20220331_g1.jpg" alt="abus-20220331_g1.jpg" style="height:328px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to explore expansion opportunities for our pipeline through internal discovery and development activities and through potential strategic alliances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GalNAc RNAi (AB-729)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNAi therapeutics represent a recent significant advancement in drug development.  RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.  We are developing RNAi therapeutics that are designed to reduce HBsAg expression and other HBV antigens in people with cHBV.  Reducing HBsAg is widely believed to be a key prerequisite to enable a patient&#8217;s immune system to reawaken and respond against the virus. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-729 is a subcutaneously-delivered RNAi therapeutic targeted to hepatocytes using our proprietary covalently conjugated GalNAc delivery technology. AB-729 reduces all HBV antigens and inhibits viral replication.  AB-729-001 is our three-part clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multi-dose AB-729 in healthy subjects and in cHBV patients and to determine the most appropriate doses and dosing intervals to take forward into Phase 2 clinical development. </span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part 1 of the trial dosed healthy subjects, and upon completion, supported advancing doses ranging from 60 mg to 180 mg into Part 2. Part 2 of the trial dosed patients with cHBV with single doses (60, 90 and 180 mg) of AB-729, and upon completion, showed that single doses of AB-729 result in comparable mean HBsAg declines at week 12 followed by a sustained plateau phase.  Part 3 of the trial is on-going and dosing HBV DNA negative and positive patients with multiple doses of AB-729 every 4, 8 or twelve weeks.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we presented a late breaker poster presentation at the 2021 AASLD liver meeting highlighting the most recent data from Part 3 of AB-729-001. Repeat dosing of 60 mg and 90 mg of AB-729 resulted in robust mean declines (ranging from 1.8-2.0 log10 at week 40) in HBsAg that were sustained up to 48 weeks, with no statistically significant differences observed to date between the 60 mg and 90 mg dose and/or dosing intervals. Data from the poster presentation also included long-term follow-up data for patients in cohort E (60 mg every four weeks) and cohort F (60 mg every eight weeks) who had been off AB-729 treatment for six months. Suppression of HBsAg to levels &lt;100 IU/mL were maintained up to 24 weeks off-treatment in 3 of 7 patients in cohort E and 1 of 3 patients with available data in cohort F. Patients who remain below this clinically relevant threshold for six months after stopping AB-729 treatment could consider discontinuing their NA therapy to assess the potential for functional cure.  We anticipate presenting additional long-term on- and off-treatment follow-up data from Part 3 of this clinical trial at a medical conference in 2022.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repeat dosing of both the 60 mg and 90 mg doses of AB-729 continues to be generally safe and well-tolerated. There were no treatment-related SAEs or discontinuations. The most common treatment emergent adverse events (&#8220;AEs&#8221;) were injection site-related, of which all were grade one and did not appear to be dose or interval dependent. Alanine transaminase (&#8220;ALT&#8221;) and Aspatate transaminase (&#8220;AST&#8221;) elevations were asymptomatic and not considered AEs by the study investigators.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The efficacy and safety data for AB-729, derived from up to one year of dosing, supported our view that 60 mg every 8 weeks was an appropriate dose to move forward in our Phase 2a clinical trials.  To advance our efforts to position AB-729 as a potential cornerstone therapeutic in future HBV combination regimens, we are evaluating AB-729 in several Phase 2a proof-of-concept combination clinical trials with other agents with potentially complementary mechanisms of action via clinical collaborations with other companies as described below. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2a proof-of-concept clinical trial to evaluate AB-729 in combination with Peg-IFN&#945;-2a (AB-729-201)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following FDA authorization in July 2021 to proceed with our Investigational New Drug (IND) application, we initiated AB-729-201, a randomized, open label, multicenter Phase 2a proof-of-concept clinical trial investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFN&#945;-2a in patients with cHBV. We are currently enrolling up to 40 stably NA-suppressed, HBeAg negative, non-cirrhotic cHBV patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After 24-weeks of dosing with AB-729 (60 mg every 8 weeks), patients will be randomized into one of four groups to receive either AB-729 plus NA therapy plus Peg-IFN&#945;-2a or NA therapy plus Peg-IFN&#945;-2a for either 24 or 12 weeks.  After completion of the assigned Peg-IFN&#945;-2a treatment period, all patients will remain on NA therapy for the initial 24-week follow-up period, and will then discontinue NA treatment, provided they meet certain stopping criteria. If patients stop NA therapy, they will enter an intensive follow-up period for 48 weeks. We anticipate preliminary data from the AB-729-201 clinical trial in the second half of 2022.      </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Assembly</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a clinical collaboration agreement with Assembly that we entered into in August 2020, Assembly is evaluating AB-729 in combination with its lead HBV core inhibitor (capsid inhibitor) candidate VBR and standard-of-care NA therapy for the treatment of patients with cHBV. The randomized, multi-center, open-label Phase 2a proof-of-concept clinical trial was designed to evaluate the safety, pharmacokinetics, and antiviral activity of the triple combination of AB-729, VBR, and an NA compared to the double combinations of VBR with an NA and AB-729 with an NA. The clinical trial was designed to enroll approximately 60 virologically-suppressed patients with HBeAg negative cHBV in the first cohort of the trial. Patients are dosed for 48 weeks with AB-729 60 mg subcutaneously every 8 weeks and VBR (300 mg orally once daily), with a 48-week follow-up period. Both parties will share in the costs of the collaboration. Assembly has completed enrollment in the clinical trial and anticipates preliminary data in the second half of 2022. Under the terms of the collaboration, both parties may also add additional cohorts in the future to evaluate other patient populations and/or combinations.  Except to the extent necessary to carry out Assembly&#8217;s responsibilities with respect to the collaboration trial, we have not provided any license grant to Assembly for use of AB-729.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Vaccitech (AB-729-202)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a clinical collaboration agreement with Vaccitech that we entered into in July 2021, we are preparing to enroll patients in AB-729-202, a Phase 2a proof-of-concept clinical trial evaluating the safety, antiviral activity and immunogenicity of Vaccitech&#8217;s VTP-300, a proprietary T cell stimulating therapeutic vaccine, administered after AB-729 in NrtI-suppressed patients with cHBV. The trial is designed to enroll 40 NA-suppressed, HBeAg negative or positive, non-cirrhotic cHBV patients. All patients will receive AB-729 (60mg every 8 weeks) plus NA therapy for 24 weeks. At week 24, treatment with AB-729 will stop.  Patients will continue only their NA therapy and will be randomized to receive VTP-300 or placebo for an additional 24 weeks. At week 48, all patients will be evaluated for eligibility to either discontinue or remain on NA therapy. This clinical trial will be managed by us, subject to oversight by a joint development committee comprised of representatives from both companies. We and Vaccitech retain full rights to our respective product candidates and will split all costs associated with the clinical trial. We filed a CTA in the fourth quarter of 2021 and anticipate starting to enroll patients in the clinical trial in the first half of 2022. Pursuant to the agreement, the parties intend to undertake a larger Phase 2b clinical trial depending on the results of the initial Phase 2a clinical trial.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with Antios</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a clinical collaboration agreement with Antios that we entered into in June 2021, Antios completed enrollment in a single cohort of its ongoing Antios Phase 2a ANTT201 clinical trial evaluating its proprietary Active Site Polymerase Inhibitor Nucleotide (ASPIN), ATI-2173, in combination with AB-729 and Viread (tenofovir disoproxil fumarate), a nucleos(t)ide reverse transcriptase inhibitor which is currently approved by the FDA, for the treatment of patients with cHBV. Antios is responsible for conducting this clinical trial and for the costs of adding this single cohort to its ongoing clinical trial. Arbutus was responsible for the manufacture and supply of AB-729.  Except to the extent necessary to carry out Antios&#8217; responsibilities with respect to the collaboration trial, we have not provided any license grant to Antios for use of AB-729. However, the majority of patients in this cohort were enrolled in Ukraine, which is currently in a state of war, and as a result these patients were lost to follow-up before completing the clinical trial.  Therefore, we and Antios do not expect to report data on this cohort. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oral Capsid Inhibitor (AB-836)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV core protein assembles into a capsid structure, which is required for viral replication. The current commercially available therapies (NAs or Peg-IFN) significantly reduce HBV DNA levels in the serum, but HBV replication continues in the liver, thereby enabling HBV infection to persist. More effective therapies for patients require new agents which will further block viral replication. We are developing capsid inhibitors (also known as core protein inhibitors) as oral therapeutics which, in combination with NAs, could further reduce HBV replication. By inhibiting assembly of functional viral capsids, the ability of HBV to replicate is impaired. Capsid inhibitor molecules also inhibit the uncoating step of the viral life cycle and thus reduce the formation of cccDNA, the viral reservoir which resides in the cell nucleus, and which is believed to play a role in viral persistence.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-836 is a capsid inhibitor from a novel chemical series differentiated from competitor compounds with the potential for increased efficacy and an enhanced resistance profile.  AB-836 leverages a novel binding site within the core protein dimer-dimer interface, has shown to be active against NA resistant variants and has the potential to address certain known capsid resistant variants.  AB-836 is anticipated to be combinable with other mechanisms of action and is also anticipated to be dosed once daily.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are enrolling patients in a double-blind, randomized, placebo-controlled Phase 1a/1b clinical trial (&#8220;AB-836-001&#8221;) designed to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple doses of AB-836 in healthy subjects and patients with cHBV. The trial consists of three parts. Part 1 evaluated alternating single doses of AB-836 or placebo ranging from 10 mg to 175 mg in a fasted or fed state in healthy subjects. Part 2 evaluated multiple ascending doses of 50 mg, 100 mg or 150 mg of AB-836 or placebo once daily for 10 days in healthy subjects. Part 3, which is still on-going, is currently randomizing HBV DNA positive cHBV patients who are HBeAg positive or negative to receive either 50 mg, 100 mg or 200 mg of AB-836 or placebo once daily for 28 days.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced preliminary data from this trial.  In Parts 1 and 2, a total of 47 healthy subjects were enrolled and dosed. There were no deaths or SAEs observed. One healthy subject that received 50 mg once daily discontinued after treatment on day 13 due to an AE of agitation. All but three AEs were mild (Grade 2 headache, agitation and bronchitis), and only one was assessed as related to AB-836 (Grade 1 rash). There were no clinically significant abnormalities in clinical laboratory tests, ECGs, vital signs or physical exams noted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Part 3, 16 cHBV patients had been dosed thus far, with enrollment continuing. Among those who received 100 mg once daily for the full 28 days (n=4), robust antiviral activity was observed at Day 28 of treatment with a mean (SE) log10 change from baseline of -3.1 (0.5). There have been no deaths or AEs. One cHBV patient that received 100 mg of AB-836 had a transient increase in ALT from baseline Grade 1 to Grade 3 at a single visit that resolved with continued dosing and had no associated symptoms. There were no clinically significant abnormalities in ECGs, vital signs or physical exams noted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are continuing to enroll and dose cHBV patients in Part 3 of this clinical trial and we anticipate reporting additional data in the first half of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oral PD-L1 Inhibitor (AB-101)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PD-L1 inhibitors complement our pipeline of agents and could potentially be an important part of a combination therapy for the treatment of HBV by reawakening the immune system.  Highly functional HBV-specific T cells within our immune system are believed to be required for long-term HBV viral resolution.  However, HBV-specific T cells become functionally defective, and greatly reduced in their frequency during cHBV. One approach to boost HBV-specific T cells is to prevent PD-L1 proteins from binding to PD-1 and thus inhibiting the HBV-specific immune function of T cells. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-101 is our oral PD-L1 inhibitor, which we believe has the potential to reawaken patients&#8217; HBV-specific immune response.  We anticipate completing IND-enabling studies for AB-101 in the second half of 2022.  We are also exploring potential oncology applications for our internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oral HBV RNA Destabilizer (AB-161) </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HBV RNA destabilizers are small molecule orally available agents that cause the destabilization and ultimate degradation of HBV RNAs. These agents result in the reduction of HBsAg and other viral proteins in both whole cell systems and animal models. They have the potential to selectively impact HBV versus other RNA or DNA viruses and demonstrate pangenotypic characteristics. HBV RNA destabilizers have demonstrated additive effects in combination with other anti-HBV mechanisms of action.  HBV RNA destabilizers have the potential to complement or replace subcutaneously delivered RNAi agents, such as AB-729, with an oral therapy in combination with a capsid inhibitor and an approved NA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AB-161 is our next-generation oral HBV specific RNA destabilizer. We have conducted extensive non-clinical safety evaluations with AB-161 that provide confidence in this molecule&#8217;s ability to circumvent the peripheral neuropathy findings seen in non-clinical safety studies with our first-generation oral RNA destabilizer, AB-452. We anticipate completing IND-enabling studies for AB-161 in the second half of 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Research Efforts </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our core mission is to find a cure for HBV, the magnitude of the coronavirus pandemic is undeniable. Given our science team&#8217;s proven expertise in the discovery of new antiviral therapies, in 2020 we initiated a drug discovery effort for treating coronaviruses, including COVID-19. To that end, we have assembled an internal team of expert scientists under the direction of our Chief Scientific Officer, Dr. Michael Sofia, to identify novel small molecule therapies to treat COVID-19 and future coronavirus outbreaks. Dr. Sofia, who was awarded the Lasker-DeBakey Award for his discovery of sofosbuvir, brings extensive antiviral drug discovery experience to this new program. Our COVID-19 research program is focused on the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discovery and development of new molecular entities that address specific viral targets including the nsp12 viral polymerase and the nsp5 viral protease. These targets are essential viral proteins which our science team has experience in targeting.    </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration with X-Chem, Inc. and Proteros biostructures GmbH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we entered into a discovery research and license agreement with X-Chem and Proteros to focus on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The agreement is designed to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks. This collaboration brought together our expertise in the discovery and development of antiviral agents with X-Chem&#8217;s industry leading DNA-encoded library (DEL) technology and Proteros&#8217; protein sciences, biophysics and structural biology capabilities and provides important synergies to potentially identify safe and effective therapies against coronaviruses, including SARS-CoV-2. The collaboration allows for the rapid screening of one of the largest small molecule libraries against M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an essential protein required for the virus to replicate itself) and the use of state-of-the-art structure guided methods to rapidly optimize M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitors, which we could potentially progress to clinical candidates. The agreement provides for payments by us to X-Chem and Proteros upon satisfaction of certain development, regulatory and commercial milestones, as well as royalties on sales. Through this collaboration, we have identified and obtained a worldwide exclusive license to several molecules that inhibit M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks. We expect to nominate an M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidate in the first half of 2022 and advance into IND-enabling studies in the second half of 2022. We are also continuing lead optimization activities for an Nsp12 viral polymerase candidate.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Impact </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials.  While we have been able to progress with our clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact our plans and timelines in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Collaborations and Royalty Entitlements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu Pharmaceutical Co., Ltd.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a technology transfer and license agreement (the &#8220;License Agreement&#8221;) with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;), pursuant to which we granted Qilu a sublicensable, royalty-bearing license, under certain intellectual property owned by us, which is non-exclusive as to development and manufacturing and exclusive with respect to commercialization of AB-729, including pharmaceutical products that include AB-729, for the treatment or prevention of hepatitis B in China, Hong Kong, Macau and Taiwan (the &#8220;Territory&#8221;).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration for the rights granted by us, Qilu paid us a one-time upfront cash payment of $40 million on January 5, 2022 and agreed to pay us milestone payments totaling up to $245 million, net of withholding taxes, upon the achievement of certain technology transfer, development, regulatory and commercialization milestones. Qilu also agreed to pay us double digit royalties into the low twenties percent based upon annual net sales of AB-729 in the Territory. The royalties are payable on a product-by-product and region-by-region basis, subject to certain limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval for, and commercializing AB-729 for the treatment or prevention of hepatitis B in the Territory. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one AB-729 product candidate in the Territory. A joint development committee has been established between us and Qilu to coordinate and review the development, manufacturing and commercialization plans. Both parties also have entered into a supply agreement and related quality agreement pursuant to which we will manufacture or have manufactured and supply Qilu with all quantities of AB-729 necessary for Qilu to develop and commercialize in the Territory until we have completed manufacturing technology transfer to Qilu and approval of a product manufactured by Qilu, or its designated contract manufacturing organization, by National Medical Products Administration in China for AB-729.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the execution of the License Agreement, we entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Anchor Life Limited, a company established pursuant to the applicable laws and regulations of Hong Kong and an affiliate of Qilu (the &#8220;Investor&#8221;), pursuant to which the Investor purchased 3,579,952 of our common shares, without par value (the &#8220;Common Shares&#8221;), at a purchase price of USD $4.19 per share, which was a 15% premium on the thirty-day average closing price of the Common Shares as of the close of trading on December 10, 2021 (the &#8220;Share Transaction&#8221;). We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received $15.0 million of gross proceeds from the Share Transaction on January 6, 2022. The Common Shares sold to the Investor in the Share Transaction represented approximately 2.5% of the Common Shares outstanding immediately prior to the execution of the Share Purchase Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two royalty entitlements to Alnylam&#8217;s global net sales of ONPATTRO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, we entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with our lipid nanoparticle (&#8220;LNP&#8221;) delivery technology. Alnylam&#8217;s ONPATTRO, which represents the first approved application of our LNP technology, was approved by the United States FDA and the European Medicines Agency (&#8220;EMA&#8221;) during the third quarter of 2018 and was launched by Alnylam immediately upon approval in the United States. Under the terms of this license agreement, we are entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to the Ontario Municipal Employees Retirement System (&#8220;OMERS&#8221;), effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of this royalty entitlement on future global net sales of ONPATTRO will revert to us. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and we are not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to us, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part. From the inception of the royalty sale through March&#160;31, 2022, an aggregate of $12.5 million of royalties have been collected by OMERS. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have rights to a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#8220;Acuitas&#8221;).  This royalty entitlement from Acuitas has been retained by us and was not part of the royalty entitlement sale to OMERS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genevant Sciences, Ltd.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), our largest shareholder, to launch Genevant Sciences Ltd. (&#8220;Genevant&#8221;), a company focused on a broad range of RNA-based therapeutics enabled by our LNP and ligand conjugate delivery technologies. We licensed rights to our LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV, except to the extent certain rights had already been licensed to other third parties (the &#8220;Genevant License&#8221;). We retained all rights to our LNP and conjugate delivery platforms for HBV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Genevant License, as amended, if a third party sublicensee of intellectual property licensed by Genevant from us commercializes a sublicensed product, we become entitled to receive a specified percentage of certain revenue that may be received by Genevant for such sublicense, including royalties, commercial milestones and other sales-related revenue, or, if less, tiered low single-digit royalties on net sales of the sublicensed product. The specified percentage is 20% in the case of a mere sublicense (i.e., naked sublicense) by Genevant without additional contribution and 14% in the case of a bona fide collaboration with Genevant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Genevant receives proceeds from an action for infringement by any third parties of our intellectual property licensed to Genevant, we would be entitled to receive, after deduction of litigation costs, 20% of the proceeds received by Genevant or, if less, tiered low single-digit royalties on net sales of the infringing product (inclusive of the proceeds from litigation or settlement, which would be treated as net sales). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Roivant recapitalized Genevant through an equity investment and conversion of previously issued convertible debt securities held by Roivant.  We participated in the recapitalization of Genevant with an equity investment of $2.5 million.  In connection with the recapitalization, the three parties entered into an Amended and Restated Shareholders Agreement that provides Roivant with substantial control of Genevant.  We have a non-voting observer seat on Genevant&#8217;s Board of Directors. As of March&#160;31, 2022, we owned approximately 16% of the common equity of Genevant and the carrying value of our investment in Genevant was zero. Our entitlement to receive future royalties or sublicensing revenue from Genevant was not impacted by the recapitalization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moderna Inter Partes Review Petitions  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2018 and March 5, 2018, Moderna Therapeutics, Inc. (&#8220;Moderna&#8221;) filed petitions requesting the United States Patent and Trademark Office to institute an Inter Partes Review of Arbutus United States Patents 9,404,127 (the &#8220;&#8217;127 Patent&#8221;) </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 9,364,435 (the &#8220;&#8217;435 Patent&#8221;).  In its petitions, Moderna sought to invalidate all claims of each patent based on Moderna&#8217;s allegation that the claims are anticipated and/or obvious.  We filed a response to Moderna&#8217;s petitions on June 14, 2018.  On September 12, 2018, the Patent Trial and Appeal Board (the &#8220;PTAB&#8221;) rendered its decision to institute Inter Partes Review of both the &#8216;127 Patent and the &#8216;435 Patent. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The status of these patents, which collectively represent only a fraction of Arbutus&#8217; extensive LNP patent portfolio, is as follows:  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8216;127 Patent</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the &#8216;127 Patent, the PTAB held all claims as invalid on September 10, 2019, by reason of anticipatory prior art.  However this decision was vacated and sent back (remanded) to the PTAB for a rehearing, pending the Supreme Court&#8217;s decision whether to grant certiorari in a different case, United States v. Athrex, Inc. (&#8220;US v. Athrex&#8221;), the holding of which could impact the findings in the &#8216;127 Patent matter.  The Supreme Court granted certiorari in US v. Athrex on October 13, 2020 (i.e. agreed to review the decision appealed from a lower court).  Until the Supreme Court rendered its opinion in US v. Athrex, the &#8216;127 Patent hearing remained in abeyance, with no decision reached as to the validity of its claims.  The Supreme Court decided on the US v. Athrex case on June 21, 2021, following which the Federal Circuit reinstated the appeal sua sponte, requiring the parties to brief how the case should proceed in light of the Supreme Court&#8217;s opinion or for the Appellant to waive the challenge.  Arbutus elected to waive the challenge and proceed with the appeal at the Federal Circuit.  The opening brief was filed on October 25, 2021.  Moderna&#8217;s responsive brief was filed on February 24, 2022 and Arbutus&#8217; reply brief was filed on April 26, 2022.  No hearing date has been set for this matter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8216;435 Patent</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the &#8216;435 Patent, the PTAB rendered its decision on September 11, 2019, holding certain claims invalid and upholding other claims as valid.  On November 13, 2019, we and Moderna both appealed the decision. Moderna filed its opening brief on May 4, 2020 and we provided our opening and responsive brief on July 27, 2020.  Moderna subsequently filed its reply and responsive brief on October 5, 2020, and we filed our reply brief on November 9, 2020. An oral hearing on the &#8216;435 Patent was held on October 7, 2021. On December 1, 2021, the Federal Circuit issued its opinion, leaving intact the PTAB&#8217;s holding regarding the validity of certain claims in the &#8216;435 patent and the invalidity of other claims in the &#8216;435 patent.   The decision in the &#8216;435 appeal was rendered final by mandate on January 25, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8216;069 Patent</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2019, Moderna filed an additional petition requesting Inter Partes Review of Arbutus United States Patent 8,058,069 (the &#8220;&#8217;069 Patent&#8221;).  The PTAB instituted Inter Partes Review of the &#8216;069 Patent and, on July 23, 2020, issued a decision upholding all claims as valid.  On September 23, 2020, Moderna appealed the &#8216;069 Inter Partes Review decision to the Federal Circuit Court of Appeals. Moderna filed its opening brief in that appeal on February 23, 2021, we filed our responsive brief on May 11, 2021, and Moderna filed its reply brief on July 1, 2021.  An oral hearing on the &#8216;069 Patent was held on October 7, 2021, in a joint hearing with the hearing regarding the &#8216;435 patent, before the U.S. Court of Appeals for the Federal Circuit.  On December 1, 2021, the Federal Circuit also issued its ruling with respect to the &#8216;069 patent, affirming the PTAB&#8217;s finding that all claims were valid.   The Federal Circuit&#8217;s decision in the &#8216;069 appeal was rendered final by mandate on January 10, 2022.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Moderna and Merck European Oppositions  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2018, Moderna and Merck, Sharp &amp; Dohme Corporation (&#8220;Merck&#8221;) filed Notices of Opposition to Arbutus&#8217; European patent EP 2279254 (&#8220;the &#8217;254 Patent&#8221;) with the European Patent Office (&#8220;EPO&#8221;), requesting that the &#8216;254 Patent be revoked in its entirety for all contracting states.  We filed a response to Moderna and Merck&#8217;s oppositions on September 3, 2018.  A hearing was conducted before the Opposition Division of the EPO on October 10, 2019.  At the conclusion of the hearing, the EPO upheld an auxiliary request adopting the amendment, as put forth by us, of certain claims of the &#8216;254 Patent.  In February 2020 Moderna and Merck filed Notices of Appeal challenging the EPO&#8217;s grant of the auxiliary request.  Merck filed its notice of appeal on February 24, 2020 and Moderna on February 27, 2020. Both Merck and Moderna perfected their appeals by filing Grounds of Appeal on April 30, 2020. We filed our response to the appeals on September 18, 2020. On March 22, 2022, Moderna filed further written submissions. The date for the oral proceedings has not been set.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are the patent holder, the &#8216;127 Patent, the &#8216;435 Patent, the &#8216;069 Patent and the &#8216;254 Patent have been licensed to Genevant and are included in the rights licensed by us to Genevant under the Genevant License.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Infringement Litigation vs. Moderna </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, we and Genevant filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna&#8217;s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use.  The lawsuit does not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273. However, we seek fair compensation for Moderna&#8217;s use of our patented technology that was developed with great effort and at great expense, without which Moderna&#8217;s COVID-19 vaccine would not have been successful.  Moderna has until May 6, 2022 to move, answer or otherwise respond to the complaint. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acuitas Declaratory Judgment Lawsuit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2022, Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;) filed a lawsuit against us and Genevant in the Southern District of New York, asking the court to enter declaratory judgment that Arbutus patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 do not infringe Pfizer and BioNTech&#8217;s COVID-19 vaccine, COMIRNATY, which uses an mRNA lipid provided, under license, by Acuitas.  Acuitas also seeks a declaration that each of the listed patents is invalid.  We have until June 24, 2022 to move, answer or otherwise respond to the complaint.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGEMENTS AND ESTIMATES</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with&#160;United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.&#160;&#160;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there have been no significant changes in our critical accounting policies and estimates as discussed in &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_79"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to note 2 to our condensed consolidated financial statements included in Part I, Item 1, &#8220;Financial Statements (Unaudited)&#8221; of this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our business.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_82"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the results of our operations for the periods shown:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,974)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,676)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,321)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,381)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend accretion of convertible preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shares</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,593)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are summarized in the following table: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:46.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborations and licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acuitas Therapeutics, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qilu Pharmaceutical Co., Ltd.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other milestone and royalty payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnylam Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased $10.5 million for the three months ended March 31, 2022 compared to the same period in 2021, primarily due to license revenue recognized related to our progress against the satisfaction of our performance obligations with respect to the technology transfer and licensing agreement with Qilu in January 2022, as well as an increase in license royalty revenue from Alnylam and Acuitas due to the growth of Alnylam&#8217;s sales of ONPATTRO.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.229%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of personnel expenses, fees paid to clinical research organizations and contract manufacturers, consumables and materials, consulting, and other third party expenses to support our clinical and pre-clinical activities, as well as a portion of stock-based compensation and general overhead costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $4.7 million for the three months ended March 31, 2022 compared to the same period in 2021. The increase was due primarily to an increase in expenses for our ongoing AB-836-001 clinical trial, an increase in expenses related to our ongoing AB-729 Phase 2a clinical trials, including our collaborations with Assembly and Vaccitech, and an increase in expenses for our early-stage development programs, including AB-101 and AB-161.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our research and development expenses are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced programs are not yet in late-stage clinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $1.0 million for the three months ended March 31, 2022 as compared to the same period in 2021, due primarily to increases in employee compensation costs, professional fees, and non-cash stock based compensation expense.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is a liability related to our acquisition of Enantigen Therapeutics, Inc. in October 2014. In general, as time passes and assuming no changes to the assumptions related to the contingency, the fair value of the contingent consideration increases as the progress of our programs get closer to triggering contingent payments based on certain sales milestones of our first commercial product for cHBV.  As AB-729 continues to progress through Phase 2a proof-of-concept clinical trials, we adjust our assumption regarding probability of success commensurate with the progression of the program, which will increase the fair value of the liability.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (loss)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our other income (loss) are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(772)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gains</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest income for the three months ended March 31, 2022 compared to the same period in 2021 was due primarily to higher interest earned on higher average cash and investment balances. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for both the three months ended March 31, 2022 and 2021 consisted primarily of non-cash amortization of discount and issuance costs related to the sale of a portion of our ONPATTRO royalty interest to OMERS in July 2019. The decrease is related to the declining balance of the unamortized discount and issuance costs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign exchange gains</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our site consolidation to Warminster, PA, our Canadian dollar-denominated expenses and cash balances have decreased significantly now that a majority of our business transactions are based in the United States. We continue to incur expenses and hold some cash balances in Canadian dollars, and as such, we will remain subject to risks associated with foreign currency fluctuations.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, we recognized income tax expense of $4.4 million for withholding taxes paid to the Chinese taxing authority by Qilu on our behalf in connection with the upfront license fee Qilu paid us.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_85"></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activities for the periods indicated:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,765)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in operating items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,881)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,056)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common shares pursuant to Share Purchase Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by other financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,952)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our incorporation, we have financed our operations through sales of equity, debt, revenues from research and development collaborations and licenses with corporate partners, royalty monetization, interest income on funds available for investment, and government contracts, grants and tax credits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, $20.6 million of cash was provided by operating activities compared to $17.9 million used in operating activities for the three months ended March 31, 2021, an increase of $38.5 million. The increase was due primarily to a January 2022 upfront cash payment of $40.0&#160;million from Qilu and a $4.0 million premium paid by Qilu as part of their $15.0&#160;million equity investment. These cash inflows were partially offset by $23.4 million of cash used in operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, net cash used in investing activities was $60.1 million, consisting primarily of  additional investments in marketable securities of $62.0 million, partially offset by maturities of investments in marketable securities of $2.0 million.  For the three months ended March 31, 2021, net cash provided by investing activities was $18.2 million, which consisted primarily of maturities of investments in marketable securities of $20.4 million, partially offset by additional investments in marketable securities of $2.0 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022, net cash provided by financing activities was $11.5 million, which included $11.0 million for the fair value of the shares purchased by Qilu as part of their $15.0&#160;million equity investment. The remaining $4.0 million was a premium paid by Qilu on the equity investment and was allocated to deferred revenue. For the three months ended March 31, 2021, net cash provided by financing activities was $26.9 million, which was primarily driven by $26.4 million in proceeds from sales of common shares under our Open Market Sale Agreement, as amended. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash, cash equivalents and investments in marketable securities of $221.8 million. We had no outstanding debt as of March&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Open Market Sale Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> with Jefferies LLC (&#8220;Jefferies&#8221;) dated December 20, 2018, as amended by Amendment No. 1, dated December 20, 2019, Amendment No. 2, dated August 7, 2020 and Amendment No. 3, dated March 4, 2021 (as amended, the &#8220;Sale Agreement&#8221;), under which we may offer and sell common shares, from time to time. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 23, 2019, we filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the &#8220;SEC&#8221;) (File No. 333-235674) and accompanying base prospectus, declared effective by the SEC on January 10, 2020 (the &#8220;January 2020 Registration Statement&#8221;), for the offer and sale of up to $150.0 million of our securities. The January 2020 Registration Statement also contained a prospectus supplement in connection with the offering of up to $75.0 million of our common shares pursuant to the Sale Agreement. This prospectus supplement was fully utilized during 2020. On August 7, 2020, we filed a prospectus supplement with the SEC (the &#8220;August 2020 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $75.0 million of our common shares pursuant to the Sale Agreement under the January 2020 Registration Statement. The August 2020 Prospectus Supplement was fully utilized during 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, we filed a shelf registration statement on Form S-3 with the SEC (File No. 333-248467) and accompanying base prospectus, which was declared effective by the SEC on October 22, 2020 (the &#8220;October 2020 Registration Statement&#8221;), for the offer and sale of up to $200.0 million of our securities. On March 4, 2021, we filed a prospectus supplement with the SEC (the &#8220;March 2021 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $75.0 million of our common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. We fully utilized the March 2021 Prospectus Supplement during 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 8, 2021, we filed a prospectus supplement with the SEC (the &#8220;October 2021 Prospectus Supplement&#8221;) for the offer and sale of up to an additional $75.0 million of our common shares pursuant to the Sale Agreement under the October 2020 Registration Statement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 4, 2021, we filed a shelf registration statement on Form S-3 with the SEC (File No. 333-248467) and accompanying base prospectus, declared effective by the SEC on November 18, 2021 (the &#8220;November 2021 Registration Statement&#8221;), for the offer and sale of up to $250.0 million of our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 3, 2022, we filed a prospectus supplement with the SEC (the &#8220;March 2022 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $100.0 million of our common shares pursuant to the Sale Agreement under: (i) the January 2020 Registration Statement; (ii) the October 2020 Registration Statement; and (iii) a shelf registration statement on Form S-3 (File No. 333-260782) that was declared effective by the SEC on November 18, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2022, we issued 69,048 common shares pursuant to the Sale Agreement, as amended, resulting in net proceeds of approximately $0.3 million. For the three months ended March 31, 2021, we issued 6,395,780 common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $26.4&#160;million. As of March&#160;31, 2022, there was approximately $152.0 million available in aggregate under the October 2021 Prospectus Supplement and the March 2022 Prospectus Supplement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Royalty Entitlements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a royalty entitlement on ONPATTRO, a drug developed by Alnylam that incorporates our LNP technology and was approved by the FDA and the EMA during the third quarter of 2018 and was launched by Alnylam immediately upon approval in the United States.  In July 2019, we sold a portion of this royalty interest to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to us. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and Arbutus is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to us, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part.  In addition to the royalty from the Alnylam LNP license agreement, we are also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas. The royalty from Acuitas has been retained by us and was not part of the royalty sale to OMERS.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into a technology transfer and licensing agreement with Qilu pursuant to which we granted Qilu a sublicensable, royalty-bearing license, under certain intellectual property owned by us, which is non-exclusive as to development and manufacturing and exclusive with respect to commercialization of AB-729, including pharmaceutical products that include AB-729, for the treatment or prevention of hepatitis B in the Territory. In partial consideration for the rights granted by us, Qilu paid us a one-time upfront cash payment of $40 million and made an equity investment of $15 million, both received in January 2022, and agreed to pay us milestone payments totaling up to $245 million, net of withholding taxes, upon the achievement of certain technology transfer, development, regulatory and commercialization milestones. Qilu also agreed to pay us double digit royalties into the low twenties percent based upon annual net sales of AB-729 in the Territory. The royalties are payable on a product-by-product and region-by-region basis, subject to certain limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash requirements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our $221.8 million of cash, cash equivalents and investments in marketable securities as of March&#160;31, 2022 will be sufficient to fund our operations into the second quarter of 2024 based on our expectation of a net cash burn between $90 million and $95 million in 2022. In the future, substantial additional funds will be required to continue with the active development of our pipeline products and technologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our funding needs may vary depending on a number of factors including:</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the effects of the COVID-19 pandemic on our business, the medical community and the global economy;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">revenue earned from our legacy collaborative partnerships and licensing agreements, including potential royalty payments from Alnylam&#8217;s ONPATTRO;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">revenue earned from ongoing collaborative partnerships, including milestone and royalty payments;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential requirement to make milestone payments related to our legacy agreements;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the extent to which we continue the development of our product candidates, add new product candidates to our pipeline, or form collaborative relationships or licensing arrangements to advance our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">delays in the development of our product candidates due to pre-clinical and clinical findings;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our decisions to in-license or acquire additional products, product candidates or technology for development;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to attract and retain development or commercialization partners, and their effectiveness in carrying out the development and ultimate commercialization of one or more of our product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">whether batches of product candidates that we manufacture fail to meet specifications resulting in clinical trial delays and investigational and remanufacturing costs;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the decisions, and the timing of decisions, made by health regulatory agencies regarding our technology and product candidates;</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">competing products, product candidates and technological and market developments; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs associated with prosecuting and enforcing our patent claims and other intellectual property rights, including litigation and arbitration arising in the course of our business activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek funding to maintain and advance our business from a variety of sources including public or private equity or debt financing, potential monetization transactions, collaborative or licensing arrangements with pharmaceutical companies and government grants and contracts. There can be no assurance that funding will be available at all or on acceptable terms to permit further development of our research and development programs. Further, the continued spread of COVID-19 has also led to severe disruption and volatility in the global capital markets, which could increase our cost of capital and adversely affect our ability to access the capital markets in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funding is not available, we may be required to delay, reduce or eliminate one or more of our research or development programs or reduce expenses associated with our non-core activities. We may need to obtain funds through arrangements with collaborators or others that may require us to relinquish most or all of our rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise seek if we were better funded. Insufficient financing may also mean failing to prosecute our patents or relinquishing rights to some of our technologies that we would otherwise develop or commercialize.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_88"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our quantitative and qualitative disclosures about market risk from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2021.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_94"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2022. The term &#8220;disclosure controls and procedures&#8221;, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure, particularly during the period in which this Quarterly Report on Form 10-Q was being prepared. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2022, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Rules 13a&#8211;15(f) and 15d&#8211;15(f) under the Exchange Act) during the three months ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_100"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;&#160;&#160; LEGAL PROCEEDINGS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Infringement Litigation vs. Moderna </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, we and Genevant filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna, Inc. and a Moderna affiliate (collectively, &#8220;Moderna&#8221;) seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna&#8217;s vaccine for COVID-19. The patents relate to nucleic acid-lipid particles and lipid vesicles, as well as compositions and methods for their use. The lawsuit does not seek an injunction or otherwise seek to impede the sale, manufacture or distribution of MRNA-1273. However, the Company seeks fair compensation for Moderna&#8217;s use of its patented technology that was developed with great effort and at great expense, without which Moderna&#8217;s COVID-19 vaccine would not have been successful.  Moderna has until May 6, 2022 to move, answer or otherwise respond to the complaint.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acuitas Declaratory Judgment Lawsuit </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2022, Acuitas Therapeutics Inc. (&#8220;Acuitas&#8221;) filed a lawsuit against us and Genevant in the U.S. District Court for the Southern District of New York, asking the court to enter declaratory judgment that Arbutus patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,006,417, 9,364,435, 9,404,127, 9,504,651, 9,518,272, and 11,141,378 do not infringe Pfizer and BioNTech&#8217;s COVID-19 vaccine, COMIRNATY, which uses an mRNA lipid provided, under license, by Acuitas.  Acuitas also seeks a declaration that each of the listed patents is invalid.  We have until June 24, 2022 to move, answer or otherwise respond to the complaint.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160; RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Several of our and our collaboration partners&#8217; current and planned clinical trials have been impacted and could be further delayed or suspended as a result of the military action by Russia in Ukraine.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia commenced a military invasion of Ukraine. A portion of our clinical trial evaluating AB-836 and a cohort of Antios&#8217; clinical trial evaluating a triple combination including AB-729 are being conducted in Ukraine. We had also planned to conduct a portion of the following clinical trials in Ukraine: (i) our Phase 2a clinical trial evaluating AB-729 in combination with ongoing NA therapy and short courses of PEG-IFN&#945;-2a in cHBV patients and (ii) our planned Phase 2a clinical trial to evaluate a triple combination of AB-729 with Vaccitech&#8217;s VTP-300 and a NA. We intend to utilize alternative clinical trial sites for our ongoing and planned clinical trials impacted by the military action in Ukraine. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia&#8217;s invasion and the ensuing response by Ukraine has disrupted our and our collaboration partners&#8217; current clinical trials in such jurisdictions and could increase our costs and disrupt future planned clinical development activities. For example, enrollment was completed in a cohort of patients in Antios&#8217; ongoing Phase 2a proof-of-concept clinical trial evaluating a triple combination of AB-729, Antios&#8217; proprietary Active Site Polymerase Inhibitor Nucleotide (ASPIN), ATI-2173, and Viread (tenofovir disoproxil fumarate), a nucleos(t)ide reverse transcriptase inhibitor. However, the majority of patients in this cohort were enrolled in Ukraine and, as a result, these patients have been lost to follow-up before completing the clinical trial. Therefore, we and Antios do not expect to report data on this cohort. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the length and impact of Russia&#8217;s military action is highly unpredictable, actions by Russia, or potentially other countries, against Ukraine and surrounding areas may adversely affect our ability to adequately conduct or complete certain clinical trials and maintain compliance with relevant protocols due to, among other reasons, the prioritization of hospital resources away from clinical trials, reallocation or evacuation of site staff and subjects, or as a result of government-imposed curfews, warfare, violence, or other governmental action or events that restrict movement. These developments may also result in our inability to access sites for monitoring or to obtain data from affected sites or patients going forward. We could also experience disruptions in our supply chain or limits to our ability to provide sufficient investigational materials in Ukraine and surrounding regions. Alternative sites to fully and timely compensate for our clinical trial activities in Ukraine may not be available and we may need to find other countries to conduct these clinical trials. If these clinical trials are further interrupted, our clinical development plans for these product candidates could be significantly delayed, which would increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year-ended December&#160;31, 2021. </span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_106"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;&#160;&#160; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the execution of the license agreement (the &#8220;License Agreement&#8221;) with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;), we entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Anchor Life Limited, a company established pursuant to the applicable laws and regulations of Hong Kong and an affiliate of Qilu (the &#8220;Investor&#8221;), pursuant to which the Investor purchased 3,579,952 of our Common Shares at a purchase price of USD $4.19 per share, which was a 15% premium on the thirty-day average closing price of the Common Shares as of the close of trading on December 10, 2021 (the &#8220;Share Transaction&#8221;). We received $15.0 million of gross proceeds from the Share Transaction on January 6, 2022. The Common Shares sold to the Investor in the Share Transaction represented approximately 2.5% of the Common Shares outstanding immediately prior to the execution of the Share Purchase Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Transaction was exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the Common Shares issued in the Share Transaction were offered and sold without registration under the Securities Act pursuant to the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder as transactions not involving a public offering, as well as similar exemptions under applicable state securities laws, in reliance upon the following facts: no general solicitation was used in the offer or sale of such securities; the recipient of the securities had adequate access to information about us; the recipient of such securities represented its acquisition thereof as principal for its own account and its lack of any arrangements or understandings regarding the distribution of such securities; the recipient of such securities represented its capability of evaluating the merits of an investment in our securities due to its knowledge, sophistication and experience in business and financial matters; and such securities were issued as restricted securities with restricted legend referring to the Securities Act. No such securities may be offered or sold in the United States in the absence of an effective registration statement or exemption from applicable registration requirements.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_109"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;&#160;&#160; DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_112"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4d1c0ae544ca49e89401026bf23c9474_115"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;&#160;&#160; OTHER INFORMATION</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160; EXHIBITS</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.983%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447028/000162828018003276/exhibit31_articlesandartic.htm">Notice of Articles and Articles of the Company, as amended (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/exhibit31amendmenttoarticl.htm">Amendment to Articles of the Company (incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the SEC on November 7, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1447028/000117184315000358/exh_21.htm">Governance Agreement between the Company and Roivant Sciences Ltd., a Bermuda exempted company, dated January 11, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K/A filed with the SEC on January 26, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-q110xqex311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-q110xqex312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-q110xqex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-q110xqex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Arbutus Biopharma Corporation&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Comprehensive Loss; (iv) Condensed Consolidated Statements of Stockholders&#8217; Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) Notes to Condensed Consolidated Financial Statements    </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover page interactive data file (embedded within the inline XBRL document and included in Exhibit 101)</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*    Filed herewith.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**  Furnished herewith.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div><div id="i4d1c0ae544ca49e89401026bf23c9474_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May&#160;5, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARBUTUS BIOPHARMA CORPORATION</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William H Collier</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H Collier</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David C. Hastings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David C. Hastings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2022-q110xqex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i82df64652a934a58af55e54bdaddbacb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i82df64652a934a58af55e54bdaddbacb_4"></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William Collier, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William Collier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; William Collier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer </font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2022-q110xqex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaf6622c2731d48778b9f78fd93026750_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Hastings, certify that&#58; </font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:67.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:94.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Hastings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; David Hastings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2022-q110xqex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ife1436b1c360491fa5a7086e0d102b67_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:15pt;padding-left:90pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:90pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William Collier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; William Collier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer </font></td></tr></table></div><div style="margin-bottom:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2022-q110xqex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i58c32631d32140ec81bcea8a2675f20b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the &#8220;Company&#8221;) for the quarter ended March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I David Hastings, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58; </font></div><div style="margin-bottom:5pt;margin-top:15pt;padding-left:90pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:90pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Hastings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; David Hastings</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer </font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abus-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abus="http://arbutusbio.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://arbutusbio.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://arbutusbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofStockholdersEquityUnaudited" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statement of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowUnaudited" roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofbusinessandfutureoperations" roleURI="http://arbutusbio.com/role/Natureofbusinessandfutureoperations">
        <link:definition>2101101 - Disclosure - Nature of business and future operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofbusinessandfutureoperationsDetails" roleURI="http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails">
        <link:definition>2402401 - Disclosure - Nature of business and future operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantaccountingpolicies" roleURI="http://arbutusbio.com/role/Significantaccountingpolicies">
        <link:definition>2103102 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesPolicies" roleURI="http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesDetails" roleURI="http://arbutusbio.com/role/SignificantaccountingpoliciesDetails">
        <link:definition>2405402 - Disclosure - Significant accounting policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://arbutusbio.com/role/Fairvaluemeasurements">
        <link:definition>2106103 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://arbutusbio.com/role/FairvaluemeasurementsTables">
        <link:definition>2307301 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>2408403 - Disclosure - Fair value measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2409404 - Disclosure - Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails" roleURI="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails">
        <link:definition>2410405 - Disclosure - Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails" roleURI="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails">
        <link:definition>2411406 - Disclosure - Fair value measurements - Changes in Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresandDisclosuresPolicies" roleURI="http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies">
        <link:definition>2212202 - Disclosure - Fair Value Measures and Disclosures (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsinmarketablesecurities" roleURI="http://arbutusbio.com/role/Investmentsinmarketablesecurities">
        <link:definition>2113104 - Disclosure - Investments in marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesTables" roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables">
        <link:definition>2314302 - Disclosure - Investments in marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails" roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails">
        <link:definition>2415407 - Disclosure - Investments in marketable securities - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesNarrativeDetails" roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails">
        <link:definition>2416408 - Disclosure - Investments in marketable securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevant" roleURI="http://arbutusbio.com/role/InvestmentinGenevant">
        <link:definition>2117105 - Disclosure - Investment in Genevant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevantDetails" roleURI="http://arbutusbio.com/role/InvestmentinGenevantDetails">
        <link:definition>2418409 - Disclosure - Investment in Genevant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountspayableandaccruedliabilities" roleURI="http://arbutusbio.com/role/Accountspayableandaccruedliabilities">
        <link:definition>2119106 - Disclosure - Accounts payable and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesTables" roleURI="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables">
        <link:definition>2320303 - Disclosure - Accounts payable and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesDetails" roleURI="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails">
        <link:definition>2421410 - Disclosure - Accounts payable and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Saleoffutureroyalties" roleURI="http://arbutusbio.com/role/Saleoffutureroyalties">
        <link:definition>2122107 - Disclosure - Sale of future royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesTables" roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesTables">
        <link:definition>2323304 - Disclosure - Sale of future royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesNarrativeDetails" roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails">
        <link:definition>2424411 - Disclosure - Sale of future royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesLiabilityActivityDetails" roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails">
        <link:definition>2425412 - Disclosure - Sale of future royalties - Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://arbutusbio.com/role/Contingenciesandcommitments">
        <link:definition>2126108 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsDetails" roleURI="http://arbutusbio.com/role/ContingenciesandcommitmentsDetails">
        <link:definition>2427413 - Disclosure - Contingencies and commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborationscontractsandlicensingagreements" roleURI="http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements">
        <link:definition>2128109 - Disclosure - Collaborations, contracts and licensing agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationscontractsandlicensingagreementsTables" roleURI="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables">
        <link:definition>2329305 - Disclosure - Collaborations, contracts and licensing agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationscontractsandlicensingagreementsDetails" roleURI="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails">
        <link:definition>2430414 - Disclosure - Collaborations, contracts and licensing agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://arbutusbio.com/role/Shareholdersequity">
        <link:definition>2131110 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityTables" roleURI="http://arbutusbio.com/role/ShareholdersequityTables">
        <link:definition>2332306 - Disclosure - Shareholders&#8217; equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityNarrativeDetails" roleURI="http://arbutusbio.com/role/ShareholdersequityNarrativeDetails">
        <link:definition>2433415 - Disclosure - Shareholders&#8217; equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityStockbasedCompensationDetails" roleURI="http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails">
        <link:definition>2434416 - Disclosure - Shareholders&#8217; equity - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactions" roleURI="http://arbutusbio.com/role/Relatedpartytransactions">
        <link:definition>2135111 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsDetails" roleURI="http://arbutusbio.com/role/RelatedpartytransactionsDetails">
        <link:definition>2436417 - Disclosure - Related party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abus_BonaFideCollaborationPercentage" abstract="false" name="BonaFideCollaborationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_XChemIncAndProterosMember" abstract="true" name="XChemIncAndProterosMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OMERSMember" abstract="true" name="OMERSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_A2019AmendedSaleAgreementMember" abstract="true" name="A2019AmendedSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonCashRoyaltyMember" abstract="true" name="NonCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" abstract="true" name="Jan2020Oct2020AndNov2021RegistrationStmtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_AccruedPayrollCurrent" abstract="false" name="AccruedPayrollCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoyaltyEntitlements" abstract="false" name="RoyaltyEntitlements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" abstract="false" name="NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_SharePurchaseAgreementMember" abstract="true" name="SharePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_AcuitasTherapeuticsInc.Member" abstract="true" name="AcuitasTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_CollaborationAndContractsMember" abstract="true" name="CollaborationAndContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OneTimeUpfrontCashPaymentMember" abstract="true" name="OneTimeUpfrontCashPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_October2021ProspectusSupplementMember" abstract="true" name="October2021ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SubLicensingRevenuePercentage" abstract="false" name="SubLicensingRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_TransactionCostsRelatedToSaleOfFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" abstract="false" name="RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" abstract="true" name="FairValueLiabilitiesMeasuredonRecurringBasisRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_USGovernmentBondsMember" abstract="true" name="USGovernmentBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_USGovernmentMoneyMarkeTFundMember" abstract="true" name="USGovernmentMoneyMarkeTFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" abstract="false" name="RoyaltyInterestSoldMaximumRoyaltiesForBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" abstract="false" name="WhollyOwnedSubsidiariesIncludedinFinancialStatements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_PremiumonClosingStockPrice" abstract="false" name="PremiumonClosingStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OtherMilestoneandRoyaltyPaymentsMember" abstract="true" name="OtherMilestoneandRoyaltyPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_March2022ProspectusSupplementMember" abstract="true" name="March2022ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyGuaranteesCommitmentsPercentage" abstract="false" name="RoyaltyGuaranteesCommitmentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" abstract="false" name="IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_Jan2020RegistrationStmtMember" abstract="true" name="Jan2020RegistrationStmtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsTable" abstract="true" name="ContingenciesandCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_GrossProceedsFromRoyaltyInterestSold" abstract="false" name="GrossProceedsFromRoyaltyInterestSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AssemblyBiosciencesIncMember" abstract="true" name="AssemblyBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SaleAgreementMember" abstract="true" name="SaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" abstract="false" name="IncreaseDecreaseInFairValueOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoivantSciencesLtdMember" abstract="true" name="RoivantSciencesLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsLineItems" abstract="true" name="ContingenciesandCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" abstract="false" name="AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ArbutusPlansMember" abstract="true" name="ArbutusPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EffectiveAnnualInterestRateOfRoyaltyLiability" abstract="false" name="EffectiveAnnualInterestRateOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_WeightedAverageNumberOfCommonSharesAbstract" abstract="true" name="WeightedAverageNumberOfCommonSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AccruedResearchAndDevelopment" abstract="false" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EmployeeStockOptionLiabilityClassifiedMember" abstract="true" name="EmployeeStockOptionLiabilityClassifiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EnantigensSellingShareholdersMember" abstract="true" name="EnantigensSellingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Aug2020ProspectusSupplementMember" abstract="true" name="Aug2020ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Jan2020ProspectusSupplementAgreementMember" abstract="true" name="Jan2020ProspectusSupplementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_QiluPharmaceuticalCoLTDMember" abstract="true" name="QiluPharmaceuticalCoLTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RegistrationStatementAxis" abstract="true" name="RegistrationStatementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_ArbutusInc.Member" abstract="true" name="ArbutusInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_GenevantSciencesCorporationMember" abstract="true" name="GenevantSciencesCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" abstract="false" name="EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ChangesInFairValueofLiabilityOptionTableTextBlock" abstract="false" name="ChangesInFairValueofLiabilityOptionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_RoyaltyPayable" abstract="false" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_USGovernmentAgencyBondsMember" abstract="true" name="USGovernmentAgencyBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Jan2020ProspectusSupplementMember" abstract="true" name="Jan2020ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Oct2020RegistrationStmtMember" abstract="true" name="Oct2020RegistrationStmtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RegistrationStatementDomain" abstract="true" name="RegistrationStatementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OtherLiabilitiesDisclosureLineItems" abstract="true" name="OtherLiabilitiesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" abstract="false" name="ArbitrationWithTheUniversityOfBritishColumbiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Mar2021ProspectusSupplementAgreementMember" abstract="true" name="Mar2021ProspectusSupplementAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AlnylamPharmaceuticalsIncMember" abstract="true" name="AlnylamPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RoyaltyPercentageofInterestSold" abstract="false" name="RoyaltyPercentageofInterestSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>abus-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_18a4b4ef-4c09-4ded-948a-33a06d3156fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_03a9c7c6-da76-4ff0-bb11-9f2b9ee4dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18a4b4ef-4c09-4ded-948a-33a06d3156fa" xlink:to="loc_us-gaap_Liabilities_03a9c7c6-da76-4ff0-bb11-9f2b9ee4dd9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bcc65e55-38a0-4481-8fee-4d739689ff94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_18a4b4ef-4c09-4ded-948a-33a06d3156fa" xlink:to="loc_us-gaap_StockholdersEquity_bcc65e55-38a0-4481-8fee-4d739689ff94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_72f6f7f0-5910-4142-b997-2b86cd244bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:to="loc_us-gaap_LiabilitiesCurrent_72f6f7f0-5910-4142-b997-2b86cd244bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_83ba3b1f-fe7f-4915-bad2-4e4751881080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_83ba3b1f-fe7f-4915-bad2-4e4751881080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b3cfc22-663c-414c-a1b8-46a93d616c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4b3cfc22-663c-414c-a1b8-46a93d616c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_6e23f803-50a6-4c2b-ad8a-c180826dca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_6e23f803-50a6-4c2b-ad8a-c180826dca8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_8067b4bb-f6c9-40e7-84c9-d8c045f2ab45" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_34ba8e40-3024-40e5-b6ee-d4e7192021e3" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_8067b4bb-f6c9-40e7-84c9-d8c045f2ab45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c316872-061f-4035-84e1-be89450e0a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e24bdc9f-c9c4-408c-90d6-b6fbff48930b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c316872-061f-4035-84e1-be89450e0a78" xlink:to="loc_us-gaap_CommonStockValue_e24bdc9f-c9c4-408c-90d6-b6fbff48930b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_43a8551c-1eb5-488a-8ab5-dd98252bb3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c316872-061f-4035-84e1-be89450e0a78" xlink:to="loc_us-gaap_AdditionalPaidInCapital_43a8551c-1eb5-488a-8ab5-dd98252bb3ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fbb8eea-4e86-46e2-8364-d048aaa4e28e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c316872-061f-4035-84e1-be89450e0a78" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fbb8eea-4e86-46e2-8364-d048aaa4e28e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_454212e4-eed8-4cbb-b75e-93a74ec3232e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6c316872-061f-4035-84e1-be89450e0a78" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_454212e4-eed8-4cbb-b75e-93a74ec3232e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16190265-e142-440d-bf91-d471cddc8c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bd95dbf1-f2e7-46d1-8461-e716ff1676af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16190265-e142-440d-bf91-d471cddc8c15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bd95dbf1-f2e7-46d1-8461-e716ff1676af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_743af3c8-cf66-4f2c-9042-bc5976788b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16190265-e142-440d-bf91-d471cddc8c15" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_743af3c8-cf66-4f2c-9042-bc5976788b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_343bd510-1869-4315-801d-0de21e67e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_16190265-e142-440d-bf91-d471cddc8c15" xlink:to="loc_us-gaap_DeferredRevenueCurrent_343bd510-1869-4315-801d-0de21e67e1ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ec57691c-2458-4b13-a08b-545d8432d302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7c8bc1a7-50ad-4201-9ef8-ea0d11286bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec57691c-2458-4b13-a08b-545d8432d302" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7c8bc1a7-50ad-4201-9ef8-ea0d11286bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_08f1c6c2-c694-4f67-8b17-812f490178f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec57691c-2458-4b13-a08b-545d8432d302" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_08f1c6c2-c694-4f67-8b17-812f490178f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9edf25fb-24a5-485e-9407-a7c6b9f89009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec57691c-2458-4b13-a08b-545d8432d302" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9edf25fb-24a5-485e-9407-a7c6b9f89009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7d780f8-7940-4af1-9fa2-8a0cb02f0db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ec57691c-2458-4b13-a08b-545d8432d302" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7d780f8-7940-4af1-9fa2-8a0cb02f0db6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9116194-160b-4946-9ac2-a74ffe9b1f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a9116194-160b-4946-9ac2-a74ffe9b1f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6bb7094a-a05a-4915-ad7c-9682bb16015a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6bb7094a-a05a-4915-ad7c-9682bb16015a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8609d7e4-c3fa-485d-9abf-b9cb896535f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:to="loc_us-gaap_AssetsCurrent_8609d7e4-c3fa-485d-9abf-b9cb896535f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_abb72369-edcb-4dc5-b29a-2f95ae3dcfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:to="loc_us-gaap_LongTermInvestments_abb72369-edcb-4dc5-b29a-2f95ae3dcfce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fd9a1e4d-6398-45b4-be5e-318077a5d5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08ffa560-ef14-4957-a249-e107c1c302ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fd9a1e4d-6398-45b4-be5e-318077a5d5ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_27c8cb13-165a-46ce-a0ea-9c19d0404438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2fce9159-5117-4319-9d38-50972f27b108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27c8cb13-165a-46ce-a0ea-9c19d0404438" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2fce9159-5117-4319-9d38-50972f27b108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_22dc9b55-6b1e-4aeb-b1b6-f4938cf41d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27c8cb13-165a-46ce-a0ea-9c19d0404438" xlink:to="loc_us-gaap_InvestmentIncomeInterest_22dc9b55-6b1e-4aeb-b1b6-f4938cf41d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b80e3410-07a8-4d9f-a94e-df811241119e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_27c8cb13-165a-46ce-a0ea-9c19d0404438" xlink:to="loc_us-gaap_InterestExpense_b80e3410-07a8-4d9f-a94e-df811241119e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5aa04589-dfc1-42f8-ad9f-6a1887c0f351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_7ecf869d-7fbe-4027-a60a-cea59fcc958f" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5aa04589-dfc1-42f8-ad9f-6a1887c0f351" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_7ecf869d-7fbe-4027-a60a-cea59fcc958f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_316892d3-5a5f-4f91-bf24-a5a29c6ae354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5aa04589-dfc1-42f8-ad9f-6a1887c0f351" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_316892d3-5a5f-4f91-bf24-a5a29c6ae354" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eeb419d4-934e-4891-90f1-ac8eacc218cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5aa04589-dfc1-42f8-ad9f-6a1887c0f351" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eeb419d4-934e-4891-90f1-ac8eacc218cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05d687e1-f35a-479f-9613-ae51eb8932bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0d3679b4-c092-4a65-b2e8-147f0ef45c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05d687e1-f35a-479f-9613-ae51eb8932bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_0d3679b4-c092-4a65-b2e8-147f0ef45c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fd47b521-9966-478c-93b7-a4ee86dd467c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05d687e1-f35a-479f-9613-ae51eb8932bb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fd47b521-9966-478c-93b7-a4ee86dd467c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a948b0c6-6519-4bb5-b6c0-82fb26fe6ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c2602989-e7f0-461e-be12-396416423809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a948b0c6-6519-4bb5-b6c0-82fb26fe6ad2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c2602989-e7f0-461e-be12-396416423809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_494855f0-633e-48df-a0e7-ab52c64fb73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a948b0c6-6519-4bb5-b6c0-82fb26fe6ad2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_494855f0-633e-48df-a0e7-ab52c64fb73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_297d1b50-3de3-4449-88f8-cdfab3ba0e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06fe92aa-f4f0-48cb-8cec-15b03708e3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_297d1b50-3de3-4449-88f8-cdfab3ba0e02" xlink:to="loc_us-gaap_NetIncomeLoss_06fe92aa-f4f0-48cb-8cec-15b03708e3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_8b5e7a14-e9f4-4ec5-b745-10935479bd97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_297d1b50-3de3-4449-88f8-cdfab3ba0e02" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_8b5e7a14-e9f4-4ec5-b745-10935479bd97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e0a43090-5948-4011-93e9-aded90e99d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_44240bc2-1980-451a-9cef-166d70e1ae69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e0a43090-5948-4011-93e9-aded90e99d5e" xlink:to="loc_us-gaap_Revenues_44240bc2-1980-451a-9cef-166d70e1ae69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9880ea5d-05e8-4305-8f07-26e2ea26951b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e0a43090-5948-4011-93e9-aded90e99d5e" xlink:to="loc_us-gaap_OperatingExpenses_9880ea5d-05e8-4305-8f07-26e2ea26951b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_23cf113d-7a5d-48df-8e69-26b8c6a39580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_88212c64-14e8-42b5-a1c7-bf9c541a38a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_23cf113d-7a5d-48df-8e69-26b8c6a39580" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_88212c64-14e8-42b5-a1c7-bf9c541a38a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51e88a9c-bae8-4d67-a180-72d8a44cbcd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_23cf113d-7a5d-48df-8e69-26b8c6a39580" xlink:to="loc_us-gaap_NetIncomeLoss_51e88a9c-bae8-4d67-a180-72d8a44cbcd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofCashFlowUnaudited"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d97ae59-8cf8-42d5-b66b-c8e49de91866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9b0feefb-dc58-4f15-915b-494a8ab560dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d97ae59-8cf8-42d5-b66b-c8e49de91866" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9b0feefb-dc58-4f15-915b-494a8ab560dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53576689-3e71-49ca-81a9-4ffc7c626c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d97ae59-8cf8-42d5-b66b-c8e49de91866" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_53576689-3e71-49ca-81a9-4ffc7c626c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186bded7-21ed-478f-88e9-52eb05f5b660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d97ae59-8cf8-42d5-b66b-c8e49de91866" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_186bded7-21ed-478f-88e9-52eb05f5b660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_584fb5ac-e775-427e-acfc-ae421bf1fda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d97ae59-8cf8-42d5-b66b-c8e49de91866" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_584fb5ac-e775-427e-acfc-ae421bf1fda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7ea7192-6a5c-40b9-982e-36d71e1f4c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_af3afd76-3ce5-418d-b538-668b4fcf06b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7ea7192-6a5c-40b9-982e-36d71e1f4c97" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_af3afd76-3ce5-418d-b538-668b4fcf06b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_527a4785-573e-418f-a8a7-7df18b9cb33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7ea7192-6a5c-40b9-982e-36d71e1f4c97" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_527a4785-573e-418f-a8a7-7df18b9cb33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b6e7131b-8b6e-4067-bbeb-63b72a162d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7ea7192-6a5c-40b9-982e-36d71e1f4c97" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b6e7131b-8b6e-4067-bbeb-63b72a162d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_3e00b598-e83f-4e51-81dd-638255dd01f1" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_3e00b598-e83f-4e51-81dd-638255dd01f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aca47146-3370-4ed4-89e1-78ba507f6feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aca47146-3370-4ed4-89e1-78ba507f6feb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_531a968b-e13f-43b2-8a64-0193dac1fd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_531a968b-e13f-43b2-8a64-0193dac1fd6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5b948dce-44c8-4c39-ae57-5c1825012d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5b948dce-44c8-4c39-ae57-5c1825012d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14c33458-e1c6-447f-ade5-48eb714ca90b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_14c33458-e1c6-447f-ade5-48eb714ca90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3d3cc94d-3d56-41d2-b28a-96913f8b1a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_NetIncomeLoss_3d3cc94d-3d56-41d2-b28a-96913f8b1a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d9af01d5-0091-48dd-976b-ec906dd5e116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d9af01d5-0091-48dd-976b-ec906dd5e116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_780e2fa2-6e30-4cf5-9cb5-b8fa8c271c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_780e2fa2-6e30-4cf5-9cb5-b8fa8c271c61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ca5c0f7-0bc7-4517-9ac2-c80a6588bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_ShareBasedCompensation_7ca5c0f7-0bc7-4517-9ac2-c80a6588bd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_55f0bf3e-337a-4eb9-9107-18d348dbf6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_55f0bf3e-337a-4eb9-9107-18d348dbf6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_315be8c6-6d6c-4af4-8ed5-e3c60f6b1fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_315be8c6-6d6c-4af4-8ed5-e3c60f6b1fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9788209e-c5cb-4434-bbac-5ea98ab81e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9788209e-c5cb-4434-bbac-5ea98ab81e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_c6e84b13-6c0e-4e10-a422-2022ac5f61b9" xlink:href="abus-20220331.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53e9f6c2-3663-4bb6-ba73-753aaa4a89a0" xlink:to="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_c6e84b13-6c0e-4e10-a422-2022ac5f61b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a62f9f9b-ee8c-4fa8-9599-609d113d0ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6a8beddc-a094-4639-aaa2-a6b51defb053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a62f9f9b-ee8c-4fa8-9599-609d113d0ffe" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6a8beddc-a094-4639-aaa2-a6b51defb053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18c310d1-adfd-49a7-8103-f6e4287dae9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a62f9f9b-ee8c-4fa8-9599-609d113d0ffe" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18c310d1-adfd-49a7-8103-f6e4287dae9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_4e2ddca7-9354-4134-962a-625d646348df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a62f9f9b-ee8c-4fa8-9599-609d113d0ffe" xlink:to="loc_us-gaap_ProceedsFromStockPlans_4e2ddca7-9354-4134-962a-625d646348df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d09b6331-0f18-451c-95d8-fb85df3313e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_9ad61495-3d50-445e-bd46-5ee2fa88ee2a" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d09b6331-0f18-451c-95d8-fb85df3313e4" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_9ad61495-3d50-445e-bd46-5ee2fa88ee2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_510e33c9-9705-452a-8fb2-eec795036c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d09b6331-0f18-451c-95d8-fb85df3313e4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_510e33c9-9705-452a-8fb2-eec795036c80" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#AccountspayableandaccruedliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_06aca8e3-900c-4f53-8eb5-9ee19ac607ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_06aca8e3-900c-4f53-8eb5-9ee19ac607ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedResearchAndDevelopment_69f79532-33d2-4981-b91b-90b87e0ee52d" xlink:href="abus-20220331.xsd#abus_AccruedResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:to="loc_abus_AccruedResearchAndDevelopment_69f79532-33d2-4981-b91b-90b87e0ee52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e4c7d72-b36a-446c-92a3-4a84f6971346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7e4c7d72-b36a-446c-92a3-4a84f6971346" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedPayrollCurrent_8018f24d-8b97-4d18-9b8d-321e6d4b4b63" xlink:href="abus-20220331.xsd#abus_AccruedPayrollCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:to="loc_abus_AccruedPayrollCurrent_8018f24d-8b97-4d18-9b8d-321e6d4b4b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_53d60d8d-533c-440e-8518-52c77f01f1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_957ef266-42fc-422c-9b30-c97ef1539a0b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_53d60d8d-533c-440e-8518-52c77f01f1a1" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>abus-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended" id="iaf784cdc6f7243289fa99f2655a30d17_CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d3a7c8c9-e806-4034-a06e-bfb8cae3b887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:to="loc_us-gaap_Revenues_d3a7c8c9-e806-4034-a06e-bfb8cae3b887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_84725f38-ad26-4480-b89b-e9768f2c86a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_84725f38-ad26-4480-b89b-e9768f2c86a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81996091-fbff-4c39-9b5a-91c98e5e3a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81996091-fbff-4c39-9b5a-91c98e5e3a31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_8dc183aa-ef9a-4def-8665-d8c8375d1ec0" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_8dc183aa-ef9a-4def-8665-d8c8375d1ec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_40f789d2-e660-4f6f-b5e5-7d5b2904398c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_OperatingExpenses_40f789d2-e660-4f6f-b5e5-7d5b2904398c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c649f77-a15f-4014-8a3a-271363944680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_OperatingIncomeLoss_1c649f77-a15f-4014-8a3a-271363944680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9fbc77d8-e239-48f5-9d30-d7c1f7c15aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9fbc77d8-e239-48f5-9d30-d7c1f7c15aae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f9f8b9bf-8fd8-486b-8e88-d4f2d693cd99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_InterestExpense_f9f8b9bf-8fd8-486b-8e88-d4f2d693cd99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_18d8a5ab-5e52-4316-8eb5-22489fec5412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_18d8a5ab-5e52-4316-8eb5-22489fec5412" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d0b9ef25-1574-4a27-9919-94581d38631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d0b9ef25-1574-4a27-9919-94581d38631f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b375ca1-9a00-4cc1-bb19-ba9066d86a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b375ca1-9a00-4cc1-bb19-ba9066d86a1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f157c48f-23af-4e01-ad02-5d79d5dd3a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NetIncomeLoss_f157c48f-23af-4e01-ad02-5d79d5dd3a37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e8624820-90bb-4e00-be22-ecfe3bd92816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e8624820-90bb-4e00-be22-ecfe3bd92816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e7e8d699-b612-4c49-a5a9-719f33f39ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e7e8d699-b612-4c49-a5a9-719f33f39ccf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_202f12c6-99ea-4504-8373-60efff6ff3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:to="loc_us-gaap_EarningsPerShareBasic_202f12c6-99ea-4504-8373-60efff6ff3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_93ab536d-edc4-455a-968c-cd86a2b888bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:to="loc_us-gaap_EarningsPerShareDiluted_93ab536d-edc4-455a-968c-cd86a2b888bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:href="abus-20220331.xsd#abus_WeightedAverageNumberOfCommonSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee1e3759-93e9-45e1-bb05-4ef0726355ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee1e3759-93e9-45e1-bb05-4ef0726355ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a48bc76-cbd7-4651-b211-f19abbcf92f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a48bc76-cbd7-4651-b211-f19abbcf92f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7a9f05c2-b7d4-4b92-9252-702279aa3782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7a9f05c2-b7d4-4b92-9252-702279aa3782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_42bcf901-f50e-4180-b777-3bc2673900ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_42bcf901-f50e-4180-b777-3bc2673900ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_430bcb07-9ab8-4d70-b56e-0fa757295c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_430bcb07-9ab8-4d70-b56e-0fa757295c91" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:to="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aefa9ba3-2f24-4fca-94bc-cf7130580b08_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:to="loc_srt_ProductsAndServicesDomain_aefa9ba3-2f24-4fca-94bc-cf7130580b08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:to="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_CollaborationAndContractsMember_09910896-350a-48c5-8e33-60700312064a" xlink:href="abus-20220331.xsd#abus_CollaborationAndContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:to="loc_abus_CollaborationAndContractsMember_09910896-350a-48c5-8e33-60700312064a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyMember_a1c26c00-7601-4347-88ae-781936786368" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:to="loc_abus_NonCashRoyaltyMember_a1c26c00-7601-4347-88ae-781936786368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:to="loc_us-gaap_EquityComponentDomain_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e71214e-2652-4833-805f-e3ca32e23646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:to="loc_us-gaap_EquityComponentDomain_9e71214e-2652-4833-805f-e3ca32e23646" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited" xlink:type="extended" id="i5a93ae64c143416aa0df54a71876d1cd_CondensedConsolidatedStatementofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6e43bf03-19ef-49c8-96ad-172cb6ebd76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_SharesIssued_6e43bf03-19ef-49c8-96ad-172cb6ebd76d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7640f81a-3972-4193-987f-c141c6cffdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockholdersEquity_7640f81a-3972-4193-987f-c141c6cffdb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_c95150dd-6b30-44e7-9c13-0b3835ba0779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_c95150dd-6b30-44e7-9c13-0b3835ba0779" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a6bb10b-26e4-48ad-9505-ccf28da77b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a6bb10b-26e4-48ad-9505-ccf28da77b1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_cf7e1d66-d49c-4331-b5bd-4e58e5d97dcf" xlink:href="abus-20220331.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_cf7e1d66-d49c-4331-b5bd-4e58e5d97dcf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9af8a5f7-a97a-4875-ba1d-8ecf3349d618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9af8a5f7-a97a-4875-ba1d-8ecf3349d618" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcd4cdc9-a223-4a83-955b-72263c770ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcd4cdc9-a223-4a83-955b-72263c770ae2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a28cc66-e5d1-4e81-8e7a-c108540aae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a28cc66-e5d1-4e81-8e7a-c108540aae75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f355e941-bc2a-49cc-99c2-f3aca169440f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f355e941-bc2a-49cc-99c2-f3aca169440f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_db0b25db-12d3-4c05-89ab-858251d2a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_db0b25db-12d3-4c05-89ab-858251d2a5e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542729b2-9d40-434b-9f02-abf24b8605d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542729b2-9d40-434b-9f02-abf24b8605d7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6950a51a-4976-4aa3-a58d-01fe9860e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6950a51a-4976-4aa3-a58d-01fe9860e1fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_beb75632-bbcb-4b44-9461-826e2a65db9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_NetIncomeLoss_beb75632-bbcb-4b44-9461-826e2a65db9f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_77954b4a-4bbc-4725-8b68-9073b038abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d537a891-13d0-49a7-99b8-0c0d8b5cd09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:to="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25b12428-d3d0-4ece-a907-579042772e32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:to="loc_us-gaap_EquityComponentDomain_25b12428-d3d0-4ece-a907-579042772e32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:to="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_58f108e0-7dc4-4b8d-a66d-02b70403c80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_CommonStockMember_58f108e0-7dc4-4b8d-a66d-02b70403c80d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14954f7c-7a77-4b41-867b-39e2909ffe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14954f7c-7a77-4b41-867b-39e2909ffe81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ab922a0-7286-42b0-b26c-ed0b183d9222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_RetainedEarningsMember_1ab922a0-7286-42b0-b26c-ed0b183d9222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a8745337-8590-4763-a123-2d67ca3b9d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a8745337-8590-4763-a123-2d67ca3b9d13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_cedd5327-ceb2-4bad-96a0-3b1201bb7852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_PreferredStockMember_cedd5327-ceb2-4bad-96a0-3b1201bb7852" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d68ee02-474f-46e1-bcd8-7d183291dcf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d68ee02-474f-46e1-bcd8-7d183291dcf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OpenMarketSaleAgreementMember_e50beb34-def3-40d2-96f3-10392e45fbf9" xlink:href="abus-20220331.xsd#abus_OpenMarketSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:to="loc_abus_OpenMarketSaleAgreementMember_e50beb34-def3-40d2-96f3-10392e45fbf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharePurchaseAgreementMember_fb5ce655-2d36-46c5-91e6-04204f31dd1e" xlink:href="abus-20220331.xsd#abus_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:to="loc_abus_SharePurchaseAgreementMember_fb5ce655-2d36-46c5-91e6-04204f31dd1e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofCashFlowUnaudited"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="extended" id="ib434120a0978465fa51e86d4f10310ad_CondensedConsolidatedStatementsofCashFlowUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ec6df8e-1ee4-4531-8b28-63d57d251eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_NetIncomeLoss_1ec6df8e-1ee4-4531-8b28-63d57d251eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c15b87fa-03d7-4f77-8ef5-bff4051cc6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c15b87fa-03d7-4f77-8ef5-bff4051cc6bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_591de1df-b509-4ded-88f8-efea79785dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_ShareBasedCompensation_591de1df-b509-4ded-88f8-efea79785dd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7b98b4a2-d7d9-489f-9468-aa208104f642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7b98b4a2-d7d9-489f-9468-aa208104f642" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a122bcf8-70e7-41ce-87d1-0724bf3ac754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a122bcf8-70e7-41ce-87d1-0724bf3ac754" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0a51f168-c25c-48f0-bafb-74b137a5ec59" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0a51f168-c25c-48f0-bafb-74b137a5ec59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b854e4f0-0f6e-4cdf-a918-b7f814d847e7" xlink:href="abus-20220331.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b854e4f0-0f6e-4cdf-a918-b7f814d847e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aa4a3d73-5205-445c-903f-0b3f76323751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aa4a3d73-5205-445c-903f-0b3f76323751" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f5f2a7c-5e21-498d-b4d6-6d088db2f987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f5f2a7c-5e21-498d-b4d6-6d088db2f987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c557ef0e-b2a0-4985-8695-07c834db0eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c557ef0e-b2a0-4985-8695-07c834db0eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed856cd-98a7-40ab-84f8-1aed622d54af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed856cd-98a7-40ab-84f8-1aed622d54af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5d2eecef-e135-4e52-b34f-d5c54552b221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5d2eecef-e135-4e52-b34f-d5c54552b221" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfbe010f-32ac-41cb-a6fc-38a0a4851a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfbe010f-32ac-41cb-a6fc-38a0a4851a60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90bee6d0-c74c-4728-9732-2cfef389c970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90bee6d0-c74c-4728-9732-2cfef389c970" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fbb9b695-2c60-4a2d-9ad6-ba5638066886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fbb9b695-2c60-4a2d-9ad6-ba5638066886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8584bcf-9294-4cc1-b95b-b58f42501c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8584bcf-9294-4cc1-b95b-b58f42501c16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8c3c487-1cb9-47ca-b382-74cead6881f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8c3c487-1cb9-47ca-b382-74cead6881f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f89e4daa-24d0-434d-a104-d505849122b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f89e4daa-24d0-434d-a104-d505849122b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9df1dc82-e9a3-499e-a8c5-18033a6e0eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9df1dc82-e9a3-499e-a8c5-18033a6e0eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b96c22b8-507d-4aad-b25a-10dda9e148cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b96c22b8-507d-4aad-b25a-10dda9e148cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7a0ee6ce-6509-40f8-96f1-7c4d2c2502b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7a0ee6ce-6509-40f8-96f1-7c4d2c2502b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_edff77db-8448-4d20-938b-c7dd8aabae42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_edff77db-8448-4d20-938b-c7dd8aabae42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edeec956-1758-45d3-b766-8fcaf27e1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edeec956-1758-45d3-b766-8fcaf27e1aa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ac041ec-e0e5-4b48-8956-fc58d8aefc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ac041ec-e0e5-4b48-8956-fc58d8aefc8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58846618-2b8d-4fda-9e81-e853330b443e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58846618-2b8d-4fda-9e81-e853330b443e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e13418bb-c95f-497b-88c0-06573ebdd596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_519183df-91fc-4439-b02a-99453af489d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:to="loc_us-gaap_DividendsPreferredStockCash_519183df-91fc-4439-b02a-99453af489d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharePurchaseAgreementMember_dccf8b50-1c7c-4ca9-bfd8-8ddfc03a014b" xlink:href="abus-20220331.xsd#abus_SharePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:to="loc_abus_SharePurchaseAgreementMember_dccf8b50-1c7c-4ca9-bfd8-8ddfc03a014b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OpenMarketSaleAgreementMember_03ef7fad-a774-4d10-9c86-4b17f25f4108" xlink:href="abus-20220331.xsd#abus_OpenMarketSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:to="loc_abus_OpenMarketSaleAgreementMember_03ef7fad-a774-4d10-9c86-4b17f25f4108" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#SignificantaccountingpoliciesDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SignificantaccountingpoliciesDetails" xlink:type="extended" id="id31f7f5e2c414bf58198c7f609465d44_SignificantaccountingpoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_affe0d89-ecbe-4c10-9662-f4c91cabed64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_affe0d89-ecbe-4c10-9662-f4c91cabed64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_93e696a5-b402-4493-9feb-e2f2cf5b08a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_93e696a5-b402-4493-9feb-e2f2cf5b08a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_f846bc21-8e84-4e0f-ac31-5596832e0cff" xlink:href="abus-20220331.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_f846bc21-8e84-4e0f-ac31-5596832e0cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_403efc64-7155-437c-908d-3b0fbf26a54e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_403efc64-7155-437c-908d-3b0fbf26a54e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_679f4c8e-6a6d-41bb-9dc4-5bc7d9b51938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:to="loc_us-gaap_EmployeeStockOptionMember_679f4c8e-6a6d-41bb-9dc4-5bc7d9b51938" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i68e16d5955a04d638e1e6d7557ece185_FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54dbde46-5be5-4444-b669-7b5cfe85c622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54dbde46-5be5-4444-b669-7b5cfe85c622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b23354da-e38e-4e1d-b44b-91e1ceecfbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b23354da-e38e-4e1d-b44b-91e1ceecfbb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2b4c21aa-5e5d-44dc-aed9-df0ae3218b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_LongTermInvestments_2b4c21aa-5e5d-44dc-aed9-df0ae3218b3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0faed7f7-7608-436f-8ed3-21e39ed753a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0faed7f7-7608-436f-8ed3-21e39ed753a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_fe7887ab-4bd2-41e0-86f3-2ac0e6f0561a" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_fe7887ab-4bd2-41e0-86f3-2ac0e6f0561a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ed2cba3-f85a-4d1a-8d4b-aa66ccb34988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ed2cba3-f85a-4d1a-8d4b-aa66ccb34988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ec56da96-6e81-4a32-b324-4caec91dcea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ec56da96-6e81-4a32-b324-4caec91dcea0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_50afc22d-6447-4658-ace9-a281660f128c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_50afc22d-6447-4658-ace9-a281660f128c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5cf8a0b3-0307-49d9-9b55-37aa9a149ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5cf8a0b3-0307-49d9-9b55-37aa9a149ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b782307b-b19b-4afc-8b63-982aaac712b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b782307b-b19b-4afc-8b63-982aaac712b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_90a3e143-c4d6-481d-9224-1cb4d362af0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_90a3e143-c4d6-481d-9224-1cb4d362af0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_17b300c6-b4fe-487c-a75d-fc791739d582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_17b300c6-b4fe-487c-a75d-fc791739d582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c859a81-ec6e-4601-9de5-60b35ff90dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c859a81-ec6e-4601-9de5-60b35ff90dfa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails" xlink:type="extended" id="i0499bb5f0a364c1c965fe9d55207e3f2_FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:href="abus-20220331.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f9e0fd14-e034-4ab6-b775-2c4dcd30c5d4" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f9e0fd14-e034-4ab6-b775-2c4dcd30c5d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_de389d49-4c58-4486-83dd-f7191429f9c1" xlink:href="abus-20220331.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_de389d49-4c58-4486-83dd-f7191429f9c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_b5bf72ad-4ca4-45a6-b33d-f6f87ec5380f" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_b5bf72ad-4ca4-45a6-b33d-f6f87ec5380f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f1b3b113-e4e3-4362-8336-13daed90857d" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:to="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5ae66ed-a765-4fc0-906c-ed195f867aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5ae66ed-a765-4fc0-906c-ed195f867aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_1e777527-8e37-4b7a-b13a-5588d4c0e96c" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:to="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_1e777527-8e37-4b7a-b13a-5588d4c0e96c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails" xlink:type="extended" id="ia59b91daff0145dab30a9d523427bba8_InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db2c90f0-7c85-4a23-948d-2128b482db95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db2c90f0-7c85-4a23-948d-2128b482db95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41b7ddb1-7a8c-401b-922d-a538484e63f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41b7ddb1-7a8c-401b-922d-a538484e63f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_178449ce-8f45-45d6-9769-617dd753ef74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_178449ce-8f45-45d6-9769-617dd753ef74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99f8be1d-ac21-405a-b9d0-12c1aa47df69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99f8be1d-ac21-405a-b9d0-12c1aa47df69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2817f200-6479-4041-be9d-8d77144ad739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2817f200-6479-4041-be9d-8d77144ad739" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2451819-40a3-4347-be24-3f447e84fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2451819-40a3-4347-be24-3f447e84fdd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_893b1758-8a98-4fac-b118-a331f8fd5d62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_893b1758-8a98-4fac-b118-a331f8fd5d62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_4a12b564-29a9-4e77-8466-64a63b9a9361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:to="loc_us-gaap_CashEquivalentsMember_4a12b564-29a9-4e77-8466-64a63b9a9361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d03788f-3f04-4148-a751-8cdb08434e32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d03788f-3f04-4148-a751-8cdb08434e32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentMoneyMarkeTFundMember_55f672b2-5781-425c-a14b-01817502d141" xlink:href="abus-20220331.xsd#abus_USGovernmentMoneyMarkeTFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentMoneyMarkeTFundMember_55f672b2-5781-425c-a14b-01817502d141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_a83c7b5d-dc34-468a-bd88-8ac92a630f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_a83c7b5d-dc34-468a-bd88-8ac92a630f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentAgencyBondsMember_bb468e46-ceab-47e9-b6d5-789c224a1988" xlink:href="abus-20220331.xsd#abus_USGovernmentAgencyBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentAgencyBondsMember_bb468e46-ceab-47e9-b6d5-789c224a1988" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentBondsMember_10ab301b-cc96-4e54-a73d-79c66126ef42" xlink:href="abus-20220331.xsd#abus_USGovernmentBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentBondsMember_10ab301b-cc96-4e54-a73d-79c66126ef42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_0977ce12-0d5b-4bfd-8020-d2adf7601807_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_0977ce12-0d5b-4bfd-8020-d2adf7601807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4b978410-13db-4a13-9604-b6727b4ba3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4b978410-13db-4a13-9604-b6727b4ba3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LongTermInvestmentsMember_f1e4aaf3-90eb-4911-b487-cbb081ec386c" xlink:href="abus-20220331.xsd#abus_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:to="loc_abus_LongTermInvestmentsMember_f1e4aaf3-90eb-4911-b487-cbb081ec386c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentinGenevantDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentinGenevantDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/InvestmentinGenevantDetails" xlink:type="extended" id="id81471649ee142808bdba7b5ae5d7ea1_InvestmentinGenevantDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SubLicensingRevenuePercentage_c9b08b1b-607b-4be1-bbfa-c95c7d9a487b" xlink:href="abus-20220331.xsd#abus_SubLicensingRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_abus_SubLicensingRevenuePercentage_c9b08b1b-607b-4be1-bbfa-c95c7d9a487b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34b299db-06b7-4bf6-9714-562717e295ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34b299db-06b7-4bf6-9714-562717e295ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0abf2eee-0ece-4fa7-ab44-87a8cbbfa11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_us-gaap_EquityMethodInvestments_0abf2eee-0ece-4fa7-ab44-87a8cbbfa11c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_BonaFideCollaborationPercentage_69f60f82-5708-4176-af9e-fd4362b1ac45" xlink:href="abus-20220331.xsd#abus_BonaFideCollaborationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_abus_BonaFideCollaborationPercentage_69f60f82-5708-4176-af9e-fd4362b1ac45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_725afed9-5c2c-4d65-8a57-77ad576fb155_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_725afed9-5c2c-4d65-8a57-77ad576fb155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_ab4048e2-4d8b-4a04-95ae-9d304ec2fdea" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:to="loc_abus_GenevantSciencesCorporationMember_ab4048e2-4d8b-4a04-95ae-9d304ec2fdea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#SaleoffutureroyaltiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="extended" id="i37ab84baafb14062982862e73eda173a_SaleoffutureroyaltiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:href="abus-20220331.xsd#abus_OtherLiabilitiesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_2ebdb7d1-0bea-45dd-8983-b757540775b2" xlink:href="abus-20220331.xsd#abus_RoyaltyPercentageofInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_2ebdb7d1-0bea-45dd-8983-b757540775b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_8c866b8e-0032-4bde-821d-458463e2a35a" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_8c866b8e-0032-4bde-821d-458463e2a35a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_760c63f9-e109-4034-b03a-52468dae4d1b" xlink:href="abus-20220331.xsd#abus_GrossProceedsFromRoyaltyInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_760c63f9-e109-4034-b03a-52468dae4d1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_f32c39c8-106f-4fc8-8b5e-ca850c5e50d1" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_f32c39c8-106f-4fc8-8b5e-ca850c5e50d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_4a94f366-12ab-4bbd-a8e7-bbec5c2509ab" xlink:href="abus-20220331.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_4a94f366-12ab-4bbd-a8e7-bbec5c2509ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPayable_fccc2dca-513f-4037-93ba-f881ccd2a06d" xlink:href="abus-20220331.xsd#abus_RoyaltyPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyPayable_fccc2dca-513f-4037-93ba-f881ccd2a06d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_013ebb3e-478a-4516-9f56-571830627891" xlink:href="abus-20220331.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_013ebb3e-478a-4516-9f56-571830627891" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_3a24f760-4fa8-4d03-a094-90f098291efb" xlink:href="abus-20220331.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_3a24f760-4fa8-4d03-a094-90f098291efb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c5c4b46c-9b34-45bb-8ff5-b36b820da8bb" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c5c4b46c-9b34-45bb-8ff5-b36b820da8bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_eb4048fa-19bc-474c-8643-7051a8fd63cb" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_eb4048fa-19bc-474c-8643-7051a8fd63cb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:to="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ed6e674-00d9-490f-a37d-ef80b5132bdb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2ed6e674-00d9-490f-a37d-ef80b5132bdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OMERSMember_fd40d50d-37e7-4042-897d-02f2212154b3" xlink:href="abus-20220331.xsd#abus_OMERSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:to="loc_abus_OMERSMember_fd40d50d-37e7-4042-897d-02f2212154b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:to="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31b300aa-9196-43ad-b9ce-b3557fe68ca9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:to="loc_srt_RangeMember_31b300aa-9196-43ad-b9ce-b3557fe68ca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:to="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_737595c6-0381-457a-bc56-53b70fb477e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:to="loc_srt_MinimumMember_737595c6-0381-457a-bc56-53b70fb477e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68084db-4fa3-4849-8502-1cdaac8a5ca3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:to="loc_srt_MaximumMember_a68084db-4fa3-4849-8502-1cdaac8a5ca3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesandcommitmentsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ContingenciesandcommitmentsDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/ContingenciesandcommitmentsDetails" xlink:type="extended" id="i02deb804e03848bfb05989b3791a9770_ContingenciesandcommitmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_7daadfe0-338f-427f-9610-702aaf6a0c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_7daadfe0-338f-427f-9610-702aaf6a0c13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_64089645-8908-474a-b2d2-c0a5eac30040" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_64089645-8908-474a-b2d2-c0a5eac30040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_6e3ea80b-80d7-4575-841c-caa52023b41e" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_6e3ea80b-80d7-4575-841c-caa52023b41e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c44a7a69-fa75-4c9d-ab30-15283e5dd503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c44a7a69-fa75-4c9d-ab30-15283e5dd503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cbf463bb-be52-4122-b84c-9377be86cd3a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:to="loc_srt_LitigationCaseTypeDomain_cbf463bb-be52-4122-b84c-9377be86cd3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:to="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_19338eff-dc1c-4f1e-9d48-5b4762ab961e" xlink:href="abus-20220331.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_19338eff-dc1c-4f1e-9d48-5b4762ab961e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6910a107-810a-414e-b7a3-136327c8462c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6910a107-810a-414e-b7a3-136327c8462c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EnantigensSellingShareholdersMember_6836723c-d172-4169-88d2-83746883f3f7" xlink:href="abus-20220331.xsd#abus_EnantigensSellingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:to="loc_abus_EnantigensSellingShareholdersMember_6836723c-d172-4169-88d2-83746883f3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_035720fc-d4cb-4ec6-933b-66efc6430c7a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:to="loc_dei_EntityDomain_035720fc-d4cb-4ec6-933b-66efc6430c7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:to="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusInc.Member_30fd52af-59ab-41f6-873e-e15b087fa55c" xlink:href="abus-20220331.xsd#abus_ArbutusInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:to="loc_abus_ArbutusInc.Member_30fd52af-59ab-41f6-873e-e15b087fa55c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e44e98e4-373d-4e21-aedc-112792914567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e44e98e4-373d-4e21-aedc-112792914567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EnantigensSellingShareholdersMember_c24169ca-6be1-436d-8f56-f342b6816dc1" xlink:href="abus-20220331.xsd#abus_EnantigensSellingShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:to="loc_abus_EnantigensSellingShareholdersMember_c24169ca-6be1-436d-8f56-f342b6816dc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b3e2887-c67d-4068-912e-692e83218753_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3b3e2887-c67d-4068-912e-692e83218753_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1c9a35a9-a2c2-4d71-9ed7-d2ee2fb510a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1c9a35a9-a2c2-4d71-9ed7-d2ee2fb510a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#CollaborationscontractsandlicensingagreementsDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails" xlink:type="extended" id="i5e5443fe12404e55a5d04bc13a7a4f19_CollaborationscontractsandlicensingagreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_98341c46-45f3-46e8-ad98-e8ea06dc3d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_98341c46-45f3-46e8-ad98-e8ea06dc3d6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyEntitlements_28d6bf9d-7efe-4cf7-9be2-d2e18e187fc0" xlink:href="abus-20220331.xsd#abus_RoyaltyEntitlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyEntitlements_28d6bf9d-7efe-4cf7-9be2-d2e18e187fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_3e4ebfb0-2c3d-43dc-bc14-d22735518457" xlink:href="abus-20220331.xsd#abus_RoyaltyPercentageofInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_3e4ebfb0-2c3d-43dc-bc14-d22735518457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_9aea46fa-a968-484b-a123-c1431140c862" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_9aea46fa-a968-484b-a123-c1431140c862" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_f54c6ce5-de64-4156-8f8f-1350f9963f75" xlink:href="abus-20220331.xsd#abus_GrossProceedsFromRoyaltyInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_f54c6ce5-de64-4156-8f8f-1350f9963f75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_5367945b-ec45-403d-a9f8-0e10a12c0f62" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_5367945b-ec45-403d-a9f8-0e10a12c0f62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_463fbb05-3014-4805-8829-61d40338ff49" xlink:href="abus-20220331.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_463fbb05-3014-4805-8829-61d40338ff49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPayable_2c53430f-940e-4a45-acf5-af73399123a0" xlink:href="abus-20220331.xsd#abus_RoyaltyPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyPayable_2c53430f-940e-4a45-acf5-af73399123a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_11e7b218-b927-4cb2-89dc-119c1e864189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_Revenues_11e7b218-b927-4cb2-89dc-119c1e864189" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PotentialMilestonePayments_af3fc3b5-8279-410d-95e0-c98400a94e53" xlink:href="abus-20220331.xsd#abus_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_PotentialMilestonePayments_af3fc3b5-8279-410d-95e0-c98400a94e53" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_8e4c31e8-a011-463c-b944-e9228e9a2296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_8e4c31e8-a011-463c-b944-e9228e9a2296" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_83a46b03-4017-4bf2-8eb1-482329d1db41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_CommonStockSharesIssued_83a46b03-4017-4bf2-8eb1-482329d1db41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3b5438eb-c8b2-4d82-846f-8b6e369e5518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_SharePrice_3b5438eb-c8b2-4d82-846f-8b6e369e5518" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d71ddf9-2f5c-4726-82f2-8adbea264902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d71ddf9-2f5c-4726-82f2-8adbea264902" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3c098d42-97aa-4eeb-90ab-6dccdd62f3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3c098d42-97aa-4eeb-90ab-6dccdd62f3fd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_605f5772-a055-4f8d-b931-129e4269d962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_605f5772-a055-4f8d-b931-129e4269d962" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1c472491-8cfa-466b-93dc-955e6b69f338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1c472491-8cfa-466b-93dc-955e6b69f338" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_58f83bf5-cfcc-499e-8eaa-d0738537a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_DeferredRevenueCurrent_58f83bf5-cfcc-499e-8eaa-d0738537a5de" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_baef82a2-1c58-48eb-9e93-63d9955a5f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_baef82a2-1c58-48eb-9e93-63d9955a5f71" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_465092ab-6ba0-44fb-9243-8c1dd08b4565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_IncomeTaxesPaid_465092ab-6ba0-44fb-9243-8c1dd08b4565" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_960e93c2-e825-4f4e-9998-235be2db0dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_960e93c2-e825-4f4e-9998-235be2db0dbe" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCostsGross_f72c6b92-3ff6-434e-acd2-456c45a39705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_OtherDeferredCostsGross_f72c6b92-3ff6-434e-acd2-456c45a39705" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PremiumonClosingStockPrice_027fd74f-6082-4192-83b3-d59b685b61c5" xlink:href="abus-20220331.xsd#abus_PremiumonClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_PremiumonClosingStockPrice_027fd74f-6082-4192-83b3-d59b685b61c5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_46b96a10-ecd5-41e4-a3a6-e4f7ee1b8515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_46b96a10-ecd5-41e4-a3a6-e4f7ee1b8515" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c4c345fb-ead1-4f2a-aeb0-d3d3f509b61d" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c4c345fb-ead1-4f2a-aeb0-d3d3f509b61d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_31b49e04-90a0-4665-9ada-8545934ba4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_PremiumsEarnedNet_31b49e04-90a0-4665-9ada-8545934ba4bd" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49a1c505-58b7-490c-88c5-849bb83d93c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_49a1c505-58b7-490c-88c5-849bb83d93c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AssemblyBiosciencesIncMember_b7d8d675-4ec3-4af8-80d8-31b383783e95" xlink:href="abus-20220331.xsd#abus_AssemblyBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AssemblyBiosciencesIncMember_b7d8d675-4ec3-4af8-80d8-31b383783e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OMERSMember_f45e9a60-463d-458d-88a6-1af6d52613e4" xlink:href="abus-20220331.xsd#abus_OMERSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_OMERSMember_f45e9a60-463d-458d-88a6-1af6d52613e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AcuitasTherapeuticsInc.Member_8ecce3e2-2a48-4238-adda-99fa42ee899e" xlink:href="abus-20220331.xsd#abus_AcuitasTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AcuitasTherapeuticsInc.Member_8ecce3e2-2a48-4238-adda-99fa42ee899e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherMilestoneandRoyaltyPaymentsMember_c6368a94-9009-460a-96ad-8a08c7c41b32" xlink:href="abus-20220331.xsd#abus_OtherMilestoneandRoyaltyPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_OtherMilestoneandRoyaltyPaymentsMember_c6368a94-9009-460a-96ad-8a08c7c41b32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AlnylamPharmaceuticalsIncMember_eba51143-d76c-410f-8058-20fe4d85fb3b" xlink:href="abus-20220331.xsd#abus_AlnylamPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AlnylamPharmaceuticalsIncMember_eba51143-d76c-410f-8058-20fe4d85fb3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_3e230b62-57c1-4230-a03a-0840433b8be6" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_3e230b62-57c1-4230-a03a-0840433b8be6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_XChemIncAndProterosMember_9ab749cb-e42f-4be6-a888-e3bca7c7d17e" xlink:href="abus-20220331.xsd#abus_XChemIncAndProterosMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_XChemIncAndProterosMember_9ab749cb-e42f-4be6-a888-e3bca7c7d17e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_624d50b2-70e4-4dd1-a396-212559270fcb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:to="loc_srt_RangeMember_624d50b2-70e4-4dd1-a396-212559270fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:to="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3630762b-3fb2-409b-909c-075430e6135f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:to="loc_srt_MinimumMember_3630762b-3fb2-409b-909c-075430e6135f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8c665c3-cc40-4f13-bead-4f0b405024ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:to="loc_srt_MaximumMember_b8c665c3-cc40-4f13-bead-4f0b405024ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_241f8b0a-8918-4e50-a1b7-70ad972e2709_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:to="loc_srt_ProductsAndServicesDomain_241f8b0a-8918-4e50-a1b7-70ad972e2709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:to="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eb537dcc-7cab-4bdb-91db-cc780c2b4c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:to="loc_us-gaap_LicenseMember_eb537dcc-7cab-4bdb-91db-cc780c2b4c1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyMember_ca654fd1-e9c8-4911-8aef-e6255dd19068" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:to="loc_abus_NonCashRoyaltyMember_ca654fd1-e9c8-4911-8aef-e6255dd19068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_63afb5ce-478a-4724-997a-6d5bc4fd77bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_63afb5ce-478a-4724-997a-6d5bc4fd77bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_6b71d5ba-5644-4310-a8d9-fb4dbda8d50b" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:to="loc_abus_GenevantSciencesCorporationMember_6b71d5ba-5644-4310-a8d9-fb4dbda8d50b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bdb138c6-1c81-461f-adb8-b2f3f9047104_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_bdb138c6-1c81-461f-adb8-b2f3f9047104_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b60bcd37-3af3-4201-a93e-dc2438440ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b60bcd37-3af3-4201-a93e-dc2438440ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0328174d-c74f-4148-a308-8ea684d709ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0328174d-c74f-4148-a308-8ea684d709ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OneTimeUpfrontCashPaymentMember_4e53cee4-2d27-4be2-9ce6-ebce8a4d23f9" xlink:href="abus-20220331.xsd#abus_OneTimeUpfrontCashPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:to="loc_abus_OneTimeUpfrontCashPaymentMember_4e53cee4-2d27-4be2-9ce6-ebce8a4d23f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_96f9625f-efcb-4532-b39e-42c64cb8b1e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:to="loc_us-gaap_ClassOfStockDomain_96f9625f-efcb-4532-b39e-42c64cb8b1e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:to="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2e6756c-e289-461c-8450-e7bf40ddad67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:to="loc_us-gaap_CommonStockMember_c2e6756c-e289-461c-8450-e7bf40ddad67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_90f4c022-18d7-46ca-b66a-e041d126204d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:to="loc_srt_OwnershipDomain_90f4c022-18d7-46ca-b66a-e041d126204d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:to="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_23d535f4-afe7-497f-9c89-66e80bbacb4c" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_23d535f4-afe7-497f-9c89-66e80bbacb4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_481ff6fa-89a7-4f4e-aca8-7f410be4c48a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:to="loc_srt_NameOfMajorCustomerDomain_481ff6fa-89a7-4f4e-aca8-7f410be4c48a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:to="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_2b530e44-508e-4f4c-a91e-5d45d324dcf2" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_2b530e44-508e-4f4c-a91e-5d45d324dcf2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ShareholdersequityNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ShareholdersequityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/ShareholdersequityNarrativeDetails" xlink:type="extended" id="if22b0c310d054792931472fb23bff59f_ShareholdersequityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_b480f6cc-2a62-41a5-a721-625dc89efbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_b480f6cc-2a62-41a5-a721-625dc89efbca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c195d87b-73b0-40f9-99b5-458568906fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c195d87b-73b0-40f9-99b5-458568906fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0210c862-4ce9-42cf-9360-e98a6b56b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0210c862-4ce9-42cf-9360-e98a6b56b565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46cf7801-7305-4914-843b-408ed1fd1e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46cf7801-7305-4914-843b-408ed1fd1e49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4db02a4a-a9ab-4e1c-acf6-0e159c7bf14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4db02a4a-a9ab-4e1c-acf6-0e159c7bf14a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PremiumonClosingStockPrice_fa1c6fc8-47e4-40ca-bdbe-c8db39211ca7" xlink:href="abus-20220331.xsd#abus_PremiumonClosingStockPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_abus_PremiumonClosingStockPrice_fa1c6fc8-47e4-40ca-bdbe-c8db39211ca7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5b230bd9-a0a8-4602-a7aa-b30fdd397ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_SharePrice_5b230bd9-a0a8-4602-a7aa-b30fdd397ef0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_a9595778-35b3-45c6-a6b6-0eb96d5e856e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_a9595778-35b3-45c6-a6b6-0eb96d5e856e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_468eb412-5d66-4800-85dd-894c9eb7ee62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_468eb412-5d66-4800-85dd-894c9eb7ee62" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6bf42ecd-d9d7-4ebf-ad22-a315daa4d954" xlink:href="abus-20220331.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6bf42ecd-d9d7-4ebf-ad22-a315daa4d954" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f490a809-cadc-4af2-92c6-e860a01af07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f490a809-cadc-4af2-92c6-e860a01af07e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afddf6d-f063-4be6-94ba-a4cfc67835ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2afddf6d-f063-4be6-94ba-a4cfc67835ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_JefferiesLLCMember_407550d5-75f6-4f0c-9c66-324ee332b949" xlink:href="abus-20220331.xsd#abus_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:to="loc_abus_JefferiesLLCMember_407550d5-75f6-4f0c-9c66-324ee332b949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoivantSciencesLtdMember_c742e745-8eb3-4834-91f0-6d90ab8acffa" xlink:href="abus-20220331.xsd#abus_RoivantSciencesLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:to="loc_abus_RoivantSciencesLtdMember_c742e745-8eb3-4834-91f0-6d90ab8acffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41f2b374-7b2d-41f5-ae13-87da8b8fc028_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:to="loc_us-gaap_ClassOfStockDomain_41f2b374-7b2d-41f5-ae13-87da8b8fc028_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:to="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8c337de4-dc65-44cb-b6c4-4fa2185985aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:to="loc_us-gaap_CommonStockMember_8c337de4-dc65-44cb-b6c4-4fa2185985aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3d5fea4c-d506-49f7-bdd1-da03924b4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3d5fea4c-d506-49f7-bdd1-da03924b4a35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33b2a9a9-c11f-4173-ac59-3b39ae734d3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_33b2a9a9-c11f-4173-ac59-3b39ae734d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_A2019AmendedSaleAgreementMember_7978ebfa-461d-46d4-bc5e-50f9a6d89499" xlink:href="abus-20220331.xsd#abus_A2019AmendedSaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_A2019AmendedSaleAgreementMember_7978ebfa-461d-46d4-bc5e-50f9a6d89499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020RegistrationStmtMember_7c2e66ca-b75d-4f65-906b-b1b9ca92aada" xlink:href="abus-20220331.xsd#abus_Jan2020RegistrationStmtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020RegistrationStmtMember_7c2e66ca-b75d-4f65-906b-b1b9ca92aada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementAgreementMember_5b2008c6-9437-4713-8e73-ddd386e2bf06" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020ProspectusSupplementAgreementMember_5b2008c6-9437-4713-8e73-ddd386e2bf06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SaleAgreementMember_6cf78e70-6434-4f1c-a0c0-5f49a2903e00" xlink:href="abus-20220331.xsd#abus_SaleAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_SaleAgreementMember_6cf78e70-6434-4f1c-a0c0-5f49a2903e00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Oct2020RegistrationStmtMember_c047ecca-6891-4817-a112-44ee8bb85e8c" xlink:href="abus-20220331.xsd#abus_Oct2020RegistrationStmtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Oct2020RegistrationStmtMember_c047ecca-6891-4817-a112-44ee8bb85e8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Mar2021ProspectusSupplementAgreementMember_86507bb0-b222-4090-9d3d-6e028ba680a3" xlink:href="abus-20220331.xsd#abus_Mar2021ProspectusSupplementAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Mar2021ProspectusSupplementAgreementMember_86507bb0-b222-4090-9d3d-6e028ba680a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_October2021ProspectusSupplementMember_516aec8d-8384-47a4-8995-cb0143c966ed" xlink:href="abus-20220331.xsd#abus_October2021ProspectusSupplementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_October2021ProspectusSupplementMember_516aec8d-8384-47a4-8995-cb0143c966ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_March2022ProspectusSupplementMember_e8a315b2-624a-401d-9451-9dc6b95791e6" xlink:href="abus-20220331.xsd#abus_March2022ProspectusSupplementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_March2022ProspectusSupplementMember_e8a315b2-624a-401d-9451-9dc6b95791e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementMember_5165d029-a6ee-429b-acc3-df70fb8a32fc" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020ProspectusSupplementMember_5165d029-a6ee-429b-acc3-df70fb8a32fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Aug2020ProspectusSupplementMember_abc21dbf-2584-40b1-85e2-0536d1d0c9ec" xlink:href="abus-20220331.xsd#abus_Aug2020ProspectusSupplementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Aug2020ProspectusSupplementMember_abc21dbf-2584-40b1-85e2-0536d1d0c9ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:href="abus-20220331.xsd#abus_RegistrationStatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementDomain_ac504ffe-690e-4610-b40c-523203ba4a7a_default" xlink:href="abus-20220331.xsd#abus_RegistrationStatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:to="loc_abus_RegistrationStatementDomain_ac504ffe-690e-4610-b40c-523203ba4a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:href="abus-20220331.xsd#abus_RegistrationStatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:to="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020RegistrationStmtMember_090de930-0801-45b3-9ec2-0dd456a394d5" xlink:href="abus-20220331.xsd#abus_Jan2020RegistrationStmtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Jan2020RegistrationStmtMember_090de930-0801-45b3-9ec2-0dd456a394d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Oct2020RegistrationStmtMember_371e3f36-864c-4184-8668-95497f8e0406" xlink:href="abus-20220331.xsd#abus_Oct2020RegistrationStmtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Oct2020RegistrationStmtMember_371e3f36-864c-4184-8668-95497f8e0406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_2b80024e-7d04-464a-baa5-e2cd24137238" xlink:href="abus-20220331.xsd#abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_2b80024e-7d04-464a-baa5-e2cd24137238" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ShareholdersequityStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails" xlink:type="extended" id="ie75d774c6efe47498178b73ac1f9259d_ShareholdersequityStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_039cccc9-d47a-4c2a-8056-ff9bb1edd8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_039cccc9-d47a-4c2a-8056-ff9bb1edd8d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d28c4f0d-8c83-40a6-8596-60afdc81e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d28c4f0d-8c83-40a6-8596-60afdc81e52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a960206-c7e8-4b77-b8ea-012972285c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a960206-c7e8-4b77-b8ea-012972285c12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:to="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f73e25c8-ca8a-4e00-98d3-a2893236faad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:to="loc_us-gaap_PlanNameDomain_f73e25c8-ca8a-4e00-98d3-a2893236faad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:to="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusPlansMember_520fb115-63a9-424a-8a4a-c1bd801304c3" xlink:href="abus-20220331.xsd#abus_ArbutusPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:to="loc_abus_ArbutusPlansMember_520fb115-63a9-424a-8a4a-c1bd801304c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cf3fc62e-4ab5-4669-8b56-b160ccc633fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cf3fc62e-4ab5-4669-8b56-b160ccc633fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5acaba0d-3537-474c-a826-78ea52398d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5acaba0d-3537-474c-a826-78ea52398d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5db18a8-c05e-49c5-9bf6-78760e237dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5db18a8-c05e-49c5-9bf6-78760e237dca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedpartytransactionsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#RelatedpartytransactionsDetails"/>
  <link:definitionLink xlink:role="http://arbutusbio.com/role/RelatedpartytransactionsDetails" xlink:type="extended" id="i3e1f7c801eae4a25baa8eac79e65d107_RelatedpartytransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_c7abb016-c238-4b49-8eff-0e4eb0efab18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_c7abb016-c238-4b49-8eff-0e4eb0efab18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:to="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502194ce-7006-440f-a635-e17b041fc5ae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_502194ce-7006-440f-a635-e17b041fc5ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_d19c0b7f-4818-4631-9733-c52882e79d98" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:to="loc_abus_GenevantSciencesCorporationMember_d19c0b7f-4818-4631-9733-c52882e79d98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember_c5f57f73-344c-475c-9762-0f2dfe776e47" xlink:href="abus-20220331.xsd#abus_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:to="loc_abus_ResearchAndDevelopmentServicesMember_c5f57f73-344c-475c-9762-0f2dfe776e47" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abus-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_63a5c5da-65f1-46d8-b480-007c0e3811cf_terseLabel_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration with the University of British Columbia</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_label_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbitration With The University Of British Columbia [Member]</link:label>
    <link:label id="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_documentation_en-US" xlink:label="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to arbitration with the University of British Columbia.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:href="abus-20220331.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:to="lab_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e4ee9f64-a7cf-43f3-9d48-6c8ad1d9b000_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_613dc872-1bad-48ef-b26a-588acd45e762_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_6de2a0d3-55f7-4c4c-ad14-f171009220d7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of accumulated dividends on Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_label_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8e05bdd8-2e79-418a-b828-a96665faf92f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RegistrationStatementAxis_91614d8e-3f24-4cf5-9e2a-8d824b478f0a_terseLabel_en-US" xlink:label="lab_abus_RegistrationStatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Axis]</link:label>
    <link:label id="lab_abus_RegistrationStatementAxis_label_en-US" xlink:label="lab_abus_RegistrationStatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Axis]</link:label>
    <link:label id="lab_abus_RegistrationStatementAxis_documentation_en-US" xlink:label="lab_abus_RegistrationStatementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementAxis" xlink:href="abus-20220331.xsd#abus_RegistrationStatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RegistrationStatementAxis" xlink:to="lab_abus_RegistrationStatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_d78fcf4e-022b-4a45-81e6-6de1548fd546_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_23159e86-d6f2-4f9c-9cf3-1b92b9c14faa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b166bcbe-4163-42c8-a306-1c47dddba0cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67fd871a-e2ee-41aa-97aa-48091bb54a40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2362c008-588f-4c2f-b77e-648e47f9f137_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_39050464-1a0e-47f7-87cc-3d6092d3f66e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b91b5318-d865-4e5d-bcd5-f215cd0aa148_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_3a7054da-544f-4a96-a498-a5bd7ee0916b_verboseLabel_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genevant</link:label>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_1013ce55-97d6-4796-8a46-d414a18d55ac_terseLabel_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genevant Sciences Corporation</link:label>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_label_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genevant Sciences Corporation [Member]</link:label>
    <link:label id="lab_abus_GenevantSciencesCorporationMember_documentation_en-US" xlink:label="lab_abus_GenevantSciencesCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genevant Sciences Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GenevantSciencesCorporationMember" xlink:to="lab_abus_GenevantSciencesCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_53607e45-08be-41ea-86b9-a3a2b6785c12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dc4ecd2a-3024-4fe3-a25f-df9e8ceb4b22_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b638636c-47cc-4a41-a76a-d2efe88db5d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_ea8a6f10-f521-4b4f-8560-e254a4aca4e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9c4b67e3-7d1b-421f-aadd-52ac00b1fef3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4d530312-91b9-447d-a43a-bc28078a234f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_OtherMilestoneandRoyaltyPaymentsMember_60de59cd-c3ef-4f29-b708-e0ff07f90037_terseLabel_en-US" xlink:label="lab_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other milestone and royalty payments</link:label>
    <link:label id="lab_abus_OtherMilestoneandRoyaltyPaymentsMember_label_en-US" xlink:label="lab_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Milestone and Royalty Payments [Member]</link:label>
    <link:label id="lab_abus_OtherMilestoneandRoyaltyPaymentsMember_documentation_en-US" xlink:label="lab_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Milestone and Royalty Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:href="abus-20220331.xsd#abus_OtherMilestoneandRoyaltyPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:to="lab_abus_OtherMilestoneandRoyaltyPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_77d083f0-d258-48e9-b6fa-ca570e4ff78f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_6627fe3a-a81a-48f2-8994-e7ee3518d254_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US treasury bills</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_45b66f6d-9f78-4966-bc98-6be84b43e8fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0b54a1ad-bd5b-4ec4-b515-dc3dc218630f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_54c947f0-f12d-4b1b-a01a-6b04053b10c2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_241f7f46-b5a5-4e2a-984f-d15a165a159c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_92f20c97-8dda-4e83-9da5-84f6cf5d22b1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f5d46a28-f921-4da1-b7b4-e6c79f9f2f7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_4689208b-9dd7-4069-9b8c-5233ddc46274_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred collaborations and contracts revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8ecb7436-7212-4199-a2ed-168eb0b1709b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8eb3f90a-2737-4a5f-87e2-afbf8619b351_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93d74f24-eaa9-4316-a015-70b3a5bb78ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ee292927-856f-46f6-8b11-4bbd03c813d8_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4768f3d9-d566-4c36-b548-f0a1d19be6d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4d227757-b964-42a4-9e5e-cff0c41210d7_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_87b2ed37-af34-48cb-aa83-c0fb2745a5ab_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b3819ea0-6798-47eb-9c3a-62c643426f4d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_USGovernmentMoneyMarkeTFundMember_0b245cbc-510c-4111-a209-fd1e11bdf4ab_terseLabel_en-US" xlink:label="lab_abus_USGovernmentMoneyMarkeTFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government money market fund</link:label>
    <link:label id="lab_abus_USGovernmentMoneyMarkeTFundMember_label_en-US" xlink:label="lab_abus_USGovernmentMoneyMarkeTFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Money Marke tFund [Member]</link:label>
    <link:label id="lab_abus_USGovernmentMoneyMarkeTFundMember_documentation_en-US" xlink:label="lab_abus_USGovernmentMoneyMarkeTFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Money Marke tFund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentMoneyMarkeTFundMember" xlink:href="abus-20220331.xsd#abus_USGovernmentMoneyMarkeTFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_USGovernmentMoneyMarkeTFundMember" xlink:to="lab_abus_USGovernmentMoneyMarkeTFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5ff9d2cc-b2c4-4525-b590-99f0bcf3f228_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_22eed285-6e95-4cf1-86f3-e36ae940b51a_terseLabel_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual interest rate on royalty liability</link:label>
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_label_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Annual Interest Rate Of Royalty Liability</link:label>
    <link:label id="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_documentation_en-US" xlink:label="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Annual Interest Rate Of Royalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:href="abus-20220331.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:to="lab_abus_EffectiveAnnualInterestRateOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bfa9029d-ff99-4d82-8eda-444ff018aed0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_b42312b4-559f-4b09-a8d1-379433bc13e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3674071d-5c81-4713-b232-b788f0c4f9cf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e049bf54-bb15-41a2-84d3-e2f447c6bbdb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_23e1bc79-f90d-4b94-895a-082c87b59254_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_October2021ProspectusSupplementMember_dad5972b-f66b-4145-8d71-a529ad3d62ac_terseLabel_en-US" xlink:label="lab_abus_October2021ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 Prospectus Supplement</link:label>
    <link:label id="lab_abus_October2021ProspectusSupplementMember_label_en-US" xlink:label="lab_abus_October2021ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 Prospectus Supplement [Member]</link:label>
    <link:label id="lab_abus_October2021ProspectusSupplementMember_documentation_en-US" xlink:label="lab_abus_October2021ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">October 2021 Prospectus Supplement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_October2021ProspectusSupplementMember" xlink:href="abus-20220331.xsd#abus_October2021ProspectusSupplementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_October2021ProspectusSupplementMember" xlink:to="lab_abus_October2021ProspectusSupplementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e5a859ec-4ba7-4375-8973-85149f0d7e19_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c678481c-bb19-4e27-af7c-96ec3c69b7c0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6e2c8406-72c7-42dd-a72e-49ba60c916b4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_35c0aaf2-3627-47b9-8337-ad0f12deca68_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_8b68dfe9-7418-40a4-894a-f0351acc27d8_terseLabel_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development services</link:label>
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_abus_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_abus_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember" xlink:href="abus-20220331.xsd#abus_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ResearchAndDevelopmentServicesMember" xlink:to="lab_abus_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_158a361b-0781-45cb-a894-b1a1f23f8312_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_2d935b3e-a6f6-468d-9d3c-099029afb0b4_terseLabel_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain fair value adjustments to liability stock option awards</link:label>
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_label_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</link:label>
    <link:label id="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_documentation_en-US" xlink:label="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:href="abus-20220331.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:to="lab_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7a881b6b-73c5-4e49-9fc4-c335005f47b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ab3c9f21-10d3-45b0-b2ba-4c23e8c42f6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_EnantigensSellingShareholdersMember_94cc5ec2-4708-41a3-a90f-5406e744f530_terseLabel_en-US" xlink:label="lab_abus_EnantigensSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enantigen's Selling Shareholders</link:label>
    <link:label id="lab_abus_EnantigensSellingShareholdersMember_label_en-US" xlink:label="lab_abus_EnantigensSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enantigen's Selling Shareholders [Member]</link:label>
    <link:label id="lab_abus_EnantigensSellingShareholdersMember_documentation_en-US" xlink:label="lab_abus_EnantigensSellingShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enantigen's Selling Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EnantigensSellingShareholdersMember" xlink:href="abus-20220331.xsd#abus_EnantigensSellingShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EnantigensSellingShareholdersMember" xlink:to="lab_abus_EnantigensSellingShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e44f7738-e089-4ad9-ba66-a785ef79bbca_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive common shares excluded from calculation of loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f6204a47-5fa3-4b66-b6e2-57529242c96e_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_97ad680f-0656-4419-b60a-8c9ee90c0af1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0f3c76c1-50ad-4fb7-9ed5-fff598cb723c_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2579c6fd-6738-472f-a6c9-f0ac88c876ab_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at end of the period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_182516f7-24db-489a-b359-b9061226158a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Collaboration Revenue Recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_31a7dbd4-9bf9-4592-9055-0734c912e4d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_cb293350-6482-4bf9-998a-6f79d399dad1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c50ba1c8-bb7c-48f5-8552-11bebd4cea8a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_09316800-6588-47f8-bb67-a5f975b7e9e6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3367c37f-fcb9-4639-bd99-6d683c2c8dfe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stated value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_fe3d2440-7c25-4231-8484-5c3f712146d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c197201d-6691-431b-b3ba-a807c08f74eb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_4316992c-eaed-42f6-9af1-f78c4c3963cb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7461c932-3412-438e-b940-37fe58f50339_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9b87c7-e26f-49e7-8ad5-798b14924e63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_60227d71-8315-4cb7-80ee-5122846b9bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d4cbc667-7673-4ee4-adca-0ff212e37ed6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e66d96ef-08f3-464e-8023-ea4537608b26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_39dd65ba-7a53-4582-b0d0-dd07f1c6e729_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6c586f3a-ee0d-4209-8fe3-720c0432846a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_eb48b412-98ff-4e1d-8988-e4328f4457ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_60e7732d-8830-4ec2-9acc-555425e33305_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_5078a24b-30a5-4433-af87-d923b0477b1f_terseLabel_en-US" xlink:label="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:href="abus-20220331.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:to="lab_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_9e43f039-28ff-4d7f-96ae-0afd38866b86_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_OneTimeUpfrontCashPaymentMember_84e5464e-8664-4580-bb6f-9b533920d0ad_terseLabel_en-US" xlink:label="lab_abus_OneTimeUpfrontCashPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Time Upfront Cash Payment</link:label>
    <link:label id="lab_abus_OneTimeUpfrontCashPaymentMember_label_en-US" xlink:label="lab_abus_OneTimeUpfrontCashPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Time Upfront Cash Payment [Member]</link:label>
    <link:label id="lab_abus_OneTimeUpfrontCashPaymentMember_documentation_en-US" xlink:label="lab_abus_OneTimeUpfrontCashPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Time Upfront Cash Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OneTimeUpfrontCashPaymentMember" xlink:href="abus-20220331.xsd#abus_OneTimeUpfrontCashPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OneTimeUpfrontCashPaymentMember" xlink:to="lab_abus_OneTimeUpfrontCashPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_13c8825b-f435-4099-9c45-e24ef8470c7e_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_f8226f91-7006-45d1-9e9f-b79eb772e087_terseLabel_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_label_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:label id="lab_abus_OtherLiabilitiesDisclosureLineItems_documentation_en-US" xlink:label="lab_abus_OtherLiabilitiesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems" xlink:href="abus-20220331.xsd#abus_OtherLiabilitiesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems" xlink:to="lab_abus_OtherLiabilitiesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_33176cd3-f7bc-4d84-af2b-203140296259_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3fb8e0ef-185c-488e-8aa2-a6f0f8d957bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a1d31913-83cb-4976-afe6-860fc1bffa10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_93500fd9-45f6-4087-969c-a6d99d0ccd7f_terseLabel_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from sale of royalty interest. before advisory fees</link:label>
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_label_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Royalty Interest Sold</link:label>
    <link:label id="lab_abus_GrossProceedsFromRoyaltyInterestSold_documentation_en-US" xlink:label="lab_abus_GrossProceedsFromRoyaltyInterestSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds From Royalty Interest Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold" xlink:href="abus-20220331.xsd#abus_GrossProceedsFromRoyaltyInterestSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_GrossProceedsFromRoyaltyInterestSold" xlink:to="lab_abus_GrossProceedsFromRoyaltyInterestSold" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_JefferiesLLCMember_47cc3ae3-6c06-49c9-a75b-a48824c1c402_terseLabel_en-US" xlink:label="lab_abus_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_abus_JefferiesLLCMember_label_en-US" xlink:label="lab_abus_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_abus_JefferiesLLCMember_documentation_en-US" xlink:label="lab_abus_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_JefferiesLLCMember" xlink:href="abus-20220331.xsd#abus_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_JefferiesLLCMember" xlink:to="lab_abus_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a2f10287-51a7-43ff-9994-f326b23343c6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4c6e743e-27d4-468e-b094-bb513e896daa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposition of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c5430fe5-63e1-45f5-b912-f439babc3cb2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_23644849-1939-4222-9647-7346811f13b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ad9dbe2d-57a7-4f11-aa95-d94739f0553e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2180ab9a-8c60-4afe-b0f9-221c2bd0519a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AlnylamPharmaceuticalsIncMember_59725fb6-38ad-46fc-ae07-ee70f4d9f568_terseLabel_en-US" xlink:label="lab_abus_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_abus_AlnylamPharmaceuticalsIncMember_label_en-US" xlink:label="lab_abus_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_abus_AlnylamPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_abus_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AlnylamPharmaceuticalsIncMember" xlink:href="abus-20220331.xsd#abus_AlnylamPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AlnylamPharmaceuticalsIncMember" xlink:to="lab_abus_AlnylamPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AccruedResearchAndDevelopment_3176f46a-adc1-4fa5-a452-377e9943706f_terseLabel_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accruals</link:label>
    <link:label id="lab_abus_AccruedResearchAndDevelopment_label_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development</link:label>
    <link:label id="lab_abus_AccruedResearchAndDevelopment_documentation_en-US" xlink:label="lab_abus_AccruedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedResearchAndDevelopment" xlink:href="abus-20220331.xsd#abus_AccruedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedResearchAndDevelopment" xlink:to="lab_abus_AccruedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a154863d-1685-42e8-8f46-e0d4805da5e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_43d45b34-5ef7-4c4c-8aa5-b4aaf3540eb3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ea430f15-256d-4f68-9f33-dc23bf36f89a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_5842d7ae-79f5-42a4-82b4-82b206c89d59_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Jan2020ProspectusSupplementMember_e6c4393a-46c9-41e1-bd30-7438bdadf02a_terseLabel_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement</link:label>
    <link:label id="lab_abus_Jan2020ProspectusSupplementMember_label_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement [Member]</link:label>
    <link:label id="lab_abus_Jan2020ProspectusSupplementMember_documentation_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementMember" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Jan2020ProspectusSupplementMember" xlink:to="lab_abus_Jan2020ProspectusSupplementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDeferredCostsGross_b1bf01cc-74b5-47ff-be10-53aed88d32b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDeferredCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Deferred Costs, Gross</link:label>
    <link:label id="lab_us-gaap_OtherDeferredCostsGross_label_en-US" xlink:label="lab_us-gaap_OtherDeferredCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Deferred Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCostsGross" xlink:to="lab_us-gaap_OtherDeferredCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a932b11f-3def-4a1e-aa61-bd46e5eb9955_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_fb56ce43-b8ad-4be9-834b-faf5ee6f4d44_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_47910e95-b41c-49d9-8214-0b6e3635fa77_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_b716908f-b05e-47b4-bf2f-25a62641e17d_terseLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to sale of future royalties</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_3645e02d-24a2-45b5-98c3-d5eb8fa7a91f_periodStartLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net liability related to sale of future royalties - beginning balance</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_1c3ac979-2ed1-456b-b53b-6b6fb2335235_periodEndLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net liability related to sale of future royalties - ending balance</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_label_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Noncurrent</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_documentation_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2ce3d609-5b59-41ea-8b56-0c5fb5e470b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_PotentialMilestonePayments_d64d2859-859d-4dfb-be47-b8bb7da8832e_terseLabel_en-US" xlink:label="lab_abus_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_abus_PotentialMilestonePayments_label_en-US" xlink:label="lab_abus_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_abus_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_abus_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the potential milestone payments amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PotentialMilestonePayments" xlink:href="abus-20220331.xsd#abus_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PotentialMilestonePayments" xlink:to="lab_abus_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_74591a64-2d31-41f5-8d6d-8847be21ae84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_8b2ceb40-c624-4d5b-97ca-28571dfb6803_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9891b53-ba10-4e9d-928d-06eadfce0d1f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bd377e45-c2fe-494a-b5ac-3d6eb027d710_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to the Open Market Sale agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_207d486a-9b90-44c8-a391-db6979a6212d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of shares under the agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_80d4c255-cdf6-48d2-bbf4-453cfd995ae7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred license revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a54c50d5-b1ad-4fad-a910-bd5c2536d61b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_7d785b0e-ae08-47e3-8275-8cf19371ad71_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsTable_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsTable" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsTable" xlink:to="lab_abus_ContingenciesandCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_397278a8-d4f0-47f2-a635-350322ebb98d_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_32be9735-4abc-4234-9827-0c8ed3776ee0_terseLabel_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly-owed subsidiaries</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_label_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly Owned Subsidiaries Included in Financial Statements</link:label>
    <link:label id="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_documentation_en-US" xlink:label="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:href="abus-20220331.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:to="lab_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8a12f201-22e7-4794-a218-60c8296cd46c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_1e6515e7-ceb0-40fc-9baf-fd1a8d9503d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_SaleAgreementMember_e22fb6c0-fba6-4cb8-995c-09366d45d680_terseLabel_en-US" xlink:label="lab_abus_SaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Agreement [Member]</link:label>
    <link:label id="lab_abus_SaleAgreementMember_label_en-US" xlink:label="lab_abus_SaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Agreement [Member]</link:label>
    <link:label id="lab_abus_SaleAgreementMember_documentation_en-US" xlink:label="lab_abus_SaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SaleAgreementMember" xlink:href="abus-20220331.xsd#abus_SaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SaleAgreementMember" xlink:to="lab_abus_SaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_10164d13-8d4e-4766-8d48-98b077c36475_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shares</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f521e1f5-7317-4c08-8895-af983d456c7a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9ce0ad26-5d1c-4bd1-b6a3-7eed5bc713d4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_4c98a36d-b3f0-406a-93a3-c0a2eb19ab1f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_f0b64876-eb4c-432d-a92e-8d5ea9265fe3_verboseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones payment per licensed compound series, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per License</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Maximum Development and Regulatory Milestone Payments Per License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:to="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_5c2a4f78-582e-49b0-937b-1e738d1e6be4_verboseLabel_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty guarantees commitments percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_label_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees Commitments Percentage</link:label>
    <link:label id="lab_abus_RoyaltyGuaranteesCommitmentsPercentage_documentation_en-US" xlink:label="lab_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the royalty guarantees commitments percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:href="abus-20220331.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:to="lab_abus_RoyaltyGuaranteesCommitmentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyEntitlements_e71586a3-43b6-4e54-a78a-ba07b5b19fe8_terseLabel_en-US" xlink:label="lab_abus_RoyaltyEntitlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of royalty entitlements</link:label>
    <link:label id="lab_abus_RoyaltyEntitlements_label_en-US" xlink:label="lab_abus_RoyaltyEntitlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Entitlements</link:label>
    <link:label id="lab_abus_RoyaltyEntitlements_documentation_en-US" xlink:label="lab_abus_RoyaltyEntitlements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Entitlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyEntitlements" xlink:href="abus-20220331.xsd#abus_RoyaltyEntitlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyEntitlements" xlink:to="lab_abus_RoyaltyEntitlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8b291268-8700-4425-9f52-9e6189783669_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_NonCashRoyaltyMember_07d0ee98-1ceb-4a2d-912c-e8d9ff83b212_terseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_NonCashRoyaltyMember_label_en-US" xlink:label="lab_abus_NonCashRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Royalty [Member]</link:label>
    <link:label id="lab_abus_NonCashRoyaltyMember_documentation_en-US" xlink:label="lab_abus_NonCashRoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyMember" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashRoyaltyMember" xlink:to="lab_abus_NonCashRoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_SharePurchaseAgreementMember_c98b615d-0c06-4929-9282-67f72f37d159_terseLabel_en-US" xlink:label="lab_abus_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:label id="lab_abus_SharePurchaseAgreementMember_label_en-US" xlink:label="lab_abus_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement [Member]</link:label>
    <link:label id="lab_abus_SharePurchaseAgreementMember_documentation_en-US" xlink:label="lab_abus_SharePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharePurchaseAgreementMember" xlink:href="abus-20220331.xsd#abus_SharePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SharePurchaseAgreementMember" xlink:to="lab_abus_SharePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_fbba86e4-6542-4e50-acab-224a9f10038d_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_2b487f4e-bc38-4554-893c-6be130b847f6_negatedLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Royalty Income</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Royalty Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e385c7-253d-40c1-89a1-cece1108816e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_SubLicensingRevenuePercentage_c0f8291a-af7a-4d6f-bc48-36b1454a3c95_terseLabel_en-US" xlink:label="lab_abus_SubLicensingRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-licensing revenue percentage</link:label>
    <link:label id="lab_abus_SubLicensingRevenuePercentage_label_en-US" xlink:label="lab_abus_SubLicensingRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-licensing revenue Percentage</link:label>
    <link:label id="lab_abus_SubLicensingRevenuePercentage_documentation_en-US" xlink:label="lab_abus_SubLicensingRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-licensing revenue Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SubLicensingRevenuePercentage" xlink:href="abus-20220331.xsd#abus_SubLicensingRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SubLicensingRevenuePercentage" xlink:to="lab_abus_SubLicensingRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a593be3d-6e2d-4312-894a-dba8f17d181e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AssemblyBiosciencesIncMember_95feb26d-0b3b-4435-840f-81c8c0bb4683_terseLabel_en-US" xlink:label="lab_abus_AssemblyBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembly Biosciences, Inc.</link:label>
    <link:label id="lab_abus_AssemblyBiosciencesIncMember_label_en-US" xlink:label="lab_abus_AssemblyBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembly Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_abus_AssemblyBiosciencesIncMember_documentation_en-US" xlink:label="lab_abus_AssemblyBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembly Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AssemblyBiosciencesIncMember" xlink:href="abus-20220331.xsd#abus_AssemblyBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AssemblyBiosciencesIncMember" xlink:to="lab_abus_AssemblyBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_798140ed-a0ad-4af4-bf96-d0b2e054b39f_verboseLabel_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, interest sold, percentage</link:label>
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_label_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Percentage of Interest Sold</link:label>
    <link:label id="lab_abus_RoyaltyPercentageofInterestSold_documentation_en-US" xlink:label="lab_abus_RoyaltyPercentageofInterestSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty, Percentage of Interest Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPercentageofInterestSold" xlink:href="abus-20220331.xsd#abus_RoyaltyPercentageofInterestSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyPercentageofInterestSold" xlink:to="lab_abus_RoyaltyPercentageofInterestSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_69ef7007-2a10-4886-b4d1-74da3aeb1986_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1898d12f-d505-4a78-a891-185b526ef132_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e003ca81-716b-42ee-8520-cb16d695dd38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_4702f6fd-d7f2-4ce5-8c89-ddd2b4926a9e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend rate as a percent</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f1597cda-ca7a-4c72-b8a3-09113f9e6e4f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3c3ea520-6fe5-4847-b6d4-4ae3a7c7ac67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AccruedPayrollCurrent_61a6d545-7b7a-430b-a838-08644bc907f3_terseLabel_en-US" xlink:label="lab_abus_AccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll accruals</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_label_en-US" xlink:label="lab_abus_AccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll Current</link:label>
    <link:label id="lab_abus_AccruedPayrollCurrent_documentation_en-US" xlink:label="lab_abus_AccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Payroll Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedPayrollCurrent" xlink:href="abus-20220331.xsd#abus_AccruedPayrollCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AccruedPayrollCurrent" xlink:to="lab_abus_AccruedPayrollCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_ad6ea919-a420-4062-ae98-1ab9e7ea25a6_terseLabel_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_label_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Of Common Shares [Abstract]</link:label>
    <link:label id="lab_abus_WeightedAverageNumberOfCommonSharesAbstract_documentation_en-US" xlink:label="lab_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:href="abus-20220331.xsd#abus_WeightedAverageNumberOfCommonSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:to="lab_abus_WeightedAverageNumberOfCommonSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_38bd163b-3605-4306-ad85-3b9178b8b156_negatedTerseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_4cf4f1a9-0fd1-449c-9658-1bea1cd946eb_verboseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_00c333ba-f158-4b40-923a-6c1fa27a6688_terseLabel_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Royalty Revenue Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:to="lab_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f3b1e80f-9e60-4a80-ace9-5e9d6db8fcc5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_adc5e038-5e00-44c2-b80a-3c1c4dfe7d9e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_724880ac-7b5f-447a-842d-4422c37b2d8d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5999186e-235d-4eb8-9899-9c4c55f08a15_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_7aae48d5-f0b9-4616-b226-9a5bc6a39864_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred license revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_50b6e4fe-c2d9-4c95-8da2-b45158271d89_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b5f92f78-91f5-4284-931d-4a557e8faca9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_eca210c6-8214-4ea5-8c75-bdf3e68a67ac_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0182424f-af19-4948-a40c-b7ac26e70f3a_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange losses (gains)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4eb7c37b-354f-47f8-ae05-a99683e27ffc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_a4690ae6-d18a-4afb-8c5a-74a8a6d1f7ac_terseLabel_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_label_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
    <link:label id="lab_abus_OpenMarketSaleAgreementMember_documentation_en-US" xlink:label="lab_abus_OpenMarketSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OpenMarketSaleAgreementMember" xlink:href="abus-20220331.xsd#abus_OpenMarketSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OpenMarketSaleAgreementMember" xlink:to="lab_abus_OpenMarketSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_faa98c17-9bff-4316-9cc5-92d0126b2d2f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_894da650-9a18-4a04-a585-9f74a133fd6b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_6cf8dc6e-b5a5-4ce3-93ce-d375e87864ba_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Items applicable to preferred shares:</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_f66fbb3b-f5ad-4d9f-82e3-2709811dc85c_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ac9bc684-1fe3-43ee-8ad8-790ce3bb80c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_USGovernmentAgencyBondsMember_30267bcd-6900-49f3-98ea-07230c8b8b3e_terseLabel_en-US" xlink:label="lab_abus_USGovernmentAgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government agency bonds</link:label>
    <link:label id="lab_abus_USGovernmentAgencyBondsMember_label_en-US" xlink:label="lab_abus_USGovernmentAgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agency Bonds [Member]</link:label>
    <link:label id="lab_abus_USGovernmentAgencyBondsMember_documentation_en-US" xlink:label="lab_abus_USGovernmentAgencyBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agency Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentAgencyBondsMember" xlink:href="abus-20220331.xsd#abus_USGovernmentAgencyBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_USGovernmentAgencyBondsMember" xlink:to="lab_abus_USGovernmentAgencyBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cecb8109-f5da-4e8b-833b-41d79f8ecc34_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyPayable_ed270682-1365-4f81-b10f-53b29127ecf5_terseLabel_en-US" xlink:label="lab_abus_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future royalty payments</link:label>
    <link:label id="lab_abus_RoyaltyPayable_label_en-US" xlink:label="lab_abus_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payable</link:label>
    <link:label id="lab_abus_RoyaltyPayable_documentation_en-US" xlink:label="lab_abus_RoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the royalty payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPayable" xlink:href="abus-20220331.xsd#abus_RoyaltyPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyPayable" xlink:to="lab_abus_RoyaltyPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_466d9b9c-d3e3-4087-94c6-9204afb8bd96_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_21a33abd-227d-47cc-a3fe-e73590ff172b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to collaboration</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_19745468-e751-4d83-8e2b-6cc4260be0c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3e611703-aa03-445c-a33c-72a89cee4430_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_057a10a1-5cd4-4aea-adbd-44b66ef69309_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ArbutusPlansMember_938f98e1-496c-4942-b4b0-439f01e36f1b_terseLabel_en-US" xlink:label="lab_abus_ArbutusPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Plans</link:label>
    <link:label id="lab_abus_ArbutusPlansMember_label_en-US" xlink:label="lab_abus_ArbutusPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Plans [Member]</link:label>
    <link:label id="lab_abus_ArbutusPlansMember_documentation_en-US" xlink:label="lab_abus_ArbutusPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusPlansMember" xlink:href="abus-20220331.xsd#abus_ArbutusPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbutusPlansMember" xlink:to="lab_abus_ArbutusPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6f4e18c8-d476-4778-86c1-e45a012b27b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a9f076c4-9e8c-49f0-9774-d20ed4304dbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_55b2867e-91e6-4528-8ea8-760c244288f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_dfb124db-997d-43ec-8453-b8cb4c3076af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_02b286a0-901b-4431-8eaf-e8653a0f6733_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_50cc3c9f-3951-4db8-89ef-ff33a994326d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_38a6ed4f-7622-4c64-9676-454f72f2ce92_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTable" xlink:to="lab_us-gaap_MarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_414e3c55-d042-44c8-873c-df8c36b7c9d9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_c0dd396d-e6af-4172-8e11-56b8601e1cac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from services (less than)</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_2693c467-9e76-413f-9f9f-4081f9e784b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_90d56ba0-81dc-471f-8f8c-c40114ca76a4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_cb3658fb-953a-4bcf-9967-04a21d9eee46_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_b1454a3e-18a3-485b-9056-f569cec7fa01_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in equity method investment (as a percentage)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ebbc26e8-648a-46c5-a042-b0a2495953b0_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_07cf53f9-5e63-4aca-a381-7f1d7d315def_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_8fae283d-cea7-46b4-9fbc-dabbf3aef10c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_78ea9b37-c7e1-497c-a86c-a20a56964ffa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8f7de88a-fafc-4d27-ba89-1bc2285dd05d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7285357a-1bb9-47b5-8923-13a334303688_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4b85d78a-fa61-4f04-a25a-1dc421ca630b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a19bd076-9dbd-414b-b247-e54731b97a8f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_151f6938-4470-4729-94a0-d6c6bec875ce_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1840aa53-213b-44cd-8639-733d218d8dd7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_20106a81-3348-4b97-8688-b5cb48661480_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_eb3cda46-5c73-4b97-8e69-d53860262ff8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_c08faa66-27cd-4524-9efa-211fd8b27fb8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_360303a3-0700-43d2-8b36-337027e4fb20_terseLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability classified stock options</link:label>
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_label_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Liability Classified [Member]</link:label>
    <link:label id="lab_abus_EmployeeStockOptionLiabilityClassifiedMember_documentation_en-US" xlink:label="lab_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option, Liability Classified [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:to="lab_abus_EmployeeStockOptionLiabilityClassifiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_de0e2e8b-e9a6-40fc-88bc-ff50cc2360f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6d220abf-ddf4-43e3-8a18-07429de6e54e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_dd2bbe73-c1cc-472e-a275-c51fd5e1c141_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, Gross Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_cc2bbde3-39cb-4220-a8c9-476f759d7f66_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_06e8bf61-3f26-4e52-aadb-1f0d98334cc3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Jan2020RegistrationStmtMember_07ababf7-5ae7-42bd-8cee-016b9af10f98_terseLabel_en-US" xlink:label="lab_abus_Jan2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Registration Stmt [Member]</link:label>
    <link:label id="lab_abus_Jan2020RegistrationStmtMember_label_en-US" xlink:label="lab_abus_Jan2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Registration Stmt [Member]</link:label>
    <link:label id="lab_abus_Jan2020RegistrationStmtMember_documentation_en-US" xlink:label="lab_abus_Jan2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Registration Stmt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020RegistrationStmtMember" xlink:href="abus-20220331.xsd#abus_Jan2020RegistrationStmtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Jan2020RegistrationStmtMember" xlink:to="lab_abus_Jan2020RegistrationStmtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_41f494e7-edb7-465c-94f0-5462b24b48ce_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, damages sought for allegedly unpaid royalties</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_09c6c3d2-cca7-4a6e-b986-2fc0854ea526_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $9,768 (December 31, 2021: $9,374)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_46cabedf-a65b-4cd6-9ce4-2c81848ea0b8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_8baf2bf8-d0e4-4802-b8ab-888e0297b973_terseLabel_en-US" xlink:label="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Oct 2020 and Nov 2021 Registration Stmts</link:label>
    <link:label id="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_label_en-US" xlink:label="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member]</link:label>
    <link:label id="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_documentation_en-US" xlink:label="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:href="abus-20220331.xsd#abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:to="lab_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_4f2e25c3-44cf-4c50-a762-70bca9d67d51_terseLabel_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entitlement of royalties to be received</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_label_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Interest Sold, Maximum Royalties For Buyer</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_documentation_en-US" xlink:label="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Interest Sold, Maximum Royalties For Buyer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:to="lab_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_2fef3f7e-16fc-4b63-88c6-15d98f1dc917_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares dividends accrued</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_81d2d2c5-1642-4d25-9d7c-0545fadf2977_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_bb2743c3-2d6d-4ea6-81e8-449dd46439da_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to the Open Market Sale Agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8a51a5f0-1a73-435b-8910-8fe9159fa124_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to the agreement</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_20119510-07b3-4dc6-928d-278309907f6c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a0577a30-d0b7-43bf-bfa5-96cb765456f7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_AcuitasTherapeuticsInc.Member_b7a15b16-500a-4980-944f-5bfaaa3d548b_terseLabel_en-US" xlink:label="lab_abus_AcuitasTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acuitas Therapeutics, Inc.</link:label>
    <link:label id="lab_abus_AcuitasTherapeuticsInc.Member_label_en-US" xlink:label="lab_abus_AcuitasTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acuitas Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_abus_AcuitasTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_abus_AcuitasTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acuitas Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AcuitasTherapeuticsInc.Member" xlink:href="abus-20220331.xsd#abus_AcuitasTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_AcuitasTherapeuticsInc.Member" xlink:to="lab_abus_AcuitasTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3755e17f-a0e4-4bef-85e6-5141e990064e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f8f189c7-a1ad-42ac-a595-076c0bd82783_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7489f2d5-a635-471d-a09a-48103469629c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6be258e9-7c84-4e68-af9b-2def46467603_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_7c543930-b749-4159-b231-c48af5a48fe9_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb3f3c08-74e4-4b46-a7b0-904480512904_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to the Open Market Sales Agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_893ecdf0-cecf-42d1-97af-77fc101a441a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fee accruals</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6bc90997-273a-4623-9ecf-134aef075183_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_3a14ad2b-e140-4bd9-8d71-26340ba35a11_terseLabel_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of liability option</link:label>
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_label_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value of Liability Option [Table Text Block]</link:label>
    <link:label id="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_documentation_en-US" xlink:label="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value of Liability Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:href="abus-20220331.xsd#abus_ChangesInFairValueofLiabilityOptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:to="lab_abus_ChangesInFairValueofLiabilityOptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_4df70df9-0cf7-4385-ac46-d3d5dbf59093_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_693ed374-dc27-4748-8972-ea7919fbc176_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued and outstanding: 148,728,237 (December 31, 2021: 144,987,736)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_7525b634-431d-4d2d-891f-cfcbdbe29467_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend accretion of convertible preferred shares.</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8586e7f5-88ea-47e3-9d19-a5c5a6ddd854_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other loss</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_71e87ed9-752c-4448-a53e-15b3355240bb_negatedTerseLabel_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liability-classified options exercised in the period</link:label>
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_label_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</link:label>
    <link:label id="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_documentation_en-US" xlink:label="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:href="abus-20220331.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:to="lab_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_73ac21bc-d186-40bf-8d01-620f69841165_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_d781408f-6e93-4681-b074-fd9042de2fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fe316aa5-0a24-415d-8e0c-dbc23ba4fa0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5674ec0c-d3c1-43e4-af20-9921f23fd5dc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_4dd6c843-ea42-43a2-8f90-0cf147cbb0c6_terseLabel_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs on sale of royalties</link:label>
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Future Royalties</link:label>
    <link:label id="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:href="abus-20220331.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:to="lab_abus_TransactionCostsRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_3210deb0-0b37-4c5a-a645-d019ecbfb713_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sale price of common shares under agreement</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_192ccd10-a9ef-4aa6-97e9-d7055c7185b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_04c86488-720c-4a45-b236-e0863f190996_terseLabel_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_label_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Expense</link:label>
    <link:label id="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_documentation_en-US" xlink:label="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Royalties, Non Cash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:to="lab_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ab0970f1-2d20-401a-bb67-d49df889ac23_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_e8b29e92-74b7-4ecf-85c9-c83fe0152ba7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_126ef6a8-59b8-4de1-82c9-3e1bf61d6956_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_190a9e04-7e15-45e6-875f-408933d7e3f9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_350315f6-9d39-4728-9cc5-95a650ef632a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4614045d-42a1-4b04-8790-95d77987b8e2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares issued upon conversion of preferred shares</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5c9e9a6f-dfa2-46d1-abe9-c6576a4384b4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_CollaborationAndContractsMember_e1500a70-3600-4cb3-8efd-ef3c535d0cfc_terseLabel_en-US" xlink:label="lab_abus_CollaborationAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations and licenses</link:label>
    <link:label id="lab_abus_CollaborationAndContractsMember_label_en-US" xlink:label="lab_abus_CollaborationAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Contracts [Member]</link:label>
    <link:label id="lab_abus_CollaborationAndContractsMember_documentation_en-US" xlink:label="lab_abus_CollaborationAndContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_CollaborationAndContractsMember" xlink:href="abus-20220331.xsd#abus_CollaborationAndContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_CollaborationAndContractsMember" xlink:to="lab_abus_CollaborationAndContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_33d0ac36-0578-42de-9dc9-37195cf40dd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion and amortization of investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LongTermInvestmentsMember_f061bb72-1657-43dc-a915-97bc2be4c0d6_terseLabel_en-US" xlink:label="lab_abus_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term securities</link:label>
    <link:label id="lab_abus_LongTermInvestmentsMember_label_en-US" xlink:label="lab_abus_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Member]</link:label>
    <link:label id="lab_abus_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_abus_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LongTermInvestmentsMember" xlink:href="abus-20220331.xsd#abus_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LongTermInvestmentsMember" xlink:to="lab_abus_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_364c7939-829d-4640-a16d-f2e8f9721e2a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_4d59b6e5-c68c-464f-914f-cefa1b4c5c91_terseLabel_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones payment per royalty, maximum</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_label_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty</link:label>
    <link:label id="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_documentation_en-US" xlink:label="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Maximum Development And Regulatory Royalty Payment per Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:to="lab_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b08c29be-b311-4cb6-9f04-7dc8a521f751_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b471577f-acf1-4328-9b58-bd4d4851c33e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f0a951d0-649f-401b-b466-feb2f8b72477_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6b455b87-b82a-4293-9029-1f3217321441_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_6a06520d-710e-4596-b8d8-241158c241ac_terseLabel_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_label_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:label id="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_documentation_en-US" xlink:label="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:href="abus-20220331.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:to="lab_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1412b5cc-9fbb-4531-ad90-f00c0bc9f50e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_89f24f1d-d85e-4088-9069-770c8cafece1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_f977d9b2-51eb-4cbd-8018-81fe0d68b86e_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_3df1f711-7d19-49f6-ba81-94164ff110bb_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e073fe6d-b302-438f-a556-f6653398c454_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_2c76d3c9-9e66-4eea-99f5-c68367d695ab_terseLabel_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:label id="lab_abus_ContingenciesandCommitmentsLineItems_label_en-US" xlink:label="lab_abus_ContingenciesandCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems" xlink:to="lab_abus_ContingenciesandCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3f13d573-e734-48af-a93e-f6742fd36b8b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued under agreement (in sales)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_0cdb7a4c-d9ab-4735-b832-bc4624603c89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains or losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1031e2a5-fb49-4acf-b431-15801c1747df_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0d1584d5-3bb4-412a-aa79-f9506de1350b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_2ec75fae-a83b-498c-90ee-67722b0738f0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_6deb716f-2ddc-42ce-956d-23ef35c19a3d_terseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in fair value of liability</link:label>
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_label_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Liability Classified Options</link:label>
    <link:label id="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Fair Value of Liability Classified Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:to="lab_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_QiluPharmaceuticalCoLTDMember_daee68f9-73c7-4a0f-9757-d288c3690bcf_terseLabel_en-US" xlink:label="lab_abus_QiluPharmaceuticalCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co, LTD. [Member]</link:label>
    <link:label id="lab_abus_QiluPharmaceuticalCoLTDMember_label_en-US" xlink:label="lab_abus_QiluPharmaceuticalCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co, LTD. [Member]</link:label>
    <link:label id="lab_abus_QiluPharmaceuticalCoLTDMember_documentation_en-US" xlink:label="lab_abus_QiluPharmaceuticalCoLTDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co, LTD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_QiluPharmaceuticalCoLTDMember" xlink:to="lab_abus_QiluPharmaceuticalCoLTDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_216513cf-05ba-4998-b0e0-8d33155eaa72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_37962c1d-9aee-4356-8fa9-cd56f7324f6b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6132b86b-2366-4687-9dc6-981ada30c1c5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_decbe74d-d457-4ce3-a83c-2c99e370cd6d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_aaaa5b35-8557-432d-a881-1de2be2d6b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_074b4ae0-e4b8-4284-8fd5-2bfbc7f66523_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborations and licenses and Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dafd7564-1d07-426c-9cb1-03d1d9134c11_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6de6b547-34d1-48c6-9030-ba586ae8f427_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_56ee444c-80db-40cc-abc7-2e5b888db2ac_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac8b6aac-972f-4c40-b95a-e34ee5294c0e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_df82deb1-e847-4a6f-8eb0-9171d24ae05f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_d14f890e-60b4-41ad-b5a9-091ea2723d94_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f12c3514-9afd-41ea-991d-b98ba6a534e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Oct2020RegistrationStmtMember_48633b41-fc5b-48ea-af5a-bf374d04f86d_terseLabel_en-US" xlink:label="lab_abus_Oct2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oct 2020 Registration Stmt [Member]</link:label>
    <link:label id="lab_abus_Oct2020RegistrationStmtMember_label_en-US" xlink:label="lab_abus_Oct2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oct 2020 Registration Stmt [Member]</link:label>
    <link:label id="lab_abus_Oct2020RegistrationStmtMember_documentation_en-US" xlink:label="lab_abus_Oct2020RegistrationStmtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oct 2020 Registration Stmt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Oct2020RegistrationStmtMember" xlink:href="abus-20220331.xsd#abus_Oct2020RegistrationStmtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Oct2020RegistrationStmtMember" xlink:to="lab_abus_Oct2020RegistrationStmtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9cb5c902-2cf6-4e5e-a7b3-7e30114cb033_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_c152283a-b2ef-4137-8e58-612e46cd357c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_USGovernmentBondsMember_9f6311ad-ee47-482b-b686-84205b9d0d4a_terseLabel_en-US" xlink:label="lab_abus_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US government bonds</link:label>
    <link:label id="lab_abus_USGovernmentBondsMember_label_en-US" xlink:label="lab_abus_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Bonds [Member]</link:label>
    <link:label id="lab_abus_USGovernmentBondsMember_documentation_en-US" xlink:label="lab_abus_USGovernmentBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentBondsMember" xlink:href="abus-20220331.xsd#abus_USGovernmentBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_USGovernmentBondsMember" xlink:to="lab_abus_USGovernmentBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e09fb3ec-ff3b-40b4-a078-846ae7f921ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b442c5f0-04e1-4b4b-9316-6fc4af9cf94e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f76bb1fe-e2a6-46ff-a1a5-40c30053218a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_38686a0c-fded-4603-80bc-96ef3c745644_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_35d91103-f1b2-4eb7-bca0-e83af3e0c3e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_029cc4e3-4fc7-4566-8047-18c12652c63e_terseLabel_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of activity related to the net liability from inception of the Agreement</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_label_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block]</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_documentation_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:href="abus-20220331.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:to="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ca1b12cc-cb40-43c2-b024-8440e3861a40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8306b793-9667-445c-8035-ed756fba6752_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_646c2ed3-2a44-48a5-aac9-aacce6e1897d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_20fc25a9-3512-40e8-a0ad-c23b2b00ca84_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f448de80-c64e-431f-b8b5-28f08aa74902_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in operating items:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9db2c830-0729-4ea6-856f-e9ddf73cdbeb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_44fc9904-f870-4c05-85ac-7aae3bb0d05b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Jan2020ProspectusSupplementAgreementMember_a9718009-ffc7-4225-a95c-478524cd0999_terseLabel_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement Agreement [Member]</link:label>
    <link:label id="lab_abus_Jan2020ProspectusSupplementAgreementMember_label_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement Agreement [Member]</link:label>
    <link:label id="lab_abus_Jan2020ProspectusSupplementAgreementMember_documentation_en-US" xlink:label="lab_abus_Jan2020ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jan 2020 Prospectus Supplement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementAgreementMember" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Jan2020ProspectusSupplementAgreementMember" xlink:to="lab_abus_Jan2020ProspectusSupplementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_03d8c8db-cf3f-4a26-b939-3403caf55470_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_77034d49-e5b3-4d9a-9ffa-4a090f67da0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_e221718f-2d23-4e90-9dd6-140695c2e1ec_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_59fb053a-ef75-4495-900d-d4567cb8d5d6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4b8d3c75-ea4f-4880-84bf-8fbbe14d9cff_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_624cf8ff-14df-41db-a616-bbda2a815914_terseLabel_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual royalty revenue</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_label_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</link:label>
    <link:label id="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_documentation_en-US" xlink:label="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:to="lab_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a65b3dff-b09e-4e2e-9216-72da23ff174d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_58e04249-50e4-457c-91ef-98b9342d4b71_netLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability-classified options</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_5b5df50a-b840-43e3-ba60-c719d4399931_periodStartLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at beginning of the period</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_3a768714-3def-4c92-907b-d8fd30f70005_periodEndLabel_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability at end of the period</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_label_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</link:label>
    <link:label id="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_documentation_en-US" xlink:label="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:to="lab_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b5cf484f-e7af-4ac7-9425-e92ab1cc2fcb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_87327983-2ca1-4017-a744-ac71978755d1_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities, Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_27769786-95ca-435e-a3fc-4dd2a5fc4999_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations, contracts and licensing agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0f8597ee-f68c-4d33-a276-e3ecb97ec6e3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_17dcde5a-1f82-4576-abcc-43b4fee12bdc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_778d7ef2-5a0c-4396-990e-6adb19f815dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f9a54a83-4560-4437-8c74-10c5f19c1d00_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_16fb8023-d79f-44b1-a18c-7fefdfafd642_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a451fb52-5bb8-4973-aae3-fee14baa060a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_debe193a-7766-49ab-ad99-f6492d939762_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421c67c4-4b5e-4e82-b927-f0a7eed5ea21_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_OMERSMember_b41db761-4f02-4f73-9704-03ee5fbaaa06_terseLabel_en-US" xlink:label="lab_abus_OMERSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS</link:label>
    <link:label id="lab_abus_OMERSMember_label_en-US" xlink:label="lab_abus_OMERSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS [Member]</link:label>
    <link:label id="lab_abus_OMERSMember_documentation_en-US" xlink:label="lab_abus_OMERSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OMERS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OMERSMember" xlink:href="abus-20220331.xsd#abus_OMERSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_OMERSMember" xlink:to="lab_abus_OMERSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Mar2021ProspectusSupplementAgreementMember_40cdc1a4-ba3d-4db7-9f59-6a728cadaffe_terseLabel_en-US" xlink:label="lab_abus_Mar2021ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mar 2021 Prospectus Supplement Agreement [Member]</link:label>
    <link:label id="lab_abus_Mar2021ProspectusSupplementAgreementMember_label_en-US" xlink:label="lab_abus_Mar2021ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mar 2021 Prospectus Supplement Agreement [Member]</link:label>
    <link:label id="lab_abus_Mar2021ProspectusSupplementAgreementMember_documentation_en-US" xlink:label="lab_abus_Mar2021ProspectusSupplementAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prospectus Supplement - Open Market Sale Agreement Mar 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Mar2021ProspectusSupplementAgreementMember" xlink:href="abus-20220331.xsd#abus_Mar2021ProspectusSupplementAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Mar2021ProspectusSupplementAgreementMember" xlink:to="lab_abus_Mar2021ProspectusSupplementAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_bda089ea-20eb-48e3-b16a-7b69295691ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_91994e53-49f4-4c7f-a28f-3a958ec6e3b9_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4b2b1fa5-c4f2-4cb8-8f90-50b48ad10b31_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e8a9684-ef23-4355-a063-06764eceddf2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_33d7a5e0-7358-48e0-9bf8-1d07bd7e327e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_0e492d40-cfa7-4e08-8d04-0d0db9314082_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_bbd2f62f-d663-4811-8ad7-dfdd240f8b89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares pursuant to ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d4343c76-e194-4cf0-bf90-b44dfcd45976_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_feb9a2a7-30d6-47ff-98d7-a4dc17d975bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a3b43b6f-3c7a-4fdc-9d86-79f1bfd975b9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68018abd-33d0-4bcc-89b2-4a541e56acca_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RegistrationStatementDomain_8b980783-d861-4e6a-8d1a-d852b5b3eb0a_terseLabel_en-US" xlink:label="lab_abus_RegistrationStatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Domain]</link:label>
    <link:label id="lab_abus_RegistrationStatementDomain_label_en-US" xlink:label="lab_abus_RegistrationStatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Domain]</link:label>
    <link:label id="lab_abus_RegistrationStatementDomain_documentation_en-US" xlink:label="lab_abus_RegistrationStatementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Statement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementDomain" xlink:href="abus-20220331.xsd#abus_RegistrationStatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RegistrationStatementDomain" xlink:to="lab_abus_RegistrationStatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_5c6d89d6-779a-474c-be94-b9db408965d3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_53d9c929-c95d-4f3e-baa6-ff939c863bef_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_XChemIncAndProterosMember_218171c7-38e7-43e7-9025-6b1679d85604_terseLabel_en-US" xlink:label="lab_abus_XChemIncAndProterosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">X-Chem, Inc. and Proteros [Member]</link:label>
    <link:label id="lab_abus_XChemIncAndProterosMember_label_en-US" xlink:label="lab_abus_XChemIncAndProterosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">X-Chem, Inc. and Proteros [Member]</link:label>
    <link:label id="lab_abus_XChemIncAndProterosMember_documentation_en-US" xlink:label="lab_abus_XChemIncAndProterosMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">X-Chem, Inc. and Proteros</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_XChemIncAndProterosMember" xlink:href="abus-20220331.xsd#abus_XChemIncAndProterosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_XChemIncAndProterosMember" xlink:to="lab_abus_XChemIncAndProterosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_b9e954dc-c5a2-4a6f-ae0d-5afa9693f37c_terseLabel_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To Sale Of Future Royalties [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:to="lab_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_718fced9-1384-4890-881f-63ed3e63a57a_terseLabel_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of future royalties</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Related To Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:href="abus-20220331.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_818f00f9-426d-4beb-ac35-68531cf22e75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of collaborations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f3f6ef98-945e-4b81-a932-6bfff9480542_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_A2019AmendedSaleAgreementMember_178582db-052b-4cbb-b662-6c1b6be7fbf8_terseLabel_en-US" xlink:label="lab_abus_A2019AmendedSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Amended Sale Agreement</link:label>
    <link:label id="lab_abus_A2019AmendedSaleAgreementMember_label_en-US" xlink:label="lab_abus_A2019AmendedSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Amended Sale Agreement [Member]</link:label>
    <link:label id="lab_abus_A2019AmendedSaleAgreementMember_documentation_en-US" xlink:label="lab_abus_A2019AmendedSaleAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Amended Sale Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_A2019AmendedSaleAgreementMember" xlink:href="abus-20220331.xsd#abus_A2019AmendedSaleAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_A2019AmendedSaleAgreementMember" xlink:to="lab_abus_A2019AmendedSaleAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_March2022ProspectusSupplementMember_0e2a9b9d-1ffb-4fd3-930a-ec4296cf9133_terseLabel_en-US" xlink:label="lab_abus_March2022ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Prospectus Supplement [Member]</link:label>
    <link:label id="lab_abus_March2022ProspectusSupplementMember_label_en-US" xlink:label="lab_abus_March2022ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Prospectus Supplement [Member]</link:label>
    <link:label id="lab_abus_March2022ProspectusSupplementMember_documentation_en-US" xlink:label="lab_abus_March2022ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2022 Prospectus Supplement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_March2022ProspectusSupplementMember" xlink:href="abus-20220331.xsd#abus_March2022ProspectusSupplementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_March2022ProspectusSupplementMember" xlink:to="lab_abus_March2022ProspectusSupplementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_PremiumonClosingStockPrice_b0b78809-e2b4-4d82-9803-e24e411c1ff4_terseLabel_en-US" xlink:label="lab_abus_PremiumonClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on closing stock price (as a percent)</link:label>
    <link:label id="lab_abus_PremiumonClosingStockPrice_label_en-US" xlink:label="lab_abus_PremiumonClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on Closing Stock Price</link:label>
    <link:label id="lab_abus_PremiumonClosingStockPrice_documentation_en-US" xlink:label="lab_abus_PremiumonClosingStockPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium on Closing Stock Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PremiumonClosingStockPrice" xlink:href="abus-20220331.xsd#abus_PremiumonClosingStockPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_PremiumonClosingStockPrice" xlink:to="lab_abus_PremiumonClosingStockPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7c4f7b93-592a-41e6-8e97-313587213acf_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_49a8d667-25f1-4597-a534-17a8f2e7dbb7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5d72ccca-4c4a-483a-856f-c6a7abf5efb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_Aug2020ProspectusSupplementMember_ca278aad-2916-483a-8137-9093c92f1bbe_terseLabel_en-US" xlink:label="lab_abus_Aug2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aug 2020 Prospectus Supplement</link:label>
    <link:label id="lab_abus_Aug2020ProspectusSupplementMember_label_en-US" xlink:label="lab_abus_Aug2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aug 2020 Prospectus Supplement [Member]</link:label>
    <link:label id="lab_abus_Aug2020ProspectusSupplementMember_documentation_en-US" xlink:label="lab_abus_Aug2020ProspectusSupplementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aug 2020 Prospectus Supplement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Aug2020ProspectusSupplementMember" xlink:href="abus-20220331.xsd#abus_Aug2020ProspectusSupplementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_Aug2020ProspectusSupplementMember" xlink:to="lab_abus_Aug2020ProspectusSupplementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_12df11d1-54cd-4a7f-b411-9fde10aef2f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_ArbutusInc.Member_c8ddfb8b-3aca-414f-b50b-43a796db5084_terseLabel_en-US" xlink:label="lab_abus_ArbutusInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Inc.</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_label_en-US" xlink:label="lab_abus_ArbutusInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:label id="lab_abus_ArbutusInc.Member_documentation_en-US" xlink:label="lab_abus_ArbutusInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arbutus Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusInc.Member" xlink:href="abus-20220331.xsd#abus_ArbutusInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_ArbutusInc.Member" xlink:to="lab_abus_ArbutusInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_44105873-ce5a-4d8a-8eb1-c575efb6eed4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_64d6c5bf-ba36-48d7-97c5-17d2e370a840_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_22ca3404-dad5-4e31-b7cc-8974c4e71d84_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_RoivantSciencesLtdMember_332f3532-765c-4ffa-a7a5-cad67f75cf8c_terseLabel_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roivant Sciences Ltd</link:label>
    <link:label id="lab_abus_RoivantSciencesLtdMember_label_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roivant Sciences Ltd [Member]</link:label>
    <link:label id="lab_abus_RoivantSciencesLtdMember_documentation_en-US" xlink:label="lab_abus_RoivantSciencesLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roivant Sciences Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoivantSciencesLtdMember" xlink:href="abus-20220331.xsd#abus_RoivantSciencesLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_RoivantSciencesLtdMember" xlink:to="lab_abus_RoivantSciencesLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_1c685d2c-2dbf-4b7d-91ed-fc53d8472c70_terseLabel_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_label_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:label id="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_documentation_en-US" xlink:label="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Fair Value Of Contingent Consideration Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:to="lab_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9dcfab00-f250-4e2a-bcce-e72b5f0d4786_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_cec4fa43-dce2-4f1a-9ab7-e92f213055d6_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborations and licenses</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9d13cfc6-bdbc-4a6f-aad7-b07d0b858e46_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d4b358b9-8aca-45d4-ac62-bb45cbd487f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_f93c3253-85c3-455c-a823-0e814e196428_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of business and future operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_1d63aa69-763e-4bd7-8457-24537b262009_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Genevant</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c5726fb7-6f8d-4dba-a4a5-b40cd5994b1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_88f281f1-908a-412b-90bc-5158be099eed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_00c5f669-f863-402c-a049-5f28c3c4f6a8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_63741301-b2ec-44ae-86aa-9f0d0c00ad0e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_72304ae4-717c-410a-b64a-f6f2d94bc57b_terseLabel_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by noncontrolling owners after conversion</link:label>
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_label_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</link:label>
    <link:label id="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_documentation_en-US" xlink:label="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:href="abus-20220331.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:to="lab_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1e9c26a0-475d-4a3f-9de0-0cd5087c3fc6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8133db33-b829-478b-b7d6-2da3aa7a08f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash items:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_abus_BonaFideCollaborationPercentage_0924230b-f5bc-4054-9a8b-d97584133390_terseLabel_en-US" xlink:label="lab_abus_BonaFideCollaborationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bona fide collaboration Percentage</link:label>
    <link:label id="lab_abus_BonaFideCollaborationPercentage_label_en-US" xlink:label="lab_abus_BonaFideCollaborationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bona fide collaboration Percentage</link:label>
    <link:label id="lab_abus_BonaFideCollaborationPercentage_documentation_en-US" xlink:label="lab_abus_BonaFideCollaborationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bona fide collaboration Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abus_BonaFideCollaborationPercentage" xlink:href="abus-20220331.xsd#abus_BonaFideCollaborationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abus_BonaFideCollaborationPercentage" xlink:to="lab_abus_BonaFideCollaborationPercentage" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abus-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f9eb3e20-957c-4f50-8702-b49f6cfda7cd,g:65c41fe5-7b76-4628-b8ad-1845793955b0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arbutusbio.com/role/Cover" xlink:type="simple" xlink:href="abus-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_da6cb6e4-8bc7-46c0-88d0-66491d7deb50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentType_da6cb6e4-8bc7-46c0-88d0-66491d7deb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d507bd36-5333-4942-8b65-727b3ae43db1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentQuarterlyReport_d507bd36-5333-4942-8b65-727b3ae43db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_70754cec-3a87-4a2d-8ab3-4ad94da6d2e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentPeriodEndDate_70754cec-3a87-4a2d-8ab3-4ad94da6d2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7c32a07a-db35-4615-8ae9-4eea0002cd29" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentTransitionReport_7c32a07a-db35-4615-8ae9-4eea0002cd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8575341e-8357-49ff-a67e-4cf635ececce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityFileNumber_8575341e-8357-49ff-a67e-4cf635ececce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4b47c5fb-33f1-41b9-9181-3c21f9366696" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityRegistrantName_4b47c5fb-33f1-41b9-9181-3c21f9366696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1183f646-0542-46a3-809b-0ff8994c89d2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1183f646-0542-46a3-809b-0ff8994c89d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_82345c33-001b-4b6c-a367-4c7d2fdc5965" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityTaxIdentificationNumber_82345c33-001b-4b6c-a367-4c7d2fdc5965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ad8a390f-6c5a-4481-a000-c03eeb040c68" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityAddressAddressLine1_ad8a390f-6c5a-4481-a000-c03eeb040c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_855bf064-d23e-44da-8d6d-34d4b06f117b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityAddressCityOrTown_855bf064-d23e-44da-8d6d-34d4b06f117b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_51edaf21-fd29-4ba8-a61e-949be55d653e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityAddressStateOrProvince_51edaf21-fd29-4ba8-a61e-949be55d653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b9ae1931-6360-48ac-937d-b24478dd7a1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityAddressPostalZipCode_b9ae1931-6360-48ac-937d-b24478dd7a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b522a3f6-e099-418c-924b-5da9631e3e18" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_CityAreaCode_b522a3f6-e099-418c-924b-5da9631e3e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f0a2070d-a03b-403b-bdf0-92ade9c5c265" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_LocalPhoneNumber_f0a2070d-a03b-403b-bdf0-92ade9c5c265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_539d4b62-de92-4001-8d72-a1de3d316588" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_Security12bTitle_539d4b62-de92-4001-8d72-a1de3d316588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c4a026b2-7261-46bb-a873-1da65bd914cb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_TradingSymbol_c4a026b2-7261-46bb-a873-1da65bd914cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0c1243d1-0162-4575-8949-5093e36d0bed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_SecurityExchangeName_0c1243d1-0162-4575-8949-5093e36d0bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3c240b13-7eaf-4b97-9b94-6a87cdc7c4ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityCurrentReportingStatus_3c240b13-7eaf-4b97-9b94-6a87cdc7c4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_00d4a745-9a2c-43d2-aa9b-1c41405dfe13" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityInteractiveDataCurrent_00d4a745-9a2c-43d2-aa9b-1c41405dfe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_794436a3-2728-4abd-879b-fc657f1e26ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityFilerCategory_794436a3-2728-4abd-879b-fc657f1e26ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ed755386-564a-41aa-aced-beb093bd1fa3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntitySmallBusiness_ed755386-564a-41aa-aced-beb093bd1fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4bb94075-ce96-49c8-950d-9b8e02af7c3e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityEmergingGrowthCompany_4bb94075-ce96-49c8-950d-9b8e02af7c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_92f76274-9b7a-4b18-9a28-c2ea5994f8ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityShellCompany_92f76274-9b7a-4b18-9a28-c2ea5994f8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_efd2bf73-822e-4995-8a70-901c028d4d42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_efd2bf73-822e-4995-8a70-901c028d4d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f79e1b12-8b16-4bca-9128-f25395aadeda" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_AmendmentFlag_f79e1b12-8b16-4bca-9128-f25395aadeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_39913064-5ad7-44e9-a305-473663362c50" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_EntityCentralIndexKey_39913064-5ad7-44e9-a305-473663362c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_11c0c030-6ac0-4e9c-8ad6-6a25adcec44b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_CurrentFiscalYearEndDate_11c0c030-6ac0-4e9c-8ad6-6a25adcec44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3dd63daf-e55a-4123-9e84-85e6172b22d9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentFiscalYearFocus_3dd63daf-e55a-4123-9e84-85e6172b22d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_44097706-1ed6-4a57-a5b8-eb716c2ccb6b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b23c0cc6-60fc-4e19-b03e-c4e574216a04" xlink:to="loc_dei_DocumentFiscalPeriodFocus_44097706-1ed6-4a57-a5b8-eb716c2ccb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d4482d6a-09c3-4f3d-bce4-247e2d276824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4482d6a-09c3-4f3d-bce4-247e2d276824" xlink:to="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d344edd6-54d6-41ce-a8b9-4c45a6342e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d344edd6-54d6-41ce-a8b9-4c45a6342e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b7b5d13d-92ca-4f56-ac16-b892477364bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b7b5d13d-92ca-4f56-ac16-b892477364bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11e87fa0-adef-4d75-a09a-c0f3454d933d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11e87fa0-adef-4d75-a09a-c0f3454d933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b1d8d6a-cb11-4457-bb9d-35d09710c7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b1d8d6a-cb11-4457-bb9d-35d09710c7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f96aea8-4c34-41bf-bcd8-564faa045b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_455e17fd-7e4d-4293-8c41-7866786a8b4f" xlink:to="loc_us-gaap_AssetsCurrent_1f96aea8-4c34-41bf-bcd8-564faa045b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ea3d761-2b0a-4037-bb17-1648446c3a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0ea3d761-2b0a-4037-bb17-1648446c3a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_0080cbcf-c0ab-4211-81cb-a630c4a0ad6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_LongTermInvestments_0080cbcf-c0ab-4211-81cb-a630c4a0ad6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfbf2c46-2643-4ef1-8920-f3afa6fae853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfbf2c46-2643-4ef1-8920-f3afa6fae853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_25f38895-0b1e-4a23-829f-979e91cc16d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_25f38895-0b1e-4a23-829f-979e91cc16d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8efcc150-e3b5-4307-a813-3a1196705327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6aadfe92-b99f-43fa-9384-c5b111c63929" xlink:to="loc_us-gaap_Assets_8efcc150-e3b5-4307-a813-3a1196705327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d4482d6a-09c3-4f3d-bce4-247e2d276824" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fd46871f-1815-40ee-9b49-b2e7402e728d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_fd46871f-1815-40ee-9b49-b2e7402e728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_bc64daab-d022-4277-87c1-3c74d58fab36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:to="loc_us-gaap_DeferredRevenueCurrent_bc64daab-d022-4277-87c1-3c74d58fab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bac8167b-66bb-4a79-a756-f09d07e14c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bac8167b-66bb-4a79-a756-f09d07e14c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2b84b0b0-643d-49da-8730-c89a52d2ddb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1a74e95b-8e38-4d23-a080-0148bed6bccb" xlink:to="loc_us-gaap_LiabilitiesCurrent_2b84b0b0-643d-49da-8730-c89a52d2ddb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_5dbbb339-e4cf-4171-92dc-492e88352c37" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_5dbbb339-e4cf-4171-92dc-492e88352c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_efae9f27-a86b-4b41-b842-326ac7498d14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_efae9f27-a86b-4b41-b842-326ac7498d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_18f6fc9b-dad3-4f2b-9fad-a23abb05a13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_18f6fc9b-dad3-4f2b-9fad-a23abb05a13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84ab0667-6bea-4215-b308-7e1d9620945c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_84ab0667-6bea-4215-b308-7e1d9620945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_966467e2-3bd8-45f0-8b4f-16d9a4437181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_Liabilities_966467e2-3bd8-45f0-8b4f-16d9a4437181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9e52df69-d3e8-454c-bdf1-f707fece14ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:to="loc_us-gaap_CommonStockValue_9e52df69-d3e8-454c-bdf1-f707fece14ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a34a29ba-a648-4c45-bbfc-14bb046bb9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a34a29ba-a648-4c45-bbfc-14bb046bb9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32cd1221-de3c-4b55-a3fc-05e4a8a06e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32cd1221-de3c-4b55-a3fc-05e4a8a06e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2781f594-6500-4b39-9f35-1ffd9d4920ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2781f594-6500-4b39-9f35-1ffd9d4920ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8dc8747-4cc4-4542-9aa2-4ef04c984f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c1347334-201b-4528-8345-2fea015eb63d" xlink:to="loc_us-gaap_StockholdersEquity_f8dc8747-4cc4-4542-9aa2-4ef04c984f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_af7e689c-caa2-43df-aeaf-3a46b97484ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b757efc5-9745-48e7-8e19-1dd46483d1d6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_af7e689c-caa2-43df-aeaf-3a46b97484ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_98ef17ca-fa08-4515-8c08-357b9657d54a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7bff3eb6-4f58-437d-a9be-7961519a60c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98ef17ca-fa08-4515-8c08-357b9657d54a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7bff3eb6-4f58-437d-a9be-7961519a60c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a37ef784-9823-4f13-a4c0-dc64b0065af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98ef17ca-fa08-4515-8c08-357b9657d54a" xlink:to="loc_us-gaap_CommonStockSharesIssued_a37ef784-9823-4f13-a4c0-dc64b0065af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f1a69662-7636-419a-bc60-e373f7ae5068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_98ef17ca-fa08-4515-8c08-357b9657d54a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f1a69662-7636-419a-bc60-e373f7ae5068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_aff48ff9-f438-403a-bb19-354bdd2769c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_aff48ff9-f438-403a-bb19-354bdd2769c7" xlink:to="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:to="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aefa9ba3-2f24-4fca-94bc-cf7130580b08" xlink:to="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_CollaborationAndContractsMember_09910896-350a-48c5-8e33-60700312064a" xlink:href="abus-20220331.xsd#abus_CollaborationAndContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:to="loc_abus_CollaborationAndContractsMember_09910896-350a-48c5-8e33-60700312064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyMember_a1c26c00-7601-4347-88ae-781936786368" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9edde381-2c2f-4bd0-94f0-9e34d0d8516d" xlink:to="loc_abus_NonCashRoyaltyMember_a1c26c00-7601-4347-88ae-781936786368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e71214e-2652-4833-805f-e3ca32e23646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc988c5e-d05f-4cb8-a34b-9f5dd309b88c" xlink:to="loc_us-gaap_EquityComponentDomain_9e71214e-2652-4833-805f-e3ca32e23646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3de5b49-3180-4122-aef9-8d9803b7e4c6" xlink:to="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d3a7c8c9-e806-4034-a06e-bfb8cae3b887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ba50485b-9e92-427a-9ee7-6df1300c2e4f" xlink:to="loc_us-gaap_Revenues_d3a7c8c9-e806-4034-a06e-bfb8cae3b887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_84725f38-ad26-4480-b89b-e9768f2c86a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_84725f38-ad26-4480-b89b-e9768f2c86a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_81996091-fbff-4c39-9b5a-91c98e5e3a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_81996091-fbff-4c39-9b5a-91c98e5e3a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_8dc183aa-ef9a-4def-8665-d8c8375d1ec0" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability_8dc183aa-ef9a-4def-8665-d8c8375d1ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_40f789d2-e660-4f6f-b5e5-7d5b2904398c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_95bc70bd-5a2a-4d6e-ab2e-b49ed2e5dee1" xlink:to="loc_us-gaap_OperatingExpenses_40f789d2-e660-4f6f-b5e5-7d5b2904398c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1c649f77-a15f-4014-8a3a-271363944680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_OperatingIncomeLoss_1c649f77-a15f-4014-8a3a-271363944680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9fbc77d8-e239-48f5-9d30-d7c1f7c15aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9fbc77d8-e239-48f5-9d30-d7c1f7c15aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f9f8b9bf-8fd8-486b-8e88-d4f2d693cd99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_InterestExpense_f9f8b9bf-8fd8-486b-8e88-d4f2d693cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_18d8a5ab-5e52-4316-8eb5-22489fec5412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_18d8a5ab-5e52-4316-8eb5-22489fec5412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d0b9ef25-1574-4a27-9919-94581d38631f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d0b9ef25-1574-4a27-9919-94581d38631f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b375ca1-9a00-4cc1-bb19-ba9066d86a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b375ca1-9a00-4cc1-bb19-ba9066d86a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f157c48f-23af-4e01-ad02-5d79d5dd3a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NetIncomeLoss_f157c48f-23af-4e01-ad02-5d79d5dd3a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e8624820-90bb-4e00-be22-ecfe3bd92816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract_3ba6c7ef-a2f0-4a8d-9c1e-630c9ae5af7f" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_e8624820-90bb-4e00-be22-ecfe3bd92816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e7e8d699-b612-4c49-a5a9-719f33f39ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e7e8d699-b612-4c49-a5a9-719f33f39ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_202f12c6-99ea-4504-8373-60efff6ff3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:to="loc_us-gaap_EarningsPerShareBasic_202f12c6-99ea-4504-8373-60efff6ff3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_93ab536d-edc4-455a-968c-cd86a2b888bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7344ed57-1d0d-4e9e-a9f9-bbecc43da013" xlink:to="loc_us-gaap_EarningsPerShareDiluted_93ab536d-edc4-455a-968c-cd86a2b888bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:href="abus-20220331.xsd#abus_WeightedAverageNumberOfCommonSharesAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee1e3759-93e9-45e1-bb05-4ef0726355ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee1e3759-93e9-45e1-bb05-4ef0726355ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a48bc76-cbd7-4651-b211-f19abbcf92f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_WeightedAverageNumberOfCommonSharesAbstract_576515b8-91ab-4b4c-b118-f9dd960683e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5a48bc76-cbd7-4651-b211-f19abbcf92f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7a9f05c2-b7d4-4b92-9252-702279aa3782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_7a9f05c2-b7d4-4b92-9252-702279aa3782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_42bcf901-f50e-4180-b777-3bc2673900ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c39598a-9357-4442-a468-bbef11e9a299" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_42bcf901-f50e-4180-b777-3bc2673900ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_430bcb07-9ab8-4d70-b56e-0fa757295c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d282f862-e82b-4757-80e0-37415159ec7a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_430bcb07-9ab8-4d70-b56e-0fa757295c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1ab69e4-25c4-443b-9286-cec83bd2c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1ab69e4-25c4-443b-9286-cec83bd2c7c3" xlink:to="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_25b12428-d3d0-4ece-a907-579042772e32" xlink:to="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_58f108e0-7dc4-4b8d-a66d-02b70403c80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_CommonStockMember_58f108e0-7dc4-4b8d-a66d-02b70403c80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_14954f7c-7a77-4b41-867b-39e2909ffe81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_14954f7c-7a77-4b41-867b-39e2909ffe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ab922a0-7286-42b0-b26c-ed0b183d9222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_RetainedEarningsMember_1ab922a0-7286-42b0-b26c-ed0b183d9222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a8745337-8590-4763-a123-2d67ca3b9d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a8745337-8590-4763-a123-2d67ca3b9d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_cedd5327-ceb2-4bad-96a0-3b1201bb7852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_933a4f37-c23c-4281-955f-2afddf63814e" xlink:to="loc_us-gaap_PreferredStockMember_cedd5327-ceb2-4bad-96a0-3b1201bb7852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d68ee02-474f-46e1-bcd8-7d183291dcf7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OpenMarketSaleAgreementMember_e50beb34-def3-40d2-96f3-10392e45fbf9" xlink:href="abus-20220331.xsd#abus_OpenMarketSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:to="loc_abus_OpenMarketSaleAgreementMember_e50beb34-def3-40d2-96f3-10392e45fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharePurchaseAgreementMember_fb5ce655-2d36-46c5-91e6-04204f31dd1e" xlink:href="abus-20220331.xsd#abus_SharePurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_67a1b280-678e-42ee-b1a5-631ac677c757" xlink:to="loc_abus_SharePurchaseAgreementMember_fb5ce655-2d36-46c5-91e6-04204f31dd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_21992dfa-b71e-4f02-b09b-f663e469636f" xlink:to="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2207ddd8-9f3d-4f47-9e5b-16b8e4cb4ded" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6e43bf03-19ef-49c8-96ad-172cb6ebd76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_SharesIssued_6e43bf03-19ef-49c8-96ad-172cb6ebd76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7640f81a-3972-4193-987f-c141c6cffdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockholdersEquity_7640f81a-3972-4193-987f-c141c6cffdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_c95150dd-6b30-44e7-9c13-0b3835ba0779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_c95150dd-6b30-44e7-9c13-0b3835ba0779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a6bb10b-26e4-48ad-9505-ccf28da77b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_7a6bb10b-26e4-48ad-9505-ccf28da77b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_cf7e1d66-d49c-4331-b5bd-4e58e5d97dcf" xlink:href="abus-20220331.xsd#abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards_cf7e1d66-d49c-4331-b5bd-4e58e5d97dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9af8a5f7-a97a-4875-ba1d-8ecf3349d618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9af8a5f7-a97a-4875-ba1d-8ecf3349d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcd4cdc9-a223-4a83-955b-72263c770ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fcd4cdc9-a223-4a83-955b-72263c770ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a28cc66-e5d1-4e81-8e7a-c108540aae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0a28cc66-e5d1-4e81-8e7a-c108540aae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f355e941-bc2a-49cc-99c2-f3aca169440f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f355e941-bc2a-49cc-99c2-f3aca169440f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_db0b25db-12d3-4c05-89ab-858251d2a5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_db0b25db-12d3-4c05-89ab-858251d2a5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542729b2-9d40-434b-9f02-abf24b8605d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_542729b2-9d40-434b-9f02-abf24b8605d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6950a51a-4976-4aa3-a58d-01fe9860e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6950a51a-4976-4aa3-a58d-01fe9860e1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_beb75632-bbcb-4b44-9461-826e2a65db9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_NetIncomeLoss_beb75632-bbcb-4b44-9461-826e2a65db9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_77954b4a-4bbc-4725-8b68-9073b038abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_SharesIssued_77954b4a-4bbc-4725-8b68-9073b038abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d537a891-13d0-49a7-99b8-0c0d8b5cd09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5c56f2f5-6a69-4a32-9369-aa0011c51125" xlink:to="loc_us-gaap_StockholdersEquity_d537a891-13d0-49a7-99b8-0c0d8b5cd09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="simple" xlink:href="abus-20220331.xsd#CondensedConsolidatedStatementsofCashFlowUnaudited"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_721ef937-964a-4877-9c0a-8d25d45b44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_721ef937-964a-4877-9c0a-8d25d45b44c4" xlink:to="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_aa4bf517-1c35-4c7d-9a6a-e698b07f69cd" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharePurchaseAgreementMember_dccf8b50-1c7c-4ca9-bfd8-8ddfc03a014b" xlink:href="abus-20220331.xsd#abus_SharePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:to="loc_abus_SharePurchaseAgreementMember_dccf8b50-1c7c-4ca9-bfd8-8ddfc03a014b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OpenMarketSaleAgreementMember_03ef7fad-a774-4d10-9c86-4b17f25f4108" xlink:href="abus-20220331.xsd#abus_OpenMarketSaleAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2698eb1-966c-48a9-90d1-feff16e5cb6e" xlink:to="loc_abus_OpenMarketSaleAgreementMember_03ef7fad-a774-4d10-9c86-4b17f25f4108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d8966f47-3683-4d1d-b161-8f475fb66257" xlink:to="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ec6df8e-1ee4-4531-8b28-63d57d251eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_NetIncomeLoss_1ec6df8e-1ee4-4531-8b28-63d57d251eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c15b87fa-03d7-4f77-8ef5-bff4051cc6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c15b87fa-03d7-4f77-8ef5-bff4051cc6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_591de1df-b509-4ded-88f8-efea79785dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_ShareBasedCompensation_591de1df-b509-4ded-88f8-efea79785dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7b98b4a2-d7d9-489f-9468-aa208104f642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7b98b4a2-d7d9-489f-9468-aa208104f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a122bcf8-70e7-41ce-87d1-0724bf3ac754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a122bcf8-70e7-41ce-87d1-0724bf3ac754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0a51f168-c25c-48f0-bafb-74b137a5ec59" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_0a51f168-c25c-48f0-bafb-74b137a5ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b854e4f0-0f6e-4cdf-a918-b7f814d847e7" xlink:href="abus-20220331.xsd#abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_b854e4f0-0f6e-4cdf-a918-b7f814d847e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aa4a3d73-5205-445c-903f-0b3f76323751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_921262dd-8678-4e38-a58c-20a662f770db" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_aa4a3d73-5205-445c-903f-0b3f76323751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f5f2a7c-5e21-498d-b4d6-6d088db2f987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f5f2a7c-5e21-498d-b4d6-6d088db2f987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c557ef0e-b2a0-4985-8695-07c834db0eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c557ef0e-b2a0-4985-8695-07c834db0eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed856cd-98a7-40ab-84f8-1aed622d54af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ed856cd-98a7-40ab-84f8-1aed622d54af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5d2eecef-e135-4e52-b34f-d5c54552b221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_5d2eecef-e135-4e52-b34f-d5c54552b221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfbe010f-32ac-41cb-a6fc-38a0a4851a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_68cfd6f7-d10e-4cf7-8899-02d5b88ba2d4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cfbe010f-32ac-41cb-a6fc-38a0a4851a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90bee6d0-c74c-4728-9732-2cfef389c970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_181e5650-cf05-4c5a-abe7-22a5bd04512b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90bee6d0-c74c-4728-9732-2cfef389c970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fbb9b695-2c60-4a2d-9ad6-ba5638066886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fbb9b695-2c60-4a2d-9ad6-ba5638066886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8584bcf-9294-4cc1-b95b-b58f42501c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_a8584bcf-9294-4cc1-b95b-b58f42501c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8c3c487-1cb9-47ca-b382-74cead6881f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d8c3c487-1cb9-47ca-b382-74cead6881f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f89e4daa-24d0-434d-a104-d505849122b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_66c514ea-cb56-4186-97dd-a083188195fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f89e4daa-24d0-434d-a104-d505849122b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9df1dc82-e9a3-499e-a8c5-18033a6e0eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9df1dc82-e9a3-499e-a8c5-18033a6e0eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b96c22b8-507d-4aad-b25a-10dda9e148cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b96c22b8-507d-4aad-b25a-10dda9e148cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_7a0ee6ce-6509-40f8-96f1-7c4d2c2502b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_ProceedsFromStockPlans_7a0ee6ce-6509-40f8-96f1-7c4d2c2502b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_edff77db-8448-4d20-938b-c7dd8aabae42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e482151f-b639-49c9-8dfa-4d7fbf76e915" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_edff77db-8448-4d20-938b-c7dd8aabae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edeec956-1758-45d3-b766-8fcaf27e1aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edeec956-1758-45d3-b766-8fcaf27e1aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ac041ec-e0e5-4b48-8956-fc58d8aefc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8ac041ec-e0e5-4b48-8956-fc58d8aefc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58846618-2b8d-4fda-9e81-e853330b443e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58846618-2b8d-4fda-9e81-e853330b443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e13418bb-c95f-497b-88c0-06573ebdd596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e13418bb-c95f-497b-88c0-06573ebdd596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2fc8c195-fdb6-489c-8fea-67c78c85d94f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_519183df-91fc-4439-b02a-99453af489d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b534c5e3-e90d-4671-b7b3-f01b6a26fe7a" xlink:to="loc_us-gaap_DividendsPreferredStockCash_519183df-91fc-4439-b02a-99453af489d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Natureofbusinessandfutureoperations" xlink:type="simple" xlink:href="abus-20220331.xsd#Natureofbusinessandfutureoperations"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Natureofbusinessandfutureoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efe2ba55-93f7-439a-b7d3-3502feaf08c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_8f95092c-0be8-440c-950a-4ae851cc7fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efe2ba55-93f7-439a-b7d3-3502feaf08c2" xlink:to="loc_us-gaap_NatureOfOperations_8f95092c-0be8-440c-950a-4ae851cc7fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#NatureofbusinessandfutureoperationsDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba56ade-0015-4608-8a04-edec2dc24301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5795180f-1da6-4678-a8a7-670ab577a8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba56ade-0015-4608-8a04-edec2dc24301" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5795180f-1da6-4678-a8a7-670ab577a8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1abfd774-f598-4971-86be-24760870d8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dba56ade-0015-4608-8a04-edec2dc24301" xlink:to="loc_us-gaap_LongTermDebt_1abfd774-f598-4971-86be-24760870d8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Significantaccountingpolicies" xlink:type="simple" xlink:href="abus-20220331.xsd#Significantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Significantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_493e728f-1eab-44a4-a58a-6daf12271a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1ebf0952-217d-450c-bcd3-3ae5b46ead55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_493e728f-1eab-44a4-a58a-6daf12271a67" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1ebf0952-217d-450c-bcd3-3ae5b46ead55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="abus-20220331.xsd#SignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b21f41d-6a80-4972-bd8f-82f43929a7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6b21f41d-6a80-4972-bd8f-82f43929a7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c12892f3-406b-49de-835f-64a0f664f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c12892f3-406b-49de-835f-64a0f664f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b80b9785-ab5d-4722-9d01-1069ed1629de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b80b9785-ab5d-4722-9d01-1069ed1629de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4c287eb0-cb1b-4315-a1e0-c01fa99fd7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_4c287eb0-cb1b-4315-a1e0-c01fa99fd7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3486b7c4-2c63-4cf1-80cf-c85d0ce9dd52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3486b7c4-2c63-4cf1-80cf-c85d0ce9dd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa6c977d-c239-4357-aa03-25a04999e6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa6c977d-c239-4357-aa03-25a04999e6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5d12d13d-2c9c-4317-aa28-3905b2bf94a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d839403b-1847-4bd8-9f35-c4e4410a8308" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5d12d13d-2c9c-4317-aa28-3905b2bf94a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SignificantaccountingpoliciesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#SignificantaccountingpoliciesDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SignificantaccountingpoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae39dd54-e5d9-4103-ab4e-d4bc293f954f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_9a49f798-8c63-44b2-ac5f-e8ca73bb814e" xlink:href="abus-20220331.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae39dd54-e5d9-4103-ab4e-d4bc293f954f" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_9a49f798-8c63-44b2-ac5f-e8ca73bb814e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae39dd54-e5d9-4103-ab4e-d4bc293f954f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_403efc64-7155-437c-908d-3b0fbf26a54e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_679f4c8e-6a6d-41bb-9dc4-5bc7d9b51938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fb0de17-073c-4670-89d7-dfe43e82b903" xlink:to="loc_us-gaap_EmployeeStockOptionMember_679f4c8e-6a6d-41bb-9dc4-5bc7d9b51938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_0109c2d8-d69e-44c3-8866-6ddd1315aeda" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_affe0d89-ecbe-4c10-9662-f4c91cabed64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_affe0d89-ecbe-4c10-9662-f4c91cabed64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_93e696a5-b402-4493-9feb-e2f2cf5b08a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_93e696a5-b402-4493-9feb-e2f2cf5b08a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_f846bc21-8e84-4e0f-ac31-5596832e0cff" xlink:href="abus-20220331.xsd#abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_4fccae46-4573-43a2-9636-fe0a04a87970" xlink:to="loc_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements_f846bc21-8e84-4e0f-ac31-5596832e0cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="abus-20220331.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bebe8dc9-d5e3-45ac-8419-cb92cf957edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_46256104-350f-409a-949a-7eee20c9af83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bebe8dc9-d5e3-45ac-8419-cb92cf957edc" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_46256104-350f-409a-949a-7eee20c9af83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b9e03c6b-175d-4e95-a8c0-f5785557e3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_897efc4c-4e42-460e-8942-55daba42ca23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9e03c6b-175d-4e95-a8c0-f5785557e3e1" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_897efc4c-4e42-460e-8942-55daba42ca23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_4a906160-8b5a-4e85-9da3-681ecc890720" xlink:href="abus-20220331.xsd#abus_ChangesInFairValueofLiabilityOptionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9e03c6b-175d-4e95-a8c0-f5785557e3e1" xlink:to="loc_abus_ChangesInFairValueofLiabilityOptionTableTextBlock_4a906160-8b5a-4e85-9da3-681ecc890720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_2a0518dd-9775-4696-b8df-8f887cd54da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b9e03c6b-175d-4e95-a8c0-f5785557e3e1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_2a0518dd-9775-4696-b8df-8f887cd54da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bf0dcb1f-188e-4586-a267-bac4a102fab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d8459afb-cc3e-4a39-9e39-a527e524735b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bf0dcb1f-188e-4586-a267-bac4a102fab0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_d8459afb-cc3e-4a39-9e39-a527e524735b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_901a0ef4-4226-45c4-ba30-03f40ee2c0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bf0dcb1f-188e-4586-a267-bac4a102fab0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_901a0ef4-4226-45c4-ba30-03f40ee2c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_186b1347-3f2e-484c-9743-2dfef61a874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_186b1347-3f2e-484c-9743-2dfef61a874e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_50afc22d-6447-4658-ace9-a281660f128c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5cf8a0b3-0307-49d9-9b55-37aa9a149ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e783814-c35b-4dbe-ab89-69b18f23925a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5cf8a0b3-0307-49d9-9b55-37aa9a149ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b782307b-b19b-4afc-8b63-982aaac712b7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_90a3e143-c4d6-481d-9224-1cb4d362af0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_90a3e143-c4d6-481d-9224-1cb4d362af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_17b300c6-b4fe-487c-a75d-fc791739d582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_17b300c6-b4fe-487c-a75d-fc791739d582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2c859a81-ec6e-4601-9de5-60b35ff90dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2b766c47-2e3b-4b2b-9ea9-b7b56544856a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2c859a81-ec6e-4601-9de5-60b35ff90dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e528b47c-2ac8-4c68-a6ea-84c768ead195" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54dbde46-5be5-4444-b669-7b5cfe85c622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_54dbde46-5be5-4444-b669-7b5cfe85c622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_b23354da-e38e-4e1d-b44b-91e1ceecfbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_b23354da-e38e-4e1d-b44b-91e1ceecfbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_2b4c21aa-5e5d-44dc-aed9-df0ae3218b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_LongTermInvestments_2b4c21aa-5e5d-44dc-aed9-df0ae3218b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0faed7f7-7608-436f-8ed3-21e39ed753a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_97495394-8c90-4112-88f4-47418f1ef598" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0faed7f7-7608-436f-8ed3-21e39ed753a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a9014d-1f5e-46fe-b6ac-9035d0e524fc" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_fe7887ab-4bd2-41e0-86f3-2ac0e6f0561a" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_fe7887ab-4bd2-41e0-86f3-2ac0e6f0561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ed2cba3-f85a-4d1a-8d4b-aa66ccb34988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6ed2cba3-f85a-4d1a-8d4b-aa66ccb34988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_ec56da96-6e81-4a32-b324-4caec91dcea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e51e0111-d8e7-4e84-bf61-5f1880e2745f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_ec56da96-6e81-4a32-b324-4caec91dcea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4cee3556-357b-4318-a9c7-301aca462114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4cee3556-357b-4318-a9c7-301aca462114" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:to="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5ae66ed-a765-4fc0-906c-ed195f867aac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_1e777527-8e37-4b7a-b13a-5588d4c0e96c" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionLiabilityClassifiedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_033a9875-b410-4b2a-9b0f-daf7c2dea689" xlink:to="loc_abus_EmployeeStockOptionLiabilityClassifiedMember_1e777527-8e37-4b7a-b13a-5588d4c0e96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_400f7047-3a3b-4aa4-a3e1-4fb4a4eaac31" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:href="abus-20220331.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_772c0c6e-0bb8-4d57-ae17-7f62cf5289b0" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f9e0fd14-e034-4ab6-b775-2c4dcd30c5d4" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f9e0fd14-e034-4ab6-b775-2c4dcd30c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_de389d49-4c58-4486-83dd-f7191429f9c1" xlink:href="abus-20220331.xsd#abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue_de389d49-4c58-4486-83dd-f7191429f9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_b5bf72ad-4ca4-45a6-b33d-f6f87ec5380f" xlink:href="abus-20220331.xsd#abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions_b5bf72ad-4ca4-45a6-b33d-f6f87ec5380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f1b3b113-e4e3-4362-8336-13daed90857d" xlink:href="abus-20220331.xsd#abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_d736b445-a4c2-4a38-9ab0-bf6404345027" xlink:to="loc_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure_f1b3b113-e4e3-4362-8336-13daed90857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_184ee827-f997-4de5-ab40-c6e5a0808e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_0e0724be-ec4d-4a8b-9e9a-e755c76667c5" xlink:href="abus-20220331.xsd#abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_184ee827-f997-4de5-ab40-c6e5a0808e47" xlink:to="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_0e0724be-ec4d-4a8b-9e9a-e755c76667c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_71053b1c-f2af-4825-ae5d-b095ac4c25be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_0e0724be-ec4d-4a8b-9e9a-e755c76667c5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_71053b1c-f2af-4825-ae5d-b095ac4c25be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1ecedf03-5059-479e-8d1d-d146b55bf127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_0e0724be-ec4d-4a8b-9e9a-e755c76667c5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1ecedf03-5059-479e-8d1d-d146b55bf127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_626075e8-fed9-47c6-b5fa-51095722a94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward_0e0724be-ec4d-4a8b-9e9a-e755c76667c5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_626075e8-fed9-47c6-b5fa-51095722a94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="simple" xlink:href="abus-20220331.xsd#FairValueMeasuresandDisclosuresPolicies"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2730aa20-01e5-4dd7-ad81-6f2da13e5389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3f9ad38e-df13-47a4-9e03-64f8910c1983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2730aa20-01e5-4dd7-ad81-6f2da13e5389" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3f9ad38e-df13-47a4-9e03-64f8910c1983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Investmentsinmarketablesecurities" xlink:type="simple" xlink:href="abus-20220331.xsd#Investmentsinmarketablesecurities"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Investmentsinmarketablesecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e14abd58-836d-4db7-99df-3d7671aa0485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_31e6550e-abe7-47bf-b2f4-d358233aad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e14abd58-836d-4db7-99df-3d7671aa0485" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_31e6550e-abe7-47bf-b2f4-d358233aad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentsinmarketablesecuritiesTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b6c8346-5d92-496a-87d5-10d448ce91af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_243ef82f-1981-4542-a9e4-6330649dc825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b6c8346-5d92-496a-87d5-10d448ce91af" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_243ef82f-1981-4542-a9e4-6330649dc825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_534b865c-723f-4054-8da3-8ac24ce6507a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_534b865c-723f-4054-8da3-8ac24ce6507a" xlink:to="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_893b1758-8a98-4fac-b118-a331f8fd5d62" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_4a12b564-29a9-4e77-8466-64a63b9a9361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14930bdf-8813-4b1e-b32b-bd215a488ac0" xlink:to="loc_us-gaap_CashEquivalentsMember_4a12b564-29a9-4e77-8466-64a63b9a9361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d03788f-3f04-4148-a751-8cdb08434e32" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentMoneyMarkeTFundMember_55f672b2-5781-425c-a14b-01817502d141" xlink:href="abus-20220331.xsd#abus_USGovernmentMoneyMarkeTFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentMoneyMarkeTFundMember_55f672b2-5781-425c-a14b-01817502d141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_a83c7b5d-dc34-468a-bd88-8ac92a630f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_a83c7b5d-dc34-468a-bd88-8ac92a630f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentAgencyBondsMember_bb468e46-ceab-47e9-b6d5-789c224a1988" xlink:href="abus-20220331.xsd#abus_USGovernmentAgencyBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentAgencyBondsMember_bb468e46-ceab-47e9-b6d5-789c224a1988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_USGovernmentBondsMember_10ab301b-cc96-4e54-a73d-79c66126ef42" xlink:href="abus-20220331.xsd#abus_USGovernmentBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85e47e86-b33b-4a0e-aac5-e7cadb118cf2" xlink:to="loc_abus_USGovernmentBondsMember_10ab301b-cc96-4e54-a73d-79c66126ef42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_0977ce12-0d5b-4bfd-8020-d2adf7601807" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_4b978410-13db-4a13-9604-b6727b4ba3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_4b978410-13db-4a13-9604-b6727b4ba3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LongTermInvestmentsMember_f1e4aaf3-90eb-4911-b487-cbb081ec386c" xlink:href="abus-20220331.xsd#abus_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4fc5271b-5531-4e68-aae3-792c6e91ca41" xlink:to="loc_abus_LongTermInvestmentsMember_f1e4aaf3-90eb-4911-b487-cbb081ec386c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesTable_d5953034-7200-41b1-831a-70e1be133070" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db2c90f0-7c85-4a23-948d-2128b482db95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db2c90f0-7c85-4a23-948d-2128b482db95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41b7ddb1-7a8c-401b-922d-a538484e63f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_41b7ddb1-7a8c-401b-922d-a538484e63f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_178449ce-8f45-45d6-9769-617dd753ef74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_178449ce-8f45-45d6-9769-617dd753ef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99f8be1d-ac21-405a-b9d0-12c1aa47df69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_99f8be1d-ac21-405a-b9d0-12c1aa47df69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2817f200-6479-4041-be9d-8d77144ad739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2817f200-6479-4041-be9d-8d77144ad739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2451819-40a3-4347-be24-3f447e84fdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8cb2d03d-4da2-40a8-87f2-767e9a9a6d25" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f2451819-40a3-4347-be24-3f447e84fdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentsinmarketablesecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_166e94e7-b3d1-40c1-927c-a83ea74003b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6656800c-5054-4c54-a450-236f2a7b7cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_166e94e7-b3d1-40c1-927c-a83ea74003b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6656800c-5054-4c54-a450-236f2a7b7cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e1402653-ecc9-4c99-a654-cccc9bf9fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_166e94e7-b3d1-40c1-927c-a83ea74003b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e1402653-ecc9-4c99-a654-cccc9bf9fd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a8635805-133f-4f5f-b482-1ff9b29029cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_166e94e7-b3d1-40c1-927c-a83ea74003b2" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_a8635805-133f-4f5f-b482-1ff9b29029cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentinGenevant" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentinGenevant"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/InvestmentinGenevant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_be45d262-89e8-46db-b29e-33dd621d4c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6df34d4d-6bdc-4d8d-a911-511b0b73bf03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_be45d262-89e8-46db-b29e-33dd621d4c68" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6df34d4d-6bdc-4d8d-a911-511b0b73bf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/InvestmentinGenevantDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#InvestmentinGenevantDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/InvestmentinGenevantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c7979a41-fb2d-429d-b1c8-84262100337c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c7979a41-fb2d-429d-b1c8-84262100337c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_725afed9-5c2c-4d65-8a57-77ad576fb155" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_ab4048e2-4d8b-4a04-95ae-9d304ec2fdea" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c4088129-af8d-40d5-9b61-9a041f2471b7" xlink:to="loc_abus_GenevantSciencesCorporationMember_ab4048e2-4d8b-4a04-95ae-9d304ec2fdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_e3b0c9ef-c2b0-40d6-a31e-84aebb807c44" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SubLicensingRevenuePercentage_c9b08b1b-607b-4be1-bbfa-c95c7d9a487b" xlink:href="abus-20220331.xsd#abus_SubLicensingRevenuePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_abus_SubLicensingRevenuePercentage_c9b08b1b-607b-4be1-bbfa-c95c7d9a487b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34b299db-06b7-4bf6-9714-562717e295ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34b299db-06b7-4bf6-9714-562717e295ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0abf2eee-0ece-4fa7-ab44-87a8cbbfa11c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_us-gaap_EquityMethodInvestments_0abf2eee-0ece-4fa7-ab44-87a8cbbfa11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_BonaFideCollaborationPercentage_69f60f82-5708-4176-af9e-fd4362b1ac45" xlink:href="abus-20220331.xsd#abus_BonaFideCollaborationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_83bfd472-c451-404e-9475-39b56503dbd9" xlink:to="loc_abus_BonaFideCollaborationPercentage_69f60f82-5708-4176-af9e-fd4362b1ac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Accountspayableandaccruedliabilities" xlink:type="simple" xlink:href="abus-20220331.xsd#Accountspayableandaccruedliabilities"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Accountspayableandaccruedliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d488dd3d-41f9-46e1-8bf6-4f82cc2566ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f3dd4375-aec8-4ba4-a402-a2a34e04f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d488dd3d-41f9-46e1-8bf6-4f82cc2566ad" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f3dd4375-aec8-4ba4-a402-a2a34e04f5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables" xlink:type="simple" xlink:href="abus-20220331.xsd#AccountspayableandaccruedliabilitiesTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_45d71fe7-a652-41b0-9ece-ebbb23b01f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_58e0d129-3144-4d4a-9cc4-822e23dcf74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_45d71fe7-a652-41b0-9ece-ebbb23b01f31" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_58e0d129-3144-4d4a-9cc4-822e23dcf74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#AccountspayableandaccruedliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_c5d1bdcb-ced6-41a1-892d-91f66697e754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_c5d1bdcb-ced6-41a1-892d-91f66697e754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedResearchAndDevelopment_35b30301-ab92-4e89-a90f-7e0efecfa25e" xlink:href="abus-20220331.xsd#abus_AccruedResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_abus_AccruedResearchAndDevelopment_35b30301-ab92-4e89-a90f-7e0efecfa25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4992a2a5-5de2-43cf-a153-d5af3ddf01d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4992a2a5-5de2-43cf-a153-d5af3ddf01d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AccruedPayrollCurrent_d9d9c600-0fc5-4ad6-8a2d-dc103440604c" xlink:href="abus-20220331.xsd#abus_AccruedPayrollCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_abus_AccruedPayrollCurrent_d9d9c600-0fc5-4ad6-8a2d-dc103440604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cc7dd801-860d-4d33-9006-0058fd8afd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cc7dd801-860d-4d33-9006-0058fd8afd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_835a25cb-a0be-444e-8401-f27e13f9e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fcaff3e1-8f5d-4fb3-bdb8-37c9d21f15ae" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_835a25cb-a0be-444e-8401-f27e13f9e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Saleoffutureroyalties" xlink:type="simple" xlink:href="abus-20220331.xsd#Saleoffutureroyalties"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Saleoffutureroyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8a0b72d3-8f38-4ece-983a-6b4ca143a70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_b38ac764-0404-4bbe-bce2-4a1070c289a2" xlink:href="abus-20220331.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_8a0b72d3-8f38-4ece-983a-6b4ca143a70c" xlink:to="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock_b38ac764-0404-4bbe-bce2-4a1070c289a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesTables" xlink:type="simple" xlink:href="abus-20220331.xsd#SaleoffutureroyaltiesTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleoffutureroyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5ba81948-1017-414f-9a02-84a75abe61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_d43f4a01-2027-45f0-a5c9-0a0802d224a1" xlink:href="abus-20220331.xsd#abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5ba81948-1017-414f-9a02-84a75abe61a9" xlink:to="loc_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock_d43f4a01-2027-45f0-a5c9-0a0802d224a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#SaleoffutureroyaltiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7ecb20bf-a6b1-43f6-8295-aeb949fced0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AirlineProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7ecb20bf-a6b1-43f6-8295-aeb949fced0b" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:to="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2ed6e674-00d9-490f-a37d-ef80b5132bdb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OMERSMember_fd40d50d-37e7-4042-897d-02f2212154b3" xlink:href="abus-20220331.xsd#abus_OMERSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b29f2c4-44d8-41d2-a966-88006202e63f" xlink:to="loc_abus_OMERSMember_fd40d50d-37e7-4042-897d-02f2212154b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:to="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31b300aa-9196-43ad-b9ce-b3557fe68ca9" xlink:to="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_737595c6-0381-457a-bc56-53b70fb477e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:to="loc_srt_MinimumMember_737595c6-0381-457a-bc56-53b70fb477e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a68084db-4fa3-4849-8502-1cdaac8a5ca3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_44b8887e-b478-43df-8acc-6245167b1b72" xlink:to="loc_srt_MaximumMember_a68084db-4fa3-4849-8502-1cdaac8a5ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:href="abus-20220331.xsd#abus_OtherLiabilitiesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_c70c32b4-ccb2-4860-9144-1a8c1a44798b" xlink:to="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_2ebdb7d1-0bea-45dd-8983-b757540775b2" xlink:href="abus-20220331.xsd#abus_RoyaltyPercentageofInterestSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_2ebdb7d1-0bea-45dd-8983-b757540775b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_8c866b8e-0032-4bde-821d-458463e2a35a" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_8c866b8e-0032-4bde-821d-458463e2a35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_760c63f9-e109-4034-b03a-52468dae4d1b" xlink:href="abus-20220331.xsd#abus_GrossProceedsFromRoyaltyInterestSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_760c63f9-e109-4034-b03a-52468dae4d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_f32c39c8-106f-4fc8-8b5e-ca850c5e50d1" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_f32c39c8-106f-4fc8-8b5e-ca850c5e50d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_4a94f366-12ab-4bbd-a8e7-bbec5c2509ab" xlink:href="abus-20220331.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_4a94f366-12ab-4bbd-a8e7-bbec5c2509ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPayable_fccc2dca-513f-4037-93ba-f881ccd2a06d" xlink:href="abus-20220331.xsd#abus_RoyaltyPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_RoyaltyPayable_fccc2dca-513f-4037-93ba-f881ccd2a06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_013ebb3e-478a-4516-9f56-571830627891" xlink:href="abus-20220331.xsd#abus_TransactionCostsRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_TransactionCostsRelatedToSaleOfFutureRoyalties_013ebb3e-478a-4516-9f56-571830627891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_3a24f760-4fa8-4d03-a094-90f098291efb" xlink:href="abus-20220331.xsd#abus_EffectiveAnnualInterestRateOfRoyaltyLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_EffectiveAnnualInterestRateOfRoyaltyLiability_3a24f760-4fa8-4d03-a094-90f098291efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c5c4b46c-9b34-45bb-8ff5-b36b820da8bb" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c5c4b46c-9b34-45bb-8ff5-b36b820da8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_eb4048fa-19bc-474c-8643-7051a8fd63cb" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_OtherLiabilitiesDisclosureLineItems_04d847f2-f25d-4ffe-8503-fa4ae36a657a" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_eb4048fa-19bc-474c-8643-7051a8fd63cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#SaleoffutureroyaltiesLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7b47a1da-0421-402c-b33b-046e3e69dcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7b47a1da-0421-402c-b33b-046e3e69dcf3" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_1e238423-3330-466a-8105-f89224f76dc7" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_1e238423-3330-466a-8105-f89224f76dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_2da2bfd8-d5ae-4ebe-8c74-4ef3d2c51d0b" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome_2da2bfd8-d5ae-4ebe-8c74-4ef3d2c51d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_3c4803e4-d245-4b4c-8a01-194c33117602" xlink:href="abus-20220331.xsd#abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:to="loc_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense_3c4803e4-d245-4b4c-8a01-194c33117602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_f3179a65-5ca7-480a-89f5-0cd9d0e950b9" xlink:href="abus-20220331.xsd#abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward_06d59edd-4796-4ec2-8b31-1c099f66f6af" xlink:to="loc_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent_f3179a65-5ca7-480a-89f5-0cd9d0e950b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Contingenciesandcommitments" xlink:type="simple" xlink:href="abus-20220331.xsd#Contingenciesandcommitments"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Contingenciesandcommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_757312c2-4109-4c54-b62e-53f67dc0d06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5fb7c0d0-19a7-49e1-92b8-a530edb265ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_757312c2-4109-4c54-b62e-53f67dc0d06a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5fb7c0d0-19a7-49e1-92b8-a530edb265ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ContingenciesandcommitmentsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ContingenciesandcommitmentsDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ContingenciesandcommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d6806d71-a187-496e-8094-0026f0c94613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d6806d71-a187-496e-8094-0026f0c94613" xlink:to="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cbf463bb-be52-4122-b84c-9377be86cd3a" xlink:to="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_19338eff-dc1c-4f1e-9d48-5b4762ab961e" xlink:href="abus-20220331.xsd#abus_ArbitrationWithTheUniversityOfBritishColumbiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_594b07e4-1bda-40af-94a9-1d5b0d956b12" xlink:to="loc_abus_ArbitrationWithTheUniversityOfBritishColumbiaMember_19338eff-dc1c-4f1e-9d48-5b4762ab961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6910a107-810a-414e-b7a3-136327c8462c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EnantigensSellingShareholdersMember_6836723c-d172-4169-88d2-83746883f3f7" xlink:href="abus-20220331.xsd#abus_EnantigensSellingShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dd92aad-1141-410c-bd6d-03c16bd8336b" xlink:to="loc_abus_EnantigensSellingShareholdersMember_6836723c-d172-4169-88d2-83746883f3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_035720fc-d4cb-4ec6-933b-66efc6430c7a" xlink:to="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusInc.Member_30fd52af-59ab-41f6-873e-e15b087fa55c" xlink:href="abus-20220331.xsd#abus_ArbutusInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2a1735d7-dd32-4977-887f-a56b2e04feb7" xlink:to="loc_abus_ArbutusInc.Member_30fd52af-59ab-41f6-873e-e15b087fa55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44e98e4-373d-4e21-aedc-112792914567" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_EnantigensSellingShareholdersMember_c24169ca-6be1-436d-8f56-f342b6816dc1" xlink:href="abus-20220331.xsd#abus_EnantigensSellingShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_03cc5222-7b9f-4952-82d3-d193beb46fbf" xlink:to="loc_abus_EnantigensSellingShareholdersMember_c24169ca-6be1-436d-8f56-f342b6816dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3b3e2887-c67d-4068-912e-692e83218753" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1c9a35a9-a2c2-4d71-9ed7-d2ee2fb510a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e49ae421-0aef-4ff9-b73b-17cf49ea4877" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1c9a35a9-a2c2-4d71-9ed7-d2ee2fb510a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:href="abus-20220331.xsd#abus_ContingenciesandCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsTable_2e8c373b-2142-461c-8909-373ba78791db" xlink:to="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_7daadfe0-338f-427f-9610-702aaf6a0c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_7daadfe0-338f-427f-9610-702aaf6a0c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_64089645-8908-474a-b2d2-c0a5eac30040" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense_64089645-8908-474a-b2d2-c0a5eac30040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_6e3ea80b-80d7-4575-841c-caa52023b41e" xlink:href="abus-20220331.xsd#abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty_6e3ea80b-80d7-4575-841c-caa52023b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c44a7a69-fa75-4c9d-ab30-15283e5dd503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_ContingenciesandCommitmentsLineItems_03656fca-1906-4dc9-8fa4-2183e87991df" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c44a7a69-fa75-4c9d-ab30-15283e5dd503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements" xlink:type="simple" xlink:href="abus-20220331.xsd#Collaborationscontractsandlicensingagreements"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_463459fa-9185-47cc-9541-3af8a528095d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f8312dad-066b-47ee-bbf3-a9557ab88ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_463459fa-9185-47cc-9541-3af8a528095d" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_f8312dad-066b-47ee-bbf3-a9557ab88ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables" xlink:type="simple" xlink:href="abus-20220331.xsd#CollaborationscontractsandlicensingagreementsTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2037d9d-fdd8-4a25-bd4f-2e54a3293291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2edc0405-4a2e-45e2-92f5-27daf13f4a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2037d9d-fdd8-4a25-bd4f-2e54a3293291" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_2edc0405-4a2e-45e2-92f5-27daf13f4a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_dba2895c-a552-496f-8c97-77eca7f570c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e2037d9d-fdd8-4a25-bd4f-2e54a3293291" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_dba2895c-a552-496f-8c97-77eca7f570c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#CollaborationscontractsandlicensingagreementsDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4e9bc07-e4cf-46af-a898-e409dd0672e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b4e9bc07-e4cf-46af-a898-e409dd0672e5" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_49a1c505-58b7-490c-88c5-849bb83d93c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AssemblyBiosciencesIncMember_b7d8d675-4ec3-4af8-80d8-31b383783e95" xlink:href="abus-20220331.xsd#abus_AssemblyBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AssemblyBiosciencesIncMember_b7d8d675-4ec3-4af8-80d8-31b383783e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OMERSMember_f45e9a60-463d-458d-88a6-1af6d52613e4" xlink:href="abus-20220331.xsd#abus_OMERSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_OMERSMember_f45e9a60-463d-458d-88a6-1af6d52613e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AcuitasTherapeuticsInc.Member_8ecce3e2-2a48-4238-adda-99fa42ee899e" xlink:href="abus-20220331.xsd#abus_AcuitasTherapeuticsInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AcuitasTherapeuticsInc.Member_8ecce3e2-2a48-4238-adda-99fa42ee899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OtherMilestoneandRoyaltyPaymentsMember_c6368a94-9009-460a-96ad-8a08c7c41b32" xlink:href="abus-20220331.xsd#abus_OtherMilestoneandRoyaltyPaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_OtherMilestoneandRoyaltyPaymentsMember_c6368a94-9009-460a-96ad-8a08c7c41b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_AlnylamPharmaceuticalsIncMember_eba51143-d76c-410f-8058-20fe4d85fb3b" xlink:href="abus-20220331.xsd#abus_AlnylamPharmaceuticalsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_AlnylamPharmaceuticalsIncMember_eba51143-d76c-410f-8058-20fe4d85fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_3e230b62-57c1-4230-a03a-0840433b8be6" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_3e230b62-57c1-4230-a03a-0840433b8be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_XChemIncAndProterosMember_9ab749cb-e42f-4be6-a888-e3bca7c7d17e" xlink:href="abus-20220331.xsd#abus_XChemIncAndProterosMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2af42da3-3707-47a0-b4ce-1bb895db0bf3" xlink:to="loc_abus_XChemIncAndProterosMember_9ab749cb-e42f-4be6-a888-e3bca7c7d17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_624d50b2-70e4-4dd1-a396-212559270fcb" xlink:to="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3630762b-3fb2-409b-909c-075430e6135f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:to="loc_srt_MinimumMember_3630762b-3fb2-409b-909c-075430e6135f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b8c665c3-cc40-4f13-bead-4f0b405024ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fc1d0e4c-5609-4440-98b2-8d5d1de130a7" xlink:to="loc_srt_MaximumMember_b8c665c3-cc40-4f13-bead-4f0b405024ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_241f8b0a-8918-4e50-a1b7-70ad972e2709" xlink:to="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_eb537dcc-7cab-4bdb-91db-cc780c2b4c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:to="loc_us-gaap_LicenseMember_eb537dcc-7cab-4bdb-91db-cc780c2b4c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyMember_ca654fd1-e9c8-4911-8aef-e6255dd19068" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8d0c152a-4c34-48fe-802a-cdc1c05713cf" xlink:to="loc_abus_NonCashRoyaltyMember_ca654fd1-e9c8-4911-8aef-e6255dd19068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_63afb5ce-478a-4724-997a-6d5bc4fd77bb" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_6b71d5ba-5644-4310-a8d9-fb4dbda8d50b" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f7be7af-9adb-4d3b-aa17-39d795562e72" xlink:to="loc_abus_GenevantSciencesCorporationMember_6b71d5ba-5644-4310-a8d9-fb4dbda8d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b60bcd37-3af3-4201-a93e-dc2438440ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_bdb138c6-1c81-461f-adb8-b2f3f9047104" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b60bcd37-3af3-4201-a93e-dc2438440ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0328174d-c74f-4148-a308-8ea684d709ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_OneTimeUpfrontCashPaymentMember_4e53cee4-2d27-4be2-9ce6-ebce8a4d23f9" xlink:href="abus-20220331.xsd#abus_OneTimeUpfrontCashPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_34457897-996f-459f-ae59-010573101f10" xlink:to="loc_abus_OneTimeUpfrontCashPaymentMember_4e53cee4-2d27-4be2-9ce6-ebce8a4d23f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_96f9625f-efcb-4532-b39e-42c64cb8b1e0" xlink:to="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c2e6756c-e289-461c-8450-e7bf40ddad67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d7e45bc2-d73a-4c98-a491-d8fd755e40b8" xlink:to="loc_us-gaap_CommonStockMember_c2e6756c-e289-461c-8450-e7bf40ddad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_90f4c022-18d7-46ca-b66a-e041d126204d" xlink:to="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_23d535f4-afe7-497f-9c89-66e80bbacb4c" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_467f3744-12a1-4bc7-a3f8-b5433e152e7a" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_23d535f4-afe7-497f-9c89-66e80bbacb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_481ff6fa-89a7-4f4e-aca8-7f410be4c48a" xlink:to="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_QiluPharmaceuticalCoLTDMember_2b530e44-508e-4f4c-a91e-5d45d324dcf2" xlink:href="abus-20220331.xsd#abus_QiluPharmaceuticalCoLTDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_43f98036-7cf3-4e69-a2da-57ec841afa24" xlink:to="loc_abus_QiluPharmaceuticalCoLTDMember_2b530e44-508e-4f4c-a91e-5d45d324dcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5064b857-69b4-47b4-b58a-d264b0b5570c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_98341c46-45f3-46e8-ad98-e8ea06dc3d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_98341c46-45f3-46e8-ad98-e8ea06dc3d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyEntitlements_28d6bf9d-7efe-4cf7-9be2-d2e18e187fc0" xlink:href="abus-20220331.xsd#abus_RoyaltyEntitlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyEntitlements_28d6bf9d-7efe-4cf7-9be2-d2e18e187fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPercentageofInterestSold_3e4ebfb0-2c3d-43dc-bc14-d22735518457" xlink:href="abus-20220331.xsd#abus_RoyaltyPercentageofInterestSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyPercentageofInterestSold_3e4ebfb0-2c3d-43dc-bc14-d22735518457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_9aea46fa-a968-484b-a123-c1431140c862" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier_9aea46fa-a968-484b-a123-c1431140c862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GrossProceedsFromRoyaltyInterestSold_f54c6ce5-de64-4156-8f8f-1350f9963f75" xlink:href="abus-20220331.xsd#abus_GrossProceedsFromRoyaltyInterestSold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_GrossProceedsFromRoyaltyInterestSold_f54c6ce5-de64-4156-8f8f-1350f9963f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_5367945b-ec45-403d-a9f8-0e10a12c0f62" xlink:href="abus-20220331.xsd#abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer_5367945b-ec45-403d-a9f8-0e10a12c0f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_463fbb05-3014-4805-8829-61d40338ff49" xlink:href="abus-20220331.xsd#abus_RoyaltyGuaranteesCommitmentsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyGuaranteesCommitmentsPercentage_463fbb05-3014-4805-8829-61d40338ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoyaltyPayable_2c53430f-940e-4a45-acf5-af73399123a0" xlink:href="abus-20220331.xsd#abus_RoyaltyPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_RoyaltyPayable_2c53430f-940e-4a45-acf5-af73399123a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_11e7b218-b927-4cb2-89dc-119c1e864189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_Revenues_11e7b218-b927-4cb2-89dc-119c1e864189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PotentialMilestonePayments_af3fc3b5-8279-410d-95e0-c98400a94e53" xlink:href="abus-20220331.xsd#abus_PotentialMilestonePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_PotentialMilestonePayments_af3fc3b5-8279-410d-95e0-c98400a94e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_8e4c31e8-a011-463c-b944-e9228e9a2296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_8e4c31e8-a011-463c-b944-e9228e9a2296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_83a46b03-4017-4bf2-8eb1-482329d1db41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_CommonStockSharesIssued_83a46b03-4017-4bf2-8eb1-482329d1db41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3b5438eb-c8b2-4d82-846f-8b6e369e5518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_SharePrice_3b5438eb-c8b2-4d82-846f-8b6e369e5518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d71ddf9-2f5c-4726-82f2-8adbea264902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4d71ddf9-2f5c-4726-82f2-8adbea264902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3c098d42-97aa-4eeb-90ab-6dccdd62f3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3c098d42-97aa-4eeb-90ab-6dccdd62f3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_605f5772-a055-4f8d-b931-129e4269d962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_605f5772-a055-4f8d-b931-129e4269d962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_1c472491-8cfa-466b-93dc-955e6b69f338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ContractWithCustomerLiability_1c472491-8cfa-466b-93dc-955e6b69f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueCurrent_58f83bf5-cfcc-499e-8eaa-d0738537a5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_DeferredRevenueCurrent_58f83bf5-cfcc-499e-8eaa-d0738537a5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_baef82a2-1c58-48eb-9e93-63d9955a5f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_baef82a2-1c58-48eb-9e93-63d9955a5f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_465092ab-6ba0-44fb-9243-8c1dd08b4565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_IncomeTaxesPaid_465092ab-6ba0-44fb-9243-8c1dd08b4565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_960e93c2-e825-4f4e-9998-235be2db0dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_960e93c2-e825-4f4e-9998-235be2db0dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDeferredCostsGross_f72c6b92-3ff6-434e-acd2-456c45a39705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDeferredCostsGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_OtherDeferredCostsGross_f72c6b92-3ff6-434e-acd2-456c45a39705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PremiumonClosingStockPrice_027fd74f-6082-4192-83b3-d59b685b61c5" xlink:href="abus-20220331.xsd#abus_PremiumonClosingStockPrice"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_PremiumonClosingStockPrice_027fd74f-6082-4192-83b3-d59b685b61c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_46b96a10-ecd5-41e4-a3a6-e4f7ee1b8515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_46b96a10-ecd5-41e4-a3a6-e4f7ee1b8515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c4c345fb-ead1-4f2a-aeb0-d3d3f509b61d" xlink:href="abus-20220331.xsd#abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties_c4c345fb-ead1-4f2a-aeb0-d3d3f509b61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_31b49e04-90a0-4665-9ada-8545934ba4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_80294ed4-b659-4bbc-92c9-5eac1a3a39e6" xlink:to="loc_us-gaap_PremiumsEarnedNet_31b49e04-90a0-4665-9ada-8545934ba4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Shareholdersequity" xlink:type="simple" xlink:href="abus-20220331.xsd#Shareholdersequity"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Shareholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cb80b246-f53e-412a-9c5b-46ac39f4f9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7bd35e4e-0580-463b-b031-d9783827ac93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cb80b246-f53e-412a-9c5b-46ac39f4f9c2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7bd35e4e-0580-463b-b031-d9783827ac93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ShareholdersequityTables" xlink:type="simple" xlink:href="abus-20220331.xsd#ShareholdersequityTables"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ShareholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8f4448a3-5048-4359-8359-a9ef6375738d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c74dbdf5-938c-4add-8bbc-6c1983a9893b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8f4448a3-5048-4359-8359-a9ef6375738d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c74dbdf5-938c-4add-8bbc-6c1983a9893b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ShareholdersequityNarrativeDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ShareholdersequityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ShareholdersequityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a42f4fb6-ac74-4049-a5de-c56d5483bca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a42f4fb6-ac74-4049-a5de-c56d5483bca2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2afddf6d-f063-4be6-94ba-a4cfc67835ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_JefferiesLLCMember_407550d5-75f6-4f0c-9c66-324ee332b949" xlink:href="abus-20220331.xsd#abus_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:to="loc_abus_JefferiesLLCMember_407550d5-75f6-4f0c-9c66-324ee332b949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RoivantSciencesLtdMember_c742e745-8eb3-4834-91f0-6d90ab8acffa" xlink:href="abus-20220331.xsd#abus_RoivantSciencesLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7543b30e-07e6-4fb5-96e5-5c6db215a968" xlink:to="loc_abus_RoivantSciencesLtdMember_c742e745-8eb3-4834-91f0-6d90ab8acffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_41f2b374-7b2d-41f5-ae13-87da8b8fc028" xlink:to="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8c337de4-dc65-44cb-b6c4-4fa2185985aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:to="loc_us-gaap_CommonStockMember_8c337de4-dc65-44cb-b6c4-4fa2185985aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3d5fea4c-d506-49f7-bdd1-da03924b4a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7ce44a5a-cc40-4200-ad63-7d77c67a718b" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3d5fea4c-d506-49f7-bdd1-da03924b4a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_33b2a9a9-c11f-4173-ac59-3b39ae734d3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_A2019AmendedSaleAgreementMember_7978ebfa-461d-46d4-bc5e-50f9a6d89499" xlink:href="abus-20220331.xsd#abus_A2019AmendedSaleAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_A2019AmendedSaleAgreementMember_7978ebfa-461d-46d4-bc5e-50f9a6d89499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020RegistrationStmtMember_7c2e66ca-b75d-4f65-906b-b1b9ca92aada" xlink:href="abus-20220331.xsd#abus_Jan2020RegistrationStmtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020RegistrationStmtMember_7c2e66ca-b75d-4f65-906b-b1b9ca92aada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementAgreementMember_5b2008c6-9437-4713-8e73-ddd386e2bf06" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020ProspectusSupplementAgreementMember_5b2008c6-9437-4713-8e73-ddd386e2bf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_SaleAgreementMember_6cf78e70-6434-4f1c-a0c0-5f49a2903e00" xlink:href="abus-20220331.xsd#abus_SaleAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_SaleAgreementMember_6cf78e70-6434-4f1c-a0c0-5f49a2903e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Oct2020RegistrationStmtMember_c047ecca-6891-4817-a112-44ee8bb85e8c" xlink:href="abus-20220331.xsd#abus_Oct2020RegistrationStmtMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Oct2020RegistrationStmtMember_c047ecca-6891-4817-a112-44ee8bb85e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Mar2021ProspectusSupplementAgreementMember_86507bb0-b222-4090-9d3d-6e028ba680a3" xlink:href="abus-20220331.xsd#abus_Mar2021ProspectusSupplementAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Mar2021ProspectusSupplementAgreementMember_86507bb0-b222-4090-9d3d-6e028ba680a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_October2021ProspectusSupplementMember_516aec8d-8384-47a4-8995-cb0143c966ed" xlink:href="abus-20220331.xsd#abus_October2021ProspectusSupplementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_October2021ProspectusSupplementMember_516aec8d-8384-47a4-8995-cb0143c966ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_March2022ProspectusSupplementMember_e8a315b2-624a-401d-9451-9dc6b95791e6" xlink:href="abus-20220331.xsd#abus_March2022ProspectusSupplementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_March2022ProspectusSupplementMember_e8a315b2-624a-401d-9451-9dc6b95791e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020ProspectusSupplementMember_5165d029-a6ee-429b-acc3-df70fb8a32fc" xlink:href="abus-20220331.xsd#abus_Jan2020ProspectusSupplementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Jan2020ProspectusSupplementMember_5165d029-a6ee-429b-acc3-df70fb8a32fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Aug2020ProspectusSupplementMember_abc21dbf-2584-40b1-85e2-0536d1d0c9ec" xlink:href="abus-20220331.xsd#abus_Aug2020ProspectusSupplementMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d817219-fef9-4622-a627-bf4b1d0e1de3" xlink:to="loc_abus_Aug2020ProspectusSupplementMember_abc21dbf-2584-40b1-85e2-0536d1d0c9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:href="abus-20220331.xsd#abus_RegistrationStatementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:href="abus-20220331.xsd#abus_RegistrationStatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_RegistrationStatementAxis_ac504ffe-690e-4610-b40c-523203ba4a7a" xlink:to="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020RegistrationStmtMember_090de930-0801-45b3-9ec2-0dd456a394d5" xlink:href="abus-20220331.xsd#abus_Jan2020RegistrationStmtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Jan2020RegistrationStmtMember_090de930-0801-45b3-9ec2-0dd456a394d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Oct2020RegistrationStmtMember_371e3f36-864c-4184-8668-95497f8e0406" xlink:href="abus-20220331.xsd#abus_Oct2020RegistrationStmtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Oct2020RegistrationStmtMember_371e3f36-864c-4184-8668-95497f8e0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_2b80024e-7d04-464a-baa5-e2cd24137238" xlink:href="abus-20220331.xsd#abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_abus_RegistrationStatementDomain_0bf168d1-d841-46c8-8832-fb93f4a8ca7c" xlink:to="loc_abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember_2b80024e-7d04-464a-baa5-e2cd24137238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b384a972-1aa8-4f78-963c-d9b1cd0e5ea5" xlink:to="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_b480f6cc-2a62-41a5-a721-625dc89efbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_b480f6cc-2a62-41a5-a721-625dc89efbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c195d87b-73b0-40f9-99b5-458568906fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c195d87b-73b0-40f9-99b5-458568906fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0210c862-4ce9-42cf-9360-e98a6b56b565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0210c862-4ce9-42cf-9360-e98a6b56b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46cf7801-7305-4914-843b-408ed1fd1e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_46cf7801-7305-4914-843b-408ed1fd1e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4db02a4a-a9ab-4e1c-acf6-0e159c7bf14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4db02a4a-a9ab-4e1c-acf6-0e159c7bf14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_PremiumonClosingStockPrice_fa1c6fc8-47e4-40ca-bdbe-c8db39211ca7" xlink:href="abus-20220331.xsd#abus_PremiumonClosingStockPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_abus_PremiumonClosingStockPrice_fa1c6fc8-47e4-40ca-bdbe-c8db39211ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_5b230bd9-a0a8-4602-a7aa-b30fdd397ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_SharePrice_5b230bd9-a0a8-4602-a7aa-b30fdd397ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_a9595778-35b3-45c6-a6b6-0eb96d5e856e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_a9595778-35b3-45c6-a6b6-0eb96d5e856e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_468eb412-5d66-4800-85dd-894c9eb7ee62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_468eb412-5d66-4800-85dd-894c9eb7ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6bf42ecd-d9d7-4ebf-ad22-a315daa4d954" xlink:href="abus-20220331.xsd#abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion_6bf42ecd-d9d7-4ebf-ad22-a315daa4d954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f490a809-cadc-4af2-92c6-e860a01af07e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ab6ce0-0bc8-46d4-bab1-dc6886419a04" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f490a809-cadc-4af2-92c6-e860a01af07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#ShareholdersequityStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7c485d0a-7bdd-4beb-aee8-39b2a591b385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7c485d0a-7bdd-4beb-aee8-39b2a591b385" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:to="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f73e25c8-ca8a-4e00-98d3-a2893236faad" xlink:to="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ArbutusPlansMember_520fb115-63a9-424a-8a4a-c1bd801304c3" xlink:href="abus-20220331.xsd#abus_ArbutusPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_41fd56e6-b9d0-4710-89f5-3dc75bfb6d26" xlink:to="loc_abus_ArbutusPlansMember_520fb115-63a9-424a-8a4a-c1bd801304c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cf3fc62e-4ab5-4669-8b56-b160ccc633fc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5acaba0d-3537-474c-a826-78ea52398d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5acaba0d-3537-474c-a826-78ea52398d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5db18a8-c05e-49c5-9bf6-78760e237dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_62ce5ee9-67ce-4a3d-a58a-696688f16903" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d5db18a8-c05e-49c5-9bf6-78760e237dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_944c68ac-1f08-4e0a-98af-6b31cf4146c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_039cccc9-d47a-4c2a-8056-ff9bb1edd8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_039cccc9-d47a-4c2a-8056-ff9bb1edd8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d28c4f0d-8c83-40a6-8596-60afdc81e52b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d28c4f0d-8c83-40a6-8596-60afdc81e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a960206-c7e8-4b77-b8ea-012972285c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_58aea7ec-9789-44d8-8c02-23e69cae9c48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6a960206-c7e8-4b77-b8ea-012972285c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/Relatedpartytransactions" xlink:type="simple" xlink:href="abus-20220331.xsd#Relatedpartytransactions"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/Relatedpartytransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_551aef25-f4e4-4275-ab68-63883695224d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e0950013-aa63-4f28-8243-22ab7f827bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_551aef25-f4e4-4275-ab68-63883695224d" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_e0950013-aa63-4f28-8243-22ab7f827bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://arbutusbio.com/role/RelatedpartytransactionsDetails" xlink:type="simple" xlink:href="abus-20220331.xsd#RelatedpartytransactionsDetails"/>
  <link:presentationLink xlink:role="http://arbutusbio.com/role/RelatedpartytransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5b7e3fa7-2614-43bc-ab7f-5f6105003d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5b7e3fa7-2614-43bc-ab7f-5f6105003d22" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:to="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_502194ce-7006-440f-a635-e17b041fc5ae" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_GenevantSciencesCorporationMember_d19c0b7f-4818-4631-9733-c52882e79d98" xlink:href="abus-20220331.xsd#abus_GenevantSciencesCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d68e3d0-a85b-4a28-99f9-6925d86ed0d9" xlink:to="loc_abus_GenevantSciencesCorporationMember_d19c0b7f-4818-4631-9733-c52882e79d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ab8f5357-dd55-4e7d-8e70-a90c8989fbc1" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abus_ResearchAndDevelopmentServicesMember_c5f57f73-344c-475c-9762-0f2dfe776e47" xlink:href="abus-20220331.xsd#abus_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_71256563-5988-49bb-9a2b-0ecd09d43cd3" xlink:to="loc_abus_ResearchAndDevelopmentServicesMember_c5f57f73-344c-475c-9762-0f2dfe776e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5c468b53-9e9c-4fb3-aa62-b156a3d09b39" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_c7abb016-c238-4b49-8eff-0e4eb0efab18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_ce38348e-a448-42f5-9215-32bb1f343d19" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_c7abb016-c238-4b49-8eff-0e4eb0efab18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>abus-20220331_g1.jpg
<TEXT>
begin 644 abus-20220331_g1.jpg
M_]C_X1XE17AI9@  34T *@    @ #P$   ,    !!$,   $!  ,    ! @P
M  $"  ,    #    P@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    R $;  4    !    T $H  ,    !  (   $Q  (
M   ?    V $R  (    4    ]P$[  (    .   !"YR=  $    <   !&>H<
M  <   @,   !-8=I  0    !   )1   $>P "  (  @ %?D    G$  5^0
M "<0061O8F4@4&AO=&]S:&]P(#(S+C(@*%=I;F1O=W,I #(P,C(Z,#4Z,#,@
M,3$Z,3$Z,C0 1VQO<FEA(%!I8VAI:0!' &P ;P!R &D 80 @ %  :0!C &@
M:0!I    '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M"9    <    $,#(S,9 #  (    4   )MI $  (    4   )RI*1  (    #
M-3@  )*2  (    #-3@  * !  ,    !__\  * "  0    !   $0Z #  0
M   !   "#.H<  <   @,   )W@     R,#(R.C U.C S(#$Q.C Y.C,P #(P
M,C(Z,#4Z,#,@,3$Z,#DZ,S  '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M               & 0,  P    $ !@   1H !0    $  !(Z 1L !0    $
M !)" 2@  P    $  @   @$ !     $  !)* @( !     $   O3
M $@    !    2     '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 30"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M7EU8E?K-LR'BNLN8(W.]K =KG?2<NC7(=,POK97U''?<_I_HM>/5V-8'[/\
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M=SRB]*Q^E=1Q!D_LUF/[BW996T'3\YOM]S%;=T?I4']4I_[;;_<HC+%$D'W
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M<0H' ^?-53A"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 )     !  $ D     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))300>       $     #A"24T$&@     #3P
M  8              @P   1#    #0!! $( 50!3 "  4 !I '  90!L &D
M;@!E     0                         !              1#   "#
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "#
M  !29VAT;&]N9P  !$,    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    !
M.$))300,      OO     0   *    !-   !X   D&    O3 !@  ?_8_^T
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M-SO:U1JRLM_T\1]/]=S"?_ 7V)*;:2!ZU_\ HOQ0'YN>VQS6X%EC0?;8VRH
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M7IIRW7/6Q]A^L6X>_!V:S[<;=_9_0;5#]G_6S@/Z9']6G_T@E[G]>/\ C_\
MKM7LG_-R_P 0_P#JUQ'Y/0G"!U+,9K,MJ,_#W9;U=Z)UKH72L[[6[J&=DC86
M>DY@#3,:O_36;MJO_8?KA_I.F_YM7_I!/]@^N/[_ $W_ #:O_2"4IPE$Q,XD
M'?\ 6#_U2NCCG&0E&$@1MZ/_ %ZZN']>^A9>75B5^LVS(>*ZRY@C<[VL!VN=
M])RZ-<ATS"^ME?4<=]S^G^BUX]78U@?L_P +Z?I5,?OV?0]W_077JAS$,<9
M0JJZ2]S_ +F#?P2R2B>.[OK'@_[J2QY'Q_@G3'D?'^"=0,RDS?HCX)TS?HCX
M)*73?G'X!.F_./P"2G__T>KMLJ'^,%E?IS><0/;9IHP"YKJI^E[K"QZW3U?I
MX.TY%6[NW>)&F[5O]5<[<)_QEU#QZ?\ QL71#+9M+O0R&Q,CTS)C^K]+^2B!
MX6B1KJ!YA3.L=.>[8S(J<[P#PI5]2P[2X56UV%C=[MKP8;^^Y09G,?(-&2V
M3[JSK W*=5]=HL(JN;Z0!]["W=(G;7N^E]%$CP/VK1+^L/L_]"55U/"N>UE5
MU5CWB6-:\$D:_1C^JY9UN7T<9%K?2M?8VPBTUM<6^I'NU_>6A3D-M?6W[/?7
MO!.Y[  V-WM?K[?HK"ZAU7IU6;=5;TAU]E;MKKG5MET?G_0=[?W%+AC<B*EM
M^C*/_H+#S&7@A&1E&-FKE&1Z?U>)MC.Z0#I1D2!/T'<)#/Z1!BC(@#7V.X69
M^VNE?^49_P"VV_\ I-+]M=*G_D,_YC?_ $FI_:_JY/\ &A_WS5^^#_.X_P#$
MR?\ >NH.H](W$>CD;N2-CI2/4.DQM]#(^&QW/*+TK'Z5U'$&3^S68_N+=EE;
M0=/SF^WW,5MW1^E0?U2G_MMO]RB,L420?<!'C%L0&>41*,L9C+4:2V<UW4NB
M,&Y]%S1,26.&O@B8F=T7,N]"ECO4(+@'@MD#Z4%7_P!C]*_[B4_]MM_N4ZNG
M8-#B^BBNIQ$%S&AICPD!"63%PFO<XNER'"OC#F.(<1Q\/6HGB8,HQV.#FUZM
M,C5'];R_%.*FZ\\I>BWS4!).YML4L;M1I^/DEZWE^*<U-D<_ZA+T6^:"EO6\
MOQ2%V@T_%/Z3?-)M38'/"2EO6\OQ4F/W$Z1 '\4WHM\T[6AI,> _BDI__]+K
M;<+-/^,"O.%%GV,8)8<D#V!\V>S?^^MAK^J:[A0=?;#K![=>?8?=]% =UNX?
M65O1O2K]$TBPV[SZFXBQVE.S9Z?Z+Z?K?V%<&=9M+W8E[1NV@$,)//NVLL=[
M/;^<B/(+9>9'DB:_JN[W-Q]FDP^R>TGZ"DQ_4-WZ05!NT_1>\G=^9])GT/WU
M(=0=[?U3(&[^2W3GZ7O\D?'N-S"\UOJ@D;;  3'YVA=[7(F^P0*_>+6J?GES
M/6;4&Q^D+'O)!UC9O8SV_06;E9?UL;D6-Q,2I^,'12\D$EOYKG;KZO=_UM=
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M &\ = !O ', : !O '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  ,@ P #( ,@    $ .$))300&       '  @    ! 0#_X0TX:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @
M0V]R92 W+C$M8S P," W.2YB,&8X8F4Y+" R,#(Q+S$R+S X+3$Y.C$Q.C(R
M(" @(" @(" B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(@>&UP.D-R
M96%T941A=&4](C(P,C(M,#4M,#-4,3$Z,#DZ,S B('AM<#I-;V1I9GE$871E
M/2(R,#(R+3 U+3 S5#$Q.C$Q.C(T+3 W.C P(B!X;7 Z365T861A=&%$871E
M/2(R,#(R+3 U+3 S5#$Q.C$Q.C(T+3 W.C P(B!D8SIF;W)M870](FEM86=E
M+VIP96<B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z8F0W9F4V8V4M-68W
M,"TU-C0X+6)A93@M,F)D,6(Y-#@U-F0T(B!X;7!-33I$;V-U;65N=$E$/2(Y
M-$4W,#DX-C8P0T)$,S8P,38S1$-%-D0X0T,X0T(T-R(@>&UP34TZ3W)I9VEN
M86Q$;V-U;65N=$E$/2(Y-$4W,#DX-C8P0T)$,S8P,38S1$-%-D0X0T,X0T(T
M-R(@<&AO=&]S:&]P.D1A=&5#<F5A=&5D/2(R,#(R+3 U+3 S5#$Q.C Y.C,P
M+C U."(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(^(#QD8SIC<F5A=&]R/B \
M<F1F.E-E<3X@/')D9CIL:3Y';&]R:6$@4&EC:&EI/"]R9&8Z;&D^(#PO<F1F
M.E-E<3X@/"]D8SIC<F5A=&]R/B \>&UP34TZ2&ES=&]R>3X@/')D9CI397$^
M(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)
M1#TB>&UP+FEI9#IB9#=F939C92TU9C<P+34V-#@M8F%E."TR8F0Q8CDT.#4V
M9#0B('-T179T.G=H96X](C(P,C(M,#4M,#-4,3$Z,3$Z,C0M,#<Z,# B('-T
M179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<" R,RXR("A7:6YD
M;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B \+W)D9CI397$^(#PO>&UP34TZ
M2&ES=&]R>3X@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM
M<&UE=&$^(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB
M=R(_/O_N  Y!9&]B90!D0     '_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$" @(" @(" @(" @,# P,# P,# P,!
M 0$! 0$! 0$! 0(" 0(" P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# __  !$( @P$0P,!$0 "$0$#$0'_W0 $ (G_
MQ &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M?W"9?;;=XIQ3$(\CGQXO0=8;>T<$$ON-M+PFIK*?/_?4A\^MBJ'_ #E_H?\
MI$^\*K3-M9_[?_">LUCBXW(C_A?^#JK'^9GV%OK8</3$.Q]W;BVG!GI>P)LK
M)MG-93#RUK8@;+.+C>3% NZVRM2>?K?_ &T\>R?+=IO-[S%]3:1RZ5@-'56I
M7Q:TU'%:9_+J!??O?&VZQY;*2%27GX$@X$-#@'A7'1*ME;7^=V^]G4>_]F;I
M[@SNTZQ:UL;DJ7N/Q5E6,1DI,+E5&/\ [[KFBPS.(?TC&Z@I/%C[E">Z]GA>
M/MV[6UK#." ?T9@ :5%62,+D'^+Y=1;M:^Z,>VM?[4CR)IJ.^VK2H_C)/E7A
MTL.C?G!W)U=O>#:G<63S&XMK_P 6_AVYJ;=%+&-V[2U5"8^;(OE'BESFC"NM
MI*#)+Y+.Q5@QO[+>:?:SD[=-O^LY7N%#%=2$";2<5 /B2?"Q/$"HXYX'?)_N
M_P ^V6YFRWV"D>L*PK;D\0#\$/D/G0]&9^=GQS[T[DW]M#<G76*_O/M7&[07
M$U&*_O'BL"^'W"<OE\@<J$RFX-O^1I<;E:4V!9A]H >3[C[VHYQV'EJ]N)MQ
MDTU\Z2'BM."(_G_AZD7WAY$WKG:UL[Z(Y0#_ 'WPK@YDC\OEY='OZ'VGN/9'
M3/7FT-Y58K-W8#;6/HLE+]T:[1.MB*'[^0".<0(?M@US<(+?CW%W.^][)S+S
MSN3VL0\-I&;2 PXH-35"K7536?,U-<UZF#E.PW2PY#VRPF:D\<:K^'R>M* D
M<,<33H<OHH41Z[\E=6GD?X^PY%'#;J1:1_E4_P#/U>A7X1F0"Y;^7^;KJ2VB
MQCMR?1KO_A^H?X>[R6D-Z%^JCJ?M/^0CIB67Z, 6Y_+]GK7KT8 6XCTCFRZR
MW/\ K^]W%PMOIC!J^ !P_P AZM%)+=]TJT2OR/\ @IU@DE<,5E^E_IQ]/]=1
M[M;1W#,SN:#\CUNXGVQ?TYY,_8_^3K&DCPQR+&FF$:/"NH-]6)DY8%OU'\_U
M]L7<E\C+($U ?$:J/0#_ %#IEA8VFW6\=D>PUI\7\53\5?,GCU2U_-155WIU
M,$%E.V]R,/J?KEL-J^O/U]Y0?=[@CWD7,$GQ%F/GQTCTT\*=8U>_"TW_ &>:
M[_LO!:G[5_ASQZ'KK[9>]>POY=.!V9U_,D.[L_@*XT(.32C_ (E!%V;49?-8
M<Y?EH$S>(HJFB+_T>QL/8+WG<]BV/W?DEFE LXYU(Q)Y0C4>#'#5.?7&.CZQ
MV_F'>_92Q@Y:_MVU@?V?X;UJ_P!J5' '_!TW_ KX]]S]-9S>^3[(Q!VOALUB
M<?28C"'<>.SCU&22LEEDRKIAMP9_"PN8;CBS^O\ H3[-/>?G;E7F06<NV3ZX
MT8!CIE%,<"'1#DTX>G'JOM%RMS7L^\J_-"X"N1_8\:5']BY]*Y].K08@BA/]
MUW)*+R]^;'G_ !M^?<"O8VKOXGA:F]:D?RKU/L+W=ZOU#-I%>% ?\W^#KD#%
M^Z OJMZA=N1?G_ 6]O2(9$5:53R^7IUJ.Z%VQM6:C#CC_8'^'K&?$$B!BY.O
M2NMN 3_7_&WNL2S2HZW/Q'CP_P G59+B/:BMM;I4'-*_YZ_X>NI@H+-X]5B-
M3:R-)_II_/T]HI/K[0!-OM_$C)^'4J_S:IZM):V(475]AC_IO^?3_DZYK)%)
MP!Y+_P"+)_O8'MP_O.+BE?S3IE)=JNC17J?L?_8ZE(%0?HT7_&HM^?\ 8^]?
M43DTD2A^T'_ .EB6\,?]D,?G_E/6?VIZMU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7__2W^/?NO=>]^Z]U7'_ #-_^R?,/_XDS;__ +I]U>Y7]DGE;G:)(VHYA<>7
MXL>?4,>^TL4');2R_")5/GY$'RZ(W\-/E[UW\==G;PP6\L)O3-9#/[FQ^7I)
MML8_&56-^Q7&1XJ/]S,YG;S* R<V4_UMQ[E+W.]J^:>9^9HY;#0QT '446E$
M7^GG /E^VO44^UGO!R[R[RQ)'=(1^H3CQ#^(^D1]1Y]!'V[O^I^87?N-K</1
MX38E+6TU'MG&_P![,WC</2TF.Q+M(V4RV3A0R2/?,UE@JEF_X &Y)/L7[%RU
MN/('(VXW,[R2!07PH9B=1%%56DID^0 &6/F>@OOG,>V\[<ZV4,,876X'%J9
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M$M65*C \A^?6NS_+Z/\ SE3L,_\ 5IWES_Y*N9]YC>[;[%;>S^V0Q_VP,?\
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M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UAU< ?UO\
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MB'_8J[7!_P!A[]U[KK^\.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X?_SZ8_\
MZ/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8__H_W[KW7
MO[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[^\.!_P"=
M_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A_P#SZ8__
M */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_ /H_W[KW
M7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X
M?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8_
M_H_W[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[
M^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A
M_P#SZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_
M /H_W[KW7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O
M[PX'_G?X?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_
MA_\ SZ8__H_W[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H
M_P!^Z]U[^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_
MO#@?^=_A_P#SZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^
M'_\ /IC_ /H_W[KW7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\
MH_W[KW7O[PX'_G?X?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>
M_O#@?^=_A_\ SZ8__H_W[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A_
M_/IC_P#H_P!^Z]U[^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^
MC_?NO=>_O#@?^=_A_P#SZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[
MPX'_ )W^'_\ /IC_ /H_W[KW7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_
M //IC_\ H_W[KW7O[PX'_G?X?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\
M^C_?NO=>_O#@?^=_A_\ SZ8__H_W[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O
M#@?^=_A__/IC_P#H_P!^Z]U[^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'
M_P#/IC_^C_?NO=>_O#@?^=_A_P#SZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_
M '[KW7O[PX'_ )W^'_\ /IC_ /H_W[KW7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\
M.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?
M_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8__H_W[KW7O[PX'_G?X?\ \^F/_P"C
M_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^
M\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A_P#SZ8__ */]^Z]U[^\.!_YW^'_\
M^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_ /H_W[KW7O[PX'_G?X?_ ,^F/_Z/
M]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X?_SZ8_\ Z/\ ?NO=>_O#
M@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8__H_W[KW7O[PX'_G?X?\
M\^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[^\.!_P"=_A__ #Z8_P#Z
M/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A_P#SZ8__ */]^Z]U[^\.
M!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_ /H_W[KW7O[PX'_G?X?_
M ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X?_SZ8_\ Z/\
M?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8__H_W[KW7O[PX
M'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[^\.!_P"=_A__
M #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A_P#SZ8__ */]
M^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_ /H_W[KW7O[P
MX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O[PX'_G?X?_SZ
M8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\ SZ8__H_W
M[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^Z]U[^\.!
M_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?^=_A_P#S
MZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\ /IC_ /H_
MW[KW7O[PX'_G?X?_ ,^F/_Z/]^Z]U[^\.!_YW^'_ //IC_\ H_W[KW7O[PX'
M_G?X?_SZ8_\ Z/\ ?NO=>_O#@?\ G?X?_P ^F/\ ^C_?NO=>_O#@?^=_A_\
MSZ8__H_W[KW7O[PX'_G?X?\ \^F/_P"C_?NO=>_O#@?^=_A__/IC_P#H_P!^
MZ]U[^\.!_P"=_A__ #Z8_P#Z/]^Z]U[^\.!_YW^'_P#/IC_^C_?NO=>_O#@?
M^=_A_P#SZ8__ */]^Z]U[^\.!_YW^'_\^F/_ .C_ '[KW7O[PX'_ )W^'_\
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MVJ^?E?M_#]58?M39?^DCY)X?+?Q[;.X<WG=RYW+_ ,1Q&S-C[HQ66_NI1?\
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M==OY7X]9CY0_(C>^P]I;2P/Q"SVX-M[=WATMLO#=;Y7K?$?(C^]'7O5VQ?\
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M!L_:/5V>VS\6L)L7<N=^\_A&W?XIBL5_EM7_ , ??NO=)7^6QU[W!U+U/O\
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M1WQ_N6Q/^5_[D/?NO=##5;2[R[0^<FW.R.Y/CKV1!U5\?\]N+;WQIR6V]T=
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MRZI<IT]DNP</_>J?XW_+WXJ]9=-U/]Z-J_Q"C^$70_:F]-Y?Z5 ?X]_S$O\
M>ZCQW\._XNO^X6D_W'_\ ??NO=(#/?!GYI;CS'<68CZ'_NKN/LGX^_*K9&_/
M[I5/Q"V%U?O#>>\-_P#\9Z?Q6S_]%N>VQV%O;!?P+$4?^Y'LK*93+?Q;W[KW
M0F]^_P O'OBKWAU)F.ENG]O_ -Q^O_A;UWM/M#JZFW1M7:6 ^0G8F'[^V7O+
MLCI;>&8_CVV-P_\ &2L%B*S<7]XO^+3ELK1?[D<A_EOOW7NA;V1\'MX93Y4;
MQ["[NZQ[PKJ&O^061["V'O;:64^%M?U_1],YC8'\&P_2W<&6S?\ SE+_ '%V
MU@LO6;,R^S,;E,KM3+?\N[_E>]^Z]T!&TOY?7=FW.@_B]UOE/CWN"AQ73_;7
M>]7\C-I; _V2W/;A[Y_OA_?3_0_W5A\1W;GMS].=H_Z-<%_N._W_ !_"\KB?
MO?\ <=_P"^^]^Z]TU=Y_R[.YLIL??^RMK] ]D=[T.8^)?5767QIW)WKVAT#7
M]H?&_<6S]_YO,[PVKN_+_P!_/[O83^\N"^SQV(R.Q_XKB?\ @)09'_<=]]7>
M_=>ZV*=D4%9AME[/P]?#X*['[7V[B<I3\_Y'D</BN??NO=*?W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW3/N+_CWLU_VH<C_P"ZH^_=>Z.][3];Z][]
MU[KWOW7NO>_=>Z__T]_CW[KW7O?NO=:Y'SJ_G%XOXJ_*CM#H>M^-5=V!4;'&
MS+[MI.[WVJ,P-X; V9O(*-J2=3;G;$%1EQC=9R8UV)L+V"@<!TUT4;_H(.PG
M_>&N5_\ 2E,7_P#<U^_9]1U[HT_PJ_F[X;Y@_)OK+X[#XUY3KK_2 V[@-V_Z
M<L;N_P#@XVAL3>.\9;X<=&;8_C09=I'' _Q2R?>W.H CWK/3G5_/^BO"?\KV
M7_ZGXO\ ^LGNFO\ U4_V>O4ZZ_T583_E>R__ %/Q?_UD]M];Z]_HJPG_ "O9
M?_J?B_\ ZR>_=>Z]_HJPG_*]E_\ J?B__K)[]U[KW^BK"?\ *]E_^I^+_P#K
M)[]U[KW^BK"?\KV7_P"I^+_^LGOW7NO?Z*L)_P KV7_ZGXO_ .LGOW7NO?Z*
ML)_RO9?_ *GXO_ZR>_=>Z]_HJPG_ "O9?_J?B_\ ZR>_=>Z]_HJPG_*]E_\
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M]E_^I^+_ /K)[]U[KW^BK"?\KV7_ .I^+_\ K)[]U[KW^BK"?\KV7_ZGXO\
M^LGOW7NO?Z*L)_RO9?\ ZGXO_P"LGOW7NF/;>Q\+F\;-6SS5\4T&=WEB?\GJ
MBO&(W3F,.+<?TQ0/OW7NGS_15A/^5[+_ /4_%_\ UD]^Z]U[_15A/^5[+_\
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MUI'I ;4RL"$%6"@$$8+SER=8;?O>]W"B*2T*B05F;07(5,Z<ZZ@ !6H3FAR
MMQ7S_P!L[_\ BAV1\JNJ=@5U3/UOG*_;&9ZM[GWQL/HS*8S=&&W+B,)EL-O#
M?&6RVY-D['F3&9B'(1-65LBO$T (5Y  93<AB[YQY2Y/W%F#W:7+JT22SN!'
M$TM!%'1GS'D B@JW $ ,)[H6-AR=SGS=;VU4LWM059](/C3"(5=HS2@<9TM3
MX30$'HR/:?<^4ZVZRA[+I^J=]=F8ZEP<FY-S4W5^>ZMG_NW@Z';S9?(9HY/L
MKL+J_$YK#P1+Z&QHKY9K K2 -J!5:\O[9>[N-C\5!+>RA%U^* Y5NRH74RC
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M>XG5$+*KDZ@'+%4C7T4ZB H7+,P7C3I7M5MN%S$PBC+  Z35*J06+$%LL'J
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z0W8O_,O]_\
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M=1NS8VZ=OXWJ"CV]USFLONN+#8C?Z9?*P]@[[VLT;X'%Y+&9-\8]2':@^X4
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M6I&7ED6*Y6<:W!K#'%$\6L+)5$D)CGDNZV&^YA,(MOW:RLU0T@N5(S106CT
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M[US)&TZS!C&G(C[6@'WE$H).?W7OT]IS3.;Z\EN[-=I%HRAX0PF=5NVEMV<
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M6LS@$C58^UDE]XBJC2,5' $D@>0H",4'Y_9T3P;5X1U  $G/^K5T(NGTV_P
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M$?\ VU_;7_!*^U7_ (4S_NG7G_;+TN_X&+[QO_3$_P#9YMG_ &U=.>"_D_\
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M_HW^A/\ [;'OW_!2^UW_ (48_P#<ON_^V3KW_ N>_/\ X3X?]EVW?]M77O\
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M_LNV[_MJZ]_PRW_,I_[QT/\ Z-_H3_[;'OW_  4OM=_X48_]R^[_ .V3KW_
MN>_/_A/A_P!EVW?]M77#_AF+^9#_ -XW-_Z./HC_ .VO[:_X)7VJ_P#"F?\
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M,=E<5DL9W5T31Y'$Y/#@G$Y'%Y,=K%T9/^1^R[<_O&?=IN00W.N#Q'T>Z?\
M;-P->C>P^[;]Y"V*^'R4..#]9MF>&"/J:@KY4X_/I9[X_E?_ ,W?MFJQU;VI
MUYV#V14X='@PLW8/R4ZKWE4XNFF8L[X@9OMC/)BGD;EF6Y)_/M)R[[]?=6V5
M'AVSF:"WC9M16*PW.,%L#40EI0G@*D< !TMW+[O/WF+UU>YY1>4@4JUYM9I3
M\-6O%-./ BE>D!_PRW_,I_[QT/\ Z-_H3_[;'LZ_X*7VN_\ "C'_ +E]W_VR
M=!S_ (%SWY_\)\/^R[;O^VKKW_#+?\RG_O'0_P#HW^A/_ML>_?\ !2^UW_A1
MC_W+[O\ [9.O?\"Y[\_^$^'_ &7;=_VU=>_X9;_F4_\ >.A_]&_T)_\ ;8]^
M_P""E]KO_"C'_N7W?_;)U[_@7/?G_P )\/\ LNV[_MJZ]_PRW_,I_P"\=#_Z
M-_H3_P"VQ[]_P4OM=_X48_\ <ON_^V3KW_ N>_/_ (3X?]EVW?\ ;5U[_AEO
M^93_ -XZ'_T;_0G_ -MCW[_@I?:[_P *,?\ N7W?_;)U[_@7/?G_ ,)\/^R[
M;O\ MJZ]_P ,M_S*?^\=#_Z-_H3_ .VQ[]_P4OM=_P"%&/\ W+[O_MDZ]_P+
MGOS_ .$^'_9=MW_;5U[_ (9;_F4_]XZ'_P!&_P!"?_;8]^_X*7VN_P#"C'_N
M7W?_ &R=>_X%SWY_\)\/^R[;O^VKKW_#+?\ ,I_[QT/_ *-_H3_[;'OW_!2^
MUW_A1C_W+[O_ +9.O?\  N>_/_A/A_V7;=_VU=.F(_DR?S&:VN@HY?C]CL#%
M4"U1ELKV_P!-F@I2!Q9,-OG<F<D_V"V]MV_WFO9'9;:0;5N-9:</#OQ7_>[5
MJ9^?3P^Z[[Q;E<Q?7;3I6OQ&6R8^7$)=JI_WGR^?6PO_ "U/Y56!^%O\0[,W
MYFZ#?/>V=H/X4<G0T\B[6V1A,@T4^4Q.SA73K+7Y/.R "?(RJC6&@)ZZUJW!
M7WQ][I^?;R0;=:M'MP?"L0':AXUT+0#T:I)H30C&=?L9['+R19I+O#5O-/Y+
MP&=$SC _A% ,4\NKI_<$=9,]>]^Z]U[W[KW2&[%_YE_O_P#\,S<W_NIR?OW7
MNES[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I$;$_P"+/6_^'GV+_P"_!W;[]U[I
M;^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7ND7NC_B^]<_^'A7?^\#O;W[KW2T]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=(;L7_ )E_O_\ \,S<W_NIR?OW7NES[]U[KWOW7NO>_=>Z
M][]U[K__T-_CW[KW7O?NO=:!O\ZW_MYM\F/];IC_ -\%U?[4+\(Z:ZJP][Z]
MU:A_)2_[>;_&?_6[G_\ ?!=H>TW3O6_C[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL8TWX_XGVWX%//JHF#8KUS]WPH^
M75N/7?O?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@_P"Q5/\ <#?0O<C9NY[\6_Y=
M&1/MFPB:S@K,>!K^7Y5]>DMTOU$R+'QH/]6:=+?7J!\9]8M?CZ_C\BWNMM<V
M\TK*OQ?G_FZ>N$F2(:&S^777[O\ QT_Y-7V_2+_57K7@S_\ *5_QD=>_=_XZ
M?\FK[]2+_57KW@S_ /*5_P 9'6/QQ?\ '+_K(W_%?:G4_P#'_+IWQ[W_ 'W_
M #7KWCB_XY?]9&_XK[]J?^/^77O'O?\ ??\ ->O>.+_CE_UD;_BOOVI_X_Y=
M>\>]_P!]_P UZ]XXO^.7_61O^*^_:G_C_EU[Q[W_ 'W_ #7KWCB_XY?]9&_X
MK[]J?^/^77O'O?\ ??\ ->O>.+_CE_UD;_BOOVI_X_Y=>\>]_P!]_P UZR:9
MO]5_R:OLM^F/\7\O]GJE&_Y2/^,]>TS?ZK_DU??OIC_%_+_9Z]1O^4C_ (SU
MSU2?T_WE?:C4X_T'^?5C$Q_T;^77CJ_M#GG^G_$>]$&2@:+'V]:)T<9_^,]8
M/'%_QR_ZR-_Q7VKU/_'_ "ZMX][_ +[_ )KU[QQ?\<O^LC?\5]^U/_'_ "Z]
MX][_ +[_ )KU[QQ?\<O^LC?\5]^U/_'_ "Z]X][_ +[_ )KTC-C1Q'#UMX[G
M^^/8?]MOQO\ W4 /K^!_O7O09O)_Y=;:XW Y:/R'FO "@\O2G^JO2Y!/X/M,
M RTI#_/IG77_ (D?\9Z[_=_K_O"^]&5EXP_SZ]X;G_B1_P 9ZP>.+_CE_P!9
M&_XK[5ZG_C_ET[X][_OO^:]>\<7_ !R_ZR-_Q7W[4_\ '_+KWCWO^^_YKUDT
MS?ZK_DU?9;],?XOY?[/5*-_RD?\ &>O:9O\ 5?\ )J^_?3'^+^7^SUZC?\I'
M_&>L?CB_XY?]9&_XK[,M3_Q_RZOX][_OO^:]>\<7_'+_ *R-_P 5]^U/_'_+
MKWCWO^^_YKUS_=_U7^\+[*/%W'_E#_XVO5=#_P#*3_QGKW[O^J_WA??O%W'_
M )0_^-KU[0__ "D_\9ZX>.+_ (Y?]9&_XK[-]3_Q_P NK>/>_P"^_P":]>\<
M7_'+_K(W_%??M3_Q_P NO>/>_P"^_P":]>\<7_'+_K(W_%??M3_Q_P NO>/>
M_P"^_P":]>\<7_'+_K(W_%??M3_Q_P NO>/>_P"^_P":]>\<7_'+_K(W_%??
MM3_Q_P NO>/>_P"^_P":]([<T<7\;Z\_;M?=]<+:VY_WX>]3_7CD>]%FJ._^
M76Q<;@ P6/M(SE>%:^GKZ=+96D/%M/\ MC[3DL>,7\^J&!E%%G_XSUV5D/U:
MW_((]^#LM L'_&NF'A=N-Q_QGK#XXO\ CE_UD;_BOM3J?^/^72GQ[W_??\UZ
M]XXO^.7_ %D;_BOOVI_X_P"77O'O?]]_S7KWCB_XY?\ 61O^*^_:G_C_ )=>
M\>]_WW_->O>.+_CE_P!9&_XK[]J?^/\ EU[Q[W_??\UZ]XXO^.7_ %D;_BOO
MVI_X_P"77O'O?]]_S7KWCB_XY?\ 61O^*^_:G_C_ )=>\>]_WW_->O>.+_CE
M_P!9&_XK[]J?^/\ EU[Q[W_??\UZ]XXO^.7_ %D;_BOOVI_X_P"77O'O?]]_
MS7K!%#"Q]-/?_IZX_P /R?9+';;-,1X63_M_\IZK]5NBXE@Q_ID_R#J=H&FU
MM _I?5_3\W_K[7(D-L/TUQ^?^6O5&#W &L4_U?EUG]N=.]>]^Z]U[W[KW2&[
M%_YE_O\ _P##,W-_[J<G[]U[I<^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1&Q/
M^+/6_P#AY]B_^_!W;[]U[I;^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND7NC_ (OO7/\
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M&'F?3JK^[7/<<AMN9-PFF=J'!BCI\_T4/^'K"?FE\O\ _O*SY(#_ ,KUV?\
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M_5'B=$-#0:O- !CT/7)OF1\PE*H_RN^219@=!/?'95TL+G3;.%3J'UO[>O\
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MZ]_LY_R^_P"\MODG_P"CT[._^OOOW^LU[*?],S:_LN/^@^O?ZZWNK_T?I?\
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M)_\ H].SO_K[[]_K->RG_3,VO[+C_H/KW^NM[J_]'Z7_ 'BV_P"@>O?[.?\
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M'7M$/_*1_P 9/7O^0/\ D[W[QY_^4/\ XV.O:(?^4C_C)Z]_R!_R=[]X\_\
MRA_\;'7M$/\ RD?\9/7O^0/^3O?O'G_Y0_\ C8Z]HA_Y2/\ C)Z]_P @?\G>
M_>//_P H?_&QU[1#_P I'_&3U[_D#_D[W[QY_P#E#_XV.O:(?^4C_C)Z]_R!
M_P G>_>//_RA_P#&QU[1#_RD?\9/7O\ D#_D[W[QY_\ E#_XV.O:(?\ E(_X
MR>O?\@?\G>_>//\ \H?_ !L=>T0_\I'_ !D]>_Y _P"3O?O'G_Y0_P#C8Z]H
MA_Y2/^,GKW_('_)WOWCS_P#*'_QL=>T0_P#*1_QD]>_Y _Y.]^\>?_E#_P"-
MCKVB'_E(_P",GKW_ "!_R=[]X\__ "A_\;'7M$/_ "D?\9/6.0(+:6U#GFQ'
M^]^T7,46V0VD45CVBO\ 3/H?Q='FU[E.]X\MX-9I\AY4_".CE? 6'.#YJ_$Y
M=I"6/.R=[[#%5X;Z3M]MS8G^]H<.?'H.":JO_P C]@+W^W+E7;_:'<EW&.MU
M):S)'F8?J-&50]H(^-EPU%]2!7H>>Q<?,.X^YVUKLSTK+$6Q&3HUUIWT_#YC
M/IU]$OWQMZ[:=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW2(V)_Q9ZW_P //L7_ -^#NWW[KW2W]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=(O='_%]ZY_\ #PKO_>!WM[]U[I:>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND
M-V+_ ,R_W_\ ^&9N;_W4Y/W[KW2Y]^Z]U[W[KW7O?NO=>]^Z]U__T]_CW[KW
M7O?NO=:!O\ZW_MYM\F/];IC_ -\%U?[4+\(Z:ZJP][Z]U:A_)2_[>;_&?_6[
MG_\ ?!=H>TW3O6_C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@
M^[%CMU_OG^B[-W,3_L<3D+_G_#VW*@N)4(/#_5\NG-M7Z=(U/\9/\_SZHQ_F
ML_RI=T_);=DOR*^.QQO^F,8W'XW>^Q\I4X;!Q]G086)L5B\KA\YFS%AL/O:/
M!1KC7;)JV-R6/IJ1?)1_9?Y7E3[&>^ ]N*V&X(3M['M8#^SKE@U(I2RFIIVE
ME8T.H'LPM^\!["7GN#>-N&WD"XJ32OQ&M5I6XBTFM#4$<*BA&=:G,?!_YD8;
M)38RJ^)GR$GJ**?[>HGP?5&^\[CW0$?N1Y7"X-\#FT/]0Q'^/O.8^\WLM_TT
MMK_O<_\ T /\'6"J^S7NIDG8WIY]UM2O_.4D?[T>FK_9,?E[_P!XB?)7_P!$
M9V?_ /6+W[_7G]E_^FEM/][G_P"@.O?ZS/NG_P!&*7_>[;_K9UQ_V3#Y>?\
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MZ?\ T89?][MO^@^O?[)A\O/^\1_DK_Z(OL__ .L7OW^O/[+_ /31VG^]S_\
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M@.O?ZT'NG_T89?\ >[;_ *#Z]_LF'R\_[Q'^2O\ Z(OL_P#^L7OW^O/[+_\
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MK_I_K>_--3C-_+_5_J'7C;QMGPL?:?\ /TM=(_K_ +Q[W27_ 'Y_(=>\)/\
M?7\^O:1_7_>/?J2_[\_D.O>$G^^OY]>TC^O^\>_4E_WY_(=>\)/]]?SZ]I']
M?]X]^I+_ +\_D.O>$G^^OY]>TC^O^\>_4E_WY_(=>\)/]]?SZ]I']?\ >/?J
M2_[\_D.O>$G^^OY]8PKD B2ZB_.@"W]?\?>]5*U;/V=.:X)5+Z/YGKH,DAT.
M;VY^A'^]6]Z>>.$59Z'[#TEUQ7;>&T6!\S_L=9=(_K_O'OU)?]^?R'3WA)_O
MK^?7M(_K_O'OU)?]^?R'7O"3_?7\^O:1_7_>/?J2_P"_/Y#KWA)_OK^?7M(_
MK_O'OU)?]^?R'7O"3_?7\^O:1_7_ 'CWZDO^_/Y#KWA)_OK^?7M(_K_O'OU)
M?]^?R'7O"3_?7\^O:1_7_>/?J2_[\_D.O>$G^^OY](W<XMG.NQ?Z[PKOQ_V8
M6]O>Z29_6_D.M^#&>,.?M/2RTH?K_P 3[:+N,>/G_2]:^G1N,?\ /_9Z[((^
MG'^^_P ?>C')(,SX^P=>JL61'_/KK2/Z_P"\>W:2_P"_/Y#KWA)_OK^?7M(_
MK_O'OU)?]^?R'7O"3_?7\^O:1_7_ 'CWZDO^_/Y#KWA)_OK^?7M(_K_O'OU)
M?]^?R'7O"3_?7\^O:1_7_>/?J2_[\_D.O>$G^^OY]>TC^O\ O'OU)?\ ?G\A
MU[PD_P!]?SZ]I']?]X]^I+_OS^0Z]X2?[Z_GU[2/Z_[Q[]27_?G\AU[PD_WU
M_/KVD?U_WCWZDO\ OS^0Z]X2?[Z_GU[2/Z_[Q[]27_?G\AU[PD_WU_/KVD?U
M_P!X]^I+_OS^0Z]X2?[Z_GU[2/Z_[Q[]27_?G\AU[PD_WU_/KVD?U_WCWZDO
M^_/Y#KWA)_OK^?2([$'_ !C_ '[S]-F[F_'_ %:,D/\ B/>Z28_6_D.M^#%_
MOC_C1Z6^D?U_WCWJDO\ OS^0ZUX2?[Z_GU[2/Z_[Q[]27_?G\AU[PD_WU_/J
M%KA5HVD;QN;Z5LS7 XO=1;VW:+?RVQ,LG?GR7_)U1+(7#K=I%\)]?]D?X.N!
M18B\B)XV!%Y=1?\ 4?\ 4$D<^ZVL,S2N+E]8'# '^#K<]Q?W(-O;K1@>/:<?
MF!_AZ=O;_3O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]TB-B?\ %GK?_#S[%_\ ?@[M]^Z]TM_?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW2+W1_Q?>N?_#PKO_>!WM[]U[I:>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND-V+
M_P R_P!__P#AF;F_]U.3]^Z]TN??NO=>]^Z]U[W[KW7O?NO=?__5W^/?NO=>
M]^Z]UH&_SK?^WFWR8_UNF/\ WP75_M0OPCIKJK#WOKW5J'\E+_MYO\9_];N?
M_P!\%VA[3=.];^/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#7
ML)+;$WPY/UV7N<_[$8;)J/S^;>W?$$41A_&#C\S7JD!\;:"A'FW\FKU7O\_O
MYDG4GP:Q%!AZK&U&_.X]S4#U^VNNL5D31R4F-C:=4W/NC*U,+08S;_\ $J-D
M-P];7R72-6L;2K[5>RVZ\]7IEM@4M-0#/VU.1J"JTJ<*Y;A7 #9TP'[L>^FU
M\D[,^WR ->\0._R-1J(@?T%!6M,FE<T3Y7_A0=\QY*B1L-UE\>J&A$Q2"GR.
MW^P<]D(5(Y,N1'9FV(23_M*#CWELGW)MHC85Y@N1_M(_^MQZQ,D^^KS$P)&V
M1Y%::U_E2TKU#_Z"#?FZ?IU_\;/_ $">P/\ [='M=']R79I17^LEU_O$?_6W
MI(?OJ<T*:KL\?^]K_P!LO7 _\*$OFN/^8!^-0_Q_N1V+_P#;F]H3]SCE@"IY
MNNO^<*?];>G3]]KG-L#EV*O_ #53_MCZX'_A0G\UO^>"^-?_ *!/8G_VYO;#
M?="Y20T/-MW_ ,X5_P"@^O?\&?SI)C^K\7_.9/\ MEZY2?\ "@[YK*BD[!^-
M>ER3QLGL3DC_ %^Y_P 7]F4_W->48H([J/G.[,;\*P+_ -;*_P AU4??0YTW
M%OI_ZO1:AG^U3_MD7_#UT/\ A0A\UBVC^X/QKN;\?W([#_I<_P#-9K_3VC;[
MG'*%E)':R<XW0=ZTI"/^MC?X1UI?OH<Y*IN5Y?BHG_#4\\?\HG^0]13_ ,*"
M?FK(?5L?XX,?\=D;^']?]3W"/:Y?N7\K7BC3S%=T_P!(O_6P=)&^^;[GVU ]
MO ?RA_R6QZ[_ .@@OYK)PFR/C@O)^FR-^GG_ )"[A]MS_<WY5L%"OS!=E?\
M2K_UL/3D7WQ/=&^-$@@ ^R$_X;=>LY_X4(?-)CSU]\:4_P ?[E=C'_>/]-+>
MW3]R[EA!4\]W-/\ GF'_ %NZ67?WQ>8P:P\KQ_G<+_VR]9U_X4'_ #1M;^XW
MQJM_3^XO8_\ Q'<X]IV^YKRHI[N>;FO_ #S#_K=TFA^^MSG;X7E>*G_-=/\
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M7G^\+_ULZ]_P9O.O_1OB_:G_ &S=>_Z"$_FS_P \)\;O_0'W_P#_ &Y/?O\
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M_P !7RC_ --)>?[PO_6SKW_!F\Z_]&^+]J?]LW7O^@A/YL_\\)\;O_0'W_\
M_;D]^_X"OE'_ *:2\_WA?^MG7O\ @S>=?^C?%^U/^V;IKRW\_P!^9^;Q63PM
M9U]\:UHLKC:[&5(CV;V01_N4C>(CT]GJ;,LAO;DD_7W9/N6\GJREN8;M@",%
M!0_(TD!H?.A!]".JM]\KG9@0+.,8/ Q?MS:GATZ?]!"?S9_YX3XW?^@/O_\
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MMZGV?NS8.Q-R[ZP"_P"G+XP=:=D/ALKM/>7>B_P7!0Y[=AK\KG_XGE,K=?\
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M/<I(EU8!"4&16M^U_JO]X;WD-JV_^+^3=0!_CWI_QWKW[7^J_P!X;W[5M_\
M%_)NO?X]Z?\ '>O?M?ZK_>&]^U;?_%_)NO?X]Z?\=Z]^U_JO]X;W[5M_\7\F
MZ]_CWI_QWKW[7^J_WAO?M6W_ ,7\FZ]_CWI_QWKW[7^J_P!X;W[5M_\ %_)N
MO?X]Z?\ '>O?M?ZK_>&]^U;?_%_)NO?X]Z?\=Z]^U_JO]X;W[5M_\7\FZ]_C
MWI_QWKW[7^J_WAO?M6W_ ,7\FZ]_CWI_QWKW[7^J_P!X;W[5M_\ %_)NO?X]
MZ?\ '>O?M?ZK_>&]^U;?_%_)NO?X]Z?\=Z]^U_JO]X;W[5M_\7\FZ]_CWI_Q
MWKW[7^J_WAO?M6W_ ,7\FZ]_CWI_QWKW[7^J_P!X;W[5M_\ %_)NO?X]Z?\
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MI<"J4 JAJIXLI->DL?N5SRA.BY4+IIE+<\:&G]B:,"2-0IP.DTXJVO\ F_\
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MWZ@&%_P==#7^1;_8@^[E+6/%*?MZ3J;EN(Q^77>I/R;_ .P/MDFS;)_Y^Z4
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M "=_QOW[7/Z?X.O?3P?ZJ_Y^D3V(H_T?[]]/TV;N;\_3_</D1_Q'O>JX]/\
M!UKZ6V]>/V_Y^EMH'^I_Y._XW[UKG]/\'6_IX/\ 57_/U[0/]3_R=_QOW[7/
MZ?X.O?3P?ZJ_Y^HZH0"!'J4\'UV_WLW]I[:224:_WGK _P"%@=;N99I 8VM-
M2'^D!UA-/'<F./D6N-1X(/\ 5F_'MV7Q[I?#,U8J^@'^8])!8VUJ!*NW]_\
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MO_/1M?\ ^S'WK_6DYA2E!!_SD/\ FZJ.?;+T;]A_Z!ZR_P"S\]6?0[4[*_\
M/3M7_P"R_P!K3[)<Y1U_Q2#_ )RK_GZ;'/=KYD_L_P"A>O'Y[=3GZ[2[*_\
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MU_P_YNMZ6Z]_"O\ :5_V_OW[QC]?\/\ FZ]I;J1_"O\ :5_V_OW[QC]?\/\
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M4$?;3_+T%<GQ^ZDD?R2[1B8_UCRNY4/_ %CS5O\ >/9VW->[KGZT@_Z2,_\
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M_0-U-_SS+?\ G\W/_P#7KVY_7/FMAW3?RA_Z Z<_J_;?P_X?^@NO?Z!NIO\
MGF6_\_FY_P#Z]>_?USYK4=LW\H?^@.O?U?MOX?\ #_T%UE_T#=5_\\V__G]W
M-_\ 7KVQ_6[>?^4O_C*?] =-_N*W_A_P_P#077+_ $$]6_\ /./_ .?S<O\
M]>O?OZW;Q_RE_P#&4_Z ZU^XK?\ A_P_]!=<_P#01U;_ ,\XW_G\W-_]>_=_
MZU;Q_P IG_&(_P#H#I1^[+/_ 'W_ #;_ #]>_P!!'5O_ #SC?^?S<W_U[]^_
MK5O'_*9_QB/_ * Z]^[+/_??\V_S]<?]!'5O_/./_P"?S<O_ ->O=/ZR;I_R
ME?\ &4_Z!Z3?N.W_ (?\/_077O\ 01U;_P \X_\ Y_-R_P#UZ]^_K)NG_*5_
MQE/^@>O?N.W_ (?\/_077?\ H*ZL_P">=?\ \_>YO_KS[U^_=U_Y2/\ C*?]
M ]._N6#T_P /_0728VKU#UYDL9639#;J2SQ;EW?2*IR>8)^QQ&ZLUA,3_P O
MCZ?P?&Q@7_Q^GT]V._[D>$U,>B?] ];_ '%$*57_  _+^ETJQT?UA_SS[_\
MGZW+_P#7GW9N9=XE!#751_I4_P"@.O?N6#T_P_\ 077?^A#K'_GGY/\ S][E
M_P#KS[3G>]R&?&_DG_0/7OW+!Z?X?^@NN/\ H3ZS_P">?_\ 6GN3_P"O'MW]
M_;G_ +_/[$_Z Z]^Y(?0?M/_ $%UR_T+]:?\\XO_ )\\W_\ 7CWK]_;I_O\
M_DG_ $#UK]R0^G^'_H+KW^A7K;_GFU_\^N:_^N_NW]:-T8?[EX_TJ?\ 0'3/
M[H3^'_5_O77+_0QUS_SS0_\ /KF/_KO[U_6#<FS]3_QE?^@>M?NB/^'_ %?[
MUU[_ $-=;?\ /.#_ ,^>9_\ KQ[]^_=S_P"4G^2?] =/_N2'T_P_]!=9/]#?
M7/\ SSH_\^.:_P#KO[]^_=T_Y2?^,I_T!U[]RP>G^'_H+KK_ $.=<?\ /.C_
M ,^.:_\ KO[I_6#<O^4C_C*?] ]>_<D'I_A_Z"Z[_P!#_7?_ #SO_K1S'_UX
M]^_K!N7_ "D?\93_ *!Z]^Y(/3_#_P!!=<O]#O7G_/-_^M/+_P#UV]L)O^X.
M:>+_ "7_ *!ZU^Z8O3_#_P!!=<?]#G7?_/-_^M+,?_7CVH&][C_RD?\ &5_Z
M!ZW^Z8O3_#_T%UW_ *'>NO\ GF__ %I9C_Z[^V_W]N'_ "D?\97_ *!ZU^YH
M/]5?^@NN7^B'KO\ YYW_ -:>6_\ KM[]^_MP_P"4C_C*_P#0/6_W+!Z?X?\
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M5['S. O@LOG23]1ROM/T[UO0^_=>Z2W]ZL?_ ,<*W_J4?^CO?NO=>_O5C_\
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M9_U)_P"DO?M:_P#*-_QKKWA2?\I@_P!XZ]_>:B_XYUG_ %)_Z2]^UK_RC?\
M&NO>%)_RF#_>.O?WFHO^.=9_U)_Z2]^UK_RC?\:Z]X4G_*8/]XZ2>XMQ4DF9
MV$?'/^UO&O7](_L[!WJ;_7\W]^UIFMKG_3=;\*3_ )3<?Z0=*S^\U%_QSK/^
MI/\ TE[]K7_E&_XUUKPI/^4P?[QU[^\U%_QSK/\ J3_TE[]K7_E&_P"-=>\*
M3_E,'^\=>_O-1?\ '.L_ZD_])>_:U_Y1O^-=>\*3_E,'^\=>_O-1?\<ZS_J3
M_P!)>_:U_P"4;_C77O"D_P"4P?[QU[^\U%_QSK/^I/\ TE[]K7_E&_XUU[PI
M/^4P?[QU[^\U%_QSK/\ J3_TE[]K7_E&_P"-=>\*3_E,'^\=>_O-1?\ '.L_
MZD_])>_:U_Y1O^-=>\*3_E,'^\=>_O-1?\<ZS_J3_P!)>_:U_P"4;_C77O"D
M_P"4P?[QU[^\U%_QSK/^I/\ TE[]K7_E&_XUU[PI/^4P?[QU[^\U%_QSK/\
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MCO?NO=>_O5C_ /CA6_\ 4H_]'>_=>Z]_>K'_ /'"M_ZE'_H[W[KW7O[U8_\
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M?OZI>Y7_ $:KO_G O^;KW^N'[6?]'%?]YNO^M?7O]/O1/_/Y.K?_ $/]M_\
MU[]^_JE[E?\ 1JN_^<"_YNO?ZX?M9_T<5_WFZ_ZU]>_T^]$_\_DZM_\ 0_VW
M_P#7OW[^J7N5_P!&J[_YP+_FZ]_KA^UG_1Q7_>;K_K7U[_3[T3_S^3JW_P!#
M_;?_ ->_?OZI>Y7_ $:KO_G O^;KW^N'[6?]'%?]YNO^M?7O]/O1/_/Y.K?_
M $/]M_\ U[]^_JE[E?\ 1JN_^<"_YNO?ZX?M9_T<5_WFZ_ZU]>_T^]$_\_DZ
MM_\ 0_VW_P#7OW[^J7N5_P!&J[_YP+_FZ]_KA^UG_1Q7_>;K_K7U[_3[T3_S
M^3JW_P!#_;?_ ->_?OZI>Y7_ $:KO_G O^;KW^N'[6?]'%?]YNO^M?7O]/O1
M/_/Y.K?_ $/]M_\ U[]^_JE[E?\ 1JN_^<"_YNO?ZX?M9_T<5_WFZ_ZU]>_T
M^]$_\_DZM_\ 0_VW_P#7OW[^J7N5_P!&J[_YP+_FZ]_KA^UG_1Q7_>;K_K7T
MG=L=\](4F/GAF[?ZT@_W/;RJ_P#*=_[;/UW5F?Z9L_UY_I[LW)_N6AH=KNJT
M'"%#Q%1P!]<CB#4&A!'7O]</VL/_ "T5_P!YNO\ K7THO]/O1/\ S^3JW_T/
M]M__ %[]U_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3J
MW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\
MS^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O
M1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7
MO]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO
M^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?
M]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?
M]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";KW^N
M'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"_P";
MKW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_ .<"
M_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]&J[_
M .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE[E?]
M&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]^_JE
M[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__ %[]
M^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?7O]/O1/\ S^3JW_T/]M__
M %[]^_JE[E?]&J[_ .<"_P";KW^N'[6?]'%?]YNO^M?2=S'?/24M?L^:+M_K
M2?[;/9"KJO\ ?_[;_P C']ULT./]S?/U]V')_N6VLC:KK S^B@\Z8J,\> K0
M5/ $]>_UQ/:S_HXK_O-U_P!:^E%_I]Z)_P"?R=6_^A_MO_Z]^Z_U2]RO^C5=
M_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?R=6_^A_MO_Z]^_?U2]RO
M^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?R=6_^A_MO_Z]^_?U
M2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?R=6_^A_MO_Z]
M^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?R=6_^A_M
MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?R=6_
M^A_MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)_P"?
MR=6_^A_MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_I]Z)
M_P"?R=6_^A_MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_UKZ]_
MI]Z)_P"?R=6_^A_MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O-U_U
MKZ]_I]Z)_P"?R=6_^A_MO_Z]^_?U2]RO^C5=_P#.!?\ -U[_ %P_:S_HXK_O
M-U_UKZ4&W^U^L-TUGV>W.Q]@[BKC_P HV%WAMBMR'/\ AALX+>T=_P L30(6
M".I'JC#_ (\1_@Z?Y?YOM[MPI H:>9X8]$^SI>7'L/#;[J-J5_P?Y^AQ/?VL
MBJY''[?E\NO>W^F.O>_=>Z][]U[I,[V_X\_=?_AK[B_]U7OW7NE-[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[I-[2_XM4W_AT;S_ />KS/OW7NE)[]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z3.?_ .+GL?\ \.C(_P#O*;T]^Z]TIO?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW29WM_QY^Z__  U]Q?\ NJ]^Z]T8[W[KW7O?NO=>]^Z]U[W[KW7_U]_C
MW[KW7O?NO=:!O\ZW_MYM\F/];IC_ -\%U?[4+\(Z:ZJP][Z]U:A_)2_[>;_&
M?_6[G_\ ?!=H>TW3O6_C[]U[H%K\CCZ_7_8>[VMC#NUJ-YOQ2Y!(''%#I'PD
M#/\ I>DEUN$^SWJ;)8#5;,02<#B Q^(,?7\70:]C=T=2=/PXRJ[8[4ZYZTCS
MU37TN#J.Q]\[7V&N8_A/_%W&'?-YS1FSI%R ;@$$_4>U6S;3=[E)+->P,;91
MBE"*G%"5((I@FOEGI#OV]VFTPI;V+UOB<C/#'\2E<@_RZ$"@KZ'*T=%DJ&KI
MZZAR%**K&9*FJC78^LQYY&5NOMNYL&NF!MLF0T_WFF,D=+8]V:UCD752[BI]
M/_MC^MY$?"?]$K_1SU*Y)4VM];\CC_BM_:.XW+?'1/IX<3 TS'^'CQ'V^G2V
MWV_ER.4A'I:14^GQ*:%LR>>H]_\ ORO]''7&X8>EK?T-O^*_U]J4COK[8MND
MV/\ Q<G57X9.#$'^TIQ()^5:<*=(WO+"RWS>QO<GU A$;289/I@8RR_V8/C>
M(NGX:E*9R3T&G3_;O7O?W7.W.VNILVVZ-@[N_B9P&=_@F5P8K/X1E,OALP5P
M^;P>VMP?\7W%5@L0#<$_XDPW_9MRV;?+6WWQ3*]I\9U*M/%C6E-)8?"4.-7"
MGSZ+.7]UVW=]C:ZV)Q =P!,)[W^I,#N)!20+X7AE3EPNJO;7'4+JWO+JGN?K
M?_2SUUNV'-]<?>;BH_[Q5&+R^UJ"D.T\O_!LP;[SP.VV(VVV+K+G\<GZ>[;M
MM.Y;3S.G)UQ;%;B@&D$,06C$JCL+UXCX7-/R(ZKM/,NV[I9M[B1/6VJQ-=7X
M28&.5!R0?]#S\^/2YV?NW:F^]N8G=.QMR8'>.U<Q2FKP.Y-J9W&YW 9CU'_B
MT9?#DX#- G^OM+%87MCOLNW21.D5CQU#2P\:/4*J>X5K6M2.!Q4=*(^8MMW
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M[(PM#GNJ,XIBGSX](Q'O$(@K'_;:M64_3T_#_I]?RII\^O6:]OP/];U7Y/\
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M.O:;C^+_  =>N?\ ?6]^\-/3KVFX_B_P=>N?]];W[PT].O:;C^+_  =>N?\
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M-/\ E-/^\?\ 0O7O"M/^C6O^]O\ ]!=>_NQ1?\=ZK_DMO?OWFG_*:?\ >/\
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MNO1?\=ZK_DMO^*^_?7K_ ,IA_P!X_P"A>O>'9_\ 1K7_ 'M_^@NN?]UL</\
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MQ_\ QWK?^II_Z-]^Z]U[^ZN/_P".];_U-/\ T;[]U[KW]U<?_P =ZW_J:?\
MHWW[KW2/[ VW1TNP][31RU ,6S]QJ+$?C$R$'_'B/W[KW2P_NKC_ /CO6_\
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MG-9O$_\ ,"?0X?(QM_M_>S[,>ZA_YU'_ +.[3_K?U[_@KON]>7.E/^H/<O\
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M[^Z0VAO;%]5;S[AZOP/96<DQT6$ZXW#O_;.)W]G&RKBCPPPVTZW)IG\T^6<
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MM%A%##)=P7)E D1G",?& D IIUC75:L0M2P4,%*P1S)[>MS-[A\R3LS+"Z0
MT--06" %?[133M].-/GU'QG1O=/QE^:N_NT.G/B]NKL#I:7XJ]=]+]8X/KO?
M?2V&CQ&7V5+B_L,'E1VIVEMG<&,PGAQ.ALAIR#@&Y%4U@')N<.7>9N4-CV#=
M^;D&\VUR\CJ]O<821Y68J8H2C$JR%5+*H IJ2E.D?]1.:M@YJWC?-@Y4:+;+
MF-%J+F!LHB*/[64O\52:+45H0PST*WP]^&/<'2?1F"P.?^06]NL-\9'?.^.U
M.P=J]0X?IK/;#FSW8^Z),N^V$R7:/2F_-Q/2;:Q)CQZOC9,4'L2+#2_L.^XG
M-FT<P<RV^_WNW)-:VPT(7:4:AD!M,1B;268%?/CJQ@"_V]Y0W;9>6=PV3;=R
M,&X3]S (C4S4BLC.A[00<XP:5'2;^#NS/D!\9J[Y,;-WU\8NS<UC^ROEI\@.
MYMI;\VKO3X[56V)]F;H6E?:D=1%E>\L'OFAS6Y&VNJQ*V*T@U].]<U&35BB6
M>XN];!O=UL6Y0<S1 +9)&R-!.K(R9*D+$R$#50$,V0?+225^U^S<Q\O6>\[;
M-RFW=,&!%U"0:AA4=Y/EP-/(4K7K)\"-B=[=8]T?+S,=G?'K?NP-M?(#N.M[
M8V?N7+;RZ*S>-P^%.)@IOX%NJ@V9VON;<$.XY)?3:AQ^1QH'_*>3]%ONKO\
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M/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O_P#;7]^_X*?;_P#IB?\
ML\;_ +9.O?\   #_ ,*G_P!TS_OH]>_X973_ +R4_P#8.O\ _;7]^_X*?;_^
MF)_[/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O_P#;7]^_X*?;_P#I
MB?\ L\;_ +9.O?\   #_ ,*G_P!TS_OH]>_X973_ +R4_P#8.O\ _;7]^_X*
M?;_^F)_[/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O_P#;7]^_X*?;
M_P#IB?\ L\;_ +9.O?\   #_ ,*G_P!TS_OH]>_X973_ +R4_P#8.O\ _;7]
M^_X*?;_^F)_[/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O_P#;7]^_
MX*?;_P#IB?\ L\;_ +9.O?\   #_ ,*G_P!TS_OH]>_X973_ +R4_P#8.O\
M_;7]^_X*?;_^F)_[/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O_P#;
M7]^_X*?;_P#IB?\ L\;_ +9.O?\   #_ ,*G_P!TS_OH]>_X973_ +R4_P#8
M.O\ _;7]^_X*?;_^F)_[/&_[9.O?\  /_"I_]TS_ +Z/7O\ AE=/^\E/_8.O
M_P#;7]^_X*?;_P#IB?\ L\;_ +9.O?\   #_ ,*G_P!TS_OH],^"_DW1YBAF
MJE^2"Q>#-[DQ@MTX_(PNY\KB/^?K_0_PT>_?\%/MW_3%?]GC?]LG6A]P$?\
MA4_^Z9_WT>GC_AE=/^\E/_8.O_\ ;7]^_P""GV__ *8G_L\;_MDZW_P  _\
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MZ]_>'$?\K7_6!_\ HWW[KW7O[PXC_E:_ZP/_ -&^_=>Z]_>'$?\ *U_U@?\
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M]^&WG=5#1K7_ %?:.JI%>I(8JX'^E_S]</XYB?\ E9'_ %*D_P"C?=_"N?\
ME+_XR.E6MO\ E*_XS_L=>_CF)_Y61_U*D_Z-]^\*Y_Y2_P#C(Z]K;_E*_P",
M_P"QUW_&\/\ \KG_ %@E_P"C?;7^,_\ *1_QD=->,W_*6/\ >?\ 8Z]_&\/_
M ,KG_6"7_HWW[_&?^4C_ (R.O>,W_*6/]Y_V.O?QO#_\KG_6"7_HWW[_ !G_
M )2/^,CKWC-_REC_ 'G_ &.O?QO#_P#*Y_U@E_Z-]^_QG_E(_P",CKWC-_RE
MC_>?]CKW\;P__*Y_U@E_Z-]^_P 9_P"4C_C(Z]XS?\I8_P!Y_P!CKW\;P_\
MRN?]8)?^C??O\9_Y2/\ C(Z]XS?\I8_WG_8Z]_&\/_RN?]8)?^C??O\ &?\
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MTE-S9K&OF=@G[H7AWCD ?V&/(V#O7@7'T&K_ &_OW7NE7_>'$?\ *U_U@?\
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MKW]X<1_RM?\ 6!_^C??NO=>_O#B/^5K_ *P/_P!&^_=>Z]_>'$?\K7_6!_\
MHWW[KW7O[PXC_E:_ZP/_ -&^_=>Z]_>'$?\ *U_U@?\ Z-]^Z]U[^\.(_P"5
MK_K _P#T;[]U[KW]X<1_RM?]8'_Z-]^Z]U[^\.(_Y6O^L#_]&^_=>Z]_>'$?
M\K7_ %@?_HWW[KW7O[PXC_E:_P"L#_\ 1OOW7NO?WAQ'_*U_U@?_ *-]^Z]T
MD^PLUCI=@[VBBJQYI=G[B(_88GG$2J38J!SK_K_O0]^Z]T(T<HF2*6.QCD&J
M_P";6N/]Y'OW7NLWOW7NO>_=>Z][]U[K_]'?X]^Z]U[W[KW6@;_.M_[>;?)C
M_6Z8_P#?!=7^U"_".FNJL/>^O=6H?R4O^WF_QG_UNY__ 'P7:'M-T[UOX^_=
M>Z"+*?\ %PKOQ_E.2_WH>ZK*X-)L)_J].K>$M (LM_J]>HGNWT&VW [W[_L?
M_..M+N&Y6^(H^W[5^7J#UX&WY_WCWKZCF%Z"F?\ FU_FZ9%MR^AR/^KG^?KU
MK_C_ 'GWKPM_8U+?]6^O>+L"$4&1_P U.N( 464<#Z"_];D\GVHM8H;KESZ!
MSWU^?^_-7R_P].V$TVY\Q?77\>F( TR#^ K^&A^?#Y==D!AI8<'ZB_\ 2Q_'
MOUS%#:\N?0(W>/M\Y-7S_P /7K^:;;.8_KMOCU1L #D#B@7\53QSP^77?MGK
MW7O?NO==%0;@\WM_O'^M[:O+:#<]ELK6O<C,?/\ B/S'^'JUE+/MF][C>%:I
M(J#R\E'V_P" =>_Q_(^@_P"-^S*]B@AWO;;P?"@?U\U*_P"7TZ+[&2>?8MQL
MG%'=D/EY,#_@'KUW?^G^'M/]);6JO!JQ<TKQ_!D>9]?E^?2\7EQ=F.?3FV%!
MP_&-/H/3Y_EUU;^GOPNH=PK-_P I''C_ *'CT'I\OSZ\MO-MPCME&+>M.'^B
M9]3Z^I_+KOVUUKKWOW7NO?[S[]=R&QRH_P!7\^O%!??$<#_5\NN_]X'^^_XG
MWJTD-]EA_J_EUX(+'X3C_5]O77O?7NO>_=>ZXZ5&DV_3?3R>+_7VHDV[;K4%
MHF^WXOEZD]:_>=[=G?@Z4,W@Z<K^'CY#T\Z=<A_A[+G+UI%Y_P"KSZMX:M_5
M[QN,/CU_V_V?[/Y=>_WW^M[,;VY\8<*G_5\NF$M1#@_ZOY]>]E]N^@Y^'I;'
M$), YZ][,/%M5J=6/SZ0^'<;/W4R?L\_]ZZZ_P!X]U^GM[BI4Y_/_..MBXN=
MP(JN/R_S#KO_ &/NOAV_K_AZMKG_ (/YCKW^Q]^\.W]?\/7M<_\ !_,=>]M]
M.=>]^Z]TF=Z_\>?NR_\ SR^XO_=3[]):FVSY?ZOF?7I'O<"P7:"WR:?YO7I3
M>R][F3\(_P '^;I;,+Z2S2BT-*_AZ];V]^\-G_WW_-_\W2']Y3_]&[_JH/\
M-UZWOW[PV?\ WW_-_P#-U[]Y3_\ 1N_ZJ#_-UQ_V/O?[PV?_ 'U_-_\ -TJK
M'_R@?\;/7O\ 8^_?O#9_]]?S?_-UZL?_ "@?\;/7O]C[]^\-G_WU_-_\W7JQ
M_P#*!_QL]>_V/OW[PV?_ 'U_-_\ -UZL?_*!_P ;/7O]C[]^\-G_ -]?S?\
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M]6/_ )0/^-GKW^Q]^_>&S_[Z_F_^;KU8_P#E _XV>O?['W[]X;/_ +Z_F_\
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M)@W !)^A%/R_S+#)"@F!:0 K00FH/ X8T!\B: G ST=P\T\IW"UIP'GXW_0
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M 7_@P?O)?]-K_P!F>U_]L74'_AQCYC_\_?'_ *+SJS_[ _?OZA<D?P?SN/\
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M/Y1Y?@MO8GVMVBZVEC<0/NA;4Y:GC7TSY750FC5'=CRIB@8["Z6[.?87\O\
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M $7!'@_#P[,ZN&K!/7=_;LL6VVCIO@MOU58&NIO]+\Q_QGK4,NY74K;>9_\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)G>W_'G[K_ /#7W%_[JO?NO=#YCO\
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M_G8/_P"<H_Z/]^Z]U[^ZA_YV#_\ G*/^C_?NO=(W9NVA+AJ__+/IO#L*F/\
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M]U[I&[\VR*38^\)ON_\ ,;9W'5?\!A]1BFN+7_&D^_=>Z%FF@%/3P17_ ,Q
ML'^V"C_>;>_=>ZF>_=>Z][]U[KWOW7NO_]??X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TANQ?^9?[_\
M_#,W-_[J<G[]U[I<^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1&Q/\ BSUO_AY]
MB_\ OP=V^_=>Z6_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I%[H_XOO7/_AX5W_O [V]^
MZ]TM/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2&[%_P"9?[__ /#,W-_[J<G[]U[I<^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z1&Q/^+/6_^'GV+_[\'=OOW7NEO[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z1>Z/^+[US_X>%=_[P.]O?NO=+3W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]TANQ?^9?[_ /\ PS-S?^ZG)^_=>Z7/OW7NO>_=>Z][]U[KWOW7NO_0
MW^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=(;L7_F7^__ /PS-S?^ZG)^_=>Z7/OW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7ND1L3_ (L];_X>?8O_ +\'=OOW7NEO[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z1>Z/^+[US_X>%=_[P.]O?NO=+3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TANQ?\
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M_=>Z_]+?X]^Z]U[W[KW6@;_.M_[>;?)C_6Z8_P#?!=7^U"_".FNJJ/%_M/\
MO/\ QOWOKW5K'\E+_MYO\9_];N?_ -\%VA[3=.];^/OW7NO>_=>Z][]U[I,Y
M7,8O 8VOR^6KZ/&XO&4M;DLAD*Z<45%0T.,0MD*_(5S?M11PQ LQ:P"J23P;
M;BVV69UC4DDD 8%:G(\QY>? >?35QN4$*,YX@'UI]@P:?SZ H?+CXLMCI\]%
M\B>B)<'!N/\ NC4YF/M[8SXN#=QH?XI_=F3*KGFI(L[_  RD,QH2PF,:%M)
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MU)M<R#./@1E_\B->(S#Y@4UZQ8+/IJQZPII]G^S^?#CBO1:EZ2P!_P!7\NA
M#@_[[_C7M&8QZ=+5F!X]=WX]TC?7Y=/ 4Z#S>?86QNOX<'+OC>6UMFP;BW+C
M=I8*;=&Y<9@!GMU9N5EP^V<0<Q+3KEL[G"A$5#&6FD .A6TW]F%O8&?5X<3,
M0*\#^>:_(TXU.*>71-?[JMK0:A_J_P!J?]7GT(WM%T<=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2&[%_YE_O_ /\
M#,W-_P"ZG)^_=>ZJ:_F;_P UW;WP4BI.NM@8/"]A_(3<>*_B=-@LK5NNS]A[
M?#R-B<OO3^",V=%1N0R%,70H 7(U$_I6K]U[K6^SO\\+^93F,A+5X_O/%;5@
ME^F%PG4'35?04G^+'-[%W/N)_P#D*_M=X2>G\ST@\1_7IF_X>R_F<?\ >2O_
M +!SH#_[4GO7A1_P_P"'K?B/_%U[_A[+^9Q_WDK_ .P<Z _^U)[]X4?\/^'K
MWB/_ !=>_P"'LOYG'_>2O_L'.@/_ +4GOWA1_P /^'KWB/\ Q=>_X>R_F<?]
MY*_^P<Z _P#M2>_>%'_#_AZ]XC_Q=>_X>R_F<?\ >2O_ +!SH#_[4GOWA1_P
M_P"'KWB/_%U[_A[+^9Q_WDK_ .P<Z _^U)[]X4?\/^'KWB/_ !=>_P"'LOYG
M'_>2O_L'.@/_ +4GOWA1_P /^'KWB/\ Q=>_X>R_F<?]Y*_^P<Z _P#M2>_>
M%'_#_AZ]XC_Q=#QT;_/T^;.P=ST4O<%7LOOW:'W>/.>P^9VGMS8.Y?X:6+%=
MGYS8V%VO@\)FKG].3QN44<6^@MOPTH:#KWB/Z];?/QJ^0W6_RMZ;VEWAU3D)
M:W:6[Z0DT>2A-%G=OY/&&2'*[9S6-;TXO/;>RIT2(UR#8_0J?:'I=T8?W[KW
M7O?NO=>]^Z]U[W[KW2(V)_Q9ZW_P\^Q?_?@[M]^Z]TM_?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW2+W1_Q?>N?_#PKO\ W@=[>_=>Z6GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I#
M=B_\R_W_ /\ AF;F_P#=3D_?NO=+GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2(
MV)_Q9ZW_ ,//L7_WX.[??NO=+?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TB]T?\ %]ZY
M_P##PKO_ '@=[>_=>Z6GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I#=B_\R_W_P#^&9N;
M_P!U.3]^Z]TN??NO=>]^Z]U[W[KW7O?NO=?_T]_CW[KW7O?NO=:!O\ZW_MYM
M\F/];IC_ -\%U?[4+\(Z:ZLDWO\ S#.JNO\ I+>VY^G/DAU#G-@Y;JW9VQ>D
M/@I_LK&V,?6[#W"V6V2<T>R<GFL'X\[A/X%A<OCLLQR9Q>5%:1C;9 T5]]>Z
M*M\ J;KRA_G@[7AZGQ>4PG7)[0^2U7LS!5N RVTY<-M\],=SZ,4NTLS@ML;@
MP.$5B/X109/&#)IB?M"2 "?:7JHZW=?=NK]-CP^83L?K*J"W_!'3\W'X7V5W
M*->;((9/B)_P/7RIU2VB%ON]Q.#Q4#_C(^WK5X^<==N#8G\S'M#Y);8::HSO
MQ,ZHZ"[F_A]'/6_?Y7KU-T5NP^V=JH@5X2<]U]OJM*FS<J">;^\XN4?W!/[%
M;+L%Z3X]X\L%0&.@B6><.?PG2(L<3J*GR/6!O/4F_P 'OK?[W9Q?HPR"3B@J
M!"J4SD5+ <.%>DMA*7<?R.^:76_R/H8*[*U_R]VG_,%QG2^-JUQN/#]2=<=/
MIU'U+CV3*!/X(=TS8NLRC$@+_EY+>DM[47&XVG*GLYS#R,\J&?:FL2Q ?^TF
MOX[J05(-5 964U\\@? KT.V[GSG[Q>WO.QC(AW)-P4"J<+>SDA'FGG4? I^9
MX]60_&K^73NK9N3Z#[0[5["Q<.^-@3="9[*;&Q'76)H<+B:'IGX\;MZ@P>PX
M\E'O[=&%CSN#J=Z25V5W!CS'CLB^/ QV-H58,(*YP]U9+OE+=^4;*U;P[UG"
ML74X:^M[QB5,"TU/"-(+*RC%6R&F?D7V<ALN>FYXNY!KLE[10C,D$EO3$YK1
M7-3X; D^1R#$?%OX13_'7L-=WY/LZ#>6(V?L#=W4O5F+H-D2;3SF*V)O'MD]
MK9A^Q]QG?VZX^S-YKFX:.B6OHL9MR$::E_L"]82A!SISK-S=;%[F#1/)*LLA
M#5!<1)#15\-= *QA@"S^?<3P&OM_R .3KV01-5 A4 C@"6;),CU^+C0?D.BF
M;Y^5/R&ZV^5/8V [&[!R6,ZXWGNKM#:WQT&P,5T9O;IBO7K_ *1R^7R>V-]Y
M@P'O;KWNO;V_:6DKY5R!R.&<K648H31K][1B_;N1MGW[E*SEM8 UVJQFXU^/
M'(HDG4(\65AE32DH:A4T4$-XF"!-QY_W?8.>+Q'3]$NP2AB(.F+(;L9U-2M*
MUXT(TFH!/X\_)#YD=I[G_EZX+</RAW3#!\UNM.],OV'+B^INA =BY'IV/^.8
M7*==-+U4PPVX=S8G;#468?<7]Y<6SUU5]A041%$:(7\S<E\EV>Q^YVZ6O+02
M;9I-O$ %Q<$,+H1JZR:I&J TFOM"L2JJ& UZ@SRCSWSS?<U^SNU3\TEH-V7=
M?&_Q:W%#:QN\9&F-3Q4#M9:<3J%!U,Z]_F ]P]G_ !?^-\U3V=V52_(#>NT/
MDEN7=/\ H3ZW^.$>XMR8[HW,Y?#8C=^8RG?^67I_9VT)L7C/O<OCZ#'_ ,4R
M62 ;'-18^E=:U-O_ +8\K[/S=SY9VFPQOLVVR[<J+)<W *B\$98($)=V+-H0
MRRA$&6$E:JBY:]TN>MQY.]H]SN>:F&X;JN[&73:VN?I)75*D1J  HKV*">!Z
M+'NCN?>W?F8^+_;G8,U%6;UW?_*V^953N;(T&/\ L,?EZ_&X;L'!')1X<D^*
M+<2XPUXC' ' MQ['Z\M;1R?=>\'(5O(6VZ>_V!02&PKS13. *LP"^,5'>#0<
M3T!4YAWOW VSV>Y]W.*FY0Q[U5:QUJ==L*E5C2NF,'$9X^H+&P3:O:N_NE/Y
M(FR^TNL\T=J;[V/\;-FY+;&<_AF&SG\*R(KL=B4)Q.9Q6XL%,@$A&AHY%!]0
M L6$7MRIM/,'WD]YY5N6KL\Y7_?F1'MZRKP='SIIEL FM>I@GYGWGD?[MVU<
MT;6E=WMY'6E8^$FX/&<NLB<'!^#RH"">B_9WY-_,O%Y[Y ;8A^4.?C.R/Y?6
M(^;6"RL?4_0KUN*[ H<%GLKD]A8AI]AS84=59S)Y 73(X[);E44--;.@+5"L
M?N>7^2(DVZX/*2GQ;^2V*BYN0I4S.B/ERVM%C'!@AU.2GP:"J+G3GTF55YN(
MTQ!ZFUMJX4$CX *,6Q@GX<\:B]1?+OY#=X[KVGM;']N_[+IAJ;^71M#YEY3<
M.U=I=4YNKW;NS>-!CA*I_P!,&V]Y;>P_6G6^3N[?8Z6EDD DR2"P!+'RIR?:
M+KN-D%T\VZ?3J&N)5$*"1AI/A,I:1D6M6( +(=( (<R7GGGJ8L$YH*!+</\
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MQ)NW$;VQ6[&' ^F&V?A?9=T9=;.OOW7NO>_=>Z][]U[KWOW7ND1L3_BSUO\
MX>?8O_OP=V^_=>Z6_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I%[H_P"+[US_ .'A7?\
MO [V]^Z]TM/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2&[%_YE_O_ /\ #,W-_P"ZG)^_
M=>Z7/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND1L3_BSUO_ (>?8O\ [\'=OOW7
MNEO[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z1>Z/^+[US_P"'A7?^\#O;W[KW2T]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=(;L7_F7^__ /PS-S?^ZG)^_=>Z7/OW7NO>_=>Z][]U
M[KWOW7NO_]3?X]^Z]U[W[KW6@;_.M_[>;?)C_6Z8_P#?!=7^U"_".FNAHS7S
MEZWWQBX*SXW?RV_A!E(.M^D<=V%\@J;M'X^[4MMS(X?+839V\-U;/S&%[9VR
M=[;%.=W;AQ_Q:_XM:N_Y3O>_SZ]THO@CW!MOOW^>1LCN7:./S.'V[V%O/O3/
M;?Q^;IL/CLC14#_'#LU5.7Q.'S>ZE#:CQ_N3//M*.JCK=F]VZOU@#(06_P!8
M'Z_[#_>O?G34IB_U>O7I1X#F8^?_ !706Y/J+J;*YS<NYLUUGL7+[DWKM8[!
MWCN7(;-P-=GMW;*>.93M3=.3;%--FMIM&S+_  ^MU4'J_3ZN7+7<=S"_0"=U
MC0U U"@XY ]34\,Y/1=<;-L\S_O.>W!D;B>_[,T/#AY?Y^F3%]+=4[>J]CY'
M"=9=>8BLZNQ>1P/6=;B]E[<H:[8& RZ+'EL1M":/&K4[5P^86-4EI*+0CJ "
M/PN]PWK<=QV_=+R2]D<7/AUU$DMX3 +J)'=2F*CM\O+IFPY=VW:KGE&RMX!6
MR%WII4!?'!+4[S2M37)KPH%K489TB+*SG25OI:S&UP 18&QO[*I+R&">^N9Q
M46P2G'&L4\AYD^A_+HQ\(26_T:FC7'Y_ :_ZLC\^N2.3IB!_4&(_V&IOZ?FW
MMR M<;6LR\2*_P#&OR\NMR7&C=5A/G_T#]G0,M\?^BY]ZYGM6?IKJYNS-PTE
M9CMP[]7K_;,6^<S05^._A&1H,GNZ'%IG\K2SX8BC='E</"/&01< TM][W:+:
M4BBNY @H=.JJX>H[::<4KGC3UZ+;KEC9[G>VNI;<&1JY[A6J4K76!GC\J]9<
M+T3TUMB?8V0V]U-UMMZNZKH]PT'64V'V;@:&KZ[H-X@'<N.V@U!0VVG!N1#I
MR24!1*X\M?@!5-OO,UTZ03[K.UK<DFX#$$/H \/54]VDJ*>E!TGL>1^3K>ZV
MNXM]G07%N)!$0TO9X@(DI5Z9!/'I,5?Q5^,>3VYM7:&4^/?2U9M38^2K<MLC
M;.3ZQV;D=O;4R68K379G([9Q4V(;&XC+9J4EY)*15<O9B2>#NUYFYSF6&YGW
MRY^IF_MCK6K",D1ZM)X!?,<*DG-:I/ZA<BV]MMMM%LT8@@,GA#5-V^*P,@%7
M)RWKPX+08ZFQ?'+H.BCV_#2=(=445%MG:NY]B86D@ZTV?3Q8?9>[9:]]V;0Q
M(3$+_#-H[C>NJVR- JB@KS5$LK>1M59>9=XW"UW:6.]F:]E\,L6DJ6T$:=6O
M#%0HTURH7'J%-QR;LTEYL,%G:*EA;^/0=YIX@J:$MJH2344/$<*#I7-U;UG6
M=>-U+-UUL:7J?^$C;QZTFVEM^38 VZQT_P $_NBV+.#.'UC_ (!^(16XM;CV
M5V>Z;G!)MNXF9_WN_B N&TMBJCN&!V4&*5&#7/1@NW;7;P[MLMW"#M"".B=U
M.[O/PG5E\Y+4^0/4"3H;IB>IR5;4=2]=S5N:V,>K,U53;*VZ:W+=8:2O^C?)
MS/CG?)[$(E93BG)QMB?V[7NJ_?'-3J@?=Y2%?6*E31LG4/1JDFN#4GS/24\E
M\G@O39T%5T_%+0_\;&.'&OV>C!NOXQ?'#?F'V;MK>O1?4>]MM]?4!P>P=O;K
MZYV;N#";&P0H<7C7Q>S\7F\-/3;?PW\.Q=%&8J 1)XZ.G0 I&JA5%NW,\$DL
ML>[RH\AJY72*FI^*E*FM>.>/SZ2R<H\F%523:5HJT'?-7AY'6?E_Q>>E=_HS
MZW.YJ;><?76S/[XT6TIMB1;N_NUAY-UTNS9:ELJ=DKN$TYS7]T9Z]O*<:)10
M>0EBA)X2C<]SEMQ<W]PT>[N2:$ASJU?%J TU(H=5:U-?B%>E-OL6VV\NQ6EA
M9:MG_5&K4RA14XH[:Z:M5!G&,"@*+V)\8OCEUI+G'Z\Z#Z8Z_?<^#J=M;JCV
M9U;LC;39_;56&,FV\RV#P=,<Q@ZCZM1N6B:P!4_0O2;UOU[9_P"[.XE5T(*N
MSB3(/'2.!\L_EGIRTV#8+2YWU-OME?7X8=!XBTP0:NQS6K'&%X4R.L--\7OC
M5'LFIZRIOCYTS3]9UV;.Y\AUU!UOL^+8E;N(-&XW%/M),1'@),\/LH+5CQ&0
ME%Y!52-P[WNNV.)'Y@<2TI54TFF#Q4$T_P W10>2.0+]2D%BC5-:?KTK09%7
M ' \!3[:]3Z7XU_'C'XS'8K%]$]1TF'Q^ZMO;\QV,7K;:4%!1;TVK118S:N[
MJ?&G$Q)3;LVSAX5HL;7HJUV/B540A0 ''YEW6_;6>8)C( 0*ZB0"02 32G 5
M P:#T Z66G)^R;8HCL>7E9/42L,@8)U,?VFO^$]9*SXW?'BL[#A[4R'174%;
MVHM?1Y4]FS]<;*GW\,YC+#'97^]_\$&>&7IU(*2"35']%('UJF\;S%;?2V<T
MKV94U[]*TX$%#Q\^G+C9>6Y+Z&[O(52^U"B_J,:^5"#I]/M\Z]#J5C'G+&X-
MM9LWUU@@6'^(_'L/636WU,[VC^)=$9%"O\VQ^SH^OG#6[1W*:+;%&K7S%,#/
M3E[,.G>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND-
MV+_S+[?W_AF;E_\ =3D_?HOP]>?@>M9O^<I_*F[-["[&S'RU^,NU,AORMW-0
M47^E_JS;E/\ Q#>'\?P^*3$8S?VRL29&?.P9[$XRECRF.QJQY5<HHK@M<M96
M-1K48!0":=(9/C/6K5F<-F-N9"NP^>P^0P>5Q]6*2JQN;Q?V&0H_];$>W.F^
MFKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=#AT;\:>\?DKNNA
MVATEUCNC?^5R%3]I]UA,7_OWL-]/]RN9W?\ \>]A,%_VL_?B0,GAU[K?!_EN
M_"/%_!CXZX_KFJR-#E>Q]S95=Z=K[FHHPM%7;DG)5,1A_(IT8#;N$6.@0$@O
M+]S6FS59'LNZ,NK%O?NO=>]^Z]U[W[KW7O?NO=(C8G_%GK?_  \^Q?\ WX.[
M??NO=+?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TB]T?\7WKG_P /"N_]X'>WOW7NEI[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z0W8O\ S+_?_P#X9FYO_=3D_?NO=+GW[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2(V)_P 6>M_\//L7_P!^#NWW[KW2W]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=(O='_%]ZY_\/"N_]X'>WOW7NEI[]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z0W8O_ #+_ '__ .&9N;_W4Y/W[KW2Y]^Z]U[W[KW7O?NO=>]^Z]U__]7?
MX]^Z]U[W[KW6@;_.M_[>;?)C_6Z8_P#?!=7^U"_".FNAP.+_ );7Q&S&\?C5
MV?6_+?*=M9C9N.ZR^0?<75V3V#0[0Q S V9O+>&U=G;2S1_O#FMC;:SV(H^?
MX6<K_D7O>>O=0/Y:_4M;T'_.CZ[Z9R&4I\S4=<[Z^1&TJ7.04@HCN+'8GI;N
M@8?*L 2&_O)@C1Y'ZD>TO51QZWC_ ';J_7+WKISKWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[I#=B_P#,O]__ /AF;F_]U.3]^Z]TN??NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=(C8G_ !9ZW_P\^Q?_ 'X.[??NO=+?W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]TB]T?\7WKG_P\*[_W@=[>_=>Z6GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I#=B_\
M,O\ ?_\ X9FYO_=3D_?NO=+GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2(V)_Q9
MZW_P\^Q?_?@[M]^Z]TM_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2+W1_Q?>N?_#PKO\
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M]LU&Q/\ 1G_?XGH'LT?WG'7A _N1J/'\/XM>_M-U7K>!]VZOTCO[UG_G7O\
M^=0_Z,]ZZ<Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]__.H?]&>_=>Z]_>L_\Z]_
M_.H?]&>_=>Z1N_-S"KV/O"'[3_/[9W'2_P# D?4XIKF]OSJ/OW7NEE_>L_\
M.O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&
M>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\
M.O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&
M>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\
M.O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&
M>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\ .O?_ ,ZA_P!&>_=>Z]_>L_\
M.O?_ ,ZA_P!&>_=>Z1NS=RB+#5_^1_7>'852?\I'T7?^<^G'YU?ZWOW7NEE_
M>L_\Z]__ #J'_1GOW7NO?WK/_.O?_P ZA_T9[]U[KW]ZS_SKW_\ .H?]&>_=
M>Z]_>L_\Z]__ #J'_1GOW7NO?WK/_.O?_P ZA_T9[]U[KW]ZS_SKW_\ .H?]
M&>_=>Z]_>L_\Z]__ #J'_1GOW7NO?WK/_.O?_P ZA_T9[]U[KW]ZS_SKW_\
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M[&G&'+92M-?_ ,7#ZH_:K==RV.RBWZX8Q\AQ^,'B5D_7D=3I15)\<R"15,9
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MH-M(LBFH)0C65(;STY*!@_F;\EJRFI.FY.P):RMR?\QO<'Q)/RI;9NPSG_\
M1]AU_C:8K%83^!1]/_Z5=Q.HQO\ $3C!B["W\/K<C[&NY<A\EW(?<-V@B;:Q
M8"8;4QNEHXMR%\2YCF2Y*+,!(*D&FJ"JJ*]1E8^X/.UM920;/*8^8VEHVYTM
MWJ/&U&EG)$80?"K%C_FI\709=O=P=G[^W9U5USOW<E9V5C/CW_.<^-O6>S.V
M,AA-HX.OW#C_ .%[OS65VMFEV;AMK[%;<77Q0XW*MCL7C5_RD_Y"I)U*;/8]
MFV;EJVO(;S5?;UM%T98Q6J?33QM"]-;.?%:-@&JJDH14D-J*]XYCWK?.:;D"
M$"/898_"J4[OK8?U<Z  %%*@^(<U 7%!RZD^5ORCW3\DNOOA%N+>S#M?J_O_
M +2R_>F_/[D;5H/[X?&O:.+Q6\NN@^&& _N]A1V.N\:+'#(8W'8W)WHJ4_?
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M,:R+FI8M1U ,9!)/"I% *K3JESR'RUS1O=I?VC![[/B2$2C2%4*G89%5JT(
M45X:J'H7LALW9V6VE-U]E=KX'*[(J<&-O56R<A@\;6;1K-NKBQBAB?X2K# ?
MP'2!?'WL?]X]HK#?)I][W'?=LNGCDL2""I(8^*C@@,0",!@3I8$8( (!7[IL
M]JNQ[?RMNZAQN+,N:X\&1'&$/^E([E^TT/2:@Z5Z=IL;L? TW4O6\&$ZMR8W
M!UU@Z;8NU_L-A[@N;97:.+_@5MF9P@W&0QO(O_7VU:;]OB[1N7,%W=R%[TK4
M5'&-V0:BHHY\Z,N*8]2Y-R_R[/OFV<MV=NJKMJM^*0XEC5SEFX'%.YCG-. C
MKTGTQ'LG,];0=3]9?Z.=P9(Y7/=?C8^VO[I;FR'\3&7_ (KF-K_P,8#,YP9W
M$@DGDFQ^OM8.8-YV[FW8["]YDDDO9$ETTCT&AA:I#J"5[<DU!-*D$]%4VP;-
M9<F;W#MW+06T+Q$CQW-2)E_B8T%3PX< *#IEHOC1\;\/CI\!BN@NDL5@ZG.;
M=W!5X7&=3[$H,?6;CV>5_N=EOX4N$5$SVV03_"<A]<7_ +#VQ^]N9=AW'9;J
M]YMD-NQE^&)4IVZ>,=7XL":4J,'#5Z5R\E\LOMF^267*H$^F(D^/*:T8>;/I
M';7%,\1P-0I^4'Q-Q7R>W/T%E-R9VBIMO=+]B_WVS>RLYL^/=6![-QN9Q7\'
MS>U<L<QGD&!P>X5MS;)_X>QGRA[J<T>WNP>XFT;/8E]SNA:*+A9HXSI#-4"-
MHI "%D=0P8,M=0((% USO[7<K^X6_>W.X;Y?E+*(7A%OX<C:F*)J_5CFB(TF
M-#E0&I08)J.=1T7TG+UO#T[)T]UE4=1P57W5+U<-D;9385'_ +EOXU?^ZPP?
M\"%\]_N1O>_\5_VWL+W>^\W6',3\P;,9Y>8I"=4@F5) -&@G6U>*5!(H:<3G
MHY'+/)E[RBO*^\L(^6(@-,=)F&)-:Y1A+_:4.6/Y@4ZXTO273%!MW:.T,?U'
MUGC]G]?[HQ^]=A[4I]C[7Q^WMC[QQ64RV9Q&Z]FX=,)_=[!9Y,WE:S(#)8T!
M@:RK_J24NX;UN)M;I8Y#XAIX9[:\5#_AIP ^+/F#6M3[;>3MJBW""Y,(#&OB
MU+Y '9P<TI_1 K^+'0/];?&.GVC\I^]OE1F-WTVX]R]O[8V9LG 8.FVLV!.P
MMF;1Q1_BV*.7;.;D_OH^Y<UB:/(FO(Q1'V?^W'',O/&X[Q[?;)[>E\;$[R.:
M+W&[E,JFA12I76P90\F30Z:4 #Y7Y"V?;O<3>/<$+_R745(LOV_21"%Q7Q"#
M72/BCC/ C56I&+%]&],8"#8U+@>H.LL+1]75>3J^KJ;';&VO08_KBOS))R^4
MV@HP079?]XP;97^'"X_K]3[#<W-%_)+;QR;O*R7"D2\>_P ,50'&=))T\*$\
M?/H50\F;#;)<3P;,!/;$>#^K)CQ"0_%R,C^*ORH>H55\>.A:_9\O7U?TGU#7
M[ FSO]ZZC955UYMC(;1K-XFQ;=)VD<&<"V<_ZN)]TL>:=TN19W<V[R&[E5UD
M:G<0I[06 J1VC]@ZO=\E\MV[7%M!LH%K;4,0\63'B#4_%ZY)/Q5IY4ZX[=Z*
MZ5V16[,J]H=1=9[9EZ\7<IV VV^O=KX-]B'>"D[Q&TI,1AC_  C^\_URO\/(
M&4_VUBO=.8=]'+_-DC;Q+N&XL;;Q(S2($"1=&IR"'HIU"M=.BF"PZ+UV;9MO
MW'VRFBVQ;#:]N_> B8.\Q)N%TN-)?4M9#3N!^.M0HZA5_P ;_CQD=YIV?4]&
M=-S]BIG:'<:[_FZSV3'NW^\.*R)RF)RTFYX\+'GILV,UBJ2V0=6LU$&%F /L
MVGYBOMKV/Z3;=ZDM=IDQ*P!=0"0N8F!U:B32E2I.H$$ AZ\Y/VW<.=+0[CM"
MW>Z;>)#&"[(66:$%B"K@+VZ6H220-.*D=/6W^C^F=J9W=.[MJ=2]9;;W3O\
M^_7?FX\-L;;&%W%N\9C*#+9<[OS6(PAW#F_[QYL7/\2)N;_4_4KGYGO;6[M7
MWN%FW*- $<R5(THJK30"HH*$5\_SJ]<[#M8C?;^6+L0[3)JU)H9N)J<RMK\S
MP/V8IU@Z^^/?174M=7Y#JSIKJOK3*9FE6DRF2V%U[MG:E?F,>A#KC,MEL)A"
M19K>S7F/FB^YDVT6W,OCW.W&A59)W90:C("A6&0,5ZWLO)^Q<F/]=RS*(=S8
M ,P5S6F?]%=UQ4\ .A=]D/0DZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[I,[V_P"//W7_ .&ON+_W5>_0_AZ\_GT4/Y5?$*C[SGAWAM+)4&W.QL=2
M&EJOXD+X#<F.^N(_C Y.%SW_ %<1[7K\(Z02?&>JV*KX,_)R*HGACZWIZZ#_
M )6:;>6P/\LOQ_SOO;G3'4?_ &1[Y1?\^Q;_ -#+8'_U^]^Z]U[_ &1[Y1?\
M^Q;_ -#+8'_U^]^Z]U[_ &1[Y1?\^Q;_ -#+8'_U^]^Z]U[_ &1[Y1?\^Q;_
M -#+8'_U^]^Z]T^[<^ OR0S.0IZ/*;;Q&U:'_E*R6;W1M6OQ]'_YY,]N?W[K
MW5O7Q[Z"VWT%LP;;PTW\5RN0JON]T;DJ:7_B\9&W_NB]EIX=*4^(=#T?S[T.
MEL7X>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3>TO^+5-_X=&\__
M 'J\S[]U[I2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDSG_^+GL?_P .C(_^\IO3W[KW
M2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=)G>W_'G[K_ /#7W%_[JO?NO=*;W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW2;VE_Q:IO\ PZ-Y_P#O5YGW[KW2D]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=)G/_P#%SV/_ .'1D?\ WE-Z>_=>Z4WOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[I,[V_X\_=?_AK[B_\ =5[]U[HQWOW7NO>_=>Z][]U[KWOW7NO_T]_C
MW[KW7O?NO=: W\['_MYM\F/^"],?_ _]8>UL; (,](3&]3CJK&_NVM?7K7AO
MZ=6F_P DW_MYO\9O];N;_P"!_P"S_;#?">E76_Q[8ZWT#/O73G7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7&6**IIYX:J&GG@J*7[.JIJG_ )3/?NO=<O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=<8HH:6/PQPT\'^5?=_P"3?[Q[]U[KE[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZXRQ0RR02RPT\XIZK[NE_P"F/_;>_=>ZY>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NN,L4533SPU4-//!44OV=535/_*9[]U[KE[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KC%%#2Q^&.&G@_P J^[_R;_>/?NO=<O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7&6*&62"66&GG%/5?=TO_3'_MO?NO=<O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW66EI8:NH@HZJ&GGH:BJ^TJJ:II?^!A_V_'OW7NAC]^Z]U[W[KW7O
M?NO=>]^Z]U__U-_CW[KW7O?NO=5Y=U_RO/@U\C.T-R=Q]Q=(G>/8N[WQ_P#>
M+<O^D_N+;AK5P^V<1M#$1G$;*WWMS Z(L!AJ2/\ S0:RDW)Y'O%I@-U[1\N@
MX_X9._EC_P#>- _]')\@O_ML>_>-_2ZUI'IT(W2G\KSX-_'/M#;?<?3O2)V=
MV+M!\A_=W<O^D_N+<9HES&V<OM#+QC$;UWWN/ Z)<!F:N/\ S1:S W!Y+M21
MTWU89[;ZWTP_W>Q'_*K_ -9W_P"CO>NG.O?W>Q'_ "J_]9W_ .CO?NO=>_N]
MB/\ E5_ZSO\ ]'>_=>Z]_=[$?\JO_6=_^CO?NO=>_N]B/^57_K.__1WOW7NO
M?W>Q'_*K_P!9W_Z.]^Z]U[^[V(_Y5?\ K.__ $=[]U[KW]WL1_RJ_P#6=_\
MH[W[KW7O[O8C_E5_ZSO_ -'>_=>Z]_=[$?\ *K_UG?\ Z.]^Z]U[^[V(_P"5
M7_K._P#T=[]U[KW]WL1_RJ_]9W_Z.]^Z]U[^[V(_Y5?^L[_]'>_=>Z]_=[$?
M\JO_ %G?_H[W[KW7O[O8C_E5_P"L[_\ 1WOW7NO?W>Q'_*K_ -9W_P"CO?NO
M=>_N]B/^57_K._\ T=[]U[KW]WL1_P JO_6=_P#H[W[KW7O[O8C_ )5?^L[_
M /1WOW7NO?W>Q'_*K_UG?_H[W[KW7O[O8C_E5_ZSO_T=[]U[KW]WL1_RJ_\
M6=_^CO?NO=>_N]B/^57_ *SO_P!'>_=>Z]_=[$?\JO\ UG?_ *.]^Z]U[^[V
M(_Y5?^L[_P#1WOW7NO?W>Q'_ "J_]9W_ .CO?NO=>_N]B/\ E5_ZSO\ ]'>_
M=>Z]_=[$?\JO_6=_^CO?NO=>_N]B/^57_K.__1WOW7NO?W>Q'_*K_P!9W_Z.
M]^Z]U[^[V(_Y5?\ K.__ $=[]U[KW]WL1_RJ_P#6=_\ H[W[KW7O[O8C_E5_
MZSO_ -'>_=>Z]_=[$?\ *K_UG?\ Z.]^Z]U[^[V(_P"57_K._P#T=[]U[KW]
MWL1_RJ_]9W_Z.]^Z]U[^[V(_Y5?^L[_]'>_=>Z]_=[$?\JO_ %G?_H[W[KW7
MO[O8C_E5_P"L[_\ 1WOW7NO?W>Q'_*K_ -9W_P"CO?NO=>_N]B/^57_K._\
MT=[]U[KW]WL1_P JO_6=_P#H[W[KW7O[O8C_ )5?^L[_ /1WOW7NO?W>Q'_*
MK_UG?_H[W[KW7O[O8C_E5_ZSO_T=[]U[KW]WL1_RJ_\ 6=_^CO?NO=>_N]B/
M^57_ *SO_P!'>_=>Z]_=[$?\JO\ UG?_ *.]^Z]U[^[V(_Y5?^L[_P#1WOW7
MNO?W>Q'_ "J_]9W_ .CO?NO=>_N]B/\ E5_ZSO\ ]'>_=>Z]_=[$?\JO_6=_
M^CO?NO=>_N]B/^57_K.__1WOW7NO?W>Q'_*K_P!9W_Z.]^Z]U[^[V(_Y5?\
MK.__ $=[]U[KW]WL1_RJ_P#6=_\ H[W[KW7O[O8C_E5_ZSO_ -'>_=>Z]_=[
M$?\ *K_UG?\ Z.]^Z]U[^[V(_P"57_K._P#T=[]U[KW]WL1_RJ_]9W_Z.]^Z
M]U[^[V(_Y5?^L[_]'>_=>Z]_=[$?\JO_ %G?_H[W[KW7O[O8C_E5_P"L[_\
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M *.]^Z]U[^[V(_Y5?^L[_P#1WOW7NO?W>Q'_ "J_]9W_ .CO?NO=>_N]B/\
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*?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971555784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARBUTUS BIOPHARMA CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0597776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">701 Veterans Circle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warminster<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">469-0914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABUS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,728,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001447028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971898376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 81,330<span></span>
</td>
<td class="nump">$ 109,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments in marketable securities, current</a></td>
<td class="nump">84,147<span></span>
</td>
<td class="nump">46,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,908<span></span>
</td>
<td class="nump">4,445<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">172,698<span></span>
</td>
<td class="nump">160,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $9,768 (December 31, 2021: $9,374)</a></td>
<td class="nump">5,664<span></span>
</td>
<td class="nump">5,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">56,318<span></span>
</td>
<td class="nump">35,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">2,007<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">236,877<span></span>
</td>
<td class="nump">204,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">8,715<span></span>
</td>
<td class="nump">10,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="nump">23,255<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,409<span></span>
</td>
<td class="nump">11,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Liability related to sale of future royalties</a></td>
<td class="nump">15,439<span></span>
</td>
<td class="nump">16,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Noncurrent</a></td>
<td class="nump">15,585<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">71,032<span></span>
</td>
<td class="nump">35,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issued and outstanding: 148,728,237 (December 31, 2021: 144,987,736)</a></td>
<td class="nump">1,298,212<span></span>
</td>
<td class="nump">1,286,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">67,151<span></span>
</td>
<td class="nump">65,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Deficit</a></td>
<td class="num">(1,150,112)<span></span>
</td>
<td class="num">(1,134,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(49,406)<span></span>
</td>
<td class="num">(48,335)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">165,845<span></span>
</td>
<td class="nump">169,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 236,877<span></span>
</td>
<td class="nump">$ 204,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812977246040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 9,768<span></span>
</td>
<td class="nump">$ 9,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares)</a></td>
<td class="nump">148,728,237<span></span>
</td>
<td class="nump">144,987,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, shares outstanding (in shares)</a></td>
<td class="nump">148,728,237<span></span>
</td>
<td class="nump">144,987,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812976644600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 12,581<span></span>
</td>
<td class="nump">$ 2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">18,462<span></span>
</td>
<td class="nump">13,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,892<span></span>
</td>
<td class="nump">3,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,555<span></span>
</td>
<td class="nump">17,789<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,974)<span></span>
</td>
<td class="num">(15,676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(506)<span></span>
</td>
<td class="num">(772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (loss) gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other loss</a></td>
<td class="num">(347)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(11,321)<span></span>
</td>
<td class="num">(16,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,765)<span></span>
</td>
<td class="num">(16,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract', window );"><strong>Items applicable to preferred shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Dividend accretion of convertible preferred shares.</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,212)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shares</a></td>
<td class="num">$ (15,765)<span></span>
</td>
<td class="num">$ (19,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WeightedAverageNumberOfCommonSharesAbstract', window );"><strong>Weighted average number of common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">148,428,326<span></span>
</td>
<td class="nump">93,434,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">148,428,326<span></span>
</td>
<td class="nump">93,434,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">$ (1,071)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(16,836)<span></span>
</td>
<td class="num">(16,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">4,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abus_CollaborationAndContractsMember', window );">Collaborations and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">11,218<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Fair Value Of Contingent Consideration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WeightedAverageNumberOfCommonSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WeightedAverageNumberOfCommonSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abus_CollaborationAndContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abus_CollaborationAndContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968773400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Open Market Sale Agreement</div></th>
<th class="th"><div>Share Purchase Agreement</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th">
<div>Common Shares </div>
<div>Open Market Sale Agreement</div>
</th>
<th class="th">
<div>Common Shares </div>
<div>Share Purchase Agreement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Preferred Shares</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,678,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 101,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 985,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,751<span></span>
</td>
<td class="num">$ (1,045,961)<span></span>
</td>
<td class="num">$ (48,171)<span></span>
</td>
<td class="nump">$ 149,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of accumulated dividends on Preferred Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability stock option awards</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to the Open Market Sales Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,395,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the Open Market Sale Agreement</a></td>
<td class="nump">26,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares pursuant to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares pursuant to ESPP</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,245,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">114,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,013,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,133<span></span>
</td>
<td class="num">(1,065,554)<span></span>
</td>
<td class="num">(48,168)<span></span>
</td>
<td class="nump">$ 152,620<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,987,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">169,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,286,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,485<span></span>
</td>
<td class="num">(1,134,347)<span></span>
</td>
<td class="num">(48,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards', window );">Certain fair value adjustments to liability stock option awards</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares pursuant to the Open Market Sales Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,048<span></span>
</td>
<td class="nump">3,579,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 10,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 10,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common shares pursuant to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common shares pursuant to ESPP</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,765)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,728,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 165,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,298,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,151<span></span>
</td>
<td class="num">$ (1,150,112)<span></span>
</td>
<td class="num">$ (49,406)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968670920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,765)<span></span>
</td>
<td class="num">$ (16,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,736<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange losses (gains)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="num">(1,363)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion and amortization of investments in marketable securities</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in operating items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(414)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,507)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(2,102)<span></span>
</td>
<td class="num">(2,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred license revenue</a></td>
<td class="nump">38,840<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">20,619<span></span>
</td>
<td class="num">(17,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(61,981)<span></span>
</td>
<td class="num">(2,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Disposition of investments</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">20,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(60,056)<span></span>
</td>
<td class="nump">18,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common shares pursuant to exercise of options</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Issuance of common shares pursuant to ESPP</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,485<span></span>
</td>
<td class="nump">26,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) Increase in cash and cash equivalents</a></td>
<td class="num">(27,952)<span></span>
</td>
<td class="nump">27,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">109,282<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">81,330<span></span>
</td>
<td class="nump">79,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred shares dividends accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,212)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abus_SharePurchaseAgreementMember', window );">Share Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares pursuant to the Open Market Sale agreement</a></td>
<td class="nump">10,973<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares pursuant to the Open Market Sale agreement</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 26,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Revenue Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_SharePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_SharePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972750456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of business and future operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of business and future operations</a></td>
<td class="text">Nature of business and future operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Description of the Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Arbutus Biopharma Corporation (&#8220;Arbutus&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company&#8217;s current focus areas include Hepatitis B virus (&#8220;HBV&#8221;) and coronaviruses, including SARS-CoV-2. In HBV, the Company is developing an RNA interference (&#8220;RNAi&#8221;) therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (&#8220;cHBV&#8221;) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. The Company is also exploring oncology applications for its internal PD-L1 portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, the Company had an aggregate of $221.8 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of March&#160;31, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company&#8217;s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company&#8217;s existing or future research and development programs or the Company&#8217;s ability to continue to fund these programs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">COVID-19 Impact </span></div>The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials.  While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company&#8217;s plans and timelines in the future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812976741704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant accounting policies</a></td>
<td class="text">Significant accounting policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation and principles of consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and its one wholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company&#8217;s financial position as of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s results of operations for the three months ended March 31, 2022 and 2021, and the Company&#8217;s cash flows for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2021, except as described below under Recent Accounting Pronouncements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss attributable to common shareholders per share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three months ended March 31, 2022 and 2021, since the effect of including potential common shares would be anti-dilutive. For the three months ended March 31, 2022, potential common shares of 15.7 million pertaining to outstanding stock options were excluded from the calculation of net loss attributable to common shareholders per share. A total of approximately 35.0 million outstanding stock options and if-converted Series A participating convertible preferred shares (&#8220;Preferred Shares&#8221;) were excluded from the calculation for the three months ended March 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, the Company&#8217;s outstanding Preferred Shares were converted into 22,833,922 common shares. Prior to that date, the Company followed the two-class method when computing net loss attributable to common shareholders per share as the Preferred Shares met the definition of participating securities. The Preferred Shares entitled the holders to participate in dividends but did not require the holders to participate in losses of the Company. Accordingly, net losses attributable to holders of the Company&#8217;s common shares were not allocated to holders of the Preferred Shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from collaborations and licenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments and royalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements fall under the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) when both parties are active participants in the arrangement and are exposed to significant risks and rewards. For certain arrangements under the scope of ASC 808, the Company analogizes to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;) for some aspects, including for the delivery of a good or service (i.e., a unit of account).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When consideration is received or is unconditionally due from a customer, collaborator or licensee prior to the Company completing its performance obligation to the customer, collaborator or licensee under the terms of a contract, deferred revenue is recorded. Deferred revenue expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a current liability. Deferred revenue not expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a long-term liability. In accordance with ASC Topic 210-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet - Offsetting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s deferred revenue is offset by a contract asset as further discussed in Note 9.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single segment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed all recently issued standards and has determined that such standards will not have a material impact on the Company&#8217;s financial statements or do not otherwise apply to the Company&#8217;s operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972775208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial instruments and other items at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs are quoted market prices for identical instruments available in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices. The Company determined the fair value of the contingent consideration was $5.5 million as of March&#160;31, 2022 and the increase of $0.2 million from December&#160;31, 2021 has been recorded as a component of total operating expenses in the statement of operations and comprehensive loss for the three months ended March 31, 2022. The assumptions used in the discounted cash flow model are level 3 inputs as defined above. The Company assessed the sensitivity of the fair value measurement to changes in these unobservable inputs, and determined that changes within a reasonable range would not result in a materially different assessment of fair value. &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value of liability-classified options exercised in the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:37.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972753480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in marketable securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in marketable securities</a></td>
<td class="text">Investments in marketable securities&#160;<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual term to maturity of the $84.1&#160;million of short-term marketable securities held by the Company as of March&#160;31, 2022 is less than one year.  As of March&#160;31, 2022, the Company held $56.3 million of long-term marketable securities with contractual maturities of more than one year, but less than five years.  As of December&#160;31, 2021, the Company&#8217;s $46.0 million of short-term marketable securities had contractual maturities of less than one year, while the Company&#8217;s $35.7 million of long-term marketable securities had maturities of more than one year, but less than five years.</span></div>There were no realized gains or losses for the three months ended March 31, 2022 or 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972753480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Genevant<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investment in Genevant</a></td>
<td class="text">Investment in Genevant<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&#8220;Roivant&#8221;), its largest shareholder, to launch Genevant Sciences Ltd. (&#8220;Genevant&#8221;), a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company&#8217;s lipid nanoparticle (&#8220;LNP&#8221;) and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV, except to the extent certain rights had already been licensed to other third parties (the &#8220;Genevant License&#8221;). The Company retained all rights to its LNP and conjugate delivery platforms for HBV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Genevant License, as amended, if a third party sublicensee of intellectual property licensed by Genevant from the Company commercializes a sublicensed product, the Company becomes entitled to receive a specified percentage of certain revenue that may be received by Genevant for such sublicense, including royalties, commercial milestones and other sales-related revenue, or, if less, tiered low single-digit royalties on net sales of the sublicensed product. The specified percentage is 20% in the case of a mere sublicense (i.e., naked sublicense) by Genevant without additional contribution and 14% in the case of a bona fide collaboration with Genevant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, if Genevant receives proceeds from an action for infringement by any third parties of the Company&#8217;s intellectual property licensed to Genevant, the Company would be entitled to receive, after deduction of litigation costs, 20% of the proceeds received by Genevant or, if less, tiered low single-digit royalties on net sales of the infringing product (inclusive of the proceeds from litigation or settlement, which would be treated as net sales). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company accounts for its interest in Genevant as equity securities without readily determinable fair values. Accordingly, an estimate of the fair value of the securities is based on the original cost less previously recognized equity method losses, less impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or a similar Genevant securities. As of March&#160;31, 2022, the carrying value of the Company&#8217;s investment in Genevant was zero and the Company owned approximately 16% of the common equity of Genevant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972775208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">Accounts payable and accrued liabilities<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fee accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972750456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of future royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock', window );">Sale of future royalties</a></td>
<td class="text">Sale of future royalties <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the &#8220;Agreement&#8221;) with the Ontario Municipal Employees Retirement System (&#8220;OMERS&#8221;), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Patisiran) (&#8220;ONPATTRO&#8221;), an RNA interference therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ONPATTRO utilizes the Company&#8217;s LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &#8220;LNP License Agreement&#8221;).&#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% to 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $30 million in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as $1.5 million of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. As of March&#160;31, 2022, the Company estimated an effective annual interest rate of approximately 16%.  Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability is effectively repaid over the life of the Agreement. From the inception of the royalty sale through March&#160;31, 2022, the Company has recorded an aggregate of $12.5 million of non-cash royalty revenue for royalties earned by OMERS. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company&#8217;s control. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, the Company recognized non-cash royalty revenue of $1.4 million and non-cash interest expense of $0.5 million. During the three months ended March 31, 2021, the Company recognized non-cash royalty revenue of $1.0 million and related non-cash interest expense of $0.8 million. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the activity related to the net liability for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the royalty from the LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#8220;Acuitas&#8221;). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972724952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and commitments</a></td>
<td class="text">Contingencies and commitments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arbitration with the University of British Columbia </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (&#8220;UBC&#8221;), as well as by the Company that was subsequently assigned to UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to certain third parties, including Alnylam.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, UBC delivered to the Company a notice of arbitration alleging that under the cross license between UBC and Arbutus, it is due royalties of $2.0 million plus interest arising from the Company&#8217;s sale to OMERS of part of its royalty interest on future global net sales of ONPATTRO, currently being sold by Alnylam. Oral hearings for this matter were held on April 25-26, 2022. The Company does not believe that any royalties are due to UBC and the Company intends to vigorously contest UBC&#8217;s allegation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Agreement with Enantigen</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2014, Arbutus Inc., the Company&#8217;s wholly-owned subsidiary, acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221;) pursuant to a stock purchase agreement. The amount paid to Enantigen&#8217;s selling shareholders could be up to an additional $102.5 million in sales performance milestones in connection with the sale of the first commercialized product by the Company for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of $1.0 million that, if paid, would be offset against the Company&#8217;s milestone payment obligations.  Certain other development milestones related to the acquisition were tied to programs which are no longer under development by the Company, and therefore the contingency related to those development milestones is zero.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is a financial liability and is measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statements of operations and comprehensive loss (see note 3).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was $5.5 million as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972769448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, contracts and licensing agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations, contracts and licensing agreements</a></td>
<td class="text">Collaborations, contracts and licensing agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qilu Pharmaceutical Co., Ltd.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021, the Company entered into a technology transfer and licensing agreement (the &#8220;License Agreement&#8221;) with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;), pursuant to which the Company granted Qilu a sublicensable, royalty-bearing license, under certain intellectual property owned by the Company, which is non-exclusive as to development and manufacturing and exclusive with respect to commercialization of AB-729, including pharmaceutical products that include AB-729, for the treatment or prevention of hepatitis B in China, Hong Kong, Macau and Taiwan (the &#8220;Territory&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration for the rights granted by the Company, Qilu paid the Company a one-time upfront cash payment of $40.0 million on January 5, 2022, and agreed to pay the Company milestone payments totaling up to $245.0 million, net of withholding taxes, upon the achievement of certain technology transfer, development, regulatory and commercialization milestones. Qilu also paid $4.4 million of withholding taxes to the Chinese taxing authority on the Company&#8217;s behalf, related to the upfront cash payment.  In addition, Qilu agreed to pay the Company double digit royalties into the low twenties percent based upon annual net sales of AB-729 in the Territory. The royalties are payable on a product-by-product and region-by-region basis, subject to certain limitations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval for, and commercializing AB-729 for the treatment or prevention of hepatitis B in the Territory. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one AB-729 product candidate in the Territory. A joint development committee has been established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans. Both parties also have entered into a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of AB-729 necessary for Qilu to develop and commercialize in the Territory until the Company has completed manufacturing technology transfer to Qilu and approval of a product manufactured by Qilu, or its designated contract manufacturing organization, by the National Medical Products Administration in China for AB-729.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the execution of the License Agreement, the Company entered into a Share Purchase Agreement (the &#8220;Share Purchase Agreement&#8221;) with Anchor Life Limited, a company established pursuant to the applicable laws and regulations of Hong Kong and an affiliate of Qilu (the &#8220;Investor&#8221;), pursuant to which the Investor purchased 3,579,952 of the Company&#8217;s common shares, without par value (the &#8220;Common Shares&#8221;), at a purchase price of USD $4.19 per share, which was a 15%  premium on the thirty-day average closing price of the Common Shares as of the close of trading on December 10, 2021 (the &#8220;Share Transaction&#8221;). The Company received $15.0 million of gross proceeds from the Share Transaction on January 6, 2022. The Common Shares sold to the Investor in the Share Transaction represented approximately 2.5% of the Common Shares outstanding immediately prior to the execution of the Share Purchase Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Agreement falls under the scope of ASC 808 as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for some aspects of this arrangement, including for the delivery of a good or service (i.e., a unit of account). In accordance </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the guidance, the Company identified the following commitments under the arrangement: (i) rights to develop, use, sell, have sold, offer for sale and import any product comprised of Licensed Product (the &#8220;Qilu License&#8221;) and (ii) drug supply obligations and manufacturing technology transfer (the &#8220;Manufacturing Obligations&#8221;). The Company determined that these two commitments are not distinct performance obligations for purposes of recognizing revenue as the manufacturing process is highly specialized and Qilu would not be able to benefit from the Qilu License without the Company&#8217;s involvement in the manufacturing activities until the transfer of the manufacturing know-how is complete. As such, the Company will combine these commitments into one performance obligation to which the transaction price will be allocated to and will recognize this transaction price associated with the bundled performance obligation over time using an inputs method based on labor hours expended by the Company on its Manufacturing Obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price of the combined performance obligation to be $49.1 million, which includes the $40.0 million upfront fee, $4.4 million of withholding taxes paid by Qilu on behalf of the Company, the premium paid for the Share Transaction of $4.1 million, and $0.7 million associated with certain manufacturing costs expected to be reimbursed by Qilu. The Company determined the Milestone Payments to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The following table outlines the transaction price and the changes to the related asset and liability balances during the three months ended March&#160;31, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:30.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Collaboration Revenue Recognized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred License Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined performance obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less contract asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of deferred license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the balance of the deferred license revenue was $39.5 million, which, in accordance with ASC 210-20, was partially offset by the contract asset associated with the manufacturing cost reimbursement of $0.7&#160;million, resulting in a net deferred license revenue liability of $38.8 million. The $4.4 million of withholding taxes paid by Qilu on behalf of the Company was recorded as income tax expense during the three months ended March&#160;31, 2022. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $0.6 million of incremental costs in obtaining the Qilu License, which the Company capitalized in other current assets and other assets and will amortize as a component of general and administrative expense commensurate with the recognition of the combined performance obligation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reevaluates the transaction price and the total estimated labor hours expected to be incurred to satisfy the performance obligations and adjusts the deferred revenue at the end of each reporting period. Such changes will result in a change to the amount of collaboration revenue recognized and deferred revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccitech plc</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a clinical collaboration agreement with Vaccitech plc (&#8220;Vaccitech&#8221;) to evaluate AB-729 followed by Vaccitech&#8217;s VTP-300, a proprietary T cell stimulating therapeutic vaccine, in nucleos(t)ide reverse transcriptase inhibitor (&#8220;NrtI&#8221;)-suppressed patients with cHBV. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for managing this Phase 2a proof-of-concept clinical trial, subject to oversight by a joint development committee comprised of representatives from the Company and Vaccitech. The Company and Vaccitech retain full rights to their respective product candidates and will split all costs associated with the clinical trial.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assembly Biosciences, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a clinical collaboration agreement with Assembly Biosciences, Inc. (&#8220;Assembly&#8221;) to evaluate AB-729 in combination with Assembly&#8217;s lead HBV core inhibitor (capsid inhibitor) candidate vebicorvir (&#8220;VBR&#8221;) and standard-of-care NA therapy for the treatment of patients with HBV infection. The Company and Assembly are sharing in the costs of the collaboration. The Company incurred $0.6 million and $0.8 million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statement of operations and comprehensive loss. Except to the extent necessary to carry out Assembly&#8217;s responsibilities with respect to the collaboration trial, the Company has not provided any license grant to Assembly for use of its AB-729 compound.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">X-Chem, Inc. and Proteros biostructures GmbH</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company entered into a discovery research and license agreement with X-Chem, Inc. (&#8220;X-Chem&#8221;) and Proteros biostructures GmbH (&#8220;Proteros&#8221;) to focus on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This collaboration brings together the Company&#8217;s expertise in the discovery and development of antiviral agents with X-Chem&#8217;s industry leading DNA-encoded library (DEL) technology and Proteros&#8217; protein sciences, biophysics and structural biology capabilities and provides important synergies to potentially identify safe and effective therapies against coronaviruses including SARS-CoV-2. The collaboration allows for the rapid screening of one of the largest small molecule libraries against M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an essential protein required for the virus to replicate itself) and the use of state-of-the-art structure guided methods to rapidly optimize M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitors, which the Company could potentially progress to clinical candidates. The agreement provides for payments by the Company to X-Chem and Proteros upon satisfaction of certain development, regulatory and commercial milestones, as well as royalties on sales. Through this collaboration, the Company has identified and obtained a worldwide exclusive license to several molecules that inhibit M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks.  The Company incurred $0.3 million and $0.9 million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Entitlements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two royalty entitlements to Alnylam Pharmaceuticals, Inc.&#8217;s (&#8220;Alnylam&#8221;) global net sales of ONPATTRO.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company&#8217;s LNP technology. Alnylam launched ONPATTRO, the first approved application of the Company&#8217;s LNP technology, in 2018. Under the terms of this license agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of this royalty entitlement on future global net sales of ONPATTRO will revert back to the Company. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to the Company, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part. From the inception of the royalty sale through March&#160;31, 2022, an aggregate of $12.5 million of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">royalties have been earned by OMERS. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has rights to a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#8220;Acuitas&#8221;).&#160; This royalty entitlement from Acuitas has been retained by the Company and was not part of the royalty entitlement sale to OMERS. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborations and licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acuitas Therapeutics, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qilu Pharmaceutical Co., Ltd.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other milestone and royalty payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnylam Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972750456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; equity</a></td>
<td class="text">Shareholders&#8217; equity<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s authorized share capital consists of an unlimited number of common shares and preferred shares, without par value, and 1,164,000  Series A participating convertible preferred shares, without par value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Open Market Sale Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Open Market Sale Agreement with Jefferies LLC (&#8220;Jefferies&#8221;) dated December 20, 2018, as amended by Amendment No. 1, dated December 20, 2019, Amendment No. 2, dated August 7, 2020 and Amendment No. 3, dated March 4, 2021 (as amended, the &#8220;Sale Agreement&#8221;), under which it may issue and sell common shares, from time to time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2019, the Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the &#8220;SEC&#8221;) (File No. 333-235674) and accompanying base prospectus, which was declared effective by the SEC on January 10, 2020 (the &#8220;January 2020 Registration Statement&#8221;), for the offer and sale of up to $150.0&#160;million of the Company&#8217;s securities. The January 2020 Registration Statement also contained a prospectus supplement in connection with the offering of up to $75.0&#160;million of the Company&#8217;s common shares pursuant to the Sale Agreement. This prospectus supplement was fully utilized during 2020. On August 7, 2020, the Company filed a prospectus supplement with the SEC (the &#8220;August 2020 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $75.0&#160;million of its common shares pursuant to the Sale Agreement under the January 2020 Registration Statement. The August 2020 Prospectus Supplement was fully utilized during 2020.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-248467) and accompanying base prospectus, which was declared effective by the SEC on October 22, 2020 (the &#8220;October 2020 Registration Statement&#8221;), for the offer and sale of up to $200.0&#160;million of the Company&#8217;s securities. On March 4, 2021, the Company filed a prospectus supplement with the SEC (the &#8220;March 2021 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $75.0 million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. The March 2021 Prospectus Supplement was fully utilized during 2021. On October 8, 2021, the Company filed a prospectus supplement with the SEC (the &#8220;October 2021 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $75.0&#160;million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2022, the Company filed a prospectus supplement with the SEC (the &#8220;March 2022 Prospectus Supplement&#8221;) in connection with the offering of up to an additional $100.0&#160;million of its common shares pursuant to the Sale Agreement under: (i) the January 2020 Registration Statement; (ii) the October 2020 Registration Statement; and (iii) a shelf registration statement on Form S-3 (File No. 333-260782) that was declared effective by the SEC on November 18, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 , the Company issued 69,048 common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $0.3 million. For the three months ended March 31, 2021, the Company issued 6,395,780 common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $26.4 million. As of March&#160;31, 2022, there was approximately $152.0 million remaining available in aggregate under the October 2021 Prospectus Supplement and the March 2022 Prospectus Supplement.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes information about the Company&#8217;s stock based compensation for the three months ended March&#160;31, 2022 and 2021 and the expense recognized in the condensed consolidated statements of operations: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series A Preferred Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into a subscription agreement with Roivant for the sale of Preferred Shares to Roivant for gross proceeds of $116.4&#160;million.  The Preferred Shares were non-voting and were convertible into common shares at a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share). The purchase price for the Preferred Shares plus an amount equal to 8.75% per annum, compounded annually, was subject to mandatory conversion into common shares on October 18, 2021, at which time the Preferred Shares were converted into 22,833,922 common shares and both the lockup and standstill periods that Roivant had previously agreed to expired. As of March&#160;31, 2022, Roivant owned approximately 26% of the Company&#8217;s outstanding common shares. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the Preferred Shares wholly as equity with no bifurcation of the conversion feature from the host contract, given that the Preferred Shares could not be cash settled and the redemption features were within the Company&#8217;s control, which included a fixed conversion ratio with predetermined timing and proceeds. The Company accrued for the 8.75% per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see statement of stockholders&#8217; equity).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972773768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related party transactions</a></td>
<td class="text">Related party transactionsDuring the three months ended March&#160;31, 2022 and 2021, Genevant purchased certain administrative services from the Company. Income from these services was less than $0.1 million in both periods and is netted against research and development expenses in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971912488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation and principles of consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021 included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and its one wholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company&#8217;s financial position as of March&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s results of operations for the three months ended March 31, 2022 and 2021, and the Company&#8217;s cash flows for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2021, except as described below under Recent Accounting Pronouncements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text">All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss attributable to common shareholders per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net loss attributable to common shareholders per share</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three months ended March 31, 2022 and 2021, since the effect of including potential common shares would be anti-dilutive. For the three months ended March 31, 2022, potential common shares of 15.7 million pertaining to outstanding stock options were excluded from the calculation of net loss attributable to common shareholders per share. A total of approximately 35.0 million outstanding stock options and if-converted Series A participating convertible preferred shares (&#8220;Preferred Shares&#8221;) were excluded from the calculation for the three months ended March 31, 2021. </span></div>On October 18, 2021, the Company&#8217;s outstanding Preferred Shares were converted into 22,833,922 common shares. Prior to that date, the Company followed the two-class method when computing net loss attributable to common shareholders per share as the Preferred Shares met the definition of participating securities. The Preferred Shares entitled the holders to participate in dividends but did not require the holders to participate in losses of the Company. Accordingly, net losses attributable to holders of the Company&#8217;s common shares were not allocated to holders of the Preferred Shares.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from collaborations and licenses and Deferred Revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from collaborations and licenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments and royalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements fall under the scope of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 808&#8221;) when both parties are active participants in the arrangement and are exposed to significant risks and rewards. For certain arrangements under the scope of ASC 808, the Company analogizes to ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 606&#8221;) for some aspects, including for the delivery of a good or service (i.e., a unit of account).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company&#8217;s best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#8217;s subsequent sales or usages occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When consideration is received or is unconditionally due from a customer, collaborator or licensee prior to the Company completing its performance obligation to the customer, collaborator or licensee under the terms of a contract, deferred revenue is recorded. Deferred revenue expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a current liability. Deferred revenue not expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a long-term liability. In accordance with ASC Topic 210-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet - Offsetting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s deferred revenue is offset by a contract asset as further discussed in Note 9.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text">Segment informationThe Company operates as a single segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reviewed all recently issued standards and has determined that such standards will not have a material impact on the Company&#8217;s financial statements or do not otherwise apply to the Company&#8217;s operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial instruments and other items at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs are quoted market prices for identical instruments available in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</span></div>To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972726232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measures and Disclosures (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial instruments and other items at fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 inputs are quoted market prices for identical instruments available in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#8217;s assumptions about market assumptions that would be used to price the asset or liability.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.</span></div>To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812978063256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,282&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability-classified stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ChangesInFairValueofLiabilityOptionTableTextBlock', window );">Changes in fair value of liability option</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s liability-classified stock options:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value of liability-classified options exercised in the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in fair value of contingent consideration</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in fair value of the Company&#8217;s contingent consideration: </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:37.609%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at beginning of the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase in fair value of liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability at end of the period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ChangesInFairValueofLiabilityOptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value of Liability Option [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ChangesInFairValueofLiabilityOptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972894856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of March 31, 2022</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.073%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.575%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable short-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in marketable long-term securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US government agency bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US treasury bills</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812976749448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities are comprised of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fee accruals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,715&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972870552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of future royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock', window );">Schedule of activity related to the net liability from inception of the Agreement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the activity related to the net liability for the three months ended March 31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash royalty revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net liability related to sale of future royalties - ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To Sale Of Future Royalties Roll Forward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972883464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, contracts and licensing agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of deferred collaborations and contracts revenue</a></td>
<td class="text">The following table outlines the transaction price and the changes to the related asset and liability balances during the three months ended March&#160;31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:30.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.067%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.674%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.676%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Transaction Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Collaboration Revenue Recognized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deferred License Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined performance obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less contract asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of deferred license revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current deferred license revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of collaborations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborations and licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acuitas Therapeutics, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qilu Pharmaceutical Co., Ltd.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other milestone and royalty payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash royalty revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alnylam Pharmaceuticals, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812972896520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock based compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes information about the Company&#8217;s stock based compensation for the three months ended March&#160;31, 2022 and 2021 and the expense recognized in the condensed consolidated statements of operations: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except share and per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock compensation expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968729384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of business and future operations (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments in marketable securities</a></td>
<td class="nump">$ 221,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971419624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>subsidiary </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 18, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements', window );">Number of wholly-owed subsidiaries | subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common shares excluded from calculation of loss per common share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,833,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements', window );">Number of wholly-owed subsidiaries | subsidiary</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common shares excluded from calculation of loss per common share (in shares)</a></td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971409464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 5,499<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase (decrease) in fair value of contingent consideration</a></td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812974129576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">$ 56,318<span></span>
</td>
<td class="nump">$ 35,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">81,330<span></span>
</td>
<td class="nump">109,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">84,147<span></span>
</td>
<td class="nump">46,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">56,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">221,795<span></span>
</td>
<td class="nump">191,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,504<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">81,330<span></span>
</td>
<td class="nump">109,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">81,330<span></span>
</td>
<td class="nump">109,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">84,147<span></span>
</td>
<td class="nump">46,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">56,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">140,465<span></span>
</td>
<td class="nump">81,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability-classified options</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 5,504<span></span>
</td>
<td class="nump">$ 5,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971279768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details) - Liability classified stock options - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue', window );">Fair value of liability-classified options exercised in the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions', window );">Decrease in fair value of liability</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure', window );">Liability at end of the period</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value of Liability Classified Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abus_EmployeeStockOptionLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abus_EmployeeStockOptionLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812976981000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Changes in Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at beginning of the period</a></td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Increase in fair value of liability</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Liability at end of the period</a></td>
<td class="nump">$ 5,499<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968217256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in marketable securities - Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 81,330<span></span>
</td>
<td class="nump">$ 109,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">84,100<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">84,698<span></span>
</td>
<td class="nump">46,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(551)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">84,147<span></span>
</td>
<td class="nump">46,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=abus_LongTermInvestmentsMember', window );">Long-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">56,988<span></span>
</td>
<td class="nump">35,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(670)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">56,318<span></span>
</td>
<td class="nump">35,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US treasury bills | Short-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">8,940<span></span>
</td>
<td class="nump">37,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">8,919<span></span>
</td>
<td class="nump">37,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentAgencyBondsMember', window );">US government agency bonds | Short-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">15,158<span></span>
</td>
<td class="nump">8,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">15,021<span></span>
</td>
<td class="nump">8,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentAgencyBondsMember', window );">US government agency bonds | Long-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="nump">13,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">12,098<span></span>
</td>
<td class="nump">13,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentBondsMember', window );">US government bonds | Short-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">60,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentBondsMember', window );">US government bonds | Long-term securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">44,677<span></span>
</td>
<td class="nump">22,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments in marketable securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments in marketable securities, Gross Unrealized Loss</a></td>
<td class="num">(457)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">44,220<span></span>
</td>
<td class="nump">22,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">37,219<span></span>
</td>
<td class="nump">62,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">37,219<span></span>
</td>
<td class="nump">62,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents | US government money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">37,219<span></span>
</td>
<td class="nump">62,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Fair Value</a></td>
<td class="nump">$ 37,219<span></span>
</td>
<td class="nump">$ 62,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=abus_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=abus_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentAgencyBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=abus_USGovernmentAgencyBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=abus_USGovernmentBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=abus_USGovernmentMoneyMarkeTFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=abus_USGovernmentMoneyMarkeTFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812976952088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in marketable securities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in marketable securities, current</a></td>
<td class="nump">$ 84.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Investments in marketable securities, non-current</a></td>
<td class="nump">56.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gains or losses</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971452664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Genevant (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember', window );">Genevant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_SubLicensingRevenuePercentage', window );">Sub-licensing revenue percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in equity method investment (as a percentage)</a></td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_BonaFideCollaborationPercentage', window );">Bona fide collaboration Percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_BonaFideCollaborationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bona fide collaboration Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_BonaFideCollaborationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_SubLicensingRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sub-licensing revenue Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_SubLicensingRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abus_GenevantSciencesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812974068280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 3,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedResearchAndDevelopment', window );">Research and development accruals</a></td>
<td class="nump">5,462<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fee accruals</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_AccruedPayrollCurrent', window );">Payroll accruals</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">4,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 8,715<span></span>
</td>
<td class="nump">$ 10,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedPayrollCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Payroll Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedPayrollCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968618104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of future royalties - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="nump">$ 959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier', window );">Annual royalty revenue</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GrossProceedsFromRoyaltyInterestSold', window );">Gross proceeds from sale of royalty interest. before advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer', window );">Entitlement of royalties to be received</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty guarantees commitments percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPayable', window );">Future royalty payments</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_TransactionCostsRelatedToSaleOfFutureRoyalties', window );">Transaction costs on sale of royalties</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_EffectiveAnnualInterestRateOfRoyaltyLiability', window );">Effective annual interest rate on royalty liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty, interest sold, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_OtherLiabilitiesDisclosureLineItems', window );"><strong>Other Liabilities Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty, interest sold, percentage</a></td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_EffectiveAnnualInterestRateOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Annual Interest Rate Of Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_EffectiveAnnualInterestRateOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GrossProceedsFromRoyaltyInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Royalty Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GrossProceedsFromRoyaltyInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Non Cash Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Revenue Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_OtherLiabilitiesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Liabilities Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_OtherLiabilitiesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyGuaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty guarantees commitments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyGuaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Maximum Royalties For Buyer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPercentageofInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty, Percentage of Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPercentageofInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_TransactionCostsRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_TransactionCostsRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_OMERSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_OMERSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812977343064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of future royalties - Liability Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward', window );"><strong>Liability Related To Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Net liability related to sale of future royalties - beginning balance</a></td>
<td class="nump">$ 16,296<span></span>
</td>
<td class="nump">$ 19,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome', window );">Non-cash royalty revenue</a></td>
<td class="num">(1,363)<span></span>
</td>
<td class="num">(959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">506<span></span>
</td>
<td class="nump">771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Net liability related to sale of future royalties - ending balance</a></td>
<td class="nump">$ 15,439<span></span>
</td>
<td class="nump">$ 19,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Non Cash Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Royalties, Non Cash Royalty Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability Related To Sale Of Future Royalties [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812971294808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,499<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">$ 3,555<span></span>
</td>
<td class="nump">$ 3,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,499<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=abus_EnantigensSellingShareholdersMember', window );">Enantigen's Selling Shareholders | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_EnantigensSellingShareholdersMember', window );">Enantigen's Selling Shareholders | Arbutus Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense', window );">Development and regulatory milestones payment per licensed compound series, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty', window );">Development and regulatory milestones payment per royalty, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember', window );">Arbitration with the University of British Columbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_ContingenciesandCommitmentsLineItems', window );"><strong>Contingencies and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought for allegedly unpaid royalties</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_ContingenciesandCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_ContingenciesandCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Maximum Development and Regulatory Milestone Payments Per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Maximum Development And Regulatory Royalty Payment per Royalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abus_EnantigensSellingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abus_EnantigensSellingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_EnantigensSellingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_EnantigensSellingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abus_ArbutusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abus_ArbutusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=abus_ArbitrationWithTheUniversityOfBritishColumbiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812965823512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations, contracts and licensing agreements (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>product </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyEntitlements', window );">Number of royalty entitlements | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,581<span></span>
</td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,728,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,728,237<span></span>
</td>
<td class="nump">144,987,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,255<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,585<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non Cash Royalty Revenue Related To Sale Of Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums Earned, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=abus_QiluPharmaceuticalCoLTDMember', window );">Qilu Pharmaceutical Co, LTD. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred Revenue, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Shares | Qilu Pharmaceutical Co, LTD. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_AssemblyBiosciencesIncMember', window );">Assembly Biosciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Costs related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier', window );">Annual royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_GrossProceedsFromRoyaltyInterestSold', window );">Gross proceeds from sale of royalty interest. before advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer', window );">Entitlement of royalties to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyGuaranteesCommitmentsPercentage', window );">Royalty guarantees commitments percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPayable', window );">Future royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties', window );">Non Cash Royalty Revenue Related To Sale Of Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty, interest sold, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OMERSMember', window );">OMERS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_RoyaltyPercentageofInterestSold', window );">Royalty, interest sold, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_AcuitasTherapeuticsInc.Member', window );">Acuitas Therapeutics, Inc. | Revenue from collaborations and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_OtherMilestoneandRoyaltyPaymentsMember', window );">Other milestone and royalty payments | Revenue from collaborations and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_AlnylamPharmaceuticalsIncMember', window );">Alnylam Pharmaceuticals, Inc. | Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember', window );">Qilu Pharmaceutical Co, LTD. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PotentialMilestonePayments', window );">Potential Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Recovery of Direct Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total deferred license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Cumulative Collaboration Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsGross', window );">Other Deferred Costs, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, Remaining Performance Obligation, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember', window );">Qilu Pharmaceutical Co, LTD. [Member] | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,579,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares pursuant to the Open Market Sale agreement</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PremiumonClosingStockPrice', window );">Premium on closing stock price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember', window );">Qilu Pharmaceutical Co, LTD. [Member] | One-Time Upfront Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember', window );">Qilu Pharmaceutical Co, LTD. [Member] | Revenue from collaborations and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_XChemIncAndProterosMember', window );">X-Chem, Inc. and Proteros [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Costs related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_GrossProceedsFromRoyaltyInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds From Royalty Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_GrossProceedsFromRoyaltyInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Royalty Revenue Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the potential milestone payments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PremiumonClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PremiumonClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyEntitlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Entitlements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyEntitlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyGuaranteesCommitmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty guarantees commitments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyGuaranteesCommitmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Maximum Royalties For Buyer</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RoyaltyPercentageofInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty, Percentage of Interest Sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RoyaltyPercentageofInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=abus_QiluPharmaceuticalCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=abus_QiluPharmaceuticalCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abus_QiluPharmaceuticalCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abus_QiluPharmaceuticalCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abus_NonCashRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_AssemblyBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_AssemblyBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_OMERSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_OMERSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_AcuitasTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_AcuitasTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_OtherMilestoneandRoyaltyPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_OtherMilestoneandRoyaltyPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_AlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_AlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_QiluPharmaceuticalCoLTDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abus_OneTimeUpfrontCashPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abus_OneTimeUpfrontCashPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_XChemIncAndProterosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_XChemIncAndProterosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812966203192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 03, 2022</div></th>
<th class="th"><div>Oct. 18, 2021</div></th>
<th class="th"><div>Oct. 08, 2021</div></th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th"><div>Oct. 22, 2020</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares issued upon conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,833,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Shares | Jan 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Shares | Oct 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued under agreement (in sales)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,048<span></span>
</td>
<td class="nump">6,395,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | Mar 2021 Prospectus Supplement Agreement [Member] | Oct 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | October 2021 Prospectus Supplement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | October 2021 Prospectus Supplement | Oct 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | March 2022 Prospectus Supplement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | March 2022 Prospectus Supplement [Member] | Jan 2020 Oct 2020 and Nov 2021 Registration Stmts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | Jan 2020 Prospectus Supplement | Jan 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember', window );">Jefferies LLC | Common Shares | Aug 2020 Prospectus Supplement | Jan 2020 Registration Stmt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Aggregate sale price of common shares under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember', window );">Roivant Sciences Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion', window );">Ownership percentage by noncontrolling owners after conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember', window );">Roivant Sciences Ltd | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares pursuant to the agreement</a></td>
<td class="nump">$ 116,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stated value (in USD per share)</a></td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abus_PremiumonClosingStockPrice', window );">Premium on closing stock price (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate as a percent</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_PremiumonClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on Closing Stock Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_PremiumonClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_Jan2020RegistrationStmtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_Jan2020RegistrationStmtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_Oct2020RegistrationStmtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_Oct2020RegistrationStmtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_SaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_SaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_Mar2021ProspectusSupplementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_Mar2021ProspectusSupplementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RegistrationStatementAxis=abus_Oct2020RegistrationStmtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RegistrationStatementAxis=abus_Oct2020RegistrationStmtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_October2021ProspectusSupplementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_October2021ProspectusSupplementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_March2022ProspectusSupplementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_March2022ProspectusSupplementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RegistrationStatementAxis=abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RegistrationStatementAxis=abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_Jan2020ProspectusSupplementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_Jan2020ProspectusSupplementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abus_RegistrationStatementAxis=abus_Jan2020RegistrationStmtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abus_RegistrationStatementAxis=abus_Jan2020RegistrationStmtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=abus_Aug2020ProspectusSupplementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=abus_Aug2020ProspectusSupplementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_RoivantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812968149336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; equity - Stock-based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 4.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="nump">$ 1,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember', window );">Arbutus Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted during period (in shares)</a></td>
<td class="nump">4,372,295<span></span>
</td>
<td class="nump">2,896,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abus_ArbutusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abus_ArbutusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139812974235112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party transactions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember', window );">Genevant | Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Income from services (less than)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abus_GenevantSciencesCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abus_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abus_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>abus-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abus="http://arbutusbio.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abus-20220331.xsd" xlink:type="simple"/>
    <context id="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ff9c3983f4b4ac4a65444acd7a38ba7_I20220503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2022-05-03</instant>
        </period>
    </context>
    <context id="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fb159623bc541d1b5ec342caea83932_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:CollaborationAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d20c312d38544f9bd612a684dcc1831_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:CollaborationAndContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01b82303f97d4df4a95fd381074c09f0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i17287f28a3a3401ab7bf4647bec4c75b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic52d6065eb09463296c5f6564f7e3bc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86367f2c4ca14273aa29c338129293e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8346a78b814432d98fb8f1fc40a22c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i106be97586e5476f95a81fc1db43de35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i052e4eb49038437097e6489137f6506c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic0bcfb45fbd545a3a593fb87947be374_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief63021f67754f038c0196c4f7a220c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5236eb0aea334ba6a6ac833d4c6c22df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0df84842ad046e9b85fd86ec798224a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i55a62aee5f464630a521ca887a7075e7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i970a3c27243f432f8c84f282ad9db987_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71d7fd13bcc74c299377045d32e83e2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2601c2c8d0a44ae9b8cb8405c6b4ef8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cc1996fb96b4d5daac0e417a6c7f2d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccf2d5f4bb024a6398e8ca10beda360a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie0453799dbcc4307847b039a4848dedd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i20fbb288c20f47a99438e41bbee9a692_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i99bbb8943c6e4d28a7642f2253e96007_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i338c23e7885d44f2925e13fde9eebadf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id5b29770c1294814900bbc415d9f0848_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iaf2f2d16cd4d4be188f3dda7b49732a6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i82d76d58cf924d8383205f275ac7662f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SharePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie6e91e406b5a42c18158f3225f58684b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idd98aaf228d443bfa99d0a12b844de6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ca92d833848428fbad2a29503fd9fbd_I20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
        </entity>
        <period>
            <instant>2021-10-18</instant>
        </period>
    </context>
    <context id="id70dcc32cab84091a414d114000ea384_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7820392be70c42cea55c46eb141bfcbd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib9a049cff7d741e796edd187de00eb6f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i711a0a90695f46ef8552c9299d3498e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifb2c2988cb54498a88205e9749e91abe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7440144805e64bbd9476e8bc698f3da0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fbfd866f2424809b3d908c81b3d684b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7455aad25d9f402397dfad6f05220540_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba87cbb7f15b4facadb3e5b5747a6fdf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd22b5593e2744f68646be67d090d0c4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i624eddd7b8ae4655ac59e95730e93120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idbad88517d4f4037b2bad380a2b21006_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i100b46b4a64d427faa1e681084d9bd07_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia387d060fc5249a1876b226e2cfa8c1a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abus:EmployeeStockOptionLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6afb52fbbc104a09b75948cb08a8bf93_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentMoneyMarkeTFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1f71f74bd334db090c35763085f2594_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iefbcc1b73bcd42d98797c743e412a754_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie39a0f5344c6417eb981eb066ec304be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i10a026a23b8a4596bd788df2c75ed5df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i27f5f771802c4176a602d03f3977a1e1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibbb2c36817bb45738c25a5631ff9a54f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentMoneyMarkeTFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cdab202f75a4297866c250a068cd12d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ide871516fa03491795c8b51d22d71071_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa844129bf484cc98902853bb3e8413b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i161fa77486694f6aa841fc6ee122232b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentAgencyBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icacc617e1d9442d58a84e6cfc75788aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">abus:USGovernmentBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">abus:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c58bd3a223344a9a04669315e016fe3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i849f8840cc1f40369b37a736474e7316_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie4dc98c87a0247e6a3f4347246739782_D20190702-20190702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="i9e0286773ab94cf7a483c6b8bc8e1785_D20190702-20190702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="i428973c6db9541269463d60bbdc135c7_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-02</instant>
        </period>
    </context>
    <context id="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-02</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i167905b8454f403bbc363d3a741afda6_D20201218-20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">abus:ArbitrationWithTheUniversityOfBritishColumbiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-18</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="i22f8361c99954dfa827a9008f0da81b3_I20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abus:ArbutusInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-31</instant>
        </period>
    </context>
    <context id="i1ce501d18c8a4c21ab64d7e145ce4bb0_I20141031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-10-31</instant>
        </period>
    </context>
    <context id="i9b3a998dc61042eda3caff10aef9779e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abus:EnantigensSellingShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abus:OneTimeUpfrontCashPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-05</startDate>
            <endDate>2022-01-05</endDate>
        </period>
    </context>
    <context id="ia483bef565574680a3a9c1bd2564b825_I20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7161a12d542a4969901ecf181c8d5cf4_I20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i6b9336fe97b44836842a01da01d42937_D20220106-20220106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-06</startDate>
            <endDate>2022-01-06</endDate>
        </period>
    </context>
    <context id="if9829026bc73479093b8029eac0806e0_I20211213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1163dbec3a7848eca95205175b1da9b0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0f3d36adae54e1d9276dd03b947cf45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i702949ca2cfd4a0a9bb7f02fd91035b8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AssemblyBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib01ce59d6936428c930e28b71f7c5359_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AssemblyBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0f12239ea971423693eb1924756cc84c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:XChemIncAndProterosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic9be38c6e9064432bd40073b87596f3c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:XChemIncAndProterosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iecc67e9256ab4b9dbea33b02a1658a89_D20130101-20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="i0cae881ec75e4bc18cff9b5347823e59_D20130101-20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="ie759772fc0d34889b5b1773813066150_D20130101-20130630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-06-30</endDate>
        </period>
    </context>
    <context id="i46281ecd5fb744a99a4fb28bba9e853c_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OMERSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i518670b3fac0479e89bccbd3cf48a756_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AcuitasTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea3e5de0afd64224841a930f2a7a0b40_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AcuitasTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1ad95e89d07d4219962809e6980f2c99_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecc54f0d5f1e425684acf6e743b66eaf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:QiluPharmaceuticalCoLTDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5a7bfc3b496414582720db787c9cf6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OtherMilestoneandRoyaltyPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i232b5a40e86b4942a256e843e353e388_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:OtherMilestoneandRoyaltyPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6007cbaa2fc842dbb22efaa19e85a21c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13c626debfbf4e20bbb17e393ea68c3d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abus:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i95f34ecb804c43bd860c37e292eda8dc_I20200110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-10</instant>
        </period>
    </context>
    <context id="i48fd91415d144f359a29ef040e182e92_I20200110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Jan2020ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-10</instant>
        </period>
    </context>
    <context id="i721c0159d357459e82fda7a1d2aaa5a2_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020RegistrationStmtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Aug2020ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="ida4e708fcedd480aa26d4c73a4f87927_I20201022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-22</instant>
        </period>
    </context>
    <context id="ieb32b3f5a01140a19a6306f86a2a8fd5_I20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:Mar2021ProspectusSupplementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-04</instant>
        </period>
    </context>
    <context id="iab6748705d0d4226ba4a82a1e22ee083_I20211008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Oct2020RegistrationStmtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:October2021ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-08</instant>
        </period>
    </context>
    <context id="ia52a417f6ada4560b9f6eb2b6fd7a96a_I20220303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="abus:RegistrationStatementAxis">abus:Jan2020Oct2020AndNov2021RegistrationStmtsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:March2022ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-03</instant>
        </period>
    </context>
    <context id="i2bf4d6c3fa5a4105a94421a222392925_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i670e4df1980948ec8c216e9200afc61f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5f2e4c170332429cb6b01ee5963528a9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i045ad8ba8ec9498a8558014661ce50fe_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:SaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6dd670c983a7433cb7bd93372158078d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:October2021ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida00744ff3624de0be467e4cae72015e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">abus:March2022ProspectusSupplementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2a5dd2c6ac51433dbaefbe4e3fc47c85_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i55d02dff95ec415dab33999ff0c85e85_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abus:ArbutusPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98fa33af9af34a29a59381fcf1cbe51d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a64dd48949e4cba85f1ccfe32f2819e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3988f17b1bc94d529eadea44681fdf65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e6d8e3249e848a0b9453c69b8b92b5d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-10-02</endDate>
        </period>
    </context>
    <context id="ib605935fd5db48b7a59105e11ada7c5f_I20171002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-02</instant>
        </period>
    </context>
    <context id="iac91ec4cb9804633b6568f3d3cafd8e5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0515a8eeb4984632a6fdb800c50fd8bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:RoivantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001447028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abus:GenevantSciencesCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abus:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>abus:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>abus:product</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8xLTEtMS0xLTI5MzIx_37ccede8-9dd6-467e-b0b4-b6536525ddb1">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8yLTEtMS0xLTI5MzIx_d01814df-4730-4123-9f2d-b88a2791c5fa">0001447028</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF8zLTEtMS0xLTI5MzIx_6eefa3d5-8af9-4945-b31f-a25dddabdb17">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF80LTEtMS0xLTI5MzIx_d14d8799-d160-4fff-9978-7a8704f21088">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80L2ZyYWc6MzNmYTkzZmJmYjIwNDU0M2I2MjRiMjU4ZGMxN2M3YzUvdGFibGU6ZmYxYmFhOGI4OTMwNDI2NTk3MGQwYmRlZTUwYWJhYzQvdGFibGVyYW5nZTpmZjFiYWE4Yjg5MzA0MjY1OTcwZDBiZGVlNTBhYmFjNF81LTEtMS0xLTI5MzIx_16566202-c1a0-4899-853c-454b30ee5559">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMx_11a65fae-c19c-4d2b-a0a8-5d8f521ff69b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQw_7b7bdcc5-fad6-454c-89ee-973acff9edda">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMTU_86dfdbfb-5205-40c3-9796-d21e2e610f76">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQx_db26ed36-a715-4ec1-bcfd-034bd1e2d1b5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM3_d82e931c-aff4-4971-99cd-281e449c40cd">001-34949</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMz_c8b21286-e29f-4779-987e-a62765e1833c">ARBUTUS BIOPHARMA CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6YTA2NDM0YmMxMTc2NDk3OWIzZDc4NDgzZjQzYTZlMmQvdGFibGVyYW5nZTphMDY0MzRiYzExNzY0OTc5YjNkNzg0ODNmNDNhNmUyZF8wLTAtMS0xLTI5MzIx_754e631a-b840-46f6-bc3f-c0e3305cada4">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6YTA2NDM0YmMxMTc2NDk3OWIzZDc4NDgzZjQzYTZlMmQvdGFibGVyYW5nZTphMDY0MzRiYzExNzY0OTc5YjNkNzg0ODNmNDNhNmUyZF8wLTItMS0xLTI5MzIx_9a3d3199-b492-40fe-bb2c-b551c2562f99">98-0597776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjMw_c928ac3f-c26a-4933-bb20-455e502a61e7">701 Veterans Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQy_1cac55e8-cbac-46f7-bb33-5a0408cf08bd">Warminster</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM4_1f6ef05c-eb3e-47cd-a57e-856b8d4a9ab9">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF81MjY_5eecea02-0454-4f93-901f-ca34dcaee7ed">18974</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF81ODM_40bffda3-a00b-487c-9f4b-00a3cfdaef69">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjQz_7d31f249-93c0-493e-827a-528f16d43bb1">469-0914</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTAtMS0xLTI5MzIx_6f4bd984-44f9-4701-baf7-03a8558c3fa8">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTEtMS0xLTI5MzIx_d3107d1e-480d-4209-be6d-ec4a05f837a1">ABUS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6ZmRlMWI4YzhiOTI3NDA1YmJjOTM2NWM1ZWQ0NTJjNjMvdGFibGVyYW5nZTpmZGUxYjhjOGI5Mjc0MDViYmM5MzY1YzVlZDQ1MmM2M18xLTItMS0xLTI5MzIx_88258794-886c-48b8-8b8a-881bae9a442b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM5_8c9f817b-c065-4d49-97dd-27705e890766">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM0_122a3ea0-c6b6-43ad-8e1f-3ddbd9b44f55">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8wLTItMS0xLTI5MzIx_ce3dc62d-00e3-4bf3-baf0-9f033ed8a8d7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8xLTMtMS0xLTI5MzIx_50ed6159-afd4-4fac-aca6-a818f7b9ff34">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGFibGU6NDhlMGM0ZjI2MWNjNDBkY2E1YWFhOWViY2MzMDEwOWIvdGFibGVyYW5nZTo0OGUwYzRmMjYxY2M0MGRjYTVhYWE5ZWJjYzMwMTA5Yl8xLTQtMS0xLTI5MzIx_540e5753-1d28-4888-8584-adb96c64e545">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMjM1_7b85875a-454d-48e9-9a7d-4cdc0e79aa90">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0ff9c3983f4b4ac4a65444acd7a38ba7_I20220503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xL2ZyYWc6NjcxMmY1MjZmNzQ3NGU2YWI2MDc1OGM5M2QyMWY1YzgvdGV4dHJlZ2lvbjo2NzEyZjUyNmY3NDc0ZTZhYjYwNzU4YzkzZDIxZjVjOF8yMTgw_53803f9b-a5e3-4215-a30a-e98bd5260ad6"
      unitRef="shares">148728237</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMy0xLTEtMS0yOTMyMQ_3d8cb485-c766-4c81-b8a6-70cdcf1f2f56"
      unitRef="usd">81330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMy0zLTEtMS0yOTMyMQ_0aa4933e-9ee8-42f5-b210-30ac9378d019"
      unitRef="usd">109282000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNC0xLTEtMS0yOTMyMQ_1d29e26b-a665-4c5f-9db3-10714b52b8ab"
      unitRef="usd">84147000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNC0zLTEtMS0yOTMyMQ_e0925597-fb67-42dc-8536-c5669d4cca22"
      unitRef="usd">46035000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNS0xLTEtMS0yOTMyMQ_c7e41ed7-a802-4932-9b00-f0a84ee5af90"
      unitRef="usd">1313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNS0zLTEtMS0yOTMyMQ_073b009b-6269-4534-80f2-9899d866d047"
      unitRef="usd">899000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNi0xLTEtMS0yOTMyMQ_7e52e537-0a44-45ee-afdc-309caf0b475f"
      unitRef="usd">5908000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNi0zLTEtMS0yOTMyMQ_6d816009-964d-40c9-b1a0-5b23be21cdc1"
      unitRef="usd">4445000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNy0xLTEtMS0yOTMyMQ_138bb0ae-0166-46af-afc1-b02258d8482d"
      unitRef="usd">172698000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfNy0zLTEtMS0yOTMyMQ_b8a3a485-16b9-4644-90f5-8fcfbab13d62"
      unitRef="usd">160661000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0wLTEtMS0yOTMyMS90ZXh0cmVnaW9uOmNjNGRkOTFlNTJjNTRmN2M5Zjc1ODhhYTIyNmZhYzc5XzYz_4f5e0368-016a-43e0-84c8-e15b9ef2f089"
      unitRef="usd">9768000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0wLTEtMS0yOTMyMS90ZXh0cmVnaW9uOmNjNGRkOTFlNTJjNTRmN2M5Zjc1ODhhYTIyNmZhYzc5Xzg3_f719effd-2cfd-480c-9f6a-1f527f446d5a"
      unitRef="usd">9374000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0xLTEtMS0yOTMyMQ_fc1f59d7-867f-4a6a-931c-28f7b7b77f2a"
      unitRef="usd">5664000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOC0zLTEtMS0yOTMyMQ_314d6f24-fff9-4d1a-a10f-0553e9be4f74"
      unitRef="usd">5983000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongTermInvestments
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOS0xLTEtMS0yOTMyMQ_9af4ade0-8f80-4aa2-8dc6-24f480f44f9f"
      unitRef="usd">56318000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfOS0zLTEtMS0yOTMyMQ_3262a6c4-7753-4a00-a546-dc686905892c"
      unitRef="usd">35688000</us-gaap:LongTermInvestments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTAtMS0xLTEtMjkzMjE_49483a58-3f88-461e-bcde-bb152c8d3e4b"
      unitRef="usd">2007000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTAtMy0xLTEtMjkzMjE_d04e7695-25c6-496e-8e87-feaec5bd1397"
      unitRef="usd">2092000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTEtMS0xLTEtMjkzMjE_48b6ba7c-3aef-4303-8d3b-84e1ddc32b96"
      unitRef="usd">190000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTEtMy0xLTEtMjkzMjE_d7a782a9-2366-43de-a4df-60ed44099c74"
      unitRef="usd">61000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTItMS0xLTEtMjkzMjE_f6dd86a8-2a4c-404e-88eb-139f3ba506ba"
      unitRef="usd">236877000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTItMy0xLTEtMjkzMjE_1808fbd4-6b40-4841-a86f-cee27e2b51dc"
      unitRef="usd">204485000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTUtMS0xLTEtMjkzMjE_5aac3118-e758-4143-9d8f-0e4f2771da07"
      unitRef="usd">8715000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTUtMy0xLTEtMjkzMjE_d852a758-9833-461d-83ad-173b8d00f5bf"
      unitRef="usd">10838000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMS0xLTEtMzIxMDc_8c447e10-3673-49ec-8a5e-b76276cd2318"
      unitRef="usd">23255000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMy0xLTEtMzIxMzc_2dfa2a4c-ed35-49f2-922d-613f36295866"
      unitRef="usd">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMS0xLTEtMjkzMjE_0cc78a12-e796-4bec-9cd4-6b851f9d938f"
      unitRef="usd">439000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTYtMy0xLTEtMjkzMjE_23c33888-3995-4053-b988-6b7d1f8d2ad1"
      unitRef="usd">383000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTctMS0xLTEtMjkzMjE_af99431e-20a1-41ca-ae46-0e90b07cbae7"
      unitRef="usd">32409000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTctMy0xLTEtMjkzMjE_ef9b17c6-7441-472c-ae2f-9d36deda5509"
      unitRef="usd">11221000</us-gaap:LiabilitiesCurrent>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTgtMS0xLTEtMjkzMjE_74d8e745-7b03-4b04-916f-6feadde77e54"
      unitRef="usd">15439000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTgtMy0xLTEtMjkzMjE_88b59b2b-0570-4eee-91ec-e6419c805dcc"
      unitRef="usd">16296000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMS0xLTEtMzIxMTU_99d5e0f3-0bb2-43b1-b745-5742b1b45a88"
      unitRef="usd">15585000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMy0xLTEtMzIxNDg_40e0eed9-4074-4589-a166-c03dc80e6516"
      unitRef="usd">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTktMS0xLTEtMjkzMjE_e9f55e9a-e853-44ed-a5ad-a455387a8bb7"
      unitRef="usd">5499000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMTktMy0xLTEtMjkzMjE_865801dd-bc66-4e8e-be85-6e47fb330375"
      unitRef="usd">5298000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMS0xLTEtMjkzMjE_6a65b3fe-526d-4d73-b205-99531292da6f"
      unitRef="usd">2100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjAtMy0xLTEtMjkzMjE_685fa6bb-c5dd-4459-828d-c696f0400b41"
      unitRef="usd">2231000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMS0xLTEtMjkzMjE_bf8f2c78-aab5-4bc9-8c51-f797ef7ff616"
      unitRef="usd">71032000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_037ca5b4-d3c2-4273-902a-8ebee405cda1"
      unitRef="usd">35046000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_45269d27-7f8c-4762-b566-014f208331de"
      unitRef="usd">35046000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjEtMy0xLTEtMjkzMjE_fa036173-de1d-44d9-9570-f53618e5dfba"
      unitRef="usd">35046000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF8yOA_29ff57d9-8a04-4197-8cd5-1b92f6fba749"
      unitRef="shares">148728237</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF8yOA_e09e3cb9-d6c1-498b-89f0-cccf1f88949f"
      unitRef="shares">148728237</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF81MQ_9ccdcd0a-27ec-4382-a60b-91119fdd909b"
      unitRef="shares">144987736</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMC0xLTEtMjkzMjEvdGV4dHJlZ2lvbjo3ZmU5YjE4OWFhZDI0ZTRjYTQxYTAzNjliNmVmYTE4MF81MQ_c947ff9c-4b20-486b-93d9-96b331e130d8"
      unitRef="shares">144987736</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMS0xLTEtMjkzMjE_9d9d572e-b65a-4e42-93b7-c770f0c0cafb"
      unitRef="usd">1298212000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjgtMy0xLTEtMjkzMjE_0aba2c60-72e2-4ad1-8311-49f141bd8416"
      unitRef="usd">1286636000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjktMS0xLTEtMjkzMjE_d0e8f76e-6f20-4577-a34c-00d5b6bbf6a9"
      unitRef="usd">67151000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMjktMy0xLTEtMjkzMjE_b7b7b937-8f85-4245-b352-1f804bc01def"
      unitRef="usd">65485000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzAtMS0xLTEtMjkzMjE_199b3cc8-234d-48ad-a4cb-ead6723cc251"
      unitRef="usd">-1150112000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzAtMy0xLTEtMjkzMjE_b5ccef7a-d692-4077-82fb-1e010ea43b99"
      unitRef="usd">-1134347000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzEtMS0xLTEtMjkzMjE_5051ce51-fc61-41d6-a294-e91a585bd849"
      unitRef="usd">-49406000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzEtMy0xLTEtMjkzMjE_93f901d1-3047-44f0-8185-2dbf4c8e318a"
      unitRef="usd">-48335000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzItMS0xLTEtMjkzMjE_c7e7ea43-8c39-4f25-b337-f42a7d241981"
      unitRef="usd">165845000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzItMy0xLTEtMjkzMjE_3b7737a1-a8ab-4df2-86a2-c863fe5df688"
      unitRef="usd">169439000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzMtMS0xLTEtMjkzMjE_e09d934a-ff52-4cf6-993d-18f3f7be6d9c"
      unitRef="usd">236877000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xNi9mcmFnOjFiZmZjZDMzMjIxYjRiMjM5NDBhOGJiNDY0MzE5MjRhL3RhYmxlOjNiODA1NGE2NDhkYjQ4MThiNjA4MzVlMDMyMmMzOWE0L3RhYmxlcmFuZ2U6M2I4MDU0YTY0OGRiNDgxOGI2MDgzNWUwMzIyYzM5YTRfMzMtMy0xLTEtMjkzMjE_8c294360-fc4e-4828-a584-6e4aa84e7852"
      unitRef="usd">204485000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i1fb159623bc541d1b5ec342caea83932_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMy0xLTEtMS0yOTMyMQ_e1c3fc1c-dc54-4236-b02d-d453a4b4da2e"
      unitRef="usd">11218000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d20c312d38544f9bd612a684dcc1831_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMy0zLTEtMS0yOTMyMQ_00810e8e-35da-4ae4-8c96-50e73bacea3a"
      unitRef="usd">1154000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01b82303f97d4df4a95fd381074c09f0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNC0xLTEtMS0yOTMyMQ_9553edd3-f0fe-4a7c-a7ec-e352a8f2ae4c"
      unitRef="usd">1363000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17287f28a3a3401ab7bf4647bec4c75b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNC0zLTEtMS0yOTMyMQ_d4fbdcb5-09d3-40a8-9032-b264185ff7fb"
      unitRef="usd">959000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNS0xLTEtMS0yOTMyMQ_a8e4f448-3a5f-4358-b865-2bccd836ee66"
      unitRef="usd">12581000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNS0zLTEtMS0yOTMyMQ_c787634b-abed-452c-8cf5-0d05cb103317"
      unitRef="usd">2113000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNy0xLTEtMS0yOTMyMQ_15d32447-b161-49df-b172-58557ef30288"
      unitRef="usd">18462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfNy0zLTEtMS0yOTMyMQ_934534d2-eb0d-4adf-8ac9-8f9faa888117"
      unitRef="usd">13782000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfOC0xLTEtMS0yOTMyMQ_947871aa-7774-4667-9c71-37715e07d9db"
      unitRef="usd">4892000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfOC0zLTEtMS0yOTMyMQ_8f34b054-18a4-42ca-83dd-824c3c11dab9"
      unitRef="usd">3878000</us-gaap:GeneralAndAdministrativeExpense>
    <abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTAtMS0xLTEtMjkzMjE_c2cdd649-e9c4-471d-a044-c30c41cb713e"
      unitRef="usd">201000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
    <abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTAtMy0xLTEtMjkzMjE_a585131f-d469-4c1f-880e-c9fa66625316"
      unitRef="usd">129000</abus:IncreaseDecreaseInFairValueOfContingentConsiderationLiability>
    <us-gaap:OperatingExpenses
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTUtMS0xLTEtMjkzMjE_c5b2cd25-d7b4-4688-8d22-ad467ad07f31"
      unitRef="usd">23555000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTUtMy0xLTEtMjkzMjE_0957aeee-66bf-4764-8f12-37561315744d"
      unitRef="usd">17789000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTYtMS0xLTEtMjkzMjE_1b0b645b-193f-4600-9114-1a91b1eabbd4"
      unitRef="usd">-10974000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTYtMy0xLTEtMjkzMjE_fd536681-29ef-461a-bba8-487e517f5621"
      unitRef="usd">-15676000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTgtMS0xLTEtMjkzMjE_181fbc1d-3e68-4b77-8c96-676e327619a0"
      unitRef="usd">159000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTgtMy0xLTEtMjkzMjE_e9d4065b-0c44-496e-ace9-8ca9f01008f1"
      unitRef="usd">39000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTktMS0xLTEtMjkzMjE_ba5655fe-0fdf-4cf1-80e7-cc37f6753450"
      unitRef="usd">506000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMTktMy0xLTEtMjkzMjE_64a109af-0f14-4fcb-b5e9-6a54df8954d3"
      unitRef="usd">772000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjAtMS0xLTEtMjkzMjE_9c88cff4-546e-40c6-84d9-acaca93396e1"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjAtMy0xLTEtMjkzMjE_dee2c9ba-709b-4a0f-b02f-e6506d33fdbf"
      unitRef="usd">28000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjItMS0xLTEtMjkzMjE_70a5ad23-3955-49f0-a940-56a72964c3b1"
      unitRef="usd">-347000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjItMy0xLTEtMjkzMjE_2a3f7527-7daf-4402-ac7f-0d9822193777"
      unitRef="usd">-705000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjMtMS0xLTEtMjkzMjE_e1e7a8e4-7f2b-451d-95b3-e0b79c90787c"
      unitRef="usd">-11321000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjMtMy0xLTEtMjkzMjE_242f45a2-7dd3-411a-95b0-6a539c65d9d7"
      unitRef="usd">-16381000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjQtMS0xLTEtMjkzMjE_a6a6475f-5d58-4b7e-b9a1-3005ebe21a12"
      unitRef="usd">4444000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjQtMy0xLTEtMjkzMjE_33d33172-692a-4cfe-bdee-4926b5dfce2f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjUtMS0xLTEtMjkzMjE_953f8108-aa9f-4e22-a23e-db4e863b16b3"
      unitRef="usd">-15765000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjUtMy0xLTEtMjkzMjE_ecc0d223-aa76-4c90-ab97-09e512e7bf00"
      unitRef="usd">-16381000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjctMS0xLTEtMjkzMjE_9ed535e7-e8fd-4cce-a7d1-6e63716481e3"
      unitRef="usd">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjctMy0xLTEtMjkzMjE_d36d2c81-41b4-4807-be6b-f9b92039a608"
      unitRef="usd">3212000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjgtMS0xLTEtMjkzMjE_18456d84-4485-4dfe-a325-0640a23eea2f"
      unitRef="usd">-15765000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMjgtMy0xLTEtMjkzMjE_9b60932c-c738-4a3c-9942-c93322bdc9a9"
      unitRef="usd">-19593000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMS0xLTEtMjkzMjE_567d724a-c232-466e-8f4a-6773b2282691"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMS0xLTEtMjkzMjE_e0189138-9da8-4d53-b684-2b030e43caab"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMy0xLTEtMjkzMjE_60709576-ba26-42d0-8d83-6752e9aad10b"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzEtMy0xLTEtMjkzMjE_63b67af4-7c7b-4f8c-b062-e45b95398e08"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMS0xLTEtMjkzMjE_8d7d7ee2-5b91-4a5a-8420-83ba42da7895"
      unitRef="shares">148428326</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMS0xLTEtMjkzMjE_d0e847ce-f714-48c0-9e09-1100ee975c28"
      unitRef="shares">148428326</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMy0xLTEtMjkzMjE_5f3db547-770d-4e2d-8fdb-bbe468febc25"
      unitRef="shares">93434378</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzMtMy0xLTEtMjkzMjE_81379fe3-444c-4d25-aa99-fbdacee9f982"
      unitRef="shares">93434378</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzYtMS0xLTEtMjkzMjE_9fefe923-c993-45ca-8484-84f2535c3620"
      unitRef="usd">-1071000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzYtMy0xLTEtMjkzMjE_48b66421-58fa-4472-8ce8-74cbbe59cc37"
      unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzgtMS0xLTEtMjkzMjE_4736409d-f7b4-41f7-ad47-a9366f232465"
      unitRef="usd">-16836000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8xOS9mcmFnOmVlMThhZTRmMDJlOTQ1ZDg4ODFhMzMxMGI3ZDIwMDlmL3RhYmxlOjBhYTNmNTU2OTljMjQ5Yzk5ZDAyMjFjOTZhNmE2MmYyL3RhYmxlcmFuZ2U6MGFhM2Y1NTY5OWMyNDljOTlkMDIyMWM5NmE2YTYyZjJfMzgtMy0xLTEtMjkzMjE_b2014198-607b-4a2a-9c5c-2bb576c74796"
      unitRef="usd">-16378000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ic52d6065eb09463296c5f6564f7e3bc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi01LTEtMS0yOTMyMQ_ad5b32ff-a58f-46ea-b25b-a33ea14b19d8"
      unitRef="shares">144987736</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic52d6065eb09463296c5f6564f7e3bc3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi03LTEtMS0yOTMyMQ_36678c1b-fbf5-491a-8d90-11629cd1f5b7"
      unitRef="usd">1286636000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86367f2c4ca14273aa29c338129293e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi05LTEtMS0yOTMyMQ_451f46b7-e8cb-44d2-a9d8-dfafda592652"
      unitRef="usd">65485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id8346a78b814432d98fb8f1fc40a22c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xMS0xLTEtMjkzMjE_ab5c784a-b982-42ee-9be2-c82f3b51e68f"
      unitRef="usd">-1134347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i106be97586e5476f95a81fc1db43de35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xMy0xLTEtMjkzMjE_9f501d79-f2c7-42df-bede-f73e2ca41fb4"
      unitRef="usd">-48335000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMi0xNS0xLTEtMjkzMjE_16d9e4e7-73b3-40e0-bf48-72ff04c446b6"
      unitRef="usd">169439000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNC05LTEtMS0yOTMyMQ_6818c709-ad23-4462-9914-92537ab6f35a"
      unitRef="usd">1736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNC0xNS0xLTEtMjkzMjE_9f6ec52b-c796-48e1-980b-cfccd41ccebb"
      unitRef="usd">1736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
      contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNS05LTEtMS0yOTMyMQ_d5f060d3-e18f-4e5f-b9e3-b5e0f69475a4"
      unitRef="usd">21000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
    <abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNS0xNS0xLTEtMjkzMjE_fabce909-a931-40a7-b00a-edfc7e5a0e38"
      unitRef="usd">21000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi01LTEtMS0yOTMyMQ_e1bfed05-efa2-457c-83fb-461bb042bc9f"
      unitRef="shares">69048</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i00065117f7544f79976bf4397b4c8e10_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi03LTEtMS0yOTMyMQ_d6356d77-8cf1-4c9b-99da-9c17afad830a"
      unitRef="usd">268000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i052e4eb49038437097e6489137f6506c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNi0xNS0xLTEtMjkzMjE_b841d452-7bfc-47ad-914e-22f15f3f4429"
      unitRef="usd">268000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy01LTEtMS0yOTMyMQ_c4e939b5-1881-497a-aaa3-42e926365402"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy03LTEtMS0yOTMyMQ_9b6041cb-3c29-45e9-b46f-03e7c12e8ea0"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy05LTEtMS0yOTMyMQ_76002b00-b1d2-4054-bf7b-0975cf682170"
      unitRef="usd">-10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfNy0xNS0xLTEtMjkzMjE_31e6f43f-3f25-4675-8523-e3237132e65c"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC01LTEtMS0yOTMyMQ_d09306c9-ab53-4b49-a313-90e563c080d7"
      unitRef="shares">86501</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icae2231d6dd04c75930db889d8f9cef8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC03LTEtMS0yOTMyMQ_178c1d98-7d99-449c-9d6d-a386dcc9b19b"
      unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i37046a3d4ec94f04b71888ed9ae18268_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC05LTEtMS0yOTMyMQ_de73ecad-3217-4657-980b-600d6595a392"
      unitRef="usd">-81000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xNS0xLTEtMjkzMjE_4a09e1c0-afb7-42c4-89c2-599ddca48903"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xLTEtMS0zMzAyMw_842f9841-7aa7-462b-b2e6-5e3386b19256"
      unitRef="shares">3579952</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie89b9e59e12443739a84cc9fd6270bdb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0zLTEtMS0zMzAyMw_49608fee-113b-4f12-bf12-795bbe8b6139"
      unitRef="usd">10973000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOC0xMS0xLTEtMzMwMjM_ebdf55ae-ff20-4b84-aff0-d3d43e2eb6cc"
      unitRef="usd">10973000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic0bcfb45fbd545a3a593fb87947be374_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOS0xMy0xLTEtMjkzMjE_0a49c2d4-ec5f-4f36-a87f-a81a3c966c3c"
      unitRef="usd">-1071000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfOS0xNS0xLTEtMjkzMjE_fbca599d-2363-49a0-8af7-3086ef025fa9"
      unitRef="usd">-1071000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ief63021f67754f038c0196c4f7a220c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTAtMTEtMS0xLTI5MzIx_81496014-5e5d-45ab-88ec-e8ce9c112c36"
      unitRef="usd">-15765000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTAtMTUtMS0xLTI5MzIx_1c5b4534-03d4-471e-9965-c16ea128050e"
      unitRef="usd">-15765000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtNS0xLTEtMjkzMjE_7cf6f9d3-b023-4b87-92c7-42a0506f528a"
      unitRef="shares">148728237</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie721e17ac72c463e96edd8cb5c1b0caf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtNy0xLTEtMjkzMjE_9434c3f7-07da-44a1-b9ba-d3d22c8a90d6"
      unitRef="usd">1298212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5236eb0aea334ba6a6ac833d4c6c22df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtOS0xLTEtMjkzMjE_6fd7a269-97f7-40f0-99bd-a764d80fc32d"
      unitRef="usd">67151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0df84842ad046e9b85fd86ec798224a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTEtMS0xLTI5MzIx_f14ee7e4-e73d-4d02-8d87-759f034400b4"
      unitRef="usd">-1150112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55a62aee5f464630a521ca887a7075e7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTMtMS0xLTI5MzIx_3d071618-8dea-4244-9b6e-402e1e49fb96"
      unitRef="usd">-49406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjJhYTgyYzIwMWNlZDQ2MjU4NjMzZjkxMzNkZWVlY2NkL3RhYmxlcmFuZ2U6MmFhODJjMjAxY2VkNDYyNTg2MzNmOTEzM2RlZWVjY2RfMTEtMTUtMS0xLTI5MzIx_a6c739a3-79f7-4f01-9d07-4e10d933e6f7"
      unitRef="usd">165845000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i970a3c27243f432f8c84f282ad9db987_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xLTEtMS0yOTMyMQ_f71c238c-4986-4428-8537-0cabe2bf6fb0"
      unitRef="shares">1164000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i970a3c27243f432f8c84f282ad9db987_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0zLTEtMS0yOTMyMQ_c6b70b76-4461-44bf-a032-0d4ca663a133"
      unitRef="usd">149408000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi01LTEtMS0yOTMyMQ_c15beb21-482c-4a62-9e16-c1b7763bb198"
      unitRef="shares">89678722</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi03LTEtMS0yOTMyMQ_6c97b1ce-56a7-43e3-b1ae-a53db8462676"
      unitRef="usd">985939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71d7fd13bcc74c299377045d32e83e2c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi05LTEtMS0yOTMyMQ_eb0897f4-2164-44bd-8e69-2c0827f9f709"
      unitRef="usd">60751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2601c2c8d0a44ae9b8cb8405c6b4ef8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xMS0xLTEtMjkzMjE_4bbcc6e0-305a-44a4-81f1-eafece26b4b9"
      unitRef="usd">-1045961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cc1996fb96b4d5daac0e417a6c7f2d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xMy0xLTEtMjkzMjE_22b82c72-c22c-4320-9cc4-52c754a6b346"
      unitRef="usd">-48171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMi0xNS0xLTEtMjkzMjE_7d71f944-91ee-4839-b418-3d9c597a6947"
      unitRef="usd">101966000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="iccf2d5f4bb024a6398e8ca10beda360a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0zLTEtMS0yOTMyMQ_36b33f5d-8a7e-4e0a-a507-09614dc2d595"
      unitRef="usd">-3212000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0xMS0xLTEtMjkzMjE_a9bc770d-e604-40e6-b365-ace8b10c9718"
      unitRef="usd">3212000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMy0xNS0xLTEtMjkzMjE_d4ebc25e-8987-4c12-b386-0da9f5ec8b74"
      unitRef="usd">0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNC05LTEtMS0yOTMyMQ_ba9f9ad9-5824-4132-bc90-78870d01d398"
      unitRef="usd">1647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNC0xNS0xLTEtMjkzMjE_5b727163-19bc-47a4-83e0-256015da8b30"
      unitRef="usd">1647000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
      contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNS05LTEtMS0yOTMyMQ_364e3396-29f1-4e94-976a-3ab79eb805b7"
      unitRef="usd">40000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
    <abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNS0xNS0xLTEtMjkzMjE_5ce28335-6be7-434d-a600-a4f77996f0d9"
      unitRef="usd">40000</abus:AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi01LTEtMS0yOTMyMQ_fcf45fa8-939b-4361-b29a-d4a7f600dfb0"
      unitRef="shares">6395780</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi03LTEtMS0yOTMyMQ_54ddb7d1-3715-492f-8032-cfd16f6f3d48"
      unitRef="usd">26419000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNi0xNS0xLTEtMjkzMjE_ae6ad3e6-91da-4901-a33f-ac2a13576434"
      unitRef="usd">26419000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy01LTEtMS0yOTMyMQ_1765be5c-e9bd-4a14-b44d-01b34dadabf4"
      unitRef="shares">65952</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy03LTEtMS0yOTMyMQ_23287805-0115-4796-ad32-a7ed40e2c0a6"
      unitRef="usd">335000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy05LTEtMS0yOTMyMQ_8e750024-05a2-4ec6-a000-22ba0ef6bb1f"
      unitRef="usd">-127000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfNy0xNS0xLTEtMjkzMjE_7ab29231-a185-46dd-aff4-bf42132af4fe"
      unitRef="usd">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC01LTEtMS0yOTMyMQ_16cac958-63b8-47f8-b7e5-abe098012cb7"
      unitRef="shares">104917</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia1badb2b9f7447889645db7f026cb867_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC03LTEtMS0yOTMyMQ_7f4f4516-2165-4ad7-ab82-667e2a60b886"
      unitRef="usd">425000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i45ea5a1167a94c8d816eae6f435af623_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC05LTEtMS0yOTMyMQ_36a48187-d974-466b-9319-ef30c7b590a5"
      unitRef="usd">-178000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOC0xNS0xLTEtMjkzMjE_ff5e378c-4cde-4fbd-a01a-28e239394ed2"
      unitRef="usd">247000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie0453799dbcc4307847b039a4848dedd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOS0xMy0xLTEtMjkzMjE_62861617-5ef5-46a8-9db3-7961c42994ff"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfOS0xNS0xLTEtMjkzMjE_d9d20688-22fe-4dd1-9978-6c1ca8761458"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iefe6ebead9b747a9b8f140de8350fe3a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTEtMS0xLTI5NDQ4_9b0a5567-455a-465a-b54e-40754d3642ac"
      unitRef="usd">-16381000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTUtMS0xLTI5NDQ4_6c101612-2986-412b-b4bc-2ef5b0967de9"
      unitRef="usd">-16381000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i20fbb288c20f47a99438e41bbee9a692_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMS0xLTEtMjkzMjE_38df985d-6c33-49c7-9a56-ec2570e7049f"
      unitRef="shares">1164000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i20fbb288c20f47a99438e41bbee9a692_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMy0xLTEtMjkzMjE_b27ee813-8cf9-4951-8646-752163d57471"
      unitRef="usd">152620000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i99bbb8943c6e4d28a7642f2253e96007_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtNS0xLTEtMjkzMjE_8b1ebd21-f2dc-4bd2-84c2-d902d5516752"
      unitRef="shares">96245371</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i99bbb8943c6e4d28a7642f2253e96007_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtNy0xLTEtMjkzMjE_3a197102-11fb-4c31-83e0-12823560836b"
      unitRef="usd">1013118000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i338c23e7885d44f2925e13fde9eebadf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtOS0xLTEtMjkzMjE_c9771aba-c22b-46da-88bb-83a285d603ec"
      unitRef="usd">62133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5b29770c1294814900bbc415d9f0848_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTEtMS0xLTI5MzIx_b56d594f-d544-4587-88de-566ab8ce57ce"
      unitRef="usd">-1065554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaf2f2d16cd4d4be188f3dda7b49732a6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTMtMS0xLTI5MzIx_7d071e5e-86a0-4a88-8d53-63adf9f4ec67"
      unitRef="usd">-48168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yMi9mcmFnOjBkMjI2N2M2ZWExNzRmYTU4YjQ0N2M2ODNiZDkwYWU5L3RhYmxlOjg2NzI0NmFlMjAwODQ3OWQ5ODE2Y2JkZmY0YzBmMDhiL3RhYmxlcmFuZ2U6ODY3MjQ2YWUyMDA4NDc5ZDk4MTZjYmRmZjRjMGYwOGJfMTAtMTUtMS0xLTI5MzIx_24c25600-9577-45ea-836f-a60aae243d86"
      unitRef="usd">114149000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMy0xLTEtMS0yOTMyMQ_3b95b8b0-d9ea-4e52-a067-2532c3aef002"
      unitRef="usd">-15765000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMy0zLTEtMS0yOTMyMQ_37c0b305-d449-4810-a83f-bfa047d3a4a3"
      unitRef="usd">-16381000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNS0xLTEtMS0yOTMyMQ_b9425cc9-7af1-44f1-af20-31829b5fd0fe"
      unitRef="usd">394000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNS0zLTEtMS0yOTMyMQ_72cbd9e9-abbd-46fa-af4c-e2237bb3c6e4"
      unitRef="usd">443000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNy0xLTEtMS0yOTMyMQ_7d82c593-d765-42a6-b166-b876188d1931"
      unitRef="usd">1736000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNy0zLTEtMS0yOTMyMQ_f60ca06e-4266-4850-a26f-aa3057997a3e"
      unitRef="usd">1635000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOC0xLTEtMS0yOTMyMQ_7be2efcc-b411-4cae-9d38-0afe8ce7216f"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOC0zLTEtMS0yOTMyMQ_cb1682ea-ec3e-4032-b1bc-074832df9fd4"
      unitRef="usd">-44000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOS0xLTEtMS0yOTMyMQ_f992fa97-5325-4ac2-82dd-195ff657aece"
      unitRef="usd">201000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfOS0zLTEtMS0yOTMyMQ_f8b5c8aa-09fd-4846-a09e-76ecacd1c4b2"
      unitRef="usd">129000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTEtMS0xLTEtMjkzMjE_4a49b08c-be20-42c5-8996-c5e37dcc8432"
      unitRef="usd">1363000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTEtMy0xLTEtMjkzMjE_a728cb60-35f1-4354-b45e-ad89776fb949"
      unitRef="usd">959000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTItMS0xLTEtMjkzMjE_8c9978db-e5d8-45fe-af4c-b7208f239d49"
      unitRef="usd">506000</abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
    <abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTItMy0xLTEtMjkzMjE_13def931-f218-4bba-928e-7072e83c14b9"
      unitRef="usd">771000</abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTMtMS0xLTEtMjkzMjE_e42e77fe-2d44-4fc7-8452-0f0da8f12fde"
      unitRef="usd">-168000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTMtMy0xLTEtMjkzMjE_6f5a28e9-9063-49aa-aefd-a9ae3113c725"
      unitRef="usd">-159000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTUtMS0xLTEtMjkzMjE_a9cc1574-72ad-468d-81ad-145e9b3806c2"
      unitRef="usd">414000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTUtMy0xLTEtMjkzMjE_e0347e38-d0eb-4c07-b03d-15a2bcd9cbe9"
      unitRef="usd">-47000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTYtMS0xLTEtMjkzMjE_070d8eed-e743-4da4-8998-1282c597871a"
      unitRef="usd">1507000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTYtMy0xLTEtMjkzMjE_92f2e416-6fff-43a0-aced-40fb90778cdc"
      unitRef="usd">857000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTctMS0xLTEtMjkzMjE_7d0b5edb-531f-44de-bde3-e4381c33be44"
      unitRef="usd">-2102000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTctMy0xLTEtMjkzMjE_cb67fcfa-5dd3-4954-b3dd-364174d01bdc"
      unitRef="usd">-2796000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMS0xLTEtMzI0OTE_ad5c02b4-23e9-4937-b336-3513fd004db2"
      unitRef="usd">38840000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMy0xLTEtMzI0OTE_f8d1a43c-e77f-49a5-8a7c-40f7f6a6d368"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTktMS0xLTEtMjkzMjE_ac7ac4a9-c610-4996-b047-c1a7c9bc218b"
      unitRef="usd">-75000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMTktMy0xLTEtMjkzMjE_7b9dd22f-5a57-4b90-83cb-91f434b2dd06"
      unitRef="usd">-116000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMS0xLTEtMjkzMjE_719b266e-eba6-437b-955b-7b65bd8793bd"
      unitRef="usd">20619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjAtMy0xLTEtMjkzMjE_f130e46b-08d2-42ff-907a-147d3f2c8ec5"
      unitRef="usd">-17881000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjItMS0xLTEtMjkzMjE_42bd118a-2714-4113-914a-f8721b8d7620"
      unitRef="usd">61981000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjItMy0xLTEtMjkzMjE_8bd38cdc-0fa4-44ee-8d80-86627a51a7cd"
      unitRef="usd">2030000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjMtMS0xLTEtMjkzMjE_365ed3bb-e971-486b-b7e2-e81d87ee6bb1"
      unitRef="usd">2000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjMtMy0xLTEtMjkzMjE_a5f03371-6e27-40cd-936a-651017a3c815"
      unitRef="usd">20350000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjYtMS0xLTEtMjkzMjE_e68907bb-27a0-4556-b12d-ab3e4de7a13f"
      unitRef="usd">75000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjYtMy0xLTEtMjkzMjE_91b2a4fe-b82e-4c95-b37b-5786bfefdbd2"
      unitRef="usd">99000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjctMS0xLTEtMjkzMjE_0d92af70-957d-4265-bac8-34ed29df462d"
      unitRef="usd">-60056000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMjctMy0xLTEtMjkzMjE_a912efde-1964-4ad8-90d1-f413bbc7cde4"
      unitRef="usd">18221000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibf4d97ee56024ff49e5953716d872ae2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMS0xLTEtMzI0OTk_42171980-b171-4c7f-8809-06e7db379bf3"
      unitRef="usd">10973000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i82d76d58cf924d8383205f275ac7662f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMy0xLTEtMzI0OTk_9c441915-b443-4127-881d-791d0ad11894"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i052e4eb49038437097e6489137f6506c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzAtMS0xLTEtMjkzMjE_5301ac7b-4dda-48e1-ac88-46141aa13c86"
      unitRef="usd">268000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie6e91e406b5a42c18158f3225f58684b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzAtMy0xLTEtMjkzMjE_4a474d79-c99b-4f18-8b9b-2e3a10300669"
      unitRef="usd">26419000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzEtMS0xLTEtMjkzMjE_401ff1fc-a5a2-414c-ba53-4d79648b6455"
      unitRef="usd">8000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzEtMy0xLTEtMjkzMjE_bdf0960f-da7d-40d9-a734-06c3957bba39"
      unitRef="usd">208000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzItMS0xLTEtMjkzMjE_d6026992-c254-4a98-be25-c86ff7a15e98"
      unitRef="usd">236000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzItMy0xLTEtMjkzMjE_e8a8325e-cdd9-453c-b1b9-5c72253a2dbd"
      unitRef="usd">247000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMS0xLTEtMjkzMjE_338323f3-874c-493b-b43c-6cdb0362fdd9"
      unitRef="usd">11485000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzMtMy0xLTEtMjkzMjE_c000863b-5507-40a3-bc71-c110a59faccf"
      unitRef="usd">26874000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzQtMS0xLTEtMjkzMjE_2ba2a089-287d-4e96-b9cb-e624e49328f6"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzQtMy0xLTEtMjkzMjE_2244aa92-155e-4a00-9d2b-1ee8d4ed44b9"
      unitRef="usd">-44000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzUtMS0xLTEtMjkzMjE_9ae15bc0-9817-4c51-8e58-1b50d921dfba"
      unitRef="usd">-27952000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzUtMy0xLTEtMjkzMjE_af9bb3f1-13cb-4d22-9fc0-0a3a4f6218e9"
      unitRef="usd">27170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzYtMS0xLTEtMjkzMjE_9ee69ca7-4b67-4a05-a8b1-84cf9e7ee56b"
      unitRef="usd">109282000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzYtMy0xLTEtMjkzMjE_7826e519-f8bc-471c-97c8-d4dc66dbf445"
      unitRef="usd">52251000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzctMS0xLTEtMjkzMjE_4b48a6a5-c0d8-49b8-bc59-0cd5d686e26a"
      unitRef="usd">81330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfMzctMy0xLTEtMjkzMjE_601d4eb5-50c7-4519-b67f-5a7402dafd18"
      unitRef="usd">79421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNDAtMS0xLTEtMjkzMjE_0091d5be-7ec2-4842-aa64-d7921d6480c0"
      unitRef="usd">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8yNS9mcmFnOmRhMzE0YzQyNmE0NjQ2ZWFhN2IzMzQ5MmU4YjNmNDgxL3RhYmxlOjE5N2FmYTYyMGY0ZTRjNDg4ZjQ3ZjdmODg1NzM0NThkL3RhYmxlcmFuZ2U6MTk3YWZhNjIwZjRlNGM0ODhmNDdmN2Y4ODU3MzQ1OGRfNDAtMy0xLTEtMjkzMjE_c20c8889-9be7-476c-b428-750d806412f4"
      unitRef="usd">3212000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:NatureOfOperations
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfNDIyOQ_c2b50469-3f6f-49ae-865c-adf684f12b8d">Nature of business and future operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Description of the Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. The Company&#x2019;s current focus areas include Hepatitis B virus (&#x201c;HBV&#x201d;) and coronaviruses, including SARS-CoV-2. In HBV, the Company is developing an RNA interference (&#x201c;RNAi&#x201d;) therapeutic, oral capsid inhibitor, oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (&#x201c;cHBV&#x201d;) by suppressing viral replication, reducing surface antigen and reawakening the immune system. The Company believes its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening, and is currently being evaluated in multiple phase 2 clinical trials. The Company has an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronaviruses, including SARS-CoV-2. The Company is also exploring oncology applications for its internal PD-L1 portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, the Company had an aggregate of $221.8 million in cash, cash equivalents and investments in marketable securities. The Company had no outstanding debt as of March&#160;31, 2022. The Company believes it has sufficient cash resources to fund its operations for at least the next 12 months.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The Company&#x2019;s research and development activities and the commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company&#x2019;s existing or future research and development programs or the Company&#x2019;s ability to continue to fund these programs in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;COVID-19 Impact &lt;/span&gt;&lt;/div&gt;The COVID-19 pandemic has resulted in and will likely continue to result in significant disruptions to businesses. Measures implemented around the world in attempts to slow the spread of COVID-19 have had, and will likely continue to have, a major impact on clinical development, at least in the near-term, including shortages and delays in the supply chain and prohibitions in certain countries on enrolling patients in new clinical trials.  While the Company has been able to progress with its clinical and pre-clinical activities to date, it is not possible to predict if the COVID-19 pandemic will materially impact the Company&#x2019;s plans and timelines in the future.</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfMjA5NA_15e32a8a-74da-4f6e-ae49-a5174cca5823"
      unitRef="usd">221800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:LongTermDebt
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zMS9mcmFnOjA3OTJmN2ZlNTZjYzQ0OWFhOTI5NDhmYzRjMDY2ODA0L3RleHRyZWdpb246MDc5MmY3ZmU1NmNjNDQ5YWE5Mjk0OGZjNGMwNjY4MDRfMTA5OTUxMTYzNDkzMQ_748fee8e-b89a-47a1-a000-6dbf6ae226c9"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyOQ_fa790ef3-3380-466e-8747-cb17bcfc982a">Significant accounting policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation and principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and its one wholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company&#x2019;s financial position as of March&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s results of operations for the three months ended March 31, 2022 and 2021, and the Company&#x2019;s cash flows for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2021, except as described below under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss attributable to common shareholders per share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three months ended March 31, 2022 and 2021, since the effect of including potential common shares would be anti-dilutive. For the three months ended March 31, 2022, potential common shares of 15.7 million pertaining to outstanding stock options were excluded from the calculation of net loss attributable to common shareholders per share. A total of approximately 35.0 million outstanding stock options and if-converted Series A participating convertible preferred shares (&#x201c;Preferred Shares&#x201d;) were excluded from the calculation for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, the Company&#x2019;s outstanding Preferred Shares were converted into 22,833,922 common shares. Prior to that date, the Company followed the two-class method when computing net loss attributable to common shareholders per share as the Preferred Shares met the definition of participating securities. The Preferred Shares entitled the holders to participate in dividends but did not require the holders to participate in losses of the Company. Accordingly, net losses attributable to holders of the Company&#x2019;s common shares were not allocated to holders of the Preferred Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from collaborations and licenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements fall under the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;) when both parties are active participants in the arrangement and are exposed to significant risks and rewards. For certain arrangements under the scope of ASC 808, the Company analogizes to ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;) for some aspects, including for the delivery of a good or service (i.e., a unit of account).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#x2019;s subsequent sales or usages occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When consideration is received or is unconditionally due from a customer, collaborator or licensee prior to the Company completing its performance obligation to the customer, collaborator or licensee under the terms of a contract, deferred revenue is recorded. Deferred revenue expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a current liability. Deferred revenue not expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a long-term liability. In accordance with ASC Topic 210-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Balance Sheet - Offsetting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s deferred revenue is offset by a contract asset as further discussed in Note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed all recently issued standards and has determined that such standards will not have a material impact on the Company&#x2019;s financial statements or do not otherwise apply to the Company&#x2019;s operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjczOA_e40e0eab-793f-4f25-80bf-68827805ed95">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation and principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial statements and accordingly, do not include all disclosures required for annual financial statements. These statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2021 included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2021. These unaudited condensed consolidated financial statements include the accounts of Arbutus Biopharma Corporation and its one wholly-owned subsidiary, Arbutus Biopharma, Inc., and reflect, in the opinion of management, all adjustments and reclassifications necessary to fairly present the Company&#x2019;s financial position as of March&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s results of operations for the three months ended March 31, 2022 and 2021, and the Company&#x2019;s cash flows for the three months ended March 31, 2022 and 2021. Such adjustments are of a normal recurring nature. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company for the year ended December&#160;31, 2021, except as described below under Recent Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0ODc2MA_ef06cdec-dcdd-4a69-8b1b-c4b78c26487a"
      unitRef="subsidiary">1</abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTYyOTk5ODg_fa5b78fc-328b-4533-95aa-e2146967c733">All intercompany balances and transactions have been eliminated. Certain prior year amounts have been reclassified to conform to the current year presentation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyMg_34f2b494-a761-4cf0-ade8-2ad4c036ef4f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net loss attributable to common shareholders per share&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to common shareholders per share is calculated based on the weighted average number of common shares outstanding. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the three months ended March 31, 2022 and 2021, since the effect of including potential common shares would be anti-dilutive. For the three months ended March 31, 2022, potential common shares of 15.7 million pertaining to outstanding stock options were excluded from the calculation of net loss attributable to common shareholders per share. A total of approximately 35.0 million outstanding stock options and if-converted Series A participating convertible preferred shares (&#x201c;Preferred Shares&#x201d;) were excluded from the calculation for the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;On October 18, 2021, the Company&#x2019;s outstanding Preferred Shares were converted into 22,833,922 common shares. Prior to that date, the Company followed the two-class method when computing net loss attributable to common shareholders per share as the Preferred Shares met the definition of participating securities. The Preferred Shares entitled the holders to participate in dividends but did not require the holders to participate in losses of the Company. Accordingly, net losses attributable to holders of the Company&#x2019;s common shares were not allocated to holders of the Preferred Shares.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idd98aaf228d443bfa99d0a12b844de6f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MzEzMA_ec946bf5-bee2-4505-90f8-5d020f2abe84"
      unitRef="shares">15700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MzA5OA_e2e3eb50-6c36-43e1-a8fb-d119e8c6273f"
      unitRef="shares">35000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i9ca92d833848428fbad2a29503fd9fbd_I20211018"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfMTA5OTUxMTY0MTU1Ng_0199f6b2-a1c5-4d0c-b617-838cf4549553"
      unitRef="shares">22833922</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjc0MA_5db1241a-c95c-4138-ba40-9e13e55b0e8b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from collaborations and licenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates revenue through certain collaboration agreements and license agreements. Such agreements may require the Company to deliver various rights and/or services, including intellectual property rights or licenses and research and development services. Under such agreements, the Company is generally eligible to receive non-refundable upfront payments, funding for research and development services, milestone payments and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements fall under the scope of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 808&#x201d;) when both parties are active participants in the arrangement and are exposed to significant risks and rewards. For certain arrangements under the scope of ASC 808, the Company analogizes to ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC 606&#x201d;) for some aspects, including for the delivery of a good or service (i.e., a unit of account).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers under a five-step model: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as a performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In contracts where the Company has more than one performance obligation to provide its customer with goods or services, each performance obligation is evaluated to determine whether it is distinct based on whether (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available and (ii) the good or service is &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;separately identifiable from other promises in the contract. The consideration under the contract is then allocated between the distinct performance obligations based on their respective relative stand-alone selling prices. The estimated stand-alone selling price of each deliverable reflects the Company&#x2019;s best estimate of what the selling price would be if the deliverable was regularly sold on a stand-alone basis and is determined by reference to market rates for the good or service when sold to others or by using an adjusted market assessment approach if the selling price on a stand-alone basis is not available.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consideration allocated to each distinct performance obligation is recognized as revenue when control is transferred to the customer for the related goods or services. Consideration associated with at-risk substantive performance milestones, including sales-based milestones, is recognized as revenue when it is probable that a significant reversal of the cumulative revenue recognized will not occur. Sales-based royalties received in connection with licenses of intellectual property are subject to a specific exception in the revenue standards, whereby the consideration is not included in the transaction price and recognized in revenue until the customer&#x2019;s subsequent sales or usages occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When consideration is received or is unconditionally due from a customer, collaborator or licensee prior to the Company completing its performance obligation to the customer, collaborator or licensee under the terms of a contract, deferred revenue is recorded. Deferred revenue expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a current liability. Deferred revenue not expected to be recognized as revenue within the 12 months following the balance sheet date is classified as a long-term liability. In accordance with ASC Topic 210-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Balance Sheet - Offsetting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s deferred revenue is offset by a contract asset as further discussed in Note 9.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjczNA_eff4c44a-22b4-4336-ad08-002356cbc34d">Segment informationThe Company operates as a single segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF8zNC9mcmFnOjRlNTQ5Mjg1ZDVmMjQ1NmNhYzEyYTU2MGUwMTIzNGE5L3RleHRyZWdpb246NGU1NDkyODVkNWYyNDU2Y2FjMTJhNTYwZTAxMjM0YTlfNjcyMQ_0dd18b6c-0a9d-47c8-938e-5e5502c0556f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has reviewed all recently issued standards and has determined that such standards will not have a material impact on the Company&#x2019;s financial statements or do not otherwise apply to the Company&#x2019;s operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwMQ_d2ae3f95-3b4d-43dd-9f64-9e592a70b02e">Fair value measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#x2019;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices. The Company determined the fair value of the contingent consideration was $5.5 million as of March&#160;31, 2022 and the increase of $0.2 million from December&#160;31, 2021 has been recorded as a component of total operating expenses in the statement of operations and comprehensive loss for the three months ended March 31, 2022. The assumptions used in the discounted cash flow model are level 3 inputs as defined above. The Company assessed the sensitivity of the fair value measurement to changes in these unobservable inputs, and determined that changes within a reasonable range would not result in a materially different assessment of fair value. &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability-classified stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability-classified stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s liability-classified stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value of liability-classified options exercised in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at end of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Increase in fair value of liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at end of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwNA_62b155d6-4b67-42f0-80f6-5a6f365a3bef">Fair value measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial instruments and other items at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximize the use of observable inputs and minimize the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 1 inputs are quoted market prices for identical instruments available in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Level 3 inputs are unobservable inputs for the asset or liability and will reflect management&#x2019;s assumptions about market assumptions that would be used to price the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments.&lt;/span&gt;&lt;/div&gt;To determine the fair value of the contingent consideration (note 8), the Company uses a probability weighted assessment of the likelihood the milestones would be met and the estimated timing of such payments, and then the potential contingent payments were discounted to their present value using a probability adjusted discount rate that reflects the early stage nature of the development program, the time to complete the program development, and overall biotech indices.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMjQ0Nw_9e33f38e-6d88-46aa-b145-0f8dee96778f"
      unitRef="usd">5500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMjQ3Mw_5dae5a1f-05c1-41d7-a092-5e4359570e7f"
      unitRef="usd">200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzM5OA_fb7ed743-651c-469c-ac0c-ad5e63d6a168">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques used to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability-classified stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in marketable securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability-classified stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy0xLTEtMS0yOTMyMQ_800ff2ac-1810-46a4-a2e8-c6d56b6d30a3"
      unitRef="usd">81330000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy0zLTEtMS0yOTMyMQ_b5253193-8d8e-4b1e-af21-681b6a257441"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy01LTEtMS0yOTMyMQ_a8334cee-bfc8-446a-b768-f14564225039"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMy03LTEtMS0yOTMyMQ_e63cc78a-f887-40c6-9d8b-1b308d09bf9a"
      unitRef="usd">81330000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC0xLTEtMS0yOTMyMQ_dc8359e1-0754-473d-a03a-bb625694d289"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC0zLTEtMS0yOTMyMQ_f2e93775-dd09-4baf-9ad9-56bcc52f233a"
      unitRef="usd">84147000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC01LTEtMS0yOTMyMQ_29a06557-13a1-4406-b053-4b9e0e0a6d0b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNC03LTEtMS0yOTMyMQ_0b8b46e4-4666-468e-b99c-07135efc5059"
      unitRef="usd">84147000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS0xLTEtMS0yOTMyMQ_fbaafd98-01b9-4aa3-9456-79aaa82c3c57"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS0zLTEtMS0yOTMyMQ_a62c885c-6604-450b-869e-75ec1ca0c3e2"
      unitRef="usd">56318000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS01LTEtMS0yOTMyMQ_af459169-e860-404d-8c8e-cb87b2fca779"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNS03LTEtMS0yOTMyMQ_10e743d1-d9a7-4ad6-933e-e4c6e8528525"
      unitRef="usd">56318000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi0xLTEtMS0yOTMyMQ_c47576d3-3b21-4fe5-800e-150855ea5128"
      unitRef="usd">81330000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi0zLTEtMS0yOTMyMQ_9412cbbc-a819-4969-a794-706c2c07c2e9"
      unitRef="usd">140465000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi01LTEtMS0yOTMyMQ_e78f0a17-83e4-4d10-b9ff-41fe24cdb4f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfNi03LTEtMS0yOTMyMQ_d966dfb2-78cb-44e2-9133-307f67b56735"
      unitRef="usd">221795000</us-gaap:AssetsFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC0xLTEtMS0yOTMyMQ_c0042b28-e58b-4bf0-9644-473e46055191"
      unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC0zLTEtMS0yOTMyMQ_eecfb603-96ab-4774-9abe-a3a19cd5f203"
      unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC01LTEtMS0yOTMyMQ_676122cf-d460-4476-b333-de6992706cd0"
      unitRef="usd">5000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOC03LTEtMS0yOTMyMQ_696ba728-e130-4940-8e58-dabbb9c093e7"
      unitRef="usd">5000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS0xLTEtMS0yOTMyMQ_cd7a1b45-802d-43fa-8c12-5113296f4472"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS0zLTEtMS0yOTMyMQ_f9a76bf0-8744-48d8-b350-5f288a8405ef"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS01LTEtMS0yOTMyMQ_f336a34d-4203-4c94-9314-7e9d33700307"
      unitRef="usd">5499000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfOS03LTEtMS0yOTMyMQ_dbd518c4-717a-473c-928d-0f32c264ac4c"
      unitRef="usd">5499000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id70dcc32cab84091a414d114000ea384_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtMS0xLTEtMjkzMjE_47025575-fe93-469b-87bc-8ceb63f138db"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7820392be70c42cea55c46eb141bfcbd_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtMy0xLTEtMjkzMjE_bcc4706a-aef8-4832-a2be-eb6e7d58696a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib9a049cff7d741e796edd187de00eb6f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtNS0xLTEtMjkzMjE_ebde8da5-4ee5-44a6-84d4-6e54b0d915aa"
      unitRef="usd">5504000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i711a0a90695f46ef8552c9299d3498e2_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmFjY2NhNjk3Y2JiMzRhYzc5MjNlZTM2ZDM3ODMxN2U2L3RhYmxlcmFuZ2U6YWNjY2E2OTdjYmIzNGFjNzkyM2VlMzZkMzc4MzE3ZTZfMTAtNy0xLTEtMjkzMjE_8b9ab7d7-a636-4f14-9d21-7f95a7408d83"
      unitRef="usd">5504000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy0xLTEtMS0yOTMyMQ_83c7956a-d5dd-43d3-9e65-a5f05810ee10"
      unitRef="usd">109282000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy0zLTEtMS0yOTMyMQ_6d31cf94-ee52-435f-9f0d-584f43c26447"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy01LTEtMS0yOTMyMQ_6f56a40d-cba3-48a5-b3b5-2d6ee2f85eaf"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfMy03LTEtMS0yOTMyMQ_036d35b2-8018-4927-84ad-f155634bc541"
      unitRef="usd">109282000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC0xLTEtMS0yOTMyMQ_bb491d8b-ade6-4dcc-adba-f89eedd9ebe4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC0zLTEtMS0yOTMyMQ_5dfe526a-6bcd-4df6-8d61-189acbb4cd97"
      unitRef="usd">46035000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC01LTEtMS0yOTMyMQ_ddceba99-2e55-4b17-a292-1da1d23babe4"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNC03LTEtMS0yOTMyMQ_bd83bfde-3cb1-489f-b333-d144fa86079f"
      unitRef="usd">46035000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0xLTEtMS0zNzc4Mw_4440cfe9-409d-4d7f-81ff-fe5320c440e6"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="iba87cbb7f15b4facadb3e5b5747a6fdf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0zLTEtMS0zMzI2Ng_fd7f938e-e59f-46a4-bc68-21fc97d556e0"
      unitRef="usd">35688000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS01LTEtMS0zNzgwMQ_fa73e004-754a-4419-b973-8e4f09854285"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="idd22b5593e2744f68646be67d090d0c4_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS03LTEtMS0zMzI2Ng_36d890c9-1fca-4a81-b91b-96fda96c6ab8"
      unitRef="usd">35688000</us-gaap:LongTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0xLTEtMS0yOTMyMQ_271c7cca-179d-4f55-a88f-ddaf2ddaa66e"
      unitRef="usd">109282000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS0zLTEtMS0yOTMyMQ_4fb8e412-102d-410d-8860-350bf5364832"
      unitRef="usd">81723000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS01LTEtMS0yOTMyMQ_3752a3a6-7bf3-44db-84d8-8cc9a04ef78d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNS03LTEtMS0yOTMyMQ_9f634dd3-891b-4ac1-86a5-f39fe2071299"
      unitRef="usd">191005000</us-gaap:AssetsFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy0xLTEtMS0yOTMyMQ_8cafc977-2d9a-467f-bda1-39855c886c1d"
      unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy0zLTEtMS0yOTMyMQ_5114c72a-c468-4ab2-a5af-d41bbcadb221"
      unitRef="usd">0</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy01LTEtMS0yOTMyMQ_a7fbdd17-7858-4a8f-a970-8e854f754bc1"
      unitRef="usd">26000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfNy03LTEtMS0yOTMyMQ_70b4db20-7f1a-401d-b797-9b5d60bcae74"
      unitRef="usd">26000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC0xLTEtMS0yOTMyMQ_f807b8f7-599b-4523-a664-8e487d2896ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC0zLTEtMS0yOTMyMQ_ac8e0db6-cc77-4906-b277-bc01ba1e0589"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC01LTEtMS0yOTMyMQ_493b185d-f932-4f0d-b6d6-e227bc24e554"
      unitRef="usd">5298000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOC03LTEtMS0yOTMyMQ_cd6ed3d6-8574-495b-9a67-dd4f2891094d"
      unitRef="usd">5298000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifb2c2988cb54498a88205e9749e91abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS0xLTEtMS0yOTMyMQ_e46e11b4-e783-4f15-ba24-b2ac1914b2ff"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7440144805e64bbd9476e8bc698f3da0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS0zLTEtMS0yOTMyMQ_c1e64a6c-95f3-4ecb-9bba-03cc68ac8b6d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0fbfd866f2424809b3d908c81b3d684b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS01LTEtMS0yOTMyMQ_fb054023-6c9d-49d9-a319-9382cd98a022"
      unitRef="usd">5324000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7455aad25d9f402397dfad6f05220540_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjI1MTNiNjAzYTI3ZDQ0MjFhOWI0NDIyMzVjMDRiNWQyL3RhYmxlcmFuZ2U6MjUxM2I2MDNhMjdkNDQyMWE5YjQ0MjIzNWMwNGI1ZDJfOS03LTEtMS0yOTMyMQ_98ee766b-0c53-43e2-8920-fdb67e1311d8"
      unitRef="usd">5324000</us-gaap:LiabilitiesFairValueDisclosure>
    <abus:ChangesInFairValueofLiabilityOptionTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzM5NA_37f88e25-9bf2-462c-b74c-4bb739ff51f5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s liability-classified stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair value of liability-classified options exercised in the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Decrease in fair value of liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at end of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</abus:ChangesInFairValueofLiabilityOptionTableTextBlock>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i624eddd7b8ae4655ac59e95730e93120_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi0xLTEtMS0yOTMyMQ_bd0552d0-2d2b-4e32-82ff-20aad24e2ce0"
      unitRef="usd">26000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue
      contextRef="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi0zLTEtMS0yOTMyMQ_8481401c-2e37-4b5e-a81b-6541a641eaee"
      unitRef="usd">0</abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue>
    <abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions
      contextRef="ib8d9337ef77d49838a8f37af0eaa858f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi01LTEtMS0yOTMyMQ_57a80f8d-1337-4eb1-b112-546af5bfa5f2"
      unitRef="usd">-21000</abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="idbad88517d4f4037b2bad380a2b21006_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMi03LTEtMS0yOTMyMQ_a2a2e568-f6bc-4906-bc60-e63699f934bf"
      unitRef="usd">5000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="i100b46b4a64d427faa1e681084d9bd07_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy0xLTEtMS0yOTMyMQ_2997ed2e-5ea8-4798-a4e0-dcd87c4bddd8"
      unitRef="usd">250000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue
      contextRef="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy0zLTEtMS0yOTMyMQ_d93c0ba9-3b43-45b4-8745-13c4b30598c7"
      unitRef="usd">0</abus:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue>
    <abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions
      contextRef="iea05b1fcbcec40cca5ef73d711f8c5b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy01LTEtMS0yOTMyMQ_6332d5ff-6de9-4d96-bd7f-6da0411146a7"
      unitRef="usd">-52000</abus:IncreaseDecreaseinFairValueofLiabilityClassifiedOptions>
    <abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure
      contextRef="ia387d060fc5249a1876b226e2cfa8c1a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOjA1MzlmYTA2NDEyODRmNmFiODU5MjZlMWUyYjBkMTQ4L3RhYmxlcmFuZ2U6MDUzOWZhMDY0MTI4NGY2YWI4NTkyNmUxZTJiMGQxNDhfMy03LTEtMS0yOTMyMQ_45c26427-de1a-4377-b09f-b959ea310199"
      unitRef="usd">198000</abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RleHRyZWdpb246ZjI3MmEwNzMxNGNhNDQ4Mzk1YzJlMjlkMmU1NWQwYjdfMzQwMA_19046e5f-2a37-465b-8498-117a08bd998e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in fair value of the Company&#x2019;s contingent consideration: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Increase in fair value of liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liability at end of the period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi0xLTEtMS0yOTMyMQ_330aa391-b12b-428f-a31d-741fe39def94"
      unitRef="usd">5298000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi0zLTEtMS0yOTMyMQ_8840635b-80df-431c-bb89-ed66fda55ee4"
      unitRef="usd">201000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMi01LTEtMS0yOTMyMQ_c97cf08d-7c42-4369-ace2-bb1990d31d4b"
      unitRef="usd">5499000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy0xLTEtMS0yOTMyMQ_7f26b2d2-a479-4459-94bc-cd7dc0db3e35"
      unitRef="usd">3426000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy0zLTEtMS0yOTMyMQ_1765b1b1-21ad-4a4e-9f81-02897ba51127"
      unitRef="usd">129000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80MC9mcmFnOmYyNzJhMDczMTRjYTQ0ODM5NWMyZTI5ZDJlNTVkMGI3L3RhYmxlOmJlMDA0MTVmZmVjMTQ3NjBiNTRkMjBmNmNjMjYxZDVhL3RhYmxlcmFuZ2U6YmUwMDQxNWZmZWMxNDc2MGI1NGQyMGY2Y2MyNjFkNWFfMy01LTEtMS0yOTMyMQ_7fbdf84b-7796-4a6e-9cc5-9a073dd1aa01"
      unitRef="usd">3555000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNzQw_01c11daa-b206-4d43-a8f6-70802d96dcc8">Investments in marketable securities&#160;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable short-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable long-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable short-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable long-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual term to maturity of the $84.1&#160;million of short-term marketable securities held by the Company as of March&#160;31, 2022 is less than one year.  As of March&#160;31, 2022, the Company held $56.3 million of long-term marketable securities with contractual maturities of more than one year, but less than five years.  As of December&#160;31, 2021, the Company&#x2019;s $46.0 million of short-term marketable securities had contractual maturities of less than one year, while the Company&#x2019;s $35.7 million of long-term marketable securities had maturities of more than one year, but less than five years.&lt;/span&gt;&lt;/div&gt;There were no realized gains or losses for the three months ended March 31, 2022 or 2021.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNzQy_fcb33477-ee7f-47ab-9505-f4072a9d1d13">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable short-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable long-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable short-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investments in marketable long-term securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US treasury bills&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized gain (loss) is pre-tax and is reported in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6afb52fbbc104a09b75948cb08a8bf93_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNC0xLTEtMS0yOTMyMQ_08f5c817-ec51-44a3-8039-01fed0d1474e"
      unitRef="usd">37219000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6afb52fbbc104a09b75948cb08a8bf93_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNC03LTEtMS0yOTMyMQ_99087be0-c0c2-4858-9f5d-507e88e4e9c2"
      unitRef="usd">37219000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia1f71f74bd334db090c35763085f2594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNi0xLTEtMS0yOTMyMQ_38705d44-bd42-4771-85cb-6fd4ddec7cf3"
      unitRef="usd">37219000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia1f71f74bd334db090c35763085f2594_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfNi03LTEtMS0yOTMyMQ_05950e5a-6dd4-4b51-b5b1-26d7d1c00c0b"
      unitRef="usd">37219000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC0xLTEtMS0yOTMyMQ_a38ed702-f952-449c-8647-b1f8bccc65db"
      unitRef="usd">15158000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC0zLTEtMS0yOTMyMQ_1efc4776-59d7-4316-8b11-92aae4fc1e9f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC01LTEtMS0yOTMyMQ_1a21e840-ee9b-4224-9737-ac4173eccfdb"
      unitRef="usd">137000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iefbcc1b73bcd42d98797c743e412a754_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOC03LTEtMS0yOTMyMQ_0a7bb387-4320-40be-b2df-0a922d9c5b10"
      unitRef="usd">15021000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS0xLTEtMS0yOTMyMQ_686c5857-560e-4f25-b5bb-f0101b97a32b"
      unitRef="usd">8940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS0zLTEtMS0yOTMyMQ_3f11ad2c-c2ca-4cdf-ac35-6f7720e29076"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS01LTEtMS0yOTMyMQ_4b40c8c1-de34-4442-b8d1-c4bddf333db4"
      unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i668e4cbfd80b4b4b9d0643f6fdaf7c1f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfOS03LTEtMS0yOTMyMQ_4fc7073c-59c6-4c03-a2d9-c734b0847370"
      unitRef="usd">8919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtMS0xLTEtMjkzMjE_de966c56-5f7b-4bce-b6b3-b749a2dcadf1"
      unitRef="usd">60600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtMy0xLTEtMjkzMjE_b6f447c6-f697-417d-b9c3-b4ef11a199b0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtNS0xLTEtMjkzMjE_894393f4-653b-4b85-8768-543c0c7d6799"
      unitRef="usd">393000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie39a0f5344c6417eb981eb066ec304be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTAtNy0xLTEtMjkzMjE_51e3af1c-82be-415d-8cc3-a833179a4353"
      unitRef="usd">60207000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtMS0xLTEtMjkzMjE_cf19e8e3-252b-4bc7-a656-78dfb3f2919b"
      unitRef="usd">84698000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtMy0xLTEtMjkzMjE_22c01f20-be08-47c2-8f46-e5a7d23cce48"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtNS0xLTEtMjkzMjE_5582a4fe-9558-4bd9-8b0b-a5248ff5b108"
      unitRef="usd">551000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTEtNy0xLTEtMjkzMjE_22052d3e-63d2-46af-a048-19eba8161d33"
      unitRef="usd">84147000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtMS0xLTEtMjkzMjE_78ac5fd3-709e-44c6-b4e5-edefe8652020"
      unitRef="usd">12311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtMy0xLTEtMjkzMjE_236ee811-0f27-4c5e-ac7b-aaaa3767ec60"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtNS0xLTEtMjkzMjE_16568708-2d6b-4035-82d4-4459720d39bc"
      unitRef="usd">213000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10a026a23b8a4596bd788df2c75ed5df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTMtNy0xLTEtMjkzMjE_18019e05-027e-449a-9a46-d38bbc10a031"
      unitRef="usd">12098000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtMS0xLTEtMjkzMjE_1c437e30-add2-4912-af82-41f6e5788e93"
      unitRef="usd">44677000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtMy0xLTEtMjkzMjE_7adf69e7-6d1b-4a7a-82e3-8d382f585bbc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtNS0xLTEtMjkzMjE_58014d73-27f7-4fe6-9603-1ad8c5e3db61"
      unitRef="usd">457000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcfea814bd6b42ea8bfdc0955a44e2a0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTUtNy0xLTEtMjkzMjE_8150e27c-8193-4502-829f-631dcd74621c"
      unitRef="usd">44220000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtMS0xLTEtMjkzMjE_9e7cec9a-1a1a-47fb-be58-d4f1b9851a2d"
      unitRef="usd">56988000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtMy0xLTEtMjkzMjE_08161b01-a270-4bcd-8b10-8bfee09b0df0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtNS0xLTEtMjkzMjE_98318ee4-05b0-4c71-a658-bd65b1cd8afd"
      unitRef="usd">670000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27f5f771802c4176a602d03f3977a1e1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjBiZTkwZjc5MmFhYTQxMjdiNDBkMzkxNTY5YjMyYWQ0L3RhYmxlcmFuZ2U6MGJlOTBmNzkyYWFhNDEyN2I0MGQzOTE1NjliMzJhZDRfMTYtNy0xLTEtMjkzMjE_ed3ec232-c65a-46ae-8601-69751485a7ec"
      unitRef="usd">56318000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibbb2c36817bb45738c25a5631ff9a54f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMy0xLTEtMS0yOTMyMQ_ca0714b3-49d0-42fb-817e-a40024c2952e"
      unitRef="usd">62836000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibbb2c36817bb45738c25a5631ff9a54f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMy03LTEtMS0yOTMyMQ_bd092645-77cb-4bfb-af14-7ffc866514cf"
      unitRef="usd">62836000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8cdab202f75a4297866c250a068cd12d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfNi0xLTEtMS0yOTMyMQ_448ae6d7-6d6e-43bc-a69f-be2bcbd62b36"
      unitRef="usd">62836000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8cdab202f75a4297866c250a068cd12d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfNi03LTEtMS0yOTMyMQ_38afcbda-b2ca-4cc0-819f-009197f3e42b"
      unitRef="usd">62836000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide871516fa03491795c8b51d22d71071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC0xLTEtMS0yOTMyMQ_17b2c148-89d8-41b5-8f23-3a9cac458217"
      unitRef="usd">8131000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide871516fa03491795c8b51d22d71071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC0zLTEtMS0yOTMyMQ_17223223-22b7-4392-a5dc-1d3e836d6322"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide871516fa03491795c8b51d22d71071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC01LTEtMS0yOTMyMQ_9e61db42-4cee-4e57-9aac-f251d05c8e8c"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide871516fa03491795c8b51d22d71071_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOC03LTEtMS0yOTMyMQ_402c11ad-2bb7-40ed-bac7-fb515df8a6a5"
      unitRef="usd">8120000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS0xLTEtMS0yOTMyMQ_9da43022-c967-4bb6-ae22-11dfb1dfe480"
      unitRef="usd">37968000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS0zLTEtMS0yOTMyMQ_9d565797-f175-4388-bd18-711834d36a8d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS01LTEtMS0yOTMyMQ_a1e458da-d034-49f3-8aff-d7bced915b4b"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc7a1f202a6f4bd2865cf0768b0ec0a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfOS03LTEtMS0yOTMyMQ_05e239cf-fe59-42d1-98b7-f7cb7e2b9efd"
      unitRef="usd">37915000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtMS0xLTEtMjkzMjE_f5f9aafe-00b8-4e2e-bf83-6158e270163a"
      unitRef="usd">46099000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtMy0xLTEtMjkzMjE_d023b511-7b94-40b0-8784-2be0411a9bf1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtNS0xLTEtMjkzMjE_98cbe178-ed09-47b7-ad16-a4662cbfb73e"
      unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa844129bf484cc98902853bb3e8413b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTEtNy0xLTEtMjkzMjE_090cbfa5-a86c-4033-abe3-9df7c73f8283"
      unitRef="usd">46035000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItMS0xLTEtMzc0MTY_cd243bf8-7a7c-4525-897c-cc60b929d3a2"
      unitRef="usd">13068000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItMy0xLTEtMzc0MTY_ba8cf9f6-57a8-4516-a906-e1dd80e6c8ca"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItNS0xLTEtMzc0MTY_c65dd550-8c0b-4f71-ad5b-2d4939fa658b"
      unitRef="usd">29000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i161fa77486694f6aa841fc6ee122232b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTItNy0xLTEtMzc0MTY_bb419982-58cb-43b2-8acd-426f6339a729"
      unitRef="usd">13039000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtMS0xLTEtMzc0MTY_c35ef218-61af-4649-9d8d-4616431c8364"
      unitRef="usd">22707000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtMy0xLTEtMzc0MTY_e645fcfb-bf5c-4a0e-be14-5b94326191fa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtNS0xLTEtMzc0MTY_b79564eb-ec5d-4e9b-84eb-5fb3b8a57c9c"
      unitRef="usd">58000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icacc617e1d9442d58a84e6cfc75788aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTMtNy0xLTEtMzc0MTY_561a4164-0ece-48d6-a32b-6227ef2cd7dc"
      unitRef="usd">22649000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtMS0xLTEtMzc0MTY_4473e704-c488-4db2-bfbe-0f8612ce69ad"
      unitRef="usd">35775000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtMy0xLTEtMzc0MTY_7f0f373e-68a0-41a1-9513-8f58b507836b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtNS0xLTEtMzc0MTY_270b8d3e-531b-486c-905f-88ea1da16759"
      unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e9c1dec7bff47c3b57eb3410ba6f7fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RhYmxlOjkxZTQ3YjU0ZGY0NDQ4OGQ4ZDY2ZmU5OWM2ZjgxOWI5L3RhYmxlcmFuZ2U6OTFlNDdiNTRkZjQ0NDg4ZDhkNjZmZTk5YzZmODE5YjlfMTQtNy0xLTEtMzc0MTY_3849bbc1-50ac-4aeb-a024-04873403e98a"
      unitRef="usd">35688000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfMzQw_b80caff0-c2d9-4f96-a2a5-fa07a4d93e1d"
      unitRef="usd">84100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNDUz_42d38d88-82a7-4ffc-a6f9-facb1e832608"
      unitRef="usd">56300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNTkz_2314e46c-c6e7-4d86-be28-40f0d77a2446"
      unitRef="usd">46000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LongTermInvestments
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfMTA5OTUxMTYyODcxNw_10473f62-4961-4e4c-a5e5-458661de91e5"
      unitRef="usd">35700000</us-gaap:LongTermInvestments>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_6ecf2e13-3be5-4a18-a6b3-efd324977150"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_9811151a-049c-4ec5-91b3-2626c10c6564"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_c6b52913-f811-46e5-887d-63516c63058d"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80My9mcmFnOmJhNjNiNTgxZWEwMzQyM2E4NzJlYmQ0ZDhjMmNkOTVlL3RleHRyZWdpb246YmE2M2I1ODFlYTAzNDIzYTg3MmViZDRkOGMyY2Q5NWVfNjg5_ccdd7243-efe6-43a4-831e-a1bd3eda27b8"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzE3MQ_80cb4674-fc74-4a4a-8292-7bc91f20fc77">Investment in Genevant&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2018, the Company entered into an agreement with Roivant Sciences Ltd. (&#x201c;Roivant&#x201d;), its largest shareholder, to launch Genevant Sciences Ltd. (&#x201c;Genevant&#x201d;), a company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics enabled by the Company&#x2019;s lipid nanoparticle (&#x201c;LNP&#x201d;) and ligand conjugate delivery technologies. The Company licensed exclusive rights to its LNP and ligand conjugate delivery platforms to Genevant for RNA-based applications outside of HBV, except to the extent certain rights had already been licensed to other third parties (the &#x201c;Genevant License&#x201d;). The Company retained all rights to its LNP and conjugate delivery platforms for HBV. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Under the Genevant License, as amended, if a third party sublicensee of intellectual property licensed by Genevant from the Company commercializes a sublicensed product, the Company becomes entitled to receive a specified percentage of certain revenue that may be received by Genevant for such sublicense, including royalties, commercial milestones and other sales-related revenue, or, if less, tiered low single-digit royalties on net sales of the sublicensed product. The specified percentage is 20% in the case of a mere sublicense (i.e., naked sublicense) by Genevant without additional contribution and 14% in the case of a bona fide collaboration with Genevant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Additionally, if Genevant receives proceeds from an action for infringement by any third parties of the Company&#x2019;s intellectual property licensed to Genevant, the Company would be entitled to receive, after deduction of litigation costs, 20% of the proceeds received by Genevant or, if less, tiered low single-digit royalties on net sales of the infringing product (inclusive of the proceeds from litigation or settlement, which would be treated as net sales). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company accounts for its interest in Genevant as equity securities without readily determinable fair values. Accordingly, an estimate of the fair value of the securities is based on the original cost less previously recognized equity method losses, less impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or a similar Genevant securities. As of March&#160;31, 2022, the carrying value of the Company&#x2019;s investment in Genevant was zero and the Company owned approximately 16% of the common equity of Genevant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <abus:SubLicensingRevenuePercentage
      contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMTYyNg_58975876-6e5e-4e44-9c01-26a654c011f3"
      unitRef="number">0.20</abus:SubLicensingRevenuePercentage>
    <abus:BonaFideCollaborationPercentage
      contextRef="i849f8840cc1f40369b37a736474e7316_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMTU2Mw_01c0ec98-cdc6-4436-8684-57d98f58894f"
      unitRef="number">0.14</abus:BonaFideCollaborationPercentage>
    <abus:SubLicensingRevenuePercentage
      contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMTA5OTUxMTYzMjY3OQ_a9613d19-fa2c-44ce-b5da-58d6de535fc8"
      unitRef="number">0.20</abus:SubLicensingRevenuePercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzA4OQ_2d7a7796-2a13-4202-bcdd-11d51949790c"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0c58bd3a223344a9a04669315e016fe3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80Ni9mcmFnOmFhYjg3NGJhODNkYjRmYTg4NzU1MGUyMjVkY2RkYTRhL3RleHRyZWdpb246YWFiODc0YmE4M2RiNGZhODg3NTUwZTIyNWRjZGRhNGFfMzEyOA_2e04eac6-f592-4ff3-804a-242a84ce213b"
      unitRef="number">0.16</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RleHRyZWdpb246ODdkYjRiMTUyYmNkNGZkYjlkMmU2ZGZkNTNjMWFiODVfMTM1_aa993319-7889-4bf1-8760-af1b57ef7661">Accounts payable and accrued liabilities&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RleHRyZWdpb246ODdkYjRiMTUyYmNkNGZkYjlkMmU2ZGZkNTNjMWFiODVfMTM3_06112874-6491-4977-bc33-9ed555348d1d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities are comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fee accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMi0xLTEtMS0yOTMyMQ_23d4a90a-f5f7-4686-b325-40e89ea677cd"
      unitRef="usd">1194000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMi0zLTEtMS0yOTMyMQ_20b99030-26e9-4ba3-ad83-09084e2ba1f9"
      unitRef="usd">3174000</us-gaap:AccountsPayableTradeCurrent>
    <abus:AccruedResearchAndDevelopment
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMy0xLTEtMS0yOTMyMQ_bcbdaca9-0dd2-4122-b2c1-2c55d9b6ea8e"
      unitRef="usd">5462000</abus:AccruedResearchAndDevelopment>
    <abus:AccruedResearchAndDevelopment
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfMy0zLTEtMS0yOTMyMQ_e25eafe9-b51f-4d57-9feb-2d9103e991b2"
      unitRef="usd">2371000</abus:AccruedResearchAndDevelopment>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNC0xLTEtMS0yOTMyMQ_66d0b9b5-af74-46fd-bb2e-e919689c63e5"
      unitRef="usd">610000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNC0zLTEtMS0yOTMyMQ_c4749ba1-9663-4479-b782-59ed89576c25"
      unitRef="usd">983000</us-gaap:AccruedProfessionalFeesCurrent>
    <abus:AccruedPayrollCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNS0xLTEtMS0yOTMyMQ_0628bfc2-67df-4776-bae8-296c09d785f3"
      unitRef="usd">1438000</abus:AccruedPayrollCurrent>
    <abus:AccruedPayrollCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfNS0zLTEtMS0yOTMyMQ_7785a84a-5604-449d-91ae-42932d1413ea"
      unitRef="usd">4279000</abus:AccruedPayrollCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOC0xLTEtMS0yOTMyMQ_8599e00d-5566-47d6-95ed-251c406075fd"
      unitRef="usd">11000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOC0zLTEtMS0yOTMyMQ_eb721ae9-aaff-47ae-a627-07a1660333d9"
      unitRef="usd">31000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOS0xLTEtMS0yOTMyMQ_19f1f8c5-f11e-4f16-b5e8-4902f44a51b8"
      unitRef="usd">8715000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF80OS9mcmFnOjg3ZGI0YjE1MmJjZDRmZGI5ZDJlNmRmZDUzYzFhYjg1L3RhYmxlOjc1ZDkyYzkyNWZiMjRhMmNiNWU1MjY0OWFiMmEwMzQ1L3RhYmxlcmFuZ2U6NzVkOTJjOTI1ZmIyNGEyY2I1ZTUyNjQ5YWIyYTAzNDVfOS0zLTEtMS0yOTMyMQ_3fe54459-fb47-4828-9d40-c95cca9a9f74"
      unitRef="usd">10838000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMzI0MQ_e96a0c2d-85d4-4277-9bb8-b0b2acb547a7">Sale of future royalties &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2019, the Company entered into a Purchase and Sale Agreement (the &#x201c;Agreement&#x201d;) with the Ontario Municipal Employees Retirement System (&#x201c;OMERS&#x201d;), pursuant to which the Company sold to OMERS part of its royalty interest on future global net sales of ONPATTRO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Patisiran) (&#x201c;ONPATTRO&#x201d;), an RNA interference therapeutic currently being sold by Alnylam Pharmaceuticals, Inc. (&#x201c;Alnylam&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ONPATTRO utilizes the Company&#x2019;s LNP technology, which was licensed to Alnylam pursuant to the Cross-License Agreement, dated November 12, 2012, by and between the Company and Alnylam (the &#x201c;LNP License Agreement&#x201d;).&#160;Under the terms of the LNP License Agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% to 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of such royalty interest on future global net sales of ONPATTRO will revert to the Company. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $30 million in royalties to be paid to OMERS is accounted for as a liability, with the difference between the liability and the gross proceeds received accounted for as a discount. The discount, as well as $1.5 million of transaction costs, will be amortized as interest expense based on the projected balance of the liability as of the beginning of each period. As of March&#160;31, 2022, the Company estimated an effective annual interest rate of approximately 16%.  Over the course of the Agreement, the actual interest rate will be affected by the amount and timing of royalty revenue recognized and changes in the timing of forecasted royalty revenue. On a quarterly basis, the Company will reassess the expected timing of the royalty revenue, recalculate the amortization and effective interest rate and adjust the accounting prospectively as needed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes non-cash royalty revenue related to the sales of ONPATTRO during the term of the Agreement. As royalties are remitted to OMERS from Alnylam, the balance of the recognized liability is effectively repaid over the life of the Agreement. From the inception of the royalty sale through March&#160;31, 2022, the Company has recorded an aggregate of $12.5 million of non-cash royalty revenue for royalties earned by OMERS. There are a number of factors that could materially affect the amount and timing of royalty payments from Alnylam, none of which are within the Company&#x2019;s control. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, the Company recognized non-cash royalty revenue of $1.4 million and non-cash interest expense of $0.5 million. During the three months ended March 31, 2021, the Company recognized non-cash royalty revenue of $1.0 million and related non-cash interest expense of $0.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the activity related to the net liability for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net liability related to sale of future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net liability related to sale of future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the royalty from the LNP License Agreement, the Company is also receiving a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#x201c;Acuitas&#x201d;). The royalty from Acuitas has been retained by the Company and was not part of the royalty sale to OMERS.&lt;/span&gt;&lt;/div&gt;</abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock>
    <abus:RoyaltyPercentageofInterestSold
      contextRef="ie4dc98c87a0247e6a3f4347246739782_D20190702-20190702"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfNzg3_9152d1ec-b350-4b74-beae-0f15f0bb30b7"
      unitRef="number">0.0100</abus:RoyaltyPercentageofInterestSold>
    <abus:RoyaltyPercentageofInterestSold
      contextRef="i9e0286773ab94cf7a483c6b8bc8e1785_D20190702-20190702"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfNzkz_b7bba55f-1fb3-47f1-9e40-a8e33bc8a122"
      unitRef="number">0.0233</abus:RoyaltyPercentageofInterestSold>
    <abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier
      contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfODcw_3a9b1670-8398-412e-80c5-fad1aa02a9f4"
      unitRef="usd">500000000</abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier>
    <abus:GrossProceedsFromRoyaltyInterestSold
      contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfOTUy_524577a2-8427-4e4c-97c4-f5cbe177ed28"
      unitRef="usd">20000000</abus:GrossProceedsFromRoyaltyInterestSold>
    <abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer
      contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA1Mg_f3a7c5d3-35e6-4b3f-b953-729264887171"
      unitRef="usd">30000000</abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer>
    <abus:RoyaltyGuaranteesCommitmentsPercentage
      contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA4NA_ea232e60-925d-453f-bfab-32cad529cac0"
      unitRef="number">1</abus:RoyaltyGuaranteesCommitmentsPercentage>
    <abus:RoyaltyPayable
      contextRef="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTIyNg_ab72d9ca-e5b4-46ed-ae36-df34ef823a59"
      unitRef="usd">30000000</abus:RoyaltyPayable>
    <abus:RoyaltyPayable
      contextRef="i2a4bdf1d4b13495782aa726ce0dd5998_I20190702"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTM3Nw_0efef4b9-80ec-484a-98a9-c72626ad0d57"
      unitRef="usd">30000000</abus:RoyaltyPayable>
    <abus:TransactionCostsRelatedToSaleOfFutureRoyalties
      contextRef="i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTU3NA_f0c59fd0-7c2c-45d4-8bf8-6cdc201b5bfc"
      unitRef="usd">1500000</abus:TransactionCostsRelatedToSaleOfFutureRoyalties>
    <abus:EffectiveAnnualInterestRateOfRoyaltyLiability
      contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTgwNA_abfa3e54-7fff-4bf4-af63-2220a5dc5f5c"
      unitRef="number">0.16</abus:EffectiveAnnualInterestRateOfRoyaltyLiability>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMjU0OQ_7a75d914-6d91-4680-bf1e-13e8e862856c"
      unitRef="usd">12500000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTYwMw_07cf36d0-0a37-4153-91fe-bf9f5e7a537a"
      unitRef="usd">1400000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
      contextRef="i38cca725b4ab4d34adf81865761bba0d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTg5NQ_6b9bb77a-da29-4fd7-89bb-4e712c154e03"
      unitRef="usd">500000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTYyMQ_f8c96f99-f763-4d07-8a1a-bea4556c1784"
      unitRef="usd">1000000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
      contextRef="icab5ba791a244e0bb0b0332e0e21701a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMTA5OTUxMTYzMTg5OQ_c8e5313a-4486-4f9f-99d3-283402074fe8"
      unitRef="usd">800000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense>
    <abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RleHRyZWdpb246ZTc4ZTg3M2EzMGJkNDdlMjhmYWIzZTFjYjhkYTQ3YTJfMzIzNA_9e6e5b07-546f-4043-9196-02b1bbd04fee">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the activity related to the net liability for the three months ended March 31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net liability related to sale of future royalties - beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net liability related to sale of future royalties - ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfMy0xLTEtMS0yOTMyMQ_f549695e-3b75-40b5-9255-11c06c34177d"
      unitRef="usd">16296000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i9224b001bc0a44cf93d53e9e5adf97cc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfMy0zLTEtMS0yOTMyMQ_b7db8f07-d14d-40fe-8b00-f573f667e21d"
      unitRef="usd">19554000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNC0xLTEtMS0yOTMyMQ_e45816c1-44fb-40e9-be9e-ddbaa5daf1df"
      unitRef="usd">1363000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNC0zLTEtMS0yOTMyMQ_bdd85158-4aea-49e0-9751-43c773b3a51a"
      unitRef="usd">959000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNS0xLTEtMS0yOTMyMQ_29ef9c6f-4315-4207-ae1b-b07a95fdaacf"
      unitRef="usd">506000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense>
    <abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNS0zLTEtMS0yOTMyMQ_d9284b35-204d-4ad5-9e22-7dc7056ca267"
      unitRef="usd">771000</abus:LiabilityFromSaleOfFutureRoyaltiesNonCashExpense>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNi0xLTEtMS0yOTMyMQ_58df21e2-853f-4cdf-a870-0ec6212fdfe9"
      unitRef="usd">15439000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i1b88e92dd2ad4208a71c7827b9a4093c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81Mi9mcmFnOmU3OGU4NzNhMzBiZDQ3ZTI4ZmFiM2UxY2I4ZGE0N2EyL3RhYmxlOjc3NzQzNTMyZGQ1NDQ5ZGVhZTllZWJiNThjZjY1ZTc1L3RhYmxlcmFuZ2U6Nzc3NDM1MzJkZDU0NDlkZWFlOWVlYmI1OGNmNjVlNzVfNi0zLTEtMS0yOTMyMQ_432e0a15-0e41-43a3-892b-bcf8bbfca454"
      unitRef="usd">19366000</abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjgzNw_bdaea566-435a-4fd7-9955-3806e490c323">Contingencies and commitments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Arbitration with the University of British Columbia &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain early work on lipid nanoparticle delivery systems and related inventions was undertaken at the University of British Columbia (&#x201c;UBC&#x201d;), as well as by the Company that was subsequently assigned to UBC. These inventions are licensed to the Company by UBC under a license agreement, initially entered into in 1998 and as amended in 2001, 2006 and 2007. The Company has granted sublicenses under the UBC license to certain third parties, including Alnylam.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 18, 2020, UBC delivered to the Company a notice of arbitration alleging that under the cross license between UBC and Arbutus, it is due royalties of $2.0 million plus interest arising from the Company&#x2019;s sale to OMERS of part of its royalty interest on future global net sales of ONPATTRO, currently being sold by Alnylam. Oral hearings for this matter were held on April 25-26, 2022. The Company does not believe that any royalties are due to UBC and the Company intends to vigorously contest UBC&#x2019;s allegation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase Agreement with Enantigen&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2014, Arbutus Inc., the Company&#x2019;s wholly-owned subsidiary, acquired all of the outstanding shares of Enantigen Therapeutics, Inc. (&#x201c;Enantigen&#x201d;) pursuant to a stock purchase agreement. The amount paid to Enantigen&#x2019;s selling shareholders could be up to an additional $102.5 million in sales performance milestones in connection with the sale of the first commercialized product by the Company for the treatment of HBV, regardless of whether such product is based upon assets acquired under this agreement, and a low single-digit royalty on net sales of such first commercialized HBV product, up to a maximum royalty payment of $1.0 million that, if paid, would be offset against the Company&#x2019;s milestone payment obligations.  Certain other development milestones related to the acquisition were tied to programs which are no longer under development by the Company, and therefore the contingency related to those development milestones is zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is a financial liability and is measured at its fair value at each reporting period, with any changes in fair value from the previous reporting period recorded in the statements of operations and comprehensive loss (see note 3).  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration was $5.5 million as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i167905b8454f403bbc363d3a741afda6_D20201218-20201218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMTE2Nw_6adeff7c-3b85-465c-9ced-d784fa6c5661"
      unitRef="usd">2000000</us-gaap:LossContingencyDamagesSoughtValue>
    <abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense
      contextRef="i22f8361c99954dfa827a9008f0da81b3_I20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMTg1Nw_d41ba7e7-2426-47d1-bc07-389fee3ae90b"
      unitRef="usd">102500000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense>
    <abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty
      contextRef="i22f8361c99954dfa827a9008f0da81b3_I20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjIwNQ_d1041672-7718-4268-8033-0979b75f194b"
      unitRef="usd">1000000</abus:LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i1ce501d18c8a4c21ab64d7e145ce4bb0_I20141031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjUwNg_2c22073a-f6f2-4296-9253-4989a46fec5f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9b3a998dc61042eda3caff10aef9779e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81NS9mcmFnOjNjYzQ3ZTRmZmM4ODQyYmE4ZTk4YWFjMmUzNTE2MmUxL3RleHRyZWdpb246M2NjNDdlNGZmYzg4NDJiYThlOThhYWMyZTM1MTYyZTFfMjgyMw_9a5ad74e-1e36-4a34-b564-871c51a743c3"
      unitRef="usd">5500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTYzMzUxMjE_1b7aa693-88b8-4af8-a1dc-c8300508be9f">Collaborations, contracts and licensing agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qilu Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In December 2021, the Company entered into a technology transfer and licensing agreement (the &#x201c;License Agreement&#x201d;) with Qilu Pharmaceutical Co., Ltd. (&#x201c;Qilu&#x201d;), pursuant to which the Company granted Qilu a sublicensable, royalty-bearing license, under certain intellectual property owned by the Company, which is non-exclusive as to development and manufacturing and exclusive with respect to commercialization of AB-729, including pharmaceutical products that include AB-729, for the treatment or prevention of hepatitis B in China, Hong Kong, Macau and Taiwan (the &#x201c;Territory&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In partial consideration for the rights granted by the Company, Qilu paid the Company a one-time upfront cash payment of $40.0 million on January 5, 2022, and agreed to pay the Company milestone payments totaling up to $245.0 million, net of withholding taxes, upon the achievement of certain technology transfer, development, regulatory and commercialization milestones. Qilu also paid $4.4 million of withholding taxes to the Chinese taxing authority on the Company&#x2019;s behalf, related to the upfront cash payment.  In addition, Qilu agreed to pay the Company double digit royalties into the low twenties percent based upon annual net sales of AB-729 in the Territory. The royalties are payable on a product-by-product and region-by-region basis, subject to certain limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval for, and commercializing AB-729 for the treatment or prevention of hepatitis B in the Territory. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one AB-729 product candidate in the Territory. A joint development committee has been established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans. Both parties also have entered into a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of AB-729 necessary for Qilu to develop and commercialize in the Territory until the Company has completed manufacturing technology transfer to Qilu and approval of a product manufactured by Qilu, or its designated contract manufacturing organization, by the National Medical Products Administration in China for AB-729.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrent with the execution of the License Agreement, the Company entered into a Share Purchase Agreement (the &#x201c;Share Purchase Agreement&#x201d;) with Anchor Life Limited, a company established pursuant to the applicable laws and regulations of Hong Kong and an affiliate of Qilu (the &#x201c;Investor&#x201d;), pursuant to which the Investor purchased 3,579,952 of the Company&#x2019;s common shares, without par value (the &#x201c;Common Shares&#x201d;), at a purchase price of USD $4.19 per share, which was a 15%  premium on the thirty-day average closing price of the Common Shares as of the close of trading on December 10, 2021 (the &#x201c;Share Transaction&#x201d;). The Company received $15.0 million of gross proceeds from the Share Transaction on January 6, 2022. The Common Shares sold to the Investor in the Share Transaction represented approximately 2.5% of the Common Shares outstanding immediately prior to the execution of the Share Purchase Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The License Agreement falls under the scope of ASC 808 as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for some aspects of this arrangement, including for the delivery of a good or service (i.e., a unit of account). In accordance &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the guidance, the Company identified the following commitments under the arrangement: (i) rights to develop, use, sell, have sold, offer for sale and import any product comprised of Licensed Product (the &#x201c;Qilu License&#x201d;) and (ii) drug supply obligations and manufacturing technology transfer (the &#x201c;Manufacturing Obligations&#x201d;). The Company determined that these two commitments are not distinct performance obligations for purposes of recognizing revenue as the manufacturing process is highly specialized and Qilu would not be able to benefit from the Qilu License without the Company&#x2019;s involvement in the manufacturing activities until the transfer of the manufacturing know-how is complete. As such, the Company will combine these commitments into one performance obligation to which the transaction price will be allocated to and will recognize this transaction price associated with the bundled performance obligation over time using an inputs method based on labor hours expended by the Company on its Manufacturing Obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price of the combined performance obligation to be $49.1 million, which includes the $40.0 million upfront fee, $4.4 million of withholding taxes paid by Qilu on behalf of the Company, the premium paid for the Share Transaction of $4.1 million, and $0.7 million associated with certain manufacturing costs expected to be reimbursed by Qilu. The Company determined the Milestone Payments to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. The following table outlines the transaction price and the changes to the related asset and liability balances during the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.676%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transaction Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Collaboration Revenue Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred License Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined performance obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the balance of the deferred license revenue was $39.5 million, which, in accordance with ASC 210-20, was partially offset by the contract asset associated with the manufacturing cost reimbursement of $0.7&#160;million, resulting in a net deferred license revenue liability of $38.8 million. The $4.4 million of withholding taxes paid by Qilu on behalf of the Company was recorded as income tax expense during the three months ended March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $0.6 million of incremental costs in obtaining the Qilu License, which the Company capitalized in other current assets and other assets and will amortize as a component of general and administrative expense commensurate with the recognition of the combined performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reevaluates the transaction price and the total estimated labor hours expected to be incurred to satisfy the performance obligations and adjusts the deferred revenue at the end of each reporting period. Such changes will result in a change to the amount of collaboration revenue recognized and deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vaccitech plc&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a clinical collaboration agreement with Vaccitech plc (&#x201c;Vaccitech&#x201d;) to evaluate AB-729 followed by Vaccitech&#x2019;s VTP-300, a proprietary T cell stimulating therapeutic vaccine, in nucleos(t)ide reverse transcriptase inhibitor (&#x201c;NrtI&#x201d;)-suppressed patients with cHBV. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for managing this Phase 2a proof-of-concept clinical trial, subject to oversight by a joint development committee comprised of representatives from the Company and Vaccitech. The Company and Vaccitech retain full rights to their respective product candidates and will split all costs associated with the clinical trial.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assembly Biosciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into a clinical collaboration agreement with Assembly Biosciences, Inc. (&#x201c;Assembly&#x201d;) to evaluate AB-729 in combination with Assembly&#x2019;s lead HBV core inhibitor (capsid inhibitor) candidate vebicorvir (&#x201c;VBR&#x201d;) and standard-of-care NA therapy for the treatment of patients with HBV infection. The Company and Assembly are sharing in the costs of the collaboration. The Company incurred $0.6 million and $0.8 million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statement of operations and comprehensive loss. Except to the extent necessary to carry out Assembly&#x2019;s responsibilities with respect to the collaboration trial, the Company has not provided any license grant to Assembly for use of its AB-729 compound.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;X-Chem, Inc. and Proteros biostructures GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into a discovery research and license agreement with X-Chem, Inc. (&#x201c;X-Chem&#x201d;) and Proteros biostructures GmbH (&#x201c;Proteros&#x201d;) to focus on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;pro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). This collaboration brings together the Company&#x2019;s expertise in the discovery and development of antiviral agents with X-Chem&#x2019;s industry leading DNA-encoded library (DEL) technology and Proteros&#x2019; protein sciences, biophysics and structural biology capabilities and provides important synergies to potentially identify safe and effective therapies against coronaviruses including SARS-CoV-2. The collaboration allows for the rapid screening of one of the largest small molecule libraries against M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;pro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (an essential protein required for the virus to replicate itself) and the use of state-of-the-art structure guided methods to rapidly optimize M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;pro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; inhibitors, which the Company could potentially progress to clinical candidates. The agreement provides for payments by the Company to X-Chem and Proteros upon satisfaction of certain development, regulatory and commercial milestones, as well as royalties on sales. Through this collaboration, the Company has identified and obtained a worldwide exclusive license to several molecules that inhibit M&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;pro&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks.  The Company incurred $0.3 million and $0.9 million of costs related to the collaboration during the three months ended March 31, 2022 and 2021, respectively, and reflected those costs in research and development in the statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Entitlements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two royalty entitlements to Alnylam Pharmaceuticals, Inc.&#x2019;s (&#x201c;Alnylam&#x201d;) global net sales of ONPATTRO.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In 2012, the Company entered into a license agreement with Alnylam that entitles Alnylam to develop and commercialize products with the Company&#x2019;s LNP technology. Alnylam launched ONPATTRO, the first approved application of the Company&#x2019;s LNP technology, in 2018. Under the terms of this license agreement, the Company is entitled to tiered royalty payments on global net sales of ONPATTRO ranging from 1.00% - 2.33% after offsets, with the highest tier applicable to annual net sales above $500 million. This royalty interest was sold to OMERS, effective as of January 1, 2019, for $20 million in gross proceeds before advisory fees. OMERS will retain this entitlement until it has received $30 million in royalties, at which point 100% of this royalty entitlement on future global net sales of ONPATTRO will revert back to the Company. OMERS has assumed the risk of collecting up to $30 million of future royalty payments from Alnylam and the Company is not obligated to reimburse OMERS if they fail to collect any such future royalties. If this royalty entitlement reverts to the Company, it has the potential to provide an active royalty stream or to be otherwise monetized again in full or in part. From the inception of the royalty sale through March&#160;31, 2022, an aggregate of $12.5 million of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;royalties have been earned by OMERS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has rights to a second, lower royalty interest on global net sales of ONPATTRO originating from a settlement agreement and subsequent license agreement with Acuitas Therapeutics, Inc. (&#x201c;Acuitas&#x201d;).&#160; This royalty entitlement from Acuitas has been retained by the Company and was not part of the royalty entitlement sale to OMERS. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue from collaborations and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acuitas Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Qilu Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other milestone and royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alnylam Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzY3OQ_7a9691df-25e1-4d0b-b588-fb09d922f805"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <abus:PotentialMilestonePayments
      contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzY5Ng_7f560ba5-34d6-4241-bec6-b9c0ba2fd9dc"
      unitRef="usd">245000000</abus:PotentialMilestonePayments>
    <us-gaap:IncomeTaxesPaid
      contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzcyNw_36b8ecd0-e59a-4643-908f-abe42c17acfd"
      unitRef="usd">4400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDEzOQ_8241c280-64a3-4678-86a0-f2a82713b0e8"
      unitRef="shares">3579952</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice
      contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDExNw_078cc951-a0b0-4886-aab2-0745f97d36f8"
      unitRef="usdPerShare">4.19</us-gaap:SharePrice>
    <abus:PremiumonClosingStockPrice
      contextRef="i7161a12d542a4969901ecf181c8d5cf4_I20211213"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDEzMw_0632c641-d9f1-45d0-8b4e-b798fbed6127"
      unitRef="number">0.15</abus:PremiumonClosingStockPrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6b9336fe97b44836842a01da01d42937_D20220106-20220106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDE3Mg_38a7c8b0-a0b1-4886-ac14-faff6bb2355a"
      unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="if9829026bc73479093b8029eac0806e0_I20211213"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDIwNA_2e54c6e0-4f73-4818-8b1a-29337c2bef20"
      unitRef="number">0.025</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4MzkwOA_1bed5c96-9c8a-4f1f-9c70-8057bed101b4"
      unitRef="usd">49100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic0ac895c64af4bfb89e93801a29feed8_D20220105-20220105"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4Mzk0MA_f029e2b2-76b5-4591-bda7-92ff9716f521"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:IncomeTaxesPaid
      contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4Mzk3Mw_43db5e92-a141-4c17-a674-2df84c9fa6b2"
      unitRef="usd">4400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:PremiumsEarnedNet
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDAwMw_82c05527-a9b1-4325-ad31-9928182072f7"
      unitRef="usd">4100000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTAzMQ_26e996d6-e1f8-433a-aa58-d2c3e85524fe"
      unitRef="usd">700000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTYzMzUxMTk_fa5f9cd9-fd3d-4581-9916-ff5bca1ee04a">The following table outlines the transaction price and the changes to the related asset and liability balances during the three months ended March&#160;31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.676%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Transaction Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Collaboration Revenue Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Deferred License Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined performance obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion of deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current deferred license revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0xLTEtMS0zMDkxMw_c31ea57a-0a76-4402-8f00-e5dcba3c16be"
      unitRef="usd">49142000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0yLTEtMS0zMDkxMw_1772d9f9-3953-4550-8910-7e7bc04c1cb6"
      unitRef="usd">9632000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMi0zLTEtMS0zMDkxMw_d9ee14f3-a46d-4e13-a3cb-0544b4f0fa83"
      unitRef="usd">39510000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfMy0zLTEtMS0zMDkxMw_4bb348a3-1b65-4a82-b03b-6cdd8c2423bf"
      unitRef="usd">670000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNC0zLTEtMS0zMDkxMw_b077a667-357b-4a82-a8e4-9cceeedc17fc"
      unitRef="usd">38840000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNi01LTEtMS0zNTg5MA_f95a1854-832c-409d-af0e-d663d9900eb7"
      unitRef="usd">23255000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="ib0f3d36adae54e1d9276dd03b947cf45_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmI5ZDc5MjUxZWQwMDQ2ZjE4NjlkMjgwY2NmOWY0ODJmL3RhYmxlcmFuZ2U6YjlkNzkyNTFlZDAwNDZmMTg2OWQyODBjY2Y5ZjQ4MmZfNS0zLTEtMS0zMDkxMw_250519d8-c8c6-45cf-b429-51c9ef5928a5"
      unitRef="usd">15585000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTEwMA_8fbdf226-d3e4-4a09-a8d1-f2ba13c7b760"
      unitRef="usd">39500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i3736e15e24d04f25b128dd75487b51d1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NTA2Ng_a438420c-be86-4803-9035-cdc23e6e2199"
      unitRef="usd">700000</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1163dbec3a7848eca95205175b1da9b0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY4NDM2MQ_fe78728e-9604-45a1-9e1f-b1682ca0686e"
      unitRef="usd">38800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:IncomeTaxesPaid
      contextRef="i420ef4b4a70d4a019e7902ff308a3764_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTQ5NzU1ODE5Mjc4OQ_36b8ecd0-e59a-4643-908f-abe42c17acfd"
      unitRef="usd">4400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OtherDeferredCostsGross
      contextRef="ia483bef565574680a3a9c1bd2564b825_I20211213"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTY0OTI2NzQ2NTM2MA_151d7176-a84e-4837-98ec-9cd16f2e8e38"
      unitRef="usd">600000</us-gaap:OtherDeferredCostsGross>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i702949ca2cfd4a0a9bb7f02fd91035b8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjQ1OA_eb48db4b-b4ee-46e0-a6d6-7751b6b9f987"
      unitRef="usd">600000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ib01ce59d6936428c930e28b71f7c5359_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjc0ODc3OTEwMzkzNw_53baa5dc-8c95-4a74-b417-a7acbcffd132"
      unitRef="usd">800000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i0f12239ea971423693eb1924756cc84c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY0NTUzNw_121d34a0-e3b0-407c-86fd-af509516acd7"
      unitRef="usd">300000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ic9be38c6e9064432bd40073b87596f3c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMjc0ODc3OTEwNDc4Nw_85ee28c3-a849-4f3b-b38c-1bb311ee5323"
      unitRef="usd">900000</us-gaap:OtherCostAndExpenseOperating>
    <abus:RoyaltyEntitlements
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDI1Ng_e7cba949-5110-4fc1-b775-0d7001282c8d"
      unitRef="product">2</abus:RoyaltyEntitlements>
    <abus:RoyaltyPercentageofInterestSold
      contextRef="iecc67e9256ab4b9dbea33b02a1658a89_D20130101-20130630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDk1MA_baec0912-2289-4b21-a2d0-2605e0091f6d"
      unitRef="number">0.0100</abus:RoyaltyPercentageofInterestSold>
    <abus:RoyaltyPercentageofInterestSold
      contextRef="i0cae881ec75e4bc18cff9b5347823e59_D20130101-20130630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNDk1NQ_b8e2078a-7a27-4f87-bed3-d3aa7c19f695"
      unitRef="number">0.0233</abus:RoyaltyPercentageofInterestSold>
    <abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier
      contextRef="ie759772fc0d34889b5b1773813066150_D20130101-20130630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTAzMg_a6d2fde9-e438-4efe-9e21-c16af1ec2e94"
      unitRef="usd">500000000</abus:RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier>
    <abus:GrossProceedsFromRoyaltyInterestSold
      contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTEwMQ_73cf6f5a-8620-4c51-b7f3-094cf9c94b6a"
      unitRef="usd">20000000</abus:GrossProceedsFromRoyaltyInterestSold>
    <abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer
      contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTIwMQ_35a76eec-355b-4f13-b9b0-6019b3e03eee"
      unitRef="usd">30000000</abus:RoyaltyInterestSoldMaximumRoyaltiesForBuyer>
    <abus:RoyaltyGuaranteesCommitmentsPercentage
      contextRef="i428973c6db9541269463d60bbdc135c7_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTIzMw_7ffb855e-c62e-4a98-bbd7-b0d4b86a806d"
      unitRef="number">1</abus:RoyaltyGuaranteesCommitmentsPercentage>
    <abus:RoyaltyPayable
      contextRef="i46281ecd5fb744a99a4fb28bba9e853c_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNTM4Mw_8043c9ac-7e8f-439b-8147-43db2fbbce08"
      unitRef="usd">30000000</abus:RoyaltyPayable>
    <abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
      contextRef="i60ec5d39ac144645bdda9e280351fa3d_D20190702-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfMTA5OTUxMTY0NjU2OQ_7a75d914-6d91-4680-bf1e-13e8e862856c"
      unitRef="usd">12500000</abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RleHRyZWdpb246MDY4OTA5NWUwY2FkNDY2OWEzMTlkMTc1NTRmOGJjYThfNjA2Nw_cf0dd0a9-cb31-484b-86ee-134f12bcf4f7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue from collaborations and licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acuitas Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Qilu Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other milestone and royalty payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-cash royalty revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alnylam Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:Revenues
      contextRef="i518670b3fac0479e89bccbd3cf48a756_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNC0xLTEtMS0yOTMyMQ_8a2c624e-8d2a-470f-8e94-6c970a99904e"
      unitRef="usd">1534000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea3e5de0afd64224841a930f2a7a0b40_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNC0zLTEtMS0yOTMyMQ_7288afe7-30b3-425a-bbee-3d80dee76dd3"
      unitRef="usd">1095000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ad95e89d07d4219962809e6980f2c99_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNS0xLTEtMS0yOTMyMQ_c6dac01e-3d41-457d-977e-4b79621c2aba"
      unitRef="usd">9632000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecc54f0d5f1e425684acf6e743b66eaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNS0zLTEtMS0yOTMyMQ_795db415-d5cf-4f50-9195-c326151dcfed"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5a7bfc3b496414582720db787c9cf6f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNi0xLTEtMS0yOTMyMQ_b359a877-80b1-43b2-b010-d8397d12e441"
      unitRef="usd">52000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i232b5a40e86b4942a256e843e353e388_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfNi0zLTEtMS0yOTMyMQ_5685c87e-46a0-41d8-9c85-a4c527e186fd"
      unitRef="usd">59000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6007cbaa2fc842dbb22efaa19e85a21c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOC0xLTEtMS0yOTMyMQ_0748b17f-8167-45dd-88ba-7293cd47cec6"
      unitRef="usd">1363000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13c626debfbf4e20bbb17e393ea68c3d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOC0zLTEtMS0yOTMyMQ_926327a8-9a48-4f8d-a7de-83553e06e697"
      unitRef="usd">959000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOS0xLTEtMS0yOTMyMQ_3db955cc-9611-4a01-b7bd-623219bced14"
      unitRef="usd">12581000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF81OC9mcmFnOjA2ODkwOTVlMGNhZDQ2NjlhMzE5ZDE3NTU0ZjhiY2E4L3RhYmxlOmRhYThhZTU0MWI0NjQwZjc5MDI0ODBkMzRkZjk4M2MzL3RhYmxlcmFuZ2U6ZGFhOGFlNTQxYjQ2NDBmNzkwMjQ4MGQzNGRmOTgzYzNfOS0zLTEtMS0yOTMyMQ_f79da025-66ef-4288-b9a2-6e6796d45ebd"
      unitRef="usd">2113000</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTYyOTQ4Nzg_466d747e-0a45-4f52-a3f5-c2256a6c50b4">Shareholders&#x2019; equity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Authorized share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s authorized share capital consists of an unlimited number of common shares and preferred shares, without par value, and 1,164,000  Series A participating convertible preferred shares, without par value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Open Market Sale Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an Open Market Sale Agreement with Jefferies LLC (&#x201c;Jefferies&#x201d;) dated December 20, 2018, as amended by Amendment No. 1, dated December 20, 2019, Amendment No. 2, dated August 7, 2020 and Amendment No. 3, dated March 4, 2021 (as amended, the &#x201c;Sale Agreement&#x201d;), under which it may issue and sell common shares, from time to time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2019, the Company filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) (File No. 333-235674) and accompanying base prospectus, which was declared effective by the SEC on January 10, 2020 (the &#x201c;January 2020 Registration Statement&#x201d;), for the offer and sale of up to $150.0&#160;million of the Company&#x2019;s securities. The January 2020 Registration Statement also contained a prospectus supplement in connection with the offering of up to $75.0&#160;million of the Company&#x2019;s common shares pursuant to the Sale Agreement. This prospectus supplement was fully utilized during 2020. On August 7, 2020, the Company filed a prospectus supplement with the SEC (the &#x201c;August 2020 Prospectus Supplement&#x201d;) in connection with the offering of up to an additional $75.0&#160;million of its common shares pursuant to the Sale Agreement under the January 2020 Registration Statement. The August 2020 Prospectus Supplement was fully utilized during 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 28, 2020, the Company filed a shelf registration statement on Form S-3 with the SEC (File No. 333-248467) and accompanying base prospectus, which was declared effective by the SEC on October 22, 2020 (the &#x201c;October 2020 Registration Statement&#x201d;), for the offer and sale of up to $200.0&#160;million of the Company&#x2019;s securities. On March 4, 2021, the Company filed a prospectus supplement with the SEC (the &#x201c;March 2021 Prospectus Supplement&#x201d;) in connection with the offering of up to an additional $75.0 million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. The March 2021 Prospectus Supplement was fully utilized during 2021. On October 8, 2021, the Company filed a prospectus supplement with the SEC (the &#x201c;October 2021 Prospectus Supplement&#x201d;) in connection with the offering of up to an additional $75.0&#160;million of its common shares pursuant to the Sale Agreement under the October 2020 Registration Statement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 3, 2022, the Company filed a prospectus supplement with the SEC (the &#x201c;March 2022 Prospectus Supplement&#x201d;) in connection with the offering of up to an additional $100.0&#160;million of its common shares pursuant to the Sale Agreement under: (i) the January 2020 Registration Statement; (ii) the October 2020 Registration Statement; and (iii) a shelf registration statement on Form S-3 (File No. 333-260782) that was declared effective by the SEC on November 18, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 , the Company issued 69,048 common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $0.3 million. For the three months ended March 31, 2021, the Company issued 6,395,780 common shares pursuant to the Sale Agreement, resulting in net proceeds of approximately $26.4 million. As of March&#160;31, 2022, there was approximately $152.0 million remaining available in aggregate under the October 2021 Prospectus Supplement and the March 2022 Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes information about the Company&#x2019;s stock based compensation for the three months ended March&#160;31, 2022 and 2021 and the expense recognized in the condensed consolidated statements of operations: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series A Preferred Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company entered into a subscription agreement with Roivant for the sale of Preferred Shares to Roivant for gross proceeds of $116.4&#160;million.  The Preferred Shares were non-voting and were convertible into common shares at a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share). The purchase price for the Preferred Shares plus an amount equal to 8.75% per annum, compounded annually, was subject to mandatory conversion into common shares on October 18, 2021, at which time the Preferred Shares were converted into 22,833,922 common shares and both the lockup and standstill periods that Roivant had previously agreed to expired. As of March&#160;31, 2022, Roivant owned approximately 26% of the Company&#x2019;s outstanding common shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded the Preferred Shares wholly as equity with no bifurcation of the conversion feature from the host contract, given that the Preferred Shares could not be cash settled and the redemption features were within the Company&#x2019;s control, which included a fixed conversion ratio with predetermined timing and proceeds. The Company accrued for the 8.75% per annum compounding coupon at each reporting period end date as an increase to preferred share capital, and an increase to deficit (see statement of stockholders&#x2019; equity).&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDg3NA_eef6e3ad-6da0-4980-9b53-4a0264444282"
      unitRef="shares">1164000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="i95f34ecb804c43bd860c37e292eda8dc_I20200110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDc4NQ_106619eb-8440-4106-85a1-64ddff1240cf"
      unitRef="usd">150000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="i48fd91415d144f359a29ef040e182e92_I20200110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgwMQ_605a3781-a1a7-41c5-a345-6c84651a9ec5"
      unitRef="usd">75000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="i721c0159d357459e82fda7a1d2aaa5a2_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgxNg_a340715c-3736-4738-866e-9065a4201da7"
      unitRef="usd">75000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ida4e708fcedd480aa26d4c73a4f87927_I20201022"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDgzMQ_1ec8f8fa-a75a-4383-99b9-c1641491dd9b"
      unitRef="usd">200000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ieb32b3f5a01140a19a6306f86a2a8fd5_I20210304"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfNzI1_05dbc33d-3a7f-4684-b204-c2639158cda9"
      unitRef="usd">75000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="iab6748705d0d4226ba4a82a1e22ee083_I20211008"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3ODEzMw_5ed62e6d-8cf3-40e0-89fc-94ae9bc25c69"
      unitRef="usd">75000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ia52a417f6ada4560b9f6eb2b6fd7a96a_I20220303"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTY0NDg0Nw_8332e85e-7b55-44ad-b15d-fc877f292da3"
      unitRef="usd">100000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i2bf4d6c3fa5a4105a94421a222392925_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfODUw_84a4d90c-83f7-4353-ba72-a9e89418fa3c"
      unitRef="shares">69048</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i670e4df1980948ec8c216e9200afc61f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfOTY0_10c35e94-9ee6-4558-9f5c-f8b5230a36bf"
      unitRef="usd">300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5f2e4c170332429cb6b01ee5963528a9_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTAyMA_979e67fe-3548-4b40-b962-6a4c356d2f01"
      unitRef="shares">6395780</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i045ad8ba8ec9498a8558014661ce50fe_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTEzNA_bb356f76-ba00-4809-9739-4012ffed9227"
      unitRef="usd">26400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="i6dd670c983a7433cb7bd93372158078d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NzIwMg_2ddc86e4-89fd-45f9-ad0d-89976cbb310e"
      unitRef="usd">152000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ida00744ff3624de0be467e4cae72015e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NzIwMg_b771850c-e8e5-49c1-9e32-04b868f26aff"
      unitRef="usd">152000000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMzM0Mg_0c9ada2f-286d-40cc-995c-33542c0aa438">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes information about the Company&#x2019;s stock based compensation for the three months ended March&#160;31, 2022 and 2021 and the expense recognized in the condensed consolidated statements of operations: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted during period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,896,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2a5dd2c6ac51433dbaefbe4e3fc47c85_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfMy0xLTEtMS0yOTMyMQ_e3a14b30-3230-444c-a4c5-7dd3c0d1eca1"
      unitRef="shares">4372295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i55d02dff95ec415dab33999ff0c85e85_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfMy0zLTEtMS0yOTMyMQ_ccbdbc00-7f93-448e-b875-ce15c7e4da8b"
      unitRef="shares">2896550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNC0xLTEtMS0yOTMyMQ_046fec56-717a-4e6b-bde3-bfe6eaef076c"
      unitRef="usdPerShare">2.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNC0zLTEtMS0yOTMyMQ_4f26c23b-6eeb-4bbf-adb5-3583c13f8829"
      unitRef="usdPerShare">4.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98fa33af9af34a29a59381fcf1cbe51d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNi0xLTEtMS0yOTMyMQ_101ef21f-29da-4243-a5a0-2a41bf603187"
      unitRef="usd">757000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a64dd48949e4cba85f1ccfe32f2819e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNi0zLTEtMS0yOTMyMQ_e457a622-0428-4fd4-81e0-43568857b443"
      unitRef="usd">840000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3988f17b1bc94d529eadea44681fdf65_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNy0xLTEtMS0yOTMyMQ_db1192bf-e719-4fa8-a1b0-b55e90ba01b6"
      unitRef="usd">979000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9e6d8e3249e848a0b9453c69b8b92b5d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfNy0zLTEtMS0yOTMyMQ_38405b47-8197-4fed-8d3a-de93089aa3be"
      unitRef="usd">795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfOC0xLTEtMS0yOTMyMQ_f4e96de6-148e-4ae3-aab5-e52069896541"
      unitRef="usd">1736000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RhYmxlOjE1YTc4YTI0MTFjNDQ5NDQ5NTQyYzUzZjQ1NTcxZDg2L3RhYmxlcmFuZ2U6MTVhNzhhMjQxMWM0NDk0NDk1NDJjNTNmNDU1NzFkODZfOC0zLTEtMS0yOTMyMQ_d3d4cbc2-a0b6-48e6-a74f-d757d7cc9d3a"
      unitRef="usd">1635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTkyMA_dfbac869-f68c-46b4-8680-ee9487398a90"
      unitRef="usd">116400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjAyNw_db3953d6-acc1-48d4-91e9-84fddd486bdd"
      unitRef="usdPerShare">7.13</us-gaap:PreferredStockParOrStatedValuePerShare>
    <abus:PremiumonClosingStockPrice
      contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjA2MA_9c5a5129-5509-4a8b-afb6-df4561cb3501"
      unitRef="number">0.15</abus:PremiumonClosingStockPrice>
    <us-gaap:SharePrice
      contextRef="ib605935fd5db48b7a59105e11ada7c5f_I20171002"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjA5NQ_973c5f71-0a9a-47c6-b2c7-97040fe38f8b"
      unitRef="usdPerShare">6.20</us-gaap:SharePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="i0550334f3f1f4939986fd0c5b7b61af4_D20171002-20171002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjE3OA_7d5f90e2-8bec-4453-9a18-0cef95d742ec"
      unitRef="number">0.0875</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i9ca92d833848428fbad2a29503fd9fbd_I20211018"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMTA5OTUxMTYzMjU1OQ_854cfc97-f330-43af-8c2d-bcab68467d58"
      unitRef="shares">22833922</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <abus:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion
      contextRef="iac91ec4cb9804633b6568f3d3cafd8e5_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMjc0ODc3OTA3NTA4Nw_42537612-4091-4629-883c-72a4dbfa9543"
      unitRef="number">0.26</abus:NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="i0515a8eeb4984632a6fdb800c50fd8bf_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82MS9mcmFnOjU5M2YwNTM3NTJhNDRlYzRiOGExN2YwMDU4OTNjMDdmL3RleHRyZWdpb246NTkzZjA1Mzc1MmE0NGVjNGI4YTE3ZjAwNTg5M2MwN2ZfMzE2Mg_df87a483-8c9a-490d-bc7f-d6c09e291255"
      unitRef="number">0.0875</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMzEx_d5d41ac0-fdba-4ad9-a311-9630de9bfb39">Related party transactionsDuring the three months ended March&#160;31, 2022 and 2021, Genevant purchased certain administrative services from the Company. Income from these services was less than $0.1 million in both periods and is netted against research and development expenses in the condensed consolidated statements of operations.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_16d1ed7b-89d6-4ab3-aee1-da7b1a86e3f4"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_9ab63c71-7033-4d55-913e-a5fe0de02667"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i771d8e9c2b654f49b396d66f5612bf18_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_9cbe55c7-b3c6-4f18-93fd-fcd2dd5eef00"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRkMWMwYWU1NDRjYTQ5ZTg5NDAxMDI2YmYyM2M5NDc0L3NlYzo0ZDFjMGFlNTQ0Y2E0OWU4OTQwMTAyNmJmMjNjOTQ3NF82NC9mcmFnOmYxNTM5YThkZTc2OTQxOGY4ZjY1ZjllNTc4M2EzOGFlL3RleHRyZWdpb246ZjE1MzlhOGRlNzY5NDE4ZjhmNjVmOWU1NzgzYTM4YWVfMTc3_cd1e1228-eb6c-4b67-b30a-46cf441abaf0"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMS]18IWOA"V$4B+.#P/.?"[U W!_*80ZGN@?*#931_\!4$L#!!0    ( +R
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MT%CQWT )Y%@N496C-.&W22KKH)0!H7RY)JFR&(PY\34W724I%U:13AS!)H[
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M[$S<MOA]Y$JG2%N)E$9L*G)KZQP5O9$!M<AY]>UVX12J]QPBC=!H4W+HMJQ
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M4KSGBTGFX.?,AOIUM=R/G)R/ADTE&B-R6&Q!7BSHK*.6P9+/D;%>N2WD^\D
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MR@H@?R&EV6ZL@_:[:/(?4$L#!!0    ( +R I53$HM.<Y 4  "@.   9
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M/^U'W[SK^!?W;FY2"=9<&A!846A\/AP$H+M9U!E6M;[_5\K2-/';FL8W:N=
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M27%)+J""!4FGM[&0!'9K5:M"&&EL+5U0N28(7C/05OBM#U0EZXZT#%0(91[
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M\A[?:W!7@V^F+ %@*\>B7!5J)"KS*(OZ<;Q2LB*FW3N\:&#NE4A450,<:=/
M'H!1 WZV%6"UJA^%V94@O'KLKC?R+&@K2E..U;>D:"RP2TA+_*6PUL)L62PD
MKHTLFPPZ;'AU>M+.8(% ^UNL2W,3LX$Q)UH6^@]6J#"9N'D]?CZ_'H%#3$N)
MR+8O/7";-F0D=2YK/TS%:8@,S'V-H% S5W@ DX-/A15RM<5J-3;T&M/%;:Y+
M.1(_&RSU[_AO)-[+1#;,^[W4.UGV]'VOJDK7IGH,^F([V\JJQC[(A*V&H-UV
M C,5H;&-FAL*F#6YE3KMZ5D*4ZIQC: CFBW  %M)I,TQ\-'M*Q/GE]/)%$!<
M%+RU4OP=TD<T$TN'1B/>!-MM2@+'U-X2F*F **4*1$FE-=0!431;FG$^OURV
M2XQ$J7AATF1N"E9/+;\I.&^SQ?I$7":YAK@#C\'B#OC7J&L],%VU;@I)HF6V
M]ZTCLFLGWOH+:YS@SB\GEZT@#C!(F^&M0]O 'WK(!MK4N8$^'X7GWHN&E#M[
M_I,5*Y7+(B/FP)J3(@T[I!$V!)FFNF91.0Z/RCXU<%PE4KW6M?=:#389C6@<
M$A11[\AJ\13NF9 \*>2G3M2R+,EW22%60BZM[Y!1$X5HJ1-Q3T88UY 5*YP
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MWDR0\:=X9$9-!_Z!5>AF]Z^I\-'8GSF2<G>Z^@=(O=_))/W?A73J3GM*B.>
MP^7BDO].KY??^;6&.X?BH#3_27SD$J^]0L])SA +EG.QO'8G1W13/+P/+>#3
M6<ELM'BV$-<@X ZV.F=,\]'R:H8/\]%LMA"'?@1TT?D9%H+YFG]L1DDPP-G]
M(BL^C;]GNW$_XVJ'NQ_#01FP:6J!99@ZG3Q?GCF7"5]JL^4?=:U,79L-?\Q1
MBJJ*!N!]9BC]=U]H@?@KOU?_ U!+ P04    " "\@*54I>?DE7D(  "5&@
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MA;:ZQMO5?;26V8HYIU"4.!QVS;RZ;$-U^".D.E^%X;L@'$^FHR/F(J/(*4;
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M>O!23Q3N(XB[L2;G#P](-6M2_KM6$IH2 =XOC;'-#0EHOT2=_Q=02P,$%
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ML^SD]42X])A,FV";^(!;V8#G8%R6>'^38P&<KRU:L]NP@^%%O_P74$L#!!0
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MJ]SY>X<?''?F: ].R4:I!W?X4LZ#V!%"@85U&1@MCWB-0KA$1.///F<P0+K
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MHX'.'5L+--U9:,F-4PZ3!G)50T9'(&.X5-+F!C[)%-/G]B'1:SE&>XZKZ$W
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MSPG"'!/K$!@-6[S$/'= )..QP0Q:2N>X/W]!_^ACIUC6S."ERN\%M]DBF 3
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M'L)K#SS<ZR0%ZM3W2T-XE;1U4VEWVY9\7G>BO^9U/Z>TI(*N-,<-N?:Z8^J
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MPYQ^.*A= .W/E;*;B4O0_,*&_P!02P,$%     @ O("E5,^"J?G;!0  ^2,
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MXS59TCLJOJWG'-Z-*BV+**%I%K$4<?IX,CBS?[T*+#F@D/A71)^SG==(NO+
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M_</9<0D4? =F^'[]F6&@W9'?BY-&:-)8::.=V]3RWPJ &Y81+(:8/L(H:QA
MF/GFIO[FC6#KXH+U Q.")<7+%24+RJ4 ?/_(9. V;^2=[>K_)4[_#U!+ P04
M    " "\@*54Y*C_&CX&  "4(   &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6R]6MMRVS80_16,FG2<F50B .J6VIZQY5SLW#Q6TSYT^@!3D,0)22@
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M4^QK01H#_+X30C]-S 9-I[SX"5!+ P04    " "\@*54N)O_S5\"  "0!0
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" "\@*54(6[.MLP#  "E'   #P   'AL+W=O<FMB;V]K+GAM;,6946_3,!"
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M5:/U&8U],9\L5+NW;+LWA&]^ U!+ P04    " "\@*54OLLS09D!  !U&0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=E-CH) $(;AJQ@.8%M5
M^#=15[-Q._$"1%LQ@A"Z)Z.W'Z,+_<@L9F/Z6Y%N0O$F)$\(++Y\5<1C<P[E
ML0V#2UV=PS(K8VP_G O;TM=%&#:M/]_.[)NN+N)MV1U<6VQ/Q<$['8TFKGN=
MD:T6KS,'FVOK_S.QV>^/6__9;+]K?XY_#'8_37<*I?<Q&VR*[N#C,G.7ZKD=
MW/T@P]OD;+#>+;-NO9/,I0Y2"-+T009!ECXHAZ \?= 8@L;I@R80-$D?-(6@
M:?J@&03-T@?-(6B>/DA&*..((*F'-8'6@EP+@=>"8 N!V()D"X'9@F@+@=J"
M; N!VX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=[:>]DFT%M1;R706U%O)=!;
M46\ET%M1;R706U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0;R/0VWH?2PCT
M-M3;"/0VU-L(]#;4VPCT-M3;"/0VU-L(]#;4VPCTSE'OG$#O'/7."?3.4>_\
MG7J'>*U\>/8\UGC_=U(=;]?ZY^WOR\=F[[G<<7;PEV7U"U!+ P04    " "\
M@*54(]5N#:@!  "X&0  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F<UNPC 0
MA%\%Y8J(L9W2'P&7MM>60U_ 338D(HDMVU!X^SKA1VI%HR(J=2ZQ$N_.C+W2
M=\GT;6?(#;9UU;A95'AO'AAS:4&U<K$VU(2=7-M:^?!JE\RH=*66Q,1X/&&I
M;CPU?N1;C6@^?:)<K2L_>-Z&SZ[4S2RR5+EH\+@O;+UFD3*F*E/EPS[;--DW
ME]'!(0Z=78TK2N.&H2!B9QW:G9\-#GVO&[*VS&BP4-:_J#I4L6W%G-]5Y.)^
MB3,9=9Z7*64Z7=>A)7;&DLI<0>3K*MZ+#ON=?;AAVC_YU?Z=3)]AJ%Q8;5R8
MF*7+[8XC:;M')@B1]67_$4^.0?KJ\U$[[8RR7WJ'Z_W0=M7-P[%NN?Z.O\[X
MI']A#@&20X+D2$!RW(#DF(#DN 7)<0>2XQXD!Q^C!$$A*D=!*D=A*D>!*D>A
M*D?!*D?A*D<!*T<AJT AJT AJT AJT AJT AJT AJT AJT AJT AJT AJT0A
MJT0AJT0AJT0AJT0AJT0AJT0AJT0AJT0AJT0A:X)"U@2%K,E_DO5=Z]5?_TMH
MU[A697/T9]T/F_DG4$L! A0#%     @ O("E5 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "\@*54
M\TW:8N\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " "\@*54F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +R I50Z1'.@.04
M %@5   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " "\@*54KFQ5\: %  #J%0  &               @(%]
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ O("E5+^!
MLJR, @  -@8  !@              ("!4Q,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( +R I51G<L)_T04  .X6   8
M  " @146  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "\
M@*54DKQ[@P '  "6(   &               @($<'   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ O("E5/A2'<[5!@  P!L  !@
M         ("!4B,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( +R I52NA]OKY@4  $L-   8              " @5TJ  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "\@*54MY,9$N4+  !6(@
M&               @(%Y,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ O("E5#K\+S\F"   *Q@  !@              ("!E#P  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( +R I52"*M5>8@0
M ",-   9              " @?!$  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ O("E5,2BTYSD!0  * X  !D              ("!
MB4D  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "\@*54
MTTW^?J("   <!@  &0              @(&D3P  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( +R I514+&,DL <  #84   9
M      " @7U2  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ O("E5&1>LX8]!@  ! X  !D              ("!9%H  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "\@*549TO_EX\3  #Q-P
M&0              @('88   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( +R I52EY^25>0@  )4:   9              " @9YT  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ O("E5-.9UM*0
M @  J@4  !D              ("!3GT  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " "\@*54*_Z2B0L.  #\*@  &0
M@($5@   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +R
MI51-DS/,N@0  -T+   9              " @5>.  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ O("E5.^+V$UK!    @X  !D
M         ("!2),  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " "\@*540['8;\X#  "="@  &0              @('JEP  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +R I53K2<K&KP(   @&
M   9              " @>^;  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ O("E5& =5O;. @  3P8  !D              ("!U9X
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " "\@*54N81M
M><T#  #1"   &0              @(':H0  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( +R I51TF?X4)P,  +0&   9
M  " @=ZE  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
MO("E5%#:*><] @  IP0  !D              ("!/*D  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " "\@*546D[%5#@#  #3"0  &0
M            @(&PJP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( +R I53Q4WM0FP(  " '   9              " @1^O  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ O("E5%RP-4?]!
MFQP  !D              ("!\;$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " "\@*54G#L[U>L"  ##!P  &0              @($E
MMP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +R I528
MT]N,N@(  ,X&   9              " @4>Z  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ O("E5,^"J?G;!0  ^2,  !D
M     ("!.+T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +R I530B&WJRP(  (\'   9              "
M@5#0  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ O("E
M5+=W!V:G P  <0T  !D              ("!4M,  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " "\@*54V!O:H3H)   [,0  &0
M        @($PUP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( +R I53DJ/\:/@8  )0@   9              " @:'@  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ O("E5!MS:11Q P  -0L
M !D              ("!%N<  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " "\@*54N)O_S5\"  "0!0  &0              @(&^Z@
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( +R I51($%A3
M%@,  &81   -              "  53M  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ O("E5)>*NQS     $P(   L              ( !E?   %]R96QS
M+RYR96QS4$L! A0#%     @ O("E5"%NSK;, P  I1P   \
M ( !?O$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +R I52^RS-!F0$
M '49   :              "  7?U  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( +R I50CU6X-J $  +@9   3              "
M 4CW  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     R #( E0T  "'Y
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>143</ContextCount>
  <ElementCount>205</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statement of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statement of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flow (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of business and future operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Natureofbusinessandfutureoperations</Role>
      <ShortName>Nature of business and future operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Significantaccountingpolicies</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Investments in marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Investmentsinmarketablesecurities</Role>
      <ShortName>Investments in marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Investment in Genevant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/InvestmentinGenevant</Role>
      <ShortName>Investment in Genevant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Accounts payable and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Accountspayableandaccruedliabilities</Role>
      <ShortName>Accounts payable and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Sale of future royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Saleoffutureroyalties</Role>
      <ShortName>Sale of future royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Contingencies and commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Contingenciesandcommitments</Role>
      <ShortName>Contingencies and commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborations, contracts and licensing agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements</Role>
      <ShortName>Collaborations, contracts and licensing agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Shareholders??? equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Shareholdersequity</Role>
      <ShortName>Shareholders??? equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/Relatedpartytransactions</Role>
      <ShortName>Related party transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2212202 - Disclosure - Fair Value Measures and Disclosures (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies</Role>
      <ShortName>Fair Value Measures and Disclosures (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Fairvaluemeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Investments in marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables</Role>
      <ShortName>Investments in marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Investmentsinmarketablesecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Accounts payable and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables</Role>
      <ShortName>Accounts payable and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Accountspayableandaccruedliabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Sale of future royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleoffutureroyaltiesTables</Role>
      <ShortName>Sale of future royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Saleoffutureroyalties</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Collaborations, contracts and licensing agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables</Role>
      <ShortName>Collaborations, contracts and licensing agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Shareholders??? equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ShareholdersequityTables</Role>
      <ShortName>Shareholders??? equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Shareholdersequity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of business and future operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails</Role>
      <ShortName>Nature of business and future operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Natureofbusinessandfutureoperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Significant accounting policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SignificantaccountingpoliciesDetails</Role>
      <ShortName>Significant accounting policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair value measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails</Role>
      <ShortName>Fair value measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails</Role>
      <ShortName>Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Fair value measurements - Changes in Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails</Role>
      <ShortName>Fair value measurements - Changes in Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Investments in marketable securities - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails</Role>
      <ShortName>Investments in marketable securities - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Investments in marketable securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails</Role>
      <ShortName>Investments in marketable securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Investment in Genevant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/InvestmentinGenevantDetails</Role>
      <ShortName>Investment in Genevant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/InvestmentinGenevant</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Accounts payable and accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails</Role>
      <ShortName>Accounts payable and accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Sale of future royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails</Role>
      <ShortName>Sale of future royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Sale of future royalties - Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails</Role>
      <ShortName>Sale of future royalties - Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Contingencies and commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ContingenciesandcommitmentsDetails</Role>
      <ShortName>Contingencies and commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Contingenciesandcommitments</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Collaborations, contracts and licensing agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails</Role>
      <ShortName>Collaborations, contracts and licensing agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Shareholders??? equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ShareholdersequityNarrativeDetails</Role>
      <ShortName>Shareholders??? equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Shareholders??? equity - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails</Role>
      <ShortName>Shareholders??? equity - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="abus-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436417 - Disclosure - Related party transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arbutusbio.com/role/RelatedpartytransactionsDetails</Role>
      <ShortName>Related party transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://arbutusbio.com/role/Relatedpartytransactions</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="abus-20220331.htm">abus-20220331.htm</File>
    <File>a2022-q110xqex311.htm</File>
    <File>a2022-q110xqex312.htm</File>
    <File>a2022-q110xqex321.htm</File>
    <File>a2022-q110xqex322.htm</File>
    <File>abus-20220331.xsd</File>
    <File>abus-20220331_cal.xml</File>
    <File>abus-20220331_def.xml</File>
    <File>abus-20220331_lab.xml</File>
    <File>abus-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>abus-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="457">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "abus-20220331.htm": {
   "axisCustom": 1,
   "axisStandard": 23,
   "contextCount": 143,
   "dts": {
    "calculationLink": {
     "local": [
      "abus-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abus-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "abus-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abus-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abus-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abus-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 370,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 32,
   "keyStandard": 173,
   "memberCustom": 34,
   "memberStandard": 19,
   "nsprefix": "abus",
   "nsuri": "http://arbutusbio.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://arbutusbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Investments in marketable securities",
     "role": "http://arbutusbio.com/role/Investmentsinmarketablesecurities",
     "shortName": "Investments in marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Investment in Genevant",
     "role": "http://arbutusbio.com/role/InvestmentinGenevant",
     "shortName": "Investment in Genevant",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Accounts payable and accrued liabilities",
     "role": "http://arbutusbio.com/role/Accountspayableandaccruedliabilities",
     "shortName": "Accounts payable and accrued liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Sale of future royalties",
     "role": "http://arbutusbio.com/role/Saleoffutureroyalties",
     "shortName": "Sale of future royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Contingencies and commitments",
     "role": "http://arbutusbio.com/role/Contingenciesandcommitments",
     "shortName": "Contingencies and commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborations, contracts and licensing agreements",
     "role": "http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements",
     "shortName": "Collaborations, contracts and licensing agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Shareholders\u2019 equity",
     "role": "http://arbutusbio.com/role/Shareholdersequity",
     "shortName": "Shareholders\u2019 equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Related party transactions",
     "role": "http://arbutusbio.com/role/Relatedpartytransactions",
     "shortName": "Related party transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant accounting policies (Policies)",
     "role": "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies",
     "shortName": "Significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2212202 - Disclosure - Fair Value Measures and Disclosures (Policies)",
     "role": "http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies",
     "shortName": "Fair Value Measures and Disclosures (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair value measurements (Tables)",
     "role": "http://arbutusbio.com/role/FairvaluemeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Investments in marketable securities (Tables)",
     "role": "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables",
     "shortName": "Investments in marketable securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Accounts payable and accrued liabilities (Tables)",
     "role": "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables",
     "shortName": "Accounts payable and accrued liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Sale of future royalties (Tables)",
     "role": "http://arbutusbio.com/role/SaleoffutureroyaltiesTables",
     "shortName": "Sale of future royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Collaborations, contracts and licensing agreements (Tables)",
     "role": "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables",
     "shortName": "Collaborations, contracts and licensing agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Shareholders\u2019 equity (Tables)",
     "role": "http://arbutusbio.com/role/ShareholdersequityTables",
     "shortName": "Shareholders\u2019 equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of business and future operations (Details)",
     "role": "http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails",
     "shortName": "Nature of business and future operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abus:WhollyOwnedSubsidiariesIncludedinFinancialStatements",
      "reportCount": 1,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Significant accounting policies (Details)",
     "role": "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails",
     "shortName": "Significant accounting policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair value measurements - Narrative (Details)",
     "role": "http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails",
     "shortName": "Fair value measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair value measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i711a0a90695f46ef8552c9299d3498e2_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abus:ChangesInFairValueofLiabilityOptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i624eddd7b8ae4655ac59e95730e93120_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)",
     "role": "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails",
     "shortName": "Fair value measurements - Changes in Fair Value of Liabilities-Classified as Stock Option (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abus:ChangesInFairValueofLiabilityOptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i624eddd7b8ae4655ac59e95730e93120_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "abus:EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Fair value measurements - Changes in Fair Value of Contingent Consideration (Details)",
     "role": "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails",
     "shortName": "Fair value measurements - Changes in Fair Value of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Investments in marketable securities - Marketable Securities (Details)",
     "role": "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails",
     "shortName": "Investments in marketable securities - Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "ice751ffe6d7e48ddb20b37ddb2b8ff36_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Investments in marketable securities - Narrative (Details)",
     "role": "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails",
     "shortName": "Investments in marketable securities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Investment in Genevant (Details)",
     "role": "http://arbutusbio.com/role/InvestmentinGenevantDetails",
     "shortName": "Investment in Genevant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Accounts payable and accrued liabilities (Details)",
     "role": "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails",
     "shortName": "Accounts payable and accrued liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "abus:NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Sale of future royalties - Narrative (Details)",
     "role": "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails",
     "shortName": "Sale of future royalties - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3303598798c74c2fbaaf1530fadcac48_D20190702-20190702",
      "decimals": "-5",
      "lang": "en-US",
      "name": "abus:TransactionCostsRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "ie484f8f1ec1b4fda8e790a3f6fc1df11_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Sale of future royalties - Liability Activity (Details)",
     "role": "http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails",
     "shortName": "Sale of future royalties - Liability Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "abus:LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i9224b001bc0a44cf93d53e9e5adf97cc_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "abus:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Contingencies and commitments (Details)",
     "role": "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
     "shortName": "Contingencies and commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i9b3a998dc61042eda3caff10aef9779e_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "abus:RoyaltyEntitlements",
      "reportCount": 1,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Collaborations, contracts and licensing agreements (Details)",
     "role": "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
     "shortName": "Collaborations, contracts and licensing agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i26d1b7d5ae1e4539afc8224daefff106_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Shareholders\u2019 equity - Narrative (Details)",
     "role": "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails",
     "shortName": "Shareholders\u2019 equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i3bcc9555d8824a6fa9ecc36b75e7ccb3_I20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Shareholders\u2019 equity - Stock-based Compensation (Details)",
     "role": "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails",
     "shortName": "Shareholders\u2019 equity - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436417 - Disclosure - Related party transactions (Details)",
     "role": "http://arbutusbio.com/role/RelatedpartytransactionsDetails",
     "shortName": "Related party transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i529fe92209cb4956a9a2e9afd9814ba5_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statement of Stockholders\u2019 Equity (Unaudited)",
     "role": "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statement of Stockholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "ibec0b4c0ef814f20b76c2af0a7ff292f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "role": "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flow (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of business and future operations",
     "role": "http://arbutusbio.com/role/Natureofbusinessandfutureoperations",
     "shortName": "Nature of business and future operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant accounting policies",
     "role": "http://arbutusbio.com/role/Significantaccountingpolicies",
     "shortName": "Significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair value measurements",
     "role": "http://arbutusbio.com/role/Fairvaluemeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "abus-20220331.htm",
      "contextRef": "i81a71982cd8541b79ec0ba98596489ce_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 60,
   "tag": {
    "abus_A2019AmendedSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Amended Sale Agreement",
        "label": "2019 Amended Sale Agreement [Member]",
        "terseLabel": "2019 Amended Sale Agreement"
       }
      }
     },
     "localname": "A2019AmendedSaleAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_AccruedPayrollCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Payroll Current",
        "label": "Accrued Payroll Current",
        "terseLabel": "Payroll accruals"
       }
      }
     },
     "localname": "AccruedPayrollCurrent",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development accruals",
        "label": "Accrued Research And Development",
        "terseLabel": "Research and development accruals"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_AcuitasTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acuitas Therapeutics Inc.",
        "label": "Acuitas Therapeutics Inc. [Member]",
        "terseLabel": "Acuitas Therapeutics, Inc."
       }
      }
     },
     "localname": "AcuitasTherapeuticsInc.Member",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards",
        "label": "Adjustments to Additional Paid in Capital, Certain Fair Value Adjustments to Liability Stock Option Awards",
        "terseLabel": "Certain fair value adjustments to liability stock option awards"
       }
      }
     },
     "localname": "AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_AlnylamPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc",
        "label": "Alnylam Pharmaceuticals, Inc [Member]",
        "terseLabel": "Alnylam Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsIncMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_ArbitrationWithTheUniversityOfBritishColumbiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to arbitration with the University of British Columbia.",
        "label": "Arbitration With The University Of British Columbia [Member]",
        "terseLabel": "Arbitration with the University of British Columbia"
       }
      }
     },
     "localname": "ArbitrationWithTheUniversityOfBritishColumbiaMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_ArbutusInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Inc. [Member]",
        "label": "Arbutus Inc. [Member]",
        "terseLabel": "Arbutus Inc."
       }
      }
     },
     "localname": "ArbutusInc.Member",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_ArbutusPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Plans [Member]",
        "label": "Arbutus Plans [Member]",
        "terseLabel": "Arbutus Plans"
       }
      }
     },
     "localname": "ArbutusPlansMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_AssemblyBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assembly Biosciences, Inc.",
        "label": "Assembly Biosciences, Inc. [Member]",
        "terseLabel": "Assembly Biosciences, Inc."
       }
      }
     },
     "localname": "AssemblyBiosciencesIncMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Aug2020ProspectusSupplementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aug 2020 Prospectus Supplement",
        "label": "Aug 2020 Prospectus Supplement [Member]",
        "terseLabel": "Aug 2020 Prospectus Supplement"
       }
      }
     },
     "localname": "Aug2020ProspectusSupplementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_BonaFideCollaborationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bona fide collaboration Percentage",
        "label": "Bona fide collaboration Percentage",
        "terseLabel": "Bona fide collaboration Percentage"
       }
      }
     },
     "localname": "BonaFideCollaborationPercentage",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_ChangesInFairValueofLiabilityOptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Fair Value of Liability Option [Table Text Block]",
        "label": "Changes In Fair Value of Liability Option [Table Text Block]",
        "terseLabel": "Changes in fair value of liability option"
       }
      }
     },
     "localname": "ChangesInFairValueofLiabilityOptionTableTextBlock",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abus_CollaborationAndContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Contracts [Member]",
        "label": "Collaboration And Contracts [Member]",
        "terseLabel": "Collaborations and licenses"
       }
      }
     },
     "localname": "CollaborationAndContractsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_ContingenciesandCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies and Commitments [Line Items]",
        "terseLabel": "Contingencies and Commitments [Line Items]"
       }
      }
     },
     "localname": "ContingenciesandCommitmentsLineItems",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_ContingenciesandCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies and Commitments [Table]",
        "terseLabel": "Contingencies and Commitments [Table]"
       }
      }
     },
     "localname": "ContingenciesandCommitmentsTable",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_EffectiveAnnualInterestRateOfRoyaltyLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Annual Interest Rate Of Royalty Liability",
        "label": "Effective Annual Interest Rate Of Royalty Liability",
        "terseLabel": "Effective annual interest rate on royalty liability"
       }
      }
     },
     "localname": "EffectiveAnnualInterestRateOfRoyaltyLiability",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_EmployeeStockOptionLiabilityClassifiedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Option, Liability Classified [Member]",
        "label": "Employee Stock Option, Liability Classified [Member]",
        "terseLabel": "Liability classified stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionLiabilityClassifiedMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure",
        "label": "Employee Stock Options, Liability Classified, Outstanding, Fair Value Disclosure",
        "netLabel": "Liability-classified options",
        "periodEndLabel": "Liability at end of the period",
        "periodStartLabel": "Liability at beginning of the period"
       }
      }
     },
     "localname": "EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_EnantigensSellingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enantigen's Selling Shareholders",
        "label": "Enantigen's Selling Shareholders [Member]",
        "terseLabel": "Enantigen's Selling Shareholders"
       }
      }
     },
     "localname": "EnantigensSellingShareholdersMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredonRecurringBasisRollForward",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_GenevantSciencesCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genevant Sciences Corporation [Member]",
        "label": "Genevant Sciences Corporation [Member]",
        "terseLabel": "Genevant Sciences Corporation",
        "verboseLabel": "Genevant"
       }
      }
     },
     "localname": "GenevantSciencesCorporationMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/InvestmentinGenevantDetails",
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_GrossProceedsFromRoyaltyInterestSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds From Royalty Interest Sold",
        "label": "Gross Proceeds From Royalty Interest Sold",
        "terseLabel": "Gross proceeds from sale of royalty interest. before advisory fees"
       }
      }
     },
     "localname": "GrossProceedsFromRoyaltyInterestSold",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_IncreaseDecreaseInFairValueOfContingentConsiderationLiability": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Fair Value Of Contingent Consideration Liability",
        "label": "Increase (Decrease) In Fair Value Of Contingent Consideration Liability",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "IncreaseDecreaseInFairValueOfContingentConsiderationLiability",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_IncreaseDecreaseinFairValueofLiabilityClassifiedOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Fair Value of Liability Classified Options",
        "label": "Increase (Decrease) in Fair Value of Liability Classified Options",
        "terseLabel": "Decrease in fair value of liability"
       }
      }
     },
     "localname": "IncreaseDecreaseinFairValueofLiabilityClassifiedOptions",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_Jan2020Oct2020AndNov2021RegistrationStmtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member]",
        "label": "Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member]",
        "terseLabel": "Jan 2020 Oct 2020 and Nov 2021 Registration Stmts"
       }
      }
     },
     "localname": "Jan2020Oct2020AndNov2021RegistrationStmtsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Jan2020ProspectusSupplementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jan 2020 Prospectus Supplement Agreement",
        "label": "Jan 2020 Prospectus Supplement Agreement [Member]",
        "terseLabel": "Jan 2020 Prospectus Supplement Agreement [Member]"
       }
      }
     },
     "localname": "Jan2020ProspectusSupplementAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Jan2020ProspectusSupplementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jan 2020 Prospectus Supplement",
        "label": "Jan 2020 Prospectus Supplement [Member]",
        "terseLabel": "Jan 2020 Prospectus Supplement"
       }
      }
     },
     "localname": "Jan2020ProspectusSupplementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Jan2020RegistrationStmtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jan 2020 Registration Stmt",
        "label": "Jan 2020 Registration Stmt [Member]",
        "terseLabel": "Jan 2020 Registration Stmt [Member]"
       }
      }
     },
     "localname": "Jan2020RegistrationStmtMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities Related To Sale Of Future Royalties Roll Forward",
        "label": "Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of activity related to the net liability from inception of the Agreement"
       }
      }
     },
     "localname": "LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities Related To Sale Of Future Royalties",
        "label": "Liabilities Related To Sale Of Future Royalties [Text Block]",
        "terseLabel": "Sale of future royalties"
       }
      }
     },
     "localname": "LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/Saleoffutureroyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability From Sale Of Future Royalties, Non Cash Expense",
        "label": "Liability From Sale Of Future Royalties, Non Cash Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRoyaltiesNonCashExpense",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability From Sale Of Future Royalties, Non Cash Royalty Income",
        "label": "Liability From Sale Of Future Royalties, Non Cash Royalty Income",
        "negatedLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties, Noncurrent",
        "label": "Liability Related To Sale Of Future Royalties, Noncurrent",
        "periodEndLabel": "Net liability related to sale of future royalties - ending balance",
        "periodStartLabel": "Net liability related to sale of future royalties - beginning balance",
        "terseLabel": "Liability related to sale of future royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_LiabilityRelatedToSaleOfFutureRoyaltiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Related To Sale Of Future Royalties [Roll Forward]",
        "label": "Liability Related To Sale Of Future Royalties [Roll Forward]",
        "terseLabel": "Liability Related To Sale Of Future Royalties [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesRollForward",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Maximum Development and Regulatory Milestone Payments Per License",
        "label": "License Agreement Maximum Development And Regulatory Milestone Payments Per License",
        "verboseLabel": "Development and regulatory milestones payment per licensed compound series, maximum"
       }
      }
     },
     "localname": "LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Maximum Development And Regulatory Royalty Payment per Royalty",
        "label": "License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty",
        "terseLabel": "Development and regulatory milestones payment per royalty, maximum"
       }
      }
     },
     "localname": "LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Investments",
        "label": "Long-Term Investments [Member]",
        "terseLabel": "Long-term securities"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Mar2021ProspectusSupplementAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prospectus Supplement - Open Market Sale Agreement Mar 2021",
        "label": "Mar 2021 Prospectus Supplement Agreement [Member]",
        "terseLabel": "Mar 2021 Prospectus Supplement Agreement [Member]"
       }
      }
     },
     "localname": "Mar2021ProspectusSupplementAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_March2022ProspectusSupplementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March 2022 Prospectus Supplement",
        "label": "March 2022 Prospectus Supplement [Member]",
        "terseLabel": "March 2022 Prospectus Supplement [Member]"
       }
      }
     },
     "localname": "March2022ProspectusSupplementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Interest Expense Related To Sale Of Future Royalties",
        "label": "Non Cash Interest Expense Related To Sale Of Future Royalties",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_NonCashRoyaltyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Royalty",
        "label": "Non-Cash Royalty [Member]",
        "terseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "negatedTerseLabel": "Non-cash royalty revenue",
        "terseLabel": "Non Cash Royalty Revenue Related To Sale Of Future Royalties",
        "verboseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion",
        "label": "Noncontrolling Interest, Ownership Percentage By Noncontrolling Owners After Conversion",
        "terseLabel": "Ownership percentage by noncontrolling owners after conversion"
       }
      }
     },
     "localname": "NoncontrollingInterestOwnershipPercentageByNoncontrollingOwnersAfterConversion",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_OMERSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OMERS",
        "label": "OMERS [Member]",
        "terseLabel": "OMERS"
       }
      }
     },
     "localname": "OMERSMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_Oct2020RegistrationStmtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oct 2020 Registration Stmt",
        "label": "Oct 2020 Registration Stmt [Member]",
        "terseLabel": "Oct 2020 Registration Stmt [Member]"
       }
      }
     },
     "localname": "Oct2020RegistrationStmtMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_October2021ProspectusSupplementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "October 2021 Prospectus Supplement",
        "label": "October 2021 Prospectus Supplement [Member]",
        "terseLabel": "October 2021 Prospectus Supplement"
       }
      }
     },
     "localname": "October2021ProspectusSupplementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_OneTimeUpfrontCashPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One-Time Upfront Cash Payment",
        "label": "One-Time Upfront Cash Payment [Member]",
        "terseLabel": "One-Time Upfront Cash Payment"
       }
      }
     },
     "localname": "OneTimeUpfrontCashPaymentMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale Agreement",
        "label": "Open Market Sale Agreement [Member]",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_OtherLiabilitiesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Liabilities Disclosure [Line Items]",
        "label": "Other Liabilities Disclosure [Line Items]",
        "terseLabel": "Other Liabilities Disclosure [Line Items]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureLineItems",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_OtherMilestoneandRoyaltyPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Milestone and Royalty Payments [Member]",
        "label": "Other Milestone and Royalty Payments [Member]",
        "terseLabel": "Other milestone and royalty payments"
       }
      }
     },
     "localname": "OtherMilestoneandRoyaltyPaymentsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the potential milestone payments amount.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential Milestone Payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_PremiumonClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on Closing Stock Price",
        "label": "Premium on Closing Stock Price",
        "terseLabel": "Premium on closing stock price (as a percent)"
       }
      }
     },
     "localname": "PremiumonClosingStockPrice",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_QiluPharmaceuticalCoLTDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co, LTD.",
        "label": "Qilu Pharmaceutical Co, LTD. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co, LTD. [Member]"
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLTDMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_RegistrationStatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Statement",
        "label": "Registration Statement [Axis]",
        "terseLabel": "Registration Statement [Axis]"
       }
      }
     },
     "localname": "RegistrationStatementAxis",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_RegistrationStatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Statement [Domain]",
        "label": "Registration Statement [Domain]",
        "terseLabel": "Registration Statement [Domain]"
       }
      }
     },
     "localname": "RegistrationStatementDomain",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Services [Member]",
        "label": "Research And Development Services [Member]",
        "terseLabel": "Research and development services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_RoivantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roivant Sciences Ltd [Member]",
        "label": "Roivant Sciences Ltd [Member]",
        "terseLabel": "Roivant Sciences Ltd"
       }
      }
     },
     "localname": "RoivantSciencesLtdMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_RoyaltyEntitlements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Entitlements",
        "label": "Royalty Entitlements",
        "terseLabel": "Number of royalty entitlements"
       }
      }
     },
     "localname": "RoyaltyEntitlements",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abus_RoyaltyGuaranteesCommitmentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty guarantees commitments percentage.",
        "label": "Royalty Guarantees Commitments Percentage",
        "verboseLabel": "Royalty guarantees commitments percentage"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsPercentage",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Interest Sold, Maximum Royalties For Buyer",
        "label": "Royalty Interest Sold, Maximum Royalties For Buyer",
        "terseLabel": "Entitlement of royalties to be received"
       }
      }
     },
     "localname": "RoyaltyInterestSoldMaximumRoyaltiesForBuyer",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier",
        "label": "Royalty Interest Sold, Percentage Of Sales, Annual Revenue Threshold Of Highest Tier",
        "terseLabel": "Annual royalty revenue"
       }
      }
     },
     "localname": "RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_RoyaltyPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty payable.",
        "label": "Royalty Payable",
        "terseLabel": "Future royalty payments"
       }
      }
     },
     "localname": "RoyaltyPayable",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_RoyaltyPercentageofInterestSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, Percentage of Interest Sold",
        "label": "Royalty, Percentage of Interest Sold",
        "verboseLabel": "Royalty, interest sold, percentage"
       }
      }
     },
     "localname": "RoyaltyPercentageofInterestSold",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_SaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Agreement",
        "label": "Sale Agreement [Member]",
        "terseLabel": "Sale Agreement [Member]"
       }
      }
     },
     "localname": "SaleAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_SharePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement",
        "label": "Share Purchase Agreement [Member]",
        "terseLabel": "Share Purchase Agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Fair Value",
        "negatedTerseLabel": "Fair value of liability-classified options exercised in the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisesinPeriodFairValue",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_SubLicensingRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sub-licensing revenue Percentage",
        "label": "Sub-licensing revenue Percentage",
        "terseLabel": "Sub-licensing revenue percentage"
       }
      }
     },
     "localname": "SubLicensingRevenuePercentage",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abus_TransactionCostsRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Related To Sale Of Future Royalties",
        "label": "Transaction Costs Related To Sale Of Future Royalties",
        "terseLabel": "Transaction costs on sale of royalties"
       }
      }
     },
     "localname": "TransactionCostsRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abus_USGovernmentAgencyBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Agency Bonds [Member]",
        "label": "US Government Agency Bonds [Member]",
        "terseLabel": "US government agency bonds"
       }
      }
     },
     "localname": "USGovernmentAgencyBondsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_USGovernmentBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Bonds [Member]",
        "label": "US Government Bonds [Member]",
        "terseLabel": "US government bonds"
       }
      }
     },
     "localname": "USGovernmentBondsMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_USGovernmentMoneyMarkeTFundMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Government Money Marke tFund",
        "label": "US Government Money Marke tFund [Member]",
        "terseLabel": "US government money market fund"
       }
      }
     },
     "localname": "USGovernmentMoneyMarkeTFundMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abus_WeightedAverageNumberOfCommonSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of common shares",
        "label": "Weighted Average Number Of Common Shares [Abstract]",
        "terseLabel": "Weighted average number of common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfCommonSharesAbstract",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "abus_WhollyOwnedSubsidiariesIncludedinFinancialStatements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of wholly owned subsidiaries included in the reporting of the financial statements.",
        "label": "Wholly Owned Subsidiaries Included in Financial Statements",
        "terseLabel": "Number of wholly-owed subsidiaries"
       }
      }
     },
     "localname": "WhollyOwnedSubsidiariesIncludedinFinancialStatements",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abus_XChemIncAndProterosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "X-Chem, Inc. and Proteros",
        "label": "X-Chem, Inc. and Proteros [Member]",
        "terseLabel": "X-Chem, Inc. and Proteros [Member]"
       }
      }
     },
     "localname": "XChemIncAndProterosMember",
     "nsuri": "http://arbutusbio.com/20220331",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://arbutusbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r39",
      "r41",
      "r90",
      "r91",
      "r209",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r154",
      "r258",
      "r262",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r275",
      "r277",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r389",
      "r425",
      "r428",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r275",
      "r277",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r389",
      "r425",
      "r428",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r154",
      "r258",
      "r262",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r152",
      "r258",
      "r261",
      "r391",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r152",
      "r258",
      "r261",
      "r391",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r208",
      "r221",
      "r264",
      "r275",
      "r277",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r389",
      "r425",
      "r428",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r208",
      "r221",
      "r264",
      "r275",
      "r277",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r389",
      "r425",
      "r428",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r90",
      "r91",
      "r209",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails",
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Accountspayableandaccruedliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r30"
     ],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net accretion and amortization of investments in marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fee accruals"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r43",
      "r44",
      "r45",
      "r412",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r42",
      "r45",
      "r52",
      "r53",
      "r54",
      "r93",
      "r94",
      "r95",
      "r316",
      "r429",
      "r430",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r17",
      "r292",
      "r358"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r289",
      "r290",
      "r291",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Non-cash items:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r278",
      "r280",
      "r294",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AirlineProductsAndServicesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of each product and service or each group of similar products and services of an entity by various financial or nonfinancial attributes.",
        "label": "Products and Services [Table]",
        "terseLabel": "Products and Services [Table]"
       }
      }
     },
     "localname": "AirlineProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SaleoffutureroyaltiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r280",
      "r286",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common shares excluded from calculation of loss per common share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r88",
      "r134",
      "r144",
      "r150",
      "r173",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r313",
      "r317",
      "r331",
      "r356",
      "r358",
      "r394",
      "r410"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r88",
      "r173",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r313",
      "r317",
      "r331",
      "r356",
      "r358"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments in marketable securities, Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments in marketable securities, Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r160",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r158",
      "r161",
      "r181",
      "r397"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Investments in marketable securities, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails",
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r159",
      "r181"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Investments in marketable securities, current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r159",
      "r181"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Investments in marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r281",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r274",
      "r276",
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r77",
      "r308"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "netLabel": "Increase in fair value of liability",
        "terseLabel": "Increase (decrease) in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "periodEndLabel": "Liability at end of the period",
        "periodStartLabel": "Liability at beginning of the period",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofContingentConsiderationDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r26",
      "r80"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents, Fair Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and investments in marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r73",
      "r80",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r73",
      "r336"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r86",
      "r88",
      "r109",
      "r110",
      "r111",
      "r114",
      "r116",
      "r123",
      "r124",
      "r125",
      "r173",
      "r197",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r219",
      "r220",
      "r224",
      "r228",
      "r331",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r309",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations, contracts and licensing agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Collaborationscontractsandlicensingagreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r196",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Contingenciesandcommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common shares, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r15",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Aggregate sale price of common shares under agreement"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r358"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Issued and outstanding: 148,728,237 (December 31, 2021: 144,987,736)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r48",
      "r50",
      "r51",
      "r61",
      "r402",
      "r419"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of deferred collaborations and contracts revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r246",
      "r247",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Total deferred license revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Cumulative Collaboration Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r13",
      "r14",
      "r231",
      "r237",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of common shares issued upon conversion of preferred shares"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails",
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gains or losses"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred Revenue, Current"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred Revenue, Noncurrent"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r78",
      "r132"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r244",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedTerseLabel": "Preferred shares dividends accrued"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r106",
      "r109",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r321",
      "r322",
      "r403",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r109",
      "r114",
      "r115",
      "r116",
      "r120",
      "r121",
      "r321",
      "r322",
      "r403",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss attributable to common shareholders per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r52",
      "r53",
      "r54",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r122",
      "r175",
      "r236",
      "r244",
      "r289",
      "r290",
      "r291",
      "r300",
      "r301",
      "r320",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r429",
      "r430",
      "r431",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest in equity method investment (as a percentage)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r27",
      "r135",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investment in Genevant"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevant"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r211",
      "r214",
      "r215",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r324",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r326",
      "r327",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Fairvaluemeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r211",
      "r265",
      "r266",
      "r271",
      "r273",
      "r324",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r211",
      "r214",
      "r215",
      "r265",
      "r266",
      "r271",
      "r273",
      "r324",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r211",
      "r214",
      "r215",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r324",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairValueMeasuresandDisclosuresPolicies",
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r211",
      "r214",
      "r215",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r273",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails",
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r212",
      "r234",
      "r319",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange (loss) gain"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r79",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Unrealized foreign exchange losses (gains)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r134",
      "r143",
      "r146",
      "r149",
      "r151",
      "r392",
      "r399",
      "r405",
      "r421"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r104",
      "r105",
      "r133",
      "r299",
      "r302",
      "r303",
      "r422"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r75",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred license revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net change in operating items:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r56",
      "r131",
      "r344",
      "r345",
      "r404"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r67",
      "r130"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r393",
      "r407",
      "r451",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Investmentsinmarketablesecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r88",
      "r145",
      "r173",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r314",
      "r317",
      "r318",
      "r331",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r88",
      "r173",
      "r331",
      "r358",
      "r396",
      "r414"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r88",
      "r173",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r314",
      "r317",
      "r318",
      "r331",
      "r356",
      "r357",
      "r358"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue from collaborations and licenses"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r210",
      "r213",
      "r214",
      "r215",
      "r395",
      "r411"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/NatureofbusinessandfutureoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Investments in marketable securities, non-current"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arbutusbio.com/role/FairvaluemeasurementsAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r193",
      "r194",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Loss contingency, damages sought for allegedly unpaid royalties"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ContingenciesandcommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of business and future operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Natureofbusinessandfutureoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r73",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r46",
      "r49",
      "r54",
      "r59",
      "r79",
      "r88",
      "r96",
      "r98",
      "r99",
      "r100",
      "r101",
      "r104",
      "r105",
      "r112",
      "r134",
      "r143",
      "r146",
      "r149",
      "r151",
      "r173",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r322",
      "r331",
      "r400",
      "r417"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r106",
      "r107",
      "r113",
      "r116",
      "r134",
      "r143",
      "r146",
      "r149",
      "r151"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common shares"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other loss"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r143",
      "r146",
      "r149",
      "r151"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r50",
      "r52",
      "r53",
      "r55",
      "r60",
      "r236",
      "r337",
      "r342",
      "r343",
      "r401",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Costs related to collaboration"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDeferredCostsGross": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.",
        "label": "Other Deferred Costs, Gross",
        "terseLabel": "Other Deferred Costs, Gross"
       }
      }
     },
     "localname": "OtherDeferredCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r281",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockAccretionOfRedemptionDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion of the preferred stock redemption discount during the period.",
        "label": "Preferred Stock, Accretion of Redemption Discount",
        "terseLabel": "Accretion of accumulated dividends on Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockAccretionOfRedemptionDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred stock dividend rate as a percent"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r107",
      "r117"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedTerseLabel": "Dividend accretion of convertible preferred shares."
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Dividends and Other Adjustments [Abstract]",
        "terseLabel": "Items applicable to preferred shares:"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Shares"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stated value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r398",
      "r416",
      "r423",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premiums Earned, Net"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common shares pursuant to the Open Market Sale agreement",
        "verboseLabel": "Proceeds from issuance of shares under the agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Disposition of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r288"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Issuance of common shares pursuant to exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Issuance of common shares pursuant to ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r187",
      "r358",
      "r408",
      "r415"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $9,768 (December 31, 2021: $9,374)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Recovery of Direct Costs"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r272",
      "r350",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "terseLabel": "Income from services (less than)"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r351",
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Relatedpartytransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r296",
      "r390",
      "r455"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r244",
      "r292",
      "r358",
      "r413",
      "r432",
      "r434"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r175",
      "r289",
      "r290",
      "r291",
      "r300",
      "r301",
      "r320",
      "r429",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue from collaborations and licenses and Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, Remaining Performance Obligation, Amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r57",
      "r88",
      "r128",
      "r129",
      "r142",
      "r147",
      "r148",
      "r152",
      "r153",
      "r154",
      "r173",
      "r197",
      "r198",
      "r199",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r331",
      "r405"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued under agreement (in sales)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/AccountspayableandaccruedliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of changes in fair value of contingent consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of collaborations"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r114",
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r280",
      "r285",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r1",
      "r88",
      "r172",
      "r173",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentinGenevantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/RelatedpartytransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r281",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r86",
      "r123",
      "r124",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r228",
      "r234",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/SignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r279",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/FairvaluemeasurementsChangesinFairValueofLiabilitiesClassifiedasStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/ShareholdersequityStockbasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r447",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term securities"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Significantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r86",
      "r88",
      "r109",
      "r110",
      "r111",
      "r114",
      "r116",
      "r123",
      "r124",
      "r125",
      "r173",
      "r197",
      "r201",
      "r202",
      "r203",
      "r206",
      "r207",
      "r219",
      "r220",
      "r224",
      "r228",
      "r236",
      "r331",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r52",
      "r53",
      "r54",
      "r93",
      "r94",
      "r95",
      "r97",
      "r103",
      "r105",
      "r122",
      "r175",
      "r236",
      "r244",
      "r289",
      "r290",
      "r291",
      "r300",
      "r301",
      "r320",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r429",
      "r430",
      "r431",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r122",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r236",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common shares pursuant to ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r236",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares pursuant to the Open Market Sales Agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r236",
      "r244",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common shares pursuant to exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r236",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common shares pursuant to ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r236",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares pursuant to the Open Market Sale Agreement",
        "verboseLabel": "Issuance of common shares pursuant to the agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r236",
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common shares pursuant to exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r20",
      "r21",
      "r88",
      "r157",
      "r173",
      "r331",
      "r358"
     ],
     "calculation": {
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r235",
      "r244",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/Shareholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementofStockholdersEquityUnaudited",
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited",
      "http://arbutusbio.com/role/ShareholdersequityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofCashFlowUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r212",
      "r234",
      "r319",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CollaborationscontractsandlicensingagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "US treasury bills"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/InvestmentsinmarketablesecuritiesMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r106",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://arbutusbio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r456": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r457": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r458": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r459": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r467": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r468": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r469": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001447028-22-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001447028-22-000025-xbrl.zip
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M=[8!OW<*W,+]_LES;_A#R,P$0U13HS**58(:B CDO AUJMD2=A (@H9""KM
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MUEQWH:%1LK#;7;YR:;'\]%<HW67.L_\ 4$L#!!0    ( +R I52)8]W13 @
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M^2N8/7_8/N,;=Q)7^=6ERN:J"YT8)7.[V>4SUQB+3W^ITEWO//D+4$L#!!0
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M=&WLO6E76TFR+OS]_ J]]'G/K5J+M',>J&KNPH#=U+&$#:+<\,4K1Q#60&O
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M)&S.!/Q9N7BD'8?*L63A![#P^G46!L2/52 1W# <$*?8(!=E0-%SBT723%F
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M]AJH#-J-(:/VBGR^A>O,BU,RGAG-$G?<>FZEX!P^!&69=E:->O0(#* I1-\
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M6'7]0'T\%[AZJ$/]ZF5[7&BDE.W)R?9-7!*QH4(8A9*3"G!)\$@+)I$74IK
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M%8\9BH"\8I%_AGS44N3'*O(WH AFREOA. K,4\0I.!8&4XMT=#%R+'RPI.2
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M\IZI))5@7 !P$/@I_FNY1V"*)?090$,IH4^2T!M807)+,) %))0 5DC>(2<
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M'3Y^._S]OV&_59=#/H(7A\?[%_M_?@H"64RD!51)#BC%$DA&!(!6&X]-X,'
M7-&3TV94M(<66;J3A3QS@[!'-//UK2]WMW=?3VA;K"!W/UPK%>2>&-Q^S(&;
MY49 (Q*N<11_F  T)!A 1ZWFG&A$2&HPE"INRM<$;87-W(;-F-0'D5KH@T31
MW),F6:P#U"($K' H;.:Y#1[-&SQBQAL<;5WB2&DTQT!YQ(%%1@A.C$%*;FQ)
MU>0B-15[<&.<=;+Y0F<*G7D0L!4Z\\3H1N;0C5LE#+(>,*X%H,038)#V0#/B
MC*0<<\$WMI1D3454@;8";:\0V@1R(CB42GX+:K%21 A(F2/82^*Q+="V$M#&
MYJ#-&RB5"!1@Q&GRU!R0GBN +918!!4$5!M;'#;%PQMS%60KR+8J+WV7!C"8
M0V2QE0YJ2G5JGV7CJ@^9Y89&)G<-M)4&,,\2:M^?ZSY(35R5N(> 0):[ME(@
M44# Z^"MQU&,1J58>UROFHHOXMSM6\ 4B"L0MRHO?1>(X]8BI7AJA&2H8T[K
MZ*12)%(CD( =+1"W:A WUY@:8R.Q%1A8G )P!$.@K*6 Q3\RJKDA-+6XDDTD
M"KX5?'L)^':7;42,J8$0&9LHG V*.$:\\DR[H(0MSNF*H-K!''$33J"@4KL^
MY#V@DBA@*)* .&69BJN3HJD/%421MBUV[EM%]_3.J5USG?I6"HRNS 'L^6R1
MW9 *Q(P3 EWK:\OY?$"U<_NC,M?ME,ZV#JM/>L_T#5N_K=)\1AK_^J F:C?-
MQ#.WEWRULKW#DF5MY-TL1-<5IMZ)1$DOK4;0>*<)A_K3;ERR(O)!!/(OMV\_
M.[:\O)J-K?4PO/?.GYVGWW=;?9N.A9?5;6FKV\5"D@R)I)P$YH#4(BYN'FJ@
M&10 *HZHLU'ZBFULD2:^I)]W08<7B X%^8MLBVR+;(ML5T>V=PFB1EK%O?':
M*2.HT,K(@"AT7A(&@R>WH6R%J:T"4UO80(JRM$) !SR'%%#H.3"$,Z"MEP9!
MJP225U&UVP=7"R*L R(4M'^YLKU34H!#1CBF/?*4$:6#E1A3IWV<%03YTX%]
M:'WW#OSPO6[!^3OB_'R\V5%O+&8>2"4%H!;AB/.2 ^BT"LQ;&1?V,0*LAU/^
M"LX29X,!1E?%QL_.?:>ODT ><I1X_;#K?NO2Y=)>ER-214I%2D5*14I%2JLK
MI3MP:LJ\9AHA+K2B5CJ)N->>!TJ8#AR3.W/J;?=YV!_D)B/'W4G)HE2Q:*]3
MURO*V\^9/.Q,<8?W_G_#5K\U\$>^][5E_;OX[EWWWMON22??Y2_='OH2=5D6
M&S_863B:8"+G5MHIP"2F@"(2R;A5$ @I!700.9+.E*(FIV))J1\%$PIR%RD5
M*:V5E)XS9E76US5:7Q>B7<P(+! G "EC 17I6 SQ$&#&(6).2T/@ZBVPKR"#
M<B<.1;<ZC:!;O<;79 @-/;&TU&&OW=*FU6X-+N+(NO9+HYOCPPW]3??<@U(I
MUP__'K0?LZ:;+D5*14I%2D5*14JK*Z7GB'MI,^Q/D_+!'"EOC4AYS3!^BP0C
M$^V9[_PQ(A=Y8^TP4XOMS"P*Y;X+Y3Y:"&D13CTAB@.L @+4*PJ4X!H0;83R
M1L)(R3>VZ(.KO19;+XA<I%2DM(Y2>HYX5EDW5VO=7 Q568\E(0QPXU,%/NJ
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MD*<:ZEZ_'SG[A_-NI[JP'X=V.X!YS:'?_>/XO9-/$"D5N,% (\L == "PY$
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M1@OAM9:>+-R@>BYF4P&LU5C8$EW6!;!6#;!F\D,)X5Y1BSR7&LPD1Y$5-J'
MB7,Y;I924@"K -8S :R'>J(7"5@%F.X#3-.N::N2"X$HI+3(P*03LD9AI*,6
M/"G!G0=@HK)@4L&DU<:DA_J1"R8]%29-^Y05=APT(HQ4(F#=81*04T8AXT20
M&-2EJ/@J8=*K*G0/GX YQW8_<U^O&>*@S\?R,W6?!2@M*M3R][,>3*/7^Z-S
MXIKM:L<O3^*/R8,8HU6CTQYF41>C;@$XM3-;NBMIK)Q."@EC'.*",F2EY#DC
M1ZM M9$QOM2,G,+?"PTV+/R] OP][;2Q7D<<G$3>*X6XP1(Y"J^<Q\19$K'0
MIO#WB^;O187<+9"_2P#+@YA\V@'"#7-$BX"2813QW%+!R2!1I%0Y3WD4@N=>
MQ*#%%19_B2R^J/BSPN*KPN+3_@0?9 R UT@+Q4&."X>,E0J%P!-HZ00;'E:,
MQ4O&:LE8+1FKBZ]V=AG^6"Z_'PE_9S-6(Y>1$,=15)J!BD4$<I9R,*:L)X9P
M1]/B6L2\BHS5@G$O#^,6Y4HJ&+<,C)OV%7D"IV:E1T;D%*_H0<=TSB+,O)?:
M>@U&9<&X@G&O&^,65G;N'AA7C.D' =VTORRY[!2A#$F?RX^88)!EQ"##-/4!
M='-,:3:F&>4%Y@K,O4J86Y1+L<#<TF!N)J]5QZBD= A[ ?H<BQ1I0S%*P4D5
M"2,DZ.<$<Y5#\5]5L7WX-S2_;8ZFW3@[ 8;P@]]]Y;$^J]S4F_^&CXVF/?%5
M1V>]?C.=#]EP\]^N^Z_-\6*KD2>>&[(0SP[(TTZOF0=^TXTM^(9O\;?OS= _
M'/'7Q%.# N1O\.4CUL&&G/5O?N3$=@^:[6K[Y%7P]!%8L[M\U*!YBC5S=6LF
M?QYV1[,YM0<1N6ZTQ\@FF.P;V_INSWMK_[JZ1%C?Y'[.MQ6WG-/@Y]2Q#^""
M4B&PI%8)PSFAR7 -*AI7E@BB*3=C/!R2SU4 U,0J8K)"H 4G3IGHL;-&"R.Y
M-CY^W08 I)A@@JH7597/B3#,/PYM^R#V/K3'L-=)XUN305CF;B;E7?C&WUL=
M?_P\0:X5__/I?/]+.'64R_VC#ZQ^\O9[XZ+^H_&^<0B Q>L7QV3OXL]6_:AU
M7#^!N7_Y^'WO**3Z!8RY]96II'6D DS-1!&7U".GN$?<.<5,2H(DL5:+( E.
M,PMWS^+:?$R];"[9/8P@S%JMSG< N=J@)<AI-_:J3B%]>-,/"")W#4E $K5O
MF29JG52]^4?G!.9\7AG7ZK=>K75G$O";&_%J@G>F[DPN=VC8LF0$515LPTZU
M[&DOOAF]^"TT>Z<M>_ZFV:[66SWTVW#X(;[E;YB&[/R%@[>'_&W,AL(JL_CP
M/FCXQ4/NWZBX?TK(#-YC>@-S<^/;>(/<^-YMPQ(&$_JY86]_3U/Y&),5DC["
M9 5CBY\LWU!,/)?)D@TCYAOVCMO,>Q;/>)P6/?/5S[A>M;O?F@;ZR')6I>]5
M%>2\9OLU%P&AVAF'A_!Z"F-VPCW6/$\%BP%J#G'P3GUWM;?OW16)=*WT&<J=
M6OP1N[[9@[^ )"N;.\?F;D</>G$OSHK^\4:7W9N/LV,[W,+3<X+TS5%D9'H+
MYS)E5WO_?JG8M',&0X3>K_?9KWE#=)Y&VLT;F7/8C;%6A\\=]FIOVP%PJVZ[
M_K#&R'HM6VY+J:;SI%OPR*F5SZ7?H*0\AA"4TS9R*83UPD0C%,/1,##B2G;E
M/3V;6Z1^T3K9V]VBC>VWYSO;GTX:)^^:.]N?1?UHOU7_\OE\[^CWX_KN1S[C
MV=S^?+'S91^^;P_7=S_PQOL]NO<%_MT]ACE^_K&_^V>S_O[CC\;V8:HW9Z)Q
M7,!"T( 1#=0A'AE%FJ:$*,XN:QZIS\V_GCB[\N<Z$#Y%TG<!IZ<')Z>#84S%
MI%3@1C-M=6+*)ARMU4*G:]V--Z+4WX>V&QVHG"$[EF*[5[E%M[K=[(+*#8;<
M^>5'_K+G^4];WVTW#!'M[5#'[S7;?U5JUAC$7GCPS=(@;3KX1G--."8>T<@4
MXDY$9#5Q2 I.K.0DV@4F8A9<*[CVD+7]LEQ@Z\&"X=45A/O0'MC4(]NZ>>T]
MRX1"-@"V E/W@ZGIT!FAK,9)!T18AJGH"'*@,B/!I4W")2L2!<V+S"#4KP6<
M5HB!7S(XW:>!H[-!:T$ F1+'3#D*?V :6^HH#"8KB_ N7:M8A$^ 2].Q+I9:
M&H74*$GGAWGN7F(4)9/&),.X2VN;BZK>O@AL6E*9]I7VO9$'-9%]84C[4WUR
MGPO2P@..2\?!E F<JF0MB5(3K'DP+F!5(2TNOK=50]K9NM74&!4#C4A$JQ%7
M1B/+(T;!!ZT\=R'DJ$(J\)/F(?^<'EA:>"\0FIY%F'.T6#B2O//1<^R]%6"H
MLJ (2=H+1ROKE(RLTUMZ>1>WV[- LVFW6S"L"NM$S'&&N' <:<4%F+< 90P+
MH[UZJ?61BK+UG)2M^_C<%H!JQ>?V9!@U[7.3C-$@4D(R1(- 80;;-JC\J\6<
M$,*E!8P2LXVRY_>YO1)=JX#3TVM<EFD5L,3)"\J-)5I)1ZF,U">K/;&#*(SB
M<UL]7)KVN7'AJ01C'H68:URS7%82FX2<$29:!M)ET#?Q:2M27>-UNSV'; $9
M8_=Z[G%RD$;YEW_[PQC.6G$GC8J[;?G_G34'*6F]W\\G?KNAU-OK35"">6Q]
M)09S&45"U.8;+RERXV.C$2'*8NV",3J^P@0EW[F^B/J;VNO(2U(;\B<3B&Y-
M2-$;FO]LALS2LV>>W62?(M7GZ=Q@CY?H\PAK>C59/D^V=R/K_?EFH:P&V3UN
M"@H1)06EI*"4@*.7Z?R(7/.D$XF>.)Z"U5$9;%F2R9.0""F%NA?C%#D!<VY[
M"]=W_SG9/_GGJ)['//J]V=B%.1_]?M(X:1S5C_9^[&__<SCM%-D[^?R]OOWQ
M1^/+_LG^%S 3MSV%L4GC_<?S>G:0T/IYX^C=<>/+N^M24QC#UC*3PR)S:@K-
MS0@9"4AQDB(S(2:SJ%K\)5"RX-:2<.NG'%&+ ;")V_/>H*;.A_;6">Q\?R?=
MA7FDH-G]T&PF*T5S+%EV>>&0$&?$(^>T03%(">)+B!AS&T,\&^]=L*Q@V6IB
M&7/>&R%$T)IR*Y,%,/-,.B6B\MZQNX*^BPZV:J@U?6'NC?():U"Z/*> 6M(@
MZR,%Z"+&X #J&'=9!^/&K!!NE8#P$A#^>L( #*7<84R<QY9SGPP+@D43A0T)
MV-??%1!>4'BU4'@V4%PE*AT-%%FN#.)<&&2X\\@'%3P.CD4FUC;9.G]XG882
MOE1P:TFX164 ^S<(&TGD@AF;O 8H"Q;4@$2PG#M@O%C"*XUFTY8P45(XXN!4
MB0V(6QZ129H@3+51S@I"J%K;)/3!&F7!LH)ERTK*<UI'0T.@-G"*M57$*TV5
M,Y9CP_Q=H9A%!ULUU)JVA%5R(6GND%)& FI)0"WO!3(6*Q8"L1:3K(,)\>#4
MZ.4&:=Y:Z'^>0+,YHC@7-,RK;Q] \,W] _+T*\;F@8 E& 78@I:;J T''0H,
MB$29-USQKYRM;:Y6TX''#!1^O$.:B="H#HEO#-A]]N<CQR=_:'^+O7ZETWYH
M;T?7WVJ'NNT>QXK]W_[O#(3%WQ%D1=5"!M[\ Y##-MN[79MQ9JO7B_W>94S_
MR@0KGX_DQ9^'C:,&8/W!C_TO;[_7+P"WZ5L.,J2U=_(1QCP\JI\TCG=V_VE-
M!ROOG;RE=?J![&R_:^WM;ETTMC]<[.T>L/K)/\W][4_'.^_KYWOT(\B>?U+C
MXN/WKYAX0H*UR%$,:!\X0U8GB136F 8C@_=Z;1BY>Q;#5I:YE C. F-&26 Y
M2:V7("L4A0=%=)I/AS9/G%<.)#L9'U6M-SZE6;0>D/\C$78UXIMF'_C(ST'J
M-S0+N7,?KNX;$R0Q[1SCE'#L,4A4ZJ2G6+A 32X_.9*?,Y)J45D#LXNX<U)3
MBXC,68HM#1H+[H76 +><$&5<;N1)_=IC9R=<<OHEC[]B%C[_FKQCC"N%8E0)
M<64=,@(+E#@&6C2!!,*>1;;!/#@QR!SH]>,XH'*<G_"<NIN (K&!!\K$S[0W
M48\0[,XVA'J4CB'DYT8MDWVRR<[7B^6A8<O/M&O(UDD'YG(! /1'I]=?F?#W
M6QUFUZ/]XYAX\^WB^VZGUZM];H,=UJHV\STHZ(^B](D-.L>,KC&SL[A =$//
MXGFNQ9('6-O\A?PZ9>85.G@8'?P7?B]T\%CI,$_>+ZC*I_^9[)<GO2.89X&#
MF87H.\.LUK,VG-V /+9Z65N]/8'#EXXRSS"=9[[5_V%[A[7XO[/F-]O*YLT<
M6L.]@T_+&"LXQAVT/3(GVYV,$K=];?GDU4\N*/*QNFM2&TJL^.WSY[]K!QV8
M4#M[1VHGL!'G0_](+<$B2PCD*[E^ES8Y09-SGF!NL7&Y4;7V#FNK73)S!Z)G
M@90O1N"?MY=B::O_A^UVSV';KBD@N;+7[#_G<QU60OJ]N;][_'W_R(OZR;M#
MF-N/^E%H-K9_/ZY?'/]H[.Z)O:/Z^=Z7CWBF$M+[/UL[N[^?-"Z.X?UWA[F2
M4H-^P/7W'R]V=M^2QE&K6;_X\W!_^U-J_#$3ZHAU$EX3A:(7!'%N&=*8&81)
MB@$'PA4'L&-JG9(2'U0 ZDG7-JQE6JBN4%VAND)U+YKJ5D89N[;Z9%'(%J:0
M39>F- 9KY2)&'GN*N!8:F20"$EA%K2./QM,55,B*AV%5/ RWY'42O4%7W<6P
MV^G;UGV36&]T4+]HJ7:_Q;\8>6=)4O _[@)C/#ALL&="28:U2!1$7W$^K*:L
MNZ;BD%98!,Z1"SG;72F"M/ .R11X@#U6/K%%R;I[,<N*%_ H</?<X>[GC,I"
MPX6&5V?5A88+#3]W&EX9M;.X61Y7]9QVLV!A!(["(AD"1]P)@IS(.?(RJ)S/
MASUVSTKU?-8UF.8M WYC8L9AI]M'_=@]N9++]1/137<XT<L8*SC&(EUDSRX(
MQQ[$MC^ON4X[S%#\?3;@A6HI+U,7B<EY3YQBS@=.@]'***\XBYQ0J\3<NLC6
M-]ML901]U^G^#>I$SF*>2%D>I9CD#)/?;:_9*RK)HE22G=E0',MT# I3E(R@
MB'/CD99<(4>2AN/V4@1028A8)Z(4X"Y85;#J"E9Y?W9RUK+]&*I<GLM4GIS1
M]7L$W(J[]L?J-Z-^'M@U4V,L)L^5DDB8H'*U;8FT(P09:FWDR9-HTL*:41?P
M*N"UM'[43XQ>.0]Q KT*2MT'I:9KBA%+2=0<HQA-[G!".3***60])XI%[U.E
M83'U@'[4!9P*.#USS>H2EZZB5+'^%HA-,PYIJYQC.BM/%"..742.AH2P-13.
MU@M'<&7]5:7F5T:!>GT)</W<BO*L>UYSS5;K9B<SO=\>7 N\SQJ=I-21>Y>"
MQH[#_YN )<_]XH)-RI-4?%0KCU)_S_BHI)9>:*&0D#@BGJC(UV8.I5PKS1EE
M&04-2J\;CE<H.'G1%Q6%MY?#V\6GLTQ>G_;IL$2(#=0C3[U%W(,R8CT32":E
M*([48"47YM,IW+["3I"G9O?B!'D 6T\[0>  L=>>@$K$..*<4^1T(,AS%T)B
MC 67&R/.&AGS^T *,[\^T5V<!DO@Y6FG 4]>8<4\$L9+$-&8(4N#05XQ[K#F
MBBE<J>//*5?P9<?K7!NH,Q<\S>NN?=;P%)FQ. G&N9><J.B,)M%A*:-GF+M8
MO :K#E,P[PQ1 \_!T?%%_>CMUQ"-E%Y()))RB#L?D9..(:>X <#R-B2RMBGQ
MNL0/]ANLW@5,X>XE<W?Q&RR7V\^O<KN3B7,%"DF21B$XYX"<\<#M/&:7 C'&
MX1<<#/+"V?U>T1-/S._%<? 0OFY,27%M.#,L<20%RU)<"Z25U$APYK%702IC
MUC;A(R\J?.*%L_,*<'-Q'2R%FZ>DM""1V40\TM1%D-(B(.U][KL%!ZB,Y4RP
M2B>G>#8>ZF4$'+R\>CC#Q<Y=L/VEQ7O=>_TO!IQ]5(*D%&50D>L0',6.J?RO
MTRDQ61PGJP_2;V<<)SX1$W5DB I:.4X4LE)(I'1(CB5JB,GQ%GQ=F@?G!-V7
M=U:\GF7!P(*!CX.!Q;VT7$R<4EPI]9@DBI&+6".N/$4Z<8FBL"I0!KHFUXN.
M2RF@6$!QE19^'R?<4Z-B<<(]!/VFG7!":&IYBLC *] (@T':88>LH!R.,Z<)
M /H)L8#XG0)Z!?16:>$K@'G%5;D4S)O1^+"@@44D6:"(2YN0Q5PCL(V=U422
MP%AE!1/^8%?ELK#O%;0;O+E>5ZO3/EA(N:[GT'ROC/' <EW//F7PH>6ZY@U,
M7KFUEPXME39"L,546LJ<MEP8Z8+2.B3JE8A!A)(*^0RTDOJ,;UYIZT4*#"EL
M(LJ7XCG"2: 88HI:"CC3G+%-UQEY<,;VZF54%+ J8%6<Z,\'O*9-*B9CU(0@
MG*A"W(N(K%<.6?@_IJ2*7BXN1K.@5T&O97F[GQJ^BK?[(3 U[>TF4DBML$8T
M2(<X9@)IF@NVP]$JB@,SSN=DU8>$G!9T*NCTS'6KXI9>"CA-Z5!$8V(B%@A3
ME0U 8Y&Q7*+ =-6,U6(XQVP XH4%9Y56G2O\R9+77/*:;T+^X%.TFG '>@RG
M,7=F#AX;(2SGD5I<7("K+P$^S[@ B>=,1881T"Y%W!"*;-+PBB09!<CV:-C:
M)N?K4JU2#D7)C'J>W%U\9LOE]BE]3]F0I(D*R4# &+7*@C$:&=*@\-$DM'#9
M&"UYS<^3W>_C9'IJ?B].IH?P]4Q()=AQ/"B&J$H*\10E,A(S1&S07D06G 0[
MCHN751;^A;/S"G!S\<HLA9NGI+0F D>J/-+$,,0%IB"E34*2D>"#XI(27^GD
M<*0K)*07FM=L5MQUL-BDYM?@#W]MW99!%(ND%-&8YN8LTDI, V:)&:4LB:3X
M2U8?F_=F_"5@//GHC075BEC$57+(1:%1X(DXHP6Q-*QM"KEN]*.G,S^G"[\"
M?07Z%@U]Q9FT7"B<4E-QSEMQF"!+%<Z5'4+NF(CA1XH1&X=#6G@ 5L'"@H4K
ML.K[>-J>&@R+I^TAH#?M:3.:$1TC1U@X #VO2"YGHY$+4CCB@[8)]#^I9@WS
MQ24O%ZPK6/>J]+[BAEP*U$WI=S&PZ"FCR$MA<\YR1%J"NB>-$H1K857TE:D+
MB/@LU+O*0?FO*G\7_@W-;YO_AA^C20V_ 678>4/T52PZ.NOUF^E\^2Q(,PM.
M;>8JS%QNB#FF_MMII]?,]/"F&T$W:7Z+O^6S1:QZ>OJP;"_F 4"](K]>7?)3
M;'JE1@':C?2HV@%8E;5?6O#77VO-7NVT&U'?_JC9=LB_=N-IIPO:5\X3[_0/
M8Q>@\00^<QC;/5AW+3^WL8@CW/RWZ_YK\\:1KGUND+,^XKX!D\$^MNQI+[X9
MO?AM%!'8;%>[43WTVXGM'C3;:,!);ZXYMNH+!V__]KT9^H=9;FS@@>P87@<,
MOWGX]D;UUA0F#-YC>@,K=N/;>(/<^-YMPQ(@.$5_:MC;WQ/DYT8MDWVRR8JY
MAKWC,NL>I05N*7?A(RA/W54J>#&^3JCE^X0Y"EK<I\;" '>&2')G39*Y38'K
MP6^PMT^SBP/1<6F"U[)#\E%DF=B@<\SH)C%,-_0=8OBJF"ET\$ ZR+Z80@</
MIX/5 \YWMMFM_6-;9_$*:,XI1E:^%-)@9F!9=[JV(B"PW6)W0!Y;O5HGU;:C
MCR<.U%Y&UFM@YI.;,RG(- G,5:-JM<__%U#[^X>=,Q@B]'Z]#PV\A#I9?]C>
M82W^[ZSYS;9RL:Q2">N5C/&J*V&==-KQ?%@4KI9@D:4<UBO)@G;.4<^D)LHY
M+A33G@HK)",I&2OX( N:$'J7HSOCYE8[Y'_>7J+G5O\/V^V>P[95"L5K\'(?
M_]B'<?:./N/]]WNXL?V1[[S_R/>W]^C^R6>Q\Z5.]X\.?NQ\^2"FO=P[NS"_
M[0#?]^EX_^@C/'L SQT>-X[V3_9WC\7>Q?[)SO9;L7?42N,(ALO^P]YB1;AC
MB)N $:?)(3C5B"S0".6>&D%!Q9%T73.Y0AG0I4S#*P2H82A-H;I"=87J"M6]
M:*I;&64L.W8J-6R[V?.M3N^L6Q2R12ID;$HA<P$;*KE 2OG<+PP4,IL(1RHE
MKZ44A/NT@@I9*4GS-"5I5F_"S^63BZSU\_+:D X7^SK#%^^W^!>C2&@?K -=
M(2EA.34*Q VH$MAB">\0&HI79R65B$9SQJO#N;:Y<PZ204;$F?/(2I.0B]1Y
M%R1U3"Y*B;@7LSQQQ80"=R\=[G[.6B\T7&AX=59=:+C0\'.GX951.XO_ZG%5
MSVG_%=,V@8IID:/>(NX]SF5\$L+8$*,2BYRZ9Z5Z+BC$8Y7#EVYN\]<[['3[
M"^GS=\?M1!EC!<=XU>6P?ZK/W[S5]E9N[??64EZF+A*B5D00F2QFW!!EA-=.
MD$!I4 0K,J\N4HI6/95*LO/'C#>,*-!%"-=(FZ 1)TX@G2A#S!IO/1=@;:FU
M3;U.V(.[_*U>D= "506J2I&IYP)=%S/012F#_R%*G4*<&8JL"!Z1P"(84$'"
MFR^X8'D!K^<$7O>JO_[$Z/42JT(M#:7(%$J9*$EPG"(.-(MX% H9:SU*%$X4
MP\E&[=<VK^FA_)RKKQ=L>D[8M +0])JK."T-FJ;=T1R#Z4=L0-1E!0J#7@KD
MK%""$Q4A:2NMJ&R_%UM*_GDXWOH@F'MGW?.::[9:/]>%;MXX]F<-3MXK2Q(
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M/.'6R%L3*Z?3=(!5%N_9[H)) BOF6(1F9;'6DFUV:]]LZRS;E%OP)=VLYV;
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M_BB3-?--:''M%I]51\7=BFOJ ZYY>Y5K%MJ.<J:'YVQ>\_/J13EG<].[5_O
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M1'J".$\N]Z4WR($ 0B$X:T6P"33FW$J%R=G2 ;_>MZS=,E6J)V^D\FQXG,H
MG!V$C02H@1F;O :])%B0+8E@^4C7CU,\7MCX/FP\HW4$ &@B-.(V6L1-Q,@H
M 5S-O%+,,2N(7=LT8K:ORI,P\:OP6=T4'K#\QBK/Q1QZ(FUC' A1,&A^#)JM
M#4Y-3,;G&VE&!.(4;" 0*0XYK*P1*5CK4ZX0\P(=-(6%GUB9*"S\4RP\K48$
M0S5W3,#99.>%#0*92"E2P2LLI+=4JK5-]?"N[L5S\>CW7[$=?N;RZZX*Y"_:
MV7R_Q;\8T%Y(&]SBAGXZ)&_.*&-"AT1)I$CGLD?<AX2L5ACAZ"4E-(44S=HF
M$>N<+:K7YMRA%D_I]RFX5W!OC'O$:1T-#8': /:*!NO3*TV5,Y9CPP;7;W/K
MJ 7WG@#WIC58GO,F+-B?./+L_K(,:4/!"/5).Y>\Y8)7UV],/M@.70KNS=&L
MY24EHWYHU_*F59P[C/D>W=:E48+[?&7-@5<[PZH\60^VM5X$Y@_KM5;G>^Q>
M6]COUHI^'3BL9MOVQV7.\XC]41E1.V[[D$/->V>N%_]WEG\=UI&?^$!5:FC+
MGS7[ME?E/P]+^\_4ZA]\9%SJO2H>=&4S1H/D5'V7*Q4-BIQ>%LB8K"V?R^SF
MBG&C]@^SE0&&50LVYB@!=RM1W4YQ<S81$M<U$7H",KV^T8Z^L='.X&?MD?)F
M1KW!)@I^;K7#']7Q',2V!T&SW>SY5J<'LF=5TF0:X[Y?C:.]BRP^/IWLG]3Y
MSO;'\[V3MWQ_]YCO?8'Q3CZ#R'A+X=\?TVDR==HXRJDQC??[)WL7![RQ_6=S
M;_>PM;-[>+CW!<3,+HB,W3WX]UVJ'QU<-+Y_=<%&6[5_9L(.,DT-6#F(:2PC
M-]@SRJ9;V'@IL>-8*B!%[K2R*EJ<E 8RA6.2?#JMYLK.#^K+7)[,[2UW%EJ9
M[^YY7UVG4V#;66L"D993&9P4RE/X*P_!"_:$"4/5B&\ U@ XYV#$K:YK]KN#
MG1C7</O<;H),[65?"0#=[UT0)[U# ,/6V8EKVA=<RN$/T"1RE>MH<YFB[YWN
M<19KK>8I:"1MV^YD[&]ZP/H06WF+ /FKMD*]*XFMS?:W7"&[T^Y50N,L-Q?I
MVV.0+[8_S_Z.!-CGW_^8Z&MS6>MN2CA513ZJ(O!CJ5E5+>K!?@Z\7#!0)?UZ
M<7)NN7+'9)>6R3'A*^"AP=2K0G]30G@=!H)95^5$KK1T@LTCQNA!<27XCI-!
M.AG\F6)<99-A.<PFPVH@DB<+YAQ4!9DK!6#XG</]&^P;3&DTE5R.=7A:_<-F
M-U1RN:HTW6S[UEGENQN6+)FIROJ22':G7=L&)6W0)T=7Z7IXO=JI(8W.'J[-
M>DQS4$3)3O _G&8\&!0&L/V);?=5I<;1QH^J.N:OJ'KN=!U8:GG?^UEM#&>3
M;M1[9G(3J0P63H.1D3AFSGDF66!6<6)3L(/;#TPHT6CTXOI21R,Y_U^8^:6,
M.=^V)_8@]O[.%9SZ_]C6V3/)WEZZ!@!C@ 8@;8@I*8^8TP)Q*3P"]2J@ ((Q
M6>E!.2"Y+<HM"?^GK;.)2HNVV^R-]?_KR@5=4:0S]2R@V=KZ73V_-FH[77CX
M$% ?WNT-TV*!EH$N<FN7[[G$TF%L5;4AMTZ[S5:-"D3E(#?V*HB%3AR8"0ZX
M+WZ+ UZJ2F=<J766V62 S+.5J6%Y[5#58?W6/.B R=R#F5=\ FL>"H5JMRJ&
MK7AW'IOCH9!7RE6SE2]7?:UR^V*4U;_[8(Q=]HS<NNH2> L:6K\)./]RA?V'
M=FW']SM9UH/TX^LCX5LY/M:O1=3OAQU0TE#G>WN@5O6:H6F[YZ!0^O^=-;-V
M "@R\F=TSOJ]OAU<?/8. :<J(!UO[&W>EO&'QATZ)[O]6=BI?':GXWZ?EX47
M=R_KT(V*3E\9;" 80/<=SRKWG0+]>5C9SL5AHP=[Z?L".+]7Q7*:-)/$&S!P
M>4A64V4-QCKA8#497. 13O"ME16'+K4Q50[;SFR#%&AU3O-?MMKA4SS(I4H[
MW?-Z$^14O]..?PW+[/T5N\,ABE)RO5)R0$ I"9PX,,\5HH!EB*M D/-8(:9-
MBI'9:+#+74ENK;@(5L- 3SB-W6JO<TW1D]&)5-5M@4#:T5\UC$?A OEU:G9[
M_<I=$;L>+*&J*-9IMQ/.?'_:1!L7V@"Q4/DV\B#_^?V?7+WVP'9#*Q>]K4HJ
MQMRK=-!<8C06*"*#RM1GIUE)[^4V<Y?<.U+3L\?VTCJKS*]:51,$N*8546@>
M@'X^TJ!@G"NJTJ"9Q74+@DF.)K(^8C/0BRK*GBX4>5]M?U6X;AA)7;CN>F?@
MA^^-CU\#P1RL,XJ4 N,+.$\CC1E#V"CCE$C$_/_LO7UST\C6+_I55-SSG((J
M*UOO+S/W4F5(F)U])@X#@3G,/U2KNY4(;,M;LA.23W_76MTMR;:<Q! @"9X:
M(+&E5JM[]7I?OQ5D-V!_H28\P)XJR.4'UH5AWJIS(E OV/(:BWE5B#4GLR4U
MU;<%'1E@WAN_34FG1[1[WSW3*U X=(*42JHT?-#-Z4L@]].*3>H.P.FTA+,$
M)F2ECUOW"<M'?6#4^4HU5%. W8T!NCR)LI:;)@O'>1N[F<O0<86;\(0%W'-9
M%@4BEFX0<AEDF7/323+F\HL%L N))O,DHU@-]C30DY_#3Z \2.4L:**VF^*R
M>?$%+,4K697-T7%^N:/S[F)T^M'CH!_%/K/S*/?@Z*01UE[[=I F*0NB7/(P
M?_(<5VKM[#SB_M(GW8.!8J=#7!1^!'D$6B *HI7F(6B82X8!&H$.5?0,Y*RH
MK'/TY^ GU("ADC/$@4<T=VK%H%N4H#3N0-AW;FQ\$K-*GA=@=*\-T<)Y:[!C
MT)7G4C=XSJURIJ??!#)@I#,03@@]/T87VM-:(B^92\M_]JB=DKBYG:75&M/&
M[;[8LH%+FODL31/!(Y!*GA3,YPRSHYG,TSA.Y89\N^_)[G;J0A,[O#RZ^)BR
MD(DXD+:+W=P"Y@=V%D:!G<0N#UT6!S[WGSP/KU/1V:;.*3_"U[7U?;>,RB?W
M.BJ?-DO[,YC&31D!/V1J_0OSW;,1QF.6E15Y4H=5A>()Q<K]2T4X?FG8R= [
MWO]\<7SR?GSTQ^CLG_V_@$F,SXZN#L)_]@_\T<D[YY]/9P6,%ZRQD_T/,/XP
M'/W][N*#]^KS:/^#=_SWP=71R?CST0EW1\"BCO_X#\S];!E&]@K^_73P$=:8
ML2CU[23)L& S3VSF"F[SQ'><T$DRF>:K\7HG%I&/[;Z2C =QGF8L<[B7),*5
M(I&8Q[":E]#L"(B!@6IC !Q*B785"J.L*&-V_LADA9M?9OGET\2-$I]Y<>*)
M((9%2QV>(I:3<!+/R<6#\?\N[\J#5I\VOGD_;_RK&"^LUV<,% Y.[E?0BE^6
M>P/KS[EXG$:"ZRE_=Q/<7@>C7TH\8-9<\K,I3.ST4K6 RS%UH?^T6D]Q'.VY
M7DN%;#S89#%<N_2-^QNO:I,UNJYOY47HSMLD.=#(K,UUP!S5@7&J(:HZH?3K
MN/M NQY,T@-&":D;+;;[FE5H?*!C[V(]>W&@IU"H=D[R"Q\OR"9A%&/L.B!P
MN6#3%M@_1O4(H 9:S1VT()6DYEBJ(6[K+&2F9=+P!38)[^9AS)973_L3=7L:
M=9EL;NOQE59DDZF\%7S"F9S!T^;P0B_0%'MY!LK[P/IW"8_Z/_#7 +1&SA8T
M]Q-67 #==O?[1%95@;[ -C/T49X@$S&BQ!A8]F6;RRPSI5"WB3>KI$,TJL(R
M2QDD)4(SPT2MQ0P,9[3HL%3_*QW!H#3S) UY!,(\R'(04#+U$\=E'KKT1=*H
M4*%M?KC>L'NMNXIBV6LK-,KJ@?1Z^(E:5G!T]<&GME9IE+HBM[U0NMCK(0,#
M+DGL/'-2D:+G'O;@>>!<Y_"%__\#S(15EU9HVA]18 (9K7*ULN4XR9J?%SD4
MRLBO:N;.@L3/9!Y&81AC8R[FLY2[F?# $LT2+S0XEJY_37G*ZW*.C(>-UR('
M.UJZ!2V%H]./,6P!F$2A[0<BL@,O<$&X\<C.4K24O%RD@C]Y[@7A-<0TH( 5
MALA !&'\E_+4V!=,^*.XF'+IGV'.C6%!37[@NF(PZ(H]BL+I^%"3@[PLUEK/
M_)X6VU@=07QQ&XH,/ <[-0<L=D3 '#=%9%4OSWTG87X<!;<&Z#",3J'_G. Z
MO(;)[$CR9I+DEZ.+CWZ4)9(+QY9ARNP@PA803I+;+).!Q]V8<32+@NN:;_71
M8I-I>89^16S.\(64J,7\K*P*%7CMBV]E\HR-\\%JB*I/MNY95J?&1POHS1Q5
ME MLNM -_Q;D^M:/P!#Q_ (YG J&<PII=<+-J@/Q4K18:6K&"=ZH4]T"&Y/F
M-E/MV_&]F='[[.S2-K%ME39]"F^"GZJ?3'M8T(L_&3U3G^1Q,0&3247]'J_.
M1EM:U*1HH\Z&"TB]T,=CU="Z2R>:CQ6H]I89KA)27)>A8:_H<]A#&&*PQMXH
M35KMY_:*]\KVM_/6N0DPO44M.\^C;JRL+J=$%#*'1\Z[1@ALNI2?;S]["O>,
M843,!34F1),XP3&326#'U?6Y#JU/)1R")>M'E9[,I6P+PH#IPU2+^@Q5XTX[
M^VYA&+TV&4-E)3",(#59GQ= #WCUDJQ9MZ_6Q<ULS#"N_:*<GYF\=B5QSAA8
M82MV;[V8S3#A?ZF"SE#(?^'T4N"L^?9ZVY3Z,+=3E$@#]-#.9T+7Z-%CZ>U5
M: WN_"^.7)C4;[T?4S#AZQK50"0QLUQZ47KV='6W+&S+/%YKKHL!MK'$EUQ>
MTCX_ #Q/,4I4/PU)8?I[0RQ+[Y>I]QK@VV-\44@LIJ %-9[ E8>6U2F;ZNT;
M&"MJQ'0NVI$49/F^-I;O4$S@H-8F\]X8L;1 :M4>,7][V<30VLPJ^47R1;?I
M\@T%JBMGX"VF!?9EAG8-_TT7+?M[AE,.PAJ>G^,D@"%( 8R'J(T>W.$(W:-$
M^B><".Q&![QMS"Y,41#Q,@H+8]*7<5(H4IQB,]YB7.BVT$2CW2D?3L]1[ZQN
M<BV9ZYH$2[$Y?40E=JYHIK$;N<SU1!AX#*'B4\>5/'<3ER<BY'G0;RL=CE[U
M55:64\K4I?6N#^MZ(6^IF?[L#)&?J9F.]@^NP/!.P#SB7N+84<!\T$SCQ$XB
MYMBYA_EQKI\YV"7/'X1Q.DA#;UT_U>=GO1$S[HO.ZE7)$.6"JIEUD+Y+=FH3
MU:FJ.S5H<V28YOS,*EU#].[M_O56T&M9T5!W0G/>*L71T*]Q,CLZ4G3T983M
MA1,$)7)MYF2.'21)9#.6>;83!V&>QL*/\@0M''<=O@;M $4HQG6,"1IL,T=1
MC<?O=G>5\Z62DV(!I/AR7*('G]C*\E;;WJ^]UU?82CKR/1X%KBW2W+6#$.S:
M) NDG<5IDF=21*X7(UC1VD[_CX4*/BZQL4RQEG)^:0LP(T'KJ]@IJ.]J[=OS
MKME+RR%TK@;E^(Q+U< 55!NRB\MN?:*C>@KW2.43U-34K)8!&SJ=AV5Q+K?S
MMT19Z@.ARS3.@B#QHP1HT7$%_@F\U(\;?TMD',O1[1W+*-@P;_PX[\B\G0?F
M%C3K'YU^]!,6\P18$_ G5_,G[@:@<>9YE&6>'X;8_OPZGR"2V2G5IL[TMK1)
M?&M4U?5&KU;N=2B92@.U.M<H5=H@61^SDG!\:DF1$S(KOL VSR681=OQRCQ-
MO!0SA7CL!W'JI'Z6.%XJ&7<0;,'IYY5KWL"C8DINID-=('E\,955?5;,7BO'
M#ISF%Y3!AC9,204UZI(=-U64>7@Q&G[T9!AP6'0[R&/0P!(7-+#,938P#!_K
MYF3N.5CUVL=.>[ECMZJJ $-7%(I&@*&6E2&V-0-HD[7RF*.5)WV&GY6S\;@+
M U#S<D8R9OCVI94X"6$B++E**MT!5ZJ/> 'O,J_-.69MAI6RPBI<_EFI<1#0
MU"]RL./@ZZJH/QL[#MLGUWO6WV?%6.J"F\Y 13/\ZO0&*QXC-BY/84W([X67
M1$Y$=G]=3C FC[%U+4Z7']&-J!M?78-#0;Z,T[(4Z+* U3]'6?VTV)-[:+PB
M]Z%+.,<Z.Q"MZ$/FF,U,E4];9%3NJH"#AUD%?&,6V$K6&%R:\"SRN1_Q@$LG
M\QV?)WF:!T$(3#"^ISVQ&X_2Z:(@XEX!-A/HS<ZIU >3U$$*EA=XHCJX0QU6
MTSE^O\%Q>F;2);HNZP4FYV!]ZD!Y2E&%&&!5$XQ!YQJ+!JEP88+U!%2"T+BH
ML4B@0,8#I_-/ \:BW81+:C*YAO05C<,*1WU:P+1$M3@U'ME.:51/0D^?=[3[
MG*.EJX_;L?K5<B&!N">$F4;9/'-"F9E?E$L+JFJHYI8H@#2F\&;=LLON?'/E
MPD)>3#P0*RZ &U^IF 9UFZ*TI3.Y\EJD =94-W4&6P3+@(S45#$V;GI5=*;P
M&2QRU,%.9G(J<V"0C?+87>O&4]+G5"FFY^58!YPU]U]Q[ZL^[ 7!V!@G=K/N
M6M(OW_)Y6E[89^4%OHIQ<>]9PYJ*-)>)F9SUG(H7I%[Y[JJ3;Y22*7I7>]F#
M..^HM<K2H]%QF>"(<!-N(B0\_,+LC!:%Z[>SNBYY0?<U9S*#DS5&QVG_A,IS
M/':45:3R]= S/@/MR9I(V 2A Y,(R809/1;L2U6KMB!B';0/&1_<NI&@'[&'
M?>,)E0:WJ6?#FBH=HJ>-FT0'YD?DX:P9WV\4 W@C)RK*^;J=8+NM.P/\YA0(
M>-[PHYM)$7(L1N0)PONY.?P4.W;BA#%\Y3IN%CQY'J1[Z\T*VJ0<G5FJ4C@5
M7]XE_CU8LG".AA]S]#MXF6?'41;:09BZ=B98;*=>GJ>Q&^6AY]Z4^&?R5F /
M![O\J(=&!?[1Q<? %UDH4\]F+L) <S>V610'MB?R) "S@469]S7Y490QIZ/K
M**!5XM-*S&I@RG#),4VW&'NWQZVW7:KQG;7(:CD.3;,^8!4(S9%\('6A/]?/
M-KP &H--<,+0 \I*T0/L>Z'-A._::>HE+IBDL9?'%*&Z1OZ@.KK-]ONQ'TDW
ME%X@G"#WPLSU$B'B,$CB+'2%>]/V]^@D'+76R^-\OP"5>/X2\[-V)' C"9P,
MK[#E6233-!*1+=T\ 1+PF<U8F-C"X[Y,@#B"7#YY[NS%UY4)+YL9)E5PV:A2
M:7-H*7!MR( .6\EBDH$%T2;\7&/;2JM) +=>M\GI.,XYJPJR)9<K++KYB_ %
M*-R8<*8J7N2,4/NLH;(KP7Y!1D; !1WL\W4,@S7KKY(2P_>8/Z*89ID9K 3R
M]RTE1)/'0P$F;DA_5B=*97IVT$@VO JBP1=YF]\U4'-B JT?,KY@ (J(- !C
M&%,<]U@?L!3P2H1#I&Y7"VQLT 9Y@1))^6*R4 Y'"PQ3?F8O9B9I5,>KR<QG
M>8Z3UGX#Y0R1P*8)Y%&;ZQK9 =>J>>S>]T<?5SED?P/!OH2'@HI2#1'7:3@5
M#=+ "9+4KNY7U_V>?/Z8LS!/N4CM7/C"QK[+("K<R,[S,./,E=()V)H3$^S.
M./"XS,(@")(PB7T>"^[ED0RR*&.K=;\G2S[!N<I=7LS1PJXWN$D,?*=!%3%=
M%W0")N%UZ3I$<S)U3S$$RU4^.0J\PU&V)C#[L]I2_HP>[(/?OD^9\4WW]3J4
M;US;Y_^O6L F!D!]/CB:9;-:_F9^^%T4]6S,+G\KIN3)H)M^URYO'3A Y_A*
MFP^:J/I:^\W39,]/772=ZW9V^L':J[Y'7O65KB3J.]_92]-PX]?.GKOQN^N&
M=9,])XJ_:MCKO_/3X,XGZWE[H.$_I,E&MQKVAOZ&-[8D=<.U:WN:5ZF8U(]I
MY)3<A%GA*!\@,I0CQ5 .6H9B&5ZRU*?G6U>ITU+LMNU\[OGR=1@]99QM;#N]
MS:O??OTTXUL9YY$L[LM6@5O"=+"TB]=Z8Z(+8K?L=[?L^S*7%6;-F]B67NX[
MY00=?OE(ENTIV0KE H80];-M%NNVC7OO=1O$E]<'A+ZE9_%CZP/9]XJ/IMOC
MMY;3?X<PWL]N\OB59K%J\C@YA.]X>/3IW9=__H;QX9Y_/AT$<-_GHT^G8"*/
M)L=_?W".]_\S66WR^ &N&5U]OAR=O!K_LS^\&.W_,SDZ.05S^J_+X_T7GSYX
M'\)_/OT5'$W^R8_:YK971_N?OQQ=?.2^*UD8,]MA<60'@>/92>Y@,;3@&?.Y
M&V420W\#-U@O,/EYG<J_DL?>NH7MCD$]; ;UK<[]-4[5YZ?KM*O5;,QHJCN6
M=8<LZW*%9;EQ[(DT3VT_1>CD,'3L)'4=.Y9QQIV NSR+GCQ/!Y&_XU@[CO50
M.);K1K[()/=9G 2)Y"P-/2=T8V!=@J4*M_TVC&JG4OUH_G2UPI]$*J4;Y+[-
M@DC8@73A)Y]GMA,&01;D3LX2_\ES/QV$[GKBS,]C4%O;K[IG]T.R7__$O. &
MMH'B,;=Q*MWTZK?Q*3WX,;SM2*%7^-P_#OWT9RJ5&S)&=NSW]NSW<HW]!EGF
M!PGS;3>+0CM@B6=GCI_9$1<BX5[@^5G^Y'D4K_/>9[=FN_VL[\>PW0?H-CQ!
MX$8X"=KE;-K'5CTNYSM2DQ_E&-=Q8#W&[=SL#X0W;\.:,T2X"$.1)%[ HIRE
MDG,_RN)0QIRK_F'?;.;OM.:[8MNCEVML.W/BF$51;/MAG"FVS1(9V"E2MA3<
MC7,.6G,R2(*[TIIO'9/:Z=/7ZM,:P(L2%%4:]IVR^H>F*.^4[7OD#C%Q;NT6
M>;E-PZ8=)[\%)R\<UW#R$;P[E@VE(7.3,+ 3W^-VX*3"9KDC;1'!EJ:IX\@L
M?O+<\P=>N(Z;L24GWRGB6QW 43FU#;O>J>/?QP/_#2KXO:.7K7WSMWSY1R.F
M,B?WA1\Q@:W>I"M2+XZ$</PL#6*>!^%7BJEM6PON)-4M)-7;-9O#"T&E2$5B
M\X1'=A#RW,X"+[5#EZ<R#U,O82$"CPW"Y)LEU8^S.?Y%6?-]V#V/#]U@N*DS
MI*J/TM45IN1HD\C;NNOH5VJG.QB#[U5">' !BF>29R+WO,@6O@SL@#FIS1+A
MVKF7,=?G<19'#@;>KFDUJJO&$%^K"XJET*#?OK0\U[$]9T $HYLI(<R.:ENN
M04>6XTN]X"?K%8EM!>+7=$W:U;+>%T(<>J/3CRSPD\!SN)W)!.1*XF!+$3^T
MN>">+R/IN6G:7\NJF%A#C)6L%V.J^D1ZI-8;&WE86U.V)?'<E:E]![[37YIV
M]F'F?WW,99S$7B+M-'* B8$I;:?2!<7$C1*/,R=*(HE^T+UD(Q-3I<L[L(W[
MOOLPIW!T]<X]WC\ [9<'QW]]MV9$MP+;(*G6E%<S+(S&7<0A%+(6<)NMRU1[
M,$H?EHK9A0$HE%FV'=#$727+'\.B5\90)('\!R(>[\Y6/V<%B_'DT!M=P?@G
M,//A1Q<TH=B-(U * PE2V8_M% Z;G7+A1KDG$^DG*)6C:\\6D$!%.AHS'9A
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MSX&,4'(WG\PKT+SI;M7@O6X(F/@$4F]K$OV^V_ ?M^&T!V   A=&Y@3<!TD
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MI3I#$ VPH)AI<BXQXU9E(J"[ +BF 1O5^4? $\>4>L!F-*16B>>P0<"&C0F
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MC!LC=1N'UOD8GV^X<\,!C\%@88Y9.<R7F!0XB!,3:+R?IOYD  M \O[+];P
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M=Q#+0?%K4<>1,M:1G!,VS4ZRR$?@+PG)-XDC7^+^V0OPEPC&!/P"@]ZX04A
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M[">7&QR*JYN?G?C9&(UBL4U@%>6ISV^6FSN,?4Z%H$ [-3#\(X\8,U-F"^A
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M-LD2X+A\29L5<4E0DDQD&?^GO-^PGU=!\=L0/7GM5Q%U UN_PK'R7K++-KB
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M;4F[HR$4ZE,2@*.<8@81DN.6Z2,3Z? $:JWQ!Q-L)W4U.,^Y839??/-]_,P
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M5]D0[TPYPC&*!,\2L1"S$-(ES=J4H^V&[S2YUU!'#<K';$$YGPQ7('-,I7D
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M<:&(^T>V5A\BE+(0G'KJC)5:9:\86)UDQBG*J+^O/L3&]]4O"Y&CC<PIDE-
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M+BC_I-UA%-S@"/;E;((QU&2"$R3TA_/Y44J#HU!0MB7Z1X$MBX:/<1Q?%AL
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M12D'XLWDTBXOTT]4S-;3( @5%&7@DB,N*$6$\=YY)EUL% QT07?$C;5::NU
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M. 3&.0E61N*$,0&LCDGX+@:G4TQ_^_V'W@5OH-=1-?E6WG^[B:945%S=G^V
MJ?K.^#8TA]\FWU=+6Q6^IX@/I7[E9* &)&$A^=( %X- Z1UA206:G-*!U=M)
M/ZS:[]A6/X36=Y%L[6#GQ3CTIPNGY._]Z=GG,_A]V/\&XPDZ)^_SRU*1?7+V
M:C28H4OC5Y7TG1 6<B8IHHF3F96+[M(2%:31W >G.T8U#WCY8;=TZZAL=$!Y
M5][)WYB9H1VCGE%#+/Y_Z2X%)!@O"!-:<!.MU+Q3B;XGD_36=OG?6\:U3\.[
M)W-T /GL4]YVTN3#\I@>H(:CI;QA(.NX]XDP)AF"I9&$I!.A(C(=DA5"U\N8
M?6(I;^VILHOT:[L:/P\]6E TH)-/,,!/?/ETYL=0ZA'@\K=<ZK05VG 126*F
M^%8:@VZ;.+'"2&VMR"*;3JY%AY<]UA2YG70T:BC@BKY$@G[O'7SQ@Y\1X?1B
MT9A#*,-I1B@R!B(A:G2A<?G4&G+44M"X7OSFAB680/S+E]&WG_#1<T/P3UF^
M)(LOYT38\-+3\1SVE6C%+<0"98%BR> N.#KX!=TT?/W-AUWR]U;!J*+\*EKK
M6WAX*9FEDB$IE0HQKG1,MR83CW$.!RHSW%E>\+'H<<MRW$R-NXBM05Q?DF#>
M#N-?5HF9-"?%,5!5KI1S8%D3:P008!BR(BRO5+?.+[<>?;B%=#\1CZK)IT%W
MA=7AT8OXSUE_LI!?82)("<Z"+(M!0B:BC^LA170.N''<,:ETFR:!6P"=S@I:
M4_(5ZY_<!:M\B<[CDOQ= #;M&'@OQ.,T#*RBT XDV5\;#?IJW \4XXBH..?$
M!)?19BKT_GD2&!$X$2!(G4.;GM9'HLL]+0./PY9=E'",0#SR$AM&3W1I,R0%
MQI^VE(C)0O*@+=,I=BO*\Z@"\4;ZV34(WT6X#5R--[X_GB=VOKSX==Y*?;X;
M\68,_YR5!-#%)9(@@-O2SDZ;4BQ96^(8!Z(=+K6",VM4FXRB#N!.SP6IK9&*
M%;UN0=P$<#EIND!LZI!T 'D<EZ2Z@K<1J+)V&C@H7:""=!YD4;&'4G\R.Q+*
MU&(F9NF@=+IK$_0<C4#W."F/@3^[*.5 O)E\+%WCQVB75T?ET95RQ8YX'DLU
M?L.(@[(]P %X#HI1WRE)I0IQUM$=WL^IKM8.M-E+)X=HCG"C_=FDY$N.?9R6
M-7VPZKWI5T<T^]UK>\![*MQTVW=T:W??%"@I10;&2^<PI;Q*5(;(A#=>9N9Z
M#WKC?K;@(TP 27+V8IBNY_J/Q^4*YN)H;8'B\^@#C/-H?/YF-)X7O+K>%HUR
M)R&5CMS*E?JVD3@>'2D73)@77CC036Q%#?3[6M/YXTJM4 2QK-;V_NL\.WWX
MI>>LD"Q*3:3* EU9L,0G9PE8*'5CHT@:FDCF+E2'MYX'9]FZ>:VFI$;M(>9;
M\8M$\TF/VZ1#=HD8R$!DS(:X +R8>6;QOR;';K?K-CS\&>F^BGQK[QC=UZI$
M@(1R*YKP6/;*1(H$5PB)V+@12C$K5;>TC4?3_N51\:"*W _0N^%![4?0^_12
M9U_J0-E2Y" 0S[@@. [!F*31ZIU:!SV=%C&/BF,'U6/M^VN=&IUD):..H$@"
M+8ED2A.;;29,*)J=TR*;;LVC'U<;F<?!HNH::-11HE/[$R6T<5(% E&JTCPA
M(:FS)11*?B:/-#_<)!V_U<SC($PK?=1N9M&U60J2-P2JB*"X_DJ+7UG+'=$L
M(5YA<Y9N%\H\FG8TCXHM-;50N['%6@,6'I60@I9[013==8_$]3'C/]D(X1RN
MC'ZG<.C@+6L>E>(?(M6*_2FN9#'W@"8]QL $SBP)CAL,QD*I0#I/#G"1@=62
MV4YEZ1ZP=[1 \(QXL)?P:S>>^#":XE#[?G"KEDC/9Y&C"&ARN'$E;S\1IX"2
MZ*RDU..XUX_,M\SX[>]X1EJO*>T&K26NN[I7&^"C,0X69!2L[,91Q@BN2!B3
M.RD).,XM.,^Y:[.MO!72,V)-7?5LV$;;._FF."ZCX:?I*/YCGADT>3N9S"#U
MK,#H.5"![BU#HQ8R&C4(B-!RP5UB*4C6A#9; #U#TM10S0;*['WR/0?S8=R/
MT$.#)P6^G$0;YMWF$8K4F=B@06@'9<^O"4NN,#Q#8CQ0 1NXL'>=L.N&K=#3
M#R.\S]>8VRL'["EE1WA6I><2U[A$%LKZ%,!S+1UMDP)Q+[1GR)RZZMI J ?O
MFZX0_MH?CL;]JXV8]W\,<?1G_:]78?7+>9FR(JG1/*-U\9&>B-39)#EQQGLB
M 2>%HSX0G6),27-TT%(3HCT8\C,DX&'4NX&8>]]_^0AQ] W&%^_SZ_X8XG3>
MV+2GJ<K*&([NFU)$9EN*VPM&&'<@N7;)K6_-5@N\-\!YAH3:7RT;R+)W=O)J
MU*6FSJL91HKG5[WM+GHLHEV5CA$;,U)9:Z1R.2MU2H$.VF4AVGA-=\)ZAN2I
MIZ8-)'KP]NT*W6O(,!Y#6FXTO5H6YE0V6Q&R(C%'7*&= W3_T20F:H15PGB5
MVF1#;<;S#&E303$;^++W;O :K&NU7(.';+DOG1I4.0LO:R<X0;1(SI44RFS:
M!/-;(?W)F@>J9P-Q'KR#O$+V%MVM<_CLO\/D@^^GGM2*.EY\J^ ID3(C'BX%
MVD$,#:@-4FG5A"YK0)XA2?91Q09J[+VO?.<*>=F7.XZ^#/O_@M1SFB)Q(R=@
M>?&[)!#GG"5<J  \!8I!Y.$]FULXGR&Q&BIR0R;?WMO2\Z&O+.;<IY]G]/2R
MX5$'QXG(N3030UP^)DYP'D2I4 *&MC%-6P ]0R;54,T&RNR7$?QA#.?]V?EH
M^&HP*C<\YIM9BRU2RDU.1F:BJ2TEQERI+A8$2<H%;570N.IV.P?=^HYGQ(*:
MTM[ @KTWI"]-61$C0EN.?K[1&0;+ZKFXK :G/:,$8D+SQD 2'*\F(+,!8,$J
MUL:,=(+WC.C43FT;R+5?4N]O\ZK+9\L,H$O  S^%]'E4\I+?YS>SZ6P,EQF#
MO2BCD J=-O")X3+*/?$0*$DBB8R>'4Z'U,GV/.#ESXA%!]'/!D+MO:F\-*23
MG_UX".DWF)9NJ=(!E65SFY9-)T6<3YY8)943,G@9VIQBW(+RC/A31QT;"++W
M1O*G> 9I5JB[AW 6!4$4U1(MI"':!4FDP7^"LIXDCC^G02E#.Y5)W_VLOMH8
M6G?C>31$/)+:'T-WGXV5J*7SZ#=2190-ADA'([$VEI9H+@0K$H:J]=HN/X82
M_\<FPGW] '91R-%JNW<!^>S[ >RDR0<5>7^(&H[&&>ZSY,D+(@Q%L 97_2 C
M$(90G4HX47*][N!/K!] >ZKL(OWJ)8HG$_1/!Q<O^Z-)[ -&GJ4<[[)H3##)
M)ET:(4(41/IL2V-.B\H,P@IC!;ANFTAWO>6Q=@#822NC%B*M73#B_:\_?_RT
MQ)&E N=U\>[+I75E$[+::\)\UDEQS03(3JJ]]M"3T^1#!59]DL99?^HGG]&M
M\5]A-NW'ZS6S+<0( CCA7EHBN2@U2#!:<RY[R0&L<QT[@=WUFI-3;CVAUB[J
M,/=?+R_;^&&ZNG\WOW:S*F"JA;;>E2B=8JBE*:+3'FGIJ8TF2K0HW2Y(=WO?
MR1&@@9AKEU1X,1A>#/SYAS,_/O=Q3E(_N+::0/"*,2E(,CJ6^U<95Q-E4<<9
M9+(J!]&M(_ ]+SHYW=<4;.TB"?^W/YC=!/9J].[SZU6'!.""!LV),I$5PT2)
MI\(3:B650@0;U@NF;5'YG:\Y.877$VKMV@;__>H,SI%Y+X;IPWB$8QZM+(_S
MP4@7 P'),Y&(@7AK+0$1HC?1)&:Z+>Q;7W%R:JXCS(I5">;C+IM5B]YR7"9%
M R>&@B0R)4:\<)IPQI5RW- <*_;=6[WV&6_C/4STM7MY%A"KUF\=8-3?G;L"
M</C]MP>J8%V)>\BO]K;:-3@YLH1 (E&Z.(=24N+*G42;5&()F*"^4XWLQZ'&
M.[;&ZFIQ%[%5UMZO**GSV?EJX=>"&LT#$;G<)*6NW*]RD5"CI*" 4;WJU(:E
MD_YNO/K 2^]#A3^J(;G*_;"7):I6.VHV:JVB(#'B2&1F@@3 ^$QF&B15E*/C
M4$^%UU_]!%7X8,E5GH7HG*59G+X??X+QMWY<6!8N6;8!XVOKF"42%'KA+!@T
M-#XYPP%M2[WSSDT(GK&CM+="*FY]7,,S04$L$4U6L4$'4-4]J*UP#N]/[:^I
MVVJO).8V1F(#.)MH9(I[4C+9B+09B*7X;4R11:H,$['>LGU@W=_AA!U(];M(
MMT&/D7?SA@5PN1.GA$DQ$A-+1]"0T,]@^$^,QM+(@XRL3:.\&S .N]174LVH
MEEQK'T3>3%I=[;-[K63&: )<1!X[QH@MS5! 8UR!48:C>NU^>*>LX:>OOSHB
MJVR;KUR6G_\YZQ=$T[-1>CO\!I-Y0=#;/P6X3*G0PN>@(J!_@JY)N6].G#.>
MZ*1"Q $9$^IM@^V#]!D[A =3<,7CDX)[&Z[E!.R"K+KW>#>FP[N0A]/MJ*EB
M*MNT>Q"R; (8GTLN/*Z8203B/3-$N&2<4IJ#Z53UYM%2Y@[/\S$R9A=]U,[(
M^06&\,T/IY^6"5ZO1N.OR^9;JXWJ8!B.SQ.E)=I=P= MM\F1'&0*";]4M-O1
M_+VO.JQO4U,IHV82;="P=X^5^.7%9WS)?"Z@G\V$C9JP:$OE4Y8)"LJ24$IY
M.2H-H[)).%,%_C/UAXY'@08]A/>1(+YB.<^[#*)IE^$JPSA.'^(CT*@>D??D
M0(/]HDJ#T33$)'"E\J63'T?&>2?0.D4NA962@F]U.?[1$OF>?L@GP^,=5-^
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M++;MI \Z B4TE/L_NI3=]H&1%+6U6C+G&R63;H13<6-OT?G]TRQ,XKC_=7Y
MU@O2TJQC)-SKTF/%*^(-HM-<)72!(8?8)B'F;ES'W?)[&!?NV/7;5_(MS@[G
M32SFZ'Z;%='@-W.4I9<WI+?#:^>HO<B<2M8$8D2@1-+LB'-!E8*=2EM'<?UM
M=)RX \I3X$PSK30X,KB_ 3SJE$9;V!W!E8,1C*N%I@2<]3JH\M\VV9_W0CL%
MKM25?\7J7%=G9PAB0=S7L_&B$U-_E/[+#V;P&_PQ_PTZ\#IF8U&'1E!5KMM*
M8J4(R&<+B>7$0':J3_* 5(4.\$Z!*/7U4+$LR;5^.8LV@(L&<'[\?CP_>UW
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M_L[38D$C65>\=+,BZP@Q;(.Z6FZ8]A!M(E;84E')2V*=4R0&RJ2(3FM(7<W
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M^"8V'/1-9L_0RA(840P6UQY?U^H)J.GEQK)O'CS$ 4$$O<*O5+ZHP$#GCN$
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M(BS]=3C 4\AM4(;GDM3)10YSP7YQC4:.$2&#!^D&E=\(BB_L,RS<*RA:(^.
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M*:;\TZ*6CZ5KG&OS@^FQ#Y*M 7!J\3XE4W&Q*E5*]CL/24)^$:8TB;0[:A*
M[U[,DZT,S^+A#QFP3U\R%#^9$83)D:COR,],>A(Y<V[^=XO5_A#^LUV-SM\Q
M+ 0IQ)^QNG_B70%J[Q9Z2Y3[W75&IV?T>\QZK/.&@XT+MSV+IIULI09N\@SV
M*CB<%EZJ4P59:H J^7*H;ULM98J<CU6N91N36SO8XV8EE)5P&G%>0& B%H82
M,6/9-1!?2EW>9$M7"_+W O,OR6Z<N5HW\FTD3B:H?&1Z&-$G$7=F<9N9K0[4
MMM@Z:JR/[DT Y7D];_!<YKYU84M$]@HK<\.!JMI)OE3\TJX%ZE]*EFC9MYM5
MF?8A*6&HX.P.M^BBB\+-I^\R\8$M.6TA>X5EZ W]F##"Y&C:S0,BD*7[^!OW
MBKVYX4UY\[NATOSB(ORGSVW%@YK>!KFZ<SZ80$M9VYNE6;P[%M:M'(T*8;G/
MDRNU+E%1&<%LYNF;DIZ59+4\:-2:\J7+T3"L?BQ/WR[E,@)TC^A"T?+F^_+G
M'WBH.Y<FJV8[6C6M;[H2:/GZ[L9KJLR,;:VZJMMFYD>]33A(VV21FSZ()8__
M$L]Z;4NF/=1&TO$>U]9]_C1AK&2G$J/[:5V39C^"C<H2Q!CD4B'$0),Z;'PW
M:$>Y8<-RV[T056)DX>'O1M2*95YG9@-%V84&UL[UF:TC'O6?M7A'L8%EA_.D
M#:ZHF*@@;;&+=8:?OW[B(9N)Y]N!]G>PEL$4P9B[LLCL>;QO]A&2.2//JOR]
MS.8X7AZW;NG#H(-!@\$-$\^,-[U!?B]EJBHFFAP.9LM#(U=)8*!'U@<ED8B4
MQSTL-_OWB][+>D-4< "?3MA!NVR;RU(U.0Y@8-VP\-[KP0$/C8>]*E?B4UF-
MR[8E,"-W1XOUD*ZCF]RS$Y53J1KJPU?LT5&%=\]5/D8@$[&M"J+;N\K%)13C
M-/7-!;EL^JY3"_,+WJIP P^P(6;XD_ Q@4@/_^L/L*N#=S?23&9S#@8^[4-N
M^@RR( ;%(F?LQJ,;5F7/=%%'^/NWZ3Y9)7NNT-3B#E&:\$2$=M\HL9J1U8'(
MM#=02_MI?77RZ4-PK]<7%4[Q(;2V>6UMP/!\\,7'01?[T&&DL*+!)Z;Z&2-T
MN8^O45R '.?.77';VS\)9Q#T5,V'X&-<B,OI\!OH6\?:/Q,#-T2.45'S3S\:
M;=.+D% >'*HVPVR"79J8DC3>/_35GN:[<T=KI7=1AB">A".*-2+6FEE[V,/7
M(ZMF/\KG$^>^3SG N@!=,%XZ@#<V,;4*,,>/#<?!JD#5;;8#!O9CVPP1B2 Z
MSDT<\,JZLKF3 1(L"UZF&3.>(O/@&T34=^ZX;B>M0NOS6#1#QY;169J^)!GO
MRKI&)Q;5U=7\BJO$[<K'IPR?"9/:@J>QNT\.\%%03^,:HE1N8=),/R3+C.0T
MX#/'V D!R:X\%D$-4L*)NX<"I6UCP ?,EH8(-318X&3W:RY^Z>?3/:6@IAG\
M(-->$,(!NK&3K=B;Q?'N 4OH!=WAUL7@>LQ' 1Q0"1KQ]9J3WJOBLV)$Q ]G
M3AG0S-)>1.:-)NQ99OK%^Z$V4/N,?9[5C. Q!(7>#@YHZH$,85_')#O4[RAK
M;Q[TE'.W/4"J=7%B_#83<,"+[5<@5ZD'Z @A$;>+E6M"K,81^K7;4457W!O>
MWPYQ/<!&3[;)M($ &K=-M8[%2XO(I;TEXV7@#$%.A*AUY9.EF K6SC>(70CH
M*3Z4-.Q'R>[7NN:L+W;1#MBL'/>=NY.V<\MX@_XPC^/W2B8(+;9L6_A:2*/(
MY=O(6N@T!EMQ7[]2SHMS#N+?H%SR-N)\.2I3/)_1!T91>%GFTYG;;A;/J8^'
M(<1 \YY/W:<'8^NCMZ^)T;YX'7%#0_'$96[=8PE=-/)=\U^,.NVETWOL C+;
MU5<?W:79L>UYXM&9CL%:I9,YV3T$R4"#BG" (0PRBG_(^IXQLDM9)(5S^CC@
M;?S.W"8A8FS!?K($O<GT2!VDM3YS<UF$=05=SO]IS7)^'H.D"L<!OIX4L _>
M?&6]31,5YP]J;B*KV^K?\&0F;KE\OO6@+JFU1?$P+Y%!@0.</5_4\2++/)77
M9..K<G% ;R#BW7[M\/WRY:L!(@00,KI-G\GNBL4>EZVM>^V*H2L>>ZKK,I=
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MK-5<0-\3*IEW[^\&:).4-(PXR)1A,(NO7X?7RDM?.[:>/0>,#-Q(>B&\?TU
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M.CF/F+G0KU*E_WVP;@ =Q.WLNE4O2^M9':L*O=,^"H%[S[,!J,>7T PKZ/0
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M#*-YK _8EYM#01+MUS P>151:SEL^L-(/_>N(9U%J>KR4X[;4LWR 2[*$73
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MI5J1E=$07$4I<J</TE] (PS3 7^P?_1I:'X,XS\ILWC*'11MA00A]HQ!=B3
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MBL ^:&4JI@)W,8 &(_#O/X[_\!V%GOPZT@4Y''K]T ."DCSNQA*LG ^ !#I
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MO7=F>9@.K;8?Y]:U'*!G+CCE$4.35V?)5NLVP@LD0%.KS!\VED"?+OV WW1
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M#3>0CMMA5[WF?3U^]F.L8[^BJ/*'R<-FX\X@5)<YT/KM'S)X"6+HH]$;T=J
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MJ@02P[-G'Y5JG]EW'+UAOB[O N-[Q=9"M.3WC]E:C6GWE>><Z@=^C,"9I4P
ML&2G,S[#^>U[JS67ZJ(>&8.U3Z7FO/AF9Q9Y^'N,BO<3<:/3^7?W[#ZK*V24
M))2%<>+WOKZ_I;A,9]?7DO/KM563W<PR?FFNPQU+O/YO12T0_5=FNT3\'UO_
M2UN[(K;Z6SYNQ+Q&'OK6L!39[H?S-^#@?ID92/W YWGR8ZH2PJ)SKGBWPY(D
MZ)J!CH3>Z_5'!8#+CY&U1SS(/C=?9KIK,,7:H0>6*?A"K*.OKQO#)\06>ZK4
ME5SH*_Y-MI?=O!C9'VWQ05S(LE<BS7;9>;#5\]C=SJ.&*<H;= ]EHXQ?W[NL
MZS!.M,YF'"8$@,\MWA\3LJ!<SLS^7G?OC>[#82-C_>ANL5<)FX%U 3]Y>0S)
MGF:T_8F>^L,CT/#FIU=>/IC-^-[5%=3S.0Y _#OQ80;\6R5W@?\3N/Y^9R[O
MY&FSO4.S&XS#7N,.7K]T1TAQG3<BC,LA''.H$0![;)UL'6VB%Z;%=QCTEC0@
M##Q1CPFQCV8^?77Z_BQ;2_]BT%,3OMKF\',A$3&=.0(@1Z'BR,7J^NG;(]4#
M.\>2_4ODM,S"']_4=TV@(/9HN&+X@^7XZJ45XH*-8J6RE3->O?STHCO23J?\
M&A,ERS,]_/;2]3>9$2^!(T+SUGSU"">I:>[!DKJM?V!*(S3WO3#>=FYSU@5@
MWS9@CU!2S@19P3-/DH+^?&?/6ST92G*XX\WAH*ZVR ;V4ASF)4+!?,E7FRT'
MU7[FJA,I<UJ]00PJTG;CYT7)# & =ED0 "^6KMK#@>]0EY-1&)-)'0OW(/T[
M6K?Y6X?(^7_<(?XOC6[_LU0U"KI\E=DNZTYW=?E>92M('K\UGNF=.J71(7\]
M>8=[^I>!<(U2ECLKJN_C7B,-Z](3O<#9T<A)X%I\)J6-FQQTAZD'"*LSO]PD
MG;9A>T3^.^KL_%MU9OW=ZM2/9@0(@--%WK<+NI"[-#0[N]2KCD9.;UM^T9"!
M9Q:RJ_Z\VR$ AG6+3V.YC:K2CWM\F^R/"LT1^6XNO H4'JL^^SS<?PJ=JGUG
MV^FVDXJ*PX=-V#P_IQ1>)OA>8V2%7'FT6IOW(G(?UF[ENI7<_9GC#RYY6Z L
MM6.OCKEZ._7_\3%N7NF/$&\+OX+H;PX)4B7Q2DFUB"IQHEQK(,NS5P#,EI]L
M.<K!U8@O1;S7/M8M='OH4J)O'[>(*]QL17;>X29&)ZNUKS%H5]$TVE<A&[ZO
M.R/4V-JH.;Y4C!4D:1OVWWK'5M<_:J^:C+BW2.)R.:#;ZMOVIZUHY+4D/FJZ
M53_@XL:1CGIM@XQ( ]X3<SZK"]NI>^C7;@?1?/=.*VU19B /.4[3"."#%.2(
M/TL/2<4U>ES?!'$A/ZPF1&0@YHG^R3A&ZZ@*\_GO=YDURJ80)/X(94J!N\@6
M(0S)<FGL9;HT!UY#V.7# L ?/$BJ.@23@AJ$9!#%"O-/)JX.9SW',?(F2,5A
M-&B>T17%9_,"K>8B^<L\#C,"9J[.>2L B,AP&F4'6$W$674@\[@-1",4:V)!
M$EMCP"(MTOIUE^'(PIJ^"O$@K;S'>A 'QG@9QBC%UP-783,V(:FHUCS[57S4
MC/\T?&/).#BU/I9:UD5,XG[D>>+W" #<Y="@]$?+"9!RU#T!@&*O2.1QP!Q&
ML^*Y9AZQ&THDA5:A<5L0]@( >=7R+\P'_\N58[-Y=.VABN#%A"T@:IY%N)5C
MCK33=WQFK)#$CJ_8^E92!./L_QPDF%/B'P_MMDODBNIYU'E2)+2?+B)G/*+^
MA6;=_T\:;RET8+BOI5*<P]C,:.!'FY,I4S*@.5L$_ZO^<2VN>*FP(Y F ';2
M/\^>&IG@*YAQW%>_<XQD^LP\T_@$5@L A,^II@,_5[C"5IEU$8A%6LY?[.'Y
M?ZW#_1?H]-6,)EP%P^ 6E_HJ8^<%@$E(N !XQ:K0"^N!M')63H'5R!'=E.K?
M2*;_BL3J_PO)M%B9<9*]1/TXQ^0G22AX4)N ?XA?(.\\'L=>0"UX7"H4%\';
MB]?X@7V(7[2GVJ^J7L4KK;.RU!8 A@+@AMY^;D[VF;.Y)U"W]Y\47E$98(FS
M#I#).7NDU-,0T8BA*3*9K_H?_?Q&Z&L!(.9#Y:EQQ6$I1>BK>87Z=[[D'#R(
MF/>CX7AJ<D364\IJ]#7[.R-W^& P7$D( +A0&?I83F3=C%S%.?&O48""[G_4
MO)1 RG]+WNE['FD95=[*W?ZR*9T'H>G4/[2W!\X'A/TD95[P12<D2J%Y,013
M8BMC7*\+MZ%@UQZ?;+0.;U:]^<(RUS&WX,Y.W<,R2DIQ-]UF0W*NR6\X@Q$
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M2:R J&7U&O5<5#DH9W6D\Z<IW%=<)B[GNT=4LZLGR#?4JX07 GD?&N"B</(
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MNR)'A#F5'T@(*V\X[HNLQJ1KN-@2<5%C/<1?+1,[O&YRGQUK&K+GWZJ/5Q0
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M^RY<Y"[V#H,0AB1?VKCIT:Y;=FQ$6@A")6!LW#=';N!J%^._>8/<\P_;( N
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MU/*CV2?92Y)X3;.YIN9R\H2>]8=L,_?N-[=.CN']Y6>VLJ[=]-)?GM'LB35
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M=I6YJ8SBEM<8X5>9#F)W9:14QE[?N?2$%KDM9QE9QDUJC=HC_D3.]J6JQ2E
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MF-E<T94U].51^??G4Z]W6_/M8NML,J\1.X+1M^:/\M^^Z$R[KFV?59DIY39
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M5_O-/T)O7O@N0KGJW@?;H;QEGV5QT%.GG>9TMIP^]C&U=B3@["X!X"+M-_C
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MD(CHB2ZV#BN:!*/<8,,: .=/P218$X#&#[I,$$A:[$KN0T#:7[^K99:",<;
MNMR!A4") !/0H[906H-@?U)VZ+%,.G: Z4];MF(C"<@VD""N0N'+',@OC0":
M'2"W$3Q> I(O#L0>1FIAF8RXC.]B0;O9D1AFX5\:?8 -B5I$SGR@$&H.@)8R
MQ0)HC_[<5LLZBC3B0$Y&!;,G4/7<![A$0K7@"C*7NH&BPY@46L??W%(-'(*-
M@%H4TK#C4G^Z260(;B"S-A+H3P$419S-;(*%@/M%$:XNA(U8U/!A743":5&.
M08&6J$D.1/FV+S]QT&72%@!=72-(S\3^TQ>6RT=PV= ?',@$@8(="J#AFA8
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MO Q/_T$VN&^S^@R9#XAW4C5R74H>*(Z61G;=Z3RCVYM;?S623[TJ5]?4^Y?
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MNY<]2?1K3AAD!Y4F9F)2/C$J^9YMO2O8!WFQ-7ZK>^X*42-5W6'ZTNDJ[4
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MP^QC.A\<^Q2<Y@6S1T:C97[B%<\,=(-;6Q<.2E$49GF R"\;MAZ'=4!L7N=
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M&O&14>A*4-.]W7OYZV%3MY39">[#F ZSH)5;:+N5KWJE*U:F1KJ/EC^I#/Q
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MX67"@5RJ,R ?U9Q.R/2GR!F^5%F\Z1(QJ)G)JLL]_AG+W%C>O).<:\ZM]4V
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M/4OM?W[[9!QGFLP3@@O3._*)1BH[K7RTJK7CRC&%8Z<KS.U/NK'4 QF^V8M
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M)IQ2DH^8'C%U]GYY0N('YY4;K0RDPGM_OQ*%BVJS3 >.L &I*G[C>;8;2I=
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MRHF*47OC0_^YLD-]E<R_V()06,1B^FGZI:$QOK@SSQ^:%:+J0._40*T)+&[
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M]B1#+I]__$<C<&Q_*P1O]ID,:-@D S9-R8!0B.IA+QG &T)<(D;FPW#FP9/
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MQS!T:N%^UY6@BQUHZ"ZE>D656\M>!B:>X5L2+]@MD?#(V^T4BI1<!VX_N>'
MO]<VE6@-\C"ZTK1S?!-<$E(-CX[8<MPI" '.<Q %\PQNK,^0 =[>]]BZ;4G%
M[B6=^_S'[*G;&/2,H6EXV3?JYBV94)/YMI%1FJH^S*DZQJ+R;NS;)Y',2#*
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M5YX%'2[IP4Q>*M!Z\=-6W&%<K+>+)R]8=VVUGSMLUJ'M*1K$.9)9@":J=8F
M6U$1*FN];4TV6HCPC+/0?O;M\NZL/B.D<.&TO5;_&='RDW%)E9,Q\62,R]?3
MGTI*@P.=*[[>%G<HGJQ]<L-I\/DYKKL1U@>O?HSC3"5AA]NUFLL;L'2LTD+>
MX+"3]4;!BW?ZAXAB5\NB=^W4YS*7V>7XZ:>D30<+6"1&)+R3B2!T=2%$IJ56
M?:-(@_X%5@\<JBXR7I)TNZ(&/81J;!<#,2>F:R84N[R]W+1SY7UW^\(?WY0^
M%GSB:TM/1^[MCBMH>?E)NGTYTKNC^DPYIW%(Y_9331JPM ,U0H:/8[-/ZNXZ
M?ZZ8UAA;;B>M6^!VHO$^-OY1AWQ+H=7=D&6DI=;-D.RT:SU+K_3"@V1&C9MN
M&+5#")4X_J@9)17TKV<['._58(4*L2%:UN0X2]L-U)YN(?1I9K"$=D1OR_!V
MV2MCJ1;8V)M I8_UQ?VF[NF=V8OJA/4#2<'Q:5CW#9N[\H61IWITMEY\]2,S
M6A9_24![]Z&$UQ>6[OI[EC %N:TGULL048+G"(\2'6X&Q7/\\HL]O;OXNK'L
M$GS\.,]WT64JK;@KPXV0M)*03S<HI!O+)1#I?4[SV<$E*A(>UG+! @7;1.S*
MY(3F>'2Y107%1% 4U\&CGLJ5HJU?F77]0D-GRN.;S$5B>_<+OD=T2ZV11(/V
M(_8/E,1<L@\[>3H.KQZ QL\E?5"Z51I]M?N:C^0M);_=5<$FK[F/<%R?.M$6
MI&:E2.Z<:7U66*ZRI\@+FAY(L$,M7 \+?%:17SZW74VTKVY,UD- :?5"9&0O
M#7W"D>K(_^EP:M:&9E'K!_7[%8\7<Y#'Q#_E\S>^%XPO4JU.L[_%:#  3PZ6
MF=9GQQKNH0/;&"6^8[S3U8B78 ]8Q0+\R2:AM<]AMSI6@Q(_3G4>S+NHPAF
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MNY@^3T,OD7AUWW6&=7)J%'RDCE3!.>S6,#A=E8B9W6H88.XCP[@2U]XG6FD
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MKS?#(O?SG4BI]+.N F.S>X2V#59FX<H,:,><JCKG5#L&$T@V#*>!TC-YB9!
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MWH7%)>6K?+P?T-0ROW$=&OX(Z2<4Y%XE?OG8U.%<-I3-&8 T1+OV6;M^'9C
MNUOG!2ODR7 *UAE539$"&_-6N']X^U>L< ]49..D%<8_WK(P/+.]XK%A\Y'
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MI_9>K*H4W.K+\^.V0]H9E6^[7E%G'(\P-=<!M"EFH-^8\LS ;F7_'FQ72V)
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M.C1KM(:R_V\,L?__]^:K7\W5\9-@@.V@J$(P148ZD[;C=4 ";ORB+_G3-#J
M8DP$TK@O\%+GI0]<U7XU9\&_,#*RN/_YB\A_PQWM1:9='90!DNGV!#QS&F*]
MDPT\"GV]QKO]U$"AWEO@Q##5:52_I.QMZ]-J,J_CXC#\D*NL4T4-%*5MY1("
M&,CJ?T#FS31=2O!E*UP]3E@L""E>;FD6,U!'FUVC ^H'G*888Q"[W_AJ.6)Q
M!\<^G:5$NL2[6[4!GC&SPTGK<(.Z_L;<W'$R2-:.0,A=.>GP9D#=F8"+KG*0
M6I#P(+"6U3B0@GS(B"IG>*Q<R)<?TOXS%">G3Q0'FIC7)' 6&T9T9^N/T7R;
M=S8OWK?/@^61%H%?< ^:#U5:'"CWN1859,Z2J03SR]*8AHXM7X-#\.VK*\<O
M-9$GN<RL9HLVDW#(T'8\ABC I*!7YPK<L$59WAJO@LZ]"W"$+(ZC(@9$%0I/
MVQD[\R9\6K);\'V3]\AHDCA2<M_9;,>?8W/9:"TK:_)G1[4N3W')VM !$&B3
M49D##DSP7VIS3*^@SO7.KBNY@(51O;SV,ZT.:0L0%P;:A4]LV2G3 444Q.7]
MK\L,6S20,C=)BV08(#F?526&3;(U(8LM0_]N^2.^']F+WF(7'TG^L-]6M) 7
MX*XU0)U<P@10ZG#(.2::B'Z8$H5PX :I'V]VA3S9]-DK!P_JWQJ"=C91L-J7
MH#\X@&VC$]03RP/LIZC>P;1T<A\-*N9 !RRAL&94Z,\PD4:EG=6IY2F&-5G<
M)")I82;#=, H'? ST*0%:HKXC_PISLAUGL4?YQLHKQP @Z#<MAE@)KQ>8MP$
MK<# ?E%A4S_#4F:!97I*&WH_K'G;11)-#,R4U$.FN$R+N)_6;\1-;8";+.F
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MP7_!2RK_%/S_*#"CC_\/4$L#!!0    ( +R I50-S^\^D*<  %+^!@ 5
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MN<[,COCG)7V4U1-M7]!6&#>B,>S?.R8T7L/Z08*]%6"E0&L'V!KR/W[>@S%
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M^:.Z,![ '+LQ/DWX<=S=DS3+O.7])TDU,\PIFR_T&N]7;>I&*Z"'#Y91QH3
M,)$%@2C&%#*<8$A)GN>9HHHD5CM]UA*GQF>UGF"Q5?0&+%=+V.KJQEJ7P;;C
MJJ 0#LQ0.UU!K>P-^+0'<J]P.%JRQB8H&5V6.BH%68-P3#SV+[K13;VI]$7>
MSZMV5^GK6KL$9IUV^V->S4B<QTA@"5.5(.T]J0P2[4]!+'""&"JPBJCU:<)9
M,5,CEJZB8*<I^-WHZK)#?1Y7BS. (&@-S"'# ^6P81\$L)&VY4\#%VB'_2(0
MO?OHY]\>;[?\H@4'>^*7G_9SP3[0>?DWNMC(7S3G;LJZV0^E_.=&+OESNR,B
M- 5RA234.#*(*,H@CF4.];(SSA!6(D.YBQ-F(7-J;&E4!K7.-Z"C-=BI[;@%
MY0*_G5L6&-2!2=430V>'S &5H"Z9C=Q1G3('(([=,I=7_4CH/2V7VNVK/LNR
MWH_YO%K,^?,W^6/]1MOPCUF2QAF1.(<B5PE$BG!(N$IAS$C""(^1HE8>FJ6\
MJ9'/KW(-%JNJ G2]+N=LLZ9L(<T)-U\]/NJYM3(V/*P6&O *:!^Z^84;$5WJ
M CL2"@CLP 2TU11H59M-P!O0: M^;_]KU :UW@$)R1*AH&1T2>:H1&0)P#$)
MV;[F1T ?EWH<RVK]_L>37%9RQN(\9YQ)B.(\A2CA&-(TRF',42&$8#3B:O8B
MMO+B\#@28S4<[.)%PX;3-%H"V:CI1B3'4-H1AP\RXQ#%#HWW%]!PIH(S-@<=
M^L<R1AWJ9PP\'MKG'@NWH*EVO_Q?<UGJ)A^VOG5>*(&+F$*92#/:*86DT'\@
M')&8L4PO=IP">IRD3\W/V"]RP$Y30)<"_'K[MX#KF_.]X;_2"8+QP$QR';Q!
MECX781I\$71>@U=?#ET$QV9A=+D1/UK3:X"/2^WORT]Z(: 71'G"HPB;\!X%
M$4\49$4A88ZP1(4B*DZ+V7H7W7]Q2!VT[D1+9RXJ#+'\<6.>0\!2$F41RA&,
M::1YOE %Q 7G,!5Y1!*1JCR7L^^R9"M;IO>&K"MEVJ Q/05F:8RAP'D&D<P$
M9%QD4"5QQD5$:8RPR^3H_Y6-N,B^!C"[^<L;AH'G)X- HQCXR:CV9W![M-_P
MF88]+CV)1- IZ%#"J%/,2>..IY#3#WD<;_Y5+N5WNEQ_Y7.IU:O>KLJG57-<
MT%X+26D194A0F"&DYPQ*<D@1T0O;C(E"2NWOYLR. NT$3H\3MRH['-I=AC6.
MXI3++-/K!I'KF47#BBG*H4 QHC$664:Y]>EQ4%#'8,VMPF"K,>BH'!3G?FX-
MC][ 9-L+G,]-L<L(.APS!T5RI./F*Q%U.WZV!JCW&/IR*^,=1UM;=' L;?]6
MB C!+R;=Q9WZK9*W5277LRS-HT*B#$:XWJN5%.*<$4A3FK"\P!F/K2X]6$F;
M&O76ZIE VTTE 34:7A,/> RMG2L;#+"!V?9%'&"M*EPIJ)4%M[W@71D$> :4
M 0, CR6^8O#?&>/[ __.O>3'(+??Z7QA%C ?5N57NI!?)=^8&Z2R>B?9>O^W
MMVT0K.!(<I%0F$8F&E#)%-(D4U H(C&7#+'$B5,<Y4^-93XNO\MJ7>]L@?D2
M/-+R'[)9#U8[U6^ 5T"R:\_84=* > ],4D8_\+6#ZLX4J%8EK+0Q-^!MZ)!E
M3[R"\I>K#J,RFB= QQSGVXSO@;;95-@%"FYS8M7AIBQ/<9[F7"]6.3?A?#&D
M14ZA2*22& N6B=B%X7ID38_-ZNVM?13O5EFG<%X;D.W(*A!T Q.3-VH>1^(7
M\0A\/'Y>WLA'Y1<-?WEL?OD5SVP8=8!-.>=R)BFFN8HCJ#(-(&)(09SE$92)
M.1JGG"+IY WMFYX:-=2:@2>C&OA)>SJ_?7VWCZ7[LV,^BSV =CS@!\O P[Y!
MI-8J8,Z)%Y:&32NQ;W[<S!$OS'J1'.+E$^[Y'[[H_I'M=A[AB.6%7IX4(F80
M);&"E H!LX3R*&*QDBJUS?C0:7=JX[)6S2/!0Q>J_D%X!0!#CT"S9UJMYYPN
M#FX=A,WI<,+VJ[,X=-L<+6_#"4.ZF1I._;/?!/E%+X'G2RFV0:FW^SP#[Z2:
M\_EZAD261FF<0!(S A$J!*0HI9#Q!$<%IDF*G"XN7Q8YM8';JN4V<UH@:S>C
MAL5KX'&^51;LHM)_ZN@+6H7/.R'.L[ ].D%G9PNQH\[:]C <S^8.;WH<YM^M
M'V3YRWPAJ_5J*>E2?%D]T\7Z^3-]KG?BMFE0(R$SP@7DJ500J81 5D08RDBI
MJ%!$(V*5]L5!YM1(IM8:/&[5KL,IRT9Q\-1J[G"(:@E\/P4-!.?01R0UDK\<
M(-GJ#+9*^YQ+6T+J<#@='MJ13JC#0.QV4.T&5N]IM653XQU9N]EV<&[M^*K[
M2NW3?#V_K[^GM[22WW0#;8Q[48@(IRJ"(LFP2=2G23M7%'*:%9%$2A78RC'L
M$S(UEM[K:;);^JSFSL)Y>6D7 J2!N=<9'Z?UW24 KE[LG14PVLKODHG=9>#%
M9_W6A+]]_5;62_3G-_/%8G^>L_75\J104B\ *8[-]2*50$P(@K*0,LUBK-D
MN:P'^\5-C0!^^PK6K;J :7T=HZPO8&NW(@R'V,!LH,'::@J,JITSX8#>@1LL
M09>!%T2.N@2T,_]X^6?YEN?QR_9(YT[5&?C:F_WO_[F9KY]=<V';M#6A;W]_
MQKA2H*OQ?P>-SL,DPG9!*>QYA97D<8\R7,!X<<KA]++O^- -?ZRJC13O]+A;
MWK<EKNI,KN\?GQ:K9RGKAS[KS_)!3_*?]3=6S5#&\ESE A+M8T-$\APR3C#,
MF<2(H51BY91%Q%./J<W-Q@)30\V,N&Y"D0H\;4KS3VMS]>?]U\^?ZW/1YM]<
M#T0]N\R6Y ;OB,%I3RL'&A- 8P-HC+AI,Q3?@*TA#2V"K2F@MB4D%UX%9F!V
M]--E9+Z\"K"7#'I=<VZ<*N1\]GZYUN3\8;Z0Y5O-WO>K\GD6F=0',160B8Q!
M)#F"+(LS*'@J>!+C/(VL=BG.M#\U#FQ4!+6.8*ND'<6=0["?N@+@,C EN4%B
M33,7##]!'Y7D?[E???]9OUDSQS^1^1$V/]9T<:[-46C@@D';X7WI,4]72-X;
M9^N+?%J5)GZ^R8ITG+LK0YR@0D50Q8F B,4,TBBFVO&)4)2E+(ZX6Q"7C=2I
M#?%6Z2N*%%EA;>FQA$9P:/^D!6^G\#C)TIQ@"NMY6$D>U\]P >.%5^'TLKL/
MT6Z!/+__H5V2Y;TT55%F"8I5H9!>9F74Y(](*"08*2CBC,:Y_G]&K*Y&GQ,P
M/8II= 1;)8'1TMZ-. GB93_B6F@&YPXG5)P\B3[3O5V)DXV.YDOTF=1U)GJ?
M\UT$F)CRW07>>B_GK2GS43Z_70DY(XE*(DX*B(6@>CQC4_U0CVP]IG.N,I$D
MS.KBB*6\J0WOUB,^T/FFN16A80:MYL"H[KITZ,?==BD1#,UQEA97 >FQX+""
MY\H%2+^,D1<D5@:_7*#8O>8;.?M=+C?R@];V[6I9[P:;$J_;RFF.IQN6K4WH
MTV\U!J:[P%;GICKQOF+? "<<CD@%COJTDSURZ*<3("_C/]U>]\R+7A^;_"+7
M#RO1N8@]TW,MRFF"H2+F5I:@,60%0U#FO""*J$05;OG03\N9W 3<G #.=QHZ
MIC@_@Z8=UP3 :.AIM8&G41%T= R8O;P?A+!9R\_(&C=;>;_!+[*47W@\R&5N
MQTGRS-L3^G!?W"\>8@:\ ,.0UXI?9X:[8/"%Z\2!9K"3DZ/)ZG*[%+L";]],
M6H3]%BK*,4DBS/3B4A0013F!A&$.LR1-A> H3PJG4#D/':8V\WWE#U)L%O49
MO=@67>6KA3:S]=.K.IJ<MZ96H&P<%+<9TJ>W[$AHX#X8F*!..^HW>P>^-J7S
M]TZ9R3K(7W(Y_UYGS?F]-G*8[?(K0 Y*?SYZC$J-5P!U3)O7-.6[2[>M!;=<
MUSO$6')6H#2'11(G$.FO&=)$"ACG6+*(Q45$F-NVW*& J9%ANWVT5])QF_TD
MB+9[;/[0C+.I9HN*Q_[9:=.OW# [:G3D';+3)KW<$COSG&=.2W/WJ.:(ZJ#2
M-4L5B2A,BE1[/313$!<R@50QA?.8L#1SRLIT4LK4AG)S(ZY3TKI)9.EX/> T
MH':.R=4P#3RL&X0:!0>J6=V'0-@TE2<EC9N>LL_8%VDI>Q_VC-AI/?D[54?T
MO:&5%&]7CZ;R49.^J2S-:5Z];?#F>?],>S'Q]@]:BMJ=F)%4%,A4K):4$HC2
M.#=1/1DL(I;2C+$"4ZMI/[AF4R.9[N*I5ALRHS?H&@>ZU@'V?/!@:R&H36P]
M>,=4<>&ZW8[67J4S!Z;"D?O1/5HI-.9A(YJ":3=NU%-H4%]$1@47X'Y9?*_#
MZ0WDE[^5=;Q'G6E2RH3H_Q4F,9^"*%<YQ"PVR?J8B%*.XU185>FY5I&IT?Y>
MZYMZ*>24XO/J7NFGZ3&Q'GSSW@UFIZOK(3"Z^GK[54J,=@4^!%3=:_)!VO/S
MD3^7*RZEJ,SI>GW3Y>ZIWN)^_T.6?*ZY=X:*'*M4$"BR/(>(IR;&%&&H(AH+
MO5:6N8C=RKE=E.DRY,8I9V1W<4^V!IBG5HU-;J[KY=ZP<TF#(CPPJ6UU;>)T
MF@MWK;I@IV\XS]$:FJ >X66IHWIZUB <>W#V+WJ>8=+JP?S?,-YWNC".X!=-
M=^6<K[6KJ/_A=BD.?]%YLKF]]W')3;X ^4XV_]5_7VS$?'F_C=[]0M?RO5*2
MF\R125(460$9R1%$"460R$Q"KE3$49S$D7"J[3FN^DY>X C%0W_:ZOQGL+7"
MU+'@VLSFQ-3\(/<&.QZ8COMI6)ZU3K;#ASZFU:;<F Q*#Z!CT0W8&]O\8W,D
M>_B[@Q<:$/8?S/XCN@$[*/;W&0P8H$$CX&'NJ_1BV'/@<4T8]PCY5;KGQ>GS
MZVCA&_M=YT?]3,OU\[>2+BO*=^4R<,$2*=("4I7J20]S!BG%*>218DF!,IJY
M;6;WR)K:/D6K*JAU!1UEO6J2](%L-WT$@FY@KO=&S2-T_B(>@</ES\L;.43^
MHN$OP^(OOW)-@HI?-W7"-Y;BF$@:P;P@&*)",DAX2F&>\!RE*,D5$N[9*9K&
MIT8/G3P,H-'0)R]%"YQME(L?'.-$N-@@X9F.XM#D +DHV@9?(1'%H2FGLU <
M/>.1J/RWKW]=?9?ETFP(_K):RN=?3'W ;Q\V2]'F9HQ8@C+..,SBB$,4QS&D
M242@$K&,8R84LIO8[<1-;?#^]A7<[S0&CT;EMH0B4%IIAS3:EY'N']OA\1MX
MM&OH]LJ"6EM0JPO61E^?5.27,73(0AX4RY$2D%_ -%#*<6MD>K.-7VYEO$3C
MUA8=Y!BW?^N::T'?Z(_W/\QIM7PCEU+-U[-,*2(2SB%+N%Y+94D&648B2(B*
M&%>I2A*K ^$+<J;&M>TM(JTG:!4%/[6J.F8K/ >LW?HI %R#']EZ(.5YX>HL
M#@-<N'HIZQ4N7)TU^/2%J_./>[ACS3;-_+N\72XW=/%QJ<>=K-9F!^=.M14.
M=I<29DDBI4AP!G-),HBXBB'.50IEFE-)4,2RV.H6L;OHJ5''3GE :^W!O%4?
ME'5.BN6NILQB:X*#V^'6*Q9NW&!8#[V V\'<* ZVFC<[Z'=J5PWET^ P.WAZ
M@\$]DM<7$G8W3] +N5ZOT*W%\3Q$+TL/O$6_%OP\QUOQ'YOV:OJWU:T0<_,!
MTL5G.A<?EV_ITWQ-%W6D(SN.AOQBCDJK^5I^E>7W.9?-&<(7R5?WR[J5O]'%
M1LZ8HB1*B(#:%240"9Q +$W.*(24BF),I8A<7-"A%9[:A%2',;11R[QCC9L?
M.W@WVSG$4^J\@6>XV\\?W]Z<CCG?AQ'?[ ^659WNRC#QWJ9P'OA8P =UY0=7
M>M0UP5A=<+RX&$VNYP3$N4DI5NTOQO\JUV_;BWL,)6F<, 2SC"B(6$0@Q4)_
M* 5!:<IXG$JG_ ]]PJ9&_%M=0;E3UI'S^Y"UY.M > W-M5NH]GK> *K6YKKD
M8K'ZHPZ-K0FVE/K[!Y]6574#WH:^/FF#5EB"[!,X+KE9F/Z"F&S><3\BOM54
M)PS=?5C0^UF:%R@J8@$SCF.(BCB%+$D3R J,31"E(MRZ>L%!RY.CBZURP&AG
M?S!\"-?E4V%O$(;F #O[G8Z#3]KJ?19\V-IH!\$GC>B> I]^X,J"9<V=$.--
MK);&]6CNIT6(,)4AR%B<0113O19$(H4R40@5/&=,N-U3[I,VM0':YN3;*^D5
MU-4/L-VL'@RVH3<)71'SK_;6A\0P5=Y.2GR=ZFY]QI^MZM;[DF]@US?ZXZ/0
MK<W5G-=+D#98*4EES'A!H"*1*5M"$,0DHS#""<<%RXAER=2+DB9'&DV@DSF?
M.U37,P#L',"7Y_U@L U-&KZ(>02*74#CRJBQ<ZV/'$)VP<B7\6277O#S+#[0
M>5GO-[R;5WRQJC;ZHW%,?]K7Q(2^8*,FJ/4$'44'R81J@TC0Z:]7X*BSGXWI
MQY.?U3L>A_5W?+W2(\1@]KE<54^2KS?5U\W3TZ*>:K<1:51DI$@85'G.M/>,
M,HA%$4.:)82*5.0)M:JA8R]R:K-AJS0P6H.]VF"OM\,AL1WH%F?PP:$<F%\N
MH^@346GY#=N?M0>'=:0S]BL^4K<C=2> >H_2[5H:[PC=R;*#HW.W-WV#+;>)
M+[[I!IJ-C8SBC$BNER:T@"@M-#63(H4XBQ%1D2AD3-SB+(]%3(V*]QH"HZ+7
M7L8)(.T<N>O@&9A>'9'Q"*8\9WS@.,H78D8.H3QGYLOHR;-/>AY)ZK6+F"\V
M)@2GK:TVE]7['^8VK!1-H9?'ITTSD=RI][1<SI?WYA)MDQ/L^70#]0?.\P(C
M''.S!4I,(41SS[7@D.22ISPGK.!NX3##Z3HURNEJ"O:J>E'/D%UL>;0ZC8X;
M^E3&K\_<CUZ'1S/LR>V ^HY[\#L\\"_.C4<0Z;Z!_:Y=77R85YPNFE"9#_IW
MU2R7"<<H,DGYN78.$R$@+1()$6$TCSB)<V:]>7U6RM3(>JLH:#3=YE&I=;7?
MM#X/ZN4-ZR!0#4R/7B@Y;51?1,%[D_I\RZ-M4%\TKKLY??EA3V^QS@J^C:M*
M,QY1JA*8YMJU0P4C$*<FF8F(5)P(R6F.75)V';3N-,A'R*CUS<@ U^3K/P3/
MTG/RA61H7Z?-S!\^KNR4P6'=D0,)XSH0IXQ[,>6??,ACI_V+K*1^PR1#>B>_
MR\7JR5!"&]]:M9N4F.58*$E@@6(,443-:3.B4$5I%E/.D\(NC;*UQ*E-WEN=
MZ_1H8J\UJ%JU'?:%K1"WV&4/C>/ 9+"#4.L+.@J#K<8^>^Q66#ILL8?&=*0=
M]@#8NNVTN^#4N]%NU=!X^^PN=AULLSN]Z!E)2.M$_.;VD\DE?:<Z2:3>K1[I
M?#F+,TS3/&8P*DQL;V8RQ6FBABRFL4I2A=,X<0HGO"AR:D1M-*YK8-1IB7]O
ME'2-*+P,M)U?%A:^@?G9$3GWR$)K,,*&%UX6.VZ,H34,+P(-[=_T\ ,[EZ+6
M1Y>BYMM+46]EN=9B=D$?!^_L[M]VTDS7!4"J62)(FK%40FH*<"#M2T(B4@XC
M8B["4L4BN_V>H16=&IFU9@!EXI^^U_%/=&^)26"_2[D JGK8-DGL :W-<?"C
MANQ]"U=V(GTZ]'+XL._V=@)CJ,F\W9JJ5\QMSW<BWX[>WEE\D(&_*=\TE9YW
M<+PG\@6,Y*]/X$MP\_='Z)[>9<*0\L=;78R XL&B9 QY5U=Z-"V_>7Z[H%75
M%/$K*,8QRQDL4IY!)!&!1'$$>9IF490I5#"G%&T]LJ8VX1]4\:L',WL&M;I7
M5U9\ ;/E$B8,>$.O7?QQNZ:2X3E$AJI-^$+>:U4;/&=X3_W LZ]XUHDN[^ER
M_I_U//UVM:Q6B[EH2A(NQ6?]:6WG\#OU8;ZD2SZGB]U%+==;$D%D36BT=.W1
M#D;7HGI_NVN3&5$[J\#>K$$N7P0%.FQUYB":C5O-.228+ZH_!VW<CP).E]ZK
MM ;_>S5?KO^F_^)Q)<JQU0D-Z_9R<*,ZZ.A>#^I:>[!5?Y#AZPE=T('JJL.H
M0](3H./!Y]O,E=<,FR-G+66[*IB;@PUJ[GR)N^47$S96SI?W^H%?5\MR^]<W
MM)I7G^9+^5&/_DJO2U).E.ZZ.!(I1!F+($L8A8@GJ<0<)2J7+LY]4.VFMAS8
MK_EO0&-?/90[%H*MB28/Z\[(^JFNF:"V$_QN+ 6UJ8X+B; ?@1T3OUK7#LS3
MK]*K_A=A0Z(_S,W9(!J^SE7;D.">O9L;5,B567 Z#N'G555O2#DZ:#9-36BT
M[]0]7$EM-1[$$7.!:)A<+GV"7R>EBP449S.[V+SKDY%>M[F>W\ME]54N]$/W
M=33^PVJAW]_&+A'$>29Y E$189,@*H641 IF*,IE@9#*4JO;4;8"I^8"[53^
M[Q5HE09=K5URH%O ;7%6&1C$H1>%%_#S";JS =(EA7Q80,=*'._[83IFB;<'
MIS\WO$4[(V:$M[?J, ^\PWNO<M/U]M$D\)Q)3<Q%D6(H(TP@HH) 1O,<T@)G
M4A6$,6Y5/22H5E.C=F,4W%V%Y*O'1^T.54;?"LC6-& ^',#I@F\6N_WHQ:JJ
MP),L#]X!/\VW;SM6- K3Y7;.Z^@=.71(RYG;K.\/^J]CD^F_K57F<E?#F7HA
M7%LVF>NOAT!/Z:)KJ]E_I2NMAV &OKQZU+@?Z[_95'JA6U5:$M.>?GNJL=9R
MM"-ASC?FNJWZU[N("+U4;J]YS52>1(BB F9*N^>(::)GN4Q@5F0)25#"22YG
MWV7)5K9\?Y4^+O30U6K .,:=[IJR.\J[\?1UG40**G*L5TY1GN40H5A/R7E$
M(>9$2A+QB*K894H>K8M&VVAN DPU/_,)=%>D4E[D/(991 5$BA602)%!I51&
M,&=%DO+94WUE52_3R_7$.NU8L^&Z;A_]1]> R?OYTM"CZ<;U@P2-'F-V7)(5
MA.=*P-SXOZA(%*0Y)U!%E&/,<9%K48U:[Y=BDMVVU6ND3I-+\7K=9>>VCM8!
M [NK6SM QY Z F;+=P>VW.Q#:V_ WIYP3FH06(,ZI]=I-*I3&@2\8V<T3*-^
M3J@19+:4_SY?/[S=5.O5HRQW4K[([W*YD6VIH?^48A;C)(MS5< $"081)A2R
M--->#8GR.$ER<Q?0Q:%Q$S\U#^;MYK'>(=#+T+>KA;9KU703:#4'>]7=Z-6Q
M5^SX=#BL!R;0K>+@#ZTYV*I^0)0.@#L3IA]N01G24851*=$/GF,.]&SERNBB
M]D#:[-Q_7BWF_+GY\YO\L7ZC;?S'+(UI(9A D#!%(,I( DF493 J4L1)G$@D
MG#**6DN>&M5U%FN/>]4=T\S8X^X8K!,2S=$"<4!'ZQO0: Q^;_]K5 >U[D.$
MU]CB-4SHS$7IKQ,68PO*V9 7ZP;\6.MTMH>V5GU[ LI90LR-)9@CG$!D2$M_
MD!1JEXV(E!!!A=.&DX7,J3'5N:PY;E1E [8=206&<&!Z.D"OF]2E53A@3A</
M@(+RD8W<49G( 8AC#G)YU8U]JG(]^URNQ(:O[\HVM4R30CF+&(TYAHP57"\%
M509QEB4PCIG4'A.7U&XI>$[ U'BEU;$>&*V:3CF/SP+93R,AX!F8,SR0L2:)
M2^;W,8)^M\,&^F_'3'"V\5&&_273MF/\XG.>T;$;5LW%G);/G1PO]0<9D33.
M<:2=B R;W71EQGA>0)HI4F2LD$3F3G>ASTF:VA _RD;D4Q?R+*AVSD(0J 8>
M[DXHN8<17T(@;.SP66GC!@Q?,OI%E/#%%_Q(X;,&5Y:E%'6#GVFI&<<$)(MZ
M@;,-?YBE:5[PM%!0<48@RE,"F2 $YB+'*4^XR=OIPA!V8J=&%SNM054KV^Z/
MF)BPW[Z^JX/%ZM@PQ] PRSZP(Y3PR [N3&Q!K36^ 5IG_0DWM\!%NW.RB^$*
MQSMN0 4E(4O1HS*2&QS'].3X]G7Q4[?\GYMY>T'"S+1*IB)!*((%3S*(DC2&
M&&$$,YZJ(DYBE(O")^CF2,[4V&AWS-S1T\N'.8>KVZG]%6B-=1[O )3W*?L9
M& 8Y/S^6]2HGXV<,/G?F?>[Q:[(S[*IAMWE3>4R*)(H%S',20Y3&#+*444AQ
M5/ (JP))IWKW)Z5,C0Z.J[9[IJ4]C:@=%5R-T\!$X Z19W:*,Q ,D(/B6-(K
M9)HX8^SI?!+G'O8;_N\D6W<J"7VG\X7)^O1A59I5TF_+4M*%.3[^JQ;U:555
M,\T%.2$)AY)* 4T>"$BHBJ$J,$<\)7G*G9C!58&ID<9>0_"3N?#R9W!OTD":
M%$U;6Z!:E; R6P#5SE W2G'N)3NV&1+[@8G(J-ZYR'(#;E^@?0,Z?6-, #\9
M(\XO+9VIRA>_H"SFK,2H!.<+T3'W>;<3\N#XMBSU-UB?5F^#;[ZM]-),?W&/
M6I.[]8,F'%/*LYWS"Y3'G*0)3%&<:"\*2\B(7F6EA9(95EF4IDZA,$&TFAJ!
MGCT^[=C5Q/[6 6WK%6AM _H/T%AWTQ:L]?+7PO2U'>..WH,#T_"8G1?HE-P3
M[!'.T5TUF\!)NR>8=F?QOHU['N[5)39I)87QL.6R:O(D[G6HWCSOG_E,GVL5
M39+E^H^Z@O-2?-;#PU1]V*ZC!6&XX 642:X@(K* F(H,%@2S&)$$R3QU.A<<
M0,FI30CM&K-6V+<RS!!]:7D<^<H]-##A-[TR$&$/B5W8,] A%!WW^'1 J%^<
MO XIZ]J\]M=,/75^]CQ*DD(4,<1IG$'$F:;X2$J8Q4F"4<X(4YYI\*]5;6K$
MWLW^'L)QO#;7_M5=;SDCO$J'#CP/C-Z75^3_#P7[0.4"KE;OE:H+A(+U?#&"
M8!+<)@E3<_O3RI3:?E@MY:^;)E&:9G:>YP4L\B*%2$H$J> 41DHE<2+30@JK
M"+]3C4^-J&O]0*T@:#2T+WS_ KA^DKP6CH%IS@$)I^+VYTSVKFG_HL'12MF?
M,Z5;P?[L,]=Z;V=2K#?3L\QS07*I8(25'K(YDMHS2U(H*<K2(H\P2]R"<JW$
M3FTP=V?J\Z4'KG2E>OO!U4T*A>Z(+I _L%?X-38X#>2S](I^)7_$!H[SOH;5
MV]?2U8D0'KWV[?SM3!*+SNUJ(D2>,0H+FIFZ##B!+!(1%"(J5,QS621.1TH!
M=9LR\?$'XS)6X+!(:[ <6B%[V)4M1^VW$2GU5,QA9>K%=?Y^/B=0R[O#7 H?
M /R!>/IZ_5Z)S(,!>Y[QPXGP3&'<E'O85E7(>89SE5(H960"JR("L9(I+)*(
M1R@U>XENN8@/FI\:.3?:.28 /@3,CBC]81CZ)*4I*3-$78G3-H?-CGLH8MPT
MMR?->Y&O]O13OO% "W,7XS,MU\_?2KJL=).&+QP_QDO-3.CS;%4%M:Z@J^P@
MGZPM,H'#,"X('3G"P@Z"E\$3EN]=61+HTZXNF&0(,Q/21K!2$,E80$PPAM),
M4PJAK*!.,< O14QMNMI7!_*OS78"2$M?_RIXAG;9W9#QKY'TPOAA*B+MQ;Q.
M_:,79IZM=O3R2?<T)9^THWO?I,^D59-;(X]D4:2)'M(XC?3@YGJ84\YAEF4H
MR62:IE%FFZ3D9?-3&]A[#8%1T3D]R0D ^P?U]; ,?>3AAHA36I+SAE^=E.1$
MTZ.E)#EO5C<A2<]3'D7)?JV;>?BXU*-$5MN\1:TO\&W5Y#CXL#$59K^LGNG"
MA,W/LJC -$$,IA'-($)I"JG"!10D25F$BH+%RKI*F8\&4QO^V@;(M1%@WEH!
M9&.&0YDMKY[H)XE1\!V81WYM".0!; W8Y4/;+BV^K4"=&.5.@<8,L+-C:/@=
MRIX-W0TCU4$;ICO<BJ1= V5OU32OAL<KHW:-W0=UU:YJR'.7<E[J?Y5M-BU3
MG;;-I]4>[A*]Z%-12F!2KP5%H2#)J80152+%.,\9=CIDOR!O:A/(5L]N)C?/
MT_1+2%ON=X;#;^ )P@\Z]\U0.T#"[HY>D#GN=JD= "_V3RU?\_!=[Y;RV_Q1
M_O:DE5VN#:.U0=]MEEB,9-:$Z^0Y,H?<D<FFIXF%96E*DDA$5%B[J1>$38U0
MM+K0Z M:A9M)NU79P2VZA+&% QH0N8&II!<TG]*YE]!S\!\#HCB2J^CW";JY
M@I:H]'I]E]H8S\&SM.; E[-]Q[-(C6[/A#1]UR[A<KVM]ARG'.,D8U"A5*__
M(T(@X2B#,D%2851$O'!*0GA2RM08M?YZY5Y+Q[HR)X&T\\6NAF=@VJR1Z2@X
M0*;R7@C"%GPY*6G<NBY]QKXHW]+[L(]792X^; O Z(7?NWG%%RM37F%W4C!3
M.$ER16)81%&N/2L10R*)@JP@DA5%(B-LE>C/5N#4N*!6&71T!GNE/8[VK'&W
M\;;"HCFTQ_5*0+HX7F$!'<OYNAI81T?,'J5^9\RBG1$=,GNK#ITRA_=\(XG:
MPESF%O-\>=]>7*/:ICNV: ^(9AK:(N<BA:I@'"*!$:0J81KW-$910O(D<\P<
M9"%U:F3=*FU*U;5J@X[>8*_XQ;+T5_2$G:<7'-^!Z3L<M!Z17@Y0!0[WLI$\
M<LR7 Q@O []<7O;<_C_*M+;/P7:8D:U3JCA5#,M(*ACCS%2YP1)B2A-(<Q4I
M+$A6,*O=.W\5ID9DW?M@\R5XI.4_Y+J^GE!U,A@NS5GTA=+%H?K(\BQA4.0'
MICBK#)%#5(OV1RWL&82[&N,>2WC#].*DPK\ESY(?S49=]6U5WQ8I96> SV@L
MTIC$*<0I9Q"1(M>NF\PASB/%8Z84C:/94M[71[8.]3YZ9%J-.M*,NA>2!SS@
MTPT]F!"RE=*TM]/6L;1'']9V-'8U=".=A[9JF@0IK:+=F\0!ZW98X!&V6D>?
MP'%K=%B8_J(RA\T['OMU?RU75?6Y7'$I1?5!J]J$;#QOHSN^KA9B1M(LBI0P
MA915#E&$"TARPK4S)0@1$>>BL(_8LY$X-=^IUAD\M4H#TZ6@:LMIE8WZN^"]
MOP F]=PN 17?Y]6J? 9*.L62676)Q5Y>:* '9IX&XZV^P"C<QGX][\/%C,ZA
MH738S0L-Z4C;>==#Z[:=YP)3[WZ>54/C;>BYV'6PH^?TH@>+_V^IE"RU=_GI
MT]OV<! 5G*=4IC#GYI"%< )ID3%(]5HX03SF*$JL.?ME^U-CZ)V&0*OHP! G
MD+.@UNOP&)A(#Z#PB3LY@8D#1UZ'S4B,:/>YN+'>><-[.>[$:^,QVGF=#_BK
MY[%A=_1F-%%QE&B',XMI 5&J%"2$(*C2)&=)FJ*4NT7V6@J>&K_9[=X-NG,7
M>+]N0HQIL4LW_L[<J^['37,7[MJ]MVMWW#H.G!'S"UV;AI]OE^+M:K&0S8WW
M.]7='$(F&Q9*)4P*@2#*3?652/,78UF<2DQR09T2JGCH,#4J>S>OGE9M^<:K
M-N4\NL-RKVY8D(?>PCO8IOA:'S%L+:BO.>QM,/@/L[OGCV#@$KWN>HQ<K]<;
MJ)?%>_V;\@TC6=/Y4HKWM#1'O]NX5)ZA-%(R@WDJ8[-GF$%&XL3$^Q)&&4\Y
MLUIZ]HN9'*U)->=SY_"/DPC:T=3UN S,1%L%P5;# 6)[^T$('+IQ4M3(L1I]
MYKX,SNA]VK=&T:I<?Y/E8X=(VN\V27.$,"(P)BF!*$D22')4P"+5GD\<JSAE
MD5NEH7.BIC;Z:TVAEO3H75^S!U<[/@B#UL"<T 'J($-Q<&*XC$;@:CQGQ8U<
M4^>2V2\KXUQ\PSVGSQ?YU!Z\W]Z7LJV3L#';W4\F15BGHA451#"9")@59H='
MQ3&DE&10$%2D1$59EEI=!W*2.C7ZZ&H)C)J.-<?<(.^GD\& ')A9/#!TRAOD
MC,G5Z83L)8Z69<@9A&[R(?>7_3R4CTM>2BWEG6S^^W'YN91/="ZTCR[+4OM#
M3<X*O3*J8^V;+)VS),81981"S/,((JK,7HTB,$EBGC 193&AVZ I.__%3Q&K
M,748234P/;5:;_,2-=D25O4E$>J10]>S?^R\H $Q'X?'M@: G[8F_-EL^6_[
M8)LQQW1!<T_G0AIC9\_I.@2#>E6>JHSJ<5T'U[$W=F5K'L$#MXOE\X(^?GZ@
MY:/^(C?K.:>+2NO1+CXR4B298CE,,140Y8I#*J,"2EE$"@FBLMRJMJ"-L*GY
M9:VZX$C?&[UVX7]Q.%*_A'$_M85&;F "ZP/-)Q[A$G@.P0D!01PI4J$/S$"!
M"Y:@]$8Q7&ICO) &2VL.XAMLW_%A5\[+C12GJPC.S U+A7)JROC%>O%+,TA1
MEL"T*"0A*"VBW#ZRME?4U)CUH%ZGZ-3KI,8*C;X+0?1B;,.MH9 ;FED;/??%
M3F\/BYT&P\R%4D-A-Q*A^G]XCJQJ@TL_I_:V,"*CVEARR*=6;_@M[L_?CG>L
M@W&YH0F-_/Z,# /4PK!')^B"ST+LJ(L[>QB.%W(.;WIFUUH]/LZ;[?KZB+^M
M$\4/9.U+NM$X0SA/!8QSG$&42 RQ=CV@C 3"429H)F.GM%M.XJ?F?ASH6T\%
M?&^/8W(NMWZP(Z?AT!U\%WZG>!MLU 6Z2UJ#5,7SPRUL#C W%<9-#N8%SXNL
M87ZM>&_FKQ[EIU55!S8UPC9:WMU36PJO>E/?MVN>^T9_R.K]#\VO6L9\2<OG
M.E^.N75MRK2O%EK2_?;:S0RE F4L13"3JH"((VZR1&20(4I5FJ%(LG2V7JWI
MPGJ_?RA=G0ATI_%PX]P8N;WI.*_- 6MCC_-)P&"=:WU<,(4N&_Y,P?303\;.
M/S>!H7M3P=[6;8^VS]?F-@DJ]N;MK@P&/7$8NA-"'TL,IN_89Q=# W_B@&-P
MD7XSS0<Z+_]F:C)_7#YMUM4GLV1-VCUF24U,:YS!),L%1"K'D*@TA8(G*5-I
MKC!QBN/OD34U5[G6#21NQ-Z'I1TQ!T)H8&(U6H):3;,C;Q2] 2U@ \2T66 2
ME.?ZY(W*4Q:&'_.,S2O7WP,RD?64K4K3<=4LPR@1!96P(,JLL2F".&'U'TF4
M<TR$6\;$LY*FQA&'=TX.5/6_U'.(K1UK!$%L8,[P >NJ&S@G@1CLGLVAM%>[
M37/2Z+X[,Z=?\,G&0)<:IDBW73U)OMY47S=/3PO9J=P@<XY2DE*(<DX@BF4,
MF4@C6* 4,T&%BA(K;\).W-3(0BL,C,9@KS+8Z^R2J. BT!9G?T'A&Y@Y^I'S
MRO5P$4*7U \AH1PK$X3?Q^B8&L(6F/Y,$1=;&3%QA*U%AWDDK-^ZXFQP&RCW
M=E6MJSKSSHS%3$4QYYI@F?;+"J4@DW$$LY1*@;%($^:41>*,G*D1;7-HN-43
MU(K>@%I5-Z_L'*X.!ZW7H37*Z:H;4'XGJN=A"'^,>D+6^&>GYPT^>6#:\WB8
M3#.'&2%N'U?E>OZ?C;PWM)I7,THT&\2Q@JF0"B(:2TAI;APTE,M,,D(RJ]+C
MO@I,C41V&M;#XKK4,A?!MR.4(2$=F&FL$D);0GYUZAE;W 9-07-1B5=-16,+
MT:64--;MN%^U_(7^QZI\NZG6JT=-!Z:D^TRQ+.<2I9#5(?M,$HA3Q*"B*I,R
M5T@@9'NG\F7S4V.HK7+@=Z.=PXW)$\CU$]#U> Q,+[90.%U\/&_QU3<<3S0]
MVE7&\V9U[RSV/!7J<N(MY^869/5%<CG_7I=91@6)(TE,)$+,(2)"#^ D1C!B
MN4SS-%.T**Z]BOA2K-6'/.K%PZV.H-PI>>U5PQ-HVWD=P1!\U6N$.T2_7$8T
MP,W!\Q -?$_PA.!7OA5X'HK+=P![WO78H-Y&I3Y_D8NZ#L/*N"AWZL-FO2EE
MDYOXL%0+*^*<1%A!%F42HH(AR%2B8)+1/,G-!G9A7PS;6?S4'(Z= 9J6:@M,
MM81M/GA56]&FA;=. N/9+VF.,ADE B:()A!E+(,$\Q0*O5#%>I*@)%:S)UG.
M5^+KFI;KU^Z=8U6&ZZ-?Y1HL7/H)0,#D_7Q9UR%C=&$J6 W:=S%/*2<%@8D4
M)DU:SB#+4@9SEBN3VC9+TJSMN_?+"[/\6#VW561:_2:78JQ.LSA0&K0;!G8:
M]LS6*@^^K>H4DN!.@<8 L+/ JG)5"- =CJ &!7^D(ZGPG>!V6N6-8>_IE7NK
MXYUF>5M\<+KEWXIO(CY:RC?:/Q1O5X\F*43]7=Z6I?Z8ZC.U-\_[1]H"0K=_
MT%+</=5QEG_5#ZZKC\O/-;4W)SH)EZG((P*U*U%')E"(69;#B&>*91(5$7/:
M_1Y QZEY@ZVFX-ZHJ@>KV)1F-FHF3/"37G-5QL+JSZ[I ,/WKMU"]Y7[;. I
MKE8=,J,[Z-H'.@8"]@RZS[5&@MK*&]#::4X(:9N0O[$U^)GA@%T1./MA>#U'
M3ILX&- O\RT.)\IC,^#S:JT%S.GBE_E"5NO54FYKS<U$CD2"]3R@_R\@$DJO
M4/04 !EFK! 4XS2Q2LUX0<[4"'VG*=BINF4 E]5\#[ 6JX@P< W,I<,CY>#Z
MAT%LM"P43[JY^I;L^D&"IQV0CSL@G[:E.&E=_/Q\NBDW[_XR3+UN?,_KX_GK
MEVTX<,PM'O?TP/F#%!OCX[]_?%JLGJ7\*LOO<R[/</RB[AO]TYWZ(OGJ?FG.
M@!L>KP->]K?$"Y21F.8()B*-M1^N,HA%+B#&J& RB:G$5B>X@VLZ-?+>&FJV
MBG17\W^ QH7C75>OS6/IZ) /UMF6;OD4NG!$YWSG=.\]HYMM]DO1Y!:@3_,U
M71B[ZJ"9C8F!_E97Q1HDN<#@/1#6)Q],VW$]\Z%!?^&?#RYPP'POCCF0G-J<
M$$_89QD9(#62%VCCIQAYG81)7N!X)1@)E$9I&W'\17Z7RXWL'#M@EG#)4 1Y
MGB"]_,T8) 6G4"^)BU@OAG,<I2X^V%E)4_.A=H'PK:;N!SV7P;7CIR"0#<Q%
M7F@YD\Y%)((2S'EIHY+)1:./B>/R"VXD(>1\UH;M/L<)^S9?+^2,$4QBEJ7:
M3XTCB"01D"18P"B75"@N(Q%;)6T]U?C4J*!6RJREXN0G]N=MY/JS'0N<1*]_
MX%^+R<!CW14.ZV'>9_>)D5U)_I?[U?>?]6OUH/XG,C_"YL=Z))]L<)3!VV?*
M=KSV/G-]5H:/5;4QH2!WRG@2J^57LQ$P8\*D5489Y(F2$!%$(<LHAZG()8N2
M0A2Q4W6RBQ*G-IBW2IH/F-=JMD>3X&E3FG]:FT ;LQ]YIY<WX)>ZR'03>4"W
M!5O\TSF<[I0D*@3".86$$4VFB&-(4Q)#P7)2$)HG<2)FWV7)5J_2+5W) ^ZC
M'V2$F'>ZJ>V?S5(/A+IG!NL(.X<L*+A#GTX<H-K]^!M]0:WP,"DW>K$9+/7&
M::FOEH*C%X2^5!S]+X:Z=W'D+,YP)!!/,CT_")5#A$4"&5-ZY9>E7 E",BH+
ME_GAHL2IS0^[E<QBSNL:0V6CY[57+HZ!MJ.:H/ -3#5G+EL<+PV'O&EQ!IR!
MKUD<2WWE.Q9G0+A\P>+<BYZ7SIN"931#/(M$!EELKF$J_0<E>LG(1*9Y)LU%
M'C.7]++NI<K&R 3[S<CPJ@/G5-=M<G7:0I==&[",VFN41>LO<W9]V;*#76%J
M=HEW>\;U$>!,K^=PQB)IJI5AB J90IP4&<1<Q20M]) LK!+>6TF;VE3^,K]]
M]\BD.21UR1-U$>W^01P<P\'/EZZ!SRT@QQ:6WK"<BXV,%YQC:\]!B([U2^[Y
M$=[_<S-?/_\BUP\KT92XEK)3##DE15)@BJ% *C*YH1)(\S2#:1:E22(9(]CJ
M:N-E45/CB'V][QO?FM,7L.TGA;"(#>[ANX+EE&/!#H>K\RU<$#-:[@4[<[MY
M&"S?\' D_OZP6BR>[_Y82O%UPZJYF--2DY!>(RPV0HKY\L-\234OT<77-5W+
M)BXU39@DA:8)1!F'*$D1)-J[@!''TFPSYU):[25[:S U,OEU8_+WF<VU/VIK
MX.H/O>ZM.N8X>!M>76+A@0P-], <U*@/:OU!UP"PM<!L.NQL 'LCAL;>(4Q[
MZ#YXG0#NY='G#U9U)W6_?U,F9==)YIU2/IDT4,M[\YKYA=KU7+4S/538]S6P
M]WJ>7@V/YXU>8_>!AWI50YY'FOJ+ZWA3F,:)2O2$KMW20GNJ!$&:Q!CF>M))
M2,X%RKG3^>5!\U.;4(QV/F[I&? LC[>\(1GZ+,L>#?=SJY-&ASVD.A0Q[HG4
M2?->'#^=?LIOX+ZGI4DC4GV6Y39H>,YGL<RS.--#ETNF5YJ1XI PJJ 2,<6"
MZ/6F<*H.<5+*U(9QK51]"_JWK^_,I>CF2-OQ,O1I0.W&]-4P#3RTM_J9.\3-
MK>,;4.L8;H3W0A!TH)^6-.IX[S7V>-CW/^RQFC31,K?;&(UMN8<D42SG$52,
MYA!QAB$A&8<12?-<H$SDV'ZQ>$+ U,9\'3&TT]&G+,$I%"W6=U=B,_! 'P86
MAZ77E?",M+(ZA"G0\J?']-[5S:GWQEN\]&A]L#;I>\[/@_E5KO>%^G;)C+^M
M.O$X>CVDVZM:WR:*<R3B%&*!3(+ /#<_:9[#+"H*GN:HR%R.NAWE3^U,O,YB
M9BJDTO6ZG+/-NKZ4N%X=AEVZ^4"N76+G'0T(],!T:C ^K&NZ4]\@W8WQ:RT(
M[E=Y@A?4XW+5851?S!.@8R_-MQGWRQ[OVCGNFWYUIK(DEN;J?9'&ICQTA"'&
M)(-4$6PJ1^>\L"K3==SPU/RUK6[ *&=_M>, JWZVN0:!@6G$SGBGBQRG+/6^
MQ''0V&@7.$Z9T+V\<?+?_5R-+[*2^J6'VZ5X9XITKIY,P^U%_QGA,J(BR6$F
M3"9T)F+(<IK"0DJ1,5[$>B"Z;)KT2IO:P-PJ6T>@B+VZ;HY#/\!V;D(PV 8>
MS0>(=33=)HX(-_=;(1)TIN^7..J\;F7\\2QN]Y)[@,_G<B4VO+XJWF9JJ-I-
M?\0)IFDN($M-;$]DKAFEFCQX1!/)8D*9W4W-7BE3(XU6T7H$M)IZ1/:<![6?
M,()!-?2!B@]*3B$]%U&X.IKGO(31 GDN&MF-X;G\L%<Q@_JNRG[[@_Z8/VX>
M.PRCQ7V1]YN%Z:OG%RG /LNR;6*F(I8C7.10,J1]C30Q\?J)A%AD4O^09TJF
M=G<1 VOF,F[&N;'8G5K-$"IW9NPSV%7;%';UL4][IZC)Q+7:Z'<J6=8)K!\;
M7)Q2B ?K<XM=Y=?IQX'YK]6HLQ_=FG7@-6G#P-ZR$UD>ZT.KMJW7Z4"GY/"O
MT9&C98T_ZM";DSU*@_2H:T+YT+A?R#0?3-R8*>A#8W24FSYX\QYS=9,#__FO
M&UKG2I=5)\Q?2^!FE-S+6<83BE2!8883DZB!1=IM+QB,99%B$<N<2>0P#]M)
MG=X<V^H-[G>*U\<'VULH3SO5'8C7L@<L9L7PJ Z]-=#"N=?XX%+/YP'A=)BC
MPL/Z.@&QI>W'&RK U0VXW@G$LJGQ)@<WVPZ(W_%5?U)_OUR;+#Y-/+@LX@R;
M;5J4LAPBF2%("TPAHU'!,A83);%UQ,L) 5/;<]G??MA^][*CK3NA'(!I3\:^
M$(W$O._#8>+.J+[8C$6?+AAY,>,I &QH\."]T3GOE-:G".[D<U=G=3\5'?CF
MN3EV?KN@57OY&;.$Q$F.(2XBD\0JR2!160*)S&-,"ISFN5-DK[,&4^/#;A;V
ML_&M-Z;,3ANF49MRT]YC,E=BOOVQ:GX)FCM_;G?6_;O2[CALT X:F(U?H6^N
MR;3NAN]0&=0MM7BMS.AN(/5D/'=LR,-=_%4W1*N'EK;;(-:H$)&4!,.82P81
M3034A,JAQ((HA5.6Q(FUOWA*PM0(4NL(N59RYR\ZI=HZ#Z2%KW@M/ /3DT'&
MZ >V'I%'G/1):!Q<QFLA&LEG/(8JD+_89WVOPWCRQ?$\QCZ]#US&W@=][GP8
MJORL>_6!5B_B\SG!+(\S 2,>Z:4P28C)%IW O%!%HM)"Q)F5;WA1TM0HKM85
M;)6UB.AW!-:"ZD+!-;1'=@8IKRLB?9"YW!4)!-U8ET9</S;'ZR,6:/3?(^EK
M8,0+)19V'-XLL7G!-V&W?)QO'BOC<TKQJUS/%&,4YQ+!/$.)V36,(.64P21!
ME*A8&VN7BNFLA*E1Y%9!T&AX [2.KGF=CT&T6\!>!<W =.B$BD>6YC.6!\[*
M?"QEY"S,9XQ\F77YW(->H5AM 723P_E<[?..Y]7<Z9@E#.%"(0D93S%$688@
M)BF'.9-Q&C&,"I7/EO+>U%2W\)'\M+#Z_DGS_7=UF?02T;-#+#RK 4$>*_ZI
M-0 8"YHB!W<*-$: G15U,1]PL!YM3!F^%YP"FX;NC=&"F ;J%=> I6OPO!"<
MY-7TF(%(U]A^%'1T55.>IS>^Y=4_S9?RXUH^5C,6RQ1GO(!)E@J((A[K"8G&
MD$LNXSC".,ZMZIZ'4VEJCFNW3FO7IFZQ5G."<+*>J[$,_&YL [5QKF<ZUW>P
MY2'/J-TVQA[#\#WF?M(3#.2P1S_7JS7N65 P&%\<#H5KV6=K=<.:N-/Y\KZM
MS=")J^.1P@F)*:2JH!")7.DU!,(PS5F,,D133C+[O=4^49,CX V#BZVVVY6!
M7TAH/\0VNZRA@!N: D]BYA7WV8^9RS9K*.S&VF?UQ=!QO]4&EOX-U]X61MQQ
MM;'D<,O5Z@U/YWA^OYRK.:>:HSE?;>JD^Y]7ND>U,[XK5#ZC&4F9U+YO+A/M
M *=QHAU@1*%@%*NX$#&.W1Q@*[&3X]B]UH#NU 9/K=Z.7JL=\I:>:7 \AZ;>
M#I1[C<%69?"[41K46H?T+9U@"NL_VHD>UT=T@N.%'^CVMH>O9VH"/;+%\YOY
MJM*-:IM,=N7VZ))D2K(D%S!B*8,(I1G$*%(0QQSSB#&48ZMB[!<E38V%MKJ"
MCK)U,-[YBQ..T%JX>*$ &YAFSF/E<Y3>"YJ#CQ<*O)%</(\/SLVYL\&CU[?K
M;6 \U\[&C@//SNH%_QLX>R]QI3XN-3?):OUUM1"S@N 815) &IDZA%0AR!3)
MH8A8(J,,L90H]_N4Y\2Y?-*C7J2\ ?-635!I/6^NND%Y%FP+-@T(X,"$ND-N
MKZL)&]]J"XRZ ;%SO]43 L-Q;_CX8>EUX^<2.#:W?\ZV,?I-H$O6G+H5=/$=
MOV7T!SHO_T87&_GF^1=)JTU9;X1^*.4_-YK5GV]_S*M93J0JHJB "8TCB##.
M(4,BA@42-*4F^Q3.7=;0%C*GYKIV] 0[1<'O1E7',Q\;P.V6SH%A')A_O1!T
M7B<[8!)TD6PC=]05L@,0Q\MCEU>]4W*;L_+/Y>K[7$CQYOFW2HJ/RSOMQ5"S
M%K_EZ_GWN3E5G\688!$G"HHL,B7J"@PI)C&,<<:R))<J3A/';-R6HITH:*1$
MW'40U5.KNSGC_&E3U56X_@Q66PL W9G@G)7;ME?L"&H8K ?F*0-S'8[SN0OS
M;UN8=\J#V\LP^V3A=D0L= )N6_%CY]YVA.5$VFW7%J[TIYJRX+=+L0T=TFVW
M="KNEE\DWY2E$;P4OZZ6Y?:OYI9B>WU7:J XQ=K-BG,&42(EQ%D20<[B7.0D
M$R*U2CP17+.I^6;&,%!;!CKS574#=J;4J<*ZQOA=P0[7MXX.WI@]-C"][COK
MJO[Q=PQ#83F,^WBU=J_C9(8"]:PK&DR ]P4?)4LMJR[0\&YN)I&E^$+7W5@)
M5$2)RI6 PE1>1UQF$'-,H! B88@D.25.1\TV0J?&Q3N=0664!J+5&NAI5@):
M ;K=JG2^''2Y ^Q8-32L Q/F'M%:WQNPU1@8E6^"!JSX0!3ZKM%EP6-?/[*&
MXL2-)/MW_8CI[W)^_["6XO:[=F3O99.\ZT[588S5W69=K?74VC(AGZDX(P47
M%')J@@QYD4"&:0HC$L>I(C*7R"J)O)?TJ5'5OIQG4\+*L8ZG&_)VU#08G@-S
MU%9OT"H.]DGD&MU!1_G@I:N\4 M*6VX:C,I?7N <$YE?(V$*#K^;+S9:]"SE
MJ:1F_9LK[5@AC K(<H$@HC*E!2\HSXMK2@ZW<J;&4JU:P<L.;V&U(Z8 8 U,
M0:?2?[5:#E=\^ B&0<L/;V6]:@'B(X,OE2 ^?MPGDH[S<E/?QM!Z+][J=9WV
MFV9Y3'.1H0P6S#@R:<0@Q2F&$<X18IQ$A7((H3LE8FH\T&IGHG?+#5VX)!T]
M#6'_P \#S,!COM4/;+%I-;P:&I> N&LA&BL2SA$JQS"X/A3ZX]].OCEBX%N?
MYH<1;[U/>C#;&:>J+01:NU:WK%J7E*]G5.22DIA BI*Z^E<":9UCD#(B"TF3
MC%I%8+@*GAH+[A8:M%UH+'<+#8]RQ,[=8,&9 X'[2@NX.[4K/MRLXW[?*N\2
M?>P"L0/W#@3U2(Q\]:?L1M$>8/42MTM[X]&YAY4')._S_M6)8]N;<5_DPJ3B
M^;8ZF5YBEF(FXCQE,,U-($P:Y9 *G,&4D;C #+,XVZ46^N:57M9*#ZN1=)A<
MZ-M_Q22T=IV"N$(JI@1&2L00(<(AR3,]+S-)8RX(RB5S"$<?JC]&#5%_I:Z(
M(IZF*:-0Q;H#$$,1)$E*8<YC19."YCFVK],Q<$>,E);Y,*U0:P5HS0#?5F>3
M$@W<519NU, =,+ [-6'LO5-'!^^#\3)+A^^+:[)0.P'ID*3:KMW7RF'M9'5/
MBFNW=CRC/?0']*O^I.I8?)6R6.)(F0HH>NE-L<GD*@G,)!&Y8%AQ;I68Y53C
M4YLSC&[ *.=UL^$ -KMS!5\P!N9O:QS<(RM.&!PV@J(K8-Q(B1.FO8B(./6,
MWR!M(L)V 6+OYA5?K$P\6&?3C&<R2K$>JG4I(VZB'2(*4QYS))0L!)%VSKFU
MS.EYXXW*;@/Y,K1VHSLH7$.?)=2ZWH!.,/%>7YMM+V<JL$8G*#]<ECHJ:5B#
M<,PD]B_ZT8O)$%?*!Y.[Z+MLLGG^*M=WZAO],2L2A#61<%BP3&EB*2C$R&07
M0DG"TX(EPB1WM[^3U"/+R4,8X1+2@:I (^Y(+7VPVI%*(+ &II-#G!HUP4^?
M-%Y_KI/ FVU>K?$-N%VORSG;K$V0,EBOP&<:YES. :Z@_-(G;U1FL3#\F%-L
M7O%CDT^KY?TW63Z^DVP]RP@A,<XE3-),DX9D&!),""0<\2Q3$::QTXJBV_C4
M5A1&-Z@%/0*CG1M7'(!F1PZ^4 S,!I8H. _N4^8&'<T' D8=OJ=,.QZO)Y_Q
MG>Z7M=?P]_GZX>VF6NNA7^YR?L\*2B7"(H,J8@2B/,XA2Y(<$IHQGM.4X!RY
MC-A>:5,;PM^,6P'$]A9"DS)3NNWJV\%LZP $ F]P%Z#1$_RA%05;36_ 3M>0
MD[P%)(&G^3Z)(T_T%L:_G.IM7@J\,S'+(F:N6$C($Z%YA),,8D$3R% 69S@I
M8H&=BBN?E31)#@FT"7'MYL.$**)WTV&$G89Q=Q@FLK/@O*-P)1WL6ORX?-JL
MJT]ZWES$;>I%EBF2J$(O &*5091@!$D:F\1V659(K"BG3H30(VMJE%#K!F+/
M&_@GL+2CA4 (#4P,W5ORC:+:;V@ NYS^T_]N_'E,AKGM?D+>Z]Q?/V_XV1OI
M/:\$38KT<?E=5H<I2G;;\)+3)(YX#G$2(X@D-3?.BPPRH5*98YH7E+O0A[L*
M4V.5C[_^[?W7;Q]__2NX??OMX]\^?OOX_FN0+$A]W6#'/,.".S A7<B*M#.B
MDQ5ID$,3?Q#'2)34I\84$B99P&29.,FF)4]W:57*^?VRN6#!G[^5=%F9C&:K
MY5_I?&EVT'];EI(NYO\IQ2R*<8(2I"!5L5Y0$80A11&'3!-?DLLB4BFUJ[?I
M(]YJ?(Y::'.O&U"-(4#^X ^FOE%]6*-'Y4_WV@[7R^Y.G6+IB(4&>B3/K(5U
MJS?H* Z,YKM3GKWZ 3TU#]#"NFXN"HSKRWE \\*Y\VDCJ+?W8;ZD2WZ8;!%)
M5IAC99AFFNE0H33)R2B#E) <IS(IE.(!4F">$#VUT^>3*3#55N_0B2]/]<55
MKMZ5"+^NB[=3?LS$ESV(C>'/G1(_!3^N!Q9+_ZVO!8\+37=/<OD++?\AUR8>
M]_:^E'4.QG9GAJ*<1%3F4,28FJ(-3"]3,PH+1/4:5<3*<IEZ6=34EJ-&6=!H
MVP29[_1U"//O![>?D<)"-C #G4?+I^9-/VP.]R""P3?2C0>/C\[M/H,5(+TW
M%_I;&.^.@I4E![<1[-YPHU AY[/WR_5\_?SUD2X6;S;5?"FK:J8H)9C'!21,
M*5.[,(>$\PR21$1QDK-$)%;IVLZT/S6R;%0$M8Y@JZ3=@#^'8#\Y!L!E8$9T
M@\1Z%%\P_(1K54G^E_O5]Y_UF[57]4]D?H3-C_6X/M?F*(/Y@D';$7SI,;^E
M7'L7Z3,MU]TEXZ==C79,D*!Y%D%"8ZS]GPA!FF$]CI7V@.(T52)G+MOTEP1.
M;6!O;]K5"A]LF%@58O<#W6ZE%A+*@;G@2A2=EV2VT 1=B%T4.NKRRQ:"XT67
M]7LALU&;[-AWZP=9WHK_V%3K.@?^[H@JYPH+GDO(,IJ9W-0I)"F74*1%)G&!
M<\3H];FI^U28&BG5'0'HT]-BSK?!]T_[[-5UKH]_#9&DNK=?[%AJ6+0'YJVC
M!-:[_-55G?6_-@!T+!CDV- ?P!'26_>J,8%DUS8PV:6^MFK)UPGCJ^^R?+Y3
M[^:EY.NWJVJM5U!YKIBILJPR4RY4$ 5QHKDO*2*"XUAPG#D%2)R4,C5FVRII
M[A@U:H):3U<'ZQ2@ME[5E3 -[DHY(N3A//4@$-AC.B5I9#>IQ]B7OE'?PWZ#
M?[N0N^7_W,RKN?&UZA]+*=^M'NE\.:.<,)YC!&.EAS]*33$E*C L2*1](<9P
MQ)V**5V4.#52V"H,.AK?@*W.X/=&:\=%V&7<[?@B*)H#<\>U0#I3B34X06GE
MLM11*<8:A&.ZL7_1X]CKMZ]_-5RV-([,[;T)&7BSTEY.>\201DE>,"Y@3DS^
M":+TF@M+"J,B237=,,Q2JWI ET5-C6Q^^PKN=]H"6JL+F-'7X?RF'UR+8Z]@
MD W,*!JMO:*@T134JOH<>_7#YG#L%0R^D8Z]KH'1[?S+"IG>\Z_^%L8[_[*R
MY.#\R^X-SUOR^]IN>J%8KQP?5@O]?O5>,_;Z><8E9SB.B%[."0J1Q SB5*_N
M4"P*HK#D/$4ND5"7!#KQZ@CQ3\U5W,5>ZWH+I>KH_7__"T[BXO\!LM;?\;[]
M)?CMG+F0H [,O)^.D'S?CYK[_7Q+*,+>V;\D=-Q[_)80O+C;;_N>A]O6IA+\
M3)^;0KLB*:(<)S!.\PPBA6/(XDC!+&4)B9-"<F65C^-$VU-SS-H$E]O,O$_T
MN=Z#<W OCK"S<,/\$1EZ%ZA%H=7,'P0'I\H?C)&\J"_R23=7;\2O'PZ^%*/P
M7P)Y4*=AZ'69CEX9ST<ZK>N!4W3F$3\OJ-D@;ZJ-=%AP6YP&Y;D@C' H4K.3
M%>$"$L1S2)+(1%9B)HA5*1 [<5,CL.:XB+;5;#J>D)NK<P%C.T<G''(#$UU[
MQM:"UE'U)EP=(#=0@CH\%T2.ZN[8F7_L[%B^=06?F%UV[4>]__%DDO?</<F2
MFMM[LR2F:4J9@$E2"(@*SB%-E82R2#,2*147B5-H4I^PJ7%)??( RC:L9KT"
M?+70MJS*>HKU()1S(#O020#H1B$3HV>S9&HTO0$[70-SR05$PC/).8'C\\@%
MTT^RR*5W_#BDN>Y;KQ5,LC4CH%Z%?95\4_I<AK=O<$*??D?IFSJ37V?3 .PU
M'R2"Q1VPH"/#0?RHX\0=EN-1X]'"E7F ]IF%JF_RQ_J-MN<?LY@4*$,YUC-O
M%D,D< JQ3!C,.4=)'C$9N949Z)4VM9FX3G?SO<Y_]2BIT=5A6\(.7SM:"H;:
MP$QT,F&8)AZC*ZB5'2(]4!\HPR0(.BGQ=5($]1E_-DE0[TM^-/+.;-#P>>VC
MZI\7LC[27HK;QU6YGO]GLP>5RCR.BRB%E.H_$,J,6Y]R6"04$RXE0FGDPB8V
M0J=&*EV=W9C$"F([0@D-W,"\TE77N#BMPK6?TU4Y'+FX !248ZP$CTHU+E <
M,X[3NYYI386HPV?HXC.=BX_+M_1IOJ:+6905-(YH##,N$$144D@%,]406)Y+
ME9,T<DMJ>EK.U.AEKR9XTGK"^1+P1E/'/*=G8+7CEP!@#4PI'9R,BF!NRK'U
MX^2>X+0?A;#I3<_(&C>Y:;_!+U*;7GC<XPSUMF2;]:8R!9VVL44DQ8I@J5<O
M).<F&9=);,PBB%*BHEBFN8JM]A+/M#\Y F@T!+6*#H>')Y"S.$6]#H^AQW@7
M"I^@M1.8.!RJ7H?-2 >KCABYG:>>1Z#W3/7$:^.=JY[7^>!LM><Q/S_F*W^0
M8E-7C=PNTYK4S]I=ZAR^_-)L1(B[Y1>S$U3.E_=O:#6OOIDCWOV^0JZ0C#''
M4* BAZ@H,,0YCZ%$&8WBA"4%2UV\GZ#:38XR:TOJU40WB*W=\Q& KH':;P69
M=0<HM^8!9NQS\ZW"=K6=1_9J'3@PQV_M,G>FNNFI.WW:#:?;VF=Z<6<AJ$T$
MO]=&@D$VJP:!/Z@#&5;#4=W.0< ]=E:'$3),1/*^UJAV<8N<(T@D-KZOBB I
M"@1%$DF!T@@)9G77PU7PU!C^.*)VK-ADQ^/'(> =F']/QRH/<M;HBLZHX<NO
M<\[H"HEK.'.@,\9;KM<RFSJ@I8T&>%'1L%U>91E+<%Y(2&*I_=8LT7ZKI!@6
M><03A!*,5>*T:V<K>6J,U5$<;&-;NK4[/SG7.+7O!,L]OB&@'7I'X.[MQS.U
M30<H8.*,4-@=06OIX^X1NH+R8M?0N0%OTEIMENNJ#9\VIQ9G(W.%8G&BG2E(
MB(E73"6'&&4I9)@SQ%/M@U&KE(@>LB=(7+7JV]C\VBNX.C+:I3.BQ,PA5+NZ
M4<P@0FELYA %)<ZSE$8J+]+4Y3K>4)TQPLV\U^\,Z[ED"(B'GDVVZ'[NH#M.
M/+L'8*$G%VOY8T\OKL"<F&"<F_ N[_M=ENNYEG*8F6KK#4><IYPHF)(Z^HYI
M;YA(!95*4TH(2I-<.!;X[9,WM:FDHRXX2M?F7-^W%V<[D@J(WL#$U /< &ZN
M)2ZA"_WVRAR[U*\- ">*_5J]YL<M339P0V#[D.%Z$W*68II+@91>5"<)1#Q'
MD.3FE"A#JDA4PB5Q6F.?E30U/MDK>A 67^OJF&+J/+IV7!($LX%9Q \N9_JX
M"$50XC@O;53*N&CT,5E<?L'7!7E\7"UKVOE:)Y>]VZRKM79DS0TQ%".9\BR#
M(D*:*1#7_D>1<B@4YFG."DZ$4PQ=G["ID46C:YMQ]Z;]+UCM%08_S;?_[%BV
MKA=S6U\D#)*#.R(UB+6>-^!KBV5'UY!>R&5$ KL@/0)']C\NF_[2^;!X)VCA
M@7JS[HO\+I<;67W01G3^K?K[?/W0?6_&(R%2D@LH<ZH@BHL$8AG',,L9SJ-8
MQMRMAG (I:9&4<UF)S ?!*AD^7W.32'-A<D"N7Z@2T=6"M)M=NPU=F<,S')G
M2R#<M$<W6YN:KNI:!?[09H&#!@8OE> %\QCE%-P4FT+)!2\H+<LR^+7M&5"R
M6MY_D^5CY];I+,E)RE%>0"+-XC!.%22**)/;)5;Z=Q@QY!0[\E+&] AUIYJY
M$/"X7P!5.Z?[!BQ72\@O;.A:HVQ'F%=B-S#_&>V@[I]'T-$O8-S'>>/#AGB<
MD#-N-,=Y0U\$;O0\ZD<!-;LH/<A,($CM3&A/\$ZU%3GIXN.R6I=U1'KU34NH
M3O]3FU^;1$([:C2".!8<HB)6$.LU(^0HBF/$:9%3)^X(J=S42&>G*>BHZIGY
M/&@GVE'3:W7-P)SFV2O.Y#8$?$%9,:B"H]+I$- >\_ @,CP3:FV3ZK1)=O:Y
M;SA+\PPK!DF64H@8UYX<T8Y=A&@2"R*E1&ZY^<Y)FAJU[A0%LM74,7W664CM
MN#$(4 ,3W1ZCK9*#!.]>A")LQJRSTL9-EW7)Z!>YLBZ^X,<-333O+W+]L!)[
ME_'NCZ4>A _SI\]2?TS+-;V7,Q:C#-%4PAC3%"*<:=:(LARJ+"=<\D+1*';A
M"FO)D^..K8IZ):CE:<7-DK"Y)  >:WOT+[8&@9]H!2AXVIGCN/EFWT%VS#,(
M[ ,S47MUH%&ZLY2\ ?N^V"L>CIJ<L0I*5?;21Z4N9U".J<R] =_JY!_-^#3[
M8M_E.[JFV\A#R1A/<HEACK#V>G*>06J.,5E$$T0R[0LQJV1#EP1-C;C:XMP=
M98'1]F(,HANZ_304$K.A6<<3+H^JYOU87%G>_$SC(]<Y[S?Q9<'S"\_['D V
MF^8[;STJN,I216 F<^W44$XA37$,"Q6+0J1Q)J13>/ZQ@*E10*N?Z_G?$6JV
M9WG^6 Q^+M<>NPVQH#EG=^"#LB,A(Q]ZG3;QY0'6F>=\AZ]N9L[74KREU</M
MLOZ/<2>^TX79+3G]VS:4%RLJ$YP*R"4M]*S/$"2*<2@H8RJE4L618]R OS)3
MHP6C9'U'H?ZAHZ[G;O-5'67++N/ /S 378&\!S%=#UE@$KM"H9$)[WKH7I)C
M@#8]4PJ9Z*Z/5;61XMW&9*+0BZ[Y2M2Y*^I_NWNJ@PG>_]"+L7DEQ:S DA*6
M%I 7=<*T@D.*<_U'$M$L)SE2BCJE#7+58&J4:72G^MLQZ65X-R(4/&U*\T]K
M<X-8MNJ;IU:-18X9@9Q[RHX^!\5_8,YLKJLTRH-&>]"H?[--\M,\TMH =D8$
M3-OCBU_8U#S.6HR;?L<7I!<I=KP;<N/'JES/?IDOYX^;QYW76 B),86**@Z1
M2 K(*"8P9CQ)<"9$E%E=M'O1\M3XK%7.CIU>XM3/.E=9/S";M'H%O/YVUMJ^
ML:]?ZHQ[_;?C,?^RU5'&\EECMF/T_ /NV[;OVM26S?!^OQ3OZ%K."CW0TJR@
M>M Q E'!,HA)DL(XI6F*TBC-,;;=KSTI86IC<:MD.ZL!K:;9>K3<MCD/Y.6M
MV:OA&7BP.B/CM!G;:[WW+NSI5D?;?NTUJKOOVO^@WT+CS:::+V55O5T]LOFR
MSEC[=K4TY]A:D/ZIF@O9E"^[+4O=T4T=E;</YL>/R]M'<]W^3IUY97OK_CF>
M(:;GXJ*>IG.]/%$1TBN33#.&X"B).<W3B,V^RY*M;!<H(VGN,K:Z^@^X(U&;
M8(ZTNZE-S2)G:XKY<6^+VWIFK ^"QH2)J,@AJ5/[QXA!EJ "R@P5:<Q(0;'3
MQOX$/X>1+A*5DNKUZT]"-C_]^;_ZEQ%GL:GQ@"%"1:2]B81 @F@$1<YS)CDN
M,BYG2[G^K_==D.:[V.H^PE?QXE/89@YRS)8Y5M_;[8U,J4_'<:NV%H..R3=@
M;P$X, %TS=:/[2:,QG3S'9Q[]6:7_2C@;;:1^ROH#LY8NH^Z[S-RAQSO%HTM
MWC<\Z:UNNS3AWD+^^'_E\RS&**(T2V$2IR8]'1<0YRF!19J*),8""U&XQ24=
M29B:=]%&V+1:@EI-H/5TC40Z!O+R.O=J> 8F9&=D/(*.SEA_9;31<:LCAQF=
M,>IE?-&Y!SW#J)627)/&^Q^\II$O>NE\MS1'=T?'=R\._0Y_T7ERED1QE%.L
MIXP4:6]5KUDT'6 ,6<89PGD>(^Q4$W$ '2='*+6)Q@%1JU+.[Y= ML8"S=X2
M-#]7IL8#WQZ\US_(O4V.X=D#=+R=E_K*W3DT >YZ<FL?, ::GC-*W[R(E[@!
M>[/ +JKB^'?O+?K9/4Q\N)X(&U ^@)[CAIX/!_2+(/4!15U=VN-$N=Z99"D7
M%.4PXT7:SA8R)U!D*<ZC)$^4PBZYC?O%.1'_".F,OZV<ZUA>P-..A,.A-#"?
M[F\M&UK\=;54NU\<Y",^6:A[D$H=/7@-59_CE,C7JLK18WY/+8Z^M_QHY3#!
M:)/QZW:S?EB5\_^48L8CK"C-<Y@4>CF*LL14#%)4+U%C)3!+"L6LSE[MQ$W-
MG]RGR*V:1'5MB!?=:>R?Z^\"\';\$P[.@?GG*-GP-N4?V"L;CF3L0 E*,A=$
MCDHR=N8?DXSE6QZ5=]\_/BU6S[(;J+7;1'N[H%4U5W,IVCBB-(_2**4IC(K(
M5.(5"<0LS?4:N(B20B+%$JM%K[/DJ5'/3E' =YHV+.062.K>!?W,,RBP0R\J
M6[4/PD,[1Q)@K[M/46 GE!W*!0^%]DB%A(.B[E9FV >YW@+$3@V.5YK8Q\Z#
MHL5>#?@YG$UNTJ_ZJZO/73Z9'M3BVM120D8RD9A!26@.4:0XQ)AQJ)0I>9'H
MZ4$Y^9N]TJ;&^6W:UIVV8*NNYS6L?JCM/,Q@  [,[5=@Y^Q@6F$2U+_LESBJ
M>VEE_+%W:?>2]T%J7]KT7&@2ITQ!(10R%=A2B&F,M8.)$B)D+C-D5>G63MS4
M*&5[D'@BW;I5MG4?Q*V/7_]KI*J_%D*?HUF_E/5.Y[2OGJ3>S=P3)[C#):J_
M_4[G"Y/>]\.J_$H7\IUDZWUUC4Z=R;^6JZKZ;5E*NC#+Y+]J-GLCS=GC-_IC
M)D3"F"Q2R&-N<ITF$M*DR"#/8B4R^?]7]ZV]C>-<FM_W5Q#8Q4PW$,[J0HGD
MN\ "J5MO!MV5;%7U.[/;'PQ>$\\D=L9VTIWY]4M*LBW?9)*F%&T#796*)?*<
MA^9#'O)<4I$BKXQ94:0:&T&Y95:N- );E8#5R;,V890Q==LT#3Y2/5.@E;]5
MZN<*;!2$1EBX-"I>@79AXJ/C=05XI1LPRD4L>!@3Z[BE$*-(-FR1Q)A@'I1/
MC-IXJ/6YH9MCMW[&Q.1<FBUB3@6'R.P<(2/"!IV5&A=48EV6?G$DW1WZS/%A
MPC^^/\P7JSIG^]0A9WL(R*Z&9RS@>K<\-X+V?G_J!DIDT[.SRX%M3Q?U#XU/
MI[="K<]K*<W7:5D9M[>+N\7\=6J4F22E(ER7!D^=E1"I(H.,20Y3G4A*\AP)
MD?O9G<<[&MN&KC&7&F&OZA,9 RE8"^QK:Y[ U]7*O!RU8>S+ , "+,MN-"ZT
M*4\T/K UV:WBH1UYYOF &\]_9C.#3_)-W4]MWC-[TO5]];1J;GX2S#CC&L."
M*6SV&%Q"(I0RU%MRRG2::.ITQ'V^J[%1@Q$66&E!6UQ@Y0VY;NM&V>$6,QIV
M/1/$D+!Y7$M&@V^@>\C3,$:Z;70"I/-ZL;N%X>X3G339N4!T>R.T!IF-Y6JB
ML<3;)_;$[M7R^_SE_F%5;>8F*-6((L.F2G*;V[$0D"*=P *5&<\01X9@_2J2
MG>EQ;,QJ!=[&88NW*R!KF<&R$MK&0P#V^*CNE7Q\ R^S9S:58#%_8X_6]O:M
M5G9N/-PLO*@H]\S!%< ?VP WXH):WB;S6,S:9H[@1*YT=J[7@>N>.8)P6 7-
M]<50K]GYLUJLWN[,EV1U/9/6S?_9KF%?U6J24%$*Z[DFA,TTRTH%.24ES+1(
M2($4*S*OJCI=G8V-B-:R5F[F:BWH%9BI*IB'M<Z(I7I>*#&MEV'SV7^C5[@D
MX*=/2E2K!LC3*[M@IW^S'^48>3O8=HR1&T/%0KYG<EJ+>04J02OL/V^Q-\+&
M=*X]#TEDU]J.#@=VK#VO^J%;K<,[D<IZ35 IS)-20U86'"(A2TB%0C 3)"6(
M*)9PKQB@@QZ\V&:HL!\PCUW,*[2(UX@HX;!X5X\5NWJ9]X>]O&^%KE,S_/2#
MX2='MV)E_S)\\77^:O'9MZLV2>TYTQG7!,K$S'-$D@QRPC@DA*@DHYA3['3(
M'-+YV+8>&_O>*%#_4(>ZO5:;B$.KW\>!WG=<W$^?^D![J/,H5Z O.*9R1MS_
MX*H/Y(<^RHHW D%'7;X0NAQ^.;<Y^'&8K[;'#LB\VPA81+Y5QSIU!26U7'V?
M/\K?V%\V0>^W]8'/E_GBP\N;F39(9RHK1&[3#6FS92P2R'"909QPP:@LL2R<
M?-1\.Q[;XE%=!3W6GN/&%MV<C-DD_EP!8ZBJZ6M'D.)EH^"P7/2$;<]+12,U
M6(L-K-Q7H)$<;$0'1G90"=\3PA[+0T](#[0T1$3<;TD(@*US.?!I;[BE($#+
MG64@Y/VPXX%/T]>I5#.YW(WLM4E))IE6.M=8P;2T50UXF1N+090P+20E.I6"
MIG@R4_?VG.Z'^T%E1Y=.,V63P'2OXSY/SC8!_K5#OURK8(\J%R^NC.\"NMNA
MPJ48#N00O);R"AQ$]EM1XQTV.. 1]=BAJ[]!#R <%-\_BG!YY>+D0TTESDTQ
M2)+*3&:B,%R",ELAI8!48@&3 A6:29U1[)2U\GQ78]LS-N)MDAX;B?\6G(-H
M'U;'*]0H8/5]=]I.,+0&K8_*F^?1Z"NST'YW[Y55Z(3:'1F%3KT1O[#<5_5G
M]<ERPGF&46Z,SDR6$B+%2DA293.R4RE1B7(JHQ63V_0Z-O9P*R"W>E#@]EG-
MS ;>!D8!&S<!KN\7JC)5X]62VPX.847*"IW E-E$<GG!(:%I HE6-"VH9FF&
M_$(@H@_/,)$0[@/$^AP/MX4@.L8]KPD.-?R,V/4#$:^NO& :K%3?MN?1E.<[
M ,.G)-_ARV&KR2]JIA;L\7HFK^73=-:<D[ZJYJ;-9DA.:6&X*<'<4)4T%BS-
MB(09)GE":8)UZ572^4Q_8UM!&G&KLW^V([ ?#YV#V8V!(H+7,_>T<=N5=7U9
M'H]P'%&)2C7G^AR49!P!V*<7U]?\@[9^+)C-$/#][8G/'R<L*3!F>0)E8CV'
M<ZXAU\R8L*7@N#0F;*F=:R[LM#PVLFB$ [5T[C%8NW!U4\%%(/0\Z1WU]PJI
M.JIK< S5;FN#!4T=5:(=)77\@8![R6OQ,EVQY8\',[.?U<MJ*I8W,_%/S04^
MQRPM>%K"(DD81)0DD"*D86'F(V.Y+!#ASC>1G5V-;6HVPH*VM%? RNMQ&=8-
MKL,%8S3(>I[(Q]"JP KQ,NE&S>/2,!IZ UT3GD0QTFV@$QZ=]W_=+0QWX^>D
MR<X=G]L;@85FV&)FR'AIK*TJZ='FO#C'1:%2K"&K/ &YTI 4RK!IBE)E;*&D
M=$MS=JZCL9%G%9CSK!;UV8QG\9938+I9/#$@ZIDLUR+:LY4Z9UDO!^_GD(A;
MQN149\/6(CFC\D%!D7//A_'!)J'%S>SY9;7\5;VJQ[Q9OC31*:$"0Y8R"5'&
M!&0%+6""2Y%P2>PQB0\E=/0U.E:PLH'<CPZZL'1CA$@(]4P*VQPU=I=I!;T"
M#6 1_40],(E*#UW]#<H0#HKODX3+*X$9#86P92V7=^S-9N"RYRJU?TOK*G";
M$^>'^FOUP>CR[Q.,"-69+" K\P(BG$JSP:#&/B-IDJ.2EAGU.F(-E&-L_+)6
M SS7>M1GL+4F;7\ SQ2%@8/D1DX#0-^[Z=>@?M="O5&B7<:HE7H+_&$5 94F
M$4GM0BSCIAD,E&78Q(*7 7:02O#"YL)(])NJ(I?OV&+U]F/!9DNS?]OF4R^Y
MR@JB*,2"& M,E00R33G,I-*H1"4N$Z_M5F=O8R/$1EA020M:X@:FKN^&VHWP
MH@'8,ZU=@)TW<3EA$I6>NGL<E(2<E-^G&K>7+MJ5V=OS^>-4V"RH?D<0IQL8
MT?=[*R182]G+*<1Y,/I8=X]U]QY+:X?:)U;/KC="%\A7-;-.2U@4**=Y CE&
M%**TH)!G>0H%(DP7#%EG,K^UL&YX?,M>)9?OVM:@Y+J,^>O>^XI5BQ1S7=I5
M,O(2U#0^\&JSJ]+APK+W>527V[HDPM:-4/%<YR(A$*/J?@"5D&&>0)H@1)(B
MS<P/$7QN][H=VWP-=[I=;KUNPVM^.HZ5&R_$'X&>6:/+Y[.6>E"GSQ- #>'U
MN=_U&-P^3\#AZ/=YZNW@?;$UYN\6<ZV62[/;9H]?U"9684)HKH34"13*!JUG
M,H44,PTQUB)-4H90ZA4_T-W=V#BL+2;02M7GCNS1_["Q"V-G^R,2<OW;(-4I
MX0YX5M1-1%)4.\0!E-BV2%>70]LC#NH?L4E<WO+W]_S4.-14MOO4FN[?U/-\
ML9J47-"$4@PSG#.(RBR'U/))FB.F=(*+U.UZM*N3L7''6DZP%134DKI[A)X$
MM)LR8L'4,U$$(.3E,WH.@F#WT9,-#^9)>DZUME/IV6<#_$L_/IB!5,N;V>8:
M=:XW56SKHK8_[&W!]N(L9REB,N-0I2@Q1I&DD$B<PJS,4<)97K#4/?N-=_=C
M(X=& 5N&35L7@=>JC(VQE!XWI9KKTN,>#I;^8]+-(OTCW3._K$&^F;5K!1F0
MM_6P:PW 'Y4.P.7^,@;N'LZNO>(_D -L+^/@YR,;#&.GWZQ_J\/YT@9KO.-?
M&]Y*H(_=?*&F][-Z*RK:ET"V,IUU0-W6AT12XT1J"A.A;3P1*2 3J(0REX7D
MNC [3C^?._>^Q[:<-*(#]9>H!@S\]&C$_1G<>Y?N]!D -[NU)UA[7CO6B*[%
MWKDKMH*#GZSH/_=3:#, L[B.?1[]#^OHYP_,@>-?0!-A9-:JFES7ZBAIKF2.
M$90B,XR%$8&$X@PJAFE*-1<I]JI6L-_!V&BI.7^VKF/S;<'HOX$4D2N<D:LL
MQT=K$*0(75&"KW!>>I[Z'T#NQE&7 -GW)G:G%OK:E;@"-A[?G-(_*JD<=#(H
M<YQ2<9\>3CX76KVDG1YLDS7L>B9O5P]J<2W_[:6IESG!159P8PV;K4PJ;78O
M:;/!:"BTX)*KC*(R)%.@NP1.W_KA$P>N1:X.W]6ZA(D9]E>U6$VMO?"\EUK0
M,9@S8(S<Z"0RY$-5-ME)+@@^;=,S&NPKP4%+\IAE3GS1BESTQ+G[@4N@^,)R
M6!#%NX4PDOLZGVT*@]S,Q/QID\^$%*146!>0$,7,CD?ED,J40E:(@I522E(@
MGS(I)WORVOH,5RZEFC76%O-CI-. NA%0%)AZYINVC* 6$OS4B'EZU^?-+F>A
MB$HFIWL;E#O.*KU/%>=?"+@DJ!P5.%LJ:395MK7JG/%ZL;!'%)9W^-OVD3OV
M9G]U_2=;R/I@:?GY+[40TZ5:3F>UY\/F$&J"4T6PDA2:39. "!E+BA6Y@FG!
M\[PH,I1P[K%7ZEG<D6ZLOAR_>8#BD2V74STU6X'Z$F()5*.;M#<6UF?KN=+0
MXY2\QR^#PS7&.X_M0$Y?5@-8J0#::H*6GH"_@?9SC:Z@4O:J.8=?7H&-PG;
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M@E@8.JC*LGZ;/SY^F2]LZ>A)R9*RR!()<9HHB I:FEDL"<Q0FA9$F+^8>X!
MH!!CF^3;"I]7H*4)6*MB*]5LE %UO>(_K#Z@4<C'^RATX!PN'0<8CIY9YO^+
MD?"X/1Q@1 :Z*NQQ9/PN!R^$M/,F,+3MX:[]+M1^YX[OTK;\-Y(?YZ]JX7@
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M%)6XW'H>E*N\P-BG)[^70Z."9LOYXU36IWOF)_&VC= KJ.9)D3.H-"X@0K2
M-$DDE*@HL>!$%K+T"Q ZW=G8^.=N,9V)J3%ZE_5-<TMRW\BA#H3=>"<6;CW3
MS8Z85Z 6%/S1_-U+;DT79"*'&W5T.'#DT7G5#X.0'-X)#4#X_J >'VUU+S9[
MFR###KDPK*$8TA 1DD""N(9$<ZY28\T)[93$]WCS8R.+QI&^$A$T,OJ&&>S
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MD&#_T^ Z& =1(.MY(@^$EH=M$ 6U@2R#D^A%L@G.8M%I$9Q^>SA[X*P&.];
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M2*$T%8:GW5TW3_<S-AYN) 7S&1"UK&!9Y<%ZMM*"G]@2,/"L%C8V_V</"NE
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MJCO_YN>7$QGPS*/H(D5PFD@7+7$*XV@7+%#NLXF#75G?2T _;#1_'7F\<)O
MR.>O,)M=4>]X-IH;B>0:1'A@MIR!ED0.7CDGL_5#/77MKML/$0W?31XIRB:
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M$/J(9]:/U&\]LVLFI%+ 3$[$@$Q$<H<1?)2,&*LU_L_;(!]+\CP6.;?(&1=
MQ^CW7J@<(^P&$//*+[^^F*?RGS?_N)A^]S-D9OEB]<HO%I?3^=E_^=D%3)+
M" _=-Z)D.9Q9!(*,."*C5%X+R4&:*@CJ15X+B#H*!EUMG30 M!??_12_/8.W
MW>(S<K3-EIG"\C6$U<W?KIZZ@PDJ,33=CD=?&AQIXB/3)%B'=MP(+<-CCO81
M1FL_0L=I[5$/?#7UU (,8RR5I,M/$ %W%O+Y*ZRN>&$,K,F>$I\ 3X-D%/'4
M>1)I%A*WF1/BL22G(S#W"%7C- JI"+"A--  FCXNX)N?IC=_?"NA$MKL#ZNO
M&"7ORFR"GD2RQ1N-Z%(0*3&P#<$E(E3"B)?1:![M.W0XJ'H0-TZWD7K8&EH?
M#4#L1^)9=MJ#MWC*"UFZ)F0,;9(M>1_9>RH5^K'U7?EQ6I-4-$D'R_AP@'0K
M/QO(!G7?8+&Z_#CS*(YY*B[CMQ(BHUF=4/ B&<T(#]274I0"=F8(T])*J:/P
MILZ)]AA5+;A,@T2 @XF^ 3OSOIN??8'%^;OY=UBN"A/+":66QA S'K\^X)Y"
M>VE9# 3#"UKJ'#R:T2KHN8>8%MR@04!SK* ;P,H'1+TOV>OOP2_A4VE3^R'_
MA@=ND=(DY)!YE)IP+061D)$9QRG)PF>OLP>K'LOL/!PUCY+5@JLS"'Z&$WX+
M2+KQSW[MYG%[ G.5A;5.$1H8E"Z")>4(!>6, \<BAI>/-E,Z D'WD=."MS,,
M<HX6=@.(V= _L9"1-$4)B*!0#M00;YD@PC/FM*%*\#HWDIOUQVG)5NT2>R]Q
M-N#SOI_Z,)VM[Z'0[5JG*W[M9BCT97'!5I<W[]1&&61-(9HE\F7!$%L>JUE*
M$OTPD5AZK&??$1Y,3PK']86K/Z=5450#5FB'K]N!*/-&@E,!Z1<80R:TIQ[=
M.\2(M &2#O'1"NI!(-?4DUL=##P,M&,4T@"TKNY'/_K+<CF*(L/O+"Z0CCLL
M3C(*QAJ6";,,)48!B O2D<#!2(I_<%OWPKH'D<V [RA</'")/;22&L#?Z^VR
MG^ [S"_@^ITG:ID\1J>)<HXAJL'-:6+IUVID4C;[(.J<I/?3,^ZY60E5 XB^
M 0#]&*!>B>KRFAL?+=,F$%UZ8TAO'/%&:9*I2]0 D_'1K.NAK@=NTS7N_5(E
M0 VHB@: =8]MY<'*0 ,E6J);*EUIUF@$)=$ZK] Y32D\5M<QI+,U[@53)0 =
M*?(10\620'M-_N4GF)7\U2]=26G 8.=B=;& 3]VEGQ76=FY#5 HA".$(R(BQ
M-#.,.)XB\LG!6J%X%+?N%>YFZAZV=#,GVO!.^@ETT8!YNJK&?]6=!PRFB^9>
M=?-B?9&9DD4]3;#8YF%O1;'#+&0/+O-R[Z)+KVK)"&XT3D3IXV"DLXG5264^
MBNQF3LUZD>7IU'HPAK_#(G1UW/\=5IC-.D>';JA/Y1Z(!^*R3\1SX4.@RK-*
MV5$/DM3,D5L/?<.HHP'K^( KNL.0E3Y0K0W1 7QY!%4D"&H).J+):4Z=5(]U
M!QH\,&CE!>@D.!M6/0W@;4=J$Z>UU ;0ZH:$'K#*E)1T(,)T<EY*89BMDX*W
M0\2X+T:GOH/=2^0-/"@](I'(A#1"2-1Q&2*BN"56H&QX!D^9@J K'7M'/AH-
M7CI^4BP-I) &#-%.2Y5-X88##).S=B0)*%M#QM(>FI%LJ,D0@4EXK,O5$<4T
MMR@9NY1O& W?+IXY1MP-P.5%2NOG5S_[Z*?IW?R5_S9%*S?Q0GKN@B<>M\ZZ
MR(>$D"-A$IV]TF;809TS[ &"QGZXK@*>(83? (8^P<ICS)K>^,4<7;KEBQ@O
MSB_6MRX83TSC=#41/";&4>$)1,2X5"GB!7)$%4AO/=7@ZL#I:=K&O5.HA*R!
M5=( R'8X6">6E?9R"_@*\^7T.Y0!?N?POELN?X75A_S%_S'AQK*L2D]C12FR
M)QS&JT(1EG-R23I.0YUDXCT)'?=2H99AJZBL!K!X5VJ3;%.T1I9A?U&68Y\3
MYSTO*;%41F=E9J=RV\>]/JB$J"-%WD#,]U0<,_'9@+8NDKCF0J1,?&G/+CP>
M^1C3V,=[WM=+'AQG:N=8=PG'*V<PL(W5+^CC6C%?836-Z'G_P-7@S8-^7.NT
MG80>X?.4;86<A<Q,]"1[6D+&,JL^XE="F>"T,DG).J[*2=H*[7J>J%-<HWP\
M?CV#]3KS].*\#*?XY_K[#]:X34S(6> 948K^44IEMIUW 8AQFBGFO*:Q3IW/
M4!R,??\Q,!(?\?E.I^@&G,$[/8S?+9<7D#"(Q]/(6$F<Y>7!C GB9:0D12T#
MI5KY7"=7Z &"QKY!J0R_(=30(IIV.V)GYK73FA.C1>G!XSP)49<J&B.R\:#H
MH[.Y!X34OJW(*]Z?G!I7ARKD&761O!;JLLO;EUK\*?+\0QQ?(OCA6TP>LG8M
MK_%H.0SD16YN3*ZIN<:USUG:G!W)LJ1:4N%+S;]#7,N02JF4BW6J$A\@Z/A[
ME>T'?BE5#A,0"50I71#,TM+!EV/,A=S:Y"P5P8",=6H ?J1C7+]M"-W?O4PY
M6,XC'I'+Q:JTP$@7<?5A\1D6WZ<17OPQ74Z06'00RVBJS"4>\65<@ P8JF?#
M!%66!MKK6,0%=C""?[N-CX<H:,2S/T";W8"B;0,:Z_N;#0?+U]VYG\XG#E("
M81GAD9=IAXDB$V5 ,@B9:+**Z5X7:_O@XRX9XX!D&,W>A<F18AX1*^OL\%?=
M#+_5;4[TTORRFZ_-ZO(76,_4ILXQ:IU&<UJZZ=BH2CF#()H:)(5QJF]?R3R0
ME__$0J.#XE@]=I6$.C9 ?NWFI2'JID[@<LN 9Y'K2"FZ^[CII9"&6.N!&,N<
M*&V_Q.WXZP%4W/?IX\3GE:!PM/@:",6OS]7-$T#Q^;MY"0;6]C-$9Q'!0!)5
M*)H8+/%"EJ1HE9*@+N!/ZSJG]Y'5R"7/X9[(\,)O $FW>+C>7(9Q)H%PK3B:
M0[2$MK #(GK!@0LMZX0W]Y+3B ][O+J[H67? ("NQ?-^.H=W^.5RDKCEV6I.
MP/) I%%H3"E0(HQDBBD'T51^-+JFI9$;P &-SF%B;@ HV[J=FV9-P2LJK<*]
M4CHV26[0S0<P1*>,;CZ-'"H-8[A-22/VY4#-WDFO.T+,#<%DDH0WT4:'0J"Z
MW"))4C+_2,C!1@\"+6N=&\0K"L:%Q7%Z?  4>PFU 3!<UV)M^UC?2,.I$ T-
MB2C/,6!+R(,/'!F1&!AP4 DJ)8$_2%(C_NTP5F08P3> H$^H!B2@3!%YC9M@
MUJT?\K=<3:PTZZ:/Q">.VT'BL1RL"P2<T3;S6+IE5[(QCY UKN$92/5W+-!0
M>F@ 5'^%.<IH5M)&TOET/BWR64V_PS4[S#E-'2,YY!(4E)SAH,JD8(P60('P
MHHYQ>H*P<4U4'6 -J8NQ;_;>S>.B%!V_ALU_W\W?^NEB7;SU(3_5:F%B4V16
M>$\PIBA2A$RLUHHD&ZTP*C&(M[)Z'K@"/(J,<2.N83%V8J4T8-GNR&\B:3;6
M)?0BM,:@->M,@@)%3%*!.RJ%JW29>(>4<<M1ZEBOX^3=0.G -0,WI3,3%K5T
MV1CB6;D3HTP2ZX4GW#"AA9-2VSKIA?<0T\@%T,!>^8'";@ O-[,>-CR\FZ/Q
MPN],7,9=9)(EP/&(EC8KXI*@))G(,OY/>5^G%OPABL:N?AL4.8.(O8'SZ8KN
M*^\NNVR#"WBHYM)<HW26LF M23+SI)V(J=(4J%N$C%W8-C!8#A?R_AAQ&XS,
MX6S="V\PJ+SM%C ]FV^:-<;++PL_7^)QC2KYJY_.B^U\"1E_IQ1Y,INL5SX0
M/&E+"173R&%0A'-I78:H)*LS9F,/(L=MFS,PQ&HIIP$3]6LW[WX\IZ_V4:+!
M0>:*,&5DF2]BB',,XU&I+$O":L'J/'@\2-*X[7,&QM0P@F_"1[KR[MZBS#8A
MY@4R=9/GO=D<F]_#+0++-W]@+(+ZFL[]XG(MRM*OK"0Y=;/96A[;\YX'C#JC
M9\3Y4LX>(]ODY@;OJ-;):L]JN5G5F!JW"'CPP[<-Y3>P#WZ%U4Z@DW'S1G10
M"1<> QU B/E$.5')N%22+?SM?L1#6<]=,GIAS3T3K!TNX ;0\?%JW74!U.OI
M]VF">5I>C[I-_\_%=JC@]4V-"%Y' YEXGA'_WB;B(@-29@LZ#\IG4^< WI_6
M?F] ])D K;*N&O#Z^G,X 12BM)P21\NL 4!3'("C7&,&$9+CEM5)KNM/X[@O
MD+71<C X]U)=.Y'P#V;^Q7<_G95TM"_=3OWHMJ/(2[^<Q@D8L!C7HU^@&2\]
MWAS!^,L1PUP6(@L78Z4X93]"^Z'TN21NU=12 \?U5;NWC[!8%RM?;UTCI(2$
MDF*))MQ3#HAW&=D*$*,4R5-6IWG&0Q3U@]5SR>091.X-'+"W^=AL E1M9CQJ
MC.=+*VY%);'"E+H=R#GKTJVCCJFZEYQQC\UA-/T$?/87>X/8>3V=7> ).W'"
M!R5T(I#6;=I*6HBVD<02"O-@K0UU!G ]0-"X^3DGP<\AHA\[+>=O4$:+0WKQ
M'1;^#'Z]*"5C)?=C?3"O.V]<RTH9C18Y6.*87T\YB20P9DEV*3E-M15PZS1[
M( EGCT7[F9W6'[FKBKH!(_0 :W<ZMVR].V @C'+$"7"X/Z!<U5&U[B!IN!:X
M8>J8IKW('.? JXN4[E1J:Q>36R-]MZF0\M*&:#2)(1DB4:HD<,9(9LZ'$+/C
ME1J'[4GH. =I"[@<1'4-(/.>MLQ7+9FOQ<>C<,I9]!P$'C!22DZ\U+;X)9DQ
M<)Y72O[H05P_R_A<TH>&UD8# 'L-8?49XL5BTUGWZK[E;;<HPQA_FR_ SZ;_
MA'25CS QZ/-2%3D))J''&APGCBM.#+INQGDOC*V3([(OI>-&H8-#Y<X8N(IZ
M:P"7C\AO(GDQU(B0K"@06:J(@S&&B!"Y-L)16BE'\A&BQHU9:Z-M*&TT< %[
MG3"PS8IY"7/(T]5$"AIBH(:@'U"&(AMD0VD@-'L\([A3L=+\DP<(ZF>^GD\N
MY?%2?X[M.;M\MU-]Q8Z<CR]7O0GG'MP.W[W]T;$6/F@'DG!5;MFD"'CV68P!
M(%H1$H^F4F/R7N0-W).3,^=XRAZM,$-[G"D>^=0%DK46(+730M=Y"VBI)^?P
MN'BB0^<^4F_ O7J\FP]7@7')+4DB42(AEIMN--+*."JY,1Q$'1__^,Y9I^KA
MN9>^]^J<M8_P&T#2 ]V;A/ R"T,B+Z/+N&7$*94)]SFEK(5ELHZ+_NPZ9^VE
M[GZ=L_:0?0, VDGLV'8A5#8S:M&S-.M'L6 3\5HG0GDP5%(1+:TS9ND.*2._
M9!^OWH=;Y1\@ZP; \L \SBTS3#HELXG$> Q 99",6&T"$0ZXHRYGJ#36^U&R
M1G[.'AQ$P^F@ 4#='L-YQ84/CG./VZ+X@Y('C$NYC@02#<R*A#^LXP'=3\^X
MY=O#0V@ J3> G1XS-*_ZZEHCE4!96>7PD#=:$,^X(#QI$[T(+E5*[NM-XKAE
MWA6,5!7=- "Z'].TMSQ$2$D)CI*"P-'H^D2<QGTDT+>D+ 1C51US=1\UXQ:!
M#P^EHR7> &H^7X3E-$W]XK(\#VTO13;Q1](6 ,-7:60F4I=4C9@L^H-H<;EC
M*>8Z]60/DM1(!\$!XOQ!A-X">F[(_]6?XY<[A>K;#::-9X%;2K2Q*"<.0 +S
MBFC!?-3&1*,JP>A)VD:._H<!P6UH#:N1L5-+/WR#^2]^\7=8%<9>G"U@O06W
MMA84#1"$) FR()(FCK86OV)4. Y2Y9!O);@\D$SZZ#(CPV1@A795I#LV3M;Y
M7!\O%O&K7]YA) <502N%GEL9]:?+G&D&FE#)*9[]+*7;-?T/P.2Q548^G"JB
M9##9MG!@W7V]1B6;E-"\NBP2'N32$ <J$*:#!1F#3)5FMS?>C7^0AXS#Q-P
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M9G[YY@]8Q"GZ0A/JN8T133W:=88&WC+<7[C=(J-62>H]F#JWFOO3.FZ3XP;
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M<?4AO_DCKJN1/J&/_&&=/5_^5\+[[WX&ZUPYE.,T8O1=?H"A_X_?V/E-% %
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MD&5BA- <-Z#0A(E4\B*I528UYC<,GD+XK/V&/?1WI-_P9IY&?Q%^(!WC%,_
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M^3L(^>.ZF<U@N8*NGS' W^/?;ICFEJ&4T=G7TCAD6F(P""X1FXQA4OID1%L
M_X'\7@!7_]\%^.&Z/K9S;!6([]:U[ I@DKE4S++"E"\M':5!SK@DZ#25UR.9
MT^U6WI50_!"%O8"J__6 .HC&GFG]V:\8;^(:WZ%FT=F=14Y1:?8X9Z<O+V-:
M@Y. $!*IG-R18?!D(O%6@#<2\1#JI$R>KKRL]\;26FE+:2SMN<J$T_*^+14E
M7.C,O0DF5AI ,Z@I;*'X;!]4'6P']U%7@T[G0WSM=-@")BG72A"(L32M=XYX
MC6Q&_#\7LLM)Z5$!V<JT[L:@>: *&P#ICWQ\V@GVBC\\\58+9:DB3)2BTJQR
M>?_BA.7L G>4NU@GH?1QNL:]>#H1^ 943>M>X73^5YC#=X]FY2C';^=S!O7M
M'J)O(/=M Y]?8/6U2SO@0F#]SVXZ7_T7_N6'/FD!I$J\].)W8(G4*1#4.! A
M4M*<)1FUK;(K]R3T6./TP'+W-1O2*0N99"(ZI(C1F$W$E]=ZQ5B@P8B0:9V^
M>_UI'->9JXFQVY:KDMZ>CQ4;)(J]^W&5;%K-R'1?V$7CC/.2D1QX(I*[1 *+
MEEB)6&2H46'J]) [L6F[N69Z8.%-D@F(0*.#3"(/%/V'I(D7#% <'D*PU$19
M*4VP%WW/RZ3M@ZV',W8&T]>(WO]RL7J2H[O?!2CSD==YOH8KO^X"K2(O9ELK
M8KTRQ!B?E-$Y,-4K>P<)V<$D_NTV'H^EM)5$GN%0TXV@PI&A^A ?V[J7**FU
MC&.@G=%]0/$IXH+&2,M3R3*7AH5>11Z]P/@X+>/ [;18Z*HH9NS,ZBMGZ'.<
MPCS"\E6W^-8M=M.+RS@A:8$7+W5=7B6)4QZ(2X)*B#PG\$]Y=_V6&@]%0RJT
MJR;=)G(,G[3M.Z^$&,8D:3B)4I5;((EL2:.(<$%I144*J4[B0'\:6\DR'/R<
MK*RNL<W6YXOP?AIAOIS.SS[!=YA?P$=8Q**\,YA$%Z@-+!!-32G' D9"R)Y$
MIZ))Z M;$WJ9K$>7:=S'.E"Q714I-W#E?[^8/OP^QQ6^3K_M,"9DX,ZE0*@.
MIE3SE31&)HG2W# #W"E(5>Q6;Q(;-UO'0:^NPII%XG)"?<@<  B%"*7=GRFS
M'"6Q)>&[;"W&3GH)U$J>\P@HVT\98Y^&+[NY?SM-\*J;X8^V#N;._M N:YIM
MZ?9#+9',H .1'1 4FM \,(]RZW4>/K%0*\G$]4[$(27=YKW^BQC+F+_E-W]9
MG$\_3S[&Q06DV<V\MD,N^'M][@ W_?O3/]"5_\?-@N4>]D59T<]NKF"3M#:E
MDB_)LB-2HZMDRRDE$2HQ<J6UK^-1/$+4T7D^6T%OE[A: 3%\(^C[GKZR2+@9
M3!FS&G&+!%_2F2@GGGLA@<JL0IU3[D""QW7SAT+5G12?$VCO^1JXPP?<[/'I
M)S)V%<?</ 9.J9)A&4Q) ^.E3IP25SPI""%P$2C+HD[[F(HF;R=)OL?V60O^
M9N<H"S252T3!T(V427KB8D2'DG/@(L5L9)TSX!BJVS5^^^#KD3X$=?7X?"W@
M$:D<^WS\B6Q@S52/QT":H\]9E',Y*SRF<Q DI&"),-$ESC)3OLYTZ-/Y?64>
M'KS:9@%'E5A(,9 ("?T0YI%SQQ-Q+&NMG0&C*A59/4Q4NR9L'W0\X;\=K(6Q
MKRZVYO83:@6)*)T07L-WF'7?2L0^$2H(*E#=/I3A9F =\8YF8H BK3%[KIXT
M1T\O,^YMZM (&5BL#=R7;IGYN.@R+)>H%C]["["\@KMTCF/XH8A*Y1U5Q$P\
M4X(DY4NTDBE+=9I=/D[7N+>G%>W.4+IHQ/2@I/!39U<<))=<U)02FF-I^H,6
MU'I>NE,S*J2DFLI^#>7N_?AQ;TAKFIHCQ-B B?FP^@J+NZ[_]8D:34H6+8#5
MM!0]B](9CVI"J;(Y69^3K%,/]#A=X_8VJ&5B!M1% \CJ$V%>L6:%PJ,7'3=/
M Q I9<GQ0$XS-\!$=J"@4J>-_D2.VZ;@1.[T8%HZ'(#=RL]J70"4FLXNYXN2
M)[[H+OWLT$>=^S]H@*"^!X4#A>]K:W/OI?<UL"PJVO D$%C"HKL<@3@K/-%!
M1L^D\(;6>;%XFK;CNNK>?/(G6/>&^=(5P7_(;]>"_W0E^)O+KR"LCT9+0F49
MCQ1P X18/#W/*$J!6^?[C278?^UQX_B!8?)C']ZZ>FCS$O+>'7[XN\MC'U?+
M'E5\6>D!-Q6\94Y:PB@S95)9+OG(O&2%&H6?J)FOXRRT8I4^8;CQMEO\[A?I
MUA5]DB)+CY0C!R@:E2GQ*CI"/;64I_4,F&&MU(.T-&^U]H'1859K&#T](RLV
M1%>G?A]<R[*=I'M3#W :B('3D(G7@1%$BR:6NY)\$)QT.4*BX9G9N.N(8[K
M'\''19<NXNIF$-)5G_6(Q[C@H710"7BN8[!+7'EP9-Y&YJ4TSM9A_0G"FC=H
M^V#F3A@XH%)&+AY\5>)96*!85Y?7!6\<D@9MT&VDR1%9[OR],(E MC0HAJRE
M7J#J53)X'P7CHF=0]78#RGIDK'R";Q>+^-4OX<79 J"\$=UF:5L)IP-WF4<,
M.60J^:V)$^\T[C!+J48,E";D@P&H-UGC%0X>K_FNMAK&?F;Y\,N;3Y^OYLJD
M4CQ)$Q$&3,F[+GU64#*49\X99TH&T<LQW_G0\91?25_= ,(;VZ#X^=EF+P@6
M!*7>HR$MLQ2%3R24#O%!*&4R:!O[1:G]#,;5LN.^Z-<Z9@Z3:@M0N)I4)8.U
MUB"=TN V$"F7*;^1Z-+I5YO @NG5A+4_&$8W$8>I[+;2#Y#?R&K_93J?GE^<
M;PDWPBBGHB94E''CRG@2HM)$B6!H1FY,OX>M7HK_8>F157^(XKHAI#BV^OT?
M.X1[;:F59<I@+IV\K73$*LH)B\G[:+V*OE>7NG[JWUUZG(-@,/4?+,71G;X'
MX_3WUT5X%'TA6;K&9[Y^K\U0^!$D>^E!:*\1X/V<P:<7&S<9JX9#4$7,8\-F
M<V=\>5-0V>5WQ9^&Y>IS-TL866'H9!)N^0"^#!A*Z );08)11DEJC+K=Q?T!
MR#RQT#BG1AV5=I7D.VHWFEUN=CFXX>Q#+C?;N-?F%WZV;5[Q!3&Q_(J_]B'_
MC^G95_PW7Z9H6&VT6@<+&*\+W'XAH3@Y0\$J*[4 [H7J9X@&(FB<0^MDZ#NI
MOL:V:.MI.VCX(T!:OD5AWR.$B=$T:I$= 4;+N!,A2:#"$\6EMLF#3*Q?OYH^
MJXUS%-9'U^"2'ALZ]]"_=0BOGU;?=HN7%Y?E;DCP*%PLK[BZ=$4O[3V# A(]
M"B\J4#3U>_'>8]%Q<IE',5.#R+T1//WUPB\\\E:ZT9V?3S>M,79:6$CO9!9:
M$\9]:>L4$O&VM/(/$%7DBCK?SQCU6V^<'.:3H6A(:3?C<6VS9"<YQLA31//)
MRBP&*@QQ(GB2K64Q)NZI3GNYXYO/'2?%^'3>]P'2&]MV?$$0+WTL.BCC7I_(
M^)E0)B $ 40:6^((IHG+Y:;*,"NHYL:Z?L?1?NOV HYY?L"I*/VQ@?4&I1!+
MIM'&\;\Z=#\A?Q_R=L-<B?5R(CR7&7VX<@5FB4PH/$^=)&5*N[/<,<C]SJ:]
MENT%*_O\8%5/]F.CZE?<*'[Y=<O#-II\8M?@<2N#U)&X@%&!5"$0F[,B06"L
MR6GR-O3#U@&+]T*8>WX(JZV'\3VBZ_U1(LY[&=K*X,T?WV"^A FL&SYG3Y@+
M$2VTC,1J*8BABGF;DQ:Q'\SV7;G?G29]?B"KJH)GE'9\+8<7Q:CC?X=./WYP
M@5IIR/TX.F$Z<I#&L^0)E>OQ[SRB51(!_ZI!@'8IYCK3MDY4<G'9.Y%_@K&)
M<I!PHYJ2S@"1$QL$(RQ2Y[+66?N\GQGKO7;[&<A[P.1^2U9'#V-[93W9VYDJ
MRH +*[D@0@AT/+7VQ#*J,$1V?.V-IFB&1-F><U[KO #61L$!B#M0)0<#[ALL
MIEWZO/*+U0E=M.N+7SR58,*3YR$G6WJ78"@- ?V1:- CA2P2CXK=J3TYUE'[
M8?T1'P%' 6 ]Y>R/0K=!X1S."OLC! DB2DL%2)*X5 3#(?102YT<<S(BMAB&
MX?N560\:)-1Y'&P2=8<HY/D=LUDPXS# (BIZ0Y!3M.D.0VX:DTL4G*+!C7C,
MUGE#;/N8W4<E1QZS;^:I5ISZJBL#5\]@'I$[/T_QY@WLD*CTL8\;( ;M3>U
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M6:Z+70A6)"?B<#-F#ZXGK8:VL9#P5/'I/FIY-L6GW&?)DQ=$&-RWTGA*@HQ
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M7433"2Y/#M.FF/U(8.E/P:VA\M]OO^$%H?QDFC_.9_31V96']"%:Y5,$5**
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MMY)'OA=%+1F2;];,8=5-@N Y@LY*9RE43J7;P_V1[D4]V7"'76D'A8[@9'R
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M97@S,3$N:'1M4$L! A0#%     @ O("E5(ECW=%,"   .2H  !4
M     ( !B @  &$R,#(R+7$Q,3!X<65X,S$R+FAT;5!+ 0(4 Q0    ( +R
MI51PWR3NU 0  ,P2   5              "  0<1  !A,C R,BUQ,3$P>'%E
M>#,R,2YH=&U02P$"% ,4    " "\@*54.9#^H=$$  #J$@  %0
M    @ $.%@  83(P,C(M<3$Q,'AQ97@S,C(N:'1M4$L! A0#%     @ O("E
M5)OX56N\H@$ O_X0 !$              ( !$AL  &%B=7,M,C R,C S,S$N
M:'1M4$L! A0#%     @ O("E5+I%XX)?#P  FYP  !$              ( !
M_;T! &%B=7,M,C R,C S,S$N>'-D4$L! A0#%     @ O("E5!6L)J]?%
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M !4              ( !$-X$ &%B=7,M,C R,C S,S%?<')E+GAM;%!+!08
1    "P + -@"   !1P4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
